molecule_chembl_id,target_chembl_id,target_pref_name,standard_type,standard_relation,standard_value,standard_units,assay_chembl_id,assay_type,assay_description,document_chembl_id,readout,smiles
CHEMBL13470,CHEMBL237,Kappa opioid receptor,IC50,=,2480.0,nM,CHEMBL857684,B,Binding affinity on cloned opioid receptor kappa 1 in human HEK293S cells using [125I]-D-Pro10-dynorphin A[1-11] as radioligand.,CHEMBL1133469,IC50,C=CCN1C[C@H](C)N([C@H](c2ccc(C(=O)N(CC)CC)cc2)c2cccc(OC)c2)C[C@H]1C
CHEMBL127802,CHEMBL237,Kappa opioid receptor,IC50,=,4270.0,nM,CHEMBL857684,B,Binding affinity on cloned opioid receptor kappa 1 in human HEK293S cells using [125I]-D-Pro10-dynorphin A[1-11] as radioligand.,CHEMBL1133469,IC50,CCCCN1CCC(=C(c2ccccc2)c2ccc(C(=O)N(CC)CC)cc2)CC1
CHEMBL415521,CHEMBL237,Kappa opioid receptor,IC50,=,7470.0,nM,CHEMBL857684,B,Binding affinity on cloned opioid receptor kappa 1 in human HEK293S cells using [125I]-D-Pro10-dynorphin A[1-11] as radioligand.,CHEMBL1133469,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCNCC2)c2ccccc2)cc1
CHEMBL126884,CHEMBL237,Kappa opioid receptor,IC50,=,2610.0,nM,CHEMBL857684,B,Binding affinity on cloned opioid receptor kappa 1 in human HEK293S cells using [125I]-D-Pro10-dynorphin A[1-11] as radioligand.,CHEMBL1133469,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCNCC2)c2c(C)cccc2C)cc1
CHEMBL338089,CHEMBL237,Kappa opioid receptor,IC50,=,3160.0,nM,CHEMBL857684,B,Binding affinity on cloned opioid receptor kappa 1 in human HEK293S cells using [125I]-D-Pro10-dynorphin A[1-11] as radioligand.,CHEMBL1133469,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCN(c3ccccc3)CC2)c2ccccc2)cc1
CHEMBL126255,CHEMBL237,Kappa opioid receptor,IC50,=,2290.0,nM,CHEMBL857684,B,Binding affinity on cloned opioid receptor kappa 1 in human HEK293S cells using [125I]-D-Pro10-dynorphin A[1-11] as radioligand.,CHEMBL1133469,IC50,C=CCN1CCC(=C(c2ccccc2)c2ccc(C(=O)N(CC)CC)cc2)CC1
CHEMBL126857,CHEMBL237,Kappa opioid receptor,IC50,=,3870.0,nM,CHEMBL857684,B,Binding affinity on cloned opioid receptor kappa 1 in human HEK293S cells using [125I]-D-Pro10-dynorphin A[1-11] as radioligand.,CHEMBL1133469,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCNCC2)c2ccc(Cl)c(Cl)c2)cc1
CHEMBL127788,CHEMBL237,Kappa opioid receptor,IC50,=,6140.0,nM,CHEMBL857684,B,Binding affinity on cloned opioid receptor kappa 1 in human HEK293S cells using [125I]-D-Pro10-dynorphin A[1-11] as radioligand.,CHEMBL1133469,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCN(CC3CC3)CC2)c2ccccc2)cc1
CHEMBL129034,CHEMBL237,Kappa opioid receptor,IC50,=,1660.0,nM,CHEMBL857684,B,Binding affinity on cloned opioid receptor kappa 1 in human HEK293S cells using [125I]-D-Pro10-dynorphin A[1-11] as radioligand.,CHEMBL1133469,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCNCC2)c2cccc3ccccc23)cc1
CHEMBL340476,CHEMBL237,Kappa opioid receptor,IC50,=,1330.0,nM,CHEMBL857684,B,Binding affinity on cloned opioid receptor kappa 1 in human HEK293S cells using [125I]-D-Pro10-dynorphin A[1-11] as radioligand.,CHEMBL1133469,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCN(C3CCCCC3)CC2)c2ccccc2)cc1
CHEMBL126141,CHEMBL237,Kappa opioid receptor,IC50,=,980.0,nM,CHEMBL857684,B,Binding affinity on cloned opioid receptor kappa 1 in human HEK293S cells using [125I]-D-Pro10-dynorphin A[1-11] as radioligand.,CHEMBL1133469,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCN(CC=C(C)C)CC2)c2ccccc2)cc1
CHEMBL339898,CHEMBL237,Kappa opioid receptor,IC50,=,5350.0,nM,CHEMBL857684,B,Binding affinity on cloned opioid receptor kappa 1 in human HEK293S cells using [125I]-D-Pro10-dynorphin A[1-11] as radioligand.,CHEMBL1133469,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCNCC2)c2cccc(C(F)(F)F)c2)cc1
CHEMBL127007,CHEMBL237,Kappa opioid receptor,IC50,=,8340.0,nM,CHEMBL857684,B,Binding affinity on cloned opioid receptor kappa 1 in human HEK293S cells using [125I]-D-Pro10-dynorphin A[1-11] as radioligand.,CHEMBL1133469,IC50,CCN(CC)C(=O)c1ccc(C(=C2CCNCC2)c2ccc(Cl)cc2)cc1
CHEMBL80,CHEMBL237,Kappa opioid receptor,IC50,=,1.5,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL332697,CHEMBL237,Kappa opioid receptor,IC50,=,4030.0,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,COc1cc(/C=C/C(=O)N2CCC(n3c(O)nc4ccccc43)CC2)c([N+](=O)[O-])cc1OC
CHEMBL324170,CHEMBL237,Kappa opioid receptor,IC50,=,5070.0,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,O=C(OCc1cc2c(cc1[N+](=O)[O-])OCO2)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL324257,CHEMBL237,Kappa opioid receptor,IC50,=,1480.0,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,O=C(OCc1ccc2nsnc2c1)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL326538,CHEMBL237,Kappa opioid receptor,IC50,=,1810.0,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,O=C(OCc1cccc(Oc2ccccc2)c1)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL324297,CHEMBL237,Kappa opioid receptor,IC50,=,37.0,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,O=[N+]([O-])c1cc2c(cc1CN1CCC(n3c(O)nc4ccccc43)CC1)OCO2
CHEMBL115229,CHEMBL237,Kappa opioid receptor,IC50,=,311.0,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,O=[N+]([O-])c1cc2c(cc1CN1CC=C(n3c(O)nc4ccccc43)CC1)OCO2
CHEMBL115444,CHEMBL237,Kappa opioid receptor,IC50,=,284.0,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,O=C(OCc1cc2c(cc1Cl)OCO2)N1CCC(n2c(O)nc3ccccc32)CC1
CHEMBL420863,CHEMBL237,Kappa opioid receptor,IC50,=,2.9,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,Cc1ccc2nc(O)n(C3CCN(Cc4cc5c(cc4Cl)OCO5)CC3)c2c1
CHEMBL114280,CHEMBL237,Kappa opioid receptor,IC50,=,507.0,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,Oc1nc2ccccc2n1CCCNCc1cc2c(cc1Cl)OCO2
CHEMBL2096625,CHEMBL237,Kappa opioid receptor,IC50,=,217.0,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.O=S(=O)(O)O
CHEMBL596,CHEMBL237,Kappa opioid receptor,IC50,=,1580.0,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1
CHEMBL325674,CHEMBL237,Kappa opioid receptor,IC50,=,617.0,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,O=C(OC1CCc2ccccc21)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL115222,CHEMBL237,Kappa opioid receptor,IC50,=,2.1,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,CNC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cc4c(cc3Cl)OCO4)CC2)C1=O
CHEMBL115284,CHEMBL237,Kappa opioid receptor,IC50,=,1060.0,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,O=C(OCc1cc2c(cc1Cl)OCO2)N1CCC(N2C(=O)CNc3ccccc32)CC1
CHEMBL325750,CHEMBL237,Kappa opioid receptor,IC50,=,104.0,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,O=C1NCN(c2ccccc2)C12CCN(Cc1ccc3nsnc3c1)CC2
CHEMBL114204,CHEMBL237,Kappa opioid receptor,IC50,=,1320.0,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,COc1cc(CC(=O)N2CCC(n3c(O)nc4ccccc43)CC2)c([N+](=O)[O-])cc1OC
CHEMBL114824,CHEMBL237,Kappa opioid receptor,IC50,=,1010.0,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,O=C(Cc1c[nH]c2ccc(Br)cc12)N1CCN(c2ccc([N+](=O)[O-])c3nonc23)CC1
CHEMBL2368861,CHEMBL237,Kappa opioid receptor,IC50,=,1.2,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5.Cl
CHEMBL114940,CHEMBL237,Kappa opioid receptor,IC50,=,6540.0,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,O=C(OCc1cc2c(cc1[N+](=O)[O-])OCO2)N1CC=C(n2c(O)nc3ccccc32)CC1
CHEMBL111918,CHEMBL237,Kappa opioid receptor,IC50,=,6570.0,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,O=C(O)CN1CN(c2ccccc2)C2(CCN(C(=O)OCc3cc4c(cc3Cl)OCO4)CC2)C1=O
CHEMBL114379,CHEMBL237,Kappa opioid receptor,IC50,=,1.7,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,Oc1nc2ccccc2n1C1CCN(Cc2cc3c(cc2Cl)OCO3)CC1
CHEMBL324479,CHEMBL237,Kappa opioid receptor,IC50,=,7240.0,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,COC(=O)c1csc(S(=O)(=O)N2CCN(C(=O)c3ccccc3Nc3ccccc3)CC2)c1OC
CHEMBL607,CHEMBL237,Kappa opioid receptor,IC50,=,2370.0,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,CCOC(=O)C1(c2ccccc2)CCN(C)CC1
CHEMBL651,CHEMBL237,Kappa opioid receptor,IC50,=,512.0,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1
CHEMBL333843,CHEMBL237,Kappa opioid receptor,IC50,=,1740.0,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,O=C(NCCCn1c(O)nc2ccccc21)OCc1cc2c(cc1Cl)OCO2
CHEMBL112191,CHEMBL237,Kappa opioid receptor,IC50,=,270.0,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,COc1ccc(CN2CCC(n3c(O)nc4ccccc43)CC2)c(Cl)c1
CHEMBL895,CHEMBL237,Kappa opioid receptor,IC50,=,83.0,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
CHEMBL326320,CHEMBL237,Kappa opioid receptor,IC50,=,797.0,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,Cc1ccc2nc(O)n(C3CCN(C(=O)OCc4cc5c(cc4Cl)OCO5)CC3)c2c1
CHEMBL420500,CHEMBL237,Kappa opioid receptor,IC50,=,2235.0,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,O=C(OCc1ccc2c(c1)OCO2)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL113811,CHEMBL237,Kappa opioid receptor,IC50,=,2280.0,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,O=C(NCc1ccc2c(c1)OCO2)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL326962,CHEMBL237,Kappa opioid receptor,IC50,=,56.1,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,O=C1NCN(c2ccccc2)C12CCN(Cc1ccc3c(c1)OCO3)CC2
CHEMBL115076,CHEMBL237,Kappa opioid receptor,IC50,=,2145.0,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,O=C(OCc1cc2c(cc1Cl)OCO2)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL325874,CHEMBL237,Kappa opioid receptor,IC50,=,3550.0,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,O=C(OCc1cccnc1)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL1707,CHEMBL237,Kappa opioid receptor,IC50,=,155.0,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1.Cl
CHEMBL115280,CHEMBL237,Kappa opioid receptor,IC50,=,101.0,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,O=C1NCN(c2ccccc2)C12CCN(Cc1cccc(Oc3ccccc3)c1)CC2
CHEMBL325842,CHEMBL237,Kappa opioid receptor,IC50,=,32.0,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,O=C1CNc2ccccc2N1C1CCN(Cc2cc3c(cc2Cl)OCO3)CC1
CHEMBL115652,CHEMBL237,Kappa opioid receptor,IC50,=,5.7,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,O=C1NCN(c2ccccc2)C12CCN(Cc1cc3c(cc1Cl)OCO3)CC2
CHEMBL114825,CHEMBL237,Kappa opioid receptor,IC50,=,333.0,nM,CHEMBL751989,B,"Binding affinity against opioid receptor kappa 1 using [3H]- U-69,593 radioligand",CHEMBL1134447,IC50,CNC(=O)CN1CN(c2ccccc2)C2(CCN(C(=O)OCc3cc4c(cc3Cl)OCO4)CC2)C1=O
CHEMBL59177,CHEMBL237,Kappa opioid receptor,IC50,=,271.0,nM,CHEMBL751993,B,Binding affinity towards kappa opioid receptor by the displacement of [125I]-(D-Pro10)-Dynorphin A,CHEMBL1135372,IC50,O=c1c(-c2cc3ccccc3o2)cccn1C(CN1CCCC1)c1ccccc1
CHEMBL64809,CHEMBL237,Kappa opioid receptor,IC50,=,5.3,nM,CHEMBL751993,B,Binding affinity towards kappa opioid receptor by the displacement of [125I]-(D-Pro10)-Dynorphin A,CHEMBL1135372,IC50,N#Cc1cccc(-c2cccn(C(CN3CCCC3)c3ccccc3)c2=O)c1
CHEMBL146191,CHEMBL237,Kappa opioid receptor,IC50,=,12.0,nM,CHEMBL751995,B,Inhibition of [3H]U-69593 binding to human Opioid receptor kappa 1 in CHO cells,CHEMBL1132115,IC50,Oc1nc2ccccc2n1C1CCN(CC2CCCCCCC2)CC1
CHEMBL304263,CHEMBL237,Kappa opioid receptor,IC50,=,19.5,nM,CHEMBL751993,B,Binding affinity towards kappa opioid receptor by the displacement of [125I]-(D-Pro10)-Dynorphin A,CHEMBL1135372,IC50,COc1ccccc1-c1cccn(C(CN2CCCC2)c2ccccc2)c1=O
CHEMBL59891,CHEMBL237,Kappa opioid receptor,IC50,=,524.0,nM,CHEMBL751993,B,Binding affinity towards kappa opioid receptor by the displacement of [125I]-(D-Pro10)-Dynorphin A,CHEMBL1135372,IC50,O=c1ccc(-c2ccc(Cl)cc2)cn1C(CN1CCCC1)c1ccccc1
CHEMBL304404,CHEMBL237,Kappa opioid receptor,IC50,=,31.9,nM,CHEMBL751993,B,Binding affinity towards kappa opioid receptor by the displacement of [125I]-(D-Pro10)-Dynorphin A,CHEMBL1135372,IC50,O=c1c(-c2ccc3ccccc3c2)cccn1C(CN1CCCC1)c1ccccc1
CHEMBL357076,CHEMBL237,Kappa opioid receptor,IC50,=,1400.0,nM,CHEMBL751991,B,Binding affinity in CHO cells stably expressing cloned human Opioid receptor kappa 1 by displacing radioligand [3H]U-69593,CHEMBL1132115,IC50,CCn1c(=O)n([C@@H]2CCN(CC3CCCCCCC3)C[C@H]2CO)c2ccccc21
CHEMBL59995,CHEMBL237,Kappa opioid receptor,IC50,=,5.7,nM,CHEMBL751993,B,Binding affinity towards kappa opioid receptor by the displacement of [125I]-(D-Pro10)-Dynorphin A,CHEMBL1135372,IC50,O=c1c(-c2ccccc2C(F)(F)F)cccn1C(CN1CCCC1)c1ccccc1
CHEMBL440765,CHEMBL237,Kappa opioid receptor,IC50,=,2.0,nM,CHEMBL751992,B,Binding affinity towards Opioid receptor kappa 1 by the displacement of [125I]-(D-Pro10)-Dynorphin A,CHEMBL1135372,IC50,CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL300616,CHEMBL237,Kappa opioid receptor,IC50,=,110.0,nM,CHEMBL751991,B,Binding affinity in CHO cells stably expressing cloned human Opioid receptor kappa 1 by displacing radioligand [3H]U-69593,CHEMBL1132115,IC50,Oc1nc2ccccc2n1C1CCN(Cc2ccccc2)CC1
CHEMBL61426,CHEMBL237,Kappa opioid receptor,IC50,=,34.2,nM,CHEMBL751993,B,Binding affinity towards kappa opioid receptor by the displacement of [125I]-(D-Pro10)-Dynorphin A,CHEMBL1135372,IC50,O=c1c(-c2ccc(OC(F)(F)F)cc2)cccn1C(CN1CCCC1)c1ccccc1
CHEMBL146013,CHEMBL237,Kappa opioid receptor,IC50,=,440.0,nM,CHEMBL751995,B,Inhibition of [3H]U-69593 binding to human Opioid receptor kappa 1 in CHO cells,CHEMBL1132115,IC50,CCn1c(=O)n(C2CCN(CC3CCCCCCC3)CC2)c2ccccc21
CHEMBL61212,CHEMBL237,Kappa opioid receptor,IC50,=,2.3,nM,CHEMBL751993,B,Binding affinity towards kappa opioid receptor by the displacement of [125I]-(D-Pro10)-Dynorphin A,CHEMBL1135372,IC50,O=c1c(-c2ccc(Cl)c(Cl)c2)cccn1C(CN1CCCC1)c1ccccc1
CHEMBL63128,CHEMBL237,Kappa opioid receptor,IC50,=,34.8,nM,CHEMBL751993,B,Binding affinity towards kappa opioid receptor by the displacement of [125I]-(D-Pro10)-Dynorphin A,CHEMBL1135372,IC50,O=c1c(-c2ccc(F)cc2)cccn1C(CN1CCCC1)c1ccccc1
CHEMBL294174,CHEMBL237,Kappa opioid receptor,IC50,=,2.4,nM,CHEMBL751993,B,Binding affinity towards kappa opioid receptor by the displacement of [125I]-(D-Pro10)-Dynorphin A,CHEMBL1135372,IC50,O=c1c(-c2cccc(Cl)c2)cccn1C(CN1CCCC1)c1ccccc1
CHEMBL278268,CHEMBL237,Kappa opioid receptor,IC50,=,56.3,nM,CHEMBL751993,B,Binding affinity towards kappa opioid receptor by the displacement of [125I]-(D-Pro10)-Dynorphin A,CHEMBL1135372,IC50,O=c1c(-c2ccccc2)cccn1C(CN1CCCC1)c1ccccc1
CHEMBL280037,CHEMBL237,Kappa opioid receptor,IC50,=,8.7,nM,CHEMBL751993,B,Binding affinity towards kappa opioid receptor by the displacement of [125I]-(D-Pro10)-Dynorphin A,CHEMBL1135372,IC50,O=c1c(-c2ccc(C(F)(F)F)cc2)cccn1C(CN1CCCC1)c1ccccc1
CHEMBL293143,CHEMBL237,Kappa opioid receptor,IC50,=,1.5,nM,CHEMBL751993,B,Binding affinity towards kappa opioid receptor by the displacement of [125I]-(D-Pro10)-Dynorphin A,CHEMBL1135372,IC50,COc1ccc(Cl)cc1-c1cccn(C(CN2CCCC2)c2ccccc2)c1=O
CHEMBL305339,CHEMBL237,Kappa opioid receptor,IC50,=,1177.0,nM,CHEMBL751993,B,Binding affinity towards kappa opioid receptor by the displacement of [125I]-(D-Pro10)-Dynorphin A,CHEMBL1135372,IC50,O=c1c(-c2cccs2)cccn1C(CN1CCCC1)c1ccccc1
CHEMBL416136,CHEMBL237,Kappa opioid receptor,IC50,=,22.5,nM,CHEMBL751993,B,Binding affinity towards kappa opioid receptor by the displacement of [125I]-(D-Pro10)-Dynorphin A,CHEMBL1135372,IC50,O=c1c(-c2cc(F)ccc2F)cccn1C(CN1CCCC1)c1ccccc1
CHEMBL59924,CHEMBL237,Kappa opioid receptor,IC50,=,1494.0,nM,CHEMBL751993,B,Binding affinity towards kappa opioid receptor by the displacement of [125I]-(D-Pro10)-Dynorphin A,CHEMBL1135372,IC50,O=c1ccc(-c2ccc(Cl)c(Cl)c2)cn1C(CN1CCCC1)c1ccccc1
CHEMBL60030,CHEMBL237,Kappa opioid receptor,IC50,=,5.5,nM,CHEMBL751993,B,Binding affinity towards kappa opioid receptor by the displacement of [125I]-(D-Pro10)-Dynorphin A,CHEMBL1135372,IC50,O=c1c(-c2ccc(Cl)cc2)cccn1C(CN1CCCC1)c1ccccc1
CHEMBL293619,CHEMBL237,Kappa opioid receptor,IC50,=,2.2,nM,CHEMBL751993,B,Binding affinity towards kappa opioid receptor by the displacement of [125I]-(D-Pro10)-Dynorphin A,CHEMBL1135372,IC50,O=c1c(-c2cccc([N+](=O)[O-])c2)cccn1C(CN1CCCC1)c1ccccc1
CHEMBL302684,CHEMBL237,Kappa opioid receptor,IC50,=,79.3,nM,CHEMBL751993,B,Binding affinity towards kappa opioid receptor by the displacement of [125I]-(D-Pro10)-Dynorphin A,CHEMBL1135372,IC50,Cc1cccc(-c2cccn(C(CN3CCCC3)c3ccccc3)c2=O)c1
CHEMBL146462,CHEMBL237,Kappa opioid receptor,IC50,=,2600.0,nM,CHEMBL751991,B,Binding affinity in CHO cells stably expressing cloned human Opioid receptor kappa 1 by displacing radioligand [3H]U-69593,CHEMBL1132115,IC50,CCn1c(=O)n([C@H]2CCN(CC3CCCCCCC3)C[C@@H]2CO)c2ccccc21
CHEMBL305552,CHEMBL237,Kappa opioid receptor,IC50,=,49.4,nM,CHEMBL751993,B,Binding affinity towards kappa opioid receptor by the displacement of [125I]-(D-Pro10)-Dynorphin A,CHEMBL1135372,IC50,COc1ccc(-c2cccn(C(CN3CCCC3)c3ccccc3)c2=O)cc1
CHEMBL146054,CHEMBL237,Kappa opioid receptor,IC50,=,32.0,nM,CHEMBL751991,B,Binding affinity in CHO cells stably expressing cloned human Opioid receptor kappa 1 by displacing radioligand [3H]U-69593,CHEMBL1132115,IC50,CC(c1ccccc1Cl)N1CCC(n2c(O)nc3ccccc32)CC1
CHEMBL64284,CHEMBL237,Kappa opioid receptor,IC50,=,3.4,nM,CHEMBL751993,B,Binding affinity towards kappa opioid receptor by the displacement of [125I]-(D-Pro10)-Dynorphin A,CHEMBL1135372,IC50,COc1ccc(F)cc1-c1cccn(C(CN2CCCC2)c2ccccc2)c1=O
CHEMBL64197,CHEMBL237,Kappa opioid receptor,IC50,=,3.44,nM,CHEMBL751993,B,Binding affinity towards kappa opioid receptor by the displacement of [125I]-(D-Pro10)-Dynorphin A,CHEMBL1135372,IC50,COc1ccc(OC)c(-c2cccn(C(CN3CCCC3)c3ccccc3)c2=O)c1
CHEMBL437242,CHEMBL237,Kappa opioid receptor,IC50,=,17.4,nM,CHEMBL754274,B,Evaluated for inhibitory activity against Opioid receptor kappa 1 of rabbit vas deferens (RVD),CHEMBL1124934,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL412769,CHEMBL237,Kappa opioid receptor,IC50,=,20.0,nM,CHEMBL754274,B,Evaluated for inhibitory activity against Opioid receptor kappa 1 of rabbit vas deferens (RVD),CHEMBL1124934,IC50,CCCCCCNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC
CHEMBL217597,CHEMBL237,Kappa opioid receptor,IC50,=,125.0,nM,CHEMBL754274,B,Evaluated for inhibitory activity against Opioid receptor kappa 1 of rabbit vas deferens (RVD),CHEMBL1124934,IC50,CN[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(N)=O
CHEMBL274875,CHEMBL237,Kappa opioid receptor,IC50,=,1183.0,nM,CHEMBL754274,B,Evaluated for inhibitory activity against Opioid receptor kappa 1 of rabbit vas deferens (RVD),CHEMBL1124934,IC50,CN[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(=O)N[C@H](Cc1ccccc1)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(N)=O
CHEMBL415410,CHEMBL237,Kappa opioid receptor,IC50,=,9.1,nM,CHEMBL754274,B,Evaluated for inhibitory activity against Opioid receptor kappa 1 of rabbit vas deferens (RVD),CHEMBL1124934,IC50,CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)N(C)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1ccc([N+](=O)[O-])cc1)NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC
CHEMBL441939,CHEMBL237,Kappa opioid receptor,IC50,=,0.06,nM,CHEMBL754274,B,Evaluated for inhibitory activity against Opioid receptor kappa 1 of rabbit vas deferens (RVD),CHEMBL1124934,IC50,CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)N(C)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1CSSC[C@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@H](Cc2ccccc2)C(=O)N1
CHEMBL410611,CHEMBL237,Kappa opioid receptor,IC50,=,5.5,nM,CHEMBL754274,B,Evaluated for inhibitory activity against Opioid receptor kappa 1 of rabbit vas deferens (RVD),CHEMBL1124934,IC50,CN[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(=O)N[C@@H](Cc1ccc([N+](=O)[O-])cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(N)=O
CHEMBL41366,CHEMBL237,Kappa opioid receptor,IC50,=,26.0,nM,CHEMBL750074,B,Compound was tested for Inhibition of [3H]-DPDPE (0.2 nM) binding to Opioid receptor kappa 1 from bovine striatal Membranes,CHEMBL1153675,IC50,C=C(Cl)C(=O)N[C@@H]1CCC2C3Cc4ccc(O)c5c4C2(CCN3C)[C@H]1O5
CHEMBL429020,CHEMBL237,Kappa opioid receptor,IC50,=,1.07,nM,CHEMBL754274,B,Evaluated for inhibitory activity against Opioid receptor kappa 1 of rabbit vas deferens (RVD),CHEMBL1124934,IC50,CN[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N(C)[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(N)=O
CHEMBL266035,CHEMBL237,Kappa opioid receptor,IC50,=,2.3,nM,CHEMBL754274,B,Evaluated for inhibitory activity against Opioid receptor kappa 1 of rabbit vas deferens (RVD),CHEMBL1124934,IC50,CN[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N(C)[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(N)=O
CHEMBL408557,CHEMBL237,Kappa opioid receptor,IC50,=,24.0,nM,CHEMBL754274,B,Evaluated for inhibitory activity against Opioid receptor kappa 1 of rabbit vas deferens (RVD),CHEMBL1124934,IC50,CN[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(N)=O
CHEMBL412325,CHEMBL237,Kappa opioid receptor,IC50,=,2.6,nM,CHEMBL754274,B,Evaluated for inhibitory activity against Opioid receptor kappa 1 of rabbit vas deferens (RVD),CHEMBL1124934,IC50,CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)N(C)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC
CHEMBL289426,CHEMBL237,Kappa opioid receptor,IC50,=,1.53,nM,CHEMBL750074,B,Compound was tested for Inhibition of [3H]-DPDPE (0.2 nM) binding to Opioid receptor kappa 1 from bovine striatal Membranes,CHEMBL1153675,IC50,C=C(Cl)C(=O)N[C@@H]1CCC2C3Cc4ccc(O)c5c4C2(CCN3CC2CC2)[C@H]1O5
CHEMBL268105,CHEMBL237,Kappa opioid receptor,IC50,=,4.9,nM,CHEMBL754274,B,Evaluated for inhibitory activity against Opioid receptor kappa 1 of rabbit vas deferens (RVD),CHEMBL1124934,IC50,CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC
CHEMBL412324,CHEMBL237,Kappa opioid receptor,IC50,=,45.5,nM,CHEMBL754274,B,Evaluated for inhibitory activity against Opioid receptor kappa 1 of rabbit vas deferens (RVD),CHEMBL1124934,IC50,CC(C)C[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL266845,CHEMBL237,Kappa opioid receptor,IC50,=,85.5,nM,CHEMBL754274,B,Evaluated for inhibitory activity against Opioid receptor kappa 1 of rabbit vas deferens (RVD),CHEMBL1124934,IC50,CN[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(N)=O
CHEMBL385736,CHEMBL237,Kappa opioid receptor,IC50,=,738.0,nM,CHEMBL754274,B,Evaluated for inhibitory activity against Opioid receptor kappa 1 of rabbit vas deferens (RVD),CHEMBL1124934,IC50,CC(C)C[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CN(C)C(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL263031,CHEMBL237,Kappa opioid receptor,IC50,=,14.3,nM,CHEMBL754274,B,Evaluated for inhibitory activity against Opioid receptor kappa 1 of rabbit vas deferens (RVD),CHEMBL1124934,IC50,CN[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(N)=O
CHEMBL290616,CHEMBL237,Kappa opioid receptor,IC50,=,184.0,nM,CHEMBL750074,B,Compound was tested for Inhibition of [3H]-DPDPE (0.2 nM) binding to Opioid receptor kappa 1 from bovine striatal Membranes,CHEMBL1153675,IC50,C=C(Cl)C(=O)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4C31CCN(C)C2C5
CHEMBL216351,CHEMBL237,Kappa opioid receptor,IC50,=,189.0,nM,CHEMBL754274,B,Evaluated for inhibitory activity against Opioid receptor kappa 1 of rabbit vas deferens (RVD),CHEMBL1124934,IC50,CN[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(=O)N[C@H](Cc1ccccc1)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(N)=O
CHEMBL306016,CHEMBL237,Kappa opioid receptor,IC50,=,13000.0,nM,CHEMBL754274,B,Evaluated for inhibitory activity against Opioid receptor kappa 1 of rabbit vas deferens (RVD),CHEMBL1124934,IC50,CN[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(=O)N[C@H](Cc1ccccc1)C(=O)N[C@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(N)=O
CHEMBL288178,CHEMBL237,Kappa opioid receptor,IC50,=,501.0,nM,CHEMBL750074,B,Compound was tested for Inhibition of [3H]-DPDPE (0.2 nM) binding to Opioid receptor kappa 1 from bovine striatal Membranes,CHEMBL1153675,IC50,C=C(Cl)C(=O)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4C31CCN(CC1CC1)C2C5
CHEMBL406034,CHEMBL237,Kappa opioid receptor,IC50,=,152.0,nM,CHEMBL754274,B,Evaluated for inhibitory activity against Opioid receptor kappa 1 of rabbit vas deferens (RVD),CHEMBL1124934,IC50,CN[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NNC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(N)=O
CHEMBL428803,CHEMBL237,Kappa opioid receptor,IC50,=,301.0,nM,CHEMBL754274,B,Evaluated for inhibitory activity against Opioid receptor kappa 1 of rabbit vas deferens (RVD),CHEMBL1124934,IC50,CN[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(N)=O
CHEMBL485,CHEMBL237,Kappa opioid receptor,IC50,=,15000.0,nM,CHEMBL751994,B,In vitro binding affinity against cloned human Opioid receptor kappa 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341
CHEMBL3707097,CHEMBL237,Kappa opioid receptor,IC50,=,7400.0,nM,CHEMBL751994,B,In vitro binding affinity against cloned human Opioid receptor kappa 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,Brc1ccc2c(c1)[C@H]1c3cc(Br)ccc3[C@H](C2)N2CCC[C@@H]12
CHEMBL592,CHEMBL237,Kappa opioid receptor,IC50,=,4.0,nM,CHEMBL751994,B,In vitro binding affinity against cloned human Opioid receptor kappa 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13
CHEMBL3707102,CHEMBL237,Kappa opioid receptor,IC50,=,640.0,nM,CHEMBL751994,B,In vitro binding affinity against cloned human Opioid receptor kappa 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,C[C@@H]1[C@H]2c3cc(NCc4ccccc4)ccc3C[C@@H](c3ccc(NCc4ccccc4)cc32)N1C
CHEMBL3707076,CHEMBL237,Kappa opioid receptor,IC50,=,7000.0,nM,CHEMBL751994,B,In vitro binding affinity against cloned human Opioid receptor kappa 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,Brc1ccc(CNc2ccc3c(c2)[C@H]2c4cc(NCc5ccc(Br)cc5)ccc4[C@H](C3)N3CCC[C@@H]23)cc1
CHEMBL2112842,CHEMBL237,Kappa opioid receptor,IC50,=,2970.0,nM,CHEMBL751994,B,In vitro binding affinity against cloned human Opioid receptor kappa 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,CC(C)C[C@H]1[C@H]2c3ccccc3C[C@H](c3ccccc32)N1C
CHEMBL3707088,CHEMBL237,Kappa opioid receptor,IC50,=,1600.0,nM,CHEMBL751994,B,In vitro binding affinity against cloned human Opioid receptor kappa 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,C[C@@H]1[C@H]2c3cc(N4CCN(C)CC4)ccc3C[C@@H](c3ccc(N4CCN(C)CC4)cc32)N1CC1CC1
CHEMBL3706637,CHEMBL237,Kappa opioid receptor,IC50,=,7400.0,nM,CHEMBL751994,B,In vitro binding affinity against cloned human Opioid receptor kappa 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,c1ccc2c(c1)C[C@@H]1c3ccccc3[C@H]2[C@@H]2CCCCN12
CHEMBL3707094,CHEMBL237,Kappa opioid receptor,IC50,=,3200.0,nM,CHEMBL751994,B,In vitro binding affinity against cloned human Opioid receptor kappa 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,C[C@@H]1[C@H]2c3cc(N4CCN(C)CC4)ccc3C[C@@H](c3ccc(N4CCN(C)CC4)cc32)N1C
CHEMBL2112841,CHEMBL237,Kappa opioid receptor,IC50,=,1710.0,nM,CHEMBL751994,B,In vitro binding affinity against cloned human Opioid receptor kappa 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,CN1[C@@H]2Cc3ccccc3[C@@H](c3ccccc32)[C@@H]1Cc1ccccc1
CHEMBL3707086,CHEMBL237,Kappa opioid receptor,IC50,=,6920.0,nM,CHEMBL751994,B,In vitro binding affinity against cloned human Opioid receptor kappa 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,C[C@@H]1[C@H]2c3cc(Br)ccc3C[C@@H](c3ccc(Br)cc32)N1C
CHEMBL3707089,CHEMBL237,Kappa opioid receptor,IC50,=,31.0,nM,CHEMBL751994,B,In vitro binding affinity against cloned human Opioid receptor kappa 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,C[C@@H]1[C@H]2c3cc(NCc4ccccc4)ccc3C[C@@H](c3ccc(NCc4ccccc4)cc32)N1CC1CC1
CHEMBL3707083,CHEMBL237,Kappa opioid receptor,IC50,=,961.0,nM,CHEMBL751994,B,In vitro binding affinity against cloned human Opioid receptor kappa 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,C[C@@H]1[C@H]2c3cc(O)ccc3C[C@@H](c3ccc(O)cc32)N1C
CHEMBL3707095,CHEMBL237,Kappa opioid receptor,IC50,=,3600.0,nM,CHEMBL751994,B,In vitro binding affinity against cloned human Opioid receptor kappa 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,C[C@@H]1[C@H]2c3cc(Nc4ccccc4)ccc3C[C@@H](c3ccc(Nc4ccccc4)cc32)N1C
CHEMBL3707080,CHEMBL237,Kappa opioid receptor,IC50,=,2020.0,nM,CHEMBL751994,B,In vitro binding affinity against cloned human Opioid receptor kappa 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,CC(=O)Oc1ccc2c(c1)[C@H]1c3cc(OC(C)=O)ccc3[C@H](C2)N(CC2CC2)[C@@H]1C
CHEMBL3707103,CHEMBL237,Kappa opioid receptor,IC50,=,1200.0,nM,CHEMBL751994,B,In vitro binding affinity against cloned human Opioid receptor kappa 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,C[C@@H]1[C@H]2c3cc(Nc4ccccc4)ccc3C[C@@H](c3ccc(Nc4ccccc4)cc32)N1CC1CC1
CHEMBL70,CHEMBL237,Kappa opioid receptor,IC50,=,1705.1,nM,CHEMBL751994,B,In vitro binding affinity against cloned human Opioid receptor kappa 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL3707082,CHEMBL237,Kappa opioid receptor,IC50,=,204.0,nM,CHEMBL751994,B,In vitro binding affinity against cloned human Opioid receptor kappa 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,C[C@@H]1[C@H]2c3cc(O)ccc3C[C@@H](c3ccc(O)cc32)N1CC1CC1
CHEMBL3707087,CHEMBL237,Kappa opioid receptor,IC50,=,6100.0,nM,CHEMBL751994,B,In vitro binding affinity against cloned human Opioid receptor kappa 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,c1ccc2c(c1)C[C@H]1c3ccccc3[C@H]2[C@@H]2CCCN12
CHEMBL2112843,CHEMBL237,Kappa opioid receptor,IC50,=,3410.0,nM,CHEMBL751994,B,In vitro binding affinity against cloned human Opioid receptor kappa 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,CC(C)[C@H]1[C@H]2c3ccccc3C[C@H](c3ccccc32)N1C
CHEMBL3707101,CHEMBL237,Kappa opioid receptor,IC50,=,5330.0,nM,CHEMBL751994,B,In vitro binding affinity against cloned human Opioid receptor kappa 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,COc1ccc2c(c1)[C@H]1c3cc(OC)ccc3[C@H](C2)N(CC2CC2)[C@@H]1C
CHEMBL3707075,CHEMBL237,Kappa opioid receptor,IC50,=,7200.0,nM,CHEMBL751994,B,In vitro binding affinity against cloned human Opioid receptor kappa 1 expressed in HEK 293S cells,CHEMBL1145019,IC50,Oc1ccc2c(c1)[C@H]1c3cc(O)ccc3[C@H](C2)N2CCC[C@@H]12
CHEMBL441765,CHEMBL237,Kappa opioid receptor,IC50,=,0.69,nM,CHEMBL751987,B,Binding activity against human Opioid receptor kappa 1 using [3H]-U 50488 as a radioligand,CHEMBL1135899,IC50,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL24035,CHEMBL237,Kappa opioid receptor,IC50,=,7574.0,nM,CHEMBL751988,B,Binding affinity against cloned human Opioid receptor kappa 1 using [125I]-D-Pro10-dynorphin A[1-11] as radioligand,CHEMBL1133468,IC50,C=CCN1CCN(C(c2ccccc2)c2ccc(C(=O)N(CC)CC)cc2)CC1
CHEMBL290701,CHEMBL237,Kappa opioid receptor,IC50,=,10.0,nM,CHEMBL753328,B,Inhibitory activity against Opioid receptor kappa1 binding to bovine striatal membrane,CHEMBL1128783,IC50,O=C(CSSCC(=O)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL2304424,CHEMBL237,Kappa opioid receptor,IC50,=,7.7,nM,CHEMBL753328,B,Inhibitory activity against Opioid receptor kappa1 binding to bovine striatal membrane,CHEMBL1128783,IC50,C[C@@]12Oc3c(O)ccc4c3[C@@]13CCN(CC1CC1)[C@H](C4)[C@]3(NC(=O)CSSCC(=O)N[C@@]13CCC(=O)[C@]4(C)Oc5c(O)ccc6c5[C@@]41CCN(CC1CC1)[C@@H]3C6)CCC2=O
CHEMBL25230,CHEMBL237,Kappa opioid receptor,IC50,=,20.0,nM,CHEMBL751988,B,Binding affinity against cloned human Opioid receptor kappa 1 using [125I]-D-Pro10-dynorphin A[1-11] as radioligand,CHEMBL1133468,IC50,C=CCN1C[C@H](C)N([C@H](c2ccc(C(=O)N(CC)CC)cc2)c2cccc(O)c2)C[C@H]1C
CHEMBL126819,CHEMBL237,Kappa opioid receptor,IC50,=,3160.0,nM,CHEMBL751988,B,Binding affinity against cloned human Opioid receptor kappa 1 using [125I]-D-Pro10-dynorphin A[1-11] as radioligand,CHEMBL1133468,IC50,CCN(CC)C(=O)c1ccc(C(c2ccc3cccnc3c2)N2CCNCC2)cc1
CHEMBL41098,CHEMBL237,Kappa opioid receptor,IC50,=,41.0,nM,CHEMBL753328,B,Inhibitory activity against Opioid receptor kappa1 binding to bovine striatal membrane,CHEMBL1128783,IC50,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(NC(=O)CSSCC(=O)N[C@@]23CCC(=O)[C@@H]4Oc6c(O)ccc7c6[C@@]42CCN(C)[C@@H]3C7)[C@H]1C5
CHEMBL124642,CHEMBL237,Kappa opioid receptor,IC50,=,6970.0,nM,CHEMBL751988,B,Binding affinity against cloned human Opioid receptor kappa 1 using [125I]-D-Pro10-dynorphin A[1-11] as radioligand,CHEMBL1133468,IC50,CCN(CC)C(=O)c1ccc(C(c2ccccc2)N2CCN(C)CC2)cc1
CHEMBL297605,CHEMBL237,Kappa opioid receptor,IC50,=,89.0,nM,CHEMBL753328,B,Inhibitory activity against Opioid receptor kappa1 binding to bovine striatal membrane,CHEMBL1128783,IC50,CN1CC[C@]23c4c5ccc(O)c4O[C@@]2(C)C(=O)CC[C@@]3(NC(=O)CSSCC(=O)N[C@@]23CCC(=O)[C@]4(C)Oc6c(O)ccc7c6[C@@]42CCN(C)C3C7)C1C5
CHEMBL129420,CHEMBL237,Kappa opioid receptor,IC50,=,7017.0,nM,CHEMBL751988,B,Binding affinity against cloned human Opioid receptor kappa 1 using [125I]-D-Pro10-dynorphin A[1-11] as radioligand,CHEMBL1133468,IC50,CCN(CC)C(=O)c1ccc(C(c2cccc3cccnc23)N2CCNCC2)cc1
CHEMBL2112649,CHEMBL237,Kappa opioid receptor,IC50,=,3967.0,nM,CHEMBL751988,B,Binding affinity against cloned human Opioid receptor kappa 1 using [125I]-D-Pro10-dynorphin A[1-11] as radioligand,CHEMBL1133468,IC50,CCN(CC)C(=O)c1ccc(C(c2ccc3cc[nH]c3c2)N2CCNCC2)cc1
CHEMBL127507,CHEMBL237,Kappa opioid receptor,IC50,=,4530.0,nM,CHEMBL751988,B,Binding affinity against cloned human Opioid receptor kappa 1 using [125I]-D-Pro10-dynorphin A[1-11] as radioligand,CHEMBL1133468,IC50,CCN(CC)C(=O)c1ccc(C(c2ccccc2)N2CCCNCC2)cc1
CHEMBL125734,CHEMBL237,Kappa opioid receptor,IC50,=,4906.0,nM,CHEMBL751988,B,Binding affinity against cloned human Opioid receptor kappa 1 using [125I]-D-Pro10-dynorphin A[1-11] as radioligand,CHEMBL1133468,IC50,CCN(CC)C(=O)c1ccc(C(c2cccc3ccccc23)N2CCNCC2)cc1
CHEMBL340724,CHEMBL237,Kappa opioid receptor,IC50,=,724.0,nM,CHEMBL751988,B,Binding affinity against cloned human Opioid receptor kappa 1 using [125I]-D-Pro10-dynorphin A[1-11] as radioligand,CHEMBL1133468,IC50,CCN(CC)C(=O)c1ccc(C(C2CCCCC2)N2CCNCC2)cc1
CHEMBL13470,CHEMBL237,Kappa opioid receptor,IC50,=,2480.0,nM,CHEMBL751988,B,Binding affinity against cloned human Opioid receptor kappa 1 using [125I]-D-Pro10-dynorphin A[1-11] as radioligand,CHEMBL1133468,IC50,C=CCN1C[C@H](C)N([C@H](c2ccc(C(=O)N(CC)CC)cc2)c2cccc(OC)c2)C[C@H]1C
CHEMBL278708,CHEMBL237,Kappa opioid receptor,IC50,=,8.4,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,Cc1cc(-c2cccn(C(CN3CCC(O)C3)c3ccccc3)c2=O)ccc1F
CHEMBL417260,CHEMBL237,Kappa opioid receptor,IC50,=,9.8,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,COc1cccc(OC)c1-c1cccn(C(CN2CCC(O)C2)c2ccccc2)c1=O
CHEMBL417623,CHEMBL237,Kappa opioid receptor,IC50,=,33.0,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,O=c1c(-c2ccc(F)cc2)cccn1C(CN1CCC(O)C1)c1ccccc1
CHEMBL279968,CHEMBL237,Kappa opioid receptor,IC50,=,47.1,nM,CHEMBL754272,B,Ability to induce 50% of maximal effect in rabbit vas deferens expressing Opioid receptor kappa 1,CHEMBL1122397,IC50,CC[C@@]12CCN(CC3CC3)C(C(=O)c3ccc(O)cc31)[C@@H]2C
CHEMBL15354,CHEMBL237,Kappa opioid receptor,IC50,=,320.0,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,COc1ccc(C(CN2CCCC2)n2cccc(-c3ccc(C(F)(F)F)cc3)c2=O)cc1
CHEMBL15114,CHEMBL237,Kappa opioid receptor,IC50,=,13.0,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,O=Cc1ccccc1-c1cccn(C(CN2CCC(O)C2)c2ccccc2)c1=O
CHEMBL15272,CHEMBL237,Kappa opioid receptor,IC50,=,38.0,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,CC(=O)c1ccc(-c2cccn(C(CN3CCC(O)C3)c3ccccc3)c2=O)s1
CHEMBL283552,CHEMBL237,Kappa opioid receptor,IC50,=,157.0,nM,CHEMBL754272,B,Ability to induce 50% of maximal effect in rabbit vas deferens expressing Opioid receptor kappa 1,CHEMBL1122397,IC50,O=C(Nc1cccc(C(F)(F)F)c1)c1cc(Br)cc(Br)c1O
CHEMBL15462,CHEMBL237,Kappa opioid receptor,IC50,=,57.0,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,O=C1COc2ccc(C(CN3CCCC3)n3cccc(-c4ccc(C(F)(F)F)cc4)c3=O)cc2N1
CHEMBL15264,CHEMBL237,Kappa opioid receptor,IC50,=,82.0,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,O=c1c(Nc2ccc(C(F)(F)F)cc2)cccn1C(CN1CCCC1)c1ccccc1
CHEMBL15428,CHEMBL237,Kappa opioid receptor,IC50,=,53.0,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,COc1ccc(Cl)cc1-c1cccn(C(CN2CCC(O)C2)c2ccccc2)c1=O
CHEMBL15257,CHEMBL237,Kappa opioid receptor,IC50,=,41.0,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,O=c1c(-c2ccc(Cl)cc2Cl)cncn1C(CN1CCCC1)c1ccccc1
CHEMBL14905,CHEMBL237,Kappa opioid receptor,IC50,=,94.0,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,Cc1ccc(Nc2cccn(C(CN3CCCC3)c3ccccc3)c2=O)cc1
CHEMBL275176,CHEMBL237,Kappa opioid receptor,IC50,=,6.9,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,COc1ccc(OC)c(-c2cccn(C(CN3CCC(O)C3)c3ccccc3)c2=O)c1
CHEMBL278268,CHEMBL237,Kappa opioid receptor,IC50,=,56.0,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,O=c1c(-c2ccccc2)cccn1C(CN1CCCC1)c1ccccc1
CHEMBL429211,CHEMBL237,Kappa opioid receptor,IC50,=,9.6,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,O=c1c(-c2cccc(CO)c2)cccn1C(CN1CCC(O)C1)c1ccccc1
CHEMBL280037,CHEMBL237,Kappa opioid receptor,IC50,=,8.7,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,O=c1c(-c2ccc(C(F)(F)F)cc2)cccn1C(CN1CCCC1)c1ccccc1
CHEMBL15498,CHEMBL237,Kappa opioid receptor,IC50,=,7.6,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,O=c1c(-c2ccc(OC(F)(F)F)cc2)cccn1C(CN1CCC(O)C1)c1ccccc1
CHEMBL14893,CHEMBL237,Kappa opioid receptor,IC50,=,465.0,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,O=c1c(-c2ccccc2)cccn1C(CN1CCC(O)C1)c1ccccc1
CHEMBL274686,CHEMBL237,Kappa opioid receptor,IC50,=,550.0,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,O=c1c(-c2ccccc2)ccnn1C(CN1CCCC1)c1ccccc1
CHEMBL14784,CHEMBL237,Kappa opioid receptor,IC50,=,330.0,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,Cc1ccc(C(C)Nc2cccn(C(CN3CCCC3)c3ccccc3)c2=O)cc1
CHEMBL277834,CHEMBL237,Kappa opioid receptor,IC50,=,3080.0,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,CCN(CC)c1ccc(C(CN2CCCC2)n2cccc(-c3ccc(C(F)(F)F)cc3)c2=O)cc1
CHEMBL15496,CHEMBL237,Kappa opioid receptor,IC50,=,5.5,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,COc1ccc(F)cc1-c1cccn(C(CN2CCC(O)C2)c2ccccc2)c1=O
CHEMBL14967,CHEMBL237,Kappa opioid receptor,IC50,=,1400.0,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,O=c1c(-c2ccc(C(F)(F)F)cc2)cccn1C(CN1C=CC=CC=N1)c1ccccc1
CHEMBL15034,CHEMBL237,Kappa opioid receptor,IC50,=,94.0,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,COc1ccccc1-c1cccn(C(CN2CCC(O)C2)c2ccccc2)c1=O
CHEMBL14969,CHEMBL237,Kappa opioid receptor,IC50,=,2.3,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,O=c1c(-c2ccc(Cl)cc2Cl)cccn1C(CN1CCCC1)c1ccccc1
CHEMBL440765,CHEMBL237,Kappa opioid receptor,IC50,=,2.0,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL14734,CHEMBL237,Kappa opioid receptor,IC50,=,2450.0,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,O=c1c(-c2ccccc2)nccn1C(CN1CCCC1)c1ccccc1
CHEMBL278268,CHEMBL237,Kappa opioid receptor,IC50,=,56.3,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,O=c1c(-c2ccccc2)cccn1C(CN1CCCC1)c1ccccc1
CHEMBL278062,CHEMBL237,Kappa opioid receptor,IC50,=,22.0,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,O=c1c(-c2cccc(OC(F)(F)F)c2)cccn1C(CN1CCC(O)C1)c1ccccc1
CHEMBL14653,CHEMBL237,Kappa opioid receptor,IC50,=,14.0,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,CC(=O)c1ccc(-c2cccn(C(CN3CCC(O)C3)c3ccccc3)c2=O)cc1
CHEMBL14893,CHEMBL237,Kappa opioid receptor,IC50,=,470.0,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,O=c1c(-c2ccccc2)cccn1C(CN1CCC(O)C1)c1ccccc1
CHEMBL46399,CHEMBL237,Kappa opioid receptor,IC50,=,121.0,nM,CHEMBL754272,B,Ability to induce 50% of maximal effect in rabbit vas deferens expressing Opioid receptor kappa 1,CHEMBL1122397,IC50,CC1C2Cc3ccc(O)cc3C1(C)CCN2CCc1ccccc1
CHEMBL14959,CHEMBL237,Kappa opioid receptor,IC50,=,25.0,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,Nc1cccc(-c2cccn(C(CN3CCC(O)C3)c3ccccc3)c2=O)c1
CHEMBL15429,CHEMBL237,Kappa opioid receptor,IC50,=,420.0,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,O=C(O)COc1cccc(C(CN2CCCC2)n2cccc(-c3ccc(C(F)(F)F)cc3)c2=O)c1
CHEMBL15005,CHEMBL237,Kappa opioid receptor,IC50,=,700.0,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,O=c1c(-c2ccc(C(F)(F)F)cc2)cccn1C(CN1CCOCC1)c1ccccc1
CHEMBL15027,CHEMBL237,Kappa opioid receptor,IC50,=,1760.0,nM,CHEMBL751852,B,Inhibition of [125I]-(D-Pro10)-Dynorphin A binding to human kappa opioid receptor from membranes of HEK293 cells,CHEMBL1136656,IC50,O=c1c(-c2ccccc2)cncn1C(CN1CCCC1)c1ccccc1
CHEMBL324297,CHEMBL237,Kappa opioid receptor,IC50,=,37.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,O=[N+]([O-])c1cc2c(cc1CN1CCC(n3c(O)nc4ccccc43)CC1)OCO2
CHEMBL324479,CHEMBL237,Kappa opioid receptor,IC50,=,7240.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,COC(=O)c1csc(S(=O)(=O)N2CCN(C(=O)c3ccccc3Nc3ccccc3)CC2)c1OC
CHEMBL114824,CHEMBL237,Kappa opioid receptor,IC50,=,1010.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,O=C(Cc1c[nH]c2ccc(Br)cc12)N1CCN(c2ccc([N+](=O)[O-])c3nonc23)CC1
CHEMBL116735,CHEMBL237,Kappa opioid receptor,IC50,=,2820.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,O=C(CCc1ccc(F)cc1)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
CHEMBL116463,CHEMBL237,Kappa opioid receptor,IC50,=,1980.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,N#Cc1ccc(CCOC(=O)NC2CCN(CCCC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
CHEMBL420863,CHEMBL237,Kappa opioid receptor,IC50,=,2.9,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,Cc1ccc2nc(O)n(C3CCN(Cc4cc5c(cc4Cl)OCO5)CC3)c2c1
CHEMBL326538,CHEMBL237,Kappa opioid receptor,IC50,=,1810.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,O=C(OCc1cccc(Oc2ccccc2)c1)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL290701,CHEMBL237,Kappa opioid receptor,IC50,=,9.98,nM,CHEMBL752146,B,Evaluation for the inhibition of kappa opioid binding to bovine striatal membranes by the affinity ligand 1 nM [3H]U-69593 radiolabeled opioid,CHEMBL1127738,IC50,O=C(CSSCC(=O)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL114379,CHEMBL237,Kappa opioid receptor,IC50,=,1.7,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,Oc1nc2ccccc2n1C1CCN(Cc2cc3c(cc2Cl)OCO3)CC1
CHEMBL115229,CHEMBL237,Kappa opioid receptor,IC50,=,311.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,O=[N+]([O-])c1cc2c(cc1CN1CC=C(n3c(O)nc4ccccc43)CC1)OCO2
CHEMBL325945,CHEMBL237,Kappa opioid receptor,IC50,=,32.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,O=c1[nH]c2ccccc2n(C2CCN(Cc3cc4c(cc3Cl)OCO4)CC2)c1=O
CHEMBL543876,CHEMBL237,Kappa opioid receptor,IC50,=,2140.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,Cl.Cl.Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
CHEMBL606710,CHEMBL237,Kappa opioid receptor,IC50,=,41.1,nM,CHEMBL752145,B,Evaluation for the inhibition of kappa opioid binding to bovine striatal membranes by the affinity ligand 1 nM [3H]U-69593,CHEMBL1127738,IC50,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(NC(=O)CS)[C@H]1C5
CHEMBL332697,CHEMBL237,Kappa opioid receptor,IC50,=,4030.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,COc1cc(/C=C/C(=O)N2CCC(n3c(O)nc4ccccc43)CC2)c([N+](=O)[O-])cc1OC
CHEMBL3215749,CHEMBL237,Kappa opioid receptor,IC50,=,1770.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,Cl.Cl.Fc1ccc(C(OCCN2CCN(C/C=C/c3ccccc3)CC2)c2ccc(F)cc2)cc1
CHEMBL333843,CHEMBL237,Kappa opioid receptor,IC50,=,1740.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,O=C(NCCCn1c(O)nc2ccccc21)OCc1cc2c(cc1Cl)OCO2
CHEMBL113956,CHEMBL237,Kappa opioid receptor,IC50,=,4120.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,CCOc1ccc(CCNC(=O)N2CCN(CCCC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
CHEMBL41098,CHEMBL237,Kappa opioid receptor,IC50,=,40.5,nM,CHEMBL752149,B,"Evaluation for the inhibition of kappa opioid binding to bovine striatal membranes by the affinity ligand 1 nM [3H]-U-69,593 radiolabeled opioid",CHEMBL1127738,IC50,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(NC(=O)CSSCC(=O)N[C@@]23CCC(=O)[C@@H]4Oc6c(O)ccc7c6[C@@]42CCN(C)[C@@H]3C7)[C@H]1C5
CHEMBL115280,CHEMBL237,Kappa opioid receptor,IC50,=,101.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,O=C1NCN(c2ccccc2)C12CCN(Cc1cccc(Oc3ccccc3)c1)CC2
CHEMBL115076,CHEMBL237,Kappa opioid receptor,IC50,=,2145.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,O=C(OCc1cc2c(cc1Cl)OCO2)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL325874,CHEMBL237,Kappa opioid receptor,IC50,=,3550.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,O=C(OCc1cccnc1)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL114825,CHEMBL237,Kappa opioid receptor,IC50,=,333.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,CNC(=O)CN1CN(c2ccccc2)C2(CCN(C(=O)OCc3cc4c(cc3Cl)OCO4)CC2)C1=O
CHEMBL326320,CHEMBL237,Kappa opioid receptor,IC50,=,797.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,Cc1ccc2nc(O)n(C3CCN(C(=O)OCc4cc5c(cc4Cl)OCO5)CC3)c2c1
CHEMBL325750,CHEMBL237,Kappa opioid receptor,IC50,=,104.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,O=C1NCN(c2ccccc2)C12CCN(Cc1ccc3nsnc3c1)CC2
CHEMBL117537,CHEMBL237,Kappa opioid receptor,IC50,=,2150.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,O=C(CCCc1ccccc1)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
CHEMBL420500,CHEMBL237,Kappa opioid receptor,IC50,=,2235.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,O=C(OCc1ccc2c(c1)OCO2)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL325674,CHEMBL237,Kappa opioid receptor,IC50,=,617.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,O=C(OC1CCc2ccccc21)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL115222,CHEMBL237,Kappa opioid receptor,IC50,=,2.1,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,CNC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cc4c(cc3Cl)OCO4)CC2)C1=O
CHEMBL420499,CHEMBL237,Kappa opioid receptor,IC50,=,3580.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,COc1ccc(CN2CCN(C(=O)CCn3cc(C)c4ccccc43)CC2)cc1OCc1ccccc1
CHEMBL114204,CHEMBL237,Kappa opioid receptor,IC50,=,1320.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,COc1cc(CC(=O)N2CCC(n3c(O)nc4ccccc43)CC2)c([N+](=O)[O-])cc1OC
CHEMBL114280,CHEMBL237,Kappa opioid receptor,IC50,=,507.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,Oc1nc2ccccc2n1CCCNCc1cc2c(cc1Cl)OCO2
CHEMBL111918,CHEMBL237,Kappa opioid receptor,IC50,=,6570.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,O=C(O)CN1CN(c2ccccc2)C2(CCN(C(=O)OCc3cc4c(cc3Cl)OCO4)CC2)C1=O
CHEMBL325516,CHEMBL237,Kappa opioid receptor,IC50,=,4230.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,O=C(OCCc1ccc(F)cc1)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
CHEMBL114613,CHEMBL237,Kappa opioid receptor,IC50,=,2200.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,COc1ccc(SCCC(=O)N2CCN(Cc3cccc(Oc4ccc(Cl)cc4)c3)CC2)cc1
CHEMBL324170,CHEMBL237,Kappa opioid receptor,IC50,=,5070.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,O=C(OCc1cc2c(cc1[N+](=O)[O-])OCO2)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL114299,CHEMBL237,Kappa opioid receptor,IC50,=,1060.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,O=C(OCc1cc2c(cc1Cl)OCO2)N1CCC(n2c(=O)c(=O)[nH]c3ccccc32)CC1
CHEMBL114484,CHEMBL237,Kappa opioid receptor,IC50,=,270.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,Cc1ccc(CN2CCC(n3c(O)nc4ccccc43)CC2)c(Cl)c1
CHEMBL1423,CHEMBL237,Kappa opioid receptor,IC50,=,990.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
CHEMBL113811,CHEMBL237,Kappa opioid receptor,IC50,=,2280.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,O=C(NCc1ccc2c(c1)OCO2)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL115652,CHEMBL237,Kappa opioid receptor,IC50,=,5.7,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,O=C1NCN(c2ccccc2)C12CCN(Cc1cc3c(cc1Cl)OCO3)CC2
CHEMBL326962,CHEMBL237,Kappa opioid receptor,IC50,=,56.1,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,O=C1NCN(c2ccccc2)C12CCN(Cc1ccc3c(c1)OCO3)CC2
CHEMBL552659,CHEMBL237,Kappa opioid receptor,IC50,=,9480.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,Cl.Cl.Fc1ccc(C(c2ccc(F)cc2)N2CCN(C/C=C/c3ccccc3)CC2)cc1
CHEMBL115444,CHEMBL237,Kappa opioid receptor,IC50,=,284.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,O=C(OCc1cc2c(cc1Cl)OCO2)N1CCC(n2c(O)nc3ccccc32)CC1
CHEMBL324257,CHEMBL237,Kappa opioid receptor,IC50,=,1480.0,nM,CHEMBL882039,B,Binding affinity against opioid receptor kappa 1 by using [3H]U-69593 as radioligand,CHEMBL1134625,IC50,O=C(OCc1ccc2nsnc2c1)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL2114982,CHEMBL237,Kappa opioid receptor,IC50,=,9440.0,nM,CHEMBL756112,B,Compound was evaluated for binding affinity towards Opioid receptor kappa 1 by displacing 125 I-DPDYN,CHEMBL1132761,IC50,COc1ccc2c(c1)CN(C(=O)[C@@H](N)Cc1c(C)cc(O)cc1C)[C@H](C(=O)O)C2
CHEMBL421520,CHEMBL237,Kappa opioid receptor,IC50,=,2.8,nM,CHEMBL751990,B,Binding affinity at cloned human opioid receptor kappa 1,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1C/N=C(/S)NC(C)(C)C
CHEMBL44732,CHEMBL237,Kappa opioid receptor,IC50,=,9290.0,nM,CHEMBL756112,B,Compound was evaluated for binding affinity towards Opioid receptor kappa 1 by displacing 125 I-DPDYN,CHEMBL1132761,IC50,Cc1cc(O)cc(C)c1CC(N)C(=O)N1Cc2cc(O)ccc2C[C@H]1C(=O)O
CHEMBL2114980,CHEMBL237,Kappa opioid receptor,IC50,=,5740.0,nM,CHEMBL756112,B,Compound was evaluated for binding affinity towards Opioid receptor kappa 1 by displacing 125 I-DPDYN,CHEMBL1132761,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2cc(-c3ccccc3)ccc2C[C@H]1C(=O)O
CHEMBL76573,CHEMBL237,Kappa opioid receptor,IC50,=,1.5,nM,CHEMBL751990,B,Binding affinity at cloned human opioid receptor kappa 1,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1CNCC(C)(C)C
CHEMBL297452,CHEMBL237,Kappa opioid receptor,IC50,=,9000.0,nM,CHEMBL756112,B,Compound was evaluated for binding affinity towards Opioid receptor kappa 1 by displacing 125 I-DPDYN,CHEMBL1132761,IC50,COc1ccc2c(c1)CN(C(=O)C(N)Cc1c(C)cc(O)cc1C)[C@H](C(=O)O)C2
CHEMBL80464,CHEMBL237,Kappa opioid receptor,IC50,=,793.0,nM,CHEMBL751990,B,Binding affinity at cloned human opioid receptor kappa 1,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1CN(C)C
CHEMBL2114978,CHEMBL237,Kappa opioid receptor,IC50,=,7560.0,nM,CHEMBL756112,B,Compound was evaluated for binding affinity towards Opioid receptor kappa 1 by displacing 125 I-DPDYN,CHEMBL1132761,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2cc(-c3ccc(F)cc3)ccc2C[C@H]1C(=O)O
CHEMBL75802,CHEMBL237,Kappa opioid receptor,IC50,=,51.4,nM,CHEMBL751990,B,Binding affinity at cloned human opioid receptor kappa 1,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1C/N=C(/S)Nc1ccccc1
CHEMBL418080,CHEMBL237,Kappa opioid receptor,IC50,=,2730.0,nM,CHEMBL756112,B,Compound was evaluated for binding affinity towards Opioid receptor kappa 1 by displacing 125 I-DPDYN,CHEMBL1132761,IC50,Cc1cc(O)cc(C)c1CC(N)C(=O)N1Cc2cc(-c3ccsc3)ccc2C[C@H]1C(=O)O
CHEMBL80319,CHEMBL237,Kappa opioid receptor,IC50,=,1450.0,nM,CHEMBL751990,B,Binding affinity at cloned human opioid receptor kappa 1,CHEMBL1134689,IC50,C=CCOC[C@@H]1Cc2ccccc2CN1C(=O)[C@@H](N)Cc1c(C)cc(O)cc1C
CHEMBL76846,CHEMBL237,Kappa opioid receptor,IC50,=,1070.0,nM,CHEMBL751990,B,Binding affinity at cloned human opioid receptor kappa 1,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1CN=[N+]=[N-]
CHEMBL309236,CHEMBL237,Kappa opioid receptor,IC50,=,345.0,nM,CHEMBL751990,B,Binding affinity at cloned human opioid receptor kappa 1,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1CN=C(N)N
CHEMBL309307,CHEMBL237,Kappa opioid receptor,IC50,=,307.0,nM,CHEMBL751990,B,Binding affinity at cloned human opioid receptor kappa 1,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1CNC(=O)c1ccccc1
CHEMBL571492,CHEMBL237,Kappa opioid receptor,IC50,=,37503.0,nM,CHEMBL756112,B,Compound was evaluated for binding affinity towards Opioid receptor kappa 1 by displacing 125 I-DPDYN,CHEMBL1132761,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O
CHEMBL307889,CHEMBL237,Kappa opioid receptor,IC50,=,394.0,nM,CHEMBL751990,B,Binding affinity at cloned human opioid receptor kappa 1,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1CNC(=O)C(C)(C)C
CHEMBL309783,CHEMBL237,Kappa opioid receptor,IC50,=,321.0,nM,CHEMBL751990,B,Binding affinity at cloned human opioid receptor kappa 1,CHEMBL1134689,IC50,CCNC(=O)NC[C@@H]1Cc2ccccc2CN1C(=O)[C@@H](N)Cc1c(C)cc(O)cc1C
CHEMBL317956,CHEMBL237,Kappa opioid receptor,IC50,=,7330.0,nM,CHEMBL751990,B,Binding affinity at cloned human opioid receptor kappa 1,CHEMBL1134689,IC50,CC(C)[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)NCC(N)=O)C(C)C
CHEMBL80823,CHEMBL237,Kappa opioid receptor,IC50,=,9380.0,nM,CHEMBL751990,B,Binding affinity at cloned human opioid receptor kappa 1,CHEMBL1134689,IC50,CC(=O)NC[C@@H]1Cc2ccccc2CN1C(=O)[C@@H](N)Cc1c(C)cc(O)cc1C
CHEMBL416788,CHEMBL237,Kappa opioid receptor,IC50,=,37500.0,nM,CHEMBL751990,B,Binding affinity at cloned human opioid receptor kappa 1,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C(NC(=O)C1Cc2ccccc2CN1)C(=O)O
CHEMBL80463,CHEMBL237,Kappa opioid receptor,IC50,=,4.8,nM,CHEMBL751990,B,Binding affinity at cloned human opioid receptor kappa 1,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1CNC(=O)Nc1ccccc1
CHEMBL312792,CHEMBL237,Kappa opioid receptor,IC50,=,3100.0,nM,CHEMBL751990,B,Binding affinity at cloned human opioid receptor kappa 1,CHEMBL1134689,IC50,CC(=O)OC[C@@H]1Cc2ccccc2CN1C(=O)[C@@H](N)Cc1c(C)cc(O)cc1C
CHEMBL310146,CHEMBL237,Kappa opioid receptor,IC50,=,996.0,nM,CHEMBL751990,B,Binding affinity at cloned human opioid receptor kappa 1,CHEMBL1134689,IC50,CC(=N)NC[C@@H]1Cc2ccccc2CN1C(=O)[C@@H](N)Cc1c(C)cc(O)cc1C
CHEMBL80197,CHEMBL237,Kappa opioid receptor,IC50,=,521.0,nM,CHEMBL751990,B,Binding affinity at cloned human opioid receptor kappa 1,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1CN
CHEMBL77196,CHEMBL237,Kappa opioid receptor,IC50,=,764.0,nM,CHEMBL751990,B,Binding affinity at cloned human opioid receptor kappa 1,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1C
CHEMBL76089,CHEMBL237,Kappa opioid receptor,IC50,=,64.6,nM,CHEMBL751990,B,Binding affinity at cloned human opioid receptor kappa 1,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1COCc1ccccc1
CHEMBL77001,CHEMBL237,Kappa opioid receptor,IC50,=,1.5,nM,CHEMBL751990,B,Binding affinity at cloned human opioid receptor kappa 1,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1CNCc1ccccc1
CHEMBL76493,CHEMBL237,Kappa opioid receptor,IC50,=,2510.0,nM,CHEMBL751990,B,Binding affinity at cloned human opioid receptor kappa 1,CHEMBL1134689,IC50,COC[C@@H]1Cc2ccccc2CN1C(=O)[C@@H](N)Cc1c(C)cc(O)cc1C
CHEMBL310842,CHEMBL237,Kappa opioid receptor,IC50,=,1.3,nM,CHEMBL751990,B,Binding affinity at cloned human opioid receptor kappa 1,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1CNC(=O)NC(C)(C)C
CHEMBL77804,CHEMBL237,Kappa opioid receptor,IC50,=,4.1,nM,CHEMBL751990,B,Binding affinity at cloned human opioid receptor kappa 1,CHEMBL1134689,IC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1CNC(=O)NC12CC3CC(CC(C3)C1)C2
CHEMBL121963,CHEMBL237,Kappa opioid receptor,IC50,=,425.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,COc1ccc(C[C@@H]2CN3C(=NC[C@@H]3C)N2CC2CCC(C)CC2)cc1
CHEMBL127814,CHEMBL237,Kappa opioid receptor,IC50,=,1523.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,COc1ccc(C[C@H]2CN3C(=NC[C@@H]3C)N2C(C)C23CC4CC(CC(C4)C2)C3)cc1
CHEMBL125137,CHEMBL237,Kappa opioid receptor,IC50,=,4424.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,C[C@H]1CN=C2N(CCC3CC4CCC3C4)[C@@H](C3CCCCC3)CN21
CHEMBL125276,CHEMBL237,Kappa opioid receptor,IC50,=,4482.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,C1CCC(CCCN2C3=NC[C@H](C4CCCCC4)N3C[C@@H]2C2CCCCC2)CC1
CHEMBL340710,CHEMBL237,Kappa opioid receptor,IC50,=,924.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,COc1ccc(C[C@@H]2CN3C(=NC[C@@H]3C3CCCCC3)N2CCC2CC3CCC2C3)cc1
CHEMBL339254,CHEMBL237,Kappa opioid receptor,IC50,=,85.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,COc1ccc(C[C@@H]2CN3C(=NC[C@@H]3C)N2CCC2CC3CCC2C3)cc1
CHEMBL332830,CHEMBL237,Kappa opioid receptor,IC50,=,2479.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,C[C@H]1CN=C2N(CCCC3CCCCC3)[C@@H](C3CCCCC3)CN21
CHEMBL125185,CHEMBL237,Kappa opioid receptor,IC50,=,276.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,COc1ccc(C[C@@H]2CN3C(=NC[C@H]3C3CCCCC3)N2CCC2CC3CCC2C3)cc1
CHEMBL121935,CHEMBL237,Kappa opioid receptor,IC50,=,524.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,C1CCC([C@H]2CN3C(=NC[C@H]3C3CCCCC3)N2CCC2CC3CCC2C3)CC1
CHEMBL127485,CHEMBL237,Kappa opioid receptor,IC50,=,1492.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,CC(N1C2=NC[C@H](C3CCCCC3)N2C[C@@H]1C1CCCCC1)C12CC3CC(CC(C3)C1)C2
CHEMBL122342,CHEMBL237,Kappa opioid receptor,IC50,=,2309.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,CC(C)C[C@@H]1CN2C(=NC[C@@H]2C)N1CCC1CC2CCC1C2
CHEMBL127486,CHEMBL237,Kappa opioid receptor,IC50,=,1206.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,CC(C)C[C@@H]1CN2C(=NC[C@@H]2C2CCCCC2)N1C(C)C12CC3CC(CC(C3)C1)C2
CHEMBL125494,CHEMBL237,Kappa opioid receptor,IC50,=,5026.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,COc1ccc(C[C@@H]2CN3C(=NC[C@@H]3C3CCCCC3)N2CCCC2CCCCC2)cc1
CHEMBL421432,CHEMBL237,Kappa opioid receptor,IC50,=,369.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,COc1ccc(C[C@@H]2CN3C(=NC[C@@H]3C3CCCCC3)N2CC2CCC(C)CC2)cc1
CHEMBL125607,CHEMBL237,Kappa opioid receptor,IC50,=,738.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,CC(C)C[C@@H]1CN2C(=NC[C@H]2C2CCCCC2)N1CC1CCC(C)CC1
CHEMBL333321,CHEMBL237,Kappa opioid receptor,IC50,=,1767.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,CC(C)C[C@@H]1CN2C(=NC[C@H]2C2CCCCC2)N1CCCC1CCCCC1
CHEMBL126169,CHEMBL237,Kappa opioid receptor,IC50,=,5061.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,CC1CCC(CN2C3=NC[C@H](C)N3C[C@@H]2C2CCCCC2)CC1
CHEMBL435414,CHEMBL237,Kappa opioid receptor,IC50,=,365.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,CC1CCC(CN2C3=NC[C@H](C4CCCCC4)N3C[C@@H]2C2CCCCC2)CC1
CHEMBL125326,CHEMBL237,Kappa opioid receptor,IC50,=,6477.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,CC(C)C[C@@H]1CN2C(=NC[C@@H]2C)N1CC1CCC(C)CC1
CHEMBL339697,CHEMBL237,Kappa opioid receptor,IC50,=,3744.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,CC(C)C[C@@H]1CN2C(=NC[C@@H]2C2CCCCC2)N1CCCC1CCCCC1
CHEMBL125875,CHEMBL237,Kappa opioid receptor,IC50,=,999.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,CC(C)C[C@@H]1CN2C(=NC[C@@H]2C2CCCCC2)N1CC1CCC(C)CC1
CHEMBL122092,CHEMBL237,Kappa opioid receptor,IC50,=,1941.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,CC(N1C2=NC[C@H](C)N2C[C@@H]1C1CCCCC1)C12CC3CC(CC(C3)C1)C2
CHEMBL123902,CHEMBL237,Kappa opioid receptor,IC50,=,5436.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,CC(C)C[C@@H]1CN2C(=NC[C@@H]2C)N1CCCC1CCCCC1
CHEMBL331764,CHEMBL237,Kappa opioid receptor,IC50,=,3456.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,COc1ccc(C[C@H]2CN3C(=NC[C@H]3C3CCCCC3)N2CCCC2CCCCC2)cc1
CHEMBL122906,CHEMBL237,Kappa opioid receptor,IC50,=,336.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,COc1ccc(C[C@H]2CN3C(=NC[C@@H]3C3CCCCC3)N2CC2CCC(C)CC2)cc1
CHEMBL332349,CHEMBL237,Kappa opioid receptor,IC50,=,362.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,COc1ccc(C[C@@H]2CN3C(=NC[C@H]3C3CCCCC3)N2CC2CCC(C)CC2)cc1
CHEMBL340110,CHEMBL237,Kappa opioid receptor,IC50,=,804.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,COc1ccc(C[C@H]2CN3C(=NC[C@H]3C3CCCCC3)N2CC2CCC(C)CC2)cc1
CHEMBL339910,CHEMBL237,Kappa opioid receptor,IC50,=,547.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,COc1ccc(C[C@@H]2CN3C(=NC[C@H]3C3CCCCC3)N2CCCC2CCCCC2)cc1
CHEMBL338799,CHEMBL237,Kappa opioid receptor,IC50,=,238.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,COc1ccc(C[C@@H]2CN3C(=NC[C@@H]3C)N2C(C)C23CC4CC(CC(C4)C2)C3)cc1
CHEMBL339710,CHEMBL237,Kappa opioid receptor,IC50,=,827.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,CC(C)C[C@@H]1CN2C(=NC[C@@H]2C2CCCCC2)N1CCC1CC2CCC1C2
CHEMBL124028,CHEMBL237,Kappa opioid receptor,IC50,=,3641.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,CC(C)C[C@@H]1CN2C(=NC[C@@H]2C)N1C(C)C12CC3CC(CC(C3)C1)C2
CHEMBL333689,CHEMBL237,Kappa opioid receptor,IC50,=,359.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,CC(C)C[C@@H]1CN2C(=NC[C@H]2C2CCCCC2)N1CCC1CC2CCC1C2
CHEMBL125424,CHEMBL237,Kappa opioid receptor,IC50,=,3872.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,COc1ccc(C[C@H]2CN3C(=NC[C@@H]3C3CCCCC3)N2CCCC2CCCCC2)cc1
CHEMBL341524,CHEMBL237,Kappa opioid receptor,IC50,=,1140.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,CC1CCC(CN2C3=NC[C@@H](C4CCCCC4)N3C[C@@H]2C2CCCCC2)CC1
CHEMBL431660,CHEMBL237,Kappa opioid receptor,IC50,=,37.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,COc1ccc(C[C@H]2CN3C(=NC[C@@H]3C)N2CCCC2CCCCC2)cc1
CHEMBL123023,CHEMBL237,Kappa opioid receptor,IC50,=,185.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,COc1ccc(C[C@H]2CN3C(=NC[C@@H]3C)N2CCC2CC3CCC2C3)cc1
CHEMBL333018,CHEMBL237,Kappa opioid receptor,IC50,=,219.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,COc1ccc(C[C@H]2CN3C(=NC[C@H]3C3CCCCC3)N2CCC2CC3CCC2C3)cc1
CHEMBL339031,CHEMBL237,Kappa opioid receptor,IC50,=,1568.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,COc1ccc(C[C@H]2CN3C(=NC[C@@H]3C)N2CC2CCC(C)CC2)cc1
CHEMBL125130,CHEMBL237,Kappa opioid receptor,IC50,=,1747.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,CC(C)C[C@@H]1CN2C(=NC[C@H]2C2CCCCC2)N1C(C)C12CC3CC(CC(C3)C1)C2
CHEMBL337992,CHEMBL237,Kappa opioid receptor,IC50,=,341.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,COc1ccc(C[C@@H]2CN3C(=NC[C@H]3C3CCCCC3)N2C(C)C23CC4CC(CC(C4)C2)C3)cc1
CHEMBL123097,CHEMBL237,Kappa opioid receptor,IC50,=,502.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,COc1ccc(C[C@@H]2CN3C(=NC[C@@H]3C)N2CCCC2CCCCC2)cc1
CHEMBL339278,CHEMBL237,Kappa opioid receptor,IC50,=,560.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,C1CCC([C@H]2CN3C(=NC[C@@H]3C3CCCCC3)N2CCC2CC3CCC2C3)CC1
CHEMBL121933,CHEMBL237,Kappa opioid receptor,IC50,=,4923.0,nM,CHEMBL756114,B,Inhibitory activity for kappa opioid receptor,CHEMBL1132386,IC50,COc1ccc(C[C@H]2CN3C(=NC[C@@H]3C3CCCCC3)N2C(C)C23CC4CC(CC(C4)C2)C3)cc1
CHEMBL610885,CHEMBL237,Kappa opioid receptor,IC50,=,39.1,nM,CHEMBL752147,B,Binding affinity against kappa opioid receptor from calf frontal cortex.,CHEMBL1126857,IC50,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)/C=C/c5ccc([N+](=O)[O-])cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL108406,CHEMBL237,Kappa opioid receptor,IC50,=,126.0,nM,CHEMBL752147,B,Binding affinity against kappa opioid receptor from calf frontal cortex.,CHEMBL1126857,IC50,C[C@@]12Oc3c(O)ccc4c3C13CCN(CC1CC1)C(C4)[C@]3(NC(=O)/C=C/c1ccc([N+](=O)[O-])cc1)CCC2=O
CHEMBL106876,CHEMBL237,Kappa opioid receptor,IC50,=,27.2,nM,CHEMBL752147,B,Binding affinity against kappa opioid receptor from calf frontal cortex.,CHEMBL1126857,IC50,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)/C=C/c5ccc([N+](=O)[O-])cc5)C(C2)N(C)CCC314
CHEMBL107164,CHEMBL237,Kappa opioid receptor,IC50,=,116.0,nM,CHEMBL752147,B,Binding affinity against kappa opioid receptor from calf frontal cortex.,CHEMBL1126857,IC50,CN1CCC23c4c5ccc(O)c4O[C@@]2(C)C(=O)CC[C@@]3(NC(=O)/C=C/c2ccc([N+](=O)[O-])cc2)C1C5
CHEMBL107157,CHEMBL237,Kappa opioid receptor,IC50,=,5.01,nM,CHEMBL752147,B,Binding affinity against kappa opioid receptor from calf frontal cortex.,CHEMBL1126857,IC50,COc1ccc2c3c1O[C@H]1C(=O)C=C[C@@]4(NC(=O)/C=C/c5ccc([N+](=O)[O-])cc5)C(C2)N(CC2CC2)CCC314
CHEMBL108794,CHEMBL237,Kappa opioid receptor,IC50,=,68.0,nM,CHEMBL752147,B,Binding affinity against kappa opioid receptor from calf frontal cortex.,CHEMBL1126857,IC50,COc1ccc2c3c1O[C@H]1C(=O)C=C[C@@]4(NC(=O)/C=C/c5ccc([N+](=O)[O-])cc5)C(C2)N(C)CCC314
CHEMBL106189,CHEMBL237,Kappa opioid receptor,IC50,=,25.5,nM,CHEMBL752147,B,Binding affinity against kappa opioid receptor from calf frontal cortex.,CHEMBL1126857,IC50,C[C@@]12Oc3c(O)ccc4c3C13CCN(CC1CC1)C(C4)[C@]3(NC(=O)/C=C/c1ccc([N+](=O)[O-])cc1)C=CC2=O
CHEMBL413258,CHEMBL237,Kappa opioid receptor,IC50,=,274.0,nM,CHEMBL752147,B,Binding affinity against kappa opioid receptor from calf frontal cortex.,CHEMBL1126857,IC50,COc1ccc2c3c1O[C@@]1(C)C(=O)C=C[C@@]4(NC(=O)/C=C/c5ccc([N+](=O)[O-])cc5)C(C2)N(CC2CC2)CCC314
CHEMBL317035,CHEMBL237,Kappa opioid receptor,IC50,=,10.8,nM,CHEMBL752147,B,Binding affinity against kappa opioid receptor from calf frontal cortex.,CHEMBL1126857,IC50,O=C(/C=C/c1ccc([N+](=O)[O-])cc1)N[C@@]12C=CC(=O)[C@@H]3Oc4c(O)ccc5c4C31CCN(CC1CC1)C2C5
CHEMBL611136,CHEMBL237,Kappa opioid receptor,IC50,=,12.1,nM,CHEMBL752147,B,Binding affinity against kappa opioid receptor from calf frontal cortex.,CHEMBL1126857,IC50,O=C(/C=C/c1ccc([N+](=O)[O-])cc1)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL607068,CHEMBL237,Kappa opioid receptor,IC50,=,6.6,nM,CHEMBL752147,B,Binding affinity against kappa opioid receptor from calf frontal cortex.,CHEMBL1126857,IC50,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(NC(=O)/C=C/c2ccc([N+](=O)[O-])cc2)[C@H]1C5
CHEMBL110238,CHEMBL237,Kappa opioid receptor,IC50,=,4.5,nM,CHEMBL752147,B,Binding affinity against kappa opioid receptor from calf frontal cortex.,CHEMBL1126857,IC50,CN1CCC23c4c5ccc(O)c4O[C@H]2C(=O)C=C[C@@]3(NC(=O)/C=C/c2ccc([N+](=O)[O-])cc2)C1C5
CHEMBL110666,CHEMBL237,Kappa opioid receptor,IC50,=,171.0,nM,CHEMBL752147,B,Binding affinity against kappa opioid receptor from calf frontal cortex.,CHEMBL1126857,IC50,COc1ccc2c3c1O[C@@]1(C)C(=O)C=C[C@@]4(NC(=O)/C=C/c5ccc([N+](=O)[O-])cc5)C(C2)N(C)CCC314
CHEMBL105827,CHEMBL237,Kappa opioid receptor,IC50,=,162.0,nM,CHEMBL752147,B,Binding affinity against kappa opioid receptor from calf frontal cortex.,CHEMBL1126857,IC50,C[C@@]12Oc3c(O)ccc4c3C13CCN(CC1CC1)C(C4)[C@]3(NC(=O)CCc1ccc([N+](=O)[O-])cc1)CCC2=O
CHEMBL323430,CHEMBL237,Kappa opioid receptor,IC50,=,184.0,nM,CHEMBL752147,B,Binding affinity against kappa opioid receptor from calf frontal cortex.,CHEMBL1126857,IC50,CN1CCC23c4c5ccc(O)c4O[C@@]2(C)C(=O)C=C[C@@]3(NC(=O)/C=C/c2ccc([N+](=O)[O-])cc2)C1C5
CHEMBL14680,CHEMBL237,Kappa opioid receptor,IC50,=,6.29,nM,CHEMBL750075,B,Compound was tested for binding activity against Opioid receptor kappa 1 in bovine striatal membranes using 1 nM [3H]U-69593 as the radioligand.,CHEMBL1128914,IC50,O=C(CSSCC(=O)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CCC1)[C@@H]2C5)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CCC1)[C@@H]2C5
CHEMBL434944,CHEMBL237,Kappa opioid receptor,IC50,=,640.0,nM,CHEMBL880422,B,"Binding affinity against human opioid receptor kappa 1 expressed in HEK293 cells using 3H-U69,593 radioligand",CHEMBL1143642,IC50,COC(=O)CN1C(=O)C2(CCN(CC3CCCCCCC3)CC2)c2ccccc21
CHEMBL373190,CHEMBL237,Kappa opioid receptor,IC50,=,2640.0,nM,CHEMBL880422,B,"Binding affinity against human opioid receptor kappa 1 expressed in HEK293 cells using 3H-U69,593 radioligand",CHEMBL1143642,IC50,CC(=O)OCCN1C(=O)C2(CCN(CC3CCCCCCC3)CC2)c2ccccc21
CHEMBL199248,CHEMBL237,Kappa opioid receptor,IC50,=,430.0,nM,CHEMBL880422,B,"Binding affinity against human opioid receptor kappa 1 expressed in HEK293 cells using 3H-U69,593 radioligand",CHEMBL1143642,IC50,O=C1Nc2ccccc2C12CCN(CC1CCCCCCC1)CC2
CHEMBL372184,CHEMBL237,Kappa opioid receptor,IC50,=,1100.0,nM,CHEMBL880422,B,"Binding affinity against human opioid receptor kappa 1 expressed in HEK293 cells using 3H-U69,593 radioligand",CHEMBL1143642,IC50,O=C1N(Cc2ccccc2)c2ccccc2C12CCN(CC1CCCCCCC1)CC2
CHEMBL198867,CHEMBL237,Kappa opioid receptor,IC50,=,480.0,nM,CHEMBL880422,B,"Binding affinity against human opioid receptor kappa 1 expressed in HEK293 cells using 3H-U69,593 radioligand",CHEMBL1143642,IC50,O=C1N(CC2CO2)c2ccccc2C12CCN(CC1CCCCCCC1)CC2
CHEMBL370613,CHEMBL237,Kappa opioid receptor,IC50,=,100.0,nM,CHEMBL880422,B,"Binding affinity against human opioid receptor kappa 1 expressed in HEK293 cells using 3H-U69,593 radioligand",CHEMBL1143642,IC50,O=C1N(CC(O)CNCCN2CCOCC2)c2ccccc2C12CCN(CC1CCCCCCC1)CC2
CHEMBL198604,CHEMBL237,Kappa opioid receptor,IC50,=,220.0,nM,CHEMBL880422,B,"Binding affinity against human opioid receptor kappa 1 expressed in HEK293 cells using 3H-U69,593 radioligand",CHEMBL1143642,IC50,CCN(Cc1ccc(C)cc1)CC(O)CN1C(=O)C2(CCN(CC3CCCCCCC3)CC2)c2ccccc21
CHEMBL381429,CHEMBL237,Kappa opioid receptor,IC50,=,1220.0,nM,CHEMBL880422,B,"Binding affinity against human opioid receptor kappa 1 expressed in HEK293 cells using 3H-U69,593 radioligand",CHEMBL1143642,IC50,COc1ccc2c(c1)N(C)C(=O)C21CCN(CC2CCCCCCC2)CC1
CHEMBL434179,CHEMBL237,Kappa opioid receptor,IC50,=,120.0,nM,CHEMBL880422,B,"Binding affinity against human opioid receptor kappa 1 expressed in HEK293 cells using 3H-U69,593 radioligand",CHEMBL1143642,IC50,CN1C(=O)C2(CCN(CC3CCCCCCC3)CC2)c2ccc(O)cc21
CHEMBL194200,CHEMBL237,Kappa opioid receptor,IC50,=,930.0,nM,CHEMBL880422,B,"Binding affinity against human opioid receptor kappa 1 expressed in HEK293 cells using 3H-U69,593 radioligand",CHEMBL1143642,IC50,CN1C(=O)C2(CCN(CC3CCCCCCC3)CC2)c2ccccc21
CHEMBL199011,CHEMBL237,Kappa opioid receptor,IC50,=,2380.0,nM,CHEMBL880422,B,"Binding affinity against human opioid receptor kappa 1 expressed in HEK293 cells using 3H-U69,593 radioligand",CHEMBL1143642,IC50,Cc1ccc2c(c1)N(C)C(=O)C21CCN(CC2CCCCCCC2)CC1
CHEMBL369945,CHEMBL237,Kappa opioid receptor,IC50,=,540.0,nM,CHEMBL880422,B,"Binding affinity against human opioid receptor kappa 1 expressed in HEK293 cells using 3H-U69,593 radioligand",CHEMBL1143642,IC50,Cc1ccc2c(c1)C1(CCN(CC3CCCCCCC3)CC1)C(=O)N2C
CHEMBL437505,CHEMBL237,Kappa opioid receptor,IC50,=,560.0,nM,CHEMBL880422,B,"Binding affinity against human opioid receptor kappa 1 expressed in HEK293 cells using 3H-U69,593 radioligand",CHEMBL1143642,IC50,Cc1cccc2c1C1(CCN(CC3CCCCCCC3)CC1)C(=O)N2C
CHEMBL197727,CHEMBL237,Kappa opioid receptor,IC50,=,250.0,nM,CHEMBL880422,B,"Binding affinity against human opioid receptor kappa 1 expressed in HEK293 cells using 3H-U69,593 radioligand",CHEMBL1143642,IC50,CN1C(=O)C2(CCN(CC3CCCCCCC3)CC2)c2cc(F)ccc21
CHEMBL373220,CHEMBL237,Kappa opioid receptor,IC50,=,4000.0,nM,CHEMBL880422,B,"Binding affinity against human opioid receptor kappa 1 expressed in HEK293 cells using 3H-U69,593 radioligand",CHEMBL1143642,IC50,CCCN1C(=O)C2(CCN(CC3CCCCCCC3)CC2)c2cc(C(C)C)ccc21
CHEMBL197895,CHEMBL237,Kappa opioid receptor,IC50,=,97.0,nM,CHEMBL880422,B,"Binding affinity against human opioid receptor kappa 1 expressed in HEK293 cells using 3H-U69,593 radioligand",CHEMBL1143642,IC50,CC(C)c1ccc2c(c1)C1(CCN(CC3CCCCCCC3)CC1)C(=O)N2C
CHEMBL357076,CHEMBL237,Kappa opioid receptor,IC50,=,1600.0,nM,CHEMBL867089,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor expressed in CHO cells,CHEMBL1149384,IC50,CCn1c(=O)n([C@@H]2CCN(CC3CCCCCCC3)C[C@H]2CO)c2ccccc21
CHEMBL201945,CHEMBL237,Kappa opioid receptor,IC50,=,2500.0,nM,CHEMBL867089,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor expressed in CHO cells,CHEMBL1149384,IC50,O=C(NCCCN1CCC2(CC1)OCc1ccccc12)[C@H]1CCCN1Cc1ccccc1
CHEMBL202225,CHEMBL237,Kappa opioid receptor,IC50,=,950.0,nM,CHEMBL867089,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor expressed in CHO cells,CHEMBL1149384,IC50,O=C(NCCCN1CCC2(CCc3ccccc32)CC1)[C@H]1CCCN1Cc1ccccc1
CHEMBL370870,CHEMBL237,Kappa opioid receptor,IC50,=,7900.0,nM,CHEMBL867089,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor expressed in CHO cells,CHEMBL1149384,IC50,O=C(NCCCN1CCC2(CCc3ccccc32)CC1)[C@@H]1CCCN1Cc1ccccc1
CHEMBL201805,CHEMBL237,Kappa opioid receptor,IC50,=,2300.0,nM,CHEMBL867089,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor expressed in CHO cells,CHEMBL1149384,IC50,O=C(NCCCN1CCC2(CCc3ccccc32)CC1)c1ccccc1OCc1ccccc1
CHEMBL202443,CHEMBL237,Kappa opioid receptor,IC50,=,9600.0,nM,CHEMBL867089,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor expressed in CHO cells,CHEMBL1149384,IC50,O=C(NCCCN1CCC2(CCc3ccccc32)CC1)c1ccccc1Oc1ccccc1
CHEMBL199639,CHEMBL237,Kappa opioid receptor,IC50,=,6900.0,nM,CHEMBL867089,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor expressed in CHO cells,CHEMBL1149384,IC50,O=C(NCCCN1CCC2(CCc3ccccc32)CC1)[C@@H](O)Cc1ccccc1
CHEMBL413571,CHEMBL237,Kappa opioid receptor,IC50,=,3700.0,nM,CHEMBL867089,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor expressed in CHO cells,CHEMBL1149384,IC50,O=C(NCCCN1CCC2(CCc3ccccc32)CC1)c1ccccc1-c1ccccc1
CHEMBL212699,CHEMBL237,Kappa opioid receptor,IC50,=,1450.0,nM,CHEMBL864850,B,Displacement of [3H]U-69593 from kappa opioid receptor,CHEMBL1145313,IC50,CNC[C@@H](Cc1ccccc1)N(C)C[C@H](Cc1ccc(O)cc1)N(C)C[C@@H](N)Cc1ccc(O)cc1
CHEMBL211696,CHEMBL237,Kappa opioid receptor,IC50,=,22457.0,nM,CHEMBL864850,B,Displacement of [3H]U-69593 from kappa opioid receptor,CHEMBL1145313,IC50,CNC[C@H](Cc1ccccc1)N(C)C[C@@H](Cc1ccc(O)cc1)N(C)C[C@@H](N)Cc1ccc(O)cc1
CHEMBL379992,CHEMBL237,Kappa opioid receptor,IC50,=,10516.0,nM,CHEMBL864850,B,Displacement of [3H]U-69593 from kappa opioid receptor,CHEMBL1145313,IC50,CNC[C@H](Cc1ccccc1)N(C)C[C@H](Cc1ccc(O)cc1)N(C)C[C@@H](Cc1ccc(O)cc1)N(C)C
CHEMBL379941,CHEMBL237,Kappa opioid receptor,IC50,=,8759.0,nM,CHEMBL864850,B,Displacement of [3H]U-69593 from kappa opioid receptor,CHEMBL1145313,IC50,CNC[C@@H](Cc1ccccc1)N(C)C[C@@H](Cc1ccc(O)cc1)N(C)C[C@@H](Cc1ccc(O)cc1)N(C)C
CHEMBL215434,CHEMBL237,Kappa opioid receptor,IC50,=,22435.0,nM,CHEMBL864850,B,Displacement of [3H]U-69593 from kappa opioid receptor,CHEMBL1145313,IC50,CNC[C@@H](Cc1ccccc1)N(C)C[C@@H](Cc1ccc(O)cc1)N(C)C[C@H](Cc1ccc(O)cc1)N(C)C
CHEMBL387368,CHEMBL237,Kappa opioid receptor,IC50,=,15589.0,nM,CHEMBL864850,B,Displacement of [3H]U-69593 from kappa opioid receptor,CHEMBL1145313,IC50,CNC[C@@H](Cc1ccccc1)N(C)C[C@H](Cc1ccc(O)cc1)N(C)C[C@@H](Cc1ccc(O)cc1)N(C)C
CHEMBL213416,CHEMBL237,Kappa opioid receptor,IC50,=,6059.0,nM,CHEMBL864850,B,Displacement of [3H]U-69593 from kappa opioid receptor,CHEMBL1145313,IC50,CNC[C@H](Cc1ccccc1)N(C)C[C@@H](Cc1ccc(O)cc1)N(C)C[C@@H](Cc1ccc(O)cc1)N(C)C
CHEMBL213418,CHEMBL237,Kappa opioid receptor,IC50,=,32160.0,nM,CHEMBL864850,B,Displacement of [3H]U-69593 from kappa opioid receptor,CHEMBL1145313,IC50,NC[C@H](Cc1ccc(O)cc1)NC[C@@H](N)Cc1ccc(O)cc1
CHEMBL379870,CHEMBL237,Kappa opioid receptor,IC50,=,9674.0,nM,CHEMBL864850,B,Displacement of [3H]U-69593 from kappa opioid receptor,CHEMBL1145313,IC50,CN[C@H](CN[C@H](CN)Cc1ccc(O)cc1)Cc1ccc(O)cc1
CHEMBL216046,CHEMBL237,Kappa opioid receptor,IC50,=,22559.0,nM,CHEMBL864850,B,Displacement of [3H]U-69593 from kappa opioid receptor,CHEMBL1145313,IC50,CN(C)[C@H](CN[C@H](CN)Cc1ccc(O)cc1)Cc1ccc(O)cc1
CHEMBL212405,CHEMBL237,Kappa opioid receptor,IC50,=,3855.0,nM,CHEMBL864850,B,Displacement of [3H]U-69593 from kappa opioid receptor,CHEMBL1145313,IC50,CN[C@@H](Cc1ccc(O)cc1)CN(C)[C@H](CNCc1ccccc1)Cc1ccc(O)cc1
CHEMBL386531,CHEMBL237,Kappa opioid receptor,IC50,=,2358.0,nM,CHEMBL864850,B,Displacement of [3H]U-69593 from kappa opioid receptor,CHEMBL1145313,IC50,CN(C)[C@@H](Cc1ccc(O)cc1)CN(C)[C@H](CNCc1ccccc1)Cc1ccc(O)cc1
CHEMBL386152,CHEMBL237,Kappa opioid receptor,IC50,=,14430.0,nM,CHEMBL864850,B,Displacement of [3H]U-69593 from kappa opioid receptor,CHEMBL1145313,IC50,CNC[C@H](Cc1ccc(O)cc1)N(Cc1ccccc1)C[C@@H](N)Cc1ccc(O)cc1
CHEMBL384093,CHEMBL237,Kappa opioid receptor,IC50,=,11130.0,nM,CHEMBL864850,B,Displacement of [3H]U-69593 from kappa opioid receptor,CHEMBL1145313,IC50,CNC[C@H](Cc1ccc(O)cc1)N(Cc1ccccc1)C[C@H](Cc1ccc(O)cc1)NC
CHEMBL378173,CHEMBL237,Kappa opioid receptor,IC50,=,10635.0,nM,CHEMBL864850,B,Displacement of [3H]U-69593 from kappa opioid receptor,CHEMBL1145313,IC50,CNC[C@H](Cc1ccc(O)cc1)N(Cc1ccccc1)C[C@H](Cc1ccc(O)cc1)N(C)C
CHEMBL210024,CHEMBL237,Kappa opioid receptor,IC50,=,4141.0,nM,CHEMBL864850,B,Displacement of [3H]U-69593 from kappa opioid receptor,CHEMBL1145313,IC50,CN(C[C@@H](N)Cc1ccc(O)cc1)[C@H](CNCc1ccccc1)Cc1ccc(O)cc1
CHEMBL379991,CHEMBL237,Kappa opioid receptor,IC50,=,1048.0,nM,CHEMBL864850,B,Displacement of [3H]U-69593 from kappa opioid receptor,CHEMBL1145313,IC50,CNC[C@H](Cc1ccccc1)N(C)C[C@H](Cc1ccc(O)cc1)N(C)C[C@H](Cc1ccc(O)cc1)N(C)C
CHEMBL407325,CHEMBL237,Kappa opioid receptor,IC50,=,60.0,nM,CHEMBL931351,B,Displacement of [3H]U-69593 from human cloned kappa opioid receptor expressed in CHO cell membrane,CHEMBL1143092,IC50,CCC(CC)Sc1nc2cc(Cl)c(N3CCN(CCO)CC3)cc2[nH]1
CHEMBL263918,CHEMBL237,Kappa opioid receptor,IC50,=,170.0,nM,CHEMBL931351,B,Displacement of [3H]U-69593 from human cloned kappa opioid receptor expressed in CHO cell membrane,CHEMBL1143092,IC50,CCC(C)(CC)Sc1nc2cc(Cl)c(N3CCN(CCO)CC3)cc2[nH]1
CHEMBL263917,CHEMBL237,Kappa opioid receptor,IC50,=,88.0,nM,CHEMBL931351,B,Displacement of [3H]U-69593 from human cloned kappa opioid receptor expressed in CHO cell membrane,CHEMBL1143092,IC50,CC1(Sc2nc3cc(Cl)c(N4CCN(CCO)CC4)cc3[nH]2)CCCCC1
CHEMBL408901,CHEMBL237,Kappa opioid receptor,IC50,=,31.0,nM,CHEMBL931351,B,Displacement of [3H]U-69593 from human cloned kappa opioid receptor expressed in CHO cell membrane,CHEMBL1143092,IC50,OCCN1CCN(c2cc3[nH]c(SC4CCCCC4)nc3cc2Cl)CC1
CHEMBL263919,CHEMBL237,Kappa opioid receptor,IC50,=,160.0,nM,CHEMBL931351,B,Displacement of [3H]U-69593 from human cloned kappa opioid receptor expressed in CHO cell membrane,CHEMBL1143092,IC50,CCC(C)(C)Sc1nc2cc(Cl)c(N3CCN(CCO)CC3)cc2[nH]1
CHEMBL259185,CHEMBL237,Kappa opioid receptor,IC50,=,120.0,nM,CHEMBL931351,B,Displacement of [3H]U-69593 from human cloned kappa opioid receptor expressed in CHO cell membrane,CHEMBL1143092,IC50,CC(C)(C)Sc1nc2cc(Cl)c(N3CCN(CCO)CC3)cc2[nH]1
CHEMBL263904,CHEMBL237,Kappa opioid receptor,IC50,=,60.0,nM,CHEMBL931351,B,Displacement of [3H]U-69593 from human cloned kappa opioid receptor expressed in CHO cell membrane,CHEMBL1143092,IC50,CC(C)Sc1nc2cc(Cl)c(N3CCN(CCO)CC3)cc2[nH]1
CHEMBL494350,CHEMBL237,Kappa opioid receptor,IC50,=,120.0,nM,CHEMBL953422,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1150320,IC50,C[C@@H]1CN(CCO)CCN1c1cc2[nH]c(SC(C)(C)C)nc2cc1Cl
CHEMBL495402,CHEMBL237,Kappa opioid receptor,IC50,=,5.3,nM,CHEMBL953422,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1150320,IC50,C[C@H]1CN(CCO)CCN1c1cc2[nH]c(SC(C)(C)C)nc2cc1Cl
CHEMBL259185,CHEMBL237,Kappa opioid receptor,IC50,=,120.0,nM,CHEMBL953422,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1150320,IC50,CC(C)(C)Sc1nc2cc(Cl)c(N3CCN(CCO)CC3)cc2[nH]1
CHEMBL461571,CHEMBL237,Kappa opioid receptor,IC50,=,3480.0,nM,CHEMBL980776,B,Displacement of radioligand from kappa opioid receptor,CHEMBL1139415,IC50,Cc1c(C(=O)c2ccc(Cl)cc2)c2ccc(OC(F)(F)F)cc2n1Cc1cccc(O[C@H](C)C(=O)O)c1
CHEMBL441765,CHEMBL237,Kappa opioid receptor,IC50,=,2.5,nM,CHEMBL947369,B,Displacement of radiolabeled U50488 from human kappa-type opioid receptor,CHEMBL1140203,IC50,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL460893,CHEMBL237,Kappa opioid receptor,IC50,=,9700.0,nM,CHEMBL953932,B,Displacement of [3H]U69593 from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1157430,IC50,Cc1nn(-c2ccccc2)cc1CN1CCC2(CC1)OCc1ccccc12
CHEMBL441765,CHEMBL237,Kappa opioid receptor,IC50,=,0.55,nM,CHEMBL983892,B,Inhibition of human kappa opioid receptor,CHEMBL1155111,IC50,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL450500,CHEMBL237,Kappa opioid receptor,IC50,=,2209.0,nM,CHEMBL1030680,B,Displacement of [125I]U69593 from human cloned kappa opioid receptor,CHEMBL1152717,IC50,COCCNC1c2ccccc2CCC1c1ccsc1
CHEMBL512394,CHEMBL237,Kappa opioid receptor,IC50,=,707.0,nM,CHEMBL1030680,B,Displacement of [125I]U69593 from human cloned kappa opioid receptor,CHEMBL1152717,IC50,COCCN[C@@H]1c2ccccc2CC[C@H]1c1ccsc1
CHEMBL459784,CHEMBL237,Kappa opioid receptor,IC50,=,7993.0,nM,CHEMBL1030680,B,Displacement of [125I]U69593 from human cloned kappa opioid receptor,CHEMBL1152717,IC50,COCCN(C(=O)Cc1ccc(Cl)cc1)C1c2ccccc2C=CC1N1CCN(c2ccccc2)CC1
CHEMBL460631,CHEMBL237,Kappa opioid receptor,IC50,=,7136.0,nM,CHEMBL1030680,B,Displacement of [125I]U69593 from human cloned kappa opioid receptor,CHEMBL1152717,IC50,COCCN(C(=O)c1sccc1Cl)C1c2ccccc2C=CC1N1CCN(c2ccccc2)CC1
CHEMBL461050,CHEMBL237,Kappa opioid receptor,IC50,=,1324.0,nM,CHEMBL1030680,B,Displacement of [125I]U69593 from human cloned kappa opioid receptor,CHEMBL1152717,IC50,COCCN(C(=O)c1sccc1Cl)[C@@H]1c2ccccc2C=C[C@H]1N1CCN(c2ccccc2)CC1
CHEMBL461257,CHEMBL237,Kappa opioid receptor,IC50,=,155.0,nM,CHEMBL1030680,B,Displacement of [125I]U69593 from human cloned kappa opioid receptor,CHEMBL1152717,IC50,COCCN(C(=O)COc1ccc(Cl)cc1)C1c2cc(OC)c(OC)cc2CCC1N(C)C
CHEMBL461258,CHEMBL237,Kappa opioid receptor,IC50,=,6002.0,nM,CHEMBL1030680,B,Displacement of [125I]U69593 from human cloned kappa opioid receptor,CHEMBL1152717,IC50,COCCN(C(=O)c1ccc(Cl)c(Cl)c1)C1c2cc(OC)c(OC)cc2CCC1N(C)C
CHEMBL459387,CHEMBL237,Kappa opioid receptor,IC50,=,922.0,nM,CHEMBL1030680,B,Displacement of [125I]U69593 from human cloned kappa opioid receptor,CHEMBL1152717,IC50,COCCN(C(=O)Cc1ccc(Cl)cc1)C1c2cc(OC)c(OC)cc2CCC1N(C)C
CHEMBL459388,CHEMBL237,Kappa opioid receptor,IC50,=,1005.0,nM,CHEMBL1030680,B,Displacement of [125I]U69593 from human cloned kappa opioid receptor,CHEMBL1152717,IC50,COCCN(C(=O)Cc1ccccc1Br)C1c2cc(OC)c(OC)cc2CCC1N(C)C
CHEMBL466648,CHEMBL237,Kappa opioid receptor,IC50,=,530.0,nM,CHEMBL1007473,B,Displacement of [3H]U69593 from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1136941,IC50,Cc1ncc(-c2c(C)c(CN[C@H]3CC[C@@H](F)C3)nn2-c2ncccc2Cl)cc1F
CHEMBL466308,CHEMBL237,Kappa opioid receptor,IC50,=,1400.0,nM,CHEMBL1014967,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1136869,IC50,CCN1CCN(c2cc3[nH]c(C(=O)[C@]4(C)CC[C@@](C)(O)CC4)nc3cc2Cl)CC1
CHEMBL494350,CHEMBL237,Kappa opioid receptor,IC50,=,120.0,nM,CHEMBL972468,B,Displacement of [3H]U69593 from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1136886,IC50,C[C@@H]1CN(CCO)CCN1c1cc2[nH]c(SC(C)(C)C)nc2cc1Cl
CHEMBL467057,CHEMBL237,Kappa opioid receptor,IC50,=,160.0,nM,CHEMBL972468,B,Displacement of [3H]U69593 from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1136886,IC50,CCN1CCN(c2cc3[nH]c(S[C@]4(C)CC[C@@H](N(C)C(C)=O)CC4)nc3cc2Cl)CC1
CHEMBL564840,CHEMBL237,Kappa opioid receptor,IC50,=,10000.0,nM,CHEMBL1025187,B,Displacement of [3H]U69593 from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1158463,IC50,Cl.O=c1n(C[C@@H](O)CO)c2ccccc2n1C1CCN(C[C@H]2[C@H]3CC[C@H](C3)C23CC3)CC1
CHEMBL563980,CHEMBL237,Kappa opioid receptor,IC50,=,6800.0,nM,CHEMBL1025187,B,Displacement of [3H]U69593 from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1158463,IC50,Cl.O=c1n(C[C@H](O)CO)c2ccccc2n1C1CCN(C[C@H]2[C@H]3CC[C@H](C3)C23CC3)CC1
CHEMBL563657,CHEMBL237,Kappa opioid receptor,IC50,=,11000.0,nM,CHEMBL1025187,B,Displacement of [3H]U69593 from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1158463,IC50,Cl.O=c1n(C(CO)CO)c2ccccc2n1C1CCN(C[C@H]2[C@H]3CC[C@H](C3)C23CC3)CC1
CHEMBL560667,CHEMBL237,Kappa opioid receptor,IC50,=,9800.0,nM,CHEMBL1060812,B,Displacement of [3H]U69593 from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1153056,IC50,Cc1c(CN[C@H]2CC[C@@H](F)C2)nn(CCC#N)c1-c1cc(F)cc(F)c1
CHEMBL441765,CHEMBL237,Kappa opioid receptor,IC50,=,1.99,nM,CHEMBL1047759,B,Displacement of [3H]dynorphin from human kappa opioid receptor expressed in C6 giloma cells,CHEMBL1152513,IC50,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL594511,CHEMBL237,Kappa opioid receptor,IC50,=,1.03,nM,CHEMBL1047759,B,Displacement of [3H]dynorphin from human kappa opioid receptor expressed in C6 giloma cells,CHEMBL1152513,IC50,Cc1cc(NCC(=O)Nc2ccccc2)c2ccccc2n1
CHEMBL1080787,CHEMBL237,Kappa opioid receptor,IC50,=,5800.0,nM,CHEMBL1112311,B,Binding affinity to kappa opioid receptor,CHEMBL1154203,IC50,CC(C)CN(C(=O)c1cccc(Cl)c1Cl)[C@H]1CCNC1
CHEMBL440765,CHEMBL237,Kappa opioid receptor,IC50,=,8.0,nM,CHEMBL1114661,B,Displacement of [3H]naloxone from kappa opioid receptor expressed in HEK293 cell membrane,CHEMBL1157800,IC50,CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL1762381,CHEMBL237,Kappa opioid receptor,IC50,=,5475.0,nM,CHEMBL1763213,B,Displacement of [3H]-naltrindole from human kappa opioid receptor expressed in human HEK293 cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,Cc1cc(N)c2cc(NC(=O)c3ccccc3COc3ccc(CNCCCNCc4ccc(OCc5ccccc5C(=O)Nc5ccc6nc(C)cc(N)c6c5)cc4)cc3)ccc2n1
CHEMBL1762382,CHEMBL237,Kappa opioid receptor,IC50,=,1091.0,nM,CHEMBL1763213,B,Displacement of [3H]-naltrindole from human kappa opioid receptor expressed in human HEK293 cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,Cc1cc(N)c2cc(NC(=O)c3ccccc3COc3ccc(CNCCCCNCc4ccc(OCc5ccccc5C(=O)Nc5ccc6nc(C)cc(N)c6c5)cc4)cc3)ccc2n1
CHEMBL1762383,CHEMBL237,Kappa opioid receptor,IC50,=,1496.0,nM,CHEMBL1763213,B,Displacement of [3H]-naltrindole from human kappa opioid receptor expressed in human HEK293 cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,Cc1cc(N)c2cc(NC(=O)c3ccccc3COc3ccc(CNCCCCCNCc4ccc(OCc5ccccc5C(=O)Nc5ccc6nc(C)cc(N)c6c5)cc4)cc3)ccc2n1
CHEMBL1762384,CHEMBL237,Kappa opioid receptor,IC50,=,1347.0,nM,CHEMBL1763213,B,Displacement of [3H]-naltrindole from human kappa opioid receptor expressed in human HEK293 cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,Cc1cc(N)c2cc(NC(=O)c3ccccc3COc3ccc(CNCCCCCCNCc4ccc(OCc5ccccc5C(=O)Nc5ccc6nc(C)cc(N)c6c5)cc4)cc3)ccc2n1
CHEMBL1762385,CHEMBL237,Kappa opioid receptor,IC50,=,1023.0,nM,CHEMBL1763213,B,Displacement of [3H]-naltrindole from human kappa opioid receptor expressed in human HEK293 cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,Cc1cc(N)c2cc(NC(=O)c3ccccc3COc3ccc(CNCCCCCCCNCc4ccc(OCc5ccccc5C(=O)Nc5ccc6nc(C)cc(N)c6c5)cc4)cc3)ccc2n1
CHEMBL1762386,CHEMBL237,Kappa opioid receptor,IC50,=,1269.0,nM,CHEMBL1763213,B,Displacement of [3H]-naltrindole from human kappa opioid receptor expressed in human HEK293 cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,Cc1cc(N)c2cc(NC(=O)c3ccccc3COc3ccc(CNCCCCCCCCNCc4ccc(OCc5ccccc5C(=O)Nc5ccc6nc(C)cc(N)c6c5)cc4)cc3)ccc2n1
CHEMBL1762387,CHEMBL237,Kappa opioid receptor,IC50,=,1049.0,nM,CHEMBL1763213,B,Displacement of [3H]-naltrindole from human kappa opioid receptor expressed in human HEK293 cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,Cc1cc(N)c2cc(NC(=O)c3ccccc3COc3ccc(CNCCCCCCCCCNCc4ccc(OCc5ccccc5C(=O)Nc5ccc6nc(C)cc(N)c6c5)cc4)cc3)ccc2n1
CHEMBL1762388,CHEMBL237,Kappa opioid receptor,IC50,=,900.0,nM,CHEMBL1763213,B,Displacement of [3H]-naltrindole from human kappa opioid receptor expressed in human HEK293 cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,Cc1cc(N)c2cc(NC(=O)c3ccccc3COc3ccc(CNCCCCCCCCCCNCc4ccc(OCc5ccccc5C(=O)Nc5ccc6nc(C)cc(N)c6c5)cc4)cc3)ccc2n1
CHEMBL1762397,CHEMBL237,Kappa opioid receptor,IC50,=,3079.0,nM,CHEMBL1763213,B,Displacement of [3H]-naltrindole from human kappa opioid receptor expressed in human HEK293 cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,CCCNCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1
CHEMBL1762398,CHEMBL237,Kappa opioid receptor,IC50,=,5924.0,nM,CHEMBL1763213,B,Displacement of [3H]-naltrindole from human kappa opioid receptor expressed in human HEK293 cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,CCCCNCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1
CHEMBL1762399,CHEMBL237,Kappa opioid receptor,IC50,=,3669.0,nM,CHEMBL1763213,B,Displacement of [3H]-naltrindole from human kappa opioid receptor expressed in human HEK293 cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,CCCCCNCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1
CHEMBL1762400,CHEMBL237,Kappa opioid receptor,IC50,=,1157.0,nM,CHEMBL1763213,B,Displacement of [3H]-naltrindole from human kappa opioid receptor expressed in human HEK293 cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,CCCCCCNCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1
CHEMBL1762401,CHEMBL237,Kappa opioid receptor,IC50,=,1850.0,nM,CHEMBL1763213,B,Displacement of [3H]-naltrindole from human kappa opioid receptor expressed in human HEK293 cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,CCCCCCCNCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1
CHEMBL1762402,CHEMBL237,Kappa opioid receptor,IC50,=,4955.0,nM,CHEMBL1763213,B,Displacement of [3H]-naltrindole from human kappa opioid receptor expressed in human HEK293 cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,CCCCCCCCNCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1
CHEMBL1762403,CHEMBL237,Kappa opioid receptor,IC50,=,2565.0,nM,CHEMBL1763213,B,Displacement of [3H]-naltrindole from human kappa opioid receptor expressed in human HEK293 cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,CCCCCCCCCNCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1
CHEMBL1762404,CHEMBL237,Kappa opioid receptor,IC50,=,4348.0,nM,CHEMBL1763213,B,Displacement of [3H]-naltrindole from human kappa opioid receptor expressed in human HEK293 cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,CCCCCCCCCCNCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1
CHEMBL1762405,CHEMBL237,Kappa opioid receptor,IC50,=,1649.0,nM,CHEMBL1763213,B,Displacement of [3H]-naltrindole from human kappa opioid receptor expressed in human HEK293 cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,Cc1cc(N)c2cc(NC(=O)c3ccccc3COc3ccc(CNCCCN)cc3)ccc2n1
CHEMBL1762406,CHEMBL237,Kappa opioid receptor,IC50,=,4257.0,nM,CHEMBL1763213,B,Displacement of [3H]-naltrindole from human kappa opioid receptor expressed in human HEK293 cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,Cc1cc(N)c2cc(NC(=O)c3ccccc3COc3ccc(CNCCCCN)cc3)ccc2n1
CHEMBL1762407,CHEMBL237,Kappa opioid receptor,IC50,=,2155.0,nM,CHEMBL1763213,B,Displacement of [3H]-naltrindole from human kappa opioid receptor expressed in human HEK293 cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,Cc1cc(N)c2cc(NC(=O)c3ccccc3COc3ccc(CNCCCCCN)cc3)ccc2n1
CHEMBL1760025,CHEMBL237,Kappa opioid receptor,IC50,=,1222.0,nM,CHEMBL1763213,B,Displacement of [3H]-naltrindole from human kappa opioid receptor expressed in human HEK293 cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,Cc1cc(N)c2cc(NC(=O)c3ccccc3COc3ccc(CNCCCCCCN)cc3)ccc2n1
CHEMBL1762408,CHEMBL237,Kappa opioid receptor,IC50,=,998.0,nM,CHEMBL1763213,B,Displacement of [3H]-naltrindole from human kappa opioid receptor expressed in human HEK293 cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,Cc1cc(N)c2cc(NC(=O)c3ccccc3COc3ccc(CNCCCCCCCN)cc3)ccc2n1
CHEMBL1762409,CHEMBL237,Kappa opioid receptor,IC50,=,872.0,nM,CHEMBL1763213,B,Displacement of [3H]-naltrindole from human kappa opioid receptor expressed in human HEK293 cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,Cc1cc(N)c2cc(NC(=O)c3ccccc3COc3ccc(CNCCCCCCCCN)cc3)ccc2n1
CHEMBL1762410,CHEMBL237,Kappa opioid receptor,IC50,=,6177.0,nM,CHEMBL1763213,B,Displacement of [3H]-naltrindole from human kappa opioid receptor expressed in human HEK293 cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,Cc1cc(N)c2cc(NC(=O)c3ccccc3COc3ccc(CNCCCCCCCCCN)cc3)ccc2n1
CHEMBL1762411,CHEMBL237,Kappa opioid receptor,IC50,=,9103.0,nM,CHEMBL1763213,B,Displacement of [3H]-naltrindole from human kappa opioid receptor expressed in human HEK293 cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,Cc1cc(N)c2cc(NC(=O)c3ccccc3COc3ccc(CNCCCCCCCCCCN)cc3)ccc2n1
CHEMBL140979,CHEMBL237,Kappa opioid receptor,IC50,=,7512.0,nM,CHEMBL1763213,B,Displacement of [3H]-naltrindole from human kappa opioid receptor expressed in human HEK293 cells after 2 hrs by scintillation counting,CHEMBL1759965,IC50,CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1
CHEMBL1813663,CHEMBL237,Kappa opioid receptor,IC50,=,32400.0,nM,CHEMBL1814859,B,Displacement of [3H]nor-Binaltorphimine from human kappa opioid receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,CHEMBL1811804,IC50,CCCCC/C=C/c1c(O)cc(CC=C(C)C)c2c1CC(O)O2
CHEMBL942,CHEMBL237,Kappa opioid receptor,IC50,=,2437.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,CC(=O)Oc1ccc(C(c2ccc(OC(C)=O)cc2)c2ccccn2)cc1
CHEMBL508112,CHEMBL237,Kappa opioid receptor,IC50,=,1243.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,c1ccc2sc(SSc3nc4ccccc4s3)nc2c1
CHEMBL296419,CHEMBL237,Kappa opioid receptor,IC50,=,6616.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1
CHEMBL633,CHEMBL237,Kappa opioid receptor,IC50,=,16680.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1
CHEMBL1289,CHEMBL237,Kappa opioid receptor,IC50,=,1147.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,Clc1cc(Cl)c(OCC#CI)cc1Cl
CHEMBL64894,CHEMBL237,Kappa opioid receptor,IC50,=,1540.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1.[Cl-]
CHEMBL808,CHEMBL237,Kappa opioid receptor,IC50,=,8616.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1
CHEMBL726,CHEMBL237,Kappa opioid receptor,IC50,=,24727.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
CHEMBL691,CHEMBL237,Kappa opioid receptor,IC50,=,25894.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C
CHEMBL104,CHEMBL237,Kappa opioid receptor,IC50,=,6303.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1
CHEMBL964,CHEMBL237,Kappa opioid receptor,IC50,=,6103.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,CCN(CC)C(=S)SSC(=S)N(CC)CC
CHEMBL411,CHEMBL237,Kappa opioid receptor,IC50,=,4563.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1
CHEMBL71,CHEMBL237,Kappa opioid receptor,IC50,=,11082.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21
CHEMBL219916,CHEMBL237,Kappa opioid receptor,IC50,=,6994.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1
CHEMBL1479,CHEMBL237,Kappa opioid receptor,IC50,=,15518.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C
CHEMBL584,CHEMBL237,Kappa opioid receptor,IC50,=,35996.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
CHEMBL19019,CHEMBL237,Kappa opioid receptor,IC50,=,18.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL1618305,CHEMBL237,Kappa opioid receptor,IC50,=,85.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2/C(=N/N=C2\CC[C@@]4(O)[C@H]6Cc7ccc(O)c8c7[C@@]4(CCN6CC=C)[C@H]2O8)CC[C@@]3(O)[C@H]1C5
CHEMBL91,CHEMBL237,Kappa opioid receptor,IC50,=,6594.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
CHEMBL80,CHEMBL237,Kappa opioid receptor,IC50,=,75.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL1276308,CHEMBL237,Kappa opioid receptor,IC50,=,20096.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C
CHEMBL841,CHEMBL237,Kappa opioid receptor,IC50,=,3125.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1
CHEMBL895,CHEMBL237,Kappa opioid receptor,IC50,=,111.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
CHEMBL479,CHEMBL237,Kappa opioid receptor,IC50,=,2490.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2
CHEMBL83,CHEMBL237,Kappa opioid receptor,IC50,=,15629.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1
CHEMBL163,CHEMBL237,Kappa opioid receptor,IC50,=,13655.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
CHEMBL114,CHEMBL237,Kappa opioid receptor,IC50,=,6951.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1
CHEMBL81,CHEMBL237,Kappa opioid receptor,IC50,=,1602.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12
CHEMBL118865,CHEMBL237,Kappa opioid receptor,IC50,=,8.3,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,IC50,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)C1CCC2(CCCO2)CC1N1CCCC1
CHEMBL441765,CHEMBL237,Kappa opioid receptor,IC50,=,0.84,nM,CHEMBL2394996,B,Binding affinity to kappa opioid receptor (unknown origin) by radioligand displacement assay,CHEMBL2390917,IC50,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL2390967,CHEMBL237,Kappa opioid receptor,IC50,=,16.0,nM,CHEMBL2395089,B,Displacement of [3H]Diprenorphine from human recombinant kappa opioid receptor expressed in HEK293 cells after 60 mins,CHEMBL2390918,IC50,CN(C(=O)Cc1ccccc1)[C@H]1C[C@]2(CCCO2)CC[C@@H]1N1CCCC1
CHEMBL441765,CHEMBL237,Kappa opioid receptor,IC50,=,0.75,nM,CHEMBL2394940,B,Binding affinity to human kappa-type opioid receptor by radioligand displacement assay,CHEMBL2390830,IC50,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL1455766,CHEMBL237,Kappa opioid receptor,IC50,=,860.0,nM,CHEMBL3268194,B,Inhibition of kappa opioid receptor (unknown origin) using dynorphin A by DiscoveryRx b-arrestin PathHunter assay,CHEMBL3259577,IC50,Cc1ccc(S(=O)(=O)NCc2ccc(C(=O)NCCN(Cc3ccccc3)C(C)C)cc2)cc1
CHEMBL1735687,CHEMBL237,Kappa opioid receptor,IC50,=,1120.0,nM,CHEMBL3268194,B,Inhibition of kappa opioid receptor (unknown origin) using dynorphin A by DiscoveryRx b-arrestin PathHunter assay,CHEMBL3259577,IC50,CCc1ccc(S(=O)(=O)NCc2ccc(C(=O)NCCN(Cc3ccccc3)C(C)C)cc2)cc1
CHEMBL1724868,CHEMBL237,Kappa opioid receptor,IC50,=,660.0,nM,CHEMBL3268194,B,Inhibition of kappa opioid receptor (unknown origin) using dynorphin A by DiscoveryRx b-arrestin PathHunter assay,CHEMBL3259577,IC50,Cc1ccc(S(=O)(=O)NCc2ccc(C(=O)NCCN(Cc3ccc(Br)cc3)C(C)C)cc2)cc1
CHEMBL1736339,CHEMBL237,Kappa opioid receptor,IC50,=,5570.0,nM,CHEMBL3268194,B,Inhibition of kappa opioid receptor (unknown origin) using dynorphin A by DiscoveryRx b-arrestin PathHunter assay,CHEMBL3259577,IC50,CCN(CCNC(=O)c1ccc(CNS(=O)(=O)c2ccc(C)cc2)cc1)Cc1ccccc1
CHEMBL1713967,CHEMBL237,Kappa opioid receptor,IC50,=,60.0,nM,CHEMBL3268194,B,Inhibition of kappa opioid receptor (unknown origin) using dynorphin A by DiscoveryRx b-arrestin PathHunter assay,CHEMBL3259577,IC50,Cc1ccc(S(=O)(=O)NCc2ccc(C(=O)NCCN(Cc3ccccc3)C(C)(C)C)cc2)cc1
CHEMBL1455045,CHEMBL237,Kappa opioid receptor,IC50,=,1950.0,nM,CHEMBL3268194,B,Inhibition of kappa opioid receptor (unknown origin) using dynorphin A by DiscoveryRx b-arrestin PathHunter assay,CHEMBL3259577,IC50,COc1ccc(N2CCN(CCCNC(=O)Cn3c(=O)c4cccn4c4cccnc43)CC2)cc1
CHEMBL1588996,CHEMBL237,Kappa opioid receptor,IC50,=,4320.0,nM,CHEMBL3268194,B,Inhibition of kappa opioid receptor (unknown origin) using dynorphin A by DiscoveryRx b-arrestin PathHunter assay,CHEMBL3259577,IC50,COc1ccc(N2CCN(CCCNC(=O)Cn3c(=O)c4cccn4c4ccccc43)CC2)cc1
CHEMBL1729417,CHEMBL237,Kappa opioid receptor,IC50,=,120.0,nM,CHEMBL3268194,B,Inhibition of kappa opioid receptor (unknown origin) using dynorphin A by DiscoveryRx b-arrestin PathHunter assay,CHEMBL3259577,IC50,COc1ccc(N2CCN(CCCNC(=O)Cn3c(=O)c4cccn4c4c(C)ccnc43)CC2)cc1
CHEMBL1702620,CHEMBL237,Kappa opioid receptor,IC50,=,190.0,nM,CHEMBL3268194,B,Inhibition of kappa opioid receptor (unknown origin) using dynorphin A by DiscoveryRx b-arrestin PathHunter assay,CHEMBL3259577,IC50,COc1ccc(N2CCN(CCCNC(=O)Cn3c(=O)c4cccn4c4c(C)ccnc43)CC2)c(OC)c1
CHEMBL1729120,CHEMBL237,Kappa opioid receptor,IC50,=,690.0,nM,CHEMBL3268194,B,Inhibition of kappa opioid receptor (unknown origin) using dynorphin A by DiscoveryRx b-arrestin PathHunter assay,CHEMBL3259577,IC50,Cc1ccnc2c1n1cccc1c(=O)n2CC(=O)NCCCN1CCN(c2ccc(Cl)cc2)CC1
CHEMBL1711929,CHEMBL237,Kappa opioid receptor,IC50,=,3050.0,nM,CHEMBL3268194,B,Inhibition of kappa opioid receptor (unknown origin) using dynorphin A by DiscoveryRx b-arrestin PathHunter assay,CHEMBL3259577,IC50,COc1ccc(N2CCN(CCCNC(=O)Cn3c(=O)c4cccn4c4cc(Br)cnc43)CC2)cc1
CHEMBL1455766,CHEMBL237,Kappa opioid receptor,IC50,=,860.0,nM,CHEMBL3268195,B,Inhibition of kappa opioid receptor (unknown origin) using dynorphin A by high content imaging beta-arrestin translocation assay,CHEMBL3259577,IC50,Cc1ccc(S(=O)(=O)NCc2ccc(C(=O)NCCN(Cc3ccccc3)C(C)C)cc2)cc1
CHEMBL1735687,CHEMBL237,Kappa opioid receptor,IC50,=,2550.0,nM,CHEMBL3268195,B,Inhibition of kappa opioid receptor (unknown origin) using dynorphin A by high content imaging beta-arrestin translocation assay,CHEMBL3259577,IC50,CCc1ccc(S(=O)(=O)NCc2ccc(C(=O)NCCN(Cc3ccccc3)C(C)C)cc2)cc1
CHEMBL1724868,CHEMBL237,Kappa opioid receptor,IC50,=,570.0,nM,CHEMBL3268195,B,Inhibition of kappa opioid receptor (unknown origin) using dynorphin A by high content imaging beta-arrestin translocation assay,CHEMBL3259577,IC50,Cc1ccc(S(=O)(=O)NCc2ccc(C(=O)NCCN(Cc3ccc(Br)cc3)C(C)C)cc2)cc1
CHEMBL1736339,CHEMBL237,Kappa opioid receptor,IC50,=,2930.0,nM,CHEMBL3268195,B,Inhibition of kappa opioid receptor (unknown origin) using dynorphin A by high content imaging beta-arrestin translocation assay,CHEMBL3259577,IC50,CCN(CCNC(=O)c1ccc(CNS(=O)(=O)c2ccc(C)cc2)cc1)Cc1ccccc1
CHEMBL1713967,CHEMBL237,Kappa opioid receptor,IC50,=,30.0,nM,CHEMBL3268195,B,Inhibition of kappa opioid receptor (unknown origin) using dynorphin A by high content imaging beta-arrestin translocation assay,CHEMBL3259577,IC50,Cc1ccc(S(=O)(=O)NCc2ccc(C(=O)NCCN(Cc3ccccc3)C(C)(C)C)cc2)cc1
CHEMBL1455045,CHEMBL237,Kappa opioid receptor,IC50,=,1300.0,nM,CHEMBL3268195,B,Inhibition of kappa opioid receptor (unknown origin) using dynorphin A by high content imaging beta-arrestin translocation assay,CHEMBL3259577,IC50,COc1ccc(N2CCN(CCCNC(=O)Cn3c(=O)c4cccn4c4cccnc43)CC2)cc1
CHEMBL1588996,CHEMBL237,Kappa opioid receptor,IC50,=,15300.0,nM,CHEMBL3268195,B,Inhibition of kappa opioid receptor (unknown origin) using dynorphin A by high content imaging beta-arrestin translocation assay,CHEMBL3259577,IC50,COc1ccc(N2CCN(CCCNC(=O)Cn3c(=O)c4cccn4c4ccccc43)CC2)cc1
CHEMBL1729417,CHEMBL237,Kappa opioid receptor,IC50,=,3.0,nM,CHEMBL3268195,B,Inhibition of kappa opioid receptor (unknown origin) using dynorphin A by high content imaging beta-arrestin translocation assay,CHEMBL3259577,IC50,COc1ccc(N2CCN(CCCNC(=O)Cn3c(=O)c4cccn4c4c(C)ccnc43)CC2)cc1
CHEMBL1702620,CHEMBL237,Kappa opioid receptor,IC50,=,4.0,nM,CHEMBL3268195,B,Inhibition of kappa opioid receptor (unknown origin) using dynorphin A by high content imaging beta-arrestin translocation assay,CHEMBL3259577,IC50,COc1ccc(N2CCN(CCCNC(=O)Cn3c(=O)c4cccn4c4c(C)ccnc43)CC2)c(OC)c1
CHEMBL1729120,CHEMBL237,Kappa opioid receptor,IC50,=,70.0,nM,CHEMBL3268195,B,Inhibition of kappa opioid receptor (unknown origin) using dynorphin A by high content imaging beta-arrestin translocation assay,CHEMBL3259577,IC50,Cc1ccnc2c1n1cccc1c(=O)n2CC(=O)NCCCN1CCN(c2ccc(Cl)cc2)CC1
CHEMBL1711929,CHEMBL237,Kappa opioid receptor,IC50,=,700.0,nM,CHEMBL3268195,B,Inhibition of kappa opioid receptor (unknown origin) using dynorphin A by high content imaging beta-arrestin translocation assay,CHEMBL3259577,IC50,COc1ccc(N2CCN(CCCNC(=O)Cn3c(=O)c4cccn4c4cc(Br)cnc43)CC2)cc1
CHEMBL3394742,CHEMBL237,Kappa opioid receptor,IC50,=,240.0,nM,CHEMBL3395054,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in HEK293 cells after 2 hrs by scintillation counting",CHEMBL3393026,IC50,CCCCN(Cc1ccccc1)C[C@H](O)CN1CN(c2ccc(F)cc2)C2(CCN(CC3CCCCCCC3)CC2)C1=O
CHEMBL3394753,CHEMBL237,Kappa opioid receptor,IC50,=,200.0,nM,CHEMBL3395054,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in HEK293 cells after 2 hrs by scintillation counting",CHEMBL3393026,IC50,COc1ccc(CCNC[C@H](O)CN2CN(c3ccc(F)cc3)C3(CCN(CC4CCCCCCC4)CC3)C2=O)cc1OC
CHEMBL1455766,CHEMBL237,Kappa opioid receptor,IC50,=,860.0,nM,CHEMBL3590950,B,Antagonist activity against human kappa opioid receptor by DiscoveRx beta-arrestin2 recruitment based PathHunter assay,CHEMBL3588796,IC50,Cc1ccc(S(=O)(=O)NCc2ccc(C(=O)NCCN(Cc3ccccc3)C(C)C)cc2)cc1
CHEMBL1724868,CHEMBL237,Kappa opioid receptor,IC50,=,660.0,nM,CHEMBL3590950,B,Antagonist activity against human kappa opioid receptor by DiscoveRx beta-arrestin2 recruitment based PathHunter assay,CHEMBL3588796,IC50,Cc1ccc(S(=O)(=O)NCc2ccc(C(=O)NCCN(Cc3ccc(Br)cc3)C(C)C)cc2)cc1
CHEMBL573214,CHEMBL237,Kappa opioid receptor,IC50,=,4.6,nM,CHEMBL3590954,B,"Antagonist activity against HA-tagged human recombinant kappa opioid receptor expressed in CHO cells assessed as inhibition of U69,593-induced ERK phosphorylation pre-incubated with compound before U69,593 stimulation for 10 mins",CHEMBL3588796,IC50,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL1455766,CHEMBL237,Kappa opioid receptor,IC50,=,591.0,nM,CHEMBL3590954,B,"Antagonist activity against HA-tagged human recombinant kappa opioid receptor expressed in CHO cells assessed as inhibition of U69,593-induced ERK phosphorylation pre-incubated with compound before U69,593 stimulation for 10 mins",CHEMBL3588796,IC50,Cc1ccc(S(=O)(=O)NCc2ccc(C(=O)NCCN(Cc3ccccc3)C(C)C)cc2)cc1
CHEMBL1724868,CHEMBL237,Kappa opioid receptor,IC50,=,750.0,nM,CHEMBL3590954,B,"Antagonist activity against HA-tagged human recombinant kappa opioid receptor expressed in CHO cells assessed as inhibition of U69,593-induced ERK phosphorylation pre-incubated with compound before U69,593 stimulation for 10 mins",CHEMBL3588796,IC50,Cc1ccc(S(=O)(=O)NCc2ccc(C(=O)NCCN(Cc3ccc(Br)cc3)C(C)C)cc2)cc1
CHEMBL3590190,CHEMBL237,Kappa opioid receptor,IC50,=,1120.0,nM,CHEMBL3590954,B,"Antagonist activity against HA-tagged human recombinant kappa opioid receptor expressed in CHO cells assessed as inhibition of U69,593-induced ERK phosphorylation pre-incubated with compound before U69,593 stimulation for 10 mins",CHEMBL3588796,IC50,Cc1cc(C)c(S(=O)(=O)N2CCc3cc(C(=O)NCCN(Cc4ccccc4)C(C)C)ccc3C2)c(C)c1
CHEMBL3590191,CHEMBL237,Kappa opioid receptor,IC50,=,406.0,nM,CHEMBL3590954,B,"Antagonist activity against HA-tagged human recombinant kappa opioid receptor expressed in CHO cells assessed as inhibition of U69,593-induced ERK phosphorylation pre-incubated with compound before U69,593 stimulation for 10 mins",CHEMBL3588796,IC50,Cc1ccc(S(=O)(=O)N2CCc3cc(C(=O)NCCN(Cc4ccc(F)cc4)C(C)C)ccc3C2)cc1
CHEMBL3590192,CHEMBL237,Kappa opioid receptor,IC50,=,400.0,nM,CHEMBL3590954,B,"Antagonist activity against HA-tagged human recombinant kappa opioid receptor expressed in CHO cells assessed as inhibition of U69,593-induced ERK phosphorylation pre-incubated with compound before U69,593 stimulation for 10 mins",CHEMBL3588796,IC50,Cc1ccc(S(=O)(=O)N2CCc3cc(C(=O)NCCN(Cc4ccc(Cl)cc4)C(C)C)ccc3C2)cc1
CHEMBL3590193,CHEMBL237,Kappa opioid receptor,IC50,=,258.0,nM,CHEMBL3590954,B,"Antagonist activity against HA-tagged human recombinant kappa opioid receptor expressed in CHO cells assessed as inhibition of U69,593-induced ERK phosphorylation pre-incubated with compound before U69,593 stimulation for 10 mins",CHEMBL3588796,IC50,Cc1ccc(S(=O)(=O)N2CCc3cc(C(=O)NCCN(Cc4ccc(Br)cc4)C(C)C)ccc3C2)cc1
CHEMBL3590194,CHEMBL237,Kappa opioid receptor,IC50,=,314.0,nM,CHEMBL3590954,B,"Antagonist activity against HA-tagged human recombinant kappa opioid receptor expressed in CHO cells assessed as inhibition of U69,593-induced ERK phosphorylation pre-incubated with compound before U69,593 stimulation for 10 mins",CHEMBL3588796,IC50,CCc1ccc(S(=O)(=O)N2CCc3cc(C(=O)NCCN(Cc4ccc(Br)cc4)C(C)C)ccc3C2)cc1
CHEMBL3590195,CHEMBL237,Kappa opioid receptor,IC50,=,49.1,nM,CHEMBL3590954,B,"Antagonist activity against HA-tagged human recombinant kappa opioid receptor expressed in CHO cells assessed as inhibition of U69,593-induced ERK phosphorylation pre-incubated with compound before U69,593 stimulation for 10 mins",CHEMBL3588796,IC50,Cc1ccc(S(=O)(=O)N2CCc3cc(C(=O)NCCN(Cc4ccccc4)C(C)(C)C)ccc3C2)cc1
CHEMBL3590196,CHEMBL237,Kappa opioid receptor,IC50,=,143.0,nM,CHEMBL3590954,B,"Antagonist activity against HA-tagged human recombinant kappa opioid receptor expressed in CHO cells assessed as inhibition of U69,593-induced ERK phosphorylation pre-incubated with compound before U69,593 stimulation for 10 mins",CHEMBL3588796,IC50,CCc1ccc(S(=O)(=O)N2CCc3cc(C(=O)NCCN(Cc4ccccc4)C(C)(C)C)ccc3C2)cc1
CHEMBL3590197,CHEMBL237,Kappa opioid receptor,IC50,=,76.0,nM,CHEMBL3590954,B,"Antagonist activity against HA-tagged human recombinant kappa opioid receptor expressed in CHO cells assessed as inhibition of U69,593-induced ERK phosphorylation pre-incubated with compound before U69,593 stimulation for 10 mins",CHEMBL3588796,IC50,Cc1ccc(S(=O)(=O)N2CCc3cc(C(=O)NCCN(Cc4ccc(F)cc4)C(C)(C)C)ccc3C2)cc1
CHEMBL3590198,CHEMBL237,Kappa opioid receptor,IC50,=,1200.0,nM,CHEMBL3590954,B,"Antagonist activity against HA-tagged human recombinant kappa opioid receptor expressed in CHO cells assessed as inhibition of U69,593-induced ERK phosphorylation pre-incubated with compound before U69,593 stimulation for 10 mins",CHEMBL3588796,IC50,Cc1cc(C)c(S(=O)(=O)N2CCc3cc(C(=O)NCCN(Cc4ccc(F)cc4)C(C)(C)C)ccc3C2)c(C)c1
CHEMBL3590199,CHEMBL237,Kappa opioid receptor,IC50,=,107.0,nM,CHEMBL3590954,B,"Antagonist activity against HA-tagged human recombinant kappa opioid receptor expressed in CHO cells assessed as inhibition of U69,593-induced ERK phosphorylation pre-incubated with compound before U69,593 stimulation for 10 mins",CHEMBL3588796,IC50,Cc1ccc(S(=O)(=O)N2CCc3cc(C(=O)NCCN(Cc4ccc(Cl)cc4)C(C)(C)C)ccc3C2)cc1
CHEMBL3590200,CHEMBL237,Kappa opioid receptor,IC50,=,87.0,nM,CHEMBL3590954,B,"Antagonist activity against HA-tagged human recombinant kappa opioid receptor expressed in CHO cells assessed as inhibition of U69,593-induced ERK phosphorylation pre-incubated with compound before U69,593 stimulation for 10 mins",CHEMBL3588796,IC50,Cc1ccc(S(=O)(=O)N2CCc3cc(C(=O)NCCN(Cc4ccc(Br)cc4)C(C)(C)C)ccc3C2)cc1
CHEMBL3590201,CHEMBL237,Kappa opioid receptor,IC50,=,1340.0,nM,CHEMBL3590954,B,"Antagonist activity against HA-tagged human recombinant kappa opioid receptor expressed in CHO cells assessed as inhibition of U69,593-induced ERK phosphorylation pre-incubated with compound before U69,593 stimulation for 10 mins",CHEMBL3588796,IC50,Cc1cc(C)c(S(=O)(=O)N2CCc3cc(C(=O)NCCN(Cc4ccc(Br)cc4)C(C)(C)C)ccc3C2)c(C)c1
CHEMBL573214,CHEMBL237,Kappa opioid receptor,IC50,=,2.5,nM,CHEMBL3590955,B,"Antagonist activity against human kappa opioid receptor expressed in human U2OS cells co-expressing beta-arrestin2 pre-treated for 15 mins before U69,593 stimulation for 90 mins by DiscoveRx beta-arrestin2 recruitment based PathHunter assay",CHEMBL3588796,IC50,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL1455766,CHEMBL237,Kappa opioid receptor,IC50,=,403.0,nM,CHEMBL3590955,B,"Antagonist activity against human kappa opioid receptor expressed in human U2OS cells co-expressing beta-arrestin2 pre-treated for 15 mins before U69,593 stimulation for 90 mins by DiscoveRx beta-arrestin2 recruitment based PathHunter assay",CHEMBL3588796,IC50,Cc1ccc(S(=O)(=O)NCc2ccc(C(=O)NCCN(Cc3ccccc3)C(C)C)cc2)cc1
CHEMBL1724868,CHEMBL237,Kappa opioid receptor,IC50,=,937.0,nM,CHEMBL3590955,B,"Antagonist activity against human kappa opioid receptor expressed in human U2OS cells co-expressing beta-arrestin2 pre-treated for 15 mins before U69,593 stimulation for 90 mins by DiscoveRx beta-arrestin2 recruitment based PathHunter assay",CHEMBL3588796,IC50,Cc1ccc(S(=O)(=O)NCc2ccc(C(=O)NCCN(Cc3ccc(Br)cc3)C(C)C)cc2)cc1
CHEMBL3590190,CHEMBL237,Kappa opioid receptor,IC50,=,930.0,nM,CHEMBL3590955,B,"Antagonist activity against human kappa opioid receptor expressed in human U2OS cells co-expressing beta-arrestin2 pre-treated for 15 mins before U69,593 stimulation for 90 mins by DiscoveRx beta-arrestin2 recruitment based PathHunter assay",CHEMBL3588796,IC50,Cc1cc(C)c(S(=O)(=O)N2CCc3cc(C(=O)NCCN(Cc4ccccc4)C(C)C)ccc3C2)c(C)c1
CHEMBL3590191,CHEMBL237,Kappa opioid receptor,IC50,=,478.0,nM,CHEMBL3590955,B,"Antagonist activity against human kappa opioid receptor expressed in human U2OS cells co-expressing beta-arrestin2 pre-treated for 15 mins before U69,593 stimulation for 90 mins by DiscoveRx beta-arrestin2 recruitment based PathHunter assay",CHEMBL3588796,IC50,Cc1ccc(S(=O)(=O)N2CCc3cc(C(=O)NCCN(Cc4ccc(F)cc4)C(C)C)ccc3C2)cc1
CHEMBL3590192,CHEMBL237,Kappa opioid receptor,IC50,=,392.0,nM,CHEMBL3590955,B,"Antagonist activity against human kappa opioid receptor expressed in human U2OS cells co-expressing beta-arrestin2 pre-treated for 15 mins before U69,593 stimulation for 90 mins by DiscoveRx beta-arrestin2 recruitment based PathHunter assay",CHEMBL3588796,IC50,Cc1ccc(S(=O)(=O)N2CCc3cc(C(=O)NCCN(Cc4ccc(Cl)cc4)C(C)C)ccc3C2)cc1
CHEMBL3590193,CHEMBL237,Kappa opioid receptor,IC50,=,388.0,nM,CHEMBL3590955,B,"Antagonist activity against human kappa opioid receptor expressed in human U2OS cells co-expressing beta-arrestin2 pre-treated for 15 mins before U69,593 stimulation for 90 mins by DiscoveRx beta-arrestin2 recruitment based PathHunter assay",CHEMBL3588796,IC50,Cc1ccc(S(=O)(=O)N2CCc3cc(C(=O)NCCN(Cc4ccc(Br)cc4)C(C)C)ccc3C2)cc1
CHEMBL3590194,CHEMBL237,Kappa opioid receptor,IC50,=,350.0,nM,CHEMBL3590955,B,"Antagonist activity against human kappa opioid receptor expressed in human U2OS cells co-expressing beta-arrestin2 pre-treated for 15 mins before U69,593 stimulation for 90 mins by DiscoveRx beta-arrestin2 recruitment based PathHunter assay",CHEMBL3588796,IC50,CCc1ccc(S(=O)(=O)N2CCc3cc(C(=O)NCCN(Cc4ccc(Br)cc4)C(C)C)ccc3C2)cc1
CHEMBL3590195,CHEMBL237,Kappa opioid receptor,IC50,=,104.0,nM,CHEMBL3590955,B,"Antagonist activity against human kappa opioid receptor expressed in human U2OS cells co-expressing beta-arrestin2 pre-treated for 15 mins before U69,593 stimulation for 90 mins by DiscoveRx beta-arrestin2 recruitment based PathHunter assay",CHEMBL3588796,IC50,Cc1ccc(S(=O)(=O)N2CCc3cc(C(=O)NCCN(Cc4ccccc4)C(C)(C)C)ccc3C2)cc1
CHEMBL3590196,CHEMBL237,Kappa opioid receptor,IC50,=,186.0,nM,CHEMBL3590955,B,"Antagonist activity against human kappa opioid receptor expressed in human U2OS cells co-expressing beta-arrestin2 pre-treated for 15 mins before U69,593 stimulation for 90 mins by DiscoveRx beta-arrestin2 recruitment based PathHunter assay",CHEMBL3588796,IC50,CCc1ccc(S(=O)(=O)N2CCc3cc(C(=O)NCCN(Cc4ccccc4)C(C)(C)C)ccc3C2)cc1
CHEMBL3590197,CHEMBL237,Kappa opioid receptor,IC50,=,104.0,nM,CHEMBL3590955,B,"Antagonist activity against human kappa opioid receptor expressed in human U2OS cells co-expressing beta-arrestin2 pre-treated for 15 mins before U69,593 stimulation for 90 mins by DiscoveRx beta-arrestin2 recruitment based PathHunter assay",CHEMBL3588796,IC50,Cc1ccc(S(=O)(=O)N2CCc3cc(C(=O)NCCN(Cc4ccc(F)cc4)C(C)(C)C)ccc3C2)cc1
CHEMBL3590198,CHEMBL237,Kappa opioid receptor,IC50,=,880.0,nM,CHEMBL3590955,B,"Antagonist activity against human kappa opioid receptor expressed in human U2OS cells co-expressing beta-arrestin2 pre-treated for 15 mins before U69,593 stimulation for 90 mins by DiscoveRx beta-arrestin2 recruitment based PathHunter assay",CHEMBL3588796,IC50,Cc1cc(C)c(S(=O)(=O)N2CCc3cc(C(=O)NCCN(Cc4ccc(F)cc4)C(C)(C)C)ccc3C2)c(C)c1
CHEMBL3590199,CHEMBL237,Kappa opioid receptor,IC50,=,84.0,nM,CHEMBL3590955,B,"Antagonist activity against human kappa opioid receptor expressed in human U2OS cells co-expressing beta-arrestin2 pre-treated for 15 mins before U69,593 stimulation for 90 mins by DiscoveRx beta-arrestin2 recruitment based PathHunter assay",CHEMBL3588796,IC50,Cc1ccc(S(=O)(=O)N2CCc3cc(C(=O)NCCN(Cc4ccc(Cl)cc4)C(C)(C)C)ccc3C2)cc1
CHEMBL3590200,CHEMBL237,Kappa opioid receptor,IC50,=,93.0,nM,CHEMBL3590955,B,"Antagonist activity against human kappa opioid receptor expressed in human U2OS cells co-expressing beta-arrestin2 pre-treated for 15 mins before U69,593 stimulation for 90 mins by DiscoveRx beta-arrestin2 recruitment based PathHunter assay",CHEMBL3588796,IC50,Cc1ccc(S(=O)(=O)N2CCc3cc(C(=O)NCCN(Cc4ccc(Br)cc4)C(C)(C)C)ccc3C2)cc1
CHEMBL3590201,CHEMBL237,Kappa opioid receptor,IC50,=,710.0,nM,CHEMBL3590955,B,"Antagonist activity against human kappa opioid receptor expressed in human U2OS cells co-expressing beta-arrestin2 pre-treated for 15 mins before U69,593 stimulation for 90 mins by DiscoveRx beta-arrestin2 recruitment based PathHunter assay",CHEMBL3588796,IC50,Cc1cc(C)c(S(=O)(=O)N2CCc3cc(C(=O)NCCN(Cc4ccc(Br)cc4)C(C)(C)C)ccc3C2)c(C)c1
CHEMBL3809864,CHEMBL237,Kappa opioid receptor,IC50,=,1200.0,nM,CHEMBL3810966,B,Binding affinity to KOP receptor (unknown origin) at 10 uM,CHEMBL3808387,IC50,Nc1ccnc(-c2cc(-c3ccon3)n(Cc3ccccc3F)n2)n1
CHEMBL441765,CHEMBL237,Kappa opioid receptor,IC50,=,0.64,nM,CHEMBL3876379,B,Displacement of [3H]U 69593 from human recombinant kappa-opioid receptor expressed in CHO cells measured after 60 mins by scintillation counting method,CHEMBL3875185,IC50,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL4114012,CHEMBL237,Kappa opioid receptor,IC50,=,66.82,nM,CHEMBL3705818,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant kippa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 ul ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty ul/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added.",CHEMBL3638511,IC50,O=C(O)/C=C1\[C@H]2Cc3ccc(O)cc3[C@]1(CCCC(=O)O)CCN2CC1CC1
CHEMBL4071661,CHEMBL237,Kappa opioid receptor,IC50,=,1096.48,nM,CHEMBL4050974,B,Antagonist activity at KOR (unknown origin) expressed in HTLA cells assessed as inhibition of Sal A-induced beta-arrestin recruitment preincubated for overnight followed by Sal-A addition at 30 mins post compound treatment measured after 20 mins by Bright-Glo luminescence assay,CHEMBL4049419,IC50,Oc1cccc(C(O)CNCc2ccc(Cl)cc2Cl)c1
CHEMBL4071661,CHEMBL237,Kappa opioid receptor,IC50,=,1100.0,nM,CHEMBL4050974,B,Antagonist activity at KOR (unknown origin) expressed in HTLA cells assessed as inhibition of Sal A-induced beta-arrestin recruitment preincubated for overnight followed by Sal-A addition at 30 mins post compound treatment measured after 20 mins by Bright-Glo luminescence assay,CHEMBL4049419,IC50,Oc1cccc(C(O)CNCc2ccc(Cl)cc2Cl)c1
CHEMBL4128926,CHEMBL237,Kappa opioid receptor,IC50,=,1.1,nM,CHEMBL4121495,B,Displacement of [3H]U69593 from human kappa receptor after 60 mins by scintillation counting analysis,CHEMBL4118122,IC50,CC(C)(C)NS(=O)(=O)c1ccc(-c2sc(C(=O)N[C@H]3C[C@H](C(=O)O)C3)nc2CC2CCCCC2)c2ccccc12
CHEMBL3183148,CHEMBL237,Kappa opioid receptor,IC50,=,410.0,nM,CHEMBL4424268,B,Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-50488-induced beta-arrestin migration after 4 hrs by FRET assay,CHEMBL4422661,IC50,CCOC(=O)c1cc(C(=O)OC)c(C)nc1N1CCC(NC2CCCCC2O)CC1
CHEMBL4461337,CHEMBL237,Kappa opioid receptor,IC50,=,1.3,nM,CHEMBL4424268,B,Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-50488-induced beta-arrestin migration after 4 hrs by FRET assay,CHEMBL4422661,IC50,Cc1cnc(N2CC[C@H](NC3CCCCC3)[C@@H](O)C2)c(-c2nc(C)no2)c1
CHEMBL4526669,CHEMBL237,Kappa opioid receptor,IC50,=,1.3,nM,CHEMBL4424268,B,Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-50488-induced beta-arrestin migration after 4 hrs by FRET assay,CHEMBL4422661,IC50,Cc1ccc2nc(N3CCC(NCC(C)C)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4471169,CHEMBL237,Kappa opioid receptor,IC50,=,2.2,nM,CHEMBL4424268,B,Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-50488-induced beta-arrestin migration after 4 hrs by FRET assay,CHEMBL4422661,IC50,Cc1ccc2nc(N3CCC(NCC4CC4)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4464264,CHEMBL237,Kappa opioid receptor,IC50,=,1.3,nM,CHEMBL4424268,B,Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-50488-induced beta-arrestin migration after 4 hrs by FRET assay,CHEMBL4422661,IC50,CCc1ccc2nc(N3CCC(NCC(C)C)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4540091,CHEMBL237,Kappa opioid receptor,IC50,=,1.7,nM,CHEMBL4424268,B,Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-50488-induced beta-arrestin migration after 4 hrs by FRET assay,CHEMBL4422661,IC50,CCc1ccc2nc(N3CCC(NCC4CC4)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4461844,CHEMBL237,Kappa opioid receptor,IC50,=,7.0,nM,CHEMBL4424268,B,Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-50488-induced beta-arrestin migration after 4 hrs by FRET assay,CHEMBL4422661,IC50,CCc1ccc2nc(N3CCC(NC4CCOCC4)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4523014,CHEMBL237,Kappa opioid receptor,IC50,=,0.76,nM,CHEMBL4424268,B,Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-50488-induced beta-arrestin migration after 4 hrs by FRET assay,CHEMBL4422661,IC50,CCc1ccc2nc(N3CCC(N[C@@H](C)C(C)C)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4576339,CHEMBL237,Kappa opioid receptor,IC50,=,0.59,nM,CHEMBL4424268,B,Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-50488-induced beta-arrestin migration after 4 hrs by FRET assay,CHEMBL4422661,IC50,CCc1ccc2nc(N3CCC(N[C@H]4CCCC[C@@H]4O)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4434885,CHEMBL237,Kappa opioid receptor,IC50,=,4.5,nM,CHEMBL4424268,B,Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-50488-induced beta-arrestin migration after 4 hrs by FRET assay,CHEMBL4422661,IC50,CCc1ccc2nc(N3CCC(NCC4(C)COC4)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4459625,CHEMBL237,Kappa opioid receptor,IC50,=,0.77,nM,CHEMBL4424268,B,Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-50488-induced beta-arrestin migration after 4 hrs by FRET assay,CHEMBL4422661,IC50,CCc1ccc2nc(N3CCC(N[C@@H]4CCCOC4)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4572131,CHEMBL237,Kappa opioid receptor,IC50,=,1.5,nM,CHEMBL4424268,B,Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-50488-induced beta-arrestin migration after 4 hrs by FRET assay,CHEMBL4422661,IC50,CCc1ccc2nc(N3CCC(N[C@H]4CCCOC4)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4441250,CHEMBL237,Kappa opioid receptor,IC50,=,9.5,nM,CHEMBL4424268,B,Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-50488-induced beta-arrestin migration after 4 hrs by FRET assay,CHEMBL4422661,IC50,CCc1ccc2nc(N3CCC(N[C@@H]4CCOC4)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4444292,CHEMBL237,Kappa opioid receptor,IC50,=,10.3,nM,CHEMBL4424268,B,Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-50488-induced beta-arrestin migration after 4 hrs by FRET assay,CHEMBL4422661,IC50,CCc1ccc2nc(N3CCC(N[C@H]4CCOC4)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4584410,CHEMBL237,Kappa opioid receptor,IC50,=,3.6,nM,CHEMBL4424268,B,Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-50488-induced beta-arrestin migration after 4 hrs by FRET assay,CHEMBL4422661,IC50,CCc1cc(F)c2nc(N3CCC(NC4CCOCC4)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4443303,CHEMBL237,Kappa opioid receptor,IC50,=,2.1,nM,CHEMBL4424268,B,Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-50488-induced beta-arrestin migration after 4 hrs by FRET assay,CHEMBL4422661,IC50,CCc1cc(F)c2nc(N3CCC(N[C@H]4CCCOC4)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4566736,CHEMBL237,Kappa opioid receptor,IC50,=,2.3,nM,CHEMBL4424268,B,Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-50488-induced beta-arrestin migration after 4 hrs by FRET assay,CHEMBL4422661,IC50,CCc1cc(F)c2nc(N3CCC(N[C@@H]4CCOC4)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4525666,CHEMBL237,Kappa opioid receptor,IC50,=,2.4,nM,CHEMBL4424268,B,Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-50488-induced beta-arrestin migration after 4 hrs by FRET assay,CHEMBL4422661,IC50,CCc1cc(F)c2nc(N3CCC(N[C@H]4CCOC4)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4544914,CHEMBL237,Kappa opioid receptor,IC50,=,0.26,nM,CHEMBL4424268,B,Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-50488-induced beta-arrestin migration after 4 hrs by FRET assay,CHEMBL4422661,IC50,CCc1cc(F)c2nc(N3CCC(N[C@@H]4CCCOC4)CC3)c(-c3nc(C)no3)c(C)c2c1
CHEMBL4440683,CHEMBL237,Kappa opioid receptor,IC50,=,0.53,nM,CHEMBL4424268,B,Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-50488-induced beta-arrestin migration after 4 hrs by FRET assay,CHEMBL4422661,IC50,CCc1cc(F)c2nc(N3CCC(N[C@H]4CCCOC4)CC3)c(-c3nc(C)no3)c(C)c2c1
CHEMBL4456582,CHEMBL237,Kappa opioid receptor,IC50,=,0.78,nM,CHEMBL4424268,B,Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-50488-induced beta-arrestin migration after 4 hrs by FRET assay,CHEMBL4422661,IC50,CCc1cc(F)c2nc(N3CCC(N[C@@H]4CCOC4)CC3)c(-c3nc(C)no3)c(C)c2c1
CHEMBL4549826,CHEMBL237,Kappa opioid receptor,IC50,=,0.88,nM,CHEMBL4424268,B,Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-50488-induced beta-arrestin migration after 4 hrs by FRET assay,CHEMBL4422661,IC50,CCc1cc(F)c2nc(N3CCC(N[C@H]4CCOC4)CC3)c(-c3nc(C)no3)c(C)c2c1
CHEMBL4440935,CHEMBL237,Kappa opioid receptor,IC50,=,3.0,nM,CHEMBL4424268,B,Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-50488-induced beta-arrestin migration after 4 hrs by FRET assay,CHEMBL4422661,IC50,Cc1ccc2nc(N3CCC(NC4CCOCC4)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4583245,CHEMBL237,Kappa opioid receptor,IC50,=,1.1,nM,CHEMBL4424268,B,Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-50488-induced beta-arrestin migration after 4 hrs by FRET assay,CHEMBL4422661,IC50,CCc1cc(F)c2nc(N3CCC(N[C@@H]4CCCOC4)CC3)c(-c3nc(C)no3)cc2c1
CHEMBL4592045,CHEMBL237,Kappa opioid receptor,IC50,=,0.8,nM,CHEMBL4424268,B,Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-50488-induced beta-arrestin migration after 4 hrs by FRET assay,CHEMBL4422661,IC50,CCc1cc(F)c2nc(N3CCC(NC4CCOCC4)CC3)c(-c3nc(C)no3)c(C)c2c1
CHEMBL3264446,CHEMBL237,Kappa opioid receptor,IC50,=,12.6,nM,CHEMBL4424268,B,Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-50488-induced beta-arrestin migration after 4 hrs by FRET assay,CHEMBL4422661,IC50,COC(=O)c1cc(Br)cnc1N1CC[C@@H](NC2CCCCC2)[C@H](O)C1
CHEMBL506616,CHEMBL237,Kappa opioid receptor,IC50,=,47.0,nM,CHEMBL4430531,B,Binding affinity to KOR (unknown origin),CHEMBL4428100,IC50,O=C1N[C@@H](Cc2ccccc2)C(=O)N2CCC[C@@H]2C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H]1Cc1c[nH]c2ccccc12
CHEMBL4639379,CHEMBL237,Kappa opioid receptor,IC50,=,398.11,nM,CHEMBL4626037,B,Displacement of [3H]U69593 from KOR (unknown origin) measured after 60 mins by scintillation counting method,CHEMBL4622972,IC50,Cc1ccc2[nH]c(C(=O)N[C@H]3Cc4ccccc4[C@@H]3C(=O)NCCN(C)C)cc2c1
CHEMBL4640438,CHEMBL237,Kappa opioid receptor,IC50,=,1995.26,nM,CHEMBL4626037,B,Displacement of [3H]U69593 from KOR (unknown origin) measured after 60 mins by scintillation counting method,CHEMBL4622972,IC50,O=C(N[C@H]1CN(S(=O)(=O)c2ccccc2)C[C@@H]1C(=O)N[C@H]1CCCNC1)c1cc(-c2ccccc2)on1
CHEMBL4639111,CHEMBL237,Kappa opioid receptor,IC50,=,794.33,nM,CHEMBL4626037,B,Displacement of [3H]U69593 from KOR (unknown origin) measured after 60 mins by scintillation counting method,CHEMBL4622972,IC50,O=C(N[C@H]1CN(S(=O)(=O)c2ccccc2)C[C@@H]1C(=O)N[C@H]1CCCNC1)c1cc(-c2ccccc2Cl)on1
CHEMBL4797769,CHEMBL237,Kappa opioid receptor,IC50,=,398.11,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O
CHEMBL4750644,CHEMBL237,Kappa opioid receptor,IC50,=,93.33,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(C)=O)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O
CHEMBL4745486,CHEMBL237,Kappa opioid receptor,IC50,=,125.89,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](C)Cc1c(C)cc(O)cc1C)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O
CHEMBL4754961,CHEMBL237,Kappa opioid receptor,IC50,=,0.5495,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O
CHEMBL4745504,CHEMBL237,Kappa opioid receptor,IC50,=,7079.46,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,IC50,CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL4780433,CHEMBL237,Kappa opioid receptor,IC50,=,186.21,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,IC50,CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL4788135,CHEMBL237,Kappa opioid receptor,IC50,=,6918.31,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,IC50,CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL4755568,CHEMBL237,Kappa opioid receptor,IC50,=,9120.11,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,IC50,CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL4761040,CHEMBL237,Kappa opioid receptor,IC50,=,1479.11,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(C)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL4762413,CHEMBL237,Kappa opioid receptor,IC50,=,114.82,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL4787539,CHEMBL237,Kappa opioid receptor,IC50,=,416.87,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](C)Cc1c(C)cc(O)cc1C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O
CHEMBL4779988,CHEMBL237,Kappa opioid receptor,IC50,=,158.49,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(C)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL4754076,CHEMBL237,Kappa opioid receptor,IC50,=,117.49,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](C)Cc1c(C)cc(O)cc1C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL4784791,CHEMBL237,Kappa opioid receptor,IC50,=,0.1318,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL4757601,CHEMBL237,Kappa opioid receptor,IC50,=,0.8913,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O
CHEMBL4760958,CHEMBL237,Kappa opioid receptor,IC50,=,0.7943,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O
CHEMBL216640,CHEMBL237,Kappa opioid receptor,IC50,=,0.1549,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL438223,CHEMBL237,Kappa opioid receptor,IC50,=,0.1096,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O
CHEMBL405618,CHEMBL237,Kappa opioid receptor,IC50,=,0.1479,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O
CHEMBL80,CHEMBL237,Kappa opioid receptor,IC50,=,140.0,nM,CHEMBL4719723,B,"Antagonist activity at human KOR expressed in CHO cell membranes assessed as reduction in U50,488 induced response incubated for 1 hr by liquid scintillation counting based [35S]GTP-gamma-S assay",CHEMBL4715797,IC50,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL4745486,CHEMBL237,Kappa opioid receptor,IC50,=,750.0,nM,CHEMBL4719723,B,"Antagonist activity at human KOR expressed in CHO cell membranes assessed as reduction in U50,488 induced response incubated for 1 hr by liquid scintillation counting based [35S]GTP-gamma-S assay",CHEMBL4715797,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](C)Cc1c(C)cc(O)cc1C)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O
CHEMBL4754076,CHEMBL237,Kappa opioid receptor,IC50,=,220.0,nM,CHEMBL4719723,B,"Antagonist activity at human KOR expressed in CHO cell membranes assessed as reduction in U50,488 induced response incubated for 1 hr by liquid scintillation counting based [35S]GTP-gamma-S assay",CHEMBL4715797,IC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](C)Cc1c(C)cc(O)cc1C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL1800685,CHEMBL237,Kappa opioid receptor,IC50,=,8030.0,nM,CHEMBL4880826,B,"Inhibition of Opiate kappa (OP2, KOP) at 10 M in the Eurofins-Panlabs radioligand binding assay (Eurofins_assay_260210)",CHEMBL4507292,IC50,O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1
CHEMBL3091687,CHEMBL237,Kappa opioid receptor,IC50,=,1600.0,nM,CHEMBL5048804,B,Inhibition of kappa opioid receptor (unknown origin),CHEMBL5046278,IC50,NCCCCN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21
CHEMBL5070958,CHEMBL237,Kappa opioid receptor,IC50,=,1100.0,nM,CHEMBL5048804,B,Inhibition of kappa opioid receptor (unknown origin),CHEMBL5046278,IC50,NCCCCN(C[C@H]1Cc2ncccc2CN1)[C@H]1CCCc2cccnc21
CHEMBL5076569,CHEMBL237,Kappa opioid receptor,IC50,=,4000.0,nM,CHEMBL5048804,B,Inhibition of kappa opioid receptor (unknown origin),CHEMBL5046278,IC50,NCCCCN(C[C@H]1Cc2cccnc2CN1)[C@H]1CCCc2cccnc21
CHEMBL5085511,CHEMBL237,Kappa opioid receptor,IC50,=,4300.0,nM,CHEMBL5048804,B,Inhibition of kappa opioid receptor (unknown origin),CHEMBL5046278,IC50,c1cnc2c(c1)CN[C@@H](CN(CCCCNC1CCOCC1)[C@H]1CCCc3cccnc31)C2
CHEMBL5077132,CHEMBL237,Kappa opioid receptor,IC50,=,8900.0,nM,CHEMBL5048804,B,Inhibition of kappa opioid receptor (unknown origin),CHEMBL5046278,IC50,CN(CCCCN(C[C@H]1Cc2ncccc2CN1)[C@H]1CCCc2cccnc21)C1CCOCC1
CHEMBL5083458,CHEMBL237,Kappa opioid receptor,IC50,=,10100.0,nM,CHEMBL5048804,B,Inhibition of kappa opioid receptor (unknown origin),CHEMBL5046278,IC50,c1cnc2c(c1)CN[C@@H](CN(CCCCNC1COC1)[C@H]1CCCc3cccnc31)C2
CHEMBL5081505,CHEMBL237,Kappa opioid receptor,IC50,=,4800.0,nM,CHEMBL5048804,B,Inhibition of kappa opioid receptor (unknown origin),CHEMBL5046278,IC50,c1cnc2c(c1)CN[C@@H](CN(CCCC1CCNCC1)[C@H]1CCCc3cccnc31)C2
CHEMBL5083183,CHEMBL237,Kappa opioid receptor,IC50,=,181.97,nM,CHEMBL5055009,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in mouse HN9.10 cells by radioligand binding assay",CHEMBL5053542,IC50,CCC(=O)N(c1ccc(Cl)c(Cl)c1)C1CCN(C(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc2ccc(O)cc2)CC1
CHEMBL5081245,CHEMBL237,Kappa opioid receptor,IC50,=,190.55,nM,CHEMBL5055009,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in mouse HN9.10 cells by radioligand binding assay",CHEMBL5053542,IC50,CCC(=O)N(c1ccc(Cl)c(Cl)c1)C1CCN(C(=O)[C@H](Cc2ccc(Cl)cc2)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc2ccc(O)cc2)CC1
CHEMBL5091642,CHEMBL237,Kappa opioid receptor,IC50,=,83.18,nM,CHEMBL5055009,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in mouse HN9.10 cells by radioligand binding assay",CHEMBL5053542,IC50,CCCC[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](Cc1ccc(F)cc1)C(=O)N1CCC(N(C(=O)CC)c2ccc(Cl)c(Cl)c2)CC1
CHEMBL5078669,CHEMBL237,Kappa opioid receptor,IC50,=,23.99,nM,CHEMBL5055009,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in mouse HN9.10 cells by radioligand binding assay",CHEMBL5053542,IC50,CCC(=O)N(c1ccc(Cl)c(Cl)c1)C1CCN(C(=O)[C@H](Cc2ccc(Cl)cc2)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)CC1
CHEMBL5086370,CHEMBL237,Kappa opioid receptor,IC50,=,6.026,nM,CHEMBL5055009,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in mouse HN9.10 cells by radioligand binding assay",CHEMBL5053542,IC50,CCCC[C@@H](NC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C)C(=O)NCC(=O)N[C@@H](Cc1ccc(F)cc1)C(=O)N1CCC(N(C(=O)CC)c2ccc(Cl)c(Cl)c2)CC1
CHEMBL5094499,CHEMBL237,Kappa opioid receptor,IC50,=,1.905,nM,CHEMBL5055009,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in mouse HN9.10 cells by radioligand binding assay",CHEMBL5053542,IC50,CCC(=O)N(c1ccc(Cl)c(Cl)c1)C1CCN(C(=O)[C@H](Cc2ccc(Cl)cc2)NC(=O)CNC(=O)[C@H]2Cc3ccccc3CN2C(=O)[C@@H](N)Cc2cc(C)c(O)c(C)c2)CC1
CHEMBL5089012,CHEMBL237,Kappa opioid receptor,IC50,=,0.537,nM,CHEMBL5055009,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in mouse HN9.10 cells by radioligand binding assay",CHEMBL5053542,IC50,CCC(=O)N(c1ccc(Cl)c(Cl)c1)C1CCN(C(=O)[C@H](Cc2ccc(F)cc2)NC(=O)CNC(=O)[C@H]2Cc3ccccc3CN2C(=O)[C@@H](N)Cc2cc(C)c(O)c(C)c2)CC1
CHEMBL5077561,CHEMBL237,Kappa opioid receptor,IC50,=,123.03,nM,CHEMBL5055009,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in mouse HN9.10 cells by radioligand binding assay",CHEMBL5053542,IC50,CCC(=O)N(c1ccc(Cl)c(Cl)c1)C1CCN(C(=O)[C@H](Cc2ccc(Cl)cc2)NC(=O)[C@H]2Cc3ccccc3CN2C(=O)[C@@H](N)Cc2cc(C)c(O)c(C)c2)CC1
CHEMBL5090705,CHEMBL237,Kappa opioid receptor,IC50,=,97.72,nM,CHEMBL5055009,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in mouse HN9.10 cells by radioligand binding assay",CHEMBL5053542,IC50,CCC(=O)N(c1ccc(Cl)c(Cl)c1)C1CCN(C(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H]2Cc3ccccc3CN2C(=O)[C@@H](N)Cc2cc(C)c(O)c(C)c2)CC1
CHEMBL235743,CHEMBL237,Kappa opioid receptor,IC50,=,223.87,nM,CHEMBL5055009,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in mouse HN9.10 cells by radioligand binding assay",CHEMBL5053542,IC50,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(N)=O
CHEMBL1729417,CHEMBL237,Kappa opioid receptor,IC50,=,120.0,nM,CHEMBL5114235,B,Antagonist at KOR expressed in human U2OS cells measured by High content imaging based beta-arrestin translocation assay,CHEMBL5113380,IC50,COc1ccc(N2CCN(CCCNC(=O)Cn3c(=O)c4cccn4c4c(C)ccnc43)CC2)cc1
CHEMBL1455045,CHEMBL237,Kappa opioid receptor,IC50,=,173.0,nM,CHEMBL5114235,B,Antagonist at KOR expressed in human U2OS cells measured by High content imaging based beta-arrestin translocation assay,CHEMBL5113380,IC50,COc1ccc(N2CCN(CCCNC(=O)Cn3c(=O)c4cccn4c4cccnc43)CC2)cc1
CHEMBL5184444,CHEMBL237,Kappa opioid receptor,IC50,=,2820.0,nM,CHEMBL5114235,B,Antagonist at KOR expressed in human U2OS cells measured by High content imaging based beta-arrestin translocation assay,CHEMBL5113380,IC50,COc1ccc(N2CCN(CCCNC(=O)CN3C(=O)C4CCCN4c4c(C)ccnc43)CC2)cc1
CHEMBL4848517,CHEMBL237,Kappa opioid receptor,IC50,=,10000.0,nM,CHEMBL5127645,B,Inhibition of KOP (unknown origin),CHEMBL5126521,IC50,C=C[C@H]1CN2CCc3c([nH]c4cccc(OC)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL4859858,CHEMBL237,Kappa opioid receptor,IC50,=,10000.0,nM,CHEMBL5127645,B,Inhibition of KOP (unknown origin),CHEMBL5126521,IC50,CC[C@H]1CN2CCc3c([nH]c4cccc(OC)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL4546925,CHEMBL237,Kappa opioid receptor,IC50,=,10000.0,nM,CHEMBL5127645,B,Inhibition of KOP (unknown origin),CHEMBL5126521,IC50,CC[C@@H]1CN2CCc3c([nH]c4cccc(OC)c34)[C@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL5178409,CHEMBL237,Kappa opioid receptor,IC50,=,691.0,nM,CHEMBL5127645,B,Inhibition of KOP (unknown origin),CHEMBL5126521,IC50,CC[C@@H]1CN2CC[C@]3(O)c4c(cccc4OC)NC3[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL3752911,CHEMBL237,Kappa opioid receptor,IC50,=,13000.0,nM,CHEMBL5214136,B,Selectivity interaction (CEREP panel (cellular receptors and 30 other enzymes)) EUB0000199c OPRK1,CHEMBL5212743,IC50,O=C(/C=C/N1C[C@H]2C[C@@H]1CN2c1ccccn1)c1ccccc1O
CHEMBL5430894,CHEMBL237,Kappa opioid receptor,IC50,=,250.0,nM,CHEMBL5384106,B,Displacement of [3H]diprenorphine from human KOR expressed in HEK293 cells incubated for 60 mins by liquid scintillation method,CHEMBL5380841,IC50,COc1cccc(Cn2nc(CNCc3cccc(OCc4ccccc4)c3)c3c4cc(OC)c(OC)cc4c(-c4ccccc4Cl)nc32)c1
CHEMBL440765,CHEMBL237,Kappa opioid receptor,IC50,=,6.69,nM,CHEMBL5384106,B,Displacement of [3H]diprenorphine from human KOR expressed in HEK293 cells incubated for 60 mins by liquid scintillation method,CHEMBL5380841,IC50,CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL108417,CHEMBL237,Kappa opioid receptor,Ki,=,4099.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,CC(c1ccccc1)N1CC[C@H]1[C@@H](N)c1cccc(Cl)c1
CHEMBL322717,CHEMBL237,Kappa opioid receptor,Ki,=,1945.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,CCCCCCC(c1ccccc1)N1CC[C@H]1[C@@H](N)c1cccc(Cl)c1
CHEMBL110138,CHEMBL237,Kappa opioid receptor,Ki,=,1841.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,Cc1ccc(C(c2ccc(C)cc2)N2CC[C@H]2[C@H](N)c2cccc(Cl)c2)cc1
CHEMBL110379,CHEMBL237,Kappa opioid receptor,Ki,=,2134.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,CCCCC(c1cccc(F)c1)N1CC[C@H]1[C@H](N)c1cccc(Cl)c1
CHEMBL448155,CHEMBL237,Kappa opioid receptor,Ki,=,1341.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,COc1ccc([C@H](N)[C@@H]2CCN2C(c2ccccc2)c2ccccc2)cc1
CHEMBL321462,CHEMBL237,Kappa opioid receptor,Ki,=,2240.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,N[C@H](c1cccc(Cl)c1)[C@@H]1CCN1C(c1ccc(F)cc1)c1ccc(F)cc1
CHEMBL107288,CHEMBL237,Kappa opioid receptor,Ki,=,3684.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,CCCCC(c1ccccc1)N1CC[C@H]1[C@@H](N)c1cccc(Cl)c1
CHEMBL108893,CHEMBL237,Kappa opioid receptor,Ki,=,3432.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,CCCCC(c1ccccc1)N1CC[C@H]1[C@H](N)c1cccc(Cl)c1
CHEMBL327118,CHEMBL237,Kappa opioid receptor,Ki,=,6037.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,N[C@H](c1cccc(Cl)c1)[C@@H]1CCN1C(c1cccc(Cl)c1)c1cccc(Cl)c1
CHEMBL554230,CHEMBL237,Kappa opioid receptor,Ki,=,5100.0,nM,CHEMBL750076,B,"Binding affinity against Opioid receptor kappa 1 of calf cortex using [3H]-U-69,593 as radioligand",CHEMBL1133410,KI,COCCC1CC2CN3CCc4c([nH]c5ccccc45)C(C(=O)OC)(C2)C13.Cl
CHEMBL108904,CHEMBL237,Kappa opioid receptor,Ki,=,607.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,N[C@@H](c1ccc(Cl)cc1)[C@@H]1CCN1C(c1ccccc1)c1ccccc1
CHEMBL324895,CHEMBL237,Kappa opioid receptor,Ki,=,6488.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,CCCCC(c1cc(F)cc(F)c1)N1CC[C@H]1[C@@H](N)c1cccc(Cl)c1
CHEMBL317479,CHEMBL237,Kappa opioid receptor,Ki,=,641.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,N[C@H](c1cccc(C(F)(F)F)c1)[C@H]1CCN1C(c1ccccc1)c1ccccc1
CHEMBL320804,CHEMBL237,Kappa opioid receptor,Ki,=,7718.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,CCC(c1ccccc1)N1CC[C@H]1[C@H](N)c1cccc(Cl)c1
CHEMBL110933,CHEMBL237,Kappa opioid receptor,Ki,=,2938.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,CCCC(c1ccccc1)N1CC[C@H]1[C@@H](N)c1cccc(Cl)c1
CHEMBL106084,CHEMBL237,Kappa opioid receptor,Ki,=,3911.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,CCCCCC(c1ccccc1)N1CC[C@H]1[C@@H](N)c1cccc(Cl)c1
CHEMBL106190,CHEMBL237,Kappa opioid receptor,Ki,=,4125.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,CCCCC(c1cccc(F)c1)N1CC[C@H]1[C@@H](N)c1cccc(Cl)c1
CHEMBL316961,CHEMBL237,Kappa opioid receptor,Ki,=,1634.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,N[C@@H](c1cccc(C(F)(F)F)c1)[C@@H]1CCN1C(c1ccccc1)c1ccccc1
CHEMBL110126,CHEMBL237,Kappa opioid receptor,Ki,=,660.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,Cc1ccc([C@H](N)[C@@H]2CCN2C(c2ccccc2)c2ccccc2)cc1
CHEMBL554230,CHEMBL237,Kappa opioid receptor,Ki,=,4800.0,nM,CHEMBL750076,B,"Binding affinity against Opioid receptor kappa 1 of calf cortex using [3H]-U-69,593 as radioligand",CHEMBL1133410,KI,COCCC1CC2CN3CCc4c([nH]c5ccccc45)C(C(=O)OC)(C2)C13.Cl
CHEMBL106359,CHEMBL237,Kappa opioid receptor,Ki,=,4262.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,CCCCC(CCCC)N1CC[C@H]1[C@@H](N)c1cccc(Cl)c1
CHEMBL324897,CHEMBL237,Kappa opioid receptor,Ki,=,3533.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,N[C@H](c1cccc(Cl)c1)[C@@H]1CCN1C(c1cccc(F)c1)c1cccc(F)c1
CHEMBL108995,CHEMBL237,Kappa opioid receptor,Ki,=,2993.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,CCCCCC(c1ccccc1)N1CC[C@H]1[C@H](N)c1cccc(Cl)c1
CHEMBL108900,CHEMBL237,Kappa opioid receptor,Ki,=,4219.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,CCCCC(c1cc(F)cc(F)c1)N1CC[C@H]1[C@H](N)c1cccc(Cl)c1
CHEMBL554230,CHEMBL237,Kappa opioid receptor,Ki,=,5500.0,nM,CHEMBL750076,B,"Binding affinity against Opioid receptor kappa 1 of calf cortex using [3H]-U-69,593 as radioligand",CHEMBL1133410,KI,COCCC1CC2CN3CCc4c([nH]c5ccccc45)C(C(=O)OC)(C2)C13.Cl
CHEMBL106235,CHEMBL237,Kappa opioid receptor,Ki,=,13130.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,CCC(c1ccccc1)N1CC[C@H]1[C@@H](N)c1cccc(Cl)c1
CHEMBL108894,CHEMBL237,Kappa opioid receptor,Ki,=,150.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,Cc1ccc([C@H](N)[C@@H]2CCN2C(c2ccccc2)c2ccccc2)cc1F
CHEMBL419179,CHEMBL237,Kappa opioid receptor,Ki,=,4015.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,N[C@@H](c1cc(F)cc(F)c1)[C@@H]1CCN1C(c1ccccc1)c1ccccc1
CHEMBL106155,CHEMBL237,Kappa opioid receptor,Ki,=,2855.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,CCCCCCC(c1ccccc1)N1CC[C@H]1[C@H](N)c1cccc(Cl)c1
CHEMBL316961,CHEMBL237,Kappa opioid receptor,Ki,=,3565.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,N[C@@H](c1cccc(C(F)(F)F)c1)[C@@H]1CCN1C(c1ccccc1)c1ccccc1
CHEMBL106785,CHEMBL237,Kappa opioid receptor,Ki,=,3251.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,N[C@H](c1cccc(Cl)c1)[C@@H]1CCN1C(c1ccc(Cl)cc1)c1ccc(Cl)cc1
CHEMBL320582,CHEMBL237,Kappa opioid receptor,Ki,=,1484.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,N[C@H](c1cccc(Cl)c1)[C@@H]1CCN1C(c1ccc(Br)cc1)c1ccc(Br)cc1
CHEMBL324635,CHEMBL237,Kappa opioid receptor,Ki,=,1232.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,N[C@@H](c1cccc(Cl)c1)[C@@H]1CCN1C(c1ccccc1)c1ccccc1
CHEMBL106043,CHEMBL237,Kappa opioid receptor,Ki,=,2772.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,N[C@@H](c1ccc(Oc2ccccc2)cc1)[C@@H]1CCN1C(c1ccccc1)c1ccccc1
CHEMBL431445,CHEMBL237,Kappa opioid receptor,Ki,=,997.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,N[C@@H](c1cccc(F)c1)[C@@H]1CCN1C(c1ccccc1)c1ccccc1
CHEMBL106366,CHEMBL237,Kappa opioid receptor,Ki,=,7172.0,nM,CHEMBL755696,B,Binding affinity at human opioid receptor kappa 1 was determined by using [3H]diprenorphine radioligand in CHO cell membranes at a concentration of 0.31 nM,CHEMBL1134945,KI,CCCC(c1ccccc1)N1CC[C@H]1[C@H](N)c1cccc(Cl)c1
CHEMBL217379,CHEMBL237,Kappa opioid receptor,Ki,=,4.6,nM,CHEMBL751030,B,In vitro binding affinity towards human Opioid receptor kappa 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O
CHEMBL2369408,CHEMBL237,Kappa opioid receptor,Ki,=,0.44,nM,CHEMBL751030,B,In vitro binding affinity towards human Opioid receptor kappa 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL413729,CHEMBL237,Kappa opioid receptor,Ki,=,2.4,nM,CHEMBL751030,B,In vitro binding affinity towards human Opioid receptor kappa 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL2369394,CHEMBL237,Kappa opioid receptor,Ki,=,5600.0,nM,CHEMBL751030,B,In vitro binding affinity towards human Opioid receptor kappa 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O
CHEMBL2369393,CHEMBL237,Kappa opioid receptor,Ki,=,41.7,nM,CHEMBL751030,B,In vitro binding affinity towards human Opioid receptor kappa 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)O
CHEMBL269483,CHEMBL237,Kappa opioid receptor,Ki,=,0.35,nM,CHEMBL751030,B,In vitro binding affinity towards human Opioid receptor kappa 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)O
CHEMBL2369366,CHEMBL237,Kappa opioid receptor,Ki,=,1.2,nM,CHEMBL751030,B,In vitro binding affinity towards human Opioid receptor kappa 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL2369391,CHEMBL237,Kappa opioid receptor,Ki,=,60.3,nM,CHEMBL751030,B,In vitro binding affinity towards human Opioid receptor kappa 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O
CHEMBL2369395,CHEMBL237,Kappa opioid receptor,Ki,=,79.4,nM,CHEMBL751030,B,In vitro binding affinity towards human Opioid receptor kappa 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL2369390,CHEMBL237,Kappa opioid receptor,Ki,=,10.7,nM,CHEMBL751030,B,In vitro binding affinity towards human Opioid receptor kappa 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O
CHEMBL2369389,CHEMBL237,Kappa opioid receptor,Ki,=,10.0,nM,CHEMBL751030,B,In vitro binding affinity towards human Opioid receptor kappa 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(N)=O
CHEMBL216640,CHEMBL237,Kappa opioid receptor,Ki,=,0.059,nM,CHEMBL751030,B,In vitro binding affinity towards human Opioid receptor kappa 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL265813,CHEMBL237,Kappa opioid receptor,Ki,=,0.23,nM,CHEMBL751030,B,In vitro binding affinity towards human Opioid receptor kappa 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O
CHEMBL573214,CHEMBL237,Kappa opioid receptor,Ki,=,0.37,nM,CHEMBL751030,B,In vitro binding affinity towards human Opioid receptor kappa 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL2369365,CHEMBL237,Kappa opioid receptor,Ki,=,3.39,nM,CHEMBL751030,B,In vitro binding affinity towards human Opioid receptor kappa 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CCCN=C(N)N)C(N)=O
CHEMBL407832,CHEMBL237,Kappa opioid receptor,Ki,=,2.5,nM,CHEMBL751030,B,In vitro binding affinity towards human Opioid receptor kappa 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O
CHEMBL63188,CHEMBL237,Kappa opioid receptor,Ki,=,404.0,nM,CHEMBL751030,B,In vitro binding affinity towards human Opioid receptor kappa 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O
CHEMBL80,CHEMBL237,Kappa opioid receptor,Ki,=,10.7,nM,CHEMBL751030,B,In vitro binding affinity towards human Opioid receptor kappa 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL2369370,CHEMBL237,Kappa opioid receptor,Ki,=,6.61,nM,CHEMBL751030,B,In vitro binding affinity towards human Opioid receptor kappa 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O
CHEMBL293465,CHEMBL237,Kappa opioid receptor,Ki,=,4.96,nM,CHEMBL751030,B,In vitro binding affinity towards human Opioid receptor kappa 1 on CHO cell membranes using [3H]diprenorphine displacement.,CHEMBL1144926,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O
CHEMBL110816,CHEMBL237,Kappa opioid receptor,Ki,=,1.57,nM,CHEMBL755685,B,Ability to displace [3H]U-69593 from human recombinant Opioid receptor kappa 1 in CHO cells,CHEMBL1145106,KI,CCC(=O)NCCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL326875,CHEMBL237,Kappa opioid receptor,Ki,=,0.3,nM,CHEMBL755685,B,Ability to displace [3H]U-69593 from human recombinant Opioid receptor kappa 1 in CHO cells,CHEMBL1145106,KI,CCCCC(=N)NCCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL573214,CHEMBL237,Kappa opioid receptor,Ki,=,0.2,nM,CHEMBL755685,B,Ability to displace [3H]U-69593 from human recombinant Opioid receptor kappa 1 in CHO cells,CHEMBL1145106,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL107655,CHEMBL237,Kappa opioid receptor,Ki,=,6.33,nM,CHEMBL755685,B,Ability to displace [3H]U-69593 from human recombinant Opioid receptor kappa 1 in CHO cells,CHEMBL1145106,KI,CCCCNC(=O)NCCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL286411,CHEMBL237,Kappa opioid receptor,Ki,=,6212.0,nM,CHEMBL752738,B,Tested for the opioid receptor kappa 1 binding affinity using membrane preparations from recombinant HEK293 cells with [3H]U-69593 radioligand,CHEMBL1147615,KI,CC(C)C1CCC(N2CCC(N3C(=O)N[C@@H]4CCCC[C@H]43)CC2)CC1
CHEMBL323987,CHEMBL237,Kappa opioid receptor,Ki,=,0.28,nM,CHEMBL755685,B,Ability to displace [3H]U-69593 from human recombinant Opioid receptor kappa 1 in CHO cells,CHEMBL1145106,KI,CCC(=N)NCCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL324644,CHEMBL237,Kappa opioid receptor,Ki,=,0.68,nM,CHEMBL755685,B,Ability to displace [3H]U-69593 from human recombinant Opioid receptor kappa 1 in CHO cells,CHEMBL1145106,KI,CCCCC(=O)NCCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL108938,CHEMBL237,Kappa opioid receptor,Ki,=,0.25,nM,CHEMBL755685,B,Ability to displace [3H]U-69593 from human recombinant Opioid receptor kappa 1 in CHO cells,CHEMBL1145106,KI,CCCC(=N)NCCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL106758,CHEMBL237,Kappa opioid receptor,Ki,=,1.6,nM,CHEMBL755685,B,Ability to displace [3H]U-69593 from human recombinant Opioid receptor kappa 1 in CHO cells,CHEMBL1145106,KI,CCC/N=C(\N)Cc1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL323726,CHEMBL237,Kappa opioid receptor,Ki,=,1.39,nM,CHEMBL755685,B,Ability to displace [3H]U-69593 from human recombinant Opioid receptor kappa 1 in CHO cells,CHEMBL1145106,KI,CC(C)CC(=N)NCCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL323398,CHEMBL237,Kappa opioid receptor,Ki,=,8.13,nM,CHEMBL755685,B,Ability to displace [3H]U-69593 from human recombinant Opioid receptor kappa 1 in CHO cells,CHEMBL1145106,KI,CCCCCCNC(=O)NCCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL2113262,CHEMBL237,Kappa opioid receptor,Ki,=,1394.0,nM,CHEMBL752738,B,Tested for the opioid receptor kappa 1 binding affinity using membrane preparations from recombinant HEK293 cells with [3H]U-69593 radioligand,CHEMBL1147615,KI,O=C1N[C@@H]2CCCC[C@H]2N1C1CCN(C2CCC3CCCCC3C2)CC1
CHEMBL432403,CHEMBL237,Kappa opioid receptor,Ki,=,5.61,nM,CHEMBL755685,B,Ability to displace [3H]U-69593 from human recombinant Opioid receptor kappa 1 in CHO cells,CHEMBL1145106,KI,CCCCCCC/N=C(\N)Cc1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL109009,CHEMBL237,Kappa opioid receptor,Ki,=,6.18,nM,CHEMBL755685,B,Ability to displace [3H]U-69593 from human recombinant Opioid receptor kappa 1 in CHO cells,CHEMBL1145106,KI,O=C(NCCCCc1ccccc1)c1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL91683,CHEMBL237,Kappa opioid receptor,Ki,=,0.29,nM,CHEMBL755685,B,Ability to displace [3H]U-69593 from human recombinant Opioid receptor kappa 1 in CHO cells,CHEMBL1145106,KI,CC(=N)NCCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL108024,CHEMBL237,Kappa opioid receptor,Ki,=,21.89,nM,CHEMBL755685,B,Ability to displace [3H]U-69593 from human recombinant Opioid receptor kappa 1 in CHO cells,CHEMBL1145106,KI,CCCCCCCNC(=O)c1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL108083,CHEMBL237,Kappa opioid receptor,Ki,=,2.21,nM,CHEMBL755685,B,Ability to displace [3H]U-69593 from human recombinant Opioid receptor kappa 1 in CHO cells,CHEMBL1145106,KI,O=C(NCCc1ccccc1)c1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL280778,CHEMBL237,Kappa opioid receptor,Ki,=,1701.0,nM,CHEMBL752738,B,Tested for the opioid receptor kappa 1 binding affinity using membrane preparations from recombinant HEK293 cells with [3H]U-69593 radioligand,CHEMBL1147615,KI,O=C1N[C@@H]2CCCC[C@H]2N1C1CCN(CC2CCCCCCC2)CC1
CHEMBL110487,CHEMBL237,Kappa opioid receptor,Ki,=,0.85,nM,CHEMBL755685,B,Ability to displace [3H]U-69593 from human recombinant Opioid receptor kappa 1 in CHO cells,CHEMBL1145106,KI,CCCC(=O)NCCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL110894,CHEMBL237,Kappa opioid receptor,Ki,=,1.44,nM,CHEMBL755685,B,Ability to displace [3H]U-69593 from human recombinant Opioid receptor kappa 1 in CHO cells,CHEMBL1145106,KI,CCCCC/N=C(\N)Cc1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL431060,CHEMBL237,Kappa opioid receptor,Ki,=,2.11,nM,CHEMBL755685,B,Ability to displace [3H]U-69593 from human recombinant Opioid receptor kappa 1 in CHO cells,CHEMBL1145106,KI,COc1ccc(CNC(=O)c2ccc3[nH]c4c(c3c2)C[C@@]2(O)C3Cc5ccc(O)c6c5[C@@]2(CCN3CC2CC2)[C@H]4O6)cc1
CHEMBL111530,CHEMBL237,Kappa opioid receptor,Ki,=,10.33,nM,CHEMBL755685,B,Ability to displace [3H]U-69593 from human recombinant Opioid receptor kappa 1 in CHO cells,CHEMBL1145106,KI,O=C(NCc1ccccc1)c1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL321408,CHEMBL237,Kappa opioid receptor,Ki,=,12.32,nM,CHEMBL755685,B,Ability to displace [3H]U-69593 from human recombinant Opioid receptor kappa 1 in CHO cells,CHEMBL1145106,KI,CCNC(=O)NCCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL169552,CHEMBL237,Kappa opioid receptor,Ki,=,2.4,nM,CHEMBL881609,B,"Binding affinity towards human kappa opioid receptor in CHO cells using [3H]- U-69,593 as radioligand",CHEMBL1132136,KI,CO[C@@]12CCC3(C[C@H]1[C@@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4C3(CCN1C)[C@H]2O5
CHEMBL117319,CHEMBL237,Kappa opioid receptor,Ki,=,452.0,nM,CHEMBL750073,B,Inhibition against kappa receptor from displacement studies using 1.5 nM [3H]U-69593 in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCCN1CC[C@@]2(C)c3cc(O)ccc3CC1[C@H]2C
CHEMBL117183,CHEMBL237,Kappa opioid receptor,Ki,=,23.0,nM,CHEMBL750073,B,Inhibition against kappa receptor from displacement studies using 1.5 nM [3H]U-69593 in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCCCCN1CC[C@]2(C)c3cc(O)ccc3CC1[C@@H]2C
CHEMBL114203,CHEMBL237,Kappa opioid receptor,Ki,=,113.0,nM,CHEMBL750073,B,Inhibition against kappa receptor from displacement studies using 1.5 nM [3H]U-69593 in rhesus monkey cortex membrane,CHEMBL1127360,KI,C[C@H]1C2Cc3ccc(O)cc3[C@@]1(C)CCN2
CHEMBL114123,CHEMBL237,Kappa opioid receptor,Ki,=,43.0,nM,CHEMBL750073,B,Inhibition against kappa receptor from displacement studies using 1.5 nM [3H]U-69593 in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCCCCCN1CC[C@]2(C)c3cc(O)ccc3CC1[C@@H]2C
CHEMBL114358,CHEMBL237,Kappa opioid receptor,Ki,=,32.0,nM,CHEMBL750073,B,Inhibition against kappa receptor from displacement studies using 1.5 nM [3H]U-69593 in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCCCCCCN1CC[C@]2(C)c3cc(O)ccc3CC1[C@@H]2C
CHEMBL324505,CHEMBL237,Kappa opioid receptor,Ki,=,2265.0,nM,CHEMBL750073,B,Inhibition against kappa receptor from displacement studies using 1.5 nM [3H]U-69593 in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCCCCCCCCCN1CC[C@]2(C)c3cc(O)ccc3CC1[C@H]2C
CHEMBL115998,CHEMBL237,Kappa opioid receptor,Ki,=,723.0,nM,CHEMBL750073,B,Inhibition against kappa receptor from displacement studies using 1.5 nM [3H]U-69593 in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCCCCCCN1CC[C@]2(C)c3cc(O)ccc3CC1[C@H]2C
CHEMBL325052,CHEMBL237,Kappa opioid receptor,Ki,=,3776.0,nM,CHEMBL750073,B,Inhibition against kappa receptor from displacement studies using 1.5 nM [3H]U-69593 in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCN1CC[C@@]2(C)c3cc(O)ccc3CC1[C@H]2C
CHEMBL116643,CHEMBL237,Kappa opioid receptor,Ki,=,2265.0,nM,CHEMBL750073,B,Inhibition against kappa receptor from displacement studies using 1.5 nM [3H]U-69593 in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCCCCCN1CC[C@@]2(C)c3cc(O)ccc3CC1[C@H]2C
CHEMBL113703,CHEMBL237,Kappa opioid receptor,Ki,=,4.9,nM,CHEMBL750073,B,Inhibition against kappa receptor from displacement studies using 1.5 nM [3H]U-69593 in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCCCN1CC[C@]2(C)c3cc(O)ccc3CC1[C@@H]2C
CHEMBL115917,CHEMBL237,Kappa opioid receptor,Ki,=,17.0,nM,CHEMBL750073,B,Inhibition against kappa receptor from displacement studies using 1.5 nM [3H]U-69593 in rhesus monkey cortex membrane,CHEMBL1127360,KI,C[C@H]1C2Cc3ccc(O)cc3[C@@]1(C)CCN2C
CHEMBL326548,CHEMBL237,Kappa opioid receptor,Ki,=,709.0,nM,CHEMBL750073,B,Inhibition against kappa receptor from displacement studies using 1.5 nM [3H]U-69593 in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCCCCCCCCN1CC[C@]2(C)c3cc(O)ccc3CC1[C@@H]2C
CHEMBL116738,CHEMBL237,Kappa opioid receptor,Ki,=,77.0,nM,CHEMBL750073,B,Inhibition against kappa receptor from displacement studies using 1.5 nM [3H]U-69593 in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCCCCCCCN1CC[C@]2(C)c3cc(O)ccc3CC1[C@@H]2C
CHEMBL326103,CHEMBL237,Kappa opioid receptor,Ki,=,16.0,nM,CHEMBL750073,B,Inhibition against kappa receptor from displacement studies using 1.5 nM [3H]U-69593 in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCN1CC[C@]2(C)c3cc(O)ccc3CC1[C@@H]2C
CHEMBL324392,CHEMBL237,Kappa opioid receptor,Ki,=,738.0,nM,CHEMBL750073,B,Inhibition against kappa receptor from displacement studies using 1.5 nM [3H]U-69593 in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCCCCN1CC[C@@]2(C)c3cc(O)ccc3CC1[C@H]2C
CHEMBL114163,CHEMBL237,Kappa opioid receptor,Ki,=,2265.0,nM,CHEMBL750073,B,Inhibition against kappa receptor from displacement studies using 1.5 nM [3H]U-69593 in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCCCCCCCN1CC[C@]2(C)c3cc(O)ccc3CC1[C@H]2C
CHEMBL117321,CHEMBL237,Kappa opioid receptor,Ki,=,2265.0,nM,CHEMBL750073,B,Inhibition against kappa receptor from displacement studies using 1.5 nM [3H]U-69593 in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCCCCCCCCN1CC[C@]2(C)c3cc(O)ccc3CC1[C@H]2C
CHEMBL117128,CHEMBL237,Kappa opioid receptor,Ki,=,3776.0,nM,CHEMBL750073,B,Inhibition against kappa receptor from displacement studies using 1.5 nM [3H]U-69593 in rhesus monkey cortex membrane,CHEMBL1127360,KI,C[C@@H]1C2Cc3ccc(O)cc3[C@]1(C)CCN2C
CHEMBL116354,CHEMBL237,Kappa opioid receptor,Ki,=,2265.0,nM,CHEMBL750073,B,Inhibition against kappa receptor from displacement studies using 1.5 nM [3H]U-69593 in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCCCCCCCCCN1CC[C@]2(C)c3cc(O)ccc3CC1[C@@H]2C
CHEMBL326571,CHEMBL237,Kappa opioid receptor,Ki,=,783.0,nM,CHEMBL750073,B,Inhibition against kappa receptor from displacement studies using 1.5 nM [3H]U-69593 in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCCCN1CC[C@@]2(C)c3cc(O)ccc3CC1[C@H]2C
CHEMBL117379,CHEMBL237,Kappa opioid receptor,Ki,=,2.0,nM,CHEMBL750073,B,Inhibition against kappa receptor from displacement studies using 1.5 nM [3H]U-69593 in rhesus monkey cortex membrane,CHEMBL1127360,KI,CCCN1CC[C@]2(C)c3cc(O)ccc3CC1[C@@H]2C
CHEMBL326370,CHEMBL237,Kappa opioid receptor,Ki,=,3776.0,nM,CHEMBL750073,B,Inhibition against kappa receptor from displacement studies using 1.5 nM [3H]U-69593 in rhesus monkey cortex membrane,CHEMBL1127360,KI,C[C@@H]1C2Cc3ccc(O)cc3[C@]1(C)CCN2
CHEMBL369719,CHEMBL237,Kappa opioid receptor,Ki,=,190.0,nM,CHEMBL750079,B,Inhibition against [3H]diprenorphine human Opioid receptor kappa 1,CHEMBL1133681,KI,COC(=O)C12CN(C)CC(C(=O)OC)(C1=O)C(c1ccc3ccccc3n1)N(C)C2c1ccc2ccccc2n1
CHEMBL177406,CHEMBL237,Kappa opioid receptor,Ki,=,210.0,nM,CHEMBL750080,B,Inhibition against [3H]diprenorphine human Opioid receptor kappa 1 at 10 umol/L,CHEMBL1133681,KI,CN1CC2(C(=O)O)C(=O)C(C(=O)O)(C1)C(c1ccccc1)N(C)C2c1ccccc1
CHEMBL179350,CHEMBL237,Kappa opioid receptor,Ki,=,820.0,nM,CHEMBL750078,B,Inhibition against [3H]-CI 977 rat Opioid receptor kappa 1 at 10 umol/L,CHEMBL1133681,KI,COC(=O)C12CN(C)CC(C(=O)OC)(C1=O)C(c1cccc(C)c1)N(C)C2c1cccc(C)c1
CHEMBL447234,CHEMBL237,Kappa opioid receptor,Ki,=,26.0,nM,CHEMBL750079,B,Inhibition against [3H]diprenorphine human Opioid receptor kappa 1,CHEMBL1133681,KI,COC(=O)C12CN(C)CC(C(=O)OC)(C1=O)C(c1cccc(F)c1)N(C)C2c1cccc(F)c1
CHEMBL366367,CHEMBL237,Kappa opioid receptor,Ki,=,1980.0,nM,CHEMBL750079,B,Inhibition against [3H]diprenorphine human Opioid receptor kappa 1,CHEMBL1133681,KI,CCOC(=O)C12CN(C)CC(C(=O)OCC)(C1=O)C(c1ccc(Cl)cc1)N(C)C2c1ccc(Cl)cc1
CHEMBL177284,CHEMBL237,Kappa opioid receptor,Ki,=,15.0,nM,CHEMBL750077,B,Inhibition against [3H]-CI 977 rat Opioid receptor kappa 1,CHEMBL1133681,KI,COC(=O)C12CN(C)CC(C(=O)OC)(C1=O)C(c1ccccn1)N(C)C2c1ccccn1
CHEMBL177957,CHEMBL237,Kappa opioid receptor,Ki,=,18.0,nM,CHEMBL750080,B,Inhibition against [3H]diprenorphine human Opioid receptor kappa 1 at 10 umol/L,CHEMBL1133681,KI,COC(=O)C12CN(C)CC(C(=O)OC)(C1=O)C(c1ccc(OC)cc1)N(C)C2c1ccc(OC)cc1
CHEMBL180074,CHEMBL237,Kappa opioid receptor,Ki,=,20.0,nM,CHEMBL750077,B,Inhibition against [3H]-CI 977 rat Opioid receptor kappa 1,CHEMBL1133681,KI,COC(=O)C12CN(C)CC(C(=O)OC)(C1=O)C(c1cccc(O)c1)N(C)C2c1cccc(O)c1
CHEMBL362207,CHEMBL237,Kappa opioid receptor,Ki,=,140.0,nM,CHEMBL750080,B,Inhibition against [3H]diprenorphine human Opioid receptor kappa 1 at 10 umol/L,CHEMBL1133681,KI,COC(=O)C12CN(C)CC(C(=O)OC)(C1=O)C(c1ccc(F)cc1)N(C)C2c1ccc(F)cc1
CHEMBL2112373,CHEMBL237,Kappa opioid receptor,Ki,=,0.49,nM,CHEMBL751037,B,Binding affinity against cloned human Opioid receptor kappa 1 transfected into chinese hamster ovary cells using [3H]U-69593 as radioligand,CHEMBL1145928,KI,N=C(N)NCCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL610799,CHEMBL237,Kappa opioid receptor,Ki,=,2.38,nM,CHEMBL751037,B,Binding affinity against cloned human Opioid receptor kappa 1 transfected into chinese hamster ovary cells using [3H]U-69593 as radioligand,CHEMBL1145928,KI,CCCN/C(=N\CC1CC1)Nc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL610040,CHEMBL237,Kappa opioid receptor,Ki,=,2.74,nM,CHEMBL751037,B,Binding affinity against cloned human Opioid receptor kappa 1 transfected into chinese hamster ovary cells using [3H]U-69593 as radioligand,CHEMBL1145928,KI,N/C(=N/Cc1cccc(O)c1)Nc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL610032,CHEMBL237,Kappa opioid receptor,Ki,=,1.61,nM,CHEMBL751037,B,Binding affinity against cloned human Opioid receptor kappa 1 transfected into chinese hamster ovary cells using [3H]U-69593 as radioligand,CHEMBL1145928,KI,N/C(=N/Cc1ccc([N+](=O)[O-])cc1)Nc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL610034,CHEMBL237,Kappa opioid receptor,Ki,=,6.96,nM,CHEMBL751037,B,Binding affinity against cloned human Opioid receptor kappa 1 transfected into chinese hamster ovary cells using [3H]U-69593 as radioligand,CHEMBL1145928,KI,CCCC/N=C(\NCCCC)Nc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL2112374,CHEMBL237,Kappa opioid receptor,Ki,=,0.18,nM,CHEMBL751037,B,Binding affinity against cloned human Opioid receptor kappa 1 transfected into chinese hamster ovary cells using [3H]U-69593 as radioligand,CHEMBL1145928,KI,N=C(N)NCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL610038,CHEMBL237,Kappa opioid receptor,Ki,=,0.95,nM,CHEMBL751037,B,Binding affinity against cloned human Opioid receptor kappa 1 transfected into chinese hamster ovary cells using [3H]U-69593 as radioligand,CHEMBL1145928,KI,N/C(=N\CCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5)NCc1ccc(N)cc1
CHEMBL610033,CHEMBL237,Kappa opioid receptor,Ki,=,2.14,nM,CHEMBL751037,B,Binding affinity against cloned human Opioid receptor kappa 1 transfected into chinese hamster ovary cells using [3H]U-69593 as radioligand,CHEMBL1145928,KI,N/C(=N\CCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5)NCc1ccc([N+](=O)[O-])cc1
CHEMBL610037,CHEMBL237,Kappa opioid receptor,Ki,=,3.91,nM,CHEMBL751037,B,Binding affinity against cloned human Opioid receptor kappa 1 transfected into chinese hamster ovary cells using [3H]U-69593 as radioligand,CHEMBL1145928,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5ccc(N/C(=N/CC6CC6)NCc6ccccc6)cc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL610036,CHEMBL237,Kappa opioid receptor,Ki,=,3.26,nM,CHEMBL751037,B,Binding affinity against cloned human Opioid receptor kappa 1 transfected into chinese hamster ovary cells using [3H]U-69593 as radioligand,CHEMBL1145928,KI,N/C(=N/Cc1ccc(O)cc1)Nc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL610044,CHEMBL237,Kappa opioid receptor,Ki,=,0.63,nM,CHEMBL751037,B,Binding affinity against cloned human Opioid receptor kappa 1 transfected into chinese hamster ovary cells using [3H]U-69593 as radioligand,CHEMBL1145928,KI,N/C(=N/Cc1ccc(N)cc1)Nc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL573214,CHEMBL237,Kappa opioid receptor,Ki,=,0.2,nM,CHEMBL751037,B,Binding affinity against cloned human Opioid receptor kappa 1 transfected into chinese hamster ovary cells using [3H]U-69593 as radioligand,CHEMBL1145928,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL610041,CHEMBL237,Kappa opioid receptor,Ki,=,2.41,nM,CHEMBL751037,B,Binding affinity against cloned human Opioid receptor kappa 1 transfected into chinese hamster ovary cells using [3H]U-69593 as radioligand,CHEMBL1145928,KI,N/C(=N\CCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5)NCc1ccc(Cl)cc1
CHEMBL610039,CHEMBL237,Kappa opioid receptor,Ki,=,4.8,nM,CHEMBL751037,B,Binding affinity against cloned human Opioid receptor kappa 1 transfected into chinese hamster ovary cells using [3H]U-69593 as radioligand,CHEMBL1145928,KI,CCCC/N=C(\NCCCC)NCCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL610043,CHEMBL237,Kappa opioid receptor,Ki,=,0.86,nM,CHEMBL751037,B,Binding affinity against cloned human Opioid receptor kappa 1 transfected into chinese hamster ovary cells using [3H]U-69593 as radioligand,CHEMBL1145928,KI,N/C(=N/Cc1ccccc1)Nc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL610035,CHEMBL237,Kappa opioid receptor,Ki,=,2.72,nM,CHEMBL751037,B,Binding affinity against cloned human Opioid receptor kappa 1 transfected into chinese hamster ovary cells using [3H]U-69593 as radioligand,CHEMBL1145928,KI,CCC/N=C(\NCCC)Nc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL610042,CHEMBL237,Kappa opioid receptor,Ki,=,1.42,nM,CHEMBL751037,B,Binding affinity against cloned human Opioid receptor kappa 1 transfected into chinese hamster ovary cells using [3H]U-69593 as radioligand,CHEMBL1145928,KI,N/C(=N\CCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5)NCc1ccccc1
CHEMBL610045,CHEMBL237,Kappa opioid receptor,Ki,=,0.66,nM,CHEMBL751037,B,Binding affinity against cloned human Opioid receptor kappa 1 transfected into chinese hamster ovary cells using [3H]U-69593 as radioligand,CHEMBL1145928,KI,N/C(=N/Cc1ccc(Cl)cc1)Nc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL334156,CHEMBL237,Kappa opioid receptor,Ki,=,0.53,nM,CHEMBL755694,B,Binding affinity against opioid receptor kappa 1 from human cloned receptor,CHEMBL1144935,KI,O=C(NCCC1CN=C(c2ccccc2)c2ccccc2N1)c1ccccc1F
CHEMBL334156,CHEMBL237,Kappa opioid receptor,Ki,=,0.537,nM,CHEMBL747228,B,Binding constant towards human Opioid receptor kappa 1 was reported,CHEMBL1144935,KI,O=C(NCCC1CN=C(c2ccccc2)c2ccccc2N1)c1ccccc1F
CHEMBL2111836,CHEMBL237,Kappa opioid receptor,Ki,=,0.43,nM,CHEMBL755694,B,Binding affinity against opioid receptor kappa 1 from human cloned receptor,CHEMBL1144935,KI,CN1c2ccccc2C(c2ccccc2)=NC[C@@H]1CCNC(=O)c1cccs1
CHEMBL2111836,CHEMBL237,Kappa opioid receptor,Ki,=,0.4266,nM,CHEMBL747228,B,Binding constant towards human Opioid receptor kappa 1 was reported,CHEMBL1144935,KI,CN1c2ccccc2C(c2ccccc2)=NC[C@@H]1CCNC(=O)c1cccs1
CHEMBL127968,CHEMBL237,Kappa opioid receptor,Ki,=,0.55,nM,CHEMBL755694,B,Binding affinity against opioid receptor kappa 1 from human cloned receptor,CHEMBL1144935,KI,CN1c2ccc(Cl)cc2C(c2ccccc2)=NCC1CCNC(=O)c1ccc(F)cc1
CHEMBL127968,CHEMBL237,Kappa opioid receptor,Ki,=,0.5495,nM,CHEMBL747228,B,Binding constant towards human Opioid receptor kappa 1 was reported,CHEMBL1144935,KI,CN1c2ccc(Cl)cc2C(c2ccccc2)=NCC1CCNC(=O)c1ccc(F)cc1
CHEMBL384227,CHEMBL237,Kappa opioid receptor,Ki,=,10.0,nM,CHEMBL751033,B,Binding affinity towards Opioid receptor kappa 1 using [3H]diprenorphine as radioligand expressed on chinese hamster ovary (CHO) cells,CHEMBL1135684,KI,CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL544956,CHEMBL237,Kappa opioid receptor,Ki,=,69.0,nM,CHEMBL752206,B,Binding affinity towards Opioid receptor kappa 1 was determined,CHEMBL1124535,KI,CN(C(=O)Cc1csc2ccccc12)[C@@H]1CCCC[C@H]1N1CCCC1.Cl
CHEMBL541804,CHEMBL237,Kappa opioid receptor,Ki,=,7.0,nM,CHEMBL753145,B,Binding affinity towards opioid receptor kappa was determined,CHEMBL1124535,KI,CN(C(=O)Cc1cccc2sccc12)[C@@H]1CCCC[C@H]1N1CCC(CO)C1.Cl
CHEMBL216696,CHEMBL237,Kappa opioid receptor,Ki,=,0.19,nM,CHEMBL751033,B,Binding affinity towards Opioid receptor kappa 1 using [3H]diprenorphine as radioligand expressed on chinese hamster ovary (CHO) cells,CHEMBL1135684,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL126596,CHEMBL237,Kappa opioid receptor,Ki,=,3.77,nM,CHEMBL755694,B,Binding affinity against opioid receptor kappa 1 from human cloned receptor,CHEMBL1144935,KI,COc1cccc2c1C(c1ccccc1)=NCC(CCNC(=O)c1cccs1)N2C
CHEMBL126596,CHEMBL237,Kappa opioid receptor,Ki,=,3.802,nM,CHEMBL747228,B,Binding constant towards human Opioid receptor kappa 1 was reported,CHEMBL1144935,KI,COc1cccc2c1C(c1ccccc1)=NCC(CCNC(=O)c1cccs1)N2C
CHEMBL341529,CHEMBL237,Kappa opioid receptor,Ki,=,0.36,nM,CHEMBL755694,B,Binding affinity against opioid receptor kappa 1 from human cloned receptor,CHEMBL1144935,KI,CN1c2ccccc2C(c2ccccc2)=NCC1CCNC(=O)c1ccccc1F
CHEMBL341529,CHEMBL237,Kappa opioid receptor,Ki,=,0.3631,nM,CHEMBL747228,B,Binding constant towards human Opioid receptor kappa 1 was reported,CHEMBL1144935,KI,CN1c2ccccc2C(c2ccccc2)=NCC1CCNC(=O)c1ccccc1F
CHEMBL123898,CHEMBL237,Kappa opioid receptor,Ki,=,0.25,nM,CHEMBL755694,B,Binding affinity against opioid receptor kappa 1 from human cloned receptor,CHEMBL1144935,KI,O=C(NCCC1CN=C(c2ccccc2)c2ccccc2N1)c1ccccc1
CHEMBL123898,CHEMBL237,Kappa opioid receptor,Ki,=,0.2512,nM,CHEMBL747228,B,Binding constant towards human Opioid receptor kappa 1 was reported,CHEMBL1144935,KI,O=C(NCCC1CN=C(c2ccccc2)c2ccccc2N1)c1ccccc1
CHEMBL567175,CHEMBL237,Kappa opioid receptor,Ki,=,4.4,nM,CHEMBL755694,B,Binding affinity against opioid receptor kappa 1 from human cloned receptor,CHEMBL1144935,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL555100,CHEMBL237,Kappa opioid receptor,Ki,=,17.0,nM,CHEMBL753145,B,Binding affinity towards opioid receptor kappa was determined,CHEMBL1124535,KI,CN(C(=O)Cc1cccc2ccsc12)[C@@H]1CCCC[C@H]1N1CCCC1.Cl
CHEMBL124015,CHEMBL237,Kappa opioid receptor,Ki,=,0.7,nM,CHEMBL755694,B,Binding affinity against opioid receptor kappa 1 from human cloned receptor,CHEMBL1144935,KI,CN1c2ccc(Cl)cc2C(c2ccccc2)=NCC1CCNC(=O)c1cccs1
CHEMBL545182,CHEMBL237,Kappa opioid receptor,Ki,=,333.0,nM,CHEMBL752206,B,Binding affinity towards Opioid receptor kappa 1 was determined,CHEMBL1124535,KI,Cl.O=C(Cc1cccc2sccc12)N[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL2111838,CHEMBL237,Kappa opioid receptor,Ki,=,0.17,nM,CHEMBL755694,B,Binding affinity against opioid receptor kappa 1 from human cloned receptor,CHEMBL1144935,KI,CN1c2ccccc2C(c2ccccc2F)=NC[C@@H]1CCNC(=O)c1ccsc1
CHEMBL2111838,CHEMBL237,Kappa opioid receptor,Ki,=,0.1698,nM,CHEMBL747228,B,Binding constant towards human Opioid receptor kappa 1 was reported,CHEMBL1144935,KI,CN1c2ccccc2C(c2ccccc2F)=NC[C@@H]1CCNC(=O)c1ccsc1
CHEMBL536550,CHEMBL237,Kappa opioid receptor,Ki,=,94.0,nM,CHEMBL753145,B,Binding affinity towards opioid receptor kappa was determined,CHEMBL1124535,KI,CN(C(=O)Cc1ccc2sccc2c1)[C@@H]1CCCC[C@H]1N1CCCC1.Cl
CHEMBL70,CHEMBL237,Kappa opioid receptor,Ki,=,64.0,nM,CHEMBL755694,B,Binding affinity against opioid receptor kappa 1 from human cloned receptor,CHEMBL1144935,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL70,CHEMBL237,Kappa opioid receptor,Ki,=,86.0,nM,CHEMBL752206,B,Binding affinity towards Opioid receptor kappa 1 was determined,CHEMBL1124535,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL544960,CHEMBL237,Kappa opioid receptor,Ki,=,3.7,nM,CHEMBL753145,B,Binding affinity towards opioid receptor kappa was determined,CHEMBL1124535,KI,CN(C(=O)Cc1cccc2sccc12)[C@@H]1CCCC[C@H]1N1CCCC1.Cl
CHEMBL556414,CHEMBL237,Kappa opioid receptor,Ki,=,18.0,nM,CHEMBL753145,B,Binding affinity towards opioid receptor kappa was determined,CHEMBL1124535,KI,CO[C@H]1C[C@H](N(C)C(=O)Cc2cccc3sccc23)[C@@H](N2CCCC2)C[C@H]1OC.Cl
CHEMBL340001,CHEMBL237,Kappa opioid receptor,Ki,=,1.31,nM,CHEMBL755694,B,Binding affinity against opioid receptor kappa 1 from human cloned receptor,CHEMBL1144935,KI,CN1c2ccc(Cl)cc2C(c2ccccc2)=NCC1CCNC(=O)c1ccc(Cl)cc1
CHEMBL340001,CHEMBL237,Kappa opioid receptor,Ki,=,1.318,nM,CHEMBL747228,B,Binding constant towards human Opioid receptor kappa 1 was reported,CHEMBL1144935,KI,CN1c2ccc(Cl)cc2C(c2ccccc2)=NCC1CCNC(=O)c1ccc(Cl)cc1
CHEMBL542102,CHEMBL237,Kappa opioid receptor,Ki,=,2000.0,nM,CHEMBL753145,B,Binding affinity towards opioid receptor kappa was determined,CHEMBL1124535,KI,CCCCCN(CCN1CCCC1)C(=O)Cc1cccc2sccc12.Cl
CHEMBL553665,CHEMBL237,Kappa opioid receptor,Ki,=,180.0,nM,CHEMBL753145,B,Binding affinity towards opioid receptor kappa was determined,CHEMBL1124535,KI,CN(C(=O)Cc1cccc2occc12)[C@@H]1CCCC[C@H]1N1CCC(COC(=O)CCCC(=O)OCC2CCN([C@H]3CCCC[C@@H]3N(C)C(=O)Cc3cccc4occc34)C2)C1.Cl.Cl
CHEMBL2111837,CHEMBL237,Kappa opioid receptor,Ki,=,0.69,nM,CHEMBL755694,B,Binding affinity against opioid receptor kappa 1 from human cloned receptor,CHEMBL1144935,KI,CN1c2ccc(Cl)cc2C(c2ccccc2)=NC[C@@H]1CCNC(=O)c1cccs1
CHEMBL2111837,CHEMBL237,Kappa opioid receptor,Ki,=,0.6918,nM,CHEMBL747228,B,Binding constant towards human Opioid receptor kappa 1 was reported,CHEMBL1144935,KI,CN1c2ccc(Cl)cc2C(c2ccccc2)=NC[C@@H]1CCNC(=O)c1cccs1
CHEMBL555990,CHEMBL237,Kappa opioid receptor,Ki,=,28000.0,nM,CHEMBL752206,B,Binding affinity towards Opioid receptor kappa 1 was determined,CHEMBL1124535,KI,Cl.O=C(Cc1cccc2sccc12)N1CC2CCCN2[C@@H]2CCCC[C@H]21
CHEMBL341056,CHEMBL237,Kappa opioid receptor,Ki,=,0.28,nM,CHEMBL755694,B,Binding affinity against opioid receptor kappa 1 from human cloned receptor,CHEMBL1144935,KI,O=C(NCCC1CN=C(c2ccccc2)c2ccccc2N1)c1ccc(F)cc1
CHEMBL341056,CHEMBL237,Kappa opioid receptor,Ki,=,0.2818,nM,CHEMBL747228,B,Binding constant towards human Opioid receptor kappa 1 was reported,CHEMBL1144935,KI,O=C(NCCC1CN=C(c2ccccc2)c2ccccc2N1)c1ccc(F)cc1
CHEMBL127463,CHEMBL237,Kappa opioid receptor,Ki,=,0.3,nM,CHEMBL755694,B,Binding affinity against opioid receptor kappa 1 from human cloned receptor,CHEMBL1144935,KI,CN1c2ccccc2C(c2ccccc2)=NCC1CCNC(=O)c1ccc(F)cc1
CHEMBL127463,CHEMBL237,Kappa opioid receptor,Ki,=,0.302,nM,CHEMBL747228,B,Binding constant towards human Opioid receptor kappa 1 was reported,CHEMBL1144935,KI,CN1c2ccccc2C(c2ccccc2)=NCC1CCNC(=O)c1ccc(F)cc1
CHEMBL2448130,CHEMBL237,Kappa opioid receptor,Ki,=,0.71,nM,CHEMBL755694,B,Binding affinity against opioid receptor kappa 1 from human cloned receptor,CHEMBL1144935,KI,CN1c2ccccc2C(c2ccccc2F)=NC[C@H]1CCNC(=O)c1ccsc1
CHEMBL543780,CHEMBL237,Kappa opioid receptor,Ki,=,53.0,nM,CHEMBL752206,B,Binding affinity towards Opioid receptor kappa 1 was determined,CHEMBL1124535,KI,CN(C(=S)Cc1cccc2sccc12)[C@@H]1CCCC[C@H]1N1CCCC1.Cl
CHEMBL545654,CHEMBL237,Kappa opioid receptor,Ki,=,261.0,nM,CHEMBL753145,B,Binding affinity towards opioid receptor kappa was determined,CHEMBL1124535,KI,Cl.O=C(Cc1cccc2sccc12)O[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL127828,CHEMBL237,Kappa opioid receptor,Ki,=,0.37,nM,CHEMBL755694,B,Binding affinity against opioid receptor kappa 1 from human cloned receptor,CHEMBL1144935,KI,CN1c2ccccc2C(c2ccccc2F)=NCC1CCNC(=O)c1ccsc1
CHEMBL553010,CHEMBL237,Kappa opioid receptor,Ki,=,154.0,nM,CHEMBL753145,B,Binding affinity towards opioid receptor kappa was determined,CHEMBL1124535,KI,CN(C(=O)Cc1cccc2sccc12)[C@@H]1CCC[C@H]1N1CCCC1.Cl
CHEMBL126282,CHEMBL237,Kappa opioid receptor,Ki,=,1.52,nM,CHEMBL755694,B,Binding affinity against opioid receptor kappa 1 from human cloned receptor,CHEMBL1144935,KI,CN1c2ccc(Cl)cc2C(c2ccccc2)=NCC1CCNC(=O)c1ccccc1F
CHEMBL126282,CHEMBL237,Kappa opioid receptor,Ki,=,1.549,nM,CHEMBL747228,B,Binding constant towards human Opioid receptor kappa 1 was reported,CHEMBL1144935,KI,CN1c2ccc(Cl)cc2C(c2ccccc2)=NCC1CCNC(=O)c1ccccc1F
CHEMBL555835,CHEMBL237,Kappa opioid receptor,Ki,=,16.0,nM,CHEMBL752206,B,Binding affinity towards Opioid receptor kappa 1 was determined,CHEMBL1124535,KI,CO[C@H]1C[C@H](N(C)C(=O)Cc2cccc3occc23)[C@@H](N2CCCC2)C[C@H]1OC.Cl
CHEMBL558227,CHEMBL237,Kappa opioid receptor,Ki,=,146.0,nM,CHEMBL753145,B,Binding affinity towards opioid receptor kappa was determined,CHEMBL1124535,KI,CN(C(=O)Cc1ccc2ccsc2c1)[C@@H]1CCCC[C@H]1N1CCCC1.Cl
CHEMBL126688,CHEMBL237,Kappa opioid receptor,Ki,=,0.45,nM,CHEMBL755694,B,Binding affinity against opioid receptor kappa 1 from human cloned receptor,CHEMBL1144935,KI,O=C(NCCC1CN=C(c2ccccc2)c2ccccc2N1)c1cccs1
CHEMBL126688,CHEMBL237,Kappa opioid receptor,Ki,=,0.4467,nM,CHEMBL747228,B,Binding constant towards human Opioid receptor kappa 1 was reported,CHEMBL1144935,KI,O=C(NCCC1CN=C(c2ccccc2)c2ccccc2N1)c1cccs1
CHEMBL555649,CHEMBL237,Kappa opioid receptor,Ki,=,8100.0,nM,CHEMBL753145,B,Binding affinity towards opioid receptor kappa was determined,CHEMBL1124535,KI,CN(CCc1cccc2sccc12)[C@@H]1CCCC[C@H]1N1CCCC1.Cl
CHEMBL127969,CHEMBL237,Kappa opioid receptor,Ki,=,0.58,nM,CHEMBL755694,B,Binding affinity against opioid receptor kappa 1 from human cloned receptor,CHEMBL1144935,KI,CN1c2ccccc2C(c2ccccc2)=NCC1CCNC(=O)c1cccs1
CHEMBL440765,CHEMBL237,Kappa opioid receptor,Ki,=,1.11,nM,CHEMBL755694,B,Binding affinity against opioid receptor kappa 1 from human cloned receptor,CHEMBL1144935,KI,CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL2448128,CHEMBL237,Kappa opioid receptor,Ki,=,1.28,nM,CHEMBL755694,B,Binding affinity against opioid receptor kappa 1 from human cloned receptor,CHEMBL1144935,KI,CN1c2ccccc2C(c2ccccc2)=NC[C@H]1CCNC(=O)c1cccs1
CHEMBL127619,CHEMBL237,Kappa opioid receptor,Ki,=,13.6,nM,CHEMBL755694,B,Binding affinity against opioid receptor kappa 1 from human cloned receptor,CHEMBL1144935,KI,CN1c2ccc(Cl)cc2C(c2ccccc2)=NCC1CCNC(=O)c1cc2ccccc2[nH]1
CHEMBL127619,CHEMBL237,Kappa opioid receptor,Ki,=,13.49,nM,CHEMBL747228,B,Binding constant towards human Opioid receptor kappa 1 was reported,CHEMBL1144935,KI,CN1c2ccc(Cl)cc2C(c2ccccc2)=NCC1CCNC(=O)c1cc2ccccc2[nH]1
CHEMBL266538,CHEMBL237,Kappa opioid receptor,Ki,=,6.6,nM,CHEMBL751033,B,Binding affinity towards Opioid receptor kappa 1 using [3H]diprenorphine as radioligand expressed on chinese hamster ovary (CHO) cells,CHEMBL1135684,KI,CSCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCN=C(N)N)NC(C)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL338393,CHEMBL237,Kappa opioid receptor,Ki,=,4.34,nM,CHEMBL755694,B,Binding affinity against opioid receptor kappa 1 from human cloned receptor,CHEMBL1144935,KI,CN(CCC1CN=C(c2ccccc2)c2ccccc2N1C)C(=O)c1cccs1
CHEMBL338393,CHEMBL237,Kappa opioid receptor,Ki,=,4.365,nM,CHEMBL747228,B,Binding constant towards human Opioid receptor kappa 1 was reported,CHEMBL1144935,KI,CN(CCC1CN=C(c2ccccc2)c2ccccc2N1C)C(=O)c1cccs1
CHEMBL540277,CHEMBL237,Kappa opioid receptor,Ki,=,180.0,nM,CHEMBL753145,B,Binding affinity towards opioid receptor kappa was determined,CHEMBL1124535,KI,CN(C(=O)Cc1cccc2occc12)[C@@H]1CCCC[C@H]1N1CCC(COC(=O)CCC(=O)OCC2CCN([C@H]3CCCC[C@@H]3N(C)C(=O)Cc3cccc4occc34)C2)C1.Cl.Cl
CHEMBL2448129,CHEMBL237,Kappa opioid receptor,Ki,=,0.79,nM,CHEMBL755694,B,Binding affinity against opioid receptor kappa 1 from human cloned receptor,CHEMBL1144935,KI,CN1c2ccc(Cl)cc2C(c2ccccc2)=NC[C@H]1CCNC(=O)c1cccs1
CHEMBL43104,CHEMBL237,Kappa opioid receptor,Ki,=,816.0,nM,CHEMBL753145,B,Binding affinity towards opioid receptor kappa was determined,CHEMBL1124535,KI,CN(C(=O)Cc1cccc2[nH]ccc12)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL554205,CHEMBL237,Kappa opioid receptor,Ki,=,25000.0,nM,CHEMBL753145,B,Binding affinity towards opioid receptor kappa was determined,CHEMBL1124535,KI,Cl.O=C(Cc1cccc2sccc12)NCCN1CCCC1
CHEMBL338391,CHEMBL237,Kappa opioid receptor,Ki,=,0.47,nM,CHEMBL755694,B,Binding affinity against opioid receptor kappa 1 from human cloned receptor,CHEMBL1144935,KI,CN1c2ccccc2C(c2ccccc2)=NCC1CCNC(=O)c1ccc([N+](=O)[O-])cc1
CHEMBL338391,CHEMBL237,Kappa opioid receptor,Ki,=,0.4786,nM,CHEMBL747228,B,Binding constant towards human Opioid receptor kappa 1 was reported,CHEMBL1144935,KI,CN1c2ccccc2C(c2ccccc2)=NCC1CCNC(=O)c1ccc([N+](=O)[O-])cc1
CHEMBL538230,CHEMBL237,Kappa opioid receptor,Ki,=,12.0,nM,CHEMBL752206,B,Binding affinity towards Opioid receptor kappa 1 was determined,CHEMBL1124535,KI,CN(C(=O)Cc1cccc2sccc12)[C@@H]1CCCCC[C@H]1N1CCCC1.Cl
CHEMBL545185,CHEMBL237,Kappa opioid receptor,Ki,=,37000.0,nM,CHEMBL752206,B,Binding affinity towards Opioid receptor kappa 1 was determined,CHEMBL1124535,KI,CN(Cc1cccc2occc12)C(=O)[C@@H]1CCCC[C@H]1N1CCCC1.Cl
CHEMBL543301,CHEMBL237,Kappa opioid receptor,Ki,=,17.0,nM,CHEMBL752206,B,Binding affinity towards Opioid receptor kappa 1 was determined,CHEMBL1124535,KI,CN(C(=O)Cc1cccc2occc12)[C@@H]1CCCC[C@H]1N1CCC(CO)C1.Cl
CHEMBL242756,CHEMBL237,Kappa opioid receptor,Ki,=,0.049,nM,CHEMBL754913,B,Inhibition of [3H]U-69593 binding to Opioid receptor kappa 1 of Chinese hamster ovary membrane,CHEMBL1149134,KI,Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1
CHEMBL299713,CHEMBL237,Kappa opioid receptor,Ki,=,13.0,nM,CHEMBL754913,B,Inhibition of [3H]U-69593 binding to Opioid receptor kappa 1 of Chinese hamster ovary membrane,CHEMBL1149134,KI,Nc1nc2cc3c(cc2s1)C(=O)[C@@H]1C2CCCC[C@]32CCN1CC1CCC1
CHEMBL332947,CHEMBL237,Kappa opioid receptor,Ki,=,21.08,nM,CHEMBL699593,B,Binding affinity towards human opioid Kappa receptor transfected into Chinese hamster ovary (CHO) cells using [3H]U-69593 as radioligand.,CHEMBL1131901,KI,CN1CCC23c4c5ccc(O)c4OC2c2nc(N)ncc2CC3(O)C1C5
CHEMBL1169583,CHEMBL237,Kappa opioid receptor,Ki,=,3.9,nM,CHEMBL755689,B,Binding affinity against cloned human Opioid receptor kappa 1 transfected onto CHO cells using [3H]U-69593,CHEMBL1132936,KI,CO[C@H](C)[C@@H]1CC23C=C[C@]1(OC)[C@H]1Oc4c(O)ccc5c4C12CCN(C)C3C5
CHEMBL2113671,CHEMBL237,Kappa opioid receptor,Ki,=,0.84,nM,CHEMBL755690,B,Binding affinity against cloned human opioid Opioid receptor kappa 1 transfected onto CHO cells using [3H]U-69593,CHEMBL1132936,KI,CO[C@]12C=C[C@@]3(C[C@H]1[C@@H](C)OCc1ccccc1)[C@H]1Cc4ccc(O)c5c4C3(CCN1C)[C@@H]2O5
CHEMBL301701,CHEMBL237,Kappa opioid receptor,Ki,=,0.49,nM,CHEMBL754913,B,Inhibition of [3H]U-69593 binding to Opioid receptor kappa 1 of Chinese hamster ovary membrane,CHEMBL1149134,KI,C[C@H]1[C@H]2Cc3cc4sc(N)nc4cc3[C@]1(C)CCN2CC1CCC1
CHEMBL112656,CHEMBL237,Kappa opioid receptor,Ki,=,45.01,nM,CHEMBL699593,B,Binding affinity towards human opioid Kappa receptor transfected into Chinese hamster ovary (CHO) cells using [3H]U-69593 as radioligand.,CHEMBL1131901,KI,CN1CCC23c4c5ccc(O)c4OC2c2nc(-c4ccccc4)ncc2CC3(O)C1C5
CHEMBL294168,CHEMBL237,Kappa opioid receptor,Ki,=,220.0,nM,CHEMBL754913,B,Inhibition of [3H]U-69593 binding to Opioid receptor kappa 1 of Chinese hamster ovary membrane,CHEMBL1149134,KI,CN1CC[C@]23c4c5cc6sc(N)nc6c4OC2[C@@H](O)CCC3[C@H]1C5
CHEMBL59092,CHEMBL237,Kappa opioid receptor,Ki,=,0.18,nM,CHEMBL754913,B,Inhibition of [3H]U-69593 binding to Opioid receptor kappa 1 of Chinese hamster ovary membrane,CHEMBL1149134,KI,C[C@H]1C2Cc3ccc(O)cc3[C@]1(C)CCN2CC1CC1
CHEMBL2113672,CHEMBL237,Kappa opioid receptor,Ki,=,1.1,nM,CHEMBL755689,B,Binding affinity against cloned human Opioid receptor kappa 1 transfected onto CHO cells using [3H]U-69593,CHEMBL1132936,KI,CO[C@]12C=C[C@@]3(C[C@H]1[C@H](C)OCc1ccccc1)[C@H]1Cc4ccc(O)c5c4C3(CCN1C)[C@@H]2O5
CHEMBL48241,CHEMBL237,Kappa opioid receptor,Ki,=,0.48,nM,CHEMBL754913,B,Inhibition of [3H]U-69593 binding to Opioid receptor kappa 1 of Chinese hamster ovary membrane,CHEMBL1149134,KI,O=C1c2ccc(O)cc2[C@@]23CCCC[C@H]2[C@@H]1N(CC1CCC1)CC3
CHEMBL1766021,CHEMBL237,Kappa opioid receptor,Ki,=,29.0,nM,CHEMBL754913,B,Inhibition of [3H]U-69593 binding to Opioid receptor kappa 1 of Chinese hamster ovary membrane,CHEMBL1149134,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1cc2sc(N)nc2cc13
CHEMBL431074,CHEMBL237,Kappa opioid receptor,Ki,=,68.5,nM,CHEMBL699593,B,Binding affinity towards human opioid Kappa receptor transfected into Chinese hamster ovary (CHO) cells using [3H]U-69593 as radioligand.,CHEMBL1131901,KI,Cc1ncc2c(n1)C1Oc3c(O)ccc4c3C13CCN(C)C(C4)C3(O)C2
CHEMBL112035,CHEMBL237,Kappa opioid receptor,Ki,=,11.92,nM,CHEMBL699593,B,Binding affinity towards human opioid Kappa receptor transfected into Chinese hamster ovary (CHO) cells using [3H]U-69593 as radioligand.,CHEMBL1131901,KI,CN1CCC23c4c5ccc(O)c4OC2c2n[nH]cc2CC3(O)C1C5
CHEMBL592,CHEMBL237,Kappa opioid receptor,Ki,=,2.3,nM,CHEMBL754913,B,Inhibition of [3H]U-69593 binding to Opioid receptor kappa 1 of Chinese hamster ovary membrane,CHEMBL1149134,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13
CHEMBL56356,CHEMBL237,Kappa opioid receptor,Ki,=,6.7,nM,CHEMBL754913,B,Inhibition of [3H]U-69593 binding to Opioid receptor kappa 1 of Chinese hamster ovary membrane,CHEMBL1149134,KI,C[C@H]1[C@H]2Cc3cc4sc(N)nc4cc3[C@]1(C)CCN2CC1CC1
CHEMBL70,CHEMBL237,Kappa opioid receptor,Ki,=,24.0,nM,CHEMBL754913,B,Inhibition of [3H]U-69593 binding to Opioid receptor kappa 1 of Chinese hamster ovary membrane,CHEMBL1149134,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL1169582,CHEMBL237,Kappa opioid receptor,Ki,=,43.3,nM,CHEMBL755690,B,Binding affinity against cloned human opioid Opioid receptor kappa 1 transfected onto CHO cells using [3H]U-69593,CHEMBL1132936,KI,CO[C@@H](C)[C@@H]1CC23C=C[C@]1(OC)[C@H]1Oc4c(O)ccc5c4C12CCN(C)C3C5
CHEMBL49269,CHEMBL237,Kappa opioid receptor,Ki,=,0.034,nM,CHEMBL754913,B,Inhibition of [3H]U-69593 binding to Opioid receptor kappa 1 of Chinese hamster ovary membrane,CHEMBL1149134,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL1766021,CHEMBL237,Kappa opioid receptor,Ki,=,6.4,nM,CHEMBL754913,B,Inhibition of [3H]U-69593 binding to Opioid receptor kappa 1 of Chinese hamster ovary membrane,CHEMBL1149134,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1cc2sc(N)nc2cc13
CHEMBL390866,CHEMBL237,Kappa opioid receptor,Ki,=,0.79,nM,CHEMBL754913,B,Inhibition of [3H]U-69593 binding to Opioid receptor kappa 1 of Chinese hamster ovary membrane,CHEMBL1149134,KI,Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CCC1
CHEMBL114803,CHEMBL237,Kappa opioid receptor,Ki,=,12.29,nM,CHEMBL699593,B,Binding affinity towards human opioid Kappa receptor transfected into Chinese hamster ovary (CHO) cells using [3H]U-69593 as radioligand.,CHEMBL1131901,KI,CN1CCC23c4c5ccc(O)c4OC2c2nc(O)ncc2CC3(O)C1C5
CHEMBL301160,CHEMBL237,Kappa opioid receptor,Ki,=,0.079,nM,CHEMBL754913,B,Inhibition of [3H]U-69593 binding to Opioid receptor kappa 1 of Chinese hamster ovary membrane,CHEMBL1149134,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL140979,CHEMBL237,Kappa opioid receptor,Ki,=,1057.0,nM,CHEMBL755700,B,"Binding affinity for opioid receptor type, human Opioid receptor kappa 1 expressed in membrane homogenates of COS-1 or CHO cells",CHEMBL1135663,KI,CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1
CHEMBL266609,CHEMBL237,Kappa opioid receptor,Ki,=,190.0,nM,CHEMBL755700,B,"Binding affinity for opioid receptor type, human Opioid receptor kappa 1 expressed in membrane homogenates of COS-1 or CHO cells",CHEMBL1135663,KI,CC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CC[C@H]2SC[C@@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)NC(Cc3ccc(Cl)cc3)C(N)=O)N2C1=O
CHEMBL356210,CHEMBL237,Kappa opioid receptor,Ki,=,1085.0,nM,CHEMBL755700,B,"Binding affinity for opioid receptor type, human Opioid receptor kappa 1 expressed in membrane homogenates of COS-1 or CHO cells",CHEMBL1135663,KI,CC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1CCCCC1)C(=O)NC1S[C@H]2CCC[C@@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)NC(Cc3ccc(Cl)cc3)C(N)=O)N2C1=O
CHEMBL355931,CHEMBL237,Kappa opioid receptor,Ki,=,441.0,nM,CHEMBL755700,B,"Binding affinity for opioid receptor type, human Opioid receptor kappa 1 expressed in membrane homogenates of COS-1 or CHO cells",CHEMBL1135663,KI,CC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1CCCCC1)C(=O)NC1CC[C@H]2CCC[C@@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)NC(Cc3ccc(Cl)cc3)C(N)=O)N2C1=O
CHEMBL2371034,CHEMBL237,Kappa opioid receptor,Ki,=,282.0,nM,CHEMBL755700,B,"Binding affinity for opioid receptor type, human Opioid receptor kappa 1 expressed in membrane homogenates of COS-1 or CHO cells",CHEMBL1135663,KI,CC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N1[C@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@@H](Cc2ccc(Cl)cc2)C(N)=O)CC[C@@H]1C(C)(C)C
CHEMBL358403,CHEMBL237,Kappa opioid receptor,Ki,=,78.0,nM,CHEMBL755700,B,"Binding affinity for opioid receptor type, human Opioid receptor kappa 1 expressed in membrane homogenates of COS-1 or CHO cells",CHEMBL1135663,KI,CC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CC[C@@H]2SC[C@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)NC(Cc3ccc(Cl)cc3)C(N)=O)N2C1=O
CHEMBL396460,CHEMBL237,Kappa opioid receptor,Ki,=,1500.0,nM,CHEMBL755700,B,"Binding affinity for opioid receptor type, human Opioid receptor kappa 1 expressed in membrane homogenates of COS-1 or CHO cells",CHEMBL1135663,KI,CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)O
CHEMBL347531,CHEMBL237,Kappa opioid receptor,Ki,=,5.7,nM,CHEMBL751202,B,Inhibition of [3H]U-69593 binding to human Opioid receptor kappa 1 expressed in HEK 293 cells,CHEMBL1133419,KI,CNC(c1cccc(O)c1)C(C)(C)C(=O)NCC1CCCCC1
CHEMBL347750,CHEMBL237,Kappa opioid receptor,Ki,=,3.6,nM,CHEMBL751202,B,Inhibition of [3H]U-69593 binding to human Opioid receptor kappa 1 expressed in HEK 293 cells,CHEMBL1133419,KI,CNC(c1cccc(O)c1)C(C)(C)C(=O)NCCCc1ccccc1
CHEMBL421789,CHEMBL237,Kappa opioid receptor,Ki,=,2.9,nM,CHEMBL751202,B,Inhibition of [3H]U-69593 binding to human Opioid receptor kappa 1 expressed in HEK 293 cells,CHEMBL1133419,KI,CN(CC1CC1)C(c1cccc(O)c1)C(C)(C)C(=O)NCCc1ccccc1
CHEMBL150839,CHEMBL237,Kappa opioid receptor,Ki,=,75.0,nM,CHEMBL751202,B,Inhibition of [3H]U-69593 binding to human Opioid receptor kappa 1 expressed in HEK 293 cells,CHEMBL1133419,KI,CCCCN(C)C(c1cccc(O)c1)C(C)(C)C(=O)NCCc1ccccc1
CHEMBL147191,CHEMBL237,Kappa opioid receptor,Ki,=,1.2,nM,CHEMBL751202,B,Inhibition of [3H]U-69593 binding to human Opioid receptor kappa 1 expressed in HEK 293 cells,CHEMBL1133419,KI,CNC(c1ccccc1)C(C)(C)C(=O)NCC1CCCCC1
CHEMBL151921,CHEMBL237,Kappa opioid receptor,Ki,=,1.3,nM,CHEMBL751202,B,Inhibition of [3H]U-69593 binding to human Opioid receptor kappa 1 expressed in HEK 293 cells,CHEMBL1133419,KI,CNC(c1cccc(O)c1)C(C)(C)C(=O)NCc1cccc2ccccc12
CHEMBL146750,CHEMBL237,Kappa opioid receptor,Ki,=,5.0,nM,CHEMBL751202,B,Inhibition of [3H]U-69593 binding to human Opioid receptor kappa 1 expressed in HEK 293 cells,CHEMBL1133419,KI,CNC(c1cccc(O)c1)C(C)(C)C(=O)NCc1ccccc1
CHEMBL146918,CHEMBL237,Kappa opioid receptor,Ki,=,49.0,nM,CHEMBL751202,B,Inhibition of [3H]U-69593 binding to human Opioid receptor kappa 1 expressed in HEK 293 cells,CHEMBL1133419,KI,CNC(c1ccccc1)C(C)(C)C(=O)NCCc1ccccc1
CHEMBL347316,CHEMBL237,Kappa opioid receptor,Ki,=,75.0,nM,CHEMBL751202,B,Inhibition of [3H]U-69593 binding to human Opioid receptor kappa 1 expressed in HEK 293 cells,CHEMBL1133419,KI,CNC(c1cccc(O)c1)C(C)(C)C(=O)NCC1CC1
CHEMBL149280,CHEMBL237,Kappa opioid receptor,Ki,=,6.3,nM,CHEMBL751202,B,Inhibition of [3H]U-69593 binding to human Opioid receptor kappa 1 expressed in HEK 293 cells,CHEMBL1133419,KI,CNC(c1cccc(O)c1)C(C)(C)C(=O)NCCc1ccccc1
CHEMBL149143,CHEMBL237,Kappa opioid receptor,Ki,=,467.0,nM,CHEMBL751202,B,Inhibition of [3H]U-69593 binding to human Opioid receptor kappa 1 expressed in HEK 293 cells,CHEMBL1133419,KI,CNC(c1ccccc1)C(C)(C)C(=O)NCc1ccccc1
CHEMBL80,CHEMBL237,Kappa opioid receptor,Ki,=,1.2,nM,CHEMBL751202,B,Inhibition of [3H]U-69593 binding to human Opioid receptor kappa 1 expressed in HEK 293 cells,CHEMBL1133419,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL2113380,CHEMBL237,Kappa opioid receptor,Ki,=,63.3,nM,CHEMBL755684,B,Displacement of [3H]U-69593 from human recombinant Opioid receptor kappa 1 on CHO cell membranes.,CHEMBL1144921,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccccc4c2C[C@@]3(CCCc2ccccc2)C1C5
CHEMBL401093,CHEMBL237,Kappa opioid receptor,Ki,=,396.0,nM,CHEMBL755684,B,Displacement of [3H]U-69593 from human recombinant Opioid receptor kappa 1 on CHO cell membranes.,CHEMBL1144921,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccccc4c2C[C@@]3(O)[C@H]1C5
CHEMBL2113379,CHEMBL237,Kappa opioid receptor,Ki,=,148.0,nM,CHEMBL755684,B,Displacement of [3H]U-69593 from human recombinant Opioid receptor kappa 1 on CHO cell membranes.,CHEMBL1144921,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccccc4c2C[C@@]3(NC(=O)Cc2ccccc2)C1C5
CHEMBL70,CHEMBL237,Kappa opioid receptor,Ki,=,260.0,nM,CHEMBL751206,B,In vitro potency was measured against human Opioid receptor kappa 1,CHEMBL1131022,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL2113377,CHEMBL237,Kappa opioid receptor,Ki,=,36.1,nM,CHEMBL755684,B,Displacement of [3H]U-69593 from human recombinant Opioid receptor kappa 1 on CHO cell membranes.,CHEMBL1144921,KI,CCCCN[C@@]12Cc3c([nH]c4ccccc34)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)C2C5
CHEMBL2113383,CHEMBL237,Kappa opioid receptor,Ki,=,63.8,nM,CHEMBL755684,B,Displacement of [3H]U-69593 from human recombinant Opioid receptor kappa 1 on CHO cell membranes.,CHEMBL1144921,KI,CCN[C@@]12Cc3c([nH]c4ccccc34)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)C2C5
CHEMBL38874,CHEMBL237,Kappa opioid receptor,Ki,=,305.0,nM,CHEMBL755684,B,Displacement of [3H]U-69593 from human recombinant Opioid receptor kappa 1 on CHO cell membranes.,CHEMBL1144921,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL2113378,CHEMBL237,Kappa opioid receptor,Ki,=,7.79,nM,CHEMBL755684,B,Displacement of [3H]U-69593 from human recombinant Opioid receptor kappa 1 on CHO cell membranes.,CHEMBL1144921,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccccc4c2C[C@@]3(NCCCc2ccccc2)C1C5
CHEMBL2113376,CHEMBL237,Kappa opioid receptor,Ki,=,399.0,nM,CHEMBL755684,B,Displacement of [3H]U-69593 from human recombinant Opioid receptor kappa 1 on CHO cell membranes.,CHEMBL1144921,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccccc4c2C[C@@]3(N)C1C5
CHEMBL2113372,CHEMBL237,Kappa opioid receptor,Ki,=,409.0,nM,CHEMBL755684,B,Displacement of [3H]U-69593 from human recombinant Opioid receptor kappa 1 on CHO cell membranes.,CHEMBL1144921,KI,CCCCCCC(=O)N[C@@]12Cc3c([nH]c4ccccc34)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)C2C5
CHEMBL2113382,CHEMBL237,Kappa opioid receptor,Ki,=,13.8,nM,CHEMBL755684,B,Displacement of [3H]U-69593 from human recombinant Opioid receptor kappa 1 on CHO cell membranes.,CHEMBL1144921,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccccc4c2C[C@@]3(NCCc2ccccc2)C1C5
CHEMBL440765,CHEMBL237,Kappa opioid receptor,Ki,=,0.3,nM,CHEMBL755684,B,Displacement of [3H]U-69593 from human recombinant Opioid receptor kappa 1 on CHO cell membranes.,CHEMBL1144921,KI,CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL573214,CHEMBL237,Kappa opioid receptor,Ki,=,0.2,nM,CHEMBL755684,B,Displacement of [3H]U-69593 from human recombinant Opioid receptor kappa 1 on CHO cell membranes.,CHEMBL1144921,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL88560,CHEMBL237,Kappa opioid receptor,Ki,=,340.0,nM,CHEMBL751206,B,In vitro potency was measured against human Opioid receptor kappa 1,CHEMBL1131022,KI,CN1CCNC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C1
CHEMBL19019,CHEMBL237,Kappa opioid receptor,Ki,=,0.4,nM,CHEMBL755684,B,Displacement of [3H]U-69593 from human recombinant Opioid receptor kappa 1 on CHO cell membranes.,CHEMBL1144921,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL2113373,CHEMBL237,Kappa opioid receptor,Ki,=,24.5,nM,CHEMBL755684,B,Displacement of [3H]U-69593 from human recombinant Opioid receptor kappa 1 on CHO cell membranes.,CHEMBL1144921,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccccc4c2C[C@@]3(NC(=O)CCc2ccccc2)C1C5
CHEMBL567175,CHEMBL237,Kappa opioid receptor,Ki,=,10.1,nM,CHEMBL755684,B,Displacement of [3H]U-69593 from human recombinant Opioid receptor kappa 1 on CHO cell membranes.,CHEMBL1144921,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL2113381,CHEMBL237,Kappa opioid receptor,Ki,=,723.0,nM,CHEMBL755684,B,Displacement of [3H]U-69593 from human recombinant Opioid receptor kappa 1 on CHO cell membranes.,CHEMBL1144921,KI,CCCCC(=O)N[C@@]12Cc3c([nH]c4ccccc34)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)C2C5
CHEMBL610541,CHEMBL237,Kappa opioid receptor,Ki,=,0.7,nM,CHEMBL752211,B,Inhibition of [3H]diprenorphine binding to Opioid receptor kappa 1,CHEMBL1133757,KI,O=Cc1ccc(C(=O)NCC(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5C3(CCN4CC3CC3)C2O6)cc1C=O
CHEMBL386272,CHEMBL237,Kappa opioid receptor,Ki,=,29.0,nM,CHEMBL750071,B,"Displacement of radioligand [3H]- U-69,593 on Opioid receptor kappa 1 in monkey brain membranes",CHEMBL1133634,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)/C=C/c5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL610542,CHEMBL237,Kappa opioid receptor,Ki,=,11.9,nM,CHEMBL750072,B,"Displacement of radioligand [3H]- U-69,593 on Opioid receptor kappa 1 in monkey brain membranes range; Value ranges from (9.7-14.2)",CHEMBL1133634,KI,O=C(/C=C/c1ccc(Cl)cc1)NC12CCC(=O)C3Oc4cccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL386492,CHEMBL237,Kappa opioid receptor,Ki,=,7.2,nM,CHEMBL750071,B,"Displacement of radioligand [3H]- U-69,593 on Opioid receptor kappa 1 in monkey brain membranes",CHEMBL1133634,KI,O=C(/C=C/c1ccc(Cl)cc1)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL405618,CHEMBL237,Kappa opioid receptor,Ki,=,0.0008,nM,CHEMBL821386,B,Binding affinity towards Wild-type kappa opioid receptor expressed in HEK cells,CHEMBL1132988,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O
CHEMBL440765,CHEMBL237,Kappa opioid receptor,Ki,=,1.4,nM,CHEMBL821386,B,Binding affinity towards Wild-type kappa opioid receptor expressed in HEK cells,CHEMBL1132988,KI,CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL216640,CHEMBL237,Kappa opioid receptor,Ki,=,0.074,nM,CHEMBL751034,B,Binding affinity towards cloned human Opioid receptor kappa 1 in CHO cell membranes.,CHEMBL1133465,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL1790761,CHEMBL237,Kappa opioid receptor,Ki,=,55.0,nM,CHEMBL873919,B,Binding affinity of Opioid receptor kappa 1 to cloned human opioid receptor in CHO cell membrane.,CHEMBL1133465,KI,CC[C@@H](C)[C@@H](NC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCCN)C(N)=O)[C@@H](C)CC
CHEMBL573214,CHEMBL237,Kappa opioid receptor,Ki,=,0.36,nM,CHEMBL751034,B,Binding affinity towards cloned human Opioid receptor kappa 1 in CHO cell membranes.,CHEMBL1133465,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL269377,CHEMBL237,Kappa opioid receptor,Ki,=,65.0,nM,CHEMBL751034,B,Binding affinity towards cloned human Opioid receptor kappa 1 in CHO cell membranes.,CHEMBL1133465,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL407389,CHEMBL237,Kappa opioid receptor,Ki,=,2.7,nM,CHEMBL751034,B,Binding affinity towards cloned human Opioid receptor kappa 1 in CHO cell membranes.,CHEMBL1133465,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H]1CCCN1C(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL407389,CHEMBL237,Kappa opioid receptor,Ki,=,7.5,nM,CHEMBL755693,B,Binding affinity at Opioid receptor kappa 1 by to cloned human opioid receptors expressed in CHO cell membranes,CHEMBL1133465,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H]1CCCN1C(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL405097,CHEMBL237,Kappa opioid receptor,Ki,=,94.0,nM,CHEMBL751034,B,Binding affinity towards cloned human Opioid receptor kappa 1 in CHO cell membranes.,CHEMBL1133465,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL405190,CHEMBL237,Kappa opioid receptor,Ki,=,0.15,nM,CHEMBL751034,B,Binding affinity towards cloned human Opioid receptor kappa 1 in CHO cell membranes.,CHEMBL1133465,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](C)NC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL413729,CHEMBL237,Kappa opioid receptor,Ki,=,160.0,nM,CHEMBL751034,B,Binding affinity towards cloned human Opioid receptor kappa 1 in CHO cell membranes.,CHEMBL1133465,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL38576,CHEMBL237,Kappa opioid receptor,Ki,=,0.054,nM,CHEMBL751205,B,In vitro binding affinity towards Opioid receptor kappa 1 by displacement of bound [3H]U-69593,CHEMBL1132816,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@H](CN1CCCC1)c1ccccc1
CHEMBL102497,CHEMBL237,Kappa opioid receptor,Ki,=,3284.0,nM,CHEMBL700230,B,Binding affinity towards opioid kappa receptor using [3H]U-69593 as radioligand,CHEMBL1131860,KI,C=CCN1CC[C@H](N(c2ccccc2)c2ccc(C(=O)N(CC)CC)cc2)[C@H](C)C1
CHEMBL316177,CHEMBL237,Kappa opioid receptor,Ki,=,0.58,nM,CHEMBL751205,B,In vitro binding affinity towards Opioid receptor kappa 1 by displacement of bound [3H]U-69593,CHEMBL1132816,KI,CN(C(=O)Cc1ccccc1N)[C@H](CN1CCCC1)c1ccccc1
CHEMBL108608,CHEMBL237,Kappa opioid receptor,Ki,=,34.6,nM,CHEMBL755695,B,Binding affinity in recombinant human Opioid receptor kappa 1 transfected into chinese hamster ovary cells by displacing [3H]U-69593 radioligand,CHEMBL1145844,KI,COc1ccc2c(c1O)[C@]13CCN(C)C(C2)[C@@]12C/C(=C\c1ccccc1)[C@@H]3c1[nH]c3ccccc3c1C2
CHEMBL87514,CHEMBL237,Kappa opioid receptor,Ki,=,0.93,nM,CHEMBL751205,B,In vitro binding affinity towards Opioid receptor kappa 1 by displacement of bound [3H]U-69593,CHEMBL1132816,KI,CN(C(=O)Cc1ccc(N)cc1)[C@H](CN1CCCC1)c1ccccc1
CHEMBL567175,CHEMBL237,Kappa opioid receptor,Ki,=,10.1,nM,CHEMBL755695,B,Binding affinity in recombinant human Opioid receptor kappa 1 transfected into chinese hamster ovary cells by displacing [3H]U-69593 radioligand,CHEMBL1145844,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL567175,CHEMBL237,Kappa opioid receptor,Ki,=,30.0,nM,CHEMBL752207,B,Displacement of [3H]U-69593 from Opioid receptor kappa 1,CHEMBL1134426,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL313484,CHEMBL237,Kappa opioid receptor,Ki,=,0.064,nM,CHEMBL751205,B,In vitro binding affinity towards Opioid receptor kappa 1 by displacement of bound [3H]U-69593,CHEMBL1132816,KI,CN(C(=O)Cc1cccc(C(F)(F)F)c1)[C@H](CN1CCCC1)c1ccccc1
CHEMBL109040,CHEMBL237,Kappa opioid receptor,Ki,=,0.2,nM,CHEMBL755695,B,Binding affinity in recombinant human Opioid receptor kappa 1 transfected into chinese hamster ovary cells by displacing [3H]U-69593 radioligand,CHEMBL1145844,KI,COc1ccc2c(c1O)[C@]13CCN(C)C(C2)[C@]12CCC(=O)[C@H]3/C(=C/c1ccccc1)C2
CHEMBL19019,CHEMBL237,Kappa opioid receptor,Ki,=,0.4,nM,CHEMBL755695,B,Binding affinity in recombinant human Opioid receptor kappa 1 transfected into chinese hamster ovary cells by displacing [3H]U-69593 radioligand,CHEMBL1145844,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL87653,CHEMBL237,Kappa opioid receptor,Ki,=,0.091,nM,CHEMBL751205,B,In vitro binding affinity towards Opioid receptor kappa 1 by displacement of bound [3H]U-69593,CHEMBL1132816,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1[N+](=O)[O-])[C@H](CN1CCCC1)c1ccccc1
CHEMBL322875,CHEMBL237,Kappa opioid receptor,Ki,=,440.0,nM,CHEMBL755695,B,Binding affinity in recombinant human Opioid receptor kappa 1 transfected into chinese hamster ovary cells by displacing [3H]U-69593 radioligand,CHEMBL1145844,KI,CC(C)=CC[C@@]12Cc3c([nH]c4ccccc34)[C@]3(C)Oc4c(O)ccc5c4[C@]13CCN(C)C2C5
CHEMBL86324,CHEMBL237,Kappa opioid receptor,Ki,=,0.058,nM,CHEMBL751205,B,In vitro binding affinity towards Opioid receptor kappa 1 by displacement of bound [3H]U-69593,CHEMBL1132816,KI,CN(C(=O)Cc1ccc(C(F)(F)F)cc1)[C@H](CN1CCCC1)c1ccccc1
CHEMBL95847,CHEMBL237,Kappa opioid receptor,Ki,=,3100.0,nM,CHEMBL752207,B,Displacement of [3H]U-69593 from Opioid receptor kappa 1,CHEMBL1134426,KI,C=C(C)CN1CCC23c4c5ccc(OC)c4O[C@H]2c2n[nH]cc2C[C@@]3(O)C1C5
CHEMBL85423,CHEMBL237,Kappa opioid receptor,Ki,=,8.6,nM,CHEMBL751205,B,In vitro binding affinity towards Opioid receptor kappa 1 by displacement of bound [3H]U-69593,CHEMBL1132816,KI,CN(C(=O)Cc1ccccc1N(S(C)(=O)=O)S(C)(=O)=O)[C@H](CN1CCCC1)c1ccccc1
CHEMBL87306,CHEMBL237,Kappa opioid receptor,Ki,=,0.13,nM,CHEMBL751205,B,In vitro binding affinity towards Opioid receptor kappa 1 by displacement of bound [3H]U-69593,CHEMBL1132816,KI,CN(C(=O)Cc1ccccc1C(F)(F)F)[C@H](CN1CCCC1)c1ccccc1
CHEMBL102690,CHEMBL237,Kappa opioid receptor,Ki,=,1367.0,nM,CHEMBL752817,B,The compound was tested for binding affinity against Opioid receptor kappa 1 by using [3H]Diprenorphine as a radioligand,CHEMBL1132332,KI,CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(N)=O
CHEMBL320306,CHEMBL237,Kappa opioid receptor,Ki,=,239.0,nM,CHEMBL755695,B,Binding affinity in recombinant human Opioid receptor kappa 1 transfected into chinese hamster ovary cells by displacing [3H]U-69593 radioligand,CHEMBL1145844,KI,C/C=C1\C[C@@]23Cc4c([nH]c5ccccc45)[C@@H]1[C@@]21CCN(C)C3Cc2ccc(OC)c(O)c21
CHEMBL82919,CHEMBL237,Kappa opioid receptor,Ki,=,0.065,nM,CHEMBL751205,B,In vitro binding affinity towards Opioid receptor kappa 1 by displacement of bound [3H]U-69593,CHEMBL1132816,KI,CN(C(=O)Cc1cccc([N+](=O)[O-])c1)[C@H](CN1CCCC1)c1ccccc1
CHEMBL329719,CHEMBL237,Kappa opioid receptor,Ki,=,580.0,nM,CHEMBL752207,B,Displacement of [3H]U-69593 from Opioid receptor kappa 1,CHEMBL1134426,KI,C=C(C)CN1CCC23c4c5ccc(O)c4O[C@H]2c2oc4ccccc4c2C[C@@]3(O)C1C5
CHEMBL318957,CHEMBL237,Kappa opioid receptor,Ki,=,3200.0,nM,CHEMBL752207,B,Displacement of [3H]U-69593 from Opioid receptor kappa 1,CHEMBL1134426,KI,C=C(C)CN1CCC23c4c5ccc(OC)c4O[C@H]2c2ncc(-c4ccc(Cl)cc4)cc2C[C@@]3(O)C1C5
CHEMBL87069,CHEMBL237,Kappa opioid receptor,Ki,=,0.086,nM,CHEMBL751205,B,In vitro binding affinity towards Opioid receptor kappa 1 by displacement of bound [3H]U-69593,CHEMBL1132816,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1N)[C@H](CN1CCCC1)c1ccccc1
CHEMBL87483,CHEMBL237,Kappa opioid receptor,Ki,=,0.93,nM,CHEMBL751205,B,In vitro binding affinity towards Opioid receptor kappa 1 by displacement of bound [3H]U-69593,CHEMBL1132816,KI,CN(C(=O)Cc1cccc(N)c1)[C@H](CN1CCCC1)c1ccccc1
CHEMBL407084,CHEMBL237,Kappa opioid receptor,Ki,=,0.19,nM,CHEMBL752817,B,The compound was tested for binding affinity against Opioid receptor kappa 1 by using [3H]Diprenorphine as a radioligand,CHEMBL1132332,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL83142,CHEMBL237,Kappa opioid receptor,Ki,=,25.0,nM,CHEMBL751205,B,In vitro binding affinity towards Opioid receptor kappa 1 by displacement of bound [3H]U-69593,CHEMBL1132816,KI,CN(C(=O)Cc1ccc(N(S(C)(=O)=O)S(C)(=O)=O)cc1)[C@H](CN1CCCC1)c1ccccc1
CHEMBL107420,CHEMBL237,Kappa opioid receptor,Ki,=,0.61,nM,CHEMBL755695,B,Binding affinity in recombinant human Opioid receptor kappa 1 transfected into chinese hamster ovary cells by displacing [3H]U-69593 radioligand,CHEMBL1145844,KI,COc1ccc2c(c1O)[C@]13CCN(C)C(C2)[C@@]12C/C(=C(/C)c1ccccc1)[C@@H]3c1[nH]c3ccccc3c1C2
CHEMBL98324,CHEMBL237,Kappa opioid receptor,Ki,=,1000.0,nM,CHEMBL752207,B,Displacement of [3H]U-69593 from Opioid receptor kappa 1,CHEMBL1134426,KI,C=C(C)CN1CCC23c4c5ccc(O)c4O[C@H]2C(=O)C2(Cc4ccccc4C2)C[C@@]3(O)C1C5
CHEMBL317536,CHEMBL237,Kappa opioid receptor,Ki,=,300.0,nM,CHEMBL752207,B,Displacement of [3H]U-69593 from Opioid receptor kappa 1,CHEMBL1134426,KI,C=C(C)CN1CCC23c4c5ccc(O)c4O[C@H]2c2ncc(-c4ccc(Cl)cc4)cc2C[C@@]3(O)C1C5
CHEMBL87986,CHEMBL237,Kappa opioid receptor,Ki,=,1.1,nM,CHEMBL751205,B,In vitro binding affinity towards Opioid receptor kappa 1 by displacement of bound [3H]U-69593,CHEMBL1132816,KI,CN(C(=O)Cc1ccc([N+](=O)[O-])cc1)[C@H](CN1CCCC1)c1ccccc1
CHEMBL412248,CHEMBL237,Kappa opioid receptor,Ki,=,19.8,nM,CHEMBL752817,B,The compound was tested for binding affinity against Opioid receptor kappa 1 by using [3H]Diprenorphine as a radioligand,CHEMBL1132332,KI,CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL85591,CHEMBL237,Kappa opioid receptor,Ki,=,6.0,nM,CHEMBL751205,B,In vitro binding affinity towards Opioid receptor kappa 1 by displacement of bound [3H]U-69593,CHEMBL1132816,KI,CN(C(=O)Cc1cccc(N(S(C)(=O)=O)S(C)(=O)=O)c1)[C@H](CN1CCCC1)c1ccccc1
CHEMBL316930,CHEMBL237,Kappa opioid receptor,Ki,=,38.0,nM,CHEMBL752207,B,Displacement of [3H]U-69593 from Opioid receptor kappa 1,CHEMBL1134426,KI,C=C(C)CN1CCC23c4c5ccc(O)c4O[C@H]2c2n[nH]cc2C[C@@]3(O)C1C5
CHEMBL110124,CHEMBL237,Kappa opioid receptor,Ki,=,0.14,nM,CHEMBL755695,B,Binding affinity in recombinant human Opioid receptor kappa 1 transfected into chinese hamster ovary cells by displacing [3H]U-69593 radioligand,CHEMBL1145844,KI,COc1ccc2c(c1O)[C@]13CCN(C)C(C2)[C@]12CCC(=O)[C@H]3/C(=C(\C)c1ccccc1)C2
CHEMBL424609,CHEMBL237,Kappa opioid receptor,Ki,=,0.096,nM,CHEMBL751205,B,In vitro binding affinity towards Opioid receptor kappa 1 by displacement of bound [3H]U-69593,CHEMBL1132816,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1N(S(C)(=O)=O)S(C)(=O)=O)[C@H](CN1CCCC1)c1ccccc1
CHEMBL95319,CHEMBL237,Kappa opioid receptor,Ki,=,3800.0,nM,CHEMBL752207,B,Displacement of [3H]U-69593 from Opioid receptor kappa 1,CHEMBL1134426,KI,C=C(C)CN1CCC23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccccc4c2C[C@@]3(O)C1C5
CHEMBL319592,CHEMBL237,Kappa opioid receptor,Ki,=,4500.0,nM,CHEMBL752207,B,Displacement of [3H]U-69593 from Opioid receptor kappa 1,CHEMBL1134426,KI,C=C(C)CN1CCC23c4c5ccc(O)c4O[C@H]2C(=O)/C(=C/c2ccccc2)C[C@@]3(O)C1C5
CHEMBL110461,CHEMBL237,Kappa opioid receptor,Ki,=,94.2,nM,CHEMBL755695,B,Binding affinity in recombinant human Opioid receptor kappa 1 transfected into chinese hamster ovary cells by displacing [3H]U-69593 radioligand,CHEMBL1145844,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@@]2(C)c2[nH]c4ccccc4c2C[C@@]3(C/C=C/c2ccccc2)C1C5
CHEMBL87207,CHEMBL237,Kappa opioid receptor,Ki,=,0.41,nM,CHEMBL751205,B,In vitro binding affinity towards Opioid receptor kappa 1 by displacement of bound [3H]U-69593,CHEMBL1132816,KI,CN(C(=O)Cc1ccccc1[N+](=O)[O-])[C@H](CN1CCCC1)c1ccccc1
CHEMBL13470,CHEMBL237,Kappa opioid receptor,Ki,=,3535.0,nM,CHEMBL700230,B,Binding affinity towards opioid kappa receptor using [3H]U-69593 as radioligand,CHEMBL1131860,KI,C=CCN1C[C@H](C)N([C@H](c2ccc(C(=O)N(CC)CC)cc2)c2cccc(OC)c2)C[C@H]1C
CHEMBL107207,CHEMBL237,Kappa opioid receptor,Ki,=,28.4,nM,CHEMBL755695,B,Binding affinity in recombinant human Opioid receptor kappa 1 transfected into chinese hamster ovary cells by displacing [3H]U-69593 radioligand,CHEMBL1145844,KI,COc1ccc2c(c1O)[C@]13CCN(C)C(C2)[C@@]12CC(=C(C)C)[C@@H]3c1[nH]c3ccccc3c1C2
CHEMBL321092,CHEMBL237,Kappa opioid receptor,Ki,=,8695.0,nM,CHEMBL700230,B,Binding affinity towards opioid kappa receptor using [3H]U-69593 as radioligand,CHEMBL1131860,KI,C=CCN1CC[C@H](N(c2ccccc2)c2ccc(C(=O)N(CC)CC)cc2)[C@@H](C)C1
CHEMBL435084,CHEMBL237,Kappa opioid receptor,Ki,=,3.4,nM,CHEMBL752737,B,Inhibitory activity against Opioid receptor kappa 1 in chinese Hamster Ovary (CHO) cell membranes was determined using [3H]U-69593 radioligand,CHEMBL1145905,KI,O=C(Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)c1cccc(C(=O)Oc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)c1
CHEMBL424328,CHEMBL237,Kappa opioid receptor,Ki,=,1.1,nM,CHEMBL752737,B,Inhibitory activity against Opioid receptor kappa 1 in chinese Hamster Ovary (CHO) cell membranes was determined using [3H]U-69593 radioligand,CHEMBL1145905,KI,O=C(CCCCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL146756,CHEMBL237,Kappa opioid receptor,Ki,=,0.078,nM,CHEMBL752737,B,Inhibitory activity against Opioid receptor kappa 1 in chinese Hamster Ovary (CHO) cell membranes was determined using [3H]U-69593 radioligand,CHEMBL1145905,KI,O=C(/C=C/C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL424327,CHEMBL237,Kappa opioid receptor,Ki,=,24.0,nM,CHEMBL752737,B,Inhibitory activity against Opioid receptor kappa 1 in chinese Hamster Ovary (CHO) cell membranes was determined using [3H]U-69593 radioligand,CHEMBL1145905,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CCCN1CC[C@]24CCCC[C@H]2[C@H]1Cc1ccc(O)cc14)CC3
CHEMBL405131,CHEMBL237,Kappa opioid receptor,Ki,=,0.65,nM,CHEMBL752737,B,Inhibitory activity against Opioid receptor kappa 1 in chinese Hamster Ovary (CHO) cell membranes was determined using [3H]U-69593 radioligand,CHEMBL1145905,KI,O=C(CCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL151872,CHEMBL237,Kappa opioid receptor,Ki,=,120.0,nM,CHEMBL752737,B,Inhibitory activity against Opioid receptor kappa 1 in chinese Hamster Ovary (CHO) cell membranes was determined using [3H]U-69593 radioligand,CHEMBL1145905,KI,c1cc2c(cc1OCCCCCCCCCCOc1ccc3c(c1)[C@@]14CCCC[C@H]1[C@@H](C3)N(CC1CCC1)CC4)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL346885,CHEMBL237,Kappa opioid receptor,Ki,=,1.2,nM,CHEMBL752737,B,Inhibitory activity against Opioid receptor kappa 1 in chinese Hamster Ovary (CHO) cell membranes was determined using [3H]U-69593 radioligand,CHEMBL1145905,KI,O=C(CCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL413512,CHEMBL237,Kappa opioid receptor,Ki,=,0.1,nM,CHEMBL752737,B,Inhibitory activity against Opioid receptor kappa 1 in chinese Hamster Ovary (CHO) cell membranes was determined using [3H]U-69593 radioligand,CHEMBL1145905,KI,O=C(CCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL592,CHEMBL237,Kappa opioid receptor,Ki,=,2.3,nM,CHEMBL752737,B,Inhibitory activity against Opioid receptor kappa 1 in chinese Hamster Ovary (CHO) cell membranes was determined using [3H]U-69593 radioligand,CHEMBL1145905,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13
CHEMBL357334,CHEMBL237,Kappa opioid receptor,Ki,=,0.07,nM,CHEMBL752737,B,Inhibitory activity against Opioid receptor kappa 1 in chinese Hamster Ovary (CHO) cell membranes was determined using [3H]U-69593 radioligand,CHEMBL1145905,KI,COC(=O)CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL358104,CHEMBL237,Kappa opioid receptor,Ki,=,0.41,nM,CHEMBL752737,B,Inhibitory activity against Opioid receptor kappa 1 in chinese Hamster Ovary (CHO) cell membranes was determined using [3H]U-69593 radioligand,CHEMBL1145905,KI,O=C(CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL356889,CHEMBL237,Kappa opioid receptor,Ki,=,50.0,nM,CHEMBL752737,B,Inhibitory activity against Opioid receptor kappa 1 in chinese Hamster Ovary (CHO) cell membranes was determined using [3H]U-69593 radioligand,CHEMBL1145905,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CCCCCCN1CC[C@]24CCCC[C@H]2[C@H]1Cc1ccc(O)cc14)CC3
CHEMBL149074,CHEMBL237,Kappa opioid receptor,Ki,=,4.2,nM,CHEMBL752737,B,Inhibitory activity against Opioid receptor kappa 1 in chinese Hamster Ovary (CHO) cell membranes was determined using [3H]U-69593 radioligand,CHEMBL1145905,KI,O=C(Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)c1ccc(C(=O)Oc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)cc1
CHEMBL147511,CHEMBL237,Kappa opioid receptor,Ki,=,0.049,nM,CHEMBL752737,B,Inhibitory activity against Opioid receptor kappa 1 in chinese Hamster Ovary (CHO) cell membranes was determined using [3H]U-69593 radioligand,CHEMBL1145905,KI,O=C(CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL49269,CHEMBL237,Kappa opioid receptor,Ki,=,0.034,nM,CHEMBL752737,B,Inhibitory activity against Opioid receptor kappa 1 in chinese Hamster Ovary (CHO) cell membranes was determined using [3H]U-69593 radioligand,CHEMBL1145905,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL150061,CHEMBL237,Kappa opioid receptor,Ki,=,0.17,nM,CHEMBL752737,B,Inhibitory activity against Opioid receptor kappa 1 in chinese Hamster Ovary (CHO) cell membranes was determined using [3H]U-69593 radioligand,CHEMBL1145905,KI,O=C(Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)[C@H]1C[C@H]1C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL301160,CHEMBL237,Kappa opioid receptor,Ki,=,0.079,nM,CHEMBL752737,B,Inhibitory activity against Opioid receptor kappa 1 in chinese Hamster Ovary (CHO) cell membranes was determined using [3H]U-69593 radioligand,CHEMBL1145905,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL433697,CHEMBL237,Kappa opioid receptor,Ki,=,0.076,nM,CHEMBL752737,B,Inhibitory activity against Opioid receptor kappa 1 in chinese Hamster Ovary (CHO) cell membranes was determined using [3H]U-69593 radioligand,CHEMBL1145905,KI,O=C(CCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL348023,CHEMBL237,Kappa opioid receptor,Ki,=,18.0,nM,CHEMBL752737,B,Inhibitory activity against Opioid receptor kappa 1 in chinese Hamster Ovary (CHO) cell membranes was determined using [3H]U-69593 radioligand,CHEMBL1145905,KI,c1cc2c(cc1OCCCCOc1ccc3c(c1)[C@@]14CCCC[C@H]1[C@@H](C3)N(CC1CCC1)CC4)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL318859,CHEMBL237,Kappa opioid receptor,Ki,=,0.27,nM,CHEMBL752737,B,Inhibitory activity against Opioid receptor kappa 1 in chinese Hamster Ovary (CHO) cell membranes was determined using [3H]U-69593 radioligand,CHEMBL1145905,KI,CN(C(=O)Cc1cccc2occc12)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL346436,CHEMBL237,Kappa opioid receptor,Ki,=,0.59,nM,CHEMBL752737,B,Inhibitory activity against Opioid receptor kappa 1 in chinese Hamster Ovary (CHO) cell membranes was determined using [3H]U-69593 radioligand,CHEMBL1145905,KI,O=C(CCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL10872,CHEMBL237,Kappa opioid receptor,Ki,=,2.18,nM,CHEMBL751031,B,Binding affinity towards human cloned Opioid receptor kappa 1 using [3H]U-69593,CHEMBL1145840,KI,CC(C)[C@@H](CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)NC(=O)[C@H]1Cc2ccccc2CN1
CHEMBL575508,CHEMBL237,Kappa opioid receptor,Ki,=,1.01,nM,CHEMBL751031,B,Binding affinity towards human cloned Opioid receptor kappa 1 using [3H]U-69593,CHEMBL1145840,KI,CC(C)[C@@H](CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1C
CHEMBL415247,CHEMBL237,Kappa opioid receptor,Ki,=,0.41,nM,CHEMBL751031,B,Binding affinity towards human cloned Opioid receptor kappa 1 using [3H]U-69593,CHEMBL1145840,KI,CC(C)[C@@H](CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1
CHEMBL573214,CHEMBL237,Kappa opioid receptor,Ki,=,0.2,nM,CHEMBL751031,B,Binding affinity towards human cloned Opioid receptor kappa 1 using [3H]U-69593,CHEMBL1145840,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL2112473,CHEMBL237,Kappa opioid receptor,Ki,=,1.82,nM,CHEMBL751031,B,Binding affinity towards human cloned Opioid receptor kappa 1 using [3H]U-69593,CHEMBL1145840,KI,CC(C)[C@@H](CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)NC[C@H]1Cc2ccc(O)cc2CN1
CHEMBL2112474,CHEMBL237,Kappa opioid receptor,Ki,=,16.2,nM,CHEMBL751031,B,Binding affinity towards human cloned Opioid receptor kappa 1 using [3H]U-69593,CHEMBL1145840,KI,CC(C)[C@@H](CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1C(=O)CN(C)C
CHEMBL319536,CHEMBL237,Kappa opioid receptor,Ki,=,52.0,nM,CHEMBL752205,B,Binding affinity against Opioid receptor kappa 1 using [3H]ethylketocyclazocine as radioligand.,CHEMBL1131144,KI,C[C@H]1CN(CCc2ccccc2)CC[C@@]1(C)c1cccc(O)c1
CHEMBL77395,CHEMBL237,Kappa opioid receptor,Ki,=,300.0,nM,CHEMBL755701,B,Binding affinity towards human Opioid receptor kappa 1,CHEMBL1148372,KI,Fc1ccc2[nH]c(CN3CCN(c4ccccn4)CC3)cc2c1
CHEMBL318723,CHEMBL237,Kappa opioid receptor,Ki,=,833.0,nM,CHEMBL752205,B,Binding affinity against Opioid receptor kappa 1 using [3H]ethylketocyclazocine as radioligand.,CHEMBL1131144,KI,C[C@H]1CN(C)CC[C@@]1(C)c1cccc(O)c1
CHEMBL136838,CHEMBL237,Kappa opioid receptor,Ki,=,120.0,nM,CHEMBL751203,B,Binding affinity at cloned human kappa opioid receptor by [3H]diprenorphine displacement.,CHEMBL1136497,KI,C[C@H]1CN(Cc2ccc(C(C)(C)C)cc2)CC[C@@]1(C)c1cccc(C(N)=O)c1
CHEMBL336234,CHEMBL237,Kappa opioid receptor,Ki,=,95.0,nM,CHEMBL751203,B,Binding affinity at cloned human kappa opioid receptor by [3H]diprenorphine displacement.,CHEMBL1136497,KI,C[C@H]1CN(CCc2ccccc2)CC[C@@]1(C)c1cccc(C(N)=O)c1
CHEMBL70,CHEMBL237,Kappa opioid receptor,Ki,=,1900.0,nM,CHEMBL823998,B,Compound was evaluated for the binding affinity to kappa opioid receptor,CHEMBL1126435,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL136612,CHEMBL237,Kappa opioid receptor,Ki,=,1400.0,nM,CHEMBL751204,B,"Concentration required to inhibit the binding of the non-selective opioid antagonist, [3H]diprenorphine, to cloned human kappa opioid receptor; ",CHEMBL1136497,KI,C[C@H]1CN(CCc2ccccc2)CC[C@@]1(C)c1cccc(N)c1
CHEMBL138473,CHEMBL237,Kappa opioid receptor,Ki,=,190.0,nM,CHEMBL751203,B,Binding affinity at cloned human kappa opioid receptor by [3H]diprenorphine displacement.,CHEMBL1136497,KI,C[C@H]1CN(Cc2cccc(Cl)c2)CC[C@@]1(C)c1cccc(C(N)=O)c1
CHEMBL538806,CHEMBL237,Kappa opioid receptor,Ki,=,10.0,nM,CHEMBL823998,B,Compound was evaluated for the binding affinity to kappa opioid receptor,CHEMBL1126435,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@H]1c2ccccc2CC[C@@H]1N1CCCC1.Cl
CHEMBL138036,CHEMBL237,Kappa opioid receptor,Ki,=,840.0,nM,CHEMBL751203,B,Binding affinity at cloned human kappa opioid receptor by [3H]diprenorphine displacement.,CHEMBL1136497,KI,C[C@H]1CN(CCc2ccccc2)CC[C@@]1(C)c1cccc(CO)c1
CHEMBL138778,CHEMBL237,Kappa opioid receptor,Ki,=,460.0,nM,CHEMBL751203,B,Binding affinity at cloned human kappa opioid receptor by [3H]diprenorphine displacement.,CHEMBL1136497,KI,C[C@H]1CN(Cc2ccc(N(C)C)cc2)CC[C@@]1(C)c1cccc(C(N)=O)c1
CHEMBL138653,CHEMBL237,Kappa opioid receptor,Ki,=,210.0,nM,CHEMBL751203,B,Binding affinity at cloned human kappa opioid receptor by [3H]diprenorphine displacement.,CHEMBL1136497,KI,C[C@H]1CN(Cc2cccn2S(=O)(=O)c2ccccc2)CC[C@@]1(C)c1cccc(C(N)=O)c1
CHEMBL138910,CHEMBL237,Kappa opioid receptor,Ki,=,300.0,nM,CHEMBL751203,B,Binding affinity at cloned human kappa opioid receptor by [3H]diprenorphine displacement.,CHEMBL1136497,KI,C[C@H]1CN(Cc2cc3ccccc3o2)CC[C@@]1(C)c1cccc(C(N)=O)c1
CHEMBL136421,CHEMBL237,Kappa opioid receptor,Ki,=,1300.0,nM,CHEMBL751203,B,Binding affinity at cloned human kappa opioid receptor by [3H]diprenorphine displacement.,CHEMBL1136497,KI,CNC(=O)c1cccc([C@]2(C)CCN(CCc3ccccc3)C[C@@H]2C)c1
CHEMBL80,CHEMBL237,Kappa opioid receptor,Ki,=,9.2,nM,CHEMBL751203,B,Binding affinity at cloned human kappa opioid receptor by [3H]diprenorphine displacement.,CHEMBL1136497,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL136196,CHEMBL237,Kappa opioid receptor,Ki,=,140.0,nM,CHEMBL751203,B,Binding affinity at cloned human kappa opioid receptor by [3H]diprenorphine displacement.,CHEMBL1136497,KI,C[C@H]1CN(CCCc2ccccc2)CC[C@@]1(C)c1cccc(C(N)=O)c1
CHEMBL334700,CHEMBL237,Kappa opioid receptor,Ki,=,140.0,nM,CHEMBL751203,B,Binding affinity at cloned human kappa opioid receptor by [3H]diprenorphine displacement.,CHEMBL1136497,KI,C[C@H]1CN(CC2CC2)CC[C@@]1(C)c1cccc(C(N)=O)c1
CHEMBL343063,CHEMBL237,Kappa opioid receptor,Ki,=,210.0,nM,CHEMBL751203,B,Binding affinity at cloned human kappa opioid receptor by [3H]diprenorphine displacement.,CHEMBL1136497,KI,C[C@H]1CN(Cc2ccccc2)CC[C@@]1(C)c1cccc(C(N)=O)c1
CHEMBL350943,CHEMBL237,Kappa opioid receptor,Ki,=,6.0,nM,CHEMBL823998,B,Compound was evaluated for the binding affinity to kappa opioid receptor,CHEMBL1126435,KI,COc1cccc2c1CC[C@H](N1CCCC1)[C@H]2N(C)C(=O)Cc1ccc(Cl)c(Cl)c1.CS(=O)(=O)O
CHEMBL441765,CHEMBL237,Kappa opioid receptor,Ki,=,15.0,nM,CHEMBL823998,B,Compound was evaluated for the binding affinity to kappa opioid receptor,CHEMBL1126435,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL336664,CHEMBL237,Kappa opioid receptor,Ki,=,120.0,nM,CHEMBL751203,B,Binding affinity at cloned human kappa opioid receptor by [3H]diprenorphine displacement.,CHEMBL1136497,KI,CSc1ccc(CN2CC[C@@](C)(c3cccc(C(N)=O)c3)[C@@H](C)C2)cc1
CHEMBL337341,CHEMBL237,Kappa opioid receptor,Ki,=,600.0,nM,CHEMBL751203,B,Binding affinity at cloned human kappa opioid receptor by [3H]diprenorphine displacement.,CHEMBL1136497,KI,C[C@H]1CN(Cc2ccc3ccccc3n2)CC[C@@]1(C)c1cccc(C(N)=O)c1
CHEMBL138930,CHEMBL237,Kappa opioid receptor,Ki,=,5.4,nM,CHEMBL751203,B,Binding affinity at cloned human kappa opioid receptor by [3H]diprenorphine displacement.,CHEMBL1136497,KI,CC(CCN1CC[C@@](C)(c2cccc(C(N)=O)c2)[C@@H](C)C1)CC(C)(C)C
CHEMBL138465,CHEMBL237,Kappa opioid receptor,Ki,=,140.0,nM,CHEMBL751203,B,Binding affinity at cloned human kappa opioid receptor by [3H]diprenorphine displacement.,CHEMBL1136497,KI,C[C@H]1CN(Cc2cccc(O)c2)CC[C@@]1(C)c1cccc(C(N)=O)c1
CHEMBL139180,CHEMBL237,Kappa opioid receptor,Ki,=,100.0,nM,CHEMBL751203,B,Binding affinity at cloned human kappa opioid receptor by [3H]diprenorphine displacement.,CHEMBL1136497,KI,CC(CCN1CC[C@@](C)(c2cccc(C(N)=O)c2)[C@@H](C)C1)c1ccccc1
CHEMBL319536,CHEMBL237,Kappa opioid receptor,Ki,=,17.0,nM,CHEMBL751203,B,Binding affinity at cloned human kappa opioid receptor by [3H]diprenorphine displacement.,CHEMBL1136497,KI,C[C@H]1CN(CCc2ccccc2)CC[C@@]1(C)c1cccc(O)c1
CHEMBL138750,CHEMBL237,Kappa opioid receptor,Ki,=,1100.0,nM,CHEMBL751203,B,Binding affinity at cloned human kappa opioid receptor by [3H]diprenorphine displacement.,CHEMBL1136497,KI,CC(=O)Nc1cccc([C@]2(C)CCN(CCc3ccccc3)C[C@@H]2C)c1
CHEMBL138842,CHEMBL237,Kappa opioid receptor,Ki,=,220.0,nM,CHEMBL751203,B,Binding affinity at cloned human kappa opioid receptor by [3H]diprenorphine displacement.,CHEMBL1136497,KI,COc1ccc(CN2CC[C@@](C)(c3cccc(C(N)=O)c3)[C@@H](C)C2)cc1
CHEMBL610525,CHEMBL237,Kappa opioid receptor,Ki,=,0.57,nM,CHEMBL872672,B,Binding affinity using [3H]diprenorphine as the radioligand against wild-type Opioid receptor kappa 1r in COS-7 cells,CHEMBL1133722,KI,N=C(N)N1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4c(c2C[C@@]3(O)[C@H]1C5)C[C@@]1(O)[C@H]2Cc3ccc(O)c5c3[C@@]1(CCN2CC1CC1)[C@H]4O5
CHEMBL610525,CHEMBL237,Kappa opioid receptor,Ki,=,189.0,nM,CHEMBL747233,B,Binding affinity using [3H]diprenorphine as the radioligand against E297K mutant Opioid receptor kappa 1 in COS-7 cells,CHEMBL1133722,KI,N=C(N)N1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4c(c2C[C@@]3(O)[C@H]1C5)C[C@@]1(O)[C@H]2Cc3ccc(O)c5c3[C@@]1(CCN2CC1CC1)[C@H]4O5
CHEMBL606959,CHEMBL237,Kappa opioid receptor,Ki,=,21.7,nM,CHEMBL747234,B,Binding affinity using [3H]diprenorphine as the radioligand against wild-type Opioid receptor kappa 1 in COS-7 cells,CHEMBL1133722,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4c(c2C[C@@]3(O)[C@H]1C5)C[C@@]1(O)[C@H]2Cc3ccc(O)c5c3[C@@]1(CCN2C)[C@H]4O5
CHEMBL287752,CHEMBL237,Kappa opioid receptor,Ki,=,23.6,nM,CHEMBL747234,B,Binding affinity using [3H]diprenorphine as the radioligand against wild-type Opioid receptor kappa 1 in COS-7 cells,CHEMBL1133722,KI,CC(=O)N1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4c(c2C[C@@]3(O)[C@H]1C5)C[C@@]1(O)[C@H]2Cc3ccc(O)c5c3[C@@]1(CCN2CC1CC1)[C@H]4O5
CHEMBL287752,CHEMBL237,Kappa opioid receptor,Ki,=,104.0,nM,CHEMBL747233,B,Binding affinity using [3H]diprenorphine as the radioligand against E297K mutant Opioid receptor kappa 1 in COS-7 cells,CHEMBL1133722,KI,CC(=O)N1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4c(c2C[C@@]3(O)[C@H]1C5)C[C@@]1(O)[C@H]2Cc3ccc(O)c5c3[C@@]1(CCN2CC1CC1)[C@H]4O5
CHEMBL287752,CHEMBL237,Kappa opioid receptor,Ki,=,104.0,nM,CHEMBL747232,B,Binding affinity using [3H]diprenorphine as the radioligand against E297A mutant Opioid receptor kappa 1 in COS-7 cells,CHEMBL1133722,KI,CC(=O)N1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4c(c2C[C@@]3(O)[C@H]1C5)C[C@@]1(O)[C@H]2Cc3ccc(O)c5c3[C@@]1(CCN2CC1CC1)[C@H]4O5
CHEMBL610524,CHEMBL237,Kappa opioid receptor,Ki,=,36.3,nM,CHEMBL747234,B,Binding affinity using [3H]diprenorphine as the radioligand against wild-type Opioid receptor kappa 1 in COS-7 cells,CHEMBL1133722,KI,COc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2C)[C@H]5O4
CHEMBL609747,CHEMBL237,Kappa opioid receptor,Ki,=,0.32,nM,CHEMBL747234,B,Binding affinity using [3H]diprenorphine as the radioligand against wild-type Opioid receptor kappa 1 in COS-7 cells,CHEMBL1133722,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4c(c2C[C@H]3[C@H]1C5)C[C@@]1(O)[C@H]2Cc3ccc(O)c5c3[C@@]1(CCN2CC1CC1)[C@H]4O5
CHEMBL609747,CHEMBL237,Kappa opioid receptor,Ki,=,39.9,nM,CHEMBL747233,B,Binding affinity using [3H]diprenorphine as the radioligand against E297K mutant Opioid receptor kappa 1 in COS-7 cells,CHEMBL1133722,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4c(c2C[C@H]3[C@H]1C5)C[C@@]1(O)[C@H]2Cc3ccc(O)c5c3[C@@]1(CCN2CC1CC1)[C@H]4O5
CHEMBL609747,CHEMBL237,Kappa opioid receptor,Ki,=,39.6,nM,CHEMBL747232,B,Binding affinity using [3H]diprenorphine as the radioligand against E297A mutant Opioid receptor kappa 1 in COS-7 cells,CHEMBL1133722,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4c(c2C[C@H]3[C@H]1C5)C[C@@]1(O)[C@H]2Cc3ccc(O)c5c3[C@@]1(CCN2CC1CC1)[C@H]4O5
CHEMBL281786,CHEMBL237,Kappa opioid receptor,Ki,=,0.28,nM,CHEMBL747234,B,Binding affinity using [3H]diprenorphine as the radioligand against wild-type Opioid receptor kappa 1 in COS-7 cells,CHEMBL1133722,KI,CO[C@]12CC[C@@]3(C[C@@H]1C(C)(C)O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL281786,CHEMBL237,Kappa opioid receptor,Ki,=,0.37,nM,CHEMBL747233,B,Binding affinity using [3H]diprenorphine as the radioligand against E297K mutant Opioid receptor kappa 1 in COS-7 cells,CHEMBL1133722,KI,CO[C@]12CC[C@@]3(C[C@@H]1C(C)(C)O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL281786,CHEMBL237,Kappa opioid receptor,Ki,=,0.38,nM,CHEMBL747232,B,Binding affinity using [3H]diprenorphine as the radioligand against E297A mutant Opioid receptor kappa 1 in COS-7 cells,CHEMBL1133722,KI,CO[C@]12CC[C@@]3(C[C@@H]1C(C)(C)O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL610523,CHEMBL237,Kappa opioid receptor,Ki,=,0.39,nM,CHEMBL747234,B,Binding affinity using [3H]diprenorphine as the radioligand against wild-type Opioid receptor kappa 1 in COS-7 cells,CHEMBL1133722,KI,COc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL610523,CHEMBL237,Kappa opioid receptor,Ki,=,28.0,nM,CHEMBL747233,B,Binding affinity using [3H]diprenorphine as the radioligand against E297K mutant Opioid receptor kappa 1 in COS-7 cells,CHEMBL1133722,KI,COc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL610523,CHEMBL237,Kappa opioid receptor,Ki,=,17.0,nM,CHEMBL747232,B,Binding affinity using [3H]diprenorphine as the radioligand against E297A mutant Opioid receptor kappa 1 in COS-7 cells,CHEMBL1133722,KI,COc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL573214,CHEMBL237,Kappa opioid receptor,Ki,=,0.13,nM,CHEMBL747234,B,Binding affinity using [3H]diprenorphine as the radioligand against wild-type Opioid receptor kappa 1 in COS-7 cells,CHEMBL1133722,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL573214,CHEMBL237,Kappa opioid receptor,Ki,=,12.9,nM,CHEMBL747233,B,Binding affinity using [3H]diprenorphine as the radioligand against E297K mutant Opioid receptor kappa 1 in COS-7 cells,CHEMBL1133722,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL573214,CHEMBL237,Kappa opioid receptor,Ki,=,12.8,nM,CHEMBL747232,B,Binding affinity using [3H]diprenorphine as the radioligand against E297A mutant Opioid receptor kappa 1 in COS-7 cells,CHEMBL1133722,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL331883,CHEMBL237,Kappa opioid receptor,Ki,=,122.2,nM,CHEMBL752204,B,Binding affinity against Opioid receptor kappa 1,CHEMBL1133578,KI,CCC(=O)N(c1ccccc1)[C@H]1CCN(C[C@H](O)c2ccccc2)C[C@H]1C
CHEMBL422551,CHEMBL237,Kappa opioid receptor,Ki,=,0.21,nM,CHEMBL752213,B,Tested in vitro for binding affinity against Opioid receptor kappa 1,CHEMBL1126961,KI,CC[C@]12CCN(CC3CC3)[C@H](C(=O)c3ccc(O)cc31)[C@@H]2C
CHEMBL596,CHEMBL237,Kappa opioid receptor,Ki,=,196.5,nM,CHEMBL752204,B,Binding affinity against Opioid receptor kappa 1,CHEMBL1133578,KI,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1
CHEMBL104169,CHEMBL237,Kappa opioid receptor,Ki,=,66.0,nM,CHEMBL752208,B,Binding affinity for Opioid receptor kappa 1 was determined.,CHEMBL1134942,KI,CS[C@@H]1Cc2ccc(O)cc2C(C)(C)[C@@H]1N
CHEMBL70,CHEMBL237,Kappa opioid receptor,Ki,=,52.14,nM,CHEMBL752208,B,Binding affinity for Opioid receptor kappa 1 was determined.,CHEMBL1134942,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL108068,CHEMBL237,Kappa opioid receptor,Ki,=,43.4,nM,CHEMBL752208,B,Binding affinity for Opioid receptor kappa 1 was determined.,CHEMBL1134942,KI,C[C@@]12CCCCS[C@@H](Cc3ccc(O)cc31)C2N
CHEMBL421038,CHEMBL237,Kappa opioid receptor,Ki,=,345.0,nM,CHEMBL752208,B,Binding affinity for Opioid receptor kappa 1 was determined.,CHEMBL1134942,KI,CC[C@@H]1Cc2ccc(O)cc2C(C)(C)[C@@H]1N
CHEMBL353654,CHEMBL237,Kappa opioid receptor,Ki,=,160.0,nM,CHEMBL752213,B,Tested in vitro for binding affinity against Opioid receptor kappa 1,CHEMBL1126961,KI,CN(C(=O)Cc1c(OCCN2CCCC2)ccc2ccccc12)C1CCCCC1
CHEMBL290429,CHEMBL237,Kappa opioid receptor,Ki,=,43.1,nM,CHEMBL752204,B,Binding affinity against Opioid receptor kappa 1,CHEMBL1133578,KI,CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCc2ccccc2)CC1
CHEMBL12391,CHEMBL237,Kappa opioid receptor,Ki,=,57.4,nM,CHEMBL752204,B,Binding affinity against Opioid receptor kappa 1,CHEMBL1133578,KI,CCC(=O)N(c1ccccc1)[C@H]1CCN(CCc2ccccc2)C[C@H]1C
CHEMBL609147,CHEMBL237,Kappa opioid receptor,Ki,=,63.0,nM,CHEMBL752204,B,Binding affinity against Opioid receptor kappa 1,CHEMBL1133578,KI,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2ccccc2)CC1
CHEMBL106432,CHEMBL237,Kappa opioid receptor,Ki,=,184.0,nM,CHEMBL752208,B,Binding affinity for Opioid receptor kappa 1 was determined.,CHEMBL1134942,KI,CO[C@@H]1Cc2ccc(O)cc2C(C)(C)[C@@H]1N
CHEMBL170603,CHEMBL237,Kappa opioid receptor,Ki,=,940.0,nM,CHEMBL752213,B,Tested in vitro for binding affinity against Opioid receptor kappa 1,CHEMBL1126961,KI,O=C(Cc1cccc2occc12)NCC12CCCN1CCC2
CHEMBL3144469,CHEMBL237,Kappa opioid receptor,Ki,=,105.0,nM,CHEMBL755691,B,Binding affinity against human Opioid receptor kappa 1 (hKOR) was determined using [3H]diprenorphine in vitro in CHO cells,CHEMBL1149132,KI,CC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC1CCCCC1)C(=O)N[C@H]1CC[C@H]2CCC[C@@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](Cc3ccc(Cl)cc3)C(N)=O)N2C1=O
CHEMBL290855,CHEMBL237,Kappa opioid receptor,Ki,=,110.0,nM,CHEMBL750588,B,Binding affinity towards opioid receptor kappa 2,CHEMBL1125447,KI,CN1CCC2(c3cccc(O)c3)CCCC1[C@H]2O
CHEMBL431002,CHEMBL237,Kappa opioid receptor,Ki,=,158.49,nM,CHEMBL700238,B,Displacement of [3H]naloxone from human kappa opioid receptor,CHEMBL1131838,KI,O=C1NCN(c2ccccc2F)C12CCN(C1Cc3cccc4cccc1c34)CC2
CHEMBL28198,CHEMBL237,Kappa opioid receptor,Ki,=,5.5,nM,CHEMBL751038,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing Opioid receptor kappa 1,CHEMBL1132995,KI,CCC(=O)N(c1ccccc1)[C@@]1(C(=O)OC)CCN(CCc2ccccc2)C[C@H]1C
CHEMBL346879,CHEMBL237,Kappa opioid receptor,Ki,=,120.0,nM,CHEMBL751036,B,Binding affinity towards recombinant human Opioid receptor kappa 1 transfected in to CHO cells for the displacement of 9 (kappa),CHEMBL1135445,KI,Oc1ccc2c3c1O[C@H]1c4c(c(-c5ccccc5)cn4Cc4ccccc4)C[C@@]4(O)C(C2)N(CC2CC2)CC[C@]314
CHEMBL1907858,CHEMBL237,Kappa opioid receptor,Ki,=,25.12,nM,CHEMBL700238,B,Displacement of [3H]naloxone from human kappa opioid receptor,CHEMBL1131838,KI,O=C1NCN(c2ccccc2)C12CCN([C@H]1Cc3cccc4cccc1c34)CC2
CHEMBL27699,CHEMBL237,Kappa opioid receptor,Ki,=,20.7,nM,CHEMBL751199,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing human Opioid receptor kappa 1,CHEMBL1132995,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCc3c(Cl)cccc3C1)CC2
CHEMBL283910,CHEMBL237,Kappa opioid receptor,Ki,=,40.1,nM,CHEMBL751199,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing human Opioid receptor kappa 1,CHEMBL1132995,KI,O=C1NCN(c2ccccc2)C12CCN([C@H]1CCc3c(Cl)ccc(Cl)c3C1)CC2
CHEMBL348268,CHEMBL237,Kappa opioid receptor,Ki,=,183.0,nM,CHEMBL751036,B,Binding affinity towards recombinant human Opioid receptor kappa 1 transfected in to CHO cells for the displacement of 9 (kappa),CHEMBL1135445,KI,Cc1c(-c2ccccc2)c2c(n1Cc1ccccc1)[C@@H]1Oc3c(O)ccc4c3[C@@]13CCN(CC1CC1)C(C4)[C@]3(O)C2
CHEMBL3144471,CHEMBL237,Kappa opioid receptor,Ki,=,78.0,nM,CHEMBL755691,B,Binding affinity against human Opioid receptor kappa 1 (hKOR) was determined using [3H]diprenorphine in vitro in CHO cells,CHEMBL1149132,KI,CC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC1CCCCC1)C(=O)N[C@H]1CC[C@@H]2SC[C@@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)NC(Cc3ccc(Cl)cc3)C(N)=O)N2C1=O
CHEMBL281274,CHEMBL237,Kappa opioid receptor,Ki,=,25.12,nM,CHEMBL700238,B,Displacement of [3H]naloxone from human kappa opioid receptor,CHEMBL1131838,KI,O=C1NCN(c2ccccc2)C12CCN(C1Cc3cccc4cccc1c34)CC2
CHEMBL447779,CHEMBL237,Kappa opioid receptor,Ki,=,16.4,nM,CHEMBL751199,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing human Opioid receptor kappa 1,CHEMBL1132995,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCc3ccc(Cl)cc3C1)CC2
CHEMBL77324,CHEMBL237,Kappa opioid receptor,Ki,=,79.43,nM,CHEMBL700238,B,Displacement of [3H]naloxone from human kappa opioid receptor,CHEMBL1131838,KI,O=C1NCN(c2ccc(Cl)cc2)C12CCN(C1Cc3cccc4cccc1c34)CC2
CHEMBL75676,CHEMBL237,Kappa opioid receptor,Ki,=,199.53,nM,CHEMBL700238,B,Displacement of [3H]naloxone from human kappa opioid receptor,CHEMBL1131838,KI,Cc1ccc(N2CNC(=O)C23CCN(C2Cc4cccc5cccc2c45)CC3)cc1
CHEMBL356473,CHEMBL237,Kappa opioid receptor,Ki,=,108.0,nM,CHEMBL751036,B,Binding affinity towards recombinant human Opioid receptor kappa 1 transfected in to CHO cells for the displacement of 9 (kappa),CHEMBL1135445,KI,Cc1ccc(-c2cn(Cc3ccccc3)c3c2C[C@@]2(O)C4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)cc1
CHEMBL3144468,CHEMBL237,Kappa opioid receptor,Ki,=,4270.0,nM,CHEMBL755691,B,Binding affinity against human Opioid receptor kappa 1 (hKOR) was determined using [3H]diprenorphine in vitro in CHO cells,CHEMBL1149132,KI,CC(=O)N[C@@H](CCCNC(N)=O)C(=O)N[C@H](CC1CCCCC1)C(=O)N[C@H]1CC[C@H]2CCC[C@@H](C(=O)N[C@H](CCCN=C(N)N)C(=O)N[C@H](Cc3ccc(Cl)cc3)C(N)=O)N2C1=O
CHEMBL281274,CHEMBL237,Kappa opioid receptor,Ki,=,26.0,nM,CHEMBL751199,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing human Opioid receptor kappa 1,CHEMBL1132995,KI,O=C1NCN(c2ccccc2)C12CCN(C1Cc3cccc4cccc1c34)CC2
CHEMBL312021,CHEMBL237,Kappa opioid receptor,Ki,=,50.12,nM,CHEMBL700238,B,Displacement of [3H]naloxone from human kappa opioid receptor,CHEMBL1131838,KI,O=C1NCN(c2cccc(Cl)c2)C12CCN(C1Cc3cccc4cccc1c34)CC2
CHEMBL419272,CHEMBL237,Kappa opioid receptor,Ki,=,79.43,nM,CHEMBL700238,B,Displacement of [3H]naloxone from human kappa opioid receptor,CHEMBL1131838,KI,O=C1NCN(c2cccc(Br)c2)C12CCN(C1Cc3cccc4cccc1c34)CC2
CHEMBL280827,CHEMBL237,Kappa opioid receptor,Ki,=,44.0,nM,CHEMBL751199,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing human Opioid receptor kappa 1,CHEMBL1132995,KI,Cc1cccc2c1CCCC2N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL283617,CHEMBL237,Kappa opioid receptor,Ki,=,48.0,nM,CHEMBL751199,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing human Opioid receptor kappa 1,CHEMBL1132995,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCc3cccc(Cl)c3C1)CC2
CHEMBL26999,CHEMBL237,Kappa opioid receptor,Ki,=,47.1,nM,CHEMBL751199,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing human Opioid receptor kappa 1,CHEMBL1132995,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCc3ccccc3C1)CC2
CHEMBL308522,CHEMBL237,Kappa opioid receptor,Ki,=,19.95,nM,CHEMBL700238,B,Displacement of [3H]naloxone from human kappa opioid receptor,CHEMBL1131838,KI,Cc1cccc(N2CNC(=O)C23CCN(C2Cc4cccc5cccc2c45)CC3)c1
CHEMBL78156,CHEMBL237,Kappa opioid receptor,Ki,=,12.59,nM,CHEMBL700238,B,Displacement of [3H]naloxone from human kappa opioid receptor,CHEMBL1131838,KI,O=C1NCN(c2cccc(F)c2)C12CCN(C1Cc3cccc4cccc1c34)CC2
CHEMBL436273,CHEMBL237,Kappa opioid receptor,Ki,=,45.0,nM,CHEMBL751035,B,Binding affinity towards recombinant human Opioid receptor kappa 1 transfected in to CHO cells for the displacement of [3H]U-69593,CHEMBL1135445,KI,Oc1ccc2c3c1O[C@H]1c4[nH]cc(-c5ccccc5)c4C[C@@]4(O)C(C2)N(CC2CC2)CC[C@]314
CHEMBL287726,CHEMBL237,Kappa opioid receptor,Ki,=,330.0,nM,CHEMBL750588,B,Binding affinity towards opioid receptor kappa 2,CHEMBL1125447,KI,C[C@@H]1C2CCCC1(c1cccc(O)c1)CCN2C
CHEMBL27729,CHEMBL237,Kappa opioid receptor,Ki,=,17.0,nM,CHEMBL751199,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing human Opioid receptor kappa 1,CHEMBL1132995,KI,CN1CN(c2ccccc2)C2(CCN(C3CCc4c(Cl)ccc(Cl)c4C3)CC2)C1=O
CHEMBL28172,CHEMBL237,Kappa opioid receptor,Ki,=,161.0,nM,CHEMBL751199,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing human Opioid receptor kappa 1,CHEMBL1132995,KI,O=C1NCN(c2ccccc2)C12CCN(C1Cc3ccccc3C1)CC2
CHEMBL283480,CHEMBL237,Kappa opioid receptor,Ki,=,44.2,nM,CHEMBL751199,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing human Opioid receptor kappa 1,CHEMBL1132995,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCc3c(Cl)ccc(Cl)c3C1)CC2
CHEMBL284414,CHEMBL237,Kappa opioid receptor,Ki,=,5.3,nM,CHEMBL751038,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing Opioid receptor kappa 1,CHEMBL1132995,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCc3ccccc31)CC2
CHEMBL283265,CHEMBL237,Kappa opioid receptor,Ki,=,26.2,nM,CHEMBL751199,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing human Opioid receptor kappa 1,CHEMBL1132995,KI,C=CCN1CN(c2ccccc2)C2(CCN(C3CCc4c(Cl)ccc(Cl)c4C3)CC2)C1=O
CHEMBL440179,CHEMBL237,Kappa opioid receptor,Ki,=,191.0,nM,CHEMBL751036,B,Binding affinity towards recombinant human Opioid receptor kappa 1 transfected in to CHO cells for the displacement of 9 (kappa),CHEMBL1135445,KI,CCCN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2c(c(-c4ccccc4)cn2Cc2ccccc2)C[C@@]3(O)C1C5
CHEMBL355202,CHEMBL237,Kappa opioid receptor,Ki,=,19.95,nM,CHEMBL700238,B,Displacement of [3H]naloxone from human kappa opioid receptor,CHEMBL1131838,KI,O=C1NCN(c2ccccc2)C12CCN([C@@H]1Cc3cccc4cccc1c34)CC2
CHEMBL283432,CHEMBL237,Kappa opioid receptor,Ki,=,17.5,nM,CHEMBL751038,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing Opioid receptor kappa 1,CHEMBL1132995,KI,COCN1CN(c2ccccc2)C2(CCN(C3CCc4cccc(Cl)c4C3)CC2)C1=O
CHEMBL26638,CHEMBL237,Kappa opioid receptor,Ki,=,17.0,nM,CHEMBL751038,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing Opioid receptor kappa 1,CHEMBL1132995,KI,O=C1NCN(c2ccccc2)C12CCN([C@H]1CCCc3ccccc31)CC2
CHEMBL27460,CHEMBL237,Kappa opioid receptor,Ki,=,10.7,nM,CHEMBL751038,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing Opioid receptor kappa 1,CHEMBL1132995,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCCc3ccccc31)CC2
CHEMBL285377,CHEMBL237,Kappa opioid receptor,Ki,=,52.0,nM,CHEMBL751199,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing human Opioid receptor kappa 1,CHEMBL1132995,KI,O=C1N(Cc2ccccc2)CN(c2ccccc2)C12CCN(C1CCc3c(Cl)ccc(Cl)c3C1)CC2
CHEMBL3144465,CHEMBL237,Kappa opioid receptor,Ki,=,153.0,nM,CHEMBL755691,B,Binding affinity against human Opioid receptor kappa 1 (hKOR) was determined using [3H]diprenorphine in vitro in CHO cells,CHEMBL1149132,KI,N=C(N)NCCCCC(=O)N[C@H](CC1CCCCC1)C(=O)N[C@H]1CC[C@H]2CCC[C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@H](Cc3ccc(Cl)cc3)C(N)=O)N2C1=O
CHEMBL287726,CHEMBL237,Kappa opioid receptor,Ki,=,250.0,nM,CHEMBL750588,B,Binding affinity towards opioid receptor kappa 2,CHEMBL1125447,KI,C[C@@H]1C2CCCC1(c1cccc(O)c1)CCN2C
CHEMBL609998,CHEMBL237,Kappa opioid receptor,Ki,=,20.1,nM,CHEMBL754914,B,Binding affinity towards opioid receptor kappa 1 from CHO cells,CHEMBL1134379,KI,O=Cc1ccc(C(=O)Nc2cccc3c4c([nH]c23)C2Oc3c(O)ccc5c3[C@@]23CCN(CC2CC2)[C@H](C5)[C@]3(O)C4)cc1C=O
CHEMBL418020,CHEMBL237,Kappa opioid receptor,Ki,=,47.3,nM,CHEMBL751199,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing human Opioid receptor kappa 1,CHEMBL1132995,KI,O=C1NCN(c2ccccc2)C12CCN([C@@H]1CCc3c(Cl)ccc(Cl)c3C1)CC2
CHEMBL567175,CHEMBL237,Kappa opioid receptor,Ki,=,10.1,nM,CHEMBL751035,B,Binding affinity towards recombinant human Opioid receptor kappa 1 transfected in to CHO cells for the displacement of [3H]U-69593,CHEMBL1135445,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL70,CHEMBL237,Kappa opioid receptor,Ki,=,33.0,nM,CHEMBL750588,B,Binding affinity towards opioid receptor kappa 2,CHEMBL1125447,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL306150,CHEMBL237,Kappa opioid receptor,Ki,=,63.1,nM,CHEMBL700238,B,Displacement of [3H]naloxone from human kappa opioid receptor,CHEMBL1131838,KI,O=C1NCN(c2ccc(F)cc2)C12CCN(C1Cc3cccc4cccc1c34)CC2
CHEMBL27093,CHEMBL237,Kappa opioid receptor,Ki,=,149.0,nM,CHEMBL751199,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing human Opioid receptor kappa 1,CHEMBL1132995,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCc3cc(Cl)ccc3C1)CC2
CHEMBL3144467,CHEMBL237,Kappa opioid receptor,Ki,=,779.0,nM,CHEMBL755691,B,Binding affinity against human Opioid receptor kappa 1 (hKOR) was determined using [3H]diprenorphine in vitro in CHO cells,CHEMBL1149132,KI,CC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H]1CC[C@H]2CCC[C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@H](Cc3ccc(Cl)cc3)C(N)=O)N2C1=O
CHEMBL285250,CHEMBL237,Kappa opioid receptor,Ki,=,78.0,nM,CHEMBL750587,B,Binding affinity towards Opioid receptor kappa 2,CHEMBL1125447,KI,CN1CCC2(c3cccc(O)c3)CCCC1C2
CHEMBL26483,CHEMBL237,Kappa opioid receptor,Ki,=,28.8,nM,CHEMBL751199,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing human Opioid receptor kappa 1,CHEMBL1132995,KI,O=C(CN1CN(c2ccccc2)C2(CCN(C3CCc4cccc(Cl)c4C3)CC2)C1=O)c1ccccc1
CHEMBL26987,CHEMBL237,Kappa opioid receptor,Ki,=,16.4,nM,CHEMBL751199,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing human Opioid receptor kappa 1,CHEMBL1132995,KI,O=C1N(CCO)CN(c2ccccc2)C12CCN(C1CCc3cccc(Cl)c3C1)CC2
CHEMBL285250,CHEMBL237,Kappa opioid receptor,Ki,=,160.0,nM,CHEMBL750588,B,Binding affinity towards opioid receptor kappa 2,CHEMBL1125447,KI,CN1CCC2(c3cccc(O)c3)CCCC1C2
CHEMBL27716,CHEMBL237,Kappa opioid receptor,Ki,=,46.3,nM,CHEMBL751038,B,Competitive binding displacement analyses was performed from permanently transfected HEK293 cells expressing Opioid receptor kappa 1,CHEMBL1132995,KI,O=C1NCN(c2ccccc2)C12CCN([C@@H]1CCCc3ccccc31)CC2
CHEMBL151476,CHEMBL237,Kappa opioid receptor,Ki,=,187.0,nM,CHEMBL751035,B,Binding affinity towards recombinant human Opioid receptor kappa 1 transfected in to CHO cells for the displacement of [3H]U-69593,CHEMBL1135445,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2c(c(-c4ccccc4)cn2Cc2ccccc2)C[C@@]3(O)C1C5
CHEMBL13470,CHEMBL237,Kappa opioid receptor,Ki,=,3535.0,nM,CHEMBL700231,B,Binding affinity towards opioid kappa receptor using [3H]U-69593 as radioligand,CHEMBL1131897,KI,C=CCN1C[C@H](C)N([C@H](c2ccc(C(=O)N(CC)CC)cc2)c2cccc(OC)c2)C[C@H]1C
CHEMBL330291,CHEMBL237,Kappa opioid receptor,Ki,=,56.23,nM,CHEMBL858426,B,Inhibition of naloxone binding to human Opioid receptor kappa 1,CHEMBL1145102,KI,CN1C[C@@H]2CN(c3ccccc3)C3(CCN(C4CCCCCCCC4)CC3)[C@@H]2C1
CHEMBL101454,CHEMBL237,Kappa opioid receptor,Ki,=,42.7,nM,CHEMBL755692,B,Binding affinity against human Opioid receptor kappa 1 on CHO cell membranes by [3H]U-69593 displacement.,CHEMBL1148282,KI,O=C1Cc2ccccc2N1C1CCN(C2CCCCCCC2)CC1
CHEMBL2112346,CHEMBL237,Kappa opioid receptor,Ki,=,169.82,nM,CHEMBL858426,B,Inhibition of naloxone binding to human Opioid receptor kappa 1,CHEMBL1145102,KI,CC(C)[C@H]1CC[C@@H](N2CCC3(CC2)[C@@H]2CN(CC4CC4)C[C@@H]2CN3c2ccc(F)cc2)CC1
CHEMBL97979,CHEMBL237,Kappa opioid receptor,Ki,=,3869.0,nM,CHEMBL755692,B,Binding affinity against human Opioid receptor kappa 1 on CHO cell membranes by [3H]U-69593 displacement.,CHEMBL1148282,KI,CC(c1ccc(C2CCCCC2)cc1)N1CCC(N2C(=O)Cc3ccccc32)CC1
CHEMBL511142,CHEMBL237,Kappa opioid receptor,Ki,=,0.8,nM,CHEMBL751032,B,Binding affinity to cloned human Opioid receptor kappa 1 transfected into hamster ovary cells using [3H]U-69593 as a radioligand.,CHEMBL1133656,KI,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL99738,CHEMBL237,Kappa opioid receptor,Ki,=,369.0,nM,CHEMBL755692,B,Binding affinity against human Opioid receptor kappa 1 on CHO cell membranes by [3H]U-69593 displacement.,CHEMBL1148282,KI,CC(C)[C@H]1CC[C@H](N2CCC(N3C(=O)Cc4ccccc43)CC2)CC1
CHEMBL100938,CHEMBL237,Kappa opioid receptor,Ki,=,175.0,nM,CHEMBL755692,B,Binding affinity against human Opioid receptor kappa 1 on CHO cell membranes by [3H]U-69593 displacement.,CHEMBL1148282,KI,CC1(C)C2CCC(CN3CCC(N4C(=O)Cc5ccccc54)CC3)C1C2
CHEMBL22650,CHEMBL237,Kappa opioid receptor,Ki,=,3722.0,nM,CHEMBL700231,B,Binding affinity towards opioid kappa receptor using [3H]U-69593 as radioligand,CHEMBL1131897,KI,C=CCN1CC[C@@H](N(c2ccccc2)c2ccc(C(=O)N(CC)CC)cc2)[C@@H](C)C1
CHEMBL316699,CHEMBL237,Kappa opioid receptor,Ki,=,52.1,nM,CHEMBL755692,B,Binding affinity against human Opioid receptor kappa 1 on CHO cell membranes by [3H]U-69593 displacement.,CHEMBL1148282,KI,O=C1Cc2ccccc2N1C1CCN(C2CCC3CCCCC3C2)CC1
CHEMBL320182,CHEMBL237,Kappa opioid receptor,Ki,=,202.0,nM,CHEMBL755692,B,Binding affinity against human Opioid receptor kappa 1 on CHO cell membranes by [3H]U-69593 displacement.,CHEMBL1148282,KI,O=C1Cc2ccccc2N1C1CCN(C2CCCC3CCCCC32)CC1
CHEMBL2112343,CHEMBL237,Kappa opioid receptor,Ki,=,154.88,nM,CHEMBL858426,B,Inhibition of naloxone binding to human Opioid receptor kappa 1,CHEMBL1145102,KI,CC(C)[C@H]1CC[C@@H](N2CCC3(CC2)[C@@H]2CN(Cc4ccccc4)C[C@@H]2CN3c2ccccc2)CC1
CHEMBL328411,CHEMBL237,Kappa opioid receptor,Ki,=,74.4,nM,CHEMBL755692,B,Binding affinity against human Opioid receptor kappa 1 on CHO cell membranes by [3H]U-69593 displacement.,CHEMBL1148282,KI,CC(c1ccc2c(c1)Cc1ccccc1-2)N1CCC(N2C(=O)Cc3ccccc32)CC1
CHEMBL418980,CHEMBL237,Kappa opioid receptor,Ki,=,148.0,nM,CHEMBL755692,B,Binding affinity against human Opioid receptor kappa 1 on CHO cell membranes by [3H]U-69593 displacement.,CHEMBL1148282,KI,CC(C)[C@H]1CC[C@@H](N2CCC(N3C(=O)Cc4ccccc43)CC2)CC1
CHEMBL281986,CHEMBL237,Kappa opioid receptor,Ki,=,1.04,nM,CHEMBL751032,B,Binding affinity to cloned human Opioid receptor kappa 1 transfected into hamster ovary cells using [3H]U-69593 as a radioligand.,CHEMBL1133656,KI,CO[C@]12C=CC3(CC14CCC[C@H]4O)C1Cc4ccc(O)c5c4C3(CCN1CC1CC1)[C@@H]2O5
CHEMBL2112345,CHEMBL237,Kappa opioid receptor,Ki,=,281.84,nM,CHEMBL858426,B,Inhibition of naloxone binding to human Opioid receptor kappa 1,CHEMBL1145102,KI,CC(C)[C@H]1CC[C@@H](N2CCC3(CC2)[C@@H]2CN(C)C[C@@H]2CN3c2ccccc2)CC1
CHEMBL315551,CHEMBL237,Kappa opioid receptor,Ki,=,26.92,nM,CHEMBL858426,B,Inhibition of naloxone binding to human Opioid receptor kappa 1,CHEMBL1145102,KI,CN1C[C@@H]2CN(c3ccccc3)C3(CCN(C4CCCCCCCCC4)CC3)[C@@H]2C1
CHEMBL115730,CHEMBL237,Kappa opioid receptor,Ki,=,3284.0,nM,CHEMBL700231,B,Binding affinity towards opioid kappa receptor using [3H]U-69593 as radioligand,CHEMBL1131897,KI,C=CCN1CCC(N(c2ccccc2)c2ccc(C(=O)N(CC)CC)cc2)C(C)C1
CHEMBL102900,CHEMBL237,Kappa opioid receptor,Ki,=,31.7,nM,CHEMBL755692,B,Binding affinity against human Opioid receptor kappa 1 on CHO cell membranes by [3H]U-69593 displacement.,CHEMBL1148282,KI,O=C1Cc2ccccc2N1C1CCN(C2C3CCCC2CCC3)CC1
CHEMBL2112407,CHEMBL237,Kappa opioid receptor,Ki,=,372.0,nM,CHEMBL755692,B,Binding affinity against human Opioid receptor kappa 1 on CHO cell membranes by [3H]U-69593 displacement.,CHEMBL1148282,KI,O=C1Cc2ccccc2N1C1CCN(C[C@H]2CC3CCC2C3)CC1
CHEMBL101676,CHEMBL237,Kappa opioid receptor,Ki,=,55.1,nM,CHEMBL755692,B,Binding affinity against human Opioid receptor kappa 1 on CHO cell membranes by [3H]U-69593 displacement.,CHEMBL1148282,KI,O=C1Cc2ccccc2N1C1CCN(C2CCc3ccccc3C2)CC1
CHEMBL102497,CHEMBL237,Kappa opioid receptor,Ki,=,1448.0,nM,CHEMBL700231,B,Binding affinity towards opioid kappa receptor using [3H]U-69593 as radioligand,CHEMBL1131897,KI,C=CCN1CC[C@H](N(c2ccccc2)c2ccc(C(=O)N(CC)CC)cc2)[C@H](C)C1
CHEMBL2112347,CHEMBL237,Kappa opioid receptor,Ki,=,512.86,nM,CHEMBL858426,B,Inhibition of naloxone binding to human Opioid receptor kappa 1,CHEMBL1145102,KI,CC(C)[C@H]1CC[C@@H](N2CCC3(CC2)[C@@H]2CN(c4ccccc4)C[C@@H]2CN3c2ccccc2)CC1
CHEMBL2112344,CHEMBL237,Kappa opioid receptor,Ki,=,257.04,nM,CHEMBL858426,B,Inhibition of naloxone binding to human Opioid receptor kappa 1,CHEMBL1145102,KI,CC(C)[C@H]1CC[C@@H](N2CCC3(CC2)[C@@H]2CNC[C@@H]2CN3c2ccccc2)CC1
CHEMBL317152,CHEMBL237,Kappa opioid receptor,Ki,=,229.0,nM,CHEMBL755692,B,Binding affinity against human Opioid receptor kappa 1 on CHO cell membranes by [3H]U-69593 displacement.,CHEMBL1148282,KI,O=C1Cc2ccccc2N1C1CCN(CC2CCCCCCC2)CC1
CHEMBL320874,CHEMBL237,Kappa opioid receptor,Ki,=,84.5,nM,CHEMBL755692,B,Binding affinity against human Opioid receptor kappa 1 on CHO cell membranes by [3H]U-69593 displacement.,CHEMBL1148282,KI,O=C1Cc2ccccc2N1C1CCN(Cc2ccccc2)CC1
CHEMBL2112345,CHEMBL237,Kappa opioid receptor,Ki,=,309.03,nM,CHEMBL858426,B,Inhibition of naloxone binding to human Opioid receptor kappa 1,CHEMBL1145102,KI,CC(C)[C@H]1CC[C@@H](N2CCC3(CC2)[C@@H]2CN(C)C[C@@H]2CN3c2ccccc2)CC1
CHEMBL2112341,CHEMBL237,Kappa opioid receptor,Ki,=,147.91,nM,CHEMBL858426,B,Inhibition of naloxone binding to human Opioid receptor kappa 1,CHEMBL1145102,KI,CC(C)[C@H]1CC[C@@H](N2CCC3(CC2)[C@@H]2CN(CCN4CCOCC4)C[C@@H]2CN3c2ccccc2)CC1
CHEMBL31030,CHEMBL237,Kappa opioid receptor,Ki,=,3.12,nM,CHEMBL751032,B,Binding affinity to cloned human Opioid receptor kappa 1 transfected into hamster ovary cells using [3H]U-69593 as a radioligand.,CHEMBL1133656,KI,CO[C@]12C=CC3(CC14CCC(C)(C)[C@H]4O)C1Cc4ccc(O)c5c4C3(CCN1CC1CC1)[C@@H]2O5
CHEMBL319307,CHEMBL237,Kappa opioid receptor,Ki,=,137.0,nM,CHEMBL755692,B,Binding affinity against human Opioid receptor kappa 1 on CHO cell membranes by [3H]U-69593 displacement.,CHEMBL1148282,KI,O=C1Cc2ccccc2N1C1CCN(C2CCC3CCCC[C@@H]3C2)CC1
CHEMBL416765,CHEMBL237,Kappa opioid receptor,Ki,=,0.87,nM,CHEMBL751032,B,Binding affinity to cloned human Opioid receptor kappa 1 transfected into hamster ovary cells using [3H]U-69593 as a radioligand.,CHEMBL1133656,KI,CO[C@]12C=CC3(CC14CCC[C@H]4O)C1Cc4ccc(O)c5c4C3(CCN1C)[C@@H]2O5
CHEMBL2112348,CHEMBL237,Kappa opioid receptor,Ki,=,131.83,nM,CHEMBL858426,B,Inhibition of naloxone binding to human Opioid receptor kappa 1,CHEMBL1145102,KI,CC(C)[C@H]1CC[C@@H](N2CCC3(CC2)[C@@H]2CN(CCO)C[C@@H]2CN3c2ccccc2)CC1
CHEMBL316086,CHEMBL237,Kappa opioid receptor,Ki,=,131.83,nM,CHEMBL858426,B,Inhibition of naloxone binding to human Opioid receptor kappa 1,CHEMBL1145102,KI,CN1C[C@@H]2CN(c3ccccc3)C3(CCN([C@H]4CC[C@@H]5CCCC[C@@H]5C4)CC3)[C@@H]2C1
CHEMBL100574,CHEMBL237,Kappa opioid receptor,Ki,=,343.0,nM,CHEMBL755692,B,Binding affinity against human Opioid receptor kappa 1 on CHO cell membranes by [3H]U-69593 displacement.,CHEMBL1148282,KI,O=C1Cc2ccccc2N1C1CCN(C(C2CCCCC2)C2CCCCC2)CC1
CHEMBL2112342,CHEMBL237,Kappa opioid receptor,Ki,=,251.19,nM,CHEMBL858426,B,Inhibition of naloxone binding to human Opioid receptor kappa 1,CHEMBL1145102,KI,CCCCN1C[C@@H]2CN(c3ccccc3)C3(CCN([C@H]4CC[C@@H](C(C)C)CC4)CC3)[C@@H]2C1
CHEMBL101118,CHEMBL237,Kappa opioid receptor,Ki,=,21.5,nM,CHEMBL755692,B,Binding affinity against human Opioid receptor kappa 1 on CHO cell membranes by [3H]U-69593 displacement.,CHEMBL1148282,KI,O=C1Cc2ccccc2N1C1CCN(C2CCCc3ccccc32)CC1
CHEMBL31605,CHEMBL237,Kappa opioid receptor,Ki,=,1.28,nM,CHEMBL751032,B,Binding affinity to cloned human Opioid receptor kappa 1 transfected into hamster ovary cells using [3H]U-69593 as a radioligand.,CHEMBL1133656,KI,CO[C@]12C=CC3(CC14CCC(C)(C)[C@H]4O)C1Cc4ccc(O)c5c4C3(CCN1C)[C@@H]2O5
CHEMBL2111608,CHEMBL237,Kappa opioid receptor,Ki,=,318.0,nM,CHEMBL755692,B,Binding affinity against human Opioid receptor kappa 1 on CHO cell membranes by [3H]U-69593 displacement.,CHEMBL1148282,KI,O=C1Cc2ccccc2N1C1CCN(C[C@@H]2CC3CCC2C3)CC1
CHEMBL140979,CHEMBL237,Kappa opioid receptor,Ki,=,1057.5,nM,CHEMBL750081,B,Inhibition of [3H]naltrindole (0.55 nM) binding from human Opioid receptor kappa 1,CHEMBL1133540,KI,CCc1ccc(OCc2ccccc2C(=O)Nc2ccc3nc(C)cc(N)c3c2)cc1
CHEMBL420903,CHEMBL237,Kappa opioid receptor,Ki,=,6400.0,nM,CHEMBL752736,B,Inhibition of binding of [3H]diprenorphine to cloned human Opioid receptor kappa 1 expressed in CHO cell membrane; range is in between (4700-8500),CHEMBL1135552,KI,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1CSC[C@@H](C(=O)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O
CHEMBL122321,CHEMBL237,Kappa opioid receptor,Ki,=,1600.0,nM,CHEMBL873802,B,Inhibition of binding of [3H]diprenorphine to cloned human Opioid receptor kappa 1 expressed in CHO cell membrane;Range is in between (1400-1900),CHEMBL1135552,KI,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1CSC[C@H](C(=O)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O
CHEMBL70,CHEMBL237,Kappa opioid receptor,Ki,=,260.0,nM,CHEMBL752735,B,Inhibition of binding of [3H]diprenorphine to cloned human Opioid receptor kappa 1 expressed in CHO cell membrane,CHEMBL1135552,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL40859,CHEMBL237,Kappa opioid receptor,Ki,=,405.0,nM,CHEMBL752210,B,Binding affinity for kappa opioid receptor,CHEMBL1136435,KI,CC(C)(C)NC(=O)NC[C@@H]1Cc2ccccc2CN1/C(S)=N/C[C@H]1CCCN1C(=O)c1ccccc1
CHEMBL40548,CHEMBL237,Kappa opioid receptor,Ki,=,530.0,nM,CHEMBL752210,B,Binding affinity for kappa opioid receptor,CHEMBL1136435,KI,O=C(NC[C@@H]1Cc2ccccc2CN1/C(S)=N/C[C@H]1CCCN1Cc1ccc(O)cc1)Nc1ccccc1
CHEMBL41946,CHEMBL237,Kappa opioid receptor,Ki,=,543.0,nM,CHEMBL752210,B,Binding affinity for kappa opioid receptor,CHEMBL1136435,KI,COc1cccc(CN2CCC[C@@H]2C/N=C(\S)N2Cc3ccccc3C[C@H]2CNC(=O)Nc2ccccc2)c1O
CHEMBL288468,CHEMBL237,Kappa opioid receptor,Ki,=,39.5,nM,CHEMBL752210,B,Binding affinity for kappa opioid receptor,CHEMBL1136435,KI,COc1cccc(CN2CCC[C@@H]2C/N=C(\S)N2Cc3ccccc3C[C@H]2CNC(=O)Nc2ccccc2)c1OC
CHEMBL40825,CHEMBL237,Kappa opioid receptor,Ki,=,480.0,nM,CHEMBL752210,B,Binding affinity for kappa opioid receptor,CHEMBL1136435,KI,CC(C)(C)NC(=O)NC[C@@H]1Cc2ccccc2CN1/C(S)=N/C[C@H]1CCCN1Cc1ccccc1
CHEMBL41883,CHEMBL237,Kappa opioid receptor,Ki,=,511.0,nM,CHEMBL752210,B,Binding affinity for kappa opioid receptor,CHEMBL1136435,KI,CC(C)(C)NC(=O)NC[C@@H]1Cc2ccccc2CN1/C(S)=N/C[C@H]1CCCO1
CHEMBL39968,CHEMBL237,Kappa opioid receptor,Ki,=,310.0,nM,CHEMBL752210,B,Binding affinity for kappa opioid receptor,CHEMBL1136435,KI,O=C(NC[C@@H]1Cc2ccccc2CN1C(=S)NC[C@H]1CCCN1)Nc1ccccc1
CHEMBL289137,CHEMBL237,Kappa opioid receptor,Ki,=,481.0,nM,CHEMBL752210,B,Binding affinity for kappa opioid receptor,CHEMBL1136435,KI,CC(C)(C)NC(=O)NC[C@@H]1Cc2ccccc2CN1/C(S)=N/CC1CCCO1
CHEMBL288205,CHEMBL237,Kappa opioid receptor,Ki,=,303.0,nM,CHEMBL752210,B,Binding affinity for kappa opioid receptor,CHEMBL1136435,KI,O=C(NC[C@@H]1Cc2ccccc2CN1C(=S)NC[C@H]1CCCN1Cc1ccccc1)Nc1ccccc1
CHEMBL41736,CHEMBL237,Kappa opioid receptor,Ki,=,194.0,nM,CHEMBL752210,B,Binding affinity for kappa opioid receptor,CHEMBL1136435,KI,O=C(NC[C@@H]1Cc2ccccc2CN1/C(S)=N/C[C@H]1CCCN1Cc1cccc(O)c1)Nc1ccccc1
CHEMBL40993,CHEMBL237,Kappa opioid receptor,Ki,=,109.0,nM,CHEMBL752210,B,Binding affinity for kappa opioid receptor,CHEMBL1136435,KI,COc1ccccc1CN1CCC[C@@H]1C/N=C(\S)N1Cc2ccccc2C[C@H]1CNC(=O)Nc1ccccc1
CHEMBL39272,CHEMBL237,Kappa opioid receptor,Ki,=,130.0,nM,CHEMBL752210,B,Binding affinity for kappa opioid receptor,CHEMBL1136435,KI,COc1cc(O)ccc1CN1CCC[C@@H]1C/N=C(\S)N1Cc2ccccc2C[C@H]1CNC(=O)Nc1ccccc1
CHEMBL70,CHEMBL237,Kappa opioid receptor,Ki,=,113.0,nM,CHEMBL872675,B,In vitro binding affinity at opioid receptor kappa 1 was determined in human CHO cells using [3H]U-69593,CHEMBL1136784,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL606924,CHEMBL237,Kappa opioid receptor,Ki,=,0.49,nM,CHEMBL872675,B,In vitro binding affinity at opioid receptor kappa 1 was determined in human CHO cells using [3H]U-69593,CHEMBL1136784,KI,O=C1CC[C@@]2(OCCCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CCC2)[C@H]1O5
CHEMBL606876,CHEMBL237,Kappa opioid receptor,Ki,=,61.4,nM,CHEMBL872675,B,In vitro binding affinity at opioid receptor kappa 1 was determined in human CHO cells using [3H]U-69593,CHEMBL1136784,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CCCO2)CC[C@]314
CHEMBL606923,CHEMBL237,Kappa opioid receptor,Ki,=,1.4,nM,CHEMBL872675,B,In vitro binding affinity at opioid receptor kappa 1 was determined in human CHO cells using [3H]U-69593,CHEMBL1136784,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CCc2ccccc2)CC[C@]314
CHEMBL606925,CHEMBL237,Kappa opioid receptor,Ki,=,0.11,nM,CHEMBL872675,B,In vitro binding affinity at opioid receptor kappa 1 was determined in human CHO cells using [3H]U-69593,CHEMBL1136784,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(OCCCc2ccccc2)[C@H]1C5
CHEMBL606986,CHEMBL237,Kappa opioid receptor,Ki,=,0.08,nM,CHEMBL872675,B,In vitro binding affinity at opioid receptor kappa 1 was determined in human CHO cells using [3H]U-69593,CHEMBL1136784,KI,O=C1CC[C@@]2(OCCCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CCCO2)[C@H]1O5
CHEMBL514774,CHEMBL237,Kappa opioid receptor,Ki,=,0.41,nM,CHEMBL872675,B,In vitro binding affinity at opioid receptor kappa 1 was determined in human CHO cells using [3H]U-69593,CHEMBL1136784,KI,O=C1CC[C@@]2(OCCCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL606987,CHEMBL237,Kappa opioid receptor,Ki,=,0.6,nM,CHEMBL872675,B,In vitro binding affinity at opioid receptor kappa 1 was determined in human CHO cells using [3H]U-69593,CHEMBL1136784,KI,O=C1CC[C@@]2(OCCCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CCc2ccccc2)[C@H]1O5
CHEMBL326684,CHEMBL237,Kappa opioid receptor,Ki,=,304.0,nM,CHEMBL872675,B,In vitro binding affinity at opioid receptor kappa 1 was determined in human CHO cells using [3H]U-69593,CHEMBL1136784,KI,CO[C@@]12CCC(=O)[C@]3(C)Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL606985,CHEMBL237,Kappa opioid receptor,Ki,=,0.37,nM,CHEMBL872675,B,In vitro binding affinity at opioid receptor kappa 1 was determined in human CHO cells using [3H]U-69593,CHEMBL1136784,KI,CCCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(OCCCc2ccccc2)[C@H]1C5
CHEMBL291901,CHEMBL237,Kappa opioid receptor,Ki,=,271.0,nM,CHEMBL755699,B,"Binding affinity for human opioid receptor kappa 1 using [3H]- U-69,593 as radioligand transfected into CHO cells",CHEMBL1146689,KI,Oc1nc2ccccc2n1[C@H]1CCN2[C@H](CCC[C@H]2c2ccccc2)C1
CHEMBL51972,CHEMBL237,Kappa opioid receptor,Ki,=,1.1,nM,CHEMBL755699,B,"Binding affinity for human opioid receptor kappa 1 using [3H]- U-69,593 as radioligand transfected into CHO cells",CHEMBL1146689,KI,Oc1nc2ccccc2n1[C@@H]1CCN2[C@H](CCC[C@H]2c2ccccc2)C1
CHEMBL299660,CHEMBL237,Kappa opioid receptor,Ki,=,987.0,nM,CHEMBL755699,B,"Binding affinity for human opioid receptor kappa 1 using [3H]- U-69,593 as radioligand transfected into CHO cells",CHEMBL1146689,KI,CCn1c(=O)n([C@H]2CCN3[C@H](CCC[C@H]3c3ccccc3)C2)c2ccccc21
CHEMBL72885,CHEMBL237,Kappa opioid receptor,Ki,=,1.08,nM,CHEMBL751201,B,Compound was evaluated for its binding affinity to CHO cells expressing cloned human Opioid receptor kappa 1 by displacing [3H]U-69593,CHEMBL1132770,KI,NCCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4C1(CCN2CC1CC1)C3O5
CHEMBL54603,CHEMBL237,Kappa opioid receptor,Ki,=,227.0,nM,CHEMBL755699,B,"Binding affinity for human opioid receptor kappa 1 using [3H]- U-69,593 as radioligand transfected into CHO cells",CHEMBL1146689,KI,Oc1nc2ccccc2n1[C@H]1CCN2[C@H](CCC[C@H]2C2CCCCC2)C1
CHEMBL70693,CHEMBL237,Kappa opioid receptor,Ki,=,0.3,nM,CHEMBL751201,B,Compound was evaluated for its binding affinity to CHO cells expressing cloned human Opioid receptor kappa 1 by displacing [3H]U-69593,CHEMBL1132770,KI,CCCCC(=N)NCCc1ccc2[nH]c3c(c2c1)C[C@@]1(O)C2Cc4ccc(O)c5c4C1(CCN2CC1CC1)C3O5
CHEMBL573214,CHEMBL237,Kappa opioid receptor,Ki,=,0.2,nM,CHEMBL751201,B,Compound was evaluated for its binding affinity to CHO cells expressing cloned human Opioid receptor kappa 1 by displacing [3H]U-69593,CHEMBL1132770,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL54735,CHEMBL237,Kappa opioid receptor,Ki,=,2.3,nM,CHEMBL755699,B,"Binding affinity for human opioid receptor kappa 1 using [3H]- U-69,593 as radioligand transfected into CHO cells",CHEMBL1146689,KI,Oc1nc2ccccc2n1[C@@H]1CCN2[C@H](CCC[C@H]2C2CCCCC2)C1
CHEMBL52604,CHEMBL237,Kappa opioid receptor,Ki,=,22.7,nM,CHEMBL755699,B,"Binding affinity for human opioid receptor kappa 1 using [3H]- U-69,593 as radioligand transfected into CHO cells",CHEMBL1146689,KI,CCn1c(=O)n([C@@H]2CCN3[C@H](CCC[C@H]3c3ccccc3)C2)c2ccccc21
CHEMBL369720,CHEMBL237,Kappa opioid receptor,Ki,=,48.0,nM,CHEMBL839646,B,In vitro binding affinity for human kappa opioid receptor was determined by using [3H]diprenorphine as radioligand,CHEMBL1141989,KI,COc1ccc(C(=O)NCC(=O)N(C)[C@H](CN2CC[C@@H](O)C2)c2ccccc2)cc1
CHEMBL38576,CHEMBL237,Kappa opioid receptor,Ki,=,0.043,nM,CHEMBL839646,B,In vitro binding affinity for human kappa opioid receptor was determined by using [3H]diprenorphine as radioligand,CHEMBL1141989,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@H](CN1CCCC1)c1ccccc1
CHEMBL360736,CHEMBL237,Kappa opioid receptor,Ki,=,258.0,nM,CHEMBL839646,B,In vitro binding affinity for human kappa opioid receptor was determined by using [3H]diprenorphine as radioligand,CHEMBL1141989,KI,CN(C(=O)C(NC=O)c1ccccc1)[C@H](CN1CCCC1)c1ccccc1
CHEMBL368250,CHEMBL237,Kappa opioid receptor,Ki,=,138.0,nM,CHEMBL839646,B,In vitro binding affinity for human kappa opioid receptor was determined by using [3H]diprenorphine as radioligand,CHEMBL1141989,KI,CN(C(=O)[C@@H](NC(=O)OCc1ccccc1)c1ccccc1)[C@H](CN1CCCC1)c1ccccc1
CHEMBL178581,CHEMBL237,Kappa opioid receptor,Ki,=,856.0,nM,CHEMBL839646,B,In vitro binding affinity for human kappa opioid receptor was determined by using [3H]diprenorphine as radioligand,CHEMBL1141989,KI,CN(C(=O)[C@H](NC(=O)OCc1ccccc1)c1ccccc1)[C@H](CN1CCCC1)c1ccccc1
CHEMBL179064,CHEMBL237,Kappa opioid receptor,Ki,=,150.0,nM,CHEMBL839646,B,In vitro binding affinity for human kappa opioid receptor was determined by using [3H]diprenorphine as radioligand,CHEMBL1141989,KI,CN(C(=O)[C@H](Cc1ccccc1)NC(=O)OCc1ccccc1)[C@H](CN1CCCC1)c1ccccc1
CHEMBL181509,CHEMBL237,Kappa opioid receptor,Ki,=,178.0,nM,CHEMBL839646,B,In vitro binding affinity for human kappa opioid receptor was determined by using [3H]diprenorphine as radioligand,CHEMBL1141989,KI,COC(=O)N[C@H](C(=O)N(C)[C@H](CN1CCCC1)c1ccccc1)c1ccccc1
CHEMBL182106,CHEMBL237,Kappa opioid receptor,Ki,=,99.0,nM,CHEMBL839646,B,In vitro binding affinity for human kappa opioid receptor was determined by using [3H]diprenorphine as radioligand,CHEMBL1141989,KI,CN(C(=O)[C@@H](NC(=O)c1ccccc1)c1ccccc1)[C@H](CN1CCCC1)c1ccccc1
CHEMBL181663,CHEMBL237,Kappa opioid receptor,Ki,=,84.0,nM,CHEMBL839646,B,In vitro binding affinity for human kappa opioid receptor was determined by using [3H]diprenorphine as radioligand,CHEMBL1141989,KI,CN(C(=O)CNC(=O)OCc1ccccc1)[C@H](CN1CCCC1)c1ccccc1
CHEMBL359543,CHEMBL237,Kappa opioid receptor,Ki,=,16.3,nM,CHEMBL839646,B,In vitro binding affinity for human kappa opioid receptor was determined by using [3H]diprenorphine as radioligand,CHEMBL1141989,KI,CN(C(=O)CNC(=O)Cc1ccccc1)[C@H](CN1CCCC1)c1ccccc1
CHEMBL178359,CHEMBL237,Kappa opioid receptor,Ki,=,6.7,nM,CHEMBL839646,B,In vitro binding affinity for human kappa opioid receptor was determined by using [3H]diprenorphine as radioligand,CHEMBL1141989,KI,CN(C(=O)CNC(=O)c1ccccc1)[C@H](CN1CCCC1)c1ccccc1
CHEMBL361199,CHEMBL237,Kappa opioid receptor,Ki,=,3.6,nM,CHEMBL839646,B,In vitro binding affinity for human kappa opioid receptor was determined by using [3H]diprenorphine as radioligand,CHEMBL1141989,KI,CN(C(=O)CNC(=O)c1ccc(Cl)c(Cl)c1)[C@H](CN1CCCC1)c1ccccc1
CHEMBL180598,CHEMBL237,Kappa opioid receptor,Ki,=,4.6,nM,CHEMBL839646,B,In vitro binding affinity for human kappa opioid receptor was determined by using [3H]diprenorphine as radioligand,CHEMBL1141989,KI,CN(C(=O)CNC(=O)c1ccc2c(c1)no[n+]2[O-])[C@H](CN1CCCC1)c1ccccc1
CHEMBL181941,CHEMBL237,Kappa opioid receptor,Ki,=,0.83,nM,CHEMBL839646,B,In vitro binding affinity for human kappa opioid receptor was determined by using [3H]diprenorphine as radioligand,CHEMBL1141989,KI,CN(C(=O)CNC(=O)c1ccc(Cl)c(Cl)c1)[C@H](CN1CC[C@@H](O)C1)c1ccccc1
CHEMBL178101,CHEMBL237,Kappa opioid receptor,Ki,=,20.0,nM,CHEMBL839646,B,In vitro binding affinity for human kappa opioid receptor was determined by using [3H]diprenorphine as radioligand,CHEMBL1141989,KI,CN(CC(=O)N(C)[C@H](CN1CC[C@@H](O)C1)c1ccccc1)C(=O)c1ccc(Cl)c(Cl)c1
CHEMBL179627,CHEMBL237,Kappa opioid receptor,Ki,=,2.0,nM,CHEMBL839646,B,In vitro binding affinity for human kappa opioid receptor was determined by using [3H]diprenorphine as radioligand,CHEMBL1141989,KI,COc1ccccc1C(=O)NCC(=O)N(C)[C@H](CN1CC[C@@H](O)C1)c1ccccc1
CHEMBL86324,CHEMBL237,Kappa opioid receptor,Ki,=,0.058,nM,CHEMBL828016,B,Displacement of bound [3H]diprenorphine from membranes expressing cloned human kappa opioid receptor,CHEMBL1144321,KI,CN(C(=O)Cc1ccc(C(F)(F)F)cc1)[C@H](CN1CCCC1)c1ccccc1
CHEMBL23472,CHEMBL237,Kappa opioid receptor,Ki,=,2.69,nM,CHEMBL828016,B,Displacement of bound [3H]diprenorphine from membranes expressing cloned human kappa opioid receptor,CHEMBL1144321,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)C(CN1CCCC1)c1cccc(OCC(=O)O)c1
CHEMBL181279,CHEMBL237,Kappa opioid receptor,Ki,=,0.44,nM,CHEMBL828016,B,Displacement of bound [3H]diprenorphine from membranes expressing cloned human kappa opioid receptor,CHEMBL1144321,KI,CN(C(=O)Cc1ccc(C(F)(F)F)cc1)C(CN1CCCC1)c1cccc(O)c1
CHEMBL180803,CHEMBL237,Kappa opioid receptor,Ki,=,0.53,nM,CHEMBL828016,B,Displacement of bound [3H]diprenorphine from membranes expressing cloned human kappa opioid receptor,CHEMBL1144321,KI,COc1cccc(C(CN2CCCC2)N(C)C(=O)Cc2ccc(C(F)(F)F)cc2)c1
CHEMBL360678,CHEMBL237,Kappa opioid receptor,Ki,=,2.9,nM,CHEMBL828016,B,Displacement of bound [3H]diprenorphine from membranes expressing cloned human kappa opioid receptor,CHEMBL1144321,KI,CN(C(=O)Cc1ccc(C(F)(F)F)cc1)C(CN1CCCC1)c1cccc(OCC(=O)OC(C)(C)C)c1
CHEMBL185554,CHEMBL237,Kappa opioid receptor,Ki,=,3.7,nM,CHEMBL828016,B,Displacement of bound [3H]diprenorphine from membranes expressing cloned human kappa opioid receptor,CHEMBL1144321,KI,CN(C(=O)Cc1ccc(C(F)(F)F)cc1)C(CN1CCCC1)c1cccc(OCC(=O)O)c1
CHEMBL365198,CHEMBL237,Kappa opioid receptor,Ki,=,0.63,nM,CHEMBL828016,B,Displacement of bound [3H]diprenorphine from membranes expressing cloned human kappa opioid receptor,CHEMBL1144321,KI,CN(C(=O)Cc1ccc(C(F)(F)F)cc1)[C@H](CN1CCCC1)c1cccc([N+](=O)[O-])c1
CHEMBL183248,CHEMBL237,Kappa opioid receptor,Ki,=,0.31,nM,CHEMBL828016,B,Displacement of bound [3H]diprenorphine from membranes expressing cloned human kappa opioid receptor,CHEMBL1144321,KI,CN(C(=O)Cc1ccc(C(F)(F)F)cc1)[C@H](CN1CCCC1)c1cccc(N)c1
CHEMBL365486,CHEMBL237,Kappa opioid receptor,Ki,=,0.36,nM,CHEMBL828016,B,Displacement of bound [3H]diprenorphine from membranes expressing cloned human kappa opioid receptor,CHEMBL1144321,KI,CN(C(=O)Cc1ccc(C(F)(F)F)cc1)[C@H](CN1CCCC1)c1cccc(NS(C)(=O)=O)c1
CHEMBL362248,CHEMBL237,Kappa opioid receptor,Ki,=,0.48,nM,CHEMBL828016,B,Displacement of bound [3H]diprenorphine from membranes expressing cloned human kappa opioid receptor,CHEMBL1144321,KI,CN(C(=O)Cc1ccc(C(F)(F)F)cc1)[C@H](CN1CCCC1)c1cccc(NS(N)(=O)=O)c1
CHEMBL181922,CHEMBL237,Kappa opioid receptor,Ki,=,9.5,nM,CHEMBL828016,B,Displacement of bound [3H]diprenorphine from membranes expressing cloned human kappa opioid receptor,CHEMBL1144321,KI,CN(C(=O)Cc1ccc(C(F)(F)F)cc1)[C@H](CN1CCCC1)c1cccc(NC(=O)CCC(=O)O)c1
CHEMBL362458,CHEMBL237,Kappa opioid receptor,Ki,=,2300.0,nM,CHEMBL828016,B,Displacement of bound [3H]diprenorphine from membranes expressing cloned human kappa opioid receptor,CHEMBL1144321,KI,CN(C(=O)Cc1ccc(C(F)(F)F)cc1)[C@H](CN1CCCC1)c1cccc(N(CC(=O)O)CC(=O)O)c1
CHEMBL363525,CHEMBL237,Kappa opioid receptor,Ki,=,17.0,nM,CHEMBL839594,B,Binding affinity for human Opioid receptor kappa 1,CHEMBL1138638,KI,O=C1[C@@H](c2ccc(Cl)c(Cl)c2)CC=CCN1C(CN1CCCC1)c1ccccc1
CHEMBL188063,CHEMBL237,Kappa opioid receptor,Ki,=,2.0,nM,CHEMBL839594,B,Binding affinity for human Opioid receptor kappa 1,CHEMBL1138638,KI,O=C1C(c2ccc(Cl)cc2)CC=CCN1C(CN1CCCC1)c1ccccc1
CHEMBL364879,CHEMBL237,Kappa opioid receptor,Ki,=,35.0,nM,CHEMBL876693,B,Binding affinity for human Kappa opioid receptor,CHEMBL1138638,KI,O=C1[C@@H](c2ccc(Cl)cc2)CC=CCN1C(CN1CCCC1)c1ccccc1
CHEMBL183533,CHEMBL237,Kappa opioid receptor,Ki,=,22.0,nM,CHEMBL876693,B,Binding affinity for human Kappa opioid receptor,CHEMBL1138638,KI,COc1ccc(C2CC=CCN(C(CN3CCCC3)c3ccccc3)C2=O)cc1
CHEMBL362329,CHEMBL237,Kappa opioid receptor,Ki,=,800.0,nM,CHEMBL876693,B,Binding affinity for human Kappa opioid receptor,CHEMBL1138638,KI,COc1ccc([C@H]2CC=CCN(C(CN3CCCC3)c3ccccc3)C2=O)cc1
CHEMBL362757,CHEMBL237,Kappa opioid receptor,Ki,=,0.72,nM,CHEMBL876693,B,Binding affinity for human Kappa opioid receptor,CHEMBL1138638,KI,O=C1C(c2ccc(C(F)(F)F)cc2)CC=CCN1C(CN1CCCC1)c1ccccc1
CHEMBL185964,CHEMBL237,Kappa opioid receptor,Ki,=,1900.0,nM,CHEMBL876693,B,Binding affinity for human Kappa opioid receptor,CHEMBL1138638,KI,O=C1C(c2cccc(S(=O)(=O)N3CCCC3)c2)CC=CCN1C(CN1CCCC1)c1ccccc1
CHEMBL363983,CHEMBL237,Kappa opioid receptor,Ki,=,2.6,nM,CHEMBL876693,B,Binding affinity for human Kappa opioid receptor,CHEMBL1138638,KI,O=C1C(Oc2ccc(Cl)c(Cl)c2)CC=CCN1C(CN1CCCC1)c1ccccc1
CHEMBL187124,CHEMBL237,Kappa opioid receptor,Ki,=,0.2,nM,CHEMBL876693,B,Binding affinity for human Kappa opioid receptor,CHEMBL1138638,KI,O=C1[C@H](c2ccc(Cl)c(Cl)c2)CC=CCN1[C@H](CN1CC[C@H](O)C1)c1ccccc1
CHEMBL361254,CHEMBL237,Kappa opioid receptor,Ki,=,12.0,nM,CHEMBL876693,B,Binding affinity for human Kappa opioid receptor,CHEMBL1138638,KI,O=C1[C@H](c2ccc(Cl)c(Cl)c2)CC=CCN1[C@H](CN1CCCC1)c1ccccc1
CHEMBL320882,CHEMBL237,Kappa opioid receptor,Ki,=,0.04,nM,CHEMBL839594,B,Binding affinity for human Opioid receptor kappa 1,CHEMBL1138638,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)C(CN1CCCC1)c1ccccc1
CHEMBL184811,CHEMBL237,Kappa opioid receptor,Ki,=,0.34,nM,CHEMBL839594,B,Binding affinity for human Opioid receptor kappa 1,CHEMBL1138638,KI,O=C1C(c2ccc(Cl)c(Cl)c2)CC=CCN1C(CN1CCCC1)c1ccccc1
CHEMBL567175,CHEMBL237,Kappa opioid receptor,Ki,=,10.1,nM,CHEMBL838854,B,Inhibition of [3H]U-69593 binding to human kappa opioid receptor expressed in CHO cells,CHEMBL1137216,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL573214,CHEMBL237,Kappa opioid receptor,Ki,=,0.2,nM,CHEMBL838854,B,Inhibition of [3H]U-69593 binding to human kappa opioid receptor expressed in CHO cells,CHEMBL1137216,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL188841,CHEMBL237,Kappa opioid receptor,Ki,=,333.0,nM,CHEMBL838854,B,Inhibition of [3H]U-69593 binding to human kappa opioid receptor expressed in CHO cells,CHEMBL1137216,KI,CN(C)C1CCc2ccc(O)cc2C1(C)C
CHEMBL185763,CHEMBL237,Kappa opioid receptor,Ki,=,251.0,nM,CHEMBL838854,B,Inhibition of [3H]U-69593 binding to human kappa opioid receptor expressed in CHO cells,CHEMBL1137216,KI,CCCNC1CCc2ccc(O)cc2C1(C)C
CHEMBL186154,CHEMBL237,Kappa opioid receptor,Ki,=,184.0,nM,CHEMBL838854,B,Inhibition of [3H]U-69593 binding to human kappa opioid receptor expressed in CHO cells,CHEMBL1137216,KI,CCCN(C)C1CCc2ccc(O)cc2C1(C)C
CHEMBL365410,CHEMBL237,Kappa opioid receptor,Ki,=,552.0,nM,CHEMBL838854,B,Inhibition of [3H]U-69593 binding to human kappa opioid receptor expressed in CHO cells,CHEMBL1137216,KI,CCCN(CCC)C1CCc2ccc(O)cc2C1(C)C
CHEMBL188920,CHEMBL237,Kappa opioid receptor,Ki,=,232.0,nM,CHEMBL838854,B,Inhibition of [3H]U-69593 binding to human kappa opioid receptor expressed in CHO cells,CHEMBL1137216,KI,CC1(C)c2cc(O)ccc2CCC1NCC1CC1
CHEMBL365228,CHEMBL237,Kappa opioid receptor,Ki,=,146.0,nM,CHEMBL838854,B,Inhibition of [3H]U-69593 binding to human kappa opioid receptor expressed in CHO cells,CHEMBL1137216,KI,CN(CC1CC1)C1CCc2ccc(O)cc2C1(C)C
CHEMBL188411,CHEMBL237,Kappa opioid receptor,Ki,=,1830.0,nM,CHEMBL838854,B,Inhibition of [3H]U-69593 binding to human kappa opioid receptor expressed in CHO cells,CHEMBL1137216,KI,CC1(C)c2cc(O)ccc2CCC1N(CC1CC1)CC1CC1
CHEMBL188805,CHEMBL237,Kappa opioid receptor,Ki,=,63.7,nM,CHEMBL838854,B,Inhibition of [3H]U-69593 binding to human kappa opioid receptor expressed in CHO cells,CHEMBL1137216,KI,C=CCNC1CCc2ccc(O)cc2C1(C)C
CHEMBL442413,CHEMBL237,Kappa opioid receptor,Ki,=,263.0,nM,CHEMBL838854,B,Inhibition of [3H]U-69593 binding to human kappa opioid receptor expressed in CHO cells,CHEMBL1137216,KI,C=CCN(C)C1CCc2ccc(O)cc2C1(C)C
CHEMBL364133,CHEMBL237,Kappa opioid receptor,Ki,=,55.8,nM,CHEMBL838854,B,Inhibition of [3H]U-69593 binding to human kappa opioid receptor expressed in CHO cells,CHEMBL1137216,KI,C=CCN(CC=C)C1CCc2ccc(O)cc2C1(C)C
CHEMBL189243,CHEMBL237,Kappa opioid receptor,Ki,=,82.3,nM,CHEMBL838854,B,Inhibition of [3H]U-69593 binding to human kappa opioid receptor expressed in CHO cells,CHEMBL1137216,KI,CC1(C)c2cc(O)ccc2CCC1NC/C=C/c1ccccc1
CHEMBL365483,CHEMBL237,Kappa opioid receptor,Ki,=,207.0,nM,CHEMBL838854,B,Inhibition of [3H]U-69593 binding to human kappa opioid receptor expressed in CHO cells,CHEMBL1137216,KI,CN(C/C=C/c1ccccc1)C1CCc2ccc(O)cc2C1(C)C
CHEMBL435305,CHEMBL237,Kappa opioid receptor,Ki,=,1250.0,nM,CHEMBL838854,B,Inhibition of [3H]U-69593 binding to human kappa opioid receptor expressed in CHO cells,CHEMBL1137216,KI,CC1(C)c2cc(O)ccc2CCC1N(C/C=C/c1ccccc1)C/C=C/c1ccccc1
CHEMBL187635,CHEMBL237,Kappa opioid receptor,Ki,=,149.0,nM,CHEMBL838854,B,Inhibition of [3H]U-69593 binding to human kappa opioid receptor expressed in CHO cells,CHEMBL1137216,KI,CO[C@H]1Cc2ccc(O)cc2C(C)(C)[C@@H]1N
CHEMBL189571,CHEMBL237,Kappa opioid receptor,Ki,=,7.5,nM,CHEMBL838854,B,Inhibition of [3H]U-69593 binding to human kappa opioid receptor expressed in CHO cells,CHEMBL1137216,KI,CO[C@H]1Cc2ccc(O)cc2C(C)(C)[C@@H]1NC/C=C/c1ccccc1
CHEMBL19019,CHEMBL237,Kappa opioid receptor,Ki,=,0.4,nM,CHEMBL838854,B,Inhibition of [3H]U-69593 binding to human kappa opioid receptor expressed in CHO cells,CHEMBL1137216,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL445332,CHEMBL237,Kappa opioid receptor,Ki,=,1.9,nM,CHEMBL839506,B,Inhibition of [125I]- IOXY binding to human Opioid receptor kappa1,CHEMBL1145160,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL370272,CHEMBL237,Kappa opioid receptor,Ki,=,1.8,nM,CHEMBL839506,B,Inhibition of [125I]- IOXY binding to human Opioid receptor kappa1,CHEMBL1145160,KI,CCC(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL188553,CHEMBL237,Kappa opioid receptor,Ki,=,19.0,nM,CHEMBL839506,B,Inhibition of [125I]- IOXY binding to human Opioid receptor kappa1,CHEMBL1145160,KI,COC(=O)[C@@H]1C[C@H](OC(=O)C(C)C)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL370912,CHEMBL237,Kappa opioid receptor,Ki,=,42.0,nM,CHEMBL839506,B,Inhibition of [125I]- IOXY binding to human Opioid receptor kappa1,CHEMBL1145160,KI,C=C(C)C(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL360404,CHEMBL237,Kappa opioid receptor,Ki,=,430.0,nM,CHEMBL839506,B,Inhibition of [125I]- IOXY binding to human Opioid receptor kappa1,CHEMBL1145160,KI,COC(=O)C(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL363324,CHEMBL237,Kappa opioid receptor,Ki,=,90.0,nM,CHEMBL839506,B,Inhibition of [125I]- IOXY binding to human Opioid receptor kappa1,CHEMBL1145160,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccccc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL191014,CHEMBL237,Kappa opioid receptor,Ki,=,1930.0,nM,CHEMBL839506,B,Inhibition of [125I]- IOXY binding to human Opioid receptor kappa1,CHEMBL1145160,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2cccnc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL365216,CHEMBL237,Kappa opioid receptor,Ki,=,2.3,nM,CHEMBL839506,B,Inhibition of [125I]- IOXY binding to human Opioid receptor kappa1,CHEMBL1145160,KI,COC(=O)[C@@H]1C[C@H](OS(C)(=O)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL427337,CHEMBL237,Kappa opioid receptor,Ki,=,1610.0,nM,CHEMBL839506,B,Inhibition of [125I]- IOXY binding to human Opioid receptor kappa1,CHEMBL1145160,KI,COC(=O)[C@@H]1C[C@H](O[Si](C)(C)C)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL445332,CHEMBL237,Kappa opioid receptor,Ki,=,38.0,nM,CHEMBL839506,B,Inhibition of [125I]- IOXY binding to human Opioid receptor kappa1,CHEMBL1145160,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL190910,CHEMBL237,Kappa opioid receptor,Ki,=,3190.0,nM,CHEMBL839506,B,Inhibition of [125I]- IOXY binding to human Opioid receptor kappa1,CHEMBL1145160,KI,COC(=O)[C@@H]1C[C@H](O)[C@H](O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL363482,CHEMBL237,Kappa opioid receptor,Ki,=,650.0,nM,CHEMBL839506,B,Inhibition of [125I]- IOXY binding to human Opioid receptor kappa1,CHEMBL1145160,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)[C@H](OC(C)=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL190902,CHEMBL237,Kappa opioid receptor,Ki,=,64.0,nM,CHEMBL839506,B,Inhibition of [125I]- IOXY binding to human Opioid receptor kappa1,CHEMBL1145160,KI,COC(=O)[C@@H]1C[C@H](OC(=N)C(Cl)(Cl)Cl)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL190785,CHEMBL237,Kappa opioid receptor,Ki,=,93.0,nM,CHEMBL839506,B,Inhibition of [125I]- IOXY binding to human Opioid receptor kappa1,CHEMBL1145160,KI,COC(=O)[C@@H]1C[C@H](OC(=O)Nc2ccccc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL191180,CHEMBL237,Kappa opioid receptor,Ki,=,120.0,nM,CHEMBL839506,B,Inhibition of [125I]- IOXY binding to human Opioid receptor kappa1,CHEMBL1145160,KI,C=CCNC(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL189643,CHEMBL237,Kappa opioid receptor,Ki,=,1.3,nM,CHEMBL827950,B,Inhibitory constant against human Opioid receptor kappa using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CN(C(=O)Cc1ccc(CNS(=O)(=O)Cc2ccccc2)cc1)[C@H](CN1CC[C@H](O)C1)c1ccccc1
CHEMBL192520,CHEMBL237,Kappa opioid receptor,Ki,=,6.1,nM,CHEMBL827950,B,Inhibitory constant against human Opioid receptor kappa using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CNC(=O)NCc1ccc(CC(=O)N(C)[C@H](CN2CCCC2)c2ccccc2)cc1
CHEMBL447185,CHEMBL237,Kappa opioid receptor,Ki,=,2.7,nM,CHEMBL827950,B,Inhibitory constant against human Opioid receptor kappa using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CC(C)S(=O)(=O)NCc1ccc(CC(=O)N(C)[C@H](CN2CC[C@H](O)C2)c2ccccc2)cc1
CHEMBL364907,CHEMBL237,Kappa opioid receptor,Ki,=,12.0,nM,CHEMBL827950,B,Inhibitory constant against human Opioid receptor kappa using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CN(C(=O)Cc1ccccc1CNS(C)(=O)=O)[C@H](CN1CCCC1)c1ccccc1
CHEMBL370538,CHEMBL237,Kappa opioid receptor,Ki,=,2.8,nM,CHEMBL827950,B,Inhibitory constant against human Opioid receptor kappa using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CN(C(=O)Cc1ccc(CNS(=O)(=O)Cc2cccs2)cc1)[C@H](CN1CC[C@H](O)C1)c1ccccc1
CHEMBL38576,CHEMBL237,Kappa opioid receptor,Ki,=,0.04,nM,CHEMBL827950,B,Inhibitory constant against human Opioid receptor kappa using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@H](CN1CCCC1)c1ccccc1
CHEMBL190030,CHEMBL237,Kappa opioid receptor,Ki,=,10.0,nM,CHEMBL827950,B,Inhibitory constant against human Opioid receptor kappa using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CN(C(=O)Cc1cccc(CNS(C)(=O)=O)c1)[C@H](CN1CCCC1)c1ccccc1
CHEMBL363822,CHEMBL237,Kappa opioid receptor,Ki,=,1.3,nM,CHEMBL827950,B,Inhibitory constant against human Opioid receptor kappa using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CCCS(=O)(=O)NCc1ccc(CC(=O)N(C)[C@H](CN2CC[C@H](O)C2)c2ccccc2)cc1
CHEMBL191987,CHEMBL237,Kappa opioid receptor,Ki,=,0.4,nM,CHEMBL827950,B,Inhibitory constant against human Opioid receptor kappa using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CN(C(=O)Cc1ccc(NS(C)(=O)=O)cc1)[C@H](CN1CC[C@H](O)C1)c1ccccc1
CHEMBL94734,CHEMBL237,Kappa opioid receptor,Ki,=,5.8,nM,CHEMBL827950,B,Inhibitory constant against human Opioid receptor kappa using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CN(C(=O)Cc1ccccc1)[C@H](CN1CCCC1)c1ccccc1
CHEMBL362741,CHEMBL237,Kappa opioid receptor,Ki,=,0.8,nM,CHEMBL827950,B,Inhibitory constant against human Opioid receptor kappa using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CCCCS(=O)(=O)NCc1ccc(CC(=O)N(C)[C@H](CN2CC[C@H](O)C2)c2ccccc2)cc1
CHEMBL189430,CHEMBL237,Kappa opioid receptor,Ki,=,2.8,nM,CHEMBL827950,B,Inhibitory constant against human Opioid receptor kappa using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CN(C(=O)Cc1ccc(CCNS(C)(=O)=O)cc1)[C@H](CN1CC[C@H](O)C1)c1ccccc1
CHEMBL192677,CHEMBL237,Kappa opioid receptor,Ki,=,10.0,nM,CHEMBL827950,B,Inhibitory constant against human Opioid receptor kappa using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CN(C(=O)Cc1ccccc1CN)[C@H](CN1CCCC1)c1ccccc1
CHEMBL189683,CHEMBL237,Kappa opioid receptor,Ki,=,2.9,nM,CHEMBL827950,B,Inhibitory constant against human Opioid receptor kappa using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CN(C(=O)Cc1ccc(CNS(C)(=O)=O)cc1)[C@H](CN1CCCC1)c1ccccc1
CHEMBL190600,CHEMBL237,Kappa opioid receptor,Ki,=,5.9,nM,CHEMBL827950,B,Inhibitory constant against human Opioid receptor kappa using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CN(C(=O)Cc1ccc(CNS(=O)(=O)c2ccccc2)cc1)[C@H](CN1CC[C@H](O)C1)c1ccccc1
CHEMBL192718,CHEMBL237,Kappa opioid receptor,Ki,=,1.7,nM,CHEMBL827950,B,Inhibitory constant against human Opioid receptor kappa using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CN(C(=O)Cc1ccc(CCCNS(C)(=O)=O)cc1)[C@H](CN1CC[C@H](O)C1)c1ccccc1
CHEMBL363718,CHEMBL237,Kappa opioid receptor,Ki,=,1.9,nM,CHEMBL827950,B,Inhibitory constant against human Opioid receptor kappa using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CN(C(=O)Cc1ccc2c(c1)CN(S(C)(=O)=O)C2)[C@H](CN1CCCC1)c1ccccc1
CHEMBL192734,CHEMBL237,Kappa opioid receptor,Ki,=,8.7,nM,CHEMBL827950,B,Inhibitory constant against human Opioid receptor kappa using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CN(C(=O)Cc1cccc(CN)c1)[C@H](CN1CCCC1)c1ccccc1
CHEMBL425897,CHEMBL237,Kappa opioid receptor,Ki,=,0.6,nM,CHEMBL827950,B,Inhibitory constant against human Opioid receptor kappa using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CN(C(=O)Cc1ccc(CNS(C)(=O)=O)cc1)[C@H](CN1CC[C@H](O)C1)c1ccccc1
CHEMBL190353,CHEMBL237,Kappa opioid receptor,Ki,=,5.9,nM,CHEMBL827950,B,Inhibitory constant against human Opioid receptor kappa using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CN(C(=O)Cc1ccc(CNS(=O)(=O)c2ccc(F)cc2)cc1)[C@H](CN1CC[C@H](O)C1)c1ccccc1
CHEMBL189257,CHEMBL237,Kappa opioid receptor,Ki,=,57.0,nM,CHEMBL827950,B,Inhibitory constant against human Opioid receptor kappa using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CN(C(=O)Cc1ccc(CN)cc1)[C@H](CN1CCCC1)c1ccccc1
CHEMBL539685,CHEMBL237,Kappa opioid receptor,Ki,=,1.9,nM,CHEMBL827950,B,Inhibitory constant against human Opioid receptor kappa using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CC(=O)NCc1ccccc1CC(=O)N(C)[C@H](CN1CCCC1)c1ccccc1
CHEMBL192964,CHEMBL237,Kappa opioid receptor,Ki,=,23.0,nM,CHEMBL827950,B,Inhibitory constant against human Opioid receptor kappa using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CC(=O)NCc1cccc(CC(=O)N(C)[C@H](CN2CCCC2)c2ccccc2)c1
CHEMBL192998,CHEMBL237,Kappa opioid receptor,Ki,=,1.7,nM,CHEMBL827950,B,Inhibitory constant against human Opioid receptor kappa using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,Cc1ccc(S(=O)(=O)NCc2ccc(CC(=O)N(C)[C@H](CN3CC[C@H](O)C3)c3ccccc3)cc2)cc1
CHEMBL190766,CHEMBL237,Kappa opioid receptor,Ki,=,1.3,nM,CHEMBL827950,B,Inhibitory constant against human Opioid receptor kappa using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CCS(=O)(=O)NCc1ccc(CC(=O)N(C)[C@H](CN2CC[C@H](O)C2)c2ccccc2)cc1
CHEMBL359557,CHEMBL237,Kappa opioid receptor,Ki,=,47.0,nM,CHEMBL827950,B,Inhibitory constant against human Opioid receptor kappa using [3H]diprenorphine as radio ligand,CHEMBL1145259,KI,CC(=O)NCc1ccc(CC(=O)N(C)[C@H](CN2CCCC2)c2ccccc2)cc1
CHEMBL573214,CHEMBL237,Kappa opioid receptor,Ki,=,0.4,nM,CHEMBL838691,B,Inhibition of [3H]diprenorphine binding to human opioid receptor kappa 1 expressed in CHO cells,CHEMBL1142711,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL2113078,CHEMBL237,Kappa opioid receptor,Ki,=,0.7,nM,CHEMBL838691,B,Inhibition of [3H]diprenorphine binding to human opioid receptor kappa 1 expressed in CHO cells,CHEMBL1142711,KI,Oc1ccc2c3c1O[C@H]1c4c(c5c(n4Cc4ccccc4)[C@@H]4Oc6c(O)ccc7c6[C@@]46CCN(CC4CC4)[C@H](C7)[C@]6(O)C5)C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL606959,CHEMBL237,Kappa opioid receptor,Ki,=,7.7,nM,CHEMBL838691,B,Inhibition of [3H]diprenorphine binding to human opioid receptor kappa 1 expressed in CHO cells,CHEMBL1142711,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4c(c2C[C@@]3(O)[C@H]1C5)C[C@@]1(O)[C@H]2Cc3ccc(O)c5c3[C@@]1(CCN2C)[C@H]4O5
CHEMBL2113073,CHEMBL237,Kappa opioid receptor,Ki,=,24.9,nM,CHEMBL838691,B,Inhibition of [3H]diprenorphine binding to human opioid receptor kappa 1 expressed in CHO cells,CHEMBL1142711,KI,C[C@H]1c2c(c3c(n2Cc2ccccc2)[C@@H]2Oc4c(O)ccc5c4[C@@]24CCN(C)[C@H](C5)[C@]4(O)C3)CC2(O)[C@H]3Cc4ccc(O)c(O)c4[C@@]12CCN3C
CHEMBL56695,CHEMBL237,Kappa opioid receptor,Ki,=,11.0,nM,CHEMBL829981,B,Binding affinity against Opioid receptor kappa 1 expressed in CHO cells using [3H]U-69593 as radioligand,CHEMBL1143538,KI,NC(=O)c1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL19019,CHEMBL237,Kappa opioid receptor,Ki,=,0.19,nM,CHEMBL829981,B,Binding affinity against Opioid receptor kappa 1 expressed in CHO cells using [3H]U-69593 as radioligand,CHEMBL1143538,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL426084,CHEMBL237,Kappa opioid receptor,Ki,=,0.23,nM,CHEMBL829981,B,Binding affinity against Opioid receptor kappa 1 expressed in CHO cells using [3H]U-69593 as radioligand,CHEMBL1143538,KI,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCC(=O)C3
CHEMBL195285,CHEMBL237,Kappa opioid receptor,Ki,=,23.0,nM,CHEMBL829981,B,Binding affinity against Opioid receptor kappa 1 expressed in CHO cells using [3H]U-69593 as radioligand,CHEMBL1143538,KI,COc1c(C(N)=O)ccc2c1[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCC(=O)C3
CHEMBL195787,CHEMBL237,Kappa opioid receptor,Ki,=,2.2,nM,CHEMBL829981,B,Binding affinity against Opioid receptor kappa 1 expressed in CHO cells using [3H]U-69593 as radioligand,CHEMBL1143538,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c(O)c4[C@@]2(CCN3CC2CC2)C1
CHEMBL370029,CHEMBL237,Kappa opioid receptor,Ki,=,0.27,nM,CHEMBL829981,B,Binding affinity against Opioid receptor kappa 1 expressed in CHO cells using [3H]U-69593 as radioligand,CHEMBL1143538,KI,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CCC4)[C@H](C2)[C@]1(O)CCC(=O)C3
CHEMBL445332,CHEMBL237,Kappa opioid receptor,Ki,=,1.3,nM,CHEMBL839963,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor kappa 1 expressed in chinese hamster ovary cells,CHEMBL1145271,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL424698,CHEMBL237,Kappa opioid receptor,Ki,=,155.0,nM,CHEMBL839963,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor kappa 1 expressed in chinese hamster ovary cells,CHEMBL1145271,KI,COC(=O)[C@@H]1C[C@H](O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL370272,CHEMBL237,Kappa opioid receptor,Ki,=,7.2,nM,CHEMBL839963,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor kappa 1 expressed in chinese hamster ovary cells,CHEMBL1145271,KI,CCC(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL379138,CHEMBL237,Kappa opioid receptor,Ki,=,4.9,nM,CHEMBL839963,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor kappa 1 expressed in chinese hamster ovary cells,CHEMBL1145271,KI,CCCC(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL3349979,CHEMBL237,Kappa opioid receptor,Ki,=,3.2,nM,CHEMBL839963,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor kappa 1 expressed in chinese hamster ovary cells,CHEMBL1145271,KI,COC(=O)[C@@H]1C[C@H](OC(N)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL3349983,CHEMBL237,Kappa opioid receptor,Ki,=,83.0,nM,CHEMBL839963,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor kappa 1 expressed in chinese hamster ovary cells,CHEMBL1145271,KI,CNC(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL3219942,CHEMBL237,Kappa opioid receptor,Ki,=,462.0,nM,CHEMBL839963,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor kappa 1 expressed in chinese hamster ovary cells,CHEMBL1145271,KI,CCNC(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL384411,CHEMBL237,Kappa opioid receptor,Ki,=,28.9,nM,CHEMBL839963,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor kappa 1 expressed in chinese hamster ovary cells,CHEMBL1145271,KI,CCN[C@@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL213567,CHEMBL237,Kappa opioid receptor,Ki,=,90.9,nM,CHEMBL839963,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor kappa 1 expressed in chinese hamster ovary cells,CHEMBL1145271,KI,COC(=O)[C@@H]1C[C@@H](N(C)C)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL413774,CHEMBL237,Kappa opioid receptor,Ki,=,220.0,nM,CHEMBL839963,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor kappa 1 expressed in chinese hamster ovary cells,CHEMBL1145271,KI,COC(=O)[C@@H]1C[C@H](OC)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL378635,CHEMBL237,Kappa opioid receptor,Ki,=,7.9,nM,CHEMBL839963,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor kappa 1 expressed in chinese hamster ovary cells,CHEMBL1145271,KI,CCO[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL255969,CHEMBL237,Kappa opioid receptor,Ki,=,28.7,nM,CHEMBL839963,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor kappa 1 expressed in chinese hamster ovary cells,CHEMBL1145271,KI,CCCO[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL3349980,CHEMBL237,Kappa opioid receptor,Ki,=,35.8,nM,CHEMBL839963,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor kappa 1 expressed in chinese hamster ovary cells,CHEMBL1145271,KI,CCCCO[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CCC3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL3349984,CHEMBL237,Kappa opioid receptor,Ki,=,60.1,nM,CHEMBL839963,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor kappa 1 expressed in chinese hamster ovary cells,CHEMBL1145271,KI,C=CCO[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CCC3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL3349987,CHEMBL237,Kappa opioid receptor,Ki,=,75.7,nM,CHEMBL839963,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor kappa 1 expressed in chinese hamster ovary cells,CHEMBL1145271,KI,COC(=O)[C@@H]1C[C@H](OCc2ccccc2)C(=O)[C@H]2[C@@]1(C)CCC1C(=O)O[C@H](c3ccoc3)C[C@@]12C
CHEMBL441765,CHEMBL237,Kappa opioid receptor,Ki,=,1.4,nM,CHEMBL839963,B,Inhibition of [3H]diprenorphine binding to human Opioid receptor kappa 1 expressed in chinese hamster ovary cells,CHEMBL1145271,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL197037,CHEMBL237,Kappa opioid receptor,Ki,=,48.6,nM,CHEMBL885362,B,Binding affinity for 1 uM [3H]diprenorphine against human Opioid receptor kappa expressed in chinese hamster ovary cells (CHO cells),CHEMBL1141037,KI,CC(=O)O[C@H]1C[C@@H](C(=O)O)[C@]2(C)CC[C@@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL362953,CHEMBL237,Kappa opioid receptor,Ki,=,28.5,nM,CHEMBL885362,B,Binding affinity for 1 uM [3H]diprenorphine against human Opioid receptor kappa expressed in chinese hamster ovary cells (CHO cells),CHEMBL1141037,KI,CCOC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL415460,CHEMBL237,Kappa opioid receptor,Ki,=,201.0,nM,CHEMBL885362,B,Binding affinity for 1 uM [3H]diprenorphine against human Opioid receptor kappa expressed in chinese hamster ovary cells (CHO cells),CHEMBL1141037,KI,C#CCCCOC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL196734,CHEMBL237,Kappa opioid receptor,Ki,=,99.6,nM,CHEMBL885362,B,Binding affinity for 1 uM [3H]diprenorphine against human Opioid receptor kappa expressed in chinese hamster ovary cells (CHO cells),CHEMBL1141037,KI,COCOC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL383785,CHEMBL237,Kappa opioid receptor,Ki,=,110.0,nM,CHEMBL885362,B,Binding affinity for 1 uM [3H]diprenorphine against human Opioid receptor kappa expressed in chinese hamster ovary cells (CHO cells),CHEMBL1141037,KI,COCOC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@@H]2[C@@]3(C)C[C@@H](c4ccoc4)OC(=O)[C@H]3CC[C@]21C
CHEMBL194896,CHEMBL237,Kappa opioid receptor,Ki,=,475.0,nM,CHEMBL885362,B,Binding affinity for 1 uM [3H]diprenorphine against human Opioid receptor kappa expressed in chinese hamster ovary cells (CHO cells),CHEMBL1141037,KI,CC(=O)O[C@H]1C[C@@H](C(=O)NC2CC2)[C@]2(C)CC[C@@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL196419,CHEMBL237,Kappa opioid receptor,Ki,=,26.9,nM,CHEMBL885362,B,Binding affinity for 1 uM [3H]diprenorphine against human Opioid receptor kappa expressed in chinese hamster ovary cells (CHO cells),CHEMBL1141037,KI,CC(=O)O[C@H]1C[C@@H](C(=O)NC(C)C(=O)OCc2ccccc2)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL263576,CHEMBL237,Kappa opioid receptor,Ki,=,470.0,nM,CHEMBL885362,B,Binding affinity for 1 uM [3H]diprenorphine against human Opioid receptor kappa expressed in chinese hamster ovary cells (CHO cells),CHEMBL1141037,KI,CC(=O)O[C@H]1C[C@@H](C(=O)NCC(=O)OCc2ccccc2)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL196096,CHEMBL237,Kappa opioid receptor,Ki,=,210.0,nM,CHEMBL885362,B,Binding affinity for 1 uM [3H]diprenorphine against human Opioid receptor kappa expressed in chinese hamster ovary cells (CHO cells),CHEMBL1141037,KI,CC(=O)O[C@H]1C[C@@H](C(=O)N2CCCC2C(=O)OCc2ccccc2)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL441765,CHEMBL237,Kappa opioid receptor,Ki,=,1.4,nM,CHEMBL885362,B,Binding affinity for 1 uM [3H]diprenorphine against human Opioid receptor kappa expressed in chinese hamster ovary cells (CHO cells),CHEMBL1141037,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL199434,CHEMBL237,Kappa opioid receptor,Ki,=,40.0,nM,CHEMBL859857,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1148550,KI,Cn1c(N2CCC(c3ccccc3)(c3nccn3Cc3ccccc3)CC2)nc2ccccc21
CHEMBL436323,CHEMBL237,Kappa opioid receptor,Ki,=,2533.0,nM,CHEMBL859857,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1148550,KI,c1ccc(Cn2ccnc2C2(c3ccccc3)CCN(c3nccs3)CC2)cc1
CHEMBL202238,CHEMBL237,Kappa opioid receptor,Ki,=,505.0,nM,CHEMBL859857,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1148550,KI,c1ccc(Cn2ccnc2C2(c3ccccc3)CCN(c3ncccn3)CC2)cc1
CHEMBL199518,CHEMBL237,Kappa opioid receptor,Ki,=,346.0,nM,CHEMBL859857,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1148550,KI,O=S(=O)(Nc1ccccc1)N1CCC(c2ccccc2)(c2nccn2Cc2ccccc2)CC1
CHEMBL200700,CHEMBL237,Kappa opioid receptor,Ki,=,2012.0,nM,CHEMBL859857,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1148550,KI,CS(=O)(=O)N1CCC(c2ccccc2)(c2nccn2Cc2ccccc2)CC1
CHEMBL200098,CHEMBL237,Kappa opioid receptor,Ki,=,152.0,nM,CHEMBL859857,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1148550,KI,COc1cccc(NC(=O)N2CCC(c3ccccc3)(c3nccn3Cc3ccccc3)CC2)c1
CHEMBL199378,CHEMBL237,Kappa opioid receptor,Ki,=,782.0,nM,CHEMBL859857,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1148550,KI,COc1ccccc1NC(=O)N1CCC(c2ccccc2)(c2nccn2Cc2ccccc2)CC1
CHEMBL201453,CHEMBL237,Kappa opioid receptor,Ki,=,148.0,nM,CHEMBL859857,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1148550,KI,O=C(Nc1ccc(F)cc1)N1CCC(c2ccccc2)(c2nccn2Cc2ccccc2)CC1
CHEMBL371266,CHEMBL237,Kappa opioid receptor,Ki,=,318.0,nM,CHEMBL859857,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1148550,KI,O=C(Nc1ccccc1F)N1CCC(c2ccccc2)(c2nccn2Cc2ccccc2)CC1
CHEMBL426470,CHEMBL237,Kappa opioid receptor,Ki,=,858.0,nM,CHEMBL859857,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1148550,KI,CN1CCN(C(=O)N2CCC(c3ccccc3)(c3nccn3Cc3ccccc3)CC2)CC1
CHEMBL198238,CHEMBL237,Kappa opioid receptor,Ki,=,242.0,nM,CHEMBL859857,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1148550,KI,CCNC(=O)N1CCC(c2ccccc2)(c2nccn2Cc2ccccc2)CC1
CHEMBL199294,CHEMBL237,Kappa opioid receptor,Ki,=,334.0,nM,CHEMBL859857,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1148550,KI,NC(=O)N1CCC(c2ccccc2)(c2nccn2Cc2ccccc2)CC1
CHEMBL199433,CHEMBL237,Kappa opioid receptor,Ki,=,397.0,nM,CHEMBL859857,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1148550,KI,CN(C(=O)N1CCC(c2ccccc2)(c2nccn2Cc2ccccc2)CC1)c1ccccc1
CHEMBL199545,CHEMBL237,Kappa opioid receptor,Ki,=,1185.0,nM,CHEMBL859857,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1148550,KI,O=C(Nc1ccccc1)N1CCC(c2ccccc2)(c2nccn2C(=O)c2ccccc2)CC1
CHEMBL197917,CHEMBL237,Kappa opioid receptor,Ki,=,46.0,nM,CHEMBL859857,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1148550,KI,O=C(Nc1ccccc1)N1CCC(c2ccccc2)(c2nccn2Cc2ccccn2)CC1
CHEMBL199289,CHEMBL237,Kappa opioid receptor,Ki,=,2059.0,nM,CHEMBL859857,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1148550,KI,COc1cccc(Cn2ccnc2C2(c3ccccc3)CCN(C(=O)Nc3ccccc3)CC2)c1
CHEMBL199684,CHEMBL237,Kappa opioid receptor,Ki,=,2156.0,nM,CHEMBL859857,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1148550,KI,O=C(Nc1ccccc1)N1CCC(c2ccccc2)(c2nccn2Cc2ccc(F)cc2)CC1
CHEMBL381674,CHEMBL237,Kappa opioid receptor,Ki,=,1877.0,nM,CHEMBL859857,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1148550,KI,O=C(Nc1ccccc1)N1CCC(c2ccccc2)(c2nccn2Cc2cccc(F)c2)CC1
CHEMBL199871,CHEMBL237,Kappa opioid receptor,Ki,=,116.0,nM,CHEMBL859857,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1148550,KI,O=C(Nc1ccccc1)N1CCC(c2ccccc2)(c2nccn2Cc2ccccc2F)CC1
CHEMBL382326,CHEMBL237,Kappa opioid receptor,Ki,=,126.0,nM,CHEMBL859857,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1148550,KI,O=C(Nc1ccccc1)N1CCC(c2ccccc2)(c2nccn2Cc2ccccc2)CC1
CHEMBL592,CHEMBL237,Kappa opioid receptor,Ki,=,2.3,nM,CHEMBL858981,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1148605,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13
CHEMBL146756,CHEMBL237,Kappa opioid receptor,Ki,=,0.08,nM,CHEMBL858981,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1148605,KI,O=C(/C=C/C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL147511,CHEMBL237,Kappa opioid receptor,Ki,=,0.049,nM,CHEMBL858981,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1148605,KI,O=C(CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL203251,CHEMBL237,Kappa opioid receptor,Ki,=,0.076,nM,CHEMBL858981,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1148605,KI,O=C(CCC(=O)Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL201219,CHEMBL237,Kappa opioid receptor,Ki,=,7.3,nM,CHEMBL858981,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1148605,KI,O=C(/C=C/C(=O)Nc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3)Nc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL201220,CHEMBL237,Kappa opioid receptor,Ki,=,7.5,nM,CHEMBL858981,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1148605,KI,O=C(CCCCCCCCC(=O)Nc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3)Nc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL372598,CHEMBL237,Kappa opioid receptor,Ki,=,3.8,nM,CHEMBL858981,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1148605,KI,O=C(CCC(=O)Nc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3)Nc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL200881,CHEMBL237,Kappa opioid receptor,Ki,=,0.38,nM,CHEMBL858981,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1148605,KI,O=C(CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3)Nc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL199827,CHEMBL237,Kappa opioid receptor,Ki,=,0.3,nM,CHEMBL858981,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1148605,KI,O=C(CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccccc1
CHEMBL199931,CHEMBL237,Kappa opioid receptor,Ki,=,0.11,nM,CHEMBL858981,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1148605,KI,CN1CC[C@]23c4c5ccc(OC(=O)CCCCCCCCC(=O)Oc6ccc7c(c6)[C@@]68CCCCC6[C@@H](C7)N(CC6CCC6)CC8)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL201271,CHEMBL237,Kappa opioid receptor,Ki,=,0.23,nM,CHEMBL858981,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1148605,KI,O=C(CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CC1)CC3)Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL193039,CHEMBL237,Kappa opioid receptor,Ki,=,1.2,nM,CHEMBL858981,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1148605,KI,O=C(CCCCCCCCC(=O)Oc1ccc2c(c1)[C@]13CCCCC1[C@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL383320,CHEMBL237,Kappa opioid receptor,Ki,=,0.29,nM,CHEMBL858981,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1148605,KI,O=C(O)CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL381750,CHEMBL237,Kappa opioid receptor,Ki,=,0.62,nM,CHEMBL858981,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1148605,KI,O=C(/C=C/C=C/C(=O)Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL372823,CHEMBL237,Kappa opioid receptor,Ki,=,10.0,nM,CHEMBL858981,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1148605,KI,C#CCN1CC[C@]23CCCCC2[C@H]1Cc1ccc(OC(=O)CCCCCCCCC(=O)Oc2ccc4c(c2)[C@@]25CCCCC2[C@@H](C4)N(CC#C)CC5)cc13
CHEMBL369919,CHEMBL237,Kappa opioid receptor,Ki,=,1.2,nM,CHEMBL858981,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1148605,KI,O=C(CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(C[C@@H]1CCCO1)CC3)Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(C[C@@H]1CCCO1)CC3
CHEMBL200295,CHEMBL237,Kappa opioid receptor,Ki,=,130.0,nM,CHEMBL858981,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1148605,KI,O=C(CCCCCCCCC(=O)Oc1ccc2c(c1)[C@]13CCCCC1[C@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@]13CCCCC1[C@H](C2)N(CC1CCC1)CC3
CHEMBL201038,CHEMBL237,Kappa opioid receptor,Ki,=,480.0,nM,CHEMBL858981,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1148605,KI,O=C(O)C(O)c1ccccc1.Oc1ccc2c(c1)[C@]13CCCCC1[C@H](C2)N(CC1CC1)CC3
CHEMBL381117,CHEMBL237,Kappa opioid receptor,Ki,=,55.0,nM,CHEMBL858981,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1148605,KI,O=C(O)C(O)c1ccccc1.Oc1ccc2c(c1)[C@]13CCCCC1[C@H](C2)N(CC1CCC1)CC3
CHEMBL70,CHEMBL237,Kappa opioid receptor,Ki,=,24.0,nM,CHEMBL858981,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1148605,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL49143,CHEMBL237,Kappa opioid receptor,Ki,=,1.8,nM,CHEMBL858981,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1148605,KI,Nc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1790045,CHEMBL237,Kappa opioid receptor,Ki,=,0.003,nM,CHEMBL858981,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1148605,KI,C#CCN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13
CHEMBL199832,CHEMBL237,Kappa opioid receptor,Ki,=,0.15,nM,CHEMBL858981,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1148605,KI,Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(C[C@@H]1CCCO1)CC3
CHEMBL49269,CHEMBL237,Kappa opioid receptor,Ki,=,0.034,nM,CHEMBL858981,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1148605,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL301160,CHEMBL237,Kappa opioid receptor,Ki,=,0.079,nM,CHEMBL858981,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1148605,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL201884,CHEMBL237,Kappa opioid receptor,Ki,=,0.17,nM,CHEMBL854075,B,Binding affinity to kappa opioid receptor,CHEMBL1149423,KI,CN(C(=O)CNc1ccccc1)[C@H](CN1CC[C@H](O)C1)c1ccccc1
CHEMBL202267,CHEMBL237,Kappa opioid receptor,Ki,=,1.5,nM,CHEMBL854075,B,Binding affinity to kappa opioid receptor,CHEMBL1149423,KI,CCCS(=O)(=O)Nc1ccc(NCC(=O)N(C)[C@H](CN2CC[C@H](O)C2)c2ccccc2)cc1
CHEMBL369993,CHEMBL237,Kappa opioid receptor,Ki,=,5.7,nM,CHEMBL854075,B,Binding affinity to kappa opioid receptor,CHEMBL1149423,KI,CN(C(=O)CNc1ccc(NS(C)(=O)=O)cc1)[C@H](CN1CC[C@H](O)C1)c1ccccc1
CHEMBL201283,CHEMBL237,Kappa opioid receptor,Ki,=,0.78,nM,CHEMBL854075,B,Binding affinity to kappa opioid receptor,CHEMBL1149423,KI,CN(C(=O)CNc1ccccc1CNS(C)(=O)=O)[C@H](CN1CC[C@H](O)C1)c1ccccc1
CHEMBL204650,CHEMBL237,Kappa opioid receptor,Ki,=,3.9,nM,CHEMBL854075,B,Binding affinity to kappa opioid receptor,CHEMBL1149423,KI,CN(C(=O)CNc1cccc(CNS(C)(=O)=O)c1)[C@H](CN1CC[C@H](O)C1)c1ccccc1
CHEMBL441124,CHEMBL237,Kappa opioid receptor,Ki,=,16.0,nM,CHEMBL854075,B,Binding affinity to kappa opioid receptor,CHEMBL1149423,KI,CN(C(=O)CNc1ccc(CNS(C)(=O)=O)cc1)[C@H](CN1CC[C@H](O)C1)c1ccccc1
CHEMBL203306,CHEMBL237,Kappa opioid receptor,Ki,=,1.0,nM,CHEMBL854075,B,Binding affinity to kappa opioid receptor,CHEMBL1149423,KI,CN(CC(=O)N(C)[C@H](CN1CC[C@H](O)C1)c1ccccc1)c1ccc(C#N)cc1
CHEMBL202591,CHEMBL237,Kappa opioid receptor,Ki,=,3.8,nM,CHEMBL854075,B,Binding affinity to kappa opioid receptor,CHEMBL1149423,KI,CC(=O)N(CC(=O)N(C)[C@H](CN1CC[C@H](O)C1)c1ccccc1)c1ccccc1
CHEMBL382932,CHEMBL237,Kappa opioid receptor,Ki,=,0.32,nM,CHEMBL854075,B,Binding affinity to kappa opioid receptor,CHEMBL1149423,KI,CN(CC(=O)N(C)[C@H](CN1CC[C@H](O)C1)c1ccccc1)c1ccccc1
CHEMBL201285,CHEMBL237,Kappa opioid receptor,Ki,=,0.39,nM,CHEMBL854075,B,Binding affinity to kappa opioid receptor,CHEMBL1149423,KI,CN(C(=O)CNc1ccccc1C#N)[C@H](CN1CC[C@H](O)C1)c1ccccc1
CHEMBL382449,CHEMBL237,Kappa opioid receptor,Ki,=,0.5,nM,CHEMBL854075,B,Binding affinity to kappa opioid receptor,CHEMBL1149423,KI,CN(C(=O)CNc1cccc(C#N)c1)[C@H](CN1CC[C@H](O)C1)c1ccccc1
CHEMBL435132,CHEMBL237,Kappa opioid receptor,Ki,=,0.66,nM,CHEMBL854075,B,Binding affinity to kappa opioid receptor,CHEMBL1149423,KI,CN(C(=O)CNc1ccc(C#N)cc1)[C@H](CN1CC[C@H](O)C1)c1ccccc1
CHEMBL201572,CHEMBL237,Kappa opioid receptor,Ki,=,0.21,nM,CHEMBL854075,B,Binding affinity to kappa opioid receptor,CHEMBL1149423,KI,CN(C(=O)CNc1ccc([N+](=O)[O-])cc1)[C@H](CN1CC[C@H](O)C1)c1ccccc1
CHEMBL201971,CHEMBL237,Kappa opioid receptor,Ki,=,0.11,nM,CHEMBL854075,B,Binding affinity to kappa opioid receptor,CHEMBL1149423,KI,CN(C(=O)CNc1ccc(Cl)c(Cl)c1)[C@H](CN1CC[C@H](O)C1)c1ccccc1
CHEMBL201905,CHEMBL237,Kappa opioid receptor,Ki,=,0.39,nM,CHEMBL854075,B,Binding affinity to kappa opioid receptor,CHEMBL1149423,KI,CN(C(=O)CNc1ccc(C(F)(F)F)cc1)[C@H](CN1CC[C@H](O)C1)c1ccccc1
CHEMBL319536,CHEMBL237,Kappa opioid receptor,Ki,=,17.0,nM,CHEMBL866453,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1149448,KI,C[C@H]1CN(CCc2ccccc2)CC[C@@]1(C)c1cccc(O)c1
CHEMBL383094,CHEMBL237,Kappa opioid receptor,Ki,=,57.0,nM,CHEMBL866453,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1149448,KI,CCCCCCCN1C[C@H](C)[C@](C)(c2cccc(O)c2)C[C@H]1CCC
CHEMBL202327,CHEMBL237,Kappa opioid receptor,Ki,=,150.0,nM,CHEMBL866453,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1149448,KI,CCCCCCN1C[C@H](C)[C@](C)(c2cccc(O)c2)C[C@H]1CCC
CHEMBL202200,CHEMBL237,Kappa opioid receptor,Ki,=,570.0,nM,CHEMBL866453,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1149448,KI,CCCCCN1C[C@H](C)[C@](C)(c2cccc(O)c2)C[C@H]1CCC
CHEMBL202150,CHEMBL237,Kappa opioid receptor,Ki,=,610.0,nM,CHEMBL866453,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1149448,KI,CCCCN1C[C@H](C)[C@](C)(c2cccc(O)c2)C[C@H]1CCC
CHEMBL202139,CHEMBL237,Kappa opioid receptor,Ki,=,360.0,nM,CHEMBL866453,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1149448,KI,CCC[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1CCC
CHEMBL202462,CHEMBL237,Kappa opioid receptor,Ki,=,270.0,nM,CHEMBL866453,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1149448,KI,CCC[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1CC
CHEMBL202461,CHEMBL237,Kappa opioid receptor,Ki,=,220.0,nM,CHEMBL866453,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1149448,KI,CCC[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1C
CHEMBL201661,CHEMBL237,Kappa opioid receptor,Ki,=,74.0,nM,CHEMBL866453,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1149448,KI,CCC[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1CCCc1ccccc1
CHEMBL201296,CHEMBL237,Kappa opioid receptor,Ki,=,360.0,nM,CHEMBL866453,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1149448,KI,CCC[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1Cc1ccccc1
CHEMBL201295,CHEMBL237,Kappa opioid receptor,Ki,=,690.0,nM,CHEMBL866453,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1149448,KI,CCC[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1
CHEMBL383044,CHEMBL237,Kappa opioid receptor,Ki,=,260.0,nM,CHEMBL866453,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1149448,KI,C[C@H]1CN(CCc2ccccc2)[C@H](CCCc2ccccc2)C[C@@]1(C)c1cccc(O)c1
CHEMBL201434,CHEMBL237,Kappa opioid receptor,Ki,=,790.0,nM,CHEMBL866453,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1149448,KI,C[C@H]1CN(CCc2ccccc2)[C@H](CCc2ccccc2)C[C@@]1(C)c1cccc(O)c1
CHEMBL203150,CHEMBL237,Kappa opioid receptor,Ki,=,920.0,nM,CHEMBL866453,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1149448,KI,C[C@H]1CN(CCc2ccccc2)[C@H](Cc2ccccc2)C[C@@]1(C)c1cccc(O)c1
CHEMBL201480,CHEMBL237,Kappa opioid receptor,Ki,=,290.0,nM,CHEMBL866453,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1149448,KI,C[C@H]1CN(CCc2ccccc2)[C@H](c2ccccc2)C[C@@]1(C)c1cccc(O)c1
CHEMBL201845,CHEMBL237,Kappa opioid receptor,Ki,=,200.0,nM,CHEMBL866453,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1149448,KI,C[C@H]1CN(CCc2ccccc2)[C@H](CCNC(=O)c2ccccc2)C[C@@]1(C)c1cccc(O)c1
CHEMBL383491,CHEMBL237,Kappa opioid receptor,Ki,=,620.0,nM,CHEMBL866453,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1149448,KI,CC(=O)NCC[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1CCc1ccccc1
CHEMBL201530,CHEMBL237,Kappa opioid receptor,Ki,=,510.0,nM,CHEMBL866453,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1149448,KI,C[C@H]1CN(CCc2ccccc2)[C@H](CCN)C[C@@]1(C)c1cccc(O)c1
CHEMBL202352,CHEMBL237,Kappa opioid receptor,Ki,=,200.0,nM,CHEMBL866453,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1149448,KI,CCCC[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1CCc1ccccc1
CHEMBL382919,CHEMBL237,Kappa opioid receptor,Ki,=,110.0,nM,CHEMBL866453,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1149448,KI,CCC[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1CCc1ccccc1
CHEMBL371970,CHEMBL237,Kappa opioid receptor,Ki,=,710.0,nM,CHEMBL866453,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1149448,KI,CC[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1CCc1ccccc1
CHEMBL203307,CHEMBL237,Kappa opioid receptor,Ki,=,100.0,nM,CHEMBL866453,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1149448,KI,C[C@@H]1C[C@@](C)(c2cccc(O)c2)[C@@H](C)CN1CCc1ccccc1
CHEMBL210514,CHEMBL237,Kappa opioid receptor,Ki,=,1960.0,nM,CHEMBL870231,B,Binding affinity to kappa opiate receptor,CHEMBL1148507,KI,COc1nc(NCCCN2CCOCC2)nc(OC)c1NC(=O)c1ccc(Oc2cc3c(cc2C)CCC3(C)C)o1
CHEMBL206044,CHEMBL237,Kappa opioid receptor,Ki,=,840.0,nM,CHEMBL870154,B,Displacement of [125I]IOXY from human kappa opioid receptor,CHEMBL1148513,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccn(S(C)(=O)=O)c3)C[C@]21C
CHEMBL377182,CHEMBL237,Kappa opioid receptor,Ki,=,8530.0,nM,CHEMBL870154,B,Displacement of [125I]IOXY from human kappa opioid receptor,CHEMBL1148513,KI,COC(=O)c1coc([C@@H]2C[C@]3(C)[C@H]4C(=O)[C@@H](OC(C)=O)C[C@@H](C(=O)OC)[C@]4(C)CC[C@H]3C(=O)O2)n1
CHEMBL378314,CHEMBL237,Kappa opioid receptor,Ki,=,1620.0,nM,CHEMBL870154,B,Displacement of [125I]IOXY from human kappa opioid receptor,CHEMBL1148513,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccn(S(=O)(=O)c4ccc(OC)cc4)c3)C[C@]21C
CHEMBL210775,CHEMBL237,Kappa opioid receptor,Ki,=,410.0,nM,CHEMBL870154,B,Displacement of [125I]IOXY from human kappa opioid receptor,CHEMBL1148513,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccn(S(=O)(=O)c4ccccc4)c3)C[C@]21C
CHEMBL212525,CHEMBL237,Kappa opioid receptor,Ki,=,4300.0,nM,CHEMBL871098,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,Cn1cc(C2CCN(C3Cc4cccc5cccc3c45)CC2O)c2cccnc21
CHEMBL379297,CHEMBL237,Kappa opioid receptor,Ki,=,2780.0,nM,CHEMBL871098,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,c1cc2c3c(cccc3c1)C(N1CCC(c3c[nH]c4ncccc34)CC1)C2
CHEMBL378633,CHEMBL237,Kappa opioid receptor,Ki,=,3890.0,nM,CHEMBL871098,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,c1cnc2[nH]cc(C3CCN(CC4CCCCCCC4)CC3)c2c1
CHEMBL377402,CHEMBL237,Kappa opioid receptor,Ki,=,710.0,nM,CHEMBL871098,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,c1ccc2c(CN3CCC(c4c[nH]c5ncccc45)CC3)cccc2c1
CHEMBL208862,CHEMBL237,Kappa opioid receptor,Ki,=,2600.0,nM,CHEMBL871098,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,Clc1cccc2c(C3CCN(C4Cc5cccc6cccc4c56)CC3)c[nH]c12
CHEMBL427395,CHEMBL237,Kappa opioid receptor,Ki,=,1170.0,nM,CHEMBL871098,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,Clc1cccc2c(C3CCN(CC4CCCCCCC4)CC3)c[nH]c12
CHEMBL384681,CHEMBL237,Kappa opioid receptor,Ki,=,1900.0,nM,CHEMBL871098,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,CN(C)C[C@@H](O)Cn1cc(C2CCN(CC3CCCCCCC3)CC2)c2cc(F)ccc21
CHEMBL211722,CHEMBL237,Kappa opioid receptor,Ki,=,1890.0,nM,CHEMBL871098,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,Fc1ccc2[nH]cc(C3CCN(C4Cc5cccc6cccc4c56)CC3)c2c1
CHEMBL211846,CHEMBL237,Kappa opioid receptor,Ki,=,180.0,nM,CHEMBL871098,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,Fc1ccc2[nH]cc(C3CCN(CC4CCCCCCC4)CC3)c2c1
CHEMBL378458,CHEMBL237,Kappa opioid receptor,Ki,=,820.0,nM,CHEMBL871098,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,Fc1ccc2[nH]cc(C3CCN(Cc4cccc5ccccc45)CC3)c2c1
CHEMBL212575,CHEMBL237,Kappa opioid receptor,Ki,=,680.0,nM,CHEMBL871098,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,Cc1[nH]c2ccc(Cl)cc2c1C1CCN(C2Cc3cccc4cccc2c34)CC1
CHEMBL212574,CHEMBL237,Kappa opioid receptor,Ki,=,330.0,nM,CHEMBL871098,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,Cc1[nH]c2ccc(Cl)cc2c1C1CCN(CC2CCCCCCC2)CC1
CHEMBL438965,CHEMBL237,Kappa opioid receptor,Ki,=,750.0,nM,CHEMBL871098,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,Cc1[nH]c2ccc(Cl)cc2c1C1CCN(Cc2cccc3ccccc23)CC1
CHEMBL210770,CHEMBL237,Kappa opioid receptor,Ki,=,330.0,nM,CHEMBL871098,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,Clc1ccc2[nH]cc(C3CCN(Cc4ccccc4)CC3)c2c1
CHEMBL211723,CHEMBL237,Kappa opioid receptor,Ki,=,1010.0,nM,CHEMBL871098,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in HEK293 cells,CHEMBL1138891,KI,Clc1ccc2[nH]cc(C3=CCN(Cc4ccccc4)CC3)c2c1
CHEMBL377340,CHEMBL237,Kappa opioid receptor,Ki,=,1500.0,nM,CHEMBL869298,B,Inhibition of (-)-[9-3H]bremazocine binding to kappa opioid receptor expressed in HEK293 cells,CHEMBL1138930,KI,CC(C)(C)c1cccc(-c2nncn2-c2cccc(O)c2)c1
CHEMBL611402,CHEMBL237,Kappa opioid receptor,Ki,=,2.4,nM,CHEMBL863625,B,Displacement of [3H]U-69593 from human recombinant KOR expressed in CHO cells,CHEMBL1146036,KI,O=C(/C=C/c1ccccc1Cl)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL610883,CHEMBL237,Kappa opioid receptor,Ki,=,1.5,nM,CHEMBL863625,B,Displacement of [3H]U-69593 from human recombinant KOR expressed in CHO cells,CHEMBL1146036,KI,Cc1ccccc1/C=C/C(=O)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL607069,CHEMBL237,Kappa opioid receptor,Ki,=,6.4,nM,CHEMBL863625,B,Displacement of [3H]U-69593 from human recombinant KOR expressed in CHO cells,CHEMBL1146036,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)/C=C/c5ccc(Cl)cc5)[C@@H](C2)N(C)CC[C@]314
CHEMBL607127,CHEMBL237,Kappa opioid receptor,Ki,=,9.9,nM,CHEMBL863625,B,Displacement of [3H]U-69593 from human recombinant KOR expressed in CHO cells,CHEMBL1146036,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)/C=C/c5ccc(C)cc5)[C@@H](C2)N(C)CC[C@]314
CHEMBL607016,CHEMBL237,Kappa opioid receptor,Ki,=,2.5,nM,CHEMBL863625,B,Displacement of [3H]U-69593 from human recombinant KOR expressed in CHO cells,CHEMBL1146036,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)/C=C/c5ccccc5Cl)[C@@H](C2)N(C)CC[C@]314
CHEMBL607017,CHEMBL237,Kappa opioid receptor,Ki,=,2.3,nM,CHEMBL863625,B,Displacement of [3H]U-69593 from human recombinant KOR expressed in CHO cells,CHEMBL1146036,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)/C=C/c5ccccc5C)[C@@H](C2)N(C)CC[C@]314
CHEMBL607018,CHEMBL237,Kappa opioid receptor,Ki,=,1.5,nM,CHEMBL863625,B,Displacement of [3H]U-69593 from human recombinant KOR expressed in CHO cells,CHEMBL1146036,KI,Cc1ccc(/C=C/C(=O)N[C@@]23CCC(=O)[C@@H]4Oc5c(O)ccc6c5[C@@]42CCN(C)[C@@H]3C6)cc1
CHEMBL607068,CHEMBL237,Kappa opioid receptor,Ki,=,5.5,nM,CHEMBL863625,B,Displacement of [3H]U-69593 from human recombinant KOR expressed in CHO cells,CHEMBL1146036,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(NC(=O)/C=C/c2ccc([N+](=O)[O-])cc2)[C@H]1C5
CHEMBL2113666,CHEMBL237,Kappa opioid receptor,Ki,=,0.54,nM,CHEMBL863625,B,Displacement of [3H]U-69593 from human recombinant KOR expressed in CHO cells,CHEMBL1146036,KI,CN1CC[C@]23c4c5cccc4O[C@H]2C(=O)CC[C@@]3(NC(=O)/C=C/c2ccccc2Cl)[C@H]1C5
CHEMBL607125,CHEMBL237,Kappa opioid receptor,Ki,=,0.23,nM,CHEMBL863625,B,Displacement of [3H]U-69593 from human recombinant KOR expressed in CHO cells,CHEMBL1146036,KI,Cc1ccccc1/C=C/C(=O)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL386272,CHEMBL237,Kappa opioid receptor,Ki,=,16.4,nM,CHEMBL863625,B,Displacement of [3H]U-69593 from human recombinant KOR expressed in CHO cells,CHEMBL1146036,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)/C=C/c5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL386492,CHEMBL237,Kappa opioid receptor,Ki,=,1.4,nM,CHEMBL863625,B,Displacement of [3H]U-69593 from human recombinant KOR expressed in CHO cells,CHEMBL1146036,KI,O=C(/C=C/c1ccc(Cl)cc1)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL70,CHEMBL237,Kappa opioid receptor,Ki,=,46.9,nM,CHEMBL863625,B,Displacement of [3H]U-69593 from human recombinant KOR expressed in CHO cells,CHEMBL1146036,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL607126,CHEMBL237,Kappa opioid receptor,Ki,=,0.57,nM,CHEMBL863625,B,Displacement of [3H]U-69593 from human recombinant KOR expressed in CHO cells,CHEMBL1146036,KI,Cc1ccc(CCC(=O)N[C@@]23CCC(=O)[C@@H]4Oc5c(O)ccc6c5[C@@]42CCN(C)[C@@H]3C6)cc1
CHEMBL19019,CHEMBL237,Kappa opioid receptor,Ki,=,0.4,nM,CHEMBL863625,B,Displacement of [3H]U-69593 from human recombinant KOR expressed in CHO cells,CHEMBL1146036,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL373984,CHEMBL237,Kappa opioid receptor,Ki,=,0.28,nM,CHEMBL870431,B,Inhibition of [3H]U-69593 binding to human kappa opioid receptor expressed in CHO cells at 10 uM,CHEMBL1146900,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1C(=O)NCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL373984,CHEMBL237,Kappa opioid receptor,Ki,=,0.28,nM,CHEMBL870430,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1146900,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1C(=O)NCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL58646,CHEMBL237,Kappa opioid receptor,Ki,=,0.06,nM,CHEMBL870417,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1146899,KI,C[C@H]1C2Cc3ccc(C(N)=O)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL214104,CHEMBL237,Kappa opioid receptor,Ki,=,1.3,nM,CHEMBL870417,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1146899,KI,CC[C@@]12CCN(CC3CC3)C(C(=O)c3ccc(C(=O)NCCc4ccc(-c5ccccc5)cc4)cc31)[C@@H]2C
CHEMBL60869,CHEMBL237,Kappa opioid receptor,Ki,=,0.47,nM,CHEMBL870417,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1146899,KI,CC[C@@]12CCN(CC3CC3)C(C(=O)c3ccc(C(N)=O)cc31)[C@@H]2C
CHEMBL215594,CHEMBL237,Kappa opioid receptor,Ki,=,11.0,nM,CHEMBL870417,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1146899,KI,C[C@H]1C2Cc3ccc(C(=O)N(C)CCc4ccc(-c5ccccc5)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL212434,CHEMBL237,Kappa opioid receptor,Ki,=,2.7,nM,CHEMBL870417,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1146899,KI,C[C@H]1C2Cc3ccc(C(=O)NCCCc4ccc(-c5ccccc5)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL378355,CHEMBL237,Kappa opioid receptor,Ki,=,8.5,nM,CHEMBL870417,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1146899,KI,C[C@@H]1[C@@H]2Cc3ccc(C(=O)NCCc4ccc(-c5ccccc5)cc4)cc3[C@]1(C)CCN2CC1CC1
CHEMBL210005,CHEMBL237,Kappa opioid receptor,Ki,=,0.35,nM,CHEMBL870417,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1146899,KI,C[C@H]1[C@H]2Cc3ccc(C(=O)NCCc4ccc(-c5ccccc5)cc4)cc3[C@]1(C)CCN2CC1CC1
CHEMBL377789,CHEMBL237,Kappa opioid receptor,Ki,=,1.8,nM,CHEMBL870417,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1146899,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccccc5)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL1162933,CHEMBL237,Kappa opioid receptor,Ki,=,26.0,nM,CHEMBL870417,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1146899,KI,C[C@H]1C2Cc3ccc(C(=O)NCc4ccc(-c5ccccc5)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL215760,CHEMBL237,Kappa opioid receptor,Ki,=,27.0,nM,CHEMBL870417,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1146899,KI,C[C@H]1C2Cc3ccc(C(=O)Nc4ccc(-c5ccccc5)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL213291,CHEMBL237,Kappa opioid receptor,Ki,=,3.0,nM,CHEMBL870417,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1146899,KI,C[C@H]1C2Cc3ccc(C(=O)NCCCc4ccccc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL209550,CHEMBL237,Kappa opioid receptor,Ki,=,1.7,nM,CHEMBL870417,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1146899,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccccc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL213880,CHEMBL237,Kappa opioid receptor,Ki,=,36.0,nM,CHEMBL870417,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1146899,KI,C[C@H]1C2Cc3ccc(C(=O)NCc4ccccc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL293103,CHEMBL237,Kappa opioid receptor,Ki,=,270.0,nM,CHEMBL870417,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1146899,KI,C[C@H]1C2Cc3ccc(C(=O)Nc4ccccc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL445332,CHEMBL237,Kappa opioid receptor,Ki,=,1.3,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL385591,CHEMBL237,Kappa opioid receptor,Ki,=,769.0,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,COC[C@@H]1C[C@H](OC(C)=O)C(=O)[C@@H]2C3(C)C[C@@H](c4ccoc4)OC[C@H]3C(=O)C[C@@]12C
CHEMBL384403,CHEMBL237,Kappa opioid receptor,Ki,=,376.0,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,CCC(=O)N(CC)[C@@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL214144,CHEMBL237,Kappa opioid receptor,Ki,=,240.0,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,CCN(C(C)=O)[C@@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL386665,CHEMBL237,Kappa opioid receptor,Ki,=,6.9,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,CCC(=O)N(C)[C@@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL213074,CHEMBL237,Kappa opioid receptor,Ki,=,16.5,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,COC(=O)[C@@H]1C[C@@H](N(C)C(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL215301,CHEMBL237,Kappa opioid receptor,Ki,=,117.0,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,CCC(=O)N[C@@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL213399,CHEMBL237,Kappa opioid receptor,Ki,=,332.0,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,COC(=O)[C@@H]1C[C@@H](NC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL213567,CHEMBL237,Kappa opioid receptor,Ki,=,90.9,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,COC(=O)[C@@H]1C[C@@H](N(C)C)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL386883,CHEMBL237,Kappa opioid receptor,Ki,=,2.3,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,COC(=O)[C@@H]1C[C@@H](NC(C)C)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL384411,CHEMBL237,Kappa opioid receptor,Ki,=,28.9,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,CCN[C@@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL212714,CHEMBL237,Kappa opioid receptor,Ki,=,223.0,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,COC(=O)[C@@H]1C[C@@H](N)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL214491,CHEMBL237,Kappa opioid receptor,Ki,=,665.0,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,CCCC(=O)O[C@@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL385846,CHEMBL237,Kappa opioid receptor,Ki,=,641.0,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,CCC(=O)O[C@@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL378767,CHEMBL237,Kappa opioid receptor,Ki,=,424.0,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,COC(=O)[C@@H]1C[C@@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL215938,CHEMBL237,Kappa opioid receptor,Ki,=,1000.0,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,CC(=O)O[C@H]1C[C@@H](CO)[C@]2(C)CC(=O)[C@H]3CO[C@H](c4ccoc4)CC3(C)[C@H]2C1=O
CHEMBL215319,CHEMBL237,Kappa opioid receptor,Ki,=,1392.0,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,CNC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL445332,CHEMBL237,Kappa opioid receptor,Ki,=,2.6,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL441765,CHEMBL237,Kappa opioid receptor,Ki,=,1.4,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL215389,CHEMBL237,Kappa opioid receptor,Ki,=,38.1,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,CCC(=O)N(CC)[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL424902,CHEMBL237,Kappa opioid receptor,Ki,=,27.6,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,CCN(C(C)=O)[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL212648,CHEMBL237,Kappa opioid receptor,Ki,=,1.6,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,CCC(=O)N(C)[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL212022,CHEMBL237,Kappa opioid receptor,Ki,=,374.0,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,CCC(=O)N[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL213155,CHEMBL237,Kappa opioid receptor,Ki,=,149.0,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,COC(=O)[C@@H]1C[C@H](NC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL212483,CHEMBL237,Kappa opioid receptor,Ki,=,168.0,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,COC(=O)[C@@H]1C[C@H](N(C)C)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL212435,CHEMBL237,Kappa opioid receptor,Ki,=,17.6,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,COC(=O)[C@@H]1C[C@H](NC(C)C)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL385548,CHEMBL237,Kappa opioid receptor,Ki,=,65.2,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,CCN[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL215560,CHEMBL237,Kappa opioid receptor,Ki,=,328.0,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,CN[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL378635,CHEMBL237,Kappa opioid receptor,Ki,=,7.9,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,CCO[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL413774,CHEMBL237,Kappa opioid receptor,Ki,=,220.0,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,COC(=O)[C@@H]1C[C@H](OC)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL424698,CHEMBL237,Kappa opioid receptor,Ki,=,155.0,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,COC(=O)[C@@H]1C[C@H](O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL379138,CHEMBL237,Kappa opioid receptor,Ki,=,4.9,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,CCCC(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL370272,CHEMBL237,Kappa opioid receptor,Ki,=,7.2,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,CCC(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL212647,CHEMBL237,Kappa opioid receptor,Ki,=,3.2,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,COC(=O)[C@@H]1C[C@H](N(C)C(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL435108,CHEMBL237,Kappa opioid receptor,Ki,=,140.0,nM,CHEMBL910349,B,Inhibition of [3H]diprenorphine binding to human KOR expressed in CHO cells,CHEMBL1149338,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@@H]2[C@@]3(C)C[C@@H](c4ccoc4)OC(=O)[C@H]3CC[C@]21C
CHEMBL386272,CHEMBL237,Kappa opioid receptor,Ki,=,16.4,nM,CHEMBL907786,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1137387,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)/C=C/c5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL387016,CHEMBL237,Kappa opioid receptor,Ki,=,128.0,nM,CHEMBL907786,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1137387,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL19019,CHEMBL237,Kappa opioid receptor,Ki,=,0.4,nM,CHEMBL907786,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1137387,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL217658,CHEMBL237,Kappa opioid receptor,Ki,=,1.53,nM,CHEMBL907786,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1137387,KI,O=C1CC[C@@]2(NCCc3ccc(Cl)cc3)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL448428,CHEMBL237,Kappa opioid receptor,Ki,=,1.0,nM,CHEMBL907786,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1137387,KI,O=C(Cc1ccc(Cl)cc1)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL217102,CHEMBL237,Kappa opioid receptor,Ki,=,5.27,nM,CHEMBL907786,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1137387,KI,O=C1CC[C@@]2(NCCCCc3ccc(Cl)cc3)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL383896,CHEMBL237,Kappa opioid receptor,Ki,=,3.69,nM,CHEMBL907786,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1137387,KI,O=C1CC[C@@]2(NCC/C=C/c3ccc(Cl)cc3)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL216558,CHEMBL237,Kappa opioid receptor,Ki,=,3.72,nM,CHEMBL907786,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1137387,KI,O=C1CC[C@@]2(NC/C=C/Cc3ccc(Cl)cc3)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL217479,CHEMBL237,Kappa opioid receptor,Ki,=,2.95,nM,CHEMBL907786,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1137387,KI,O=C(CCCc1ccc(Cl)cc1)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL217710,CHEMBL237,Kappa opioid receptor,Ki,=,4.94,nM,CHEMBL907786,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1137387,KI,O=C(C/C=C/c1ccc(Cl)cc1)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL386492,CHEMBL237,Kappa opioid receptor,Ki,=,1.41,nM,CHEMBL907786,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1137387,KI,O=C(/C=C/c1ccc(Cl)cc1)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL387101,CHEMBL237,Kappa opioid receptor,Ki,=,13.1,nM,CHEMBL907786,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1137387,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NCCc5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL277530,CHEMBL237,Kappa opioid receptor,Ki,=,2.59,nM,CHEMBL907786,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1137387,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)Cc5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL215926,CHEMBL237,Kappa opioid receptor,Ki,=,41.5,nM,CHEMBL907786,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1137387,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NCCCCc5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL411089,CHEMBL237,Kappa opioid receptor,Ki,=,33.5,nM,CHEMBL907786,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1137387,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NCC/C=C/c5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL384118,CHEMBL237,Kappa opioid receptor,Ki,=,25.9,nM,CHEMBL907786,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1137387,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC/C=C/Cc5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL263482,CHEMBL237,Kappa opioid receptor,Ki,=,7.51,nM,CHEMBL907786,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1137387,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)CCCc5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL216365,CHEMBL237,Kappa opioid receptor,Ki,=,21.5,nM,CHEMBL907786,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1137387,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)C/C=C/c5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL217790,CHEMBL237,Kappa opioid receptor,Ki,=,25.2,nM,CHEMBL907786,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1137387,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)/C=C/Cc5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL385482,CHEMBL237,Kappa opioid receptor,Ki,=,0.91,nM,CHEMBL907185,B,Displacement of [3H]diprenorphine from human recombinant kappa opioid receptor expressed in C6 cells,CHEMBL1137387,KI,O=C1CC[C@@]2(NC/C=C/c3ccc(Cl)cc3)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL376413,CHEMBL237,Kappa opioid receptor,Ki,=,84.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(CC3CCCCC3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL373707,CHEMBL237,Kappa opioid receptor,Ki,=,11.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2C[C@H](c3ccccc3)NC[C@H]2C[C@@]1(C)c1cccc(C(N)=O)c1
CHEMBL373925,CHEMBL237,Kappa opioid receptor,Ki,=,460.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2C[C@H](c3ccccc3)N(Cc3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(C(N)=O)c1
CHEMBL412996,CHEMBL237,Kappa opioid receptor,Ki,=,120.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2C[C@H](c3ccccc3)N(Cc3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL218520,CHEMBL237,Kappa opioid receptor,Ki,=,13.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2C[C@H](c3ccccc3)N(C)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL218706,CHEMBL237,Kappa opioid receptor,Ki,=,620.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,CC(=O)N1C[C@H]2C[C@@](C)(c3cccc(O)c3)[C@@H](C)CN2C[C@@H]1c1ccccc1
CHEMBL219319,CHEMBL237,Kappa opioid receptor,Ki,=,18.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2C[C@H](c3ccccc3)NC[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL426523,CHEMBL237,Kappa opioid receptor,Ki,=,9.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2C[C@H](c3ccccc3)CC[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL319536,CHEMBL237,Kappa opioid receptor,Ki,=,17.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN(CCc2ccccc2)CC[C@@]1(C)c1cccc(O)c1
CHEMBL19019,CHEMBL237,Kappa opioid receptor,Ki,=,4.4,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL80,CHEMBL237,Kappa opioid receptor,Ki,=,9.2,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL219097,CHEMBL237,Kappa opioid receptor,Ki,=,57.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,CC(C)[C@H]1CN2C[C@H](C)[C@](C)(c3cccc(O)c3)C[C@@H]2CN1
CHEMBL375119,CHEMBL237,Kappa opioid receptor,Ki,=,16.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2C[C@H](C3CCCCC3)NC[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL218980,CHEMBL237,Kappa opioid receptor,Ki,=,130.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2C[C@@H](Cc3ccccc3)NC[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL435746,CHEMBL237,Kappa opioid receptor,Ki,=,86.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2C[C@H](Cc3ccccc3)NC[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL218506,CHEMBL237,Kappa opioid receptor,Ki,=,430.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2C[C@@H](c3ccccc3)NC[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL219317,CHEMBL237,Kappa opioid receptor,Ki,=,420.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(C(=O)Nc3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL374678,CHEMBL237,Kappa opioid receptor,Ki,=,540.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCCN(Cc3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL219495,CHEMBL237,Kappa opioid receptor,Ki,=,110.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(CCc3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL376690,CHEMBL237,Kappa opioid receptor,Ki,=,43.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL220248,CHEMBL237,Kappa opioid receptor,Ki,=,3700.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(c3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL218135,CHEMBL237,Kappa opioid receptor,Ki,=,540.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(C(=O)Cc3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL218404,CHEMBL237,Kappa opioid receptor,Ki,=,180.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(C(=O)c3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL375165,CHEMBL237,Kappa opioid receptor,Ki,=,950.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(CCCc3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL219044,CHEMBL237,Kappa opioid receptor,Ki,=,140.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,COC(=O)c1cccc(CN2CCN3C[C@H](C)[C@](C)(c4cccc(O)c4)C[C@@H]3C2)c1
CHEMBL375803,CHEMBL237,Kappa opioid receptor,Ki,=,270.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3ccc(O)cc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL218909,CHEMBL237,Kappa opioid receptor,Ki,=,56.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3cccc(O)c3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL218242,CHEMBL237,Kappa opioid receptor,Ki,=,76.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3ccccc3O)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL218705,CHEMBL237,Kappa opioid receptor,Ki,=,280.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3ccc(Cl)cc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL373641,CHEMBL237,Kappa opioid receptor,Ki,=,83.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3cccc(Cl)c3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL219318,CHEMBL237,Kappa opioid receptor,Ki,=,16.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3ccccc3Cl)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL217999,CHEMBL237,Kappa opioid receptor,Ki,=,300.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,Cc1ccc(CN2CCN3C[C@H](C)[C@](C)(c4cccc(O)c4)C[C@@H]3C2)cc1
CHEMBL217998,CHEMBL237,Kappa opioid receptor,Ki,=,130.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,Cc1cccc(CN2CCN3C[C@H](C)[C@](C)(c4cccc(O)c4)C[C@@H]3C2)c1
CHEMBL219599,CHEMBL237,Kappa opioid receptor,Ki,=,30.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,Cc1ccccc1CN1CCN2C[C@H](C)[C@](C)(c3cccc(O)c3)C[C@@H]2C1
CHEMBL219554,CHEMBL237,Kappa opioid receptor,Ki,=,38.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3ccsc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL373446,CHEMBL237,Kappa opioid receptor,Ki,=,37.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3cccs3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL217950,CHEMBL237,Kappa opioid receptor,Ki,=,120.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3ccoc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL374455,CHEMBL237,Kappa opioid receptor,Ki,=,430.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3ccco3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL219099,CHEMBL237,Kappa opioid receptor,Ki,=,400.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3cccnc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL219466,CHEMBL237,Kappa opioid receptor,Ki,=,390.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3ccccn3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL375633,CHEMBL237,Kappa opioid receptor,Ki,=,230.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3cccc4ccccc34)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL218136,CHEMBL237,Kappa opioid receptor,Ki,=,980.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3ccc4ccccc4c3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL384895,CHEMBL237,Kappa opioid receptor,Ki,=,33.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3cccc(OCc4ccccc4)c3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL219154,CHEMBL237,Kappa opioid receptor,Ki,=,24.0,nM,CHEMBL909852,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137297,KI,C[C@H]1CN2CCN(Cc3cccc(Oc4ccccc4)c3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL80,CHEMBL237,Kappa opioid receptor,Ki,=,9.2,nM,CHEMBL909313,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137299,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL216662,CHEMBL237,Kappa opioid receptor,Ki,=,520.0,nM,CHEMBL909313,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137299,KI,C[C@H]1[C@H]2CCCCN2CC[C@@]1(C)c1cccc(O)c1
CHEMBL219012,CHEMBL237,Kappa opioid receptor,Ki,=,69.0,nM,CHEMBL909313,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137299,KI,C[C@H]1[C@@H]2CCCCN2CC[C@@]1(C)c1cccc(O)c1
CHEMBL219011,CHEMBL237,Kappa opioid receptor,Ki,=,520.0,nM,CHEMBL909313,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137299,KI,C[C@H]1CN2CCCC[C@@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL262420,CHEMBL237,Kappa opioid receptor,Ki,=,16.0,nM,CHEMBL909313,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137299,KI,C[C@H]1[C@H]2CC[C@@H](c3ccccc3)CN2CC[C@@]1(C)c1cccc(O)c1
CHEMBL385280,CHEMBL237,Kappa opioid receptor,Ki,=,35.0,nM,CHEMBL909313,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137299,KI,C[C@H]1[C@H]2CC[C@H](c3ccccc3)CN2CC[C@@]1(C)c1cccc(O)c1
CHEMBL438821,CHEMBL237,Kappa opioid receptor,Ki,=,65.0,nM,CHEMBL909313,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137299,KI,C[C@H]1[C@@H]2CC[C@@H](c3ccccc3)CN2CC[C@@]1(C)c1cccc(O)c1
CHEMBL385392,CHEMBL237,Kappa opioid receptor,Ki,=,100.0,nM,CHEMBL909313,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137299,KI,C[C@H]1[C@@H]2CC[C@H](c3ccccc3)CN2CC[C@@]1(C)c1cccc(O)c1
CHEMBL374559,CHEMBL237,Kappa opioid receptor,Ki,=,440.0,nM,CHEMBL909313,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137299,KI,C[C@H]1CN2C[C@@H](c3ccccc3)CC[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL219079,CHEMBL237,Kappa opioid receptor,Ki,=,1400.0,nM,CHEMBL909313,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137299,KI,C[C@H]1CN2C[C@@H](c3ccccc3)CC[C@@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL426523,CHEMBL237,Kappa opioid receptor,Ki,=,9.0,nM,CHEMBL909313,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137299,KI,C[C@H]1CN2C[C@H](c3ccccc3)CC[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL387248,CHEMBL237,Kappa opioid receptor,Ki,=,430.0,nM,CHEMBL909313,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137299,KI,C[C@H]1CN2C[C@H](c3ccccc3)CC[C@@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL319536,CHEMBL237,Kappa opioid receptor,Ki,=,17.0,nM,CHEMBL909313,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137299,KI,C[C@H]1CN(CCc2ccccc2)CC[C@@]1(C)c1cccc(O)c1
CHEMBL19019,CHEMBL237,Kappa opioid receptor,Ki,=,4.4,nM,CHEMBL909313,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells,CHEMBL1137299,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL445332,CHEMBL237,Kappa opioid receptor,Ki,=,1.3,nM,CHEMBL909560,B,Displacement of [3H]diprenorphine binding from human kappa opioid receptor expressed in CHO cells,CHEMBL1139705,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL441765,CHEMBL237,Kappa opioid receptor,Ki,=,1.4,nM,CHEMBL909560,B,Displacement of [3H]diprenorphine binding from human kappa opioid receptor expressed in CHO cells,CHEMBL1139705,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL217971,CHEMBL237,Kappa opioid receptor,Ki,=,613.0,nM,CHEMBL909560,B,Displacement of [3H]diprenorphine binding from human kappa opioid receptor expressed in CHO cells,CHEMBL1139705,KI,COCCOCC(=O)OC[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL386185,CHEMBL237,Kappa opioid receptor,Ki,=,221.0,nM,CHEMBL909560,B,Displacement of [3H]diprenorphine binding from human kappa opioid receptor expressed in CHO cells,CHEMBL1139705,KI,CC(=O)O[C@H]1C[C@@H](COC(=O)C2CC2)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL425016,CHEMBL237,Kappa opioid receptor,Ki,=,43.4,nM,CHEMBL909560,B,Displacement of [3H]diprenorphine binding from human kappa opioid receptor expressed in CHO cells,CHEMBL1139705,KI,CC(=O)O[C@H]1C[C@@H](CO)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL197037,CHEMBL237,Kappa opioid receptor,Ki,=,48.6,nM,CHEMBL909560,B,Displacement of [3H]diprenorphine binding from human kappa opioid receptor expressed in CHO cells,CHEMBL1139705,KI,CC(=O)O[C@H]1C[C@@H](C(=O)O)[C@]2(C)CC[C@@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL346879,CHEMBL237,Kappa opioid receptor,Ki,=,120.0,nM,CHEMBL919063,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1149288,KI,Oc1ccc2c3c1O[C@H]1c4c(c(-c5ccccc5)cn4Cc4ccccc4)C[C@@]4(O)C(C2)N(CC2CC2)CC[C@]314
CHEMBL567175,CHEMBL237,Kappa opioid receptor,Ki,=,10.1,nM,CHEMBL919063,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1149288,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL222814,CHEMBL237,Kappa opioid receptor,Ki,=,163.0,nM,CHEMBL919063,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1149288,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2c(c4c(n2CCc2ccccc2)CCCC4)C[C@@]3(O)C1C5
CHEMBL222579,CHEMBL237,Kappa opioid receptor,Ki,=,262.0,nM,CHEMBL919063,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1149288,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2c(c4c(n2CC2CCCCC2)CCCC4)C[C@@]3(O)C1C5
CHEMBL221421,CHEMBL237,Kappa opioid receptor,Ki,=,289.0,nM,CHEMBL919063,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1149288,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2c(c4c(n2Cc2ccccc2)CCCC4)C[C@@]3(O)C1C5
CHEMBL222704,CHEMBL237,Kappa opioid receptor,Ki,=,168.0,nM,CHEMBL919063,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1149288,KI,CCn1c2c(c3c1[C@@H]1Oc4c(O)ccc5c4[C@@]14CCN(C)C(C5)[C@]4(O)C3)CCCC2
CHEMBL374228,CHEMBL237,Kappa opioid receptor,Ki,=,89.1,nM,CHEMBL919063,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1149288,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2c(c4c(n2C)CCCC4)C[C@@]3(O)C1C5
CHEMBL222762,CHEMBL237,Kappa opioid receptor,Ki,=,8.97,nM,CHEMBL919063,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1149288,KI,Oc1ccc2c3c1O[C@H]1c4c(c5c(n4CCc4ccccc4)CCCC5)C[C@@]4(O)C(C2)N(CC2CC2)CC[C@]314
CHEMBL385316,CHEMBL237,Kappa opioid receptor,Ki,=,24.9,nM,CHEMBL919063,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1149288,KI,Oc1ccc2c3c1O[C@H]1c4c(c5c(n4CC4CCCCC4)CCCC5)C[C@@]4(O)C(C2)N(CC2CC2)CC[C@]314
CHEMBL222647,CHEMBL237,Kappa opioid receptor,Ki,=,6.29,nM,CHEMBL919063,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1149288,KI,Oc1ccc2c3c1O[C@H]1c4c(c5c(n4Cc4ccccc4)CCCC5)C[C@@]4(O)C(C2)N(CC2CC2)CC[C@]314
CHEMBL222597,CHEMBL237,Kappa opioid receptor,Ki,=,2.51,nM,CHEMBL919063,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1149288,KI,Oc1ccc2c3c1O[C@H]1c4c(c5c(n4CC4CC4)CCCC5)C[C@@]4(O)C(C2)N(CC2CC2)CC[C@]314
CHEMBL222486,CHEMBL237,Kappa opioid receptor,Ki,=,7.38,nM,CHEMBL919063,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1149288,KI,CCn1c2c(c3c1[C@@H]1Oc4c(O)ccc5c4[C@@]14CCN(CC1CC1)C(C5)[C@]4(O)C3)CCCC2
CHEMBL610534,CHEMBL237,Kappa opioid receptor,Ki,=,4.11,nM,CHEMBL919063,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1149288,KI,Cn1c2c(c3c1[C@@H]1Oc4c(O)ccc5c4[C@@]14CCN(CC1CC1)[C@H](C5)[C@]4(O)C3)CCCC2
CHEMBL373910,CHEMBL237,Kappa opioid receptor,Ki,=,24.3,nM,CHEMBL919063,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1149288,KI,CCn1cc(-c2ccccc2)c2c1[C@@H]1Oc3c(O)ccc4c3[C@@]13CCN(CC1CC1)C(C4)[C@]3(O)C2
CHEMBL221419,CHEMBL237,Kappa opioid receptor,Ki,=,18.5,nM,CHEMBL919063,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1149288,KI,Cn1cc(-c2ccccc2)c2c1[C@@H]1Oc3c(O)ccc4c3[C@@]13CCN(CC1CC1)C(C4)[C@]3(O)C2
CHEMBL301160,CHEMBL237,Kappa opioid receptor,Ki,=,0.079,nM,CHEMBL917910,B,Displacement of [3H]U-69593 from human opioid kappa receptor expressed in CHO cells,CHEMBL1147138,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL2113275,CHEMBL237,Kappa opioid receptor,Ki,=,0.13,nM,CHEMBL917910,B,Displacement of [3H]U-69593 from human opioid kappa receptor expressed in CHO cells,CHEMBL1147138,KI,C=CCN1CC[C@]23c4c5ccc(OC(=O)CCCCCCCCC(=O)Oc6ccc7c(c6)[C@@]68CCCCC6[C@@H](C7)N(CC6CCC6)CC8)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL224014,CHEMBL237,Kappa opioid receptor,Ki,=,0.12,nM,CHEMBL917910,B,Displacement of [3H]U-69593 from human opioid kappa receptor expressed in CHO cells,CHEMBL1147138,KI,O=C(CCCCCCCCC(=O)Oc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL224671,CHEMBL237,Kappa opioid receptor,Ki,=,0.34,nM,CHEMBL917910,B,Displacement of [3H]U-69593 from human opioid kappa receptor expressed in CHO cells,CHEMBL1147138,KI,O=C(CCCCCCCCC(=O)Oc1ccc2c3c1O[C@H]1[C@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314)Oc1ccc2c(c1)[C@@]13CCCCC1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL80,CHEMBL237,Kappa opioid receptor,Ki,=,1.1,nM,CHEMBL917910,B,Displacement of [3H]U-69593 from human opioid kappa receptor expressed in CHO cells,CHEMBL1147138,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL19019,CHEMBL237,Kappa opioid receptor,Ki,=,0.25,nM,CHEMBL917910,B,Displacement of [3H]U-69593 from human opioid kappa receptor expressed in CHO cells,CHEMBL1147138,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL895,CHEMBL237,Kappa opioid receptor,Ki,=,2.2,nM,CHEMBL917910,B,Displacement of [3H]U-69593 from human opioid kappa receptor expressed in CHO cells,CHEMBL1147138,KI,Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
CHEMBL389072,CHEMBL237,Kappa opioid receptor,Ki,=,390.0,nM,CHEMBL904885,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO membrane,CHEMBL1143667,KI,COc1ccc2c(c1)[C@]13CCN(C)[C@H](C2)[C@@H]1Cc1c([nH]c2ccccc12)C3
CHEMBL376355,CHEMBL237,Kappa opioid receptor,Ki,=,0.14,nM,CHEMBL904885,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO membrane,CHEMBL1143667,KI,Nc1nc2c(s1)C[C@H]1[C@H]3Cc4ccc(O)cc4[C@@]1(CCN3CC1CCC1)C2
CHEMBL226217,CHEMBL237,Kappa opioid receptor,Ki,=,0.07,nM,CHEMBL904885,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO membrane,CHEMBL1143667,KI,Nc1nc2c(s1)C[C@H]1[C@H]3Cc4ccc(O)cc4[C@@]1(CCN3CC1CC1)C2
CHEMBL226167,CHEMBL237,Kappa opioid receptor,Ki,=,2.2,nM,CHEMBL904885,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO membrane,CHEMBL1143667,KI,CN1CC[C@]23Cc4nc(N)sc4C[C@H]2[C@H]1Cc1ccc(O)cc13
CHEMBL375504,CHEMBL237,Kappa opioid receptor,Ki,=,1.0,nM,CHEMBL904885,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO membrane,CHEMBL1143667,KI,Oc1ccc2c(c1)[C@]13CCN(CC4CCC4)[C@H](C2)[C@@H]1Cc1c([nH]c2ccccc12)C3
CHEMBL226166,CHEMBL237,Kappa opioid receptor,Ki,=,0.64,nM,CHEMBL904885,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO membrane,CHEMBL1143667,KI,Oc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@@H]1Cc1c([nH]c2ccccc12)C3
CHEMBL226114,CHEMBL237,Kappa opioid receptor,Ki,=,14.0,nM,CHEMBL904885,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO membrane,CHEMBL1143667,KI,CN1CC[C@]23Cc4[nH]c5ccccc5c4C[C@H]2[C@H]1Cc1ccc(O)cc13
CHEMBL375503,CHEMBL237,Kappa opioid receptor,Ki,=,89.0,nM,CHEMBL904885,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO membrane,CHEMBL1143667,KI,COc1ccc2c(c1)[C@]13CCN(CC4CCC4)[C@H](C2)[C@@H]1Cc1c([nH]c2ccccc12)C3
CHEMBL226113,CHEMBL237,Kappa opioid receptor,Ki,=,1.4,nM,CHEMBL904885,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO membrane,CHEMBL1143667,KI,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@@H]1Cc1c([nH]c2ccccc12)C3
CHEMBL592,CHEMBL237,Kappa opioid receptor,Ki,=,2.3,nM,CHEMBL887389,B,Displacement of [3H]U-69593 from human kappa opioid receptors expressed in CHO cell membrane,CHEMBL1144610,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13
CHEMBL394624,CHEMBL237,Kappa opioid receptor,Ki,=,0.3,nM,CHEMBL887389,B,Displacement of [3H]U-69593 from human kappa opioid receptors expressed in CHO cell membrane,CHEMBL1144610,KI,O=C(NCc1ccccc1)Oc1ccc2c(c1)C13CCCCC1C(C2)N(CC1CCC1)CC3
CHEMBL242048,CHEMBL237,Kappa opioid receptor,Ki,=,0.051,nM,CHEMBL887389,B,Displacement of [3H]U-69593 from human kappa opioid receptors expressed in CHO cell membrane,CHEMBL1144610,KI,O=C(Nc1ccccc1)Oc1ccc2c(c1)C13CCCCC1C(C2)N(CC1CCC1)CC3
CHEMBL242047,CHEMBL237,Kappa opioid receptor,Ki,=,4.3,nM,CHEMBL887389,B,Displacement of [3H]U-69593 from human kappa opioid receptors expressed in CHO cell membrane,CHEMBL1144610,KI,CCNC(=O)Oc1ccc2c(c1)C13CCCCC1C(C2)N(CC1CCC1)CC3
CHEMBL242046,CHEMBL237,Kappa opioid receptor,Ki,=,0.81,nM,CHEMBL887389,B,Displacement of [3H]U-69593 from human kappa opioid receptors expressed in CHO cell membrane,CHEMBL1144610,KI,CNC(=O)Oc1ccc2c(c1)C13CCCCC1C(C2)N(CC1CCC1)CC3
CHEMBL301160,CHEMBL237,Kappa opioid receptor,Ki,=,0.079,nM,CHEMBL887389,B,Displacement of [3H]U-69593 from human kappa opioid receptors expressed in CHO cell membrane,CHEMBL1144610,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL263096,CHEMBL237,Kappa opioid receptor,Ki,=,0.14,nM,CHEMBL887389,B,Displacement of [3H]U-69593 from human kappa opioid receptors expressed in CHO cell membrane,CHEMBL1144610,KI,O=C(NCc1ccccc1)Oc1ccc2c(c1)C13CCCCC1C(C2)N(CC1CC1)CC3
CHEMBL397035,CHEMBL237,Kappa opioid receptor,Ki,=,0.046,nM,CHEMBL887389,B,Displacement of [3H]U-69593 from human kappa opioid receptors expressed in CHO cell membrane,CHEMBL1144610,KI,O=C(Nc1ccccc1)Oc1ccc2c(c1)C13CCCCC1C(C2)N(CC1CC1)CC3
CHEMBL427862,CHEMBL237,Kappa opioid receptor,Ki,=,0.14,nM,CHEMBL887389,B,Displacement of [3H]U-69593 from human kappa opioid receptors expressed in CHO cell membrane,CHEMBL1144610,KI,CCNC(=O)Oc1ccc2c(c1)C13CCCCC1C(C2)N(CC1CC1)CC3
CHEMBL241824,CHEMBL237,Kappa opioid receptor,Ki,=,3.4,nM,CHEMBL887389,B,Displacement of [3H]U-69593 from human kappa opioid receptors expressed in CHO cell membrane,CHEMBL1144610,KI,CNC(=O)Oc1ccc2c(c1)C13CCCCC1C(C2)N(CC1CC1)CC3
CHEMBL49269,CHEMBL237,Kappa opioid receptor,Ki,=,0.034,nM,CHEMBL887389,B,Displacement of [3H]U-69593 from human kappa opioid receptors expressed in CHO cell membrane,CHEMBL1144610,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL241823,CHEMBL237,Kappa opioid receptor,Ki,=,36.0,nM,CHEMBL887389,B,Displacement of [3H]U-69593 from human kappa opioid receptors expressed in CHO cell membrane,CHEMBL1144610,KI,CCNC(=O)Oc1ccc2c(c1)C13CCCCC1C(C2)N(C)CC3
CHEMBL245049,CHEMBL237,Kappa opioid receptor,Ki,=,3.3,nM,CHEMBL887389,B,Displacement of [3H]U-69593 from human kappa opioid receptors expressed in CHO cell membrane,CHEMBL1144610,KI,CNC(=O)Oc1ccc2c(c1)C13CCCCC1C(C2)N(C)CC3
CHEMBL230249,CHEMBL237,Kappa opioid receptor,Ki,=,4149.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,CC(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL388123,CHEMBL237,Kappa opioid receptor,Ki,=,802.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,Cc1ccccc1C(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL229018,CHEMBL237,Kappa opioid receptor,Ki,=,13390.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,c1ccc(COC2(c3ccccc3)CCN(C(c3ccccc3)c3ccccc3)CC2)cc1
CHEMBL229017,CHEMBL237,Kappa opioid receptor,Ki,=,1484.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,CCCOC1(c2ccccc2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL229016,CHEMBL237,Kappa opioid receptor,Ki,=,488.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,CCOC1(c2ccccc2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL228965,CHEMBL237,Kappa opioid receptor,Ki,=,343.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,COC1(c2ccccc2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL388122,CHEMBL237,Kappa opioid receptor,Ki,=,2878.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,COc1ccc(C(c2ccc(OC)cc2)N2CCC(O)(c3ccccc3)CC2)cc1
CHEMBL228964,CHEMBL237,Kappa opioid receptor,Ki,=,306.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,COc1ccccc1C(c1ccccc1OC)N1CCC(O)(c2ccccc2)CC1
CHEMBL228913,CHEMBL237,Kappa opioid receptor,Ki,=,123.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccc(F)cc2)c2ccc(F)cc2)CC1
CHEMBL228912,CHEMBL237,Kappa opioid receptor,Ki,=,1172.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccccc2F)c2ccccc2F)CC1
CHEMBL228911,CHEMBL237,Kappa opioid receptor,Ki,=,635.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccccc2Cl)c2ccccc2Cl)CC1
CHEMBL389665,CHEMBL237,Kappa opioid receptor,Ki,=,1712.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,Cc1ccccc1C(c1ccccc1C)N1CCC(O)(c2ccccc2)CC1
CHEMBL437742,CHEMBL237,Kappa opioid receptor,Ki,=,8057.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,O=C(O)c1ccccc1C(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL228858,CHEMBL237,Kappa opioid receptor,Ki,=,1174.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OCc1ccccc1C(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL228857,CHEMBL237,Kappa opioid receptor,Ki,=,519.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,COc1ccccc1C(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL228856,CHEMBL237,Kappa opioid receptor,Ki,=,2443.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccccc2)c2ccc(Br)cc2)CC1
CHEMBL388314,CHEMBL237,Kappa opioid receptor,Ki,=,1144.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccccc2)c2ccccc2Br)CC1
CHEMBL228802,CHEMBL237,Kappa opioid receptor,Ki,=,1479.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccccc2)c2ccccc2F)CC1
CHEMBL228850,CHEMBL237,Kappa opioid receptor,Ki,=,164.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1
CHEMBL390498,CHEMBL237,Kappa opioid receptor,Ki,=,1971.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccccc2)c2cccc(Cl)c2)CC1
CHEMBL228849,CHEMBL237,Kappa opioid receptor,Ki,=,1136.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccccc2)c2ccccc2Cl)CC1
CHEMBL228848,CHEMBL237,Kappa opioid receptor,Ki,=,535.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,CCc1ccccc1C(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL228795,CHEMBL237,Kappa opioid receptor,Ki,=,4294.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccccc2)c2ccc(C(F)(F)F)cc2)CC1
CHEMBL390280,CHEMBL237,Kappa opioid receptor,Ki,=,6621.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccccc2)c2cccc(C(F)(F)F)c2)CC1
CHEMBL228794,CHEMBL237,Kappa opioid receptor,Ki,=,1362.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccccc2)c2ccccc2C(F)(F)F)CC1
CHEMBL228793,CHEMBL237,Kappa opioid receptor,Ki,=,2687.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,Cc1ccc(C(c2ccccc2)N2CCC(O)(c3ccccc3)CC2)cc1
CHEMBL390279,CHEMBL237,Kappa opioid receptor,Ki,=,1095.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,Cc1cccc(C(c2ccccc2)N2CCC(O)(c3ccccc3)CC2)c1
CHEMBL541636,CHEMBL237,Kappa opioid receptor,Ki,=,1205.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,Br.Cc1ccccc1C(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL535844,CHEMBL237,Kappa opioid receptor,Ki,=,295.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,Cc1ccccc1C(c1ccccc1)N1CCC(O)(c2ccccc2)CC1.Cl
CHEMBL228740,CHEMBL237,Kappa opioid receptor,Ki,=,971.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccccc2)c2cccs2)CC1
CHEMBL374603,CHEMBL237,Kappa opioid receptor,Ki,=,2993.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccccc2)c2cccnc2)CC1
CHEMBL374602,CHEMBL237,Kappa opioid receptor,Ki,=,5935.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccccc2)c2ccccn2)CC1
CHEMBL228690,CHEMBL237,Kappa opioid receptor,Ki,=,364.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL228738,CHEMBL237,Kappa opioid receptor,Ki,=,4381.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,O=C(Nc1c(F)cccc1F)C(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL228736,CHEMBL237,Kappa opioid receptor,Ki,=,6753.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,COC(=O)C(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL228687,CHEMBL237,Kappa opioid receptor,Ki,=,1028.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,CCOCC(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL228686,CHEMBL237,Kappa opioid receptor,Ki,=,1771.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,COCC(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL397945,CHEMBL237,Kappa opioid receptor,Ki,=,288.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(Cc2ccccc2)c2ccccc2)CC1
CHEMBL231608,CHEMBL237,Kappa opioid receptor,Ki,=,312.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,OC1(c2ccccc2)CCN(C(c2ccccc2)C2CCCC2)CC1
CHEMBL231607,CHEMBL237,Kappa opioid receptor,Ki,=,335.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,CCCCCCC(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL413791,CHEMBL237,Kappa opioid receptor,Ki,=,185.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,CC(C)CCC(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL230253,CHEMBL237,Kappa opioid receptor,Ki,=,220.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,CCCCCC(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL390882,CHEMBL237,Kappa opioid receptor,Ki,=,36.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,CCCCC(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL230145,CHEMBL237,Kappa opioid receptor,Ki,=,245.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,CCCC(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL433814,CHEMBL237,Kappa opioid receptor,Ki,=,1427.0,nM,CHEMBL888954,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membranes,CHEMBL1144652,KI,CCC(c1ccccc1)N1CCC(O)(c2ccccc2)CC1
CHEMBL2113281,CHEMBL237,Kappa opioid receptor,Ki,=,153.0,nM,CHEMBL887340,B,Displacement of [3H]diprenorphine from kappa opioid receptor expressed in human HEK293 cells,CHEMBL1145404,KI,O=Cc1cc2ccc(C(=O)Nc3cccc4c5c([nH]c34)[C@@H]3Oc4c(O)ccc6c4[C@@]34CCN(CC3CC3)[C@H](C6)[C@]4(O)C5)cc2cc1C=O
CHEMBL424698,CHEMBL237,Kappa opioid receptor,Ki,=,280.0,nM,CHEMBL890203,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1145447,KI,COC(=O)[C@@H]1C[C@H](O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL226785,CHEMBL237,Kappa opioid receptor,Ki,=,125.0,nM,CHEMBL890203,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1145447,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H]([C@@H]3C[C@@H](OC)O[C@H]3OC)C[C@]21C
CHEMBL226784,CHEMBL237,Kappa opioid receptor,Ki,=,25.0,nM,CHEMBL890203,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1145447,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H]([C@@H]3C[C@@H](OC)O[C@@H]3OC)C[C@]21C
CHEMBL434746,CHEMBL237,Kappa opioid receptor,Ki,=,180.0,nM,CHEMBL890203,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1145447,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C3=C[C@@H](OC)O[C@H]3OC)C[C@]21C
CHEMBL226732,CHEMBL237,Kappa opioid receptor,Ki,=,420.0,nM,CHEMBL890203,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1145447,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C3=C[C@@H](OC)O[C@@H]3OC)C[C@]21C
CHEMBL226731,CHEMBL237,Kappa opioid receptor,Ki,=,990.0,nM,CHEMBL890203,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1145447,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@@H]2[C@@]3(C)C[C@@H](c4nc(C)no4)OC(=O)[C@H]3CC[C@]21C
CHEMBL210564,CHEMBL237,Kappa opioid receptor,Ki,=,56.0,nM,CHEMBL890203,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1145447,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3nc(C)no3)C[C@]21C
CHEMBL387772,CHEMBL237,Kappa opioid receptor,Ki,=,300.0,nM,CHEMBL890203,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1145447,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C3=NCCO3)C[C@]21C
CHEMBL226730,CHEMBL237,Kappa opioid receptor,Ki,=,3400.0,nM,CHEMBL890203,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1145447,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)OCC[C@]21C
CHEMBL226677,CHEMBL237,Kappa opioid receptor,Ki,=,910.0,nM,CHEMBL890203,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1145447,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@@H]2[C@@](C)(CCC3CCOC3)[C@H](C(=O)O)CC[C@]21C
CHEMBL427280,CHEMBL237,Kappa opioid receptor,Ki,=,3.7,nM,CHEMBL890203,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1145447,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H]([C@@H]3CCOC3)C[C@]21C
CHEMBL364058,CHEMBL237,Kappa opioid receptor,Ki,=,14.0,nM,CHEMBL890203,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1145447,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C3CCOC3)C[C@]21C
CHEMBL2113278,CHEMBL237,Kappa opioid receptor,Ki,=,40.0,nM,CHEMBL890203,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1145447,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C3CC(OC)OC3OC)C[C@]21C
CHEMBL387557,CHEMBL237,Kappa opioid receptor,Ki,=,440.0,nM,CHEMBL890203,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1145447,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C3=CC(OC)OC3OC)C[C@]21C
CHEMBL390935,CHEMBL237,Kappa opioid receptor,Ki,=,3.0,nM,CHEMBL890203,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1145447,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3Br)C[C@]21C
CHEMBL2113369,CHEMBL237,Kappa opioid receptor,Ki,=,7020.0,nM,CHEMBL890203,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1145447,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@@H]2[C@@]3(C)C[C@@H]([C@]4(O)[C@@H](OC)O[C@@H](OC)[C@H]4O)CC(=O)[C@@H]3CC[C@]21C
CHEMBL560302,CHEMBL237,Kappa opioid receptor,Ki,=,390.0,nM,CHEMBL890203,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1145447,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H]([C@]3(O)[C@H](OC)O[C@H](OC)[C@H]3O)C[C@]21C
CHEMBL2113282,CHEMBL237,Kappa opioid receptor,Ki,=,3830.0,nM,CHEMBL895005,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1148706,KI,O=C1[C@@H]2CCC[C@@]1(c1cccc(O)c1)CCN2CCc1ccccc1
CHEMBL334898,CHEMBL237,Kappa opioid receptor,Ki,=,14.5,nM,CHEMBL895005,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1148706,KI,C[C@H]1C2CCCC1(c1cccc(O)c1)CCN2CCc1ccccc1
CHEMBL397276,CHEMBL237,Kappa opioid receptor,Ki,=,4.0,nM,CHEMBL895005,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1148706,KI,C[C@H]1[C@H]2CCC[C@]1(c1cccc(O)c1)CCN2CCc1ccccc1
CHEMBL414889,CHEMBL237,Kappa opioid receptor,Ki,=,15.0,nM,CHEMBL895005,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1148706,KI,C[C@@H]1[C@@H]2CCC[C@@]1(c1cccc(O)c1)CCN2CCc1ccccc1
CHEMBL242226,CHEMBL237,Kappa opioid receptor,Ki,=,0.65,nM,CHEMBL895005,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1148706,KI,C=C1[C@H]2CCC[C@@]1(c1cccc(O)c1)CCN2CCc1ccccc1
CHEMBL437949,CHEMBL237,Kappa opioid receptor,Ki,=,18.0,nM,CHEMBL895005,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1148706,KI,C=C1[C@@H]2CCC[C@]1(c1cccc(O)c1)CCN2CCc1ccccc1
CHEMBL243301,CHEMBL237,Kappa opioid receptor,Ki,=,235.0,nM,CHEMBL895005,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1148706,KI,Oc1cccc([C@@]23CCC[C@@H]([C@@H]2O)N(CCc2ccccc2)CC3)c1
CHEMBL388873,CHEMBL237,Kappa opioid receptor,Ki,=,184.0,nM,CHEMBL895005,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1148706,KI,Oc1cccc([C@]23CCC[C@H]([C@H]2O)N(CCc2ccccc2)CC3)c1
CHEMBL243300,CHEMBL237,Kappa opioid receptor,Ki,=,245.0,nM,CHEMBL895005,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1148706,KI,Oc1cccc([C@]23CCC[C@H]([C@@H]2O)N(CCc2ccccc2)CC3)c1
CHEMBL243092,CHEMBL237,Kappa opioid receptor,Ki,=,690.0,nM,CHEMBL895005,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1148706,KI,Oc1cccc([C@@]23CCC[C@@H]([C@H]2O)N(CCc2ccccc2)CC3)c1
CHEMBL243091,CHEMBL237,Kappa opioid receptor,Ki,=,150.0,nM,CHEMBL895005,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1148706,KI,O=C1[C@H]2CCC[C@]1(c1cccc(O)c1)CCN2CCc1ccccc1
CHEMBL2113294,CHEMBL237,Kappa opioid receptor,Ki,=,23.7,nM,CHEMBL896953,B,Displacement of [3H]U-69593 from human cloned kappa opioid receptor,CHEMBL1148829,KI,COc1ccc2c3c1O[C@H]1[C@]4(OC)CC[C@@]5(C[C@@H]4CNC(=O)/C=C/c4ccccc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL70,CHEMBL237,Kappa opioid receptor,Ki,=,46.9,nM,CHEMBL896953,B,Displacement of [3H]U-69593 from human cloned kappa opioid receptor,CHEMBL1148829,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL19019,CHEMBL237,Kappa opioid receptor,Ki,=,0.4,nM,CHEMBL896953,B,Displacement of [3H]U-69593 from human cloned kappa opioid receptor,CHEMBL1148829,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL511142,CHEMBL237,Kappa opioid receptor,Ki,=,0.8,nM,CHEMBL896953,B,Displacement of [3H]U-69593 from human cloned kappa opioid receptor,CHEMBL1148829,KI,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2113666,CHEMBL237,Kappa opioid receptor,Ki,=,0.54,nM,CHEMBL896953,B,Displacement of [3H]U-69593 from human cloned kappa opioid receptor,CHEMBL1148829,KI,CN1CC[C@]23c4c5cccc4O[C@H]2C(=O)CC[C@@]3(NC(=O)/C=C/c2ccccc2Cl)[C@H]1C5
CHEMBL2113314,CHEMBL237,Kappa opioid receptor,Ki,=,1.41,nM,CHEMBL896953,B,Displacement of [3H]U-69593 from human cloned kappa opioid receptor,CHEMBL1148829,KI,CO[C@@]12C=C[C@@]3([C@@H]4CN(C(=O)/C=C/c5ccc(C)cc5)C[C@@H]41)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL2113313,CHEMBL237,Kappa opioid receptor,Ki,=,0.52,nM,CHEMBL896953,B,Displacement of [3H]U-69593 from human cloned kappa opioid receptor,CHEMBL1148829,KI,CO[C@@]12C=C[C@@]3([C@@H]4CN(C(=O)/C=C/c5ccccc5C)C[C@@H]41)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL2113312,CHEMBL237,Kappa opioid receptor,Ki,=,9.95,nM,CHEMBL896953,B,Displacement of [3H]U-69593 from human cloned kappa opioid receptor,CHEMBL1148829,KI,CO[C@@]12CC[C@@]3(C[C@@H]1CNC/C=C/c1ccc(Cl)cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL2113311,CHEMBL237,Kappa opioid receptor,Ki,=,6.6,nM,CHEMBL896953,B,Displacement of [3H]U-69593 from human cloned kappa opioid receptor,CHEMBL1148829,KI,CO[C@@]12CC[C@@]3(C[C@@H]1CNC/C=C/c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL2113310,CHEMBL237,Kappa opioid receptor,Ki,=,67.9,nM,CHEMBL896953,B,Displacement of [3H]U-69593 from human cloned kappa opioid receptor,CHEMBL1148829,KI,COc1ccc2c3c1O[C@H]1[C@]4(OC)CC[C@@]5(C[C@@H]4CNC/C=C/c4ccc(Cl)cc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL2113309,CHEMBL237,Kappa opioid receptor,Ki,=,26.4,nM,CHEMBL896953,B,Displacement of [3H]U-69593 from human cloned kappa opioid receptor,CHEMBL1148829,KI,COc1ccc2c3c1O[C@H]1[C@]4(OC)CC[C@@]5(C[C@@H]4CNC/C=C/c4ccccc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL2113308,CHEMBL237,Kappa opioid receptor,Ki,=,1.72,nM,CHEMBL896953,B,Displacement of [3H]U-69593 from human cloned kappa opioid receptor,CHEMBL1148829,KI,CO[C@@]12CC[C@@]3(C[C@@H]1CNC(=O)/C=C/c1ccc([N+](=O)[O-])cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL2113307,CHEMBL237,Kappa opioid receptor,Ki,=,1.85,nM,CHEMBL896953,B,Displacement of [3H]U-69593 from human cloned kappa opioid receptor,CHEMBL1148829,KI,CO[C@@]12CC[C@@]3(C[C@@H]1CNC(=O)/C=C/c1ccc(Cl)cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL2113306,CHEMBL237,Kappa opioid receptor,Ki,=,3.11,nM,CHEMBL896953,B,Displacement of [3H]U-69593 from human cloned kappa opioid receptor,CHEMBL1148829,KI,CO[C@@]12CC[C@@]3(C[C@@H]1CNC(=O)/C=C/c1ccc(C)cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL2113305,CHEMBL237,Kappa opioid receptor,Ki,=,1.64,nM,CHEMBL896953,B,Displacement of [3H]U-69593 from human cloned kappa opioid receptor,CHEMBL1148829,KI,CO[C@@]12CC[C@@]3(C[C@@H]1CNC(=O)/C=C/c1ccccc1Cl)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL2113304,CHEMBL237,Kappa opioid receptor,Ki,=,1.82,nM,CHEMBL896953,B,Displacement of [3H]U-69593 from human cloned kappa opioid receptor,CHEMBL1148829,KI,CO[C@@]12CC[C@@]3(C[C@@H]1CNC(=O)/C=C/c1ccccc1C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL2113303,CHEMBL237,Kappa opioid receptor,Ki,=,5.3,nM,CHEMBL896953,B,Displacement of [3H]U-69593 from human cloned kappa opioid receptor,CHEMBL1148829,KI,CO[C@@]12CC[C@@]3(C[C@@H]1CNC(=O)/C=C/c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL2113302,CHEMBL237,Kappa opioid receptor,Ki,=,109.0,nM,CHEMBL896953,B,Displacement of [3H]U-69593 from human cloned kappa opioid receptor,CHEMBL1148829,KI,COc1ccc(/C=C/C(=O)NC[C@H]2C[C@@]34CC[C@@]2(OC)[C@@H]2Oc5c(OC)ccc6c5[C@@]23CCN(C)[C@@H]4C6)cc1
CHEMBL2113301,CHEMBL237,Kappa opioid receptor,Ki,=,44.7,nM,CHEMBL896953,B,Displacement of [3H]U-69593 from human cloned kappa opioid receptor,CHEMBL1148829,KI,COc1ccccc1/C=C/C(=O)NC[C@H]1C[C@@]23CC[C@@]1(OC)[C@@H]1Oc4c(OC)ccc5c4[C@@]12CCN(C)[C@@H]3C5
CHEMBL2113300,CHEMBL237,Kappa opioid receptor,Ki,=,29.8,nM,CHEMBL896953,B,Displacement of [3H]U-69593 from human cloned kappa opioid receptor,CHEMBL1148829,KI,COc1ccc2c3c1O[C@H]1[C@]4(OC)CC[C@@]5(C[C@@H]4CNC(=O)/C=C/c4ccccc4[N+](=O)[O-])[C@@H](C2)N(C)CC[C@]315
CHEMBL2113299,CHEMBL237,Kappa opioid receptor,Ki,=,58.0,nM,CHEMBL896953,B,Displacement of [3H]U-69593 from human cloned kappa opioid receptor,CHEMBL1148829,KI,COc1ccc2c3c1O[C@H]1[C@]4(OC)CC[C@@]5(C[C@@H]4CNC(=O)/C=C/c4ccc([N+](=O)[O-])cc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL2113298,CHEMBL237,Kappa opioid receptor,Ki,=,155.0,nM,CHEMBL896953,B,Displacement of [3H]U-69593 from human cloned kappa opioid receptor,CHEMBL1148829,KI,COc1ccc2c3c1O[C@H]1[C@]4(OC)CC[C@@]5(C[C@@H]4CNC(=O)/C=C/c4ccc(Cl)cc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL2113297,CHEMBL237,Kappa opioid receptor,Ki,=,159.0,nM,CHEMBL896953,B,Displacement of [3H]U-69593 from human cloned kappa opioid receptor,CHEMBL1148829,KI,COc1ccc2c3c1O[C@H]1[C@]4(OC)CC[C@@]5(C[C@@H]4CNC(=O)/C=C/c4ccc(C)cc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL2113296,CHEMBL237,Kappa opioid receptor,Ki,=,22.2,nM,CHEMBL896953,B,Displacement of [3H]U-69593 from human cloned kappa opioid receptor,CHEMBL1148829,KI,COc1ccc2c3c1O[C@H]1[C@]4(OC)CC[C@@]5(C[C@@H]4CNC(=O)/C=C/c4ccccc4Cl)[C@@H](C2)N(C)CC[C@]315
CHEMBL2113295,CHEMBL237,Kappa opioid receptor,Ki,=,21.0,nM,CHEMBL896953,B,Displacement of [3H]U-69593 from human cloned kappa opioid receptor,CHEMBL1148829,KI,COc1ccc2c3c1O[C@H]1[C@]4(OC)CC[C@@]5(C[C@@H]4CNC(=O)/C=C/c4ccccc4C)[C@@H](C2)N(C)CC[C@]315
CHEMBL49269,CHEMBL237,Kappa opioid receptor,Ki,=,0.034,nM,CHEMBL893243,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO membrane",CHEMBL1147995,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL243195,CHEMBL237,Kappa opioid receptor,Ki,=,20.0,nM,CHEMBL893243,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO membrane",CHEMBL1147995,KI,CNC(=O)Nc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL428038,CHEMBL237,Kappa opioid receptor,Ki,=,2.3,nM,CHEMBL893243,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO membrane",CHEMBL1147995,KI,CNC(=O)Nc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL394573,CHEMBL237,Kappa opioid receptor,Ki,=,8.9,nM,CHEMBL893243,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO membrane",CHEMBL1147995,KI,NC(=O)Nc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL242968,CHEMBL237,Kappa opioid receptor,Ki,=,0.61,nM,CHEMBL893243,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO membrane",CHEMBL1147995,KI,NC(=O)Nc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL390912,CHEMBL237,Kappa opioid receptor,Ki,=,1.9,nM,CHEMBL893243,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO membrane",CHEMBL1147995,KI,O=c1[nH]c2cc3c(cc2o1)[C@@]12CCCC[C@H]1[C@@H](C3)N(CC1CCC1)CC2
CHEMBL242967,CHEMBL237,Kappa opioid receptor,Ki,=,47.0,nM,CHEMBL893243,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO membrane",CHEMBL1147995,KI,O=c1[nH]c2cc3c(cc2o1)[C@@]12CCCC[C@H]1[C@@H](C3)N(CC1CC1)CC2
CHEMBL242757,CHEMBL237,Kappa opioid receptor,Ki,=,6.6,nM,CHEMBL893243,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO membrane",CHEMBL1147995,KI,Nc1nc2cc3c(cc2o1)[C@@]12CCCC[C@H]1[C@@H](C3)N(CC1CCC1)CC2
CHEMBL390911,CHEMBL237,Kappa opioid receptor,Ki,=,52.0,nM,CHEMBL893243,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO membrane",CHEMBL1147995,KI,Nc1nc2cc3c(cc2o1)[C@@]12CCCC[C@H]1[C@@H](C3)N(CC1CC1)CC2
CHEMBL390866,CHEMBL237,Kappa opioid receptor,Ki,=,0.79,nM,CHEMBL893243,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO membrane",CHEMBL1147995,KI,Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CCC1
CHEMBL242756,CHEMBL237,Kappa opioid receptor,Ki,=,0.049,nM,CHEMBL893243,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO membrane",CHEMBL1147995,KI,Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1
CHEMBL49143,CHEMBL237,Kappa opioid receptor,Ki,=,1.8,nM,CHEMBL893243,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO membrane",CHEMBL1147995,KI,Nc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL299220,CHEMBL237,Kappa opioid receptor,Ki,=,0.18,nM,CHEMBL893243,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO membrane",CHEMBL1147995,KI,Nc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL301160,CHEMBL237,Kappa opioid receptor,Ki,=,0.079,nM,CHEMBL893243,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO membrane",CHEMBL1147995,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL228690,CHEMBL237,Kappa opioid receptor,Ki,=,364.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,OC1(c2ccccc2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL232286,CHEMBL237,Kappa opioid receptor,Ki,=,186.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CC(C)S(=O)(=O)N1CCN(Cc2ccccc2C2(O)CCN(C(c3ccccc3Cl)c3ccccc3Cl)CC2)CC1
CHEMBL232285,CHEMBL237,Kappa opioid receptor,Ki,=,146.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CCS(=O)(=O)N1CCN(Cc2ccccc2C2(O)CCN(C(c3ccccc3Cl)c3ccccc3Cl)CC2)CC1
CHEMBL232076,CHEMBL237,Kappa opioid receptor,Ki,=,139.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CN1CCN(Cc2ccccc2C2(O)CCN(C(c3ccccc3Cl)c3ccccc3Cl)CC2)CC1
CHEMBL232075,CHEMBL237,Kappa opioid receptor,Ki,=,261.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,OC1(c2ccccc2CN2CCNCC2)CCN(C(c2ccccc2Cl)c2ccccc2Cl)CC1
CHEMBL394222,CHEMBL237,Kappa opioid receptor,Ki,=,323.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,OC1(c2ccccc2CN2CCOCC2)CCN(C(c2ccccc2Cl)c2ccccc2Cl)CC1
CHEMBL232074,CHEMBL237,Kappa opioid receptor,Ki,=,330.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CCNC(=O)NCc1ccccc1C1(O)CCN(C(c2ccccc2Cl)c2ccccc2Cl)CC1
CHEMBL231866,CHEMBL237,Kappa opioid receptor,Ki,=,215.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CNC(=O)NCc1ccccc1C1(O)CCN(C(c2ccccc2Cl)c2ccccc2Cl)CC1
CHEMBL437177,CHEMBL237,Kappa opioid receptor,Ki,=,174.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CC(C)S(=O)(=O)NCc1ccccc1C1(O)CCN(C(c2ccccc2Cl)c2ccccc2Cl)CC1
CHEMBL232478,CHEMBL237,Kappa opioid receptor,Ki,=,122.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CCCS(=O)(=O)NCc1ccccc1C1(O)CCN(C(c2ccccc2Cl)c2ccccc2Cl)CC1
CHEMBL232477,CHEMBL237,Kappa opioid receptor,Ki,=,255.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CNCc1ccccc1C1(O)CCN(C(c2ccccc2Cl)c2ccccc2Cl)CC1
CHEMBL233957,CHEMBL237,Kappa opioid receptor,Ki,=,1354.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CC1(C)CCC(N2CCC(O)(c3ccccc3CN)CC2)c2ccccc21
CHEMBL233535,CHEMBL237,Kappa opioid receptor,Ki,=,664.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,NCc1ccccc1C1(O)CCN(CC2CCCCCC2)CC1
CHEMBL233956,CHEMBL237,Kappa opioid receptor,Ki,=,278.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,NCc1ccccc1C1(O)CCN(C(c2ccccc2Br)c2ccccc2Br)CC1
CHEMBL400036,CHEMBL237,Kappa opioid receptor,Ki,=,771.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,NCc1ccccc1C1(O)CCN(C(c2cccc(F)c2)c2cccc(F)c2)CC1
CHEMBL233955,CHEMBL237,Kappa opioid receptor,Ki,=,116.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,NCc1ccccc1C1(O)CCN(C(c2ccccc2F)c2ccccc2F)CC1
CHEMBL233750,CHEMBL237,Kappa opioid receptor,Ki,=,747.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,NCc1ccccc1C1(O)CCN(C(c2ccccc2Cl)c2ccccc2Cl)CC1
CHEMBL233749,CHEMBL237,Kappa opioid receptor,Ki,=,2092.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,NCc1ccccc1C1(O)CCN(C(c2ccc(Cl)cc2)c2ccc(Cl)cc2)CC1
CHEMBL233748,CHEMBL237,Kappa opioid receptor,Ki,=,1056.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,Cc1ccc(C(c2ccc(C)cc2)N2CCC(O)(c3ccccc3CN)CC2)cc1
CHEMBL400035,CHEMBL237,Kappa opioid receptor,Ki,=,450.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,Cc1ccccc1C(c1ccccc1C)N1CCC(O)(c2ccccc2CN)CC1
CHEMBL233536,CHEMBL237,Kappa opioid receptor,Ki,=,279.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,NCc1ccccc1C1(O)CCN(C(c2ccccc2)c2ccccc2Br)CC1
CHEMBL398794,CHEMBL237,Kappa opioid receptor,Ki,=,425.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,NCc1ccccc1C1(O)CCN(C(c2ccccc2)c2ccccc2Cl)CC1
CHEMBL233327,CHEMBL237,Kappa opioid receptor,Ki,=,725.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,Cc1ccccc1C(c1ccccc1)N1CCC(O)(c2ccccc2CN)CC1
CHEMBL233503,CHEMBL237,Kappa opioid receptor,Ki,=,1658.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,NCc1ccccc1C1(O)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL441914,CHEMBL237,Kappa opioid receptor,Ki,=,30.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CCCCCC(c1ccccc1)N1CCC(O)(c2ccccc2CN)CC1
CHEMBL233326,CHEMBL237,Kappa opioid receptor,Ki,=,15.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CCCCC(c1ccccc1)N1CCC(O)(c2ccccc2CN)CC1
CHEMBL393971,CHEMBL237,Kappa opioid receptor,Ki,=,13180.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,OC1(c2ccccn2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL393356,CHEMBL237,Kappa opioid receptor,Ki,=,2574.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,Cc1ccsc1C1(O)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL233323,CHEMBL237,Kappa opioid receptor,Ki,=,3412.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,OC1(c2cccs2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL231874,CHEMBL237,Kappa opioid receptor,Ki,=,9644.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,OC1(c2ccco2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL231664,CHEMBL237,Kappa opioid receptor,Ki,=,1801.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,OC1(CCCc2ccccc2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL231661,CHEMBL237,Kappa opioid receptor,Ki,=,1438.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,OC1(Cc2ccccc2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL394695,CHEMBL237,Kappa opioid receptor,Ki,=,387.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,OC1(C2CCCCC2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL234773,CHEMBL237,Kappa opioid receptor,Ki,=,9221.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CCCCCCC1(O)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL234771,CHEMBL237,Kappa opioid receptor,Ki,=,1073.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CC(C)(C)C1(O)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL397761,CHEMBL237,Kappa opioid receptor,Ki,=,4563.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CCCCC1(O)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL233721,CHEMBL237,Kappa opioid receptor,Ki,=,7390.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CC(C)C1(O)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL398039,CHEMBL237,Kappa opioid receptor,Ki,=,26405.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,OC1(C2CC2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL233503,CHEMBL237,Kappa opioid receptor,Ki,=,1658.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,NCc1ccccc1C1(O)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL233502,CHEMBL237,Kappa opioid receptor,Ki,=,2769.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,OCc1ccccc1C1(O)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL233501,CHEMBL237,Kappa opioid receptor,Ki,=,61045.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,N#Cc1ccc(C2(O)CCN(C(c3ccccc3)c3ccccc3)CC2)cc1
CHEMBL401234,CHEMBL237,Kappa opioid receptor,Ki,=,10298.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,COc1ccc(C2(O)CCN(C(c3ccccc3)c3ccccc3)CC2)cc1
CHEMBL233494,CHEMBL237,Kappa opioid receptor,Ki,=,3668.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,COc1cccc(C2(O)CCN(C(c3ccccc3)c3ccccc3)CC2)c1
CHEMBL233493,CHEMBL237,Kappa opioid receptor,Ki,=,4160.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,COc1ccccc1C1(O)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL393675,CHEMBL237,Kappa opioid receptor,Ki,=,19695.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CCCc1ccc(C2(O)CCN(C(c3ccccc3)c3ccccc3)CC2)cc1
CHEMBL234543,CHEMBL237,Kappa opioid receptor,Ki,=,11355.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,CCc1ccc(C2(O)CCN(C(c3ccccc3)c3ccccc3)CC2)cc1
CHEMBL393985,CHEMBL237,Kappa opioid receptor,Ki,=,4054.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,Cc1ccc(C2(O)CCN(C(c3ccccc3)c3ccccc3)CC2)cc1
CHEMBL437380,CHEMBL237,Kappa opioid receptor,Ki,=,1151.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,Cc1cccc(C2(O)CCN(C(c3ccccc3)c3ccccc3)CC2)c1
CHEMBL232273,CHEMBL237,Kappa opioid receptor,Ki,=,818.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,Cc1ccccc1C1(O)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL232067,CHEMBL237,Kappa opioid receptor,Ki,=,2612.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,OC1(c2ccc(Br)cc2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL392753,CHEMBL237,Kappa opioid receptor,Ki,=,1702.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,OC1(c2ccc(Cl)cc2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL232066,CHEMBL237,Kappa opioid receptor,Ki,=,759.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,OC1(c2ccc(F)cc2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL395838,CHEMBL237,Kappa opioid receptor,Ki,=,1994.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,OC1(c2cccc(F)c2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL232476,CHEMBL237,Kappa opioid receptor,Ki,=,1738.0,nM,CHEMBL892113,B,Displacement of [3H]diprenorphine from human KOP receptor expressed in CHO cell membrane,CHEMBL1147989,KI,OC1(c2ccccc2F)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL573214,CHEMBL237,Kappa opioid receptor,Ki,=,0.1259,nM,CHEMBL894814,B,Displacement of [3H]diprenorphine from human recombinant kappa opioid receptor expressed in in CHO cells,CHEMBL1148695,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL2372052,CHEMBL237,Kappa opioid receptor,Ki,=,28.18,nM,CHEMBL894814,B,Displacement of [3H]diprenorphine from human recombinant kappa opioid receptor expressed in in CHO cells,CHEMBL1148695,KI,C[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)C(C)(C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)CNC(=O)[C@H](CN)NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O
CHEMBL409969,CHEMBL237,Kappa opioid receptor,Ki,=,4.365,nM,CHEMBL894814,B,Displacement of [3H]diprenorphine from human recombinant kappa opioid receptor expressed in in CHO cells,CHEMBL1148695,KI,C[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)C(C)(C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O
CHEMBL269068,CHEMBL237,Kappa opioid receptor,Ki,=,676.08,nM,CHEMBL894814,B,Displacement of [3H]diprenorphine from human recombinant kappa opioid receptor expressed in in CHO cells,CHEMBL1148695,KI,C[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)C(C)(C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O
CHEMBL232383,CHEMBL237,Kappa opioid receptor,Ki,=,1008.0,nM,CHEMBL896481,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1149528,KI,CC(=O)N1CCC(c2ccccc2)(c2nccn2Cc2ccccc2)CC1
CHEMBL234389,CHEMBL237,Kappa opioid receptor,Ki,=,3116.0,nM,CHEMBL896481,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1149528,KI,CCOC(=O)N1CCC(c2ccccc2)(c2nccn2-c2ccc3ccccc3c2C)CC1
CHEMBL393965,CHEMBL237,Kappa opioid receptor,Ki,=,25.0,nM,CHEMBL896481,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1149528,KI,CCOC(=O)N1CCC(c2ccccc2)(c2nccn2Cc2ccc(C(=O)OC)cc2)CC1
CHEMBL391623,CHEMBL237,Kappa opioid receptor,Ki,=,108.0,nM,CHEMBL896481,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1149528,KI,CCOC(=O)N1CCC(c2ccccc2)(c2nccn2Cc2ccc(O)cc2)CC1
CHEMBL231781,CHEMBL237,Kappa opioid receptor,Ki,=,201.0,nM,CHEMBL896481,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1149528,KI,CCOC(=O)N1CCC(c2ccccc2)(c2nccn2Cc2ccc(OC)cc2)CC1
CHEMBL233570,CHEMBL237,Kappa opioid receptor,Ki,=,366.0,nM,CHEMBL896481,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1149528,KI,CCOC(=O)N1CCC(c2ccccc2)(c2nccn2Cc2cccc(OC)c2)CC1
CHEMBL391852,CHEMBL237,Kappa opioid receptor,Ki,=,62.0,nM,CHEMBL896481,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1149528,KI,CCOC(=O)N1CCC(c2ccccc2)(c2nccn2C(C)c2ccccc2)CC1
CHEMBL233368,CHEMBL237,Kappa opioid receptor,Ki,=,121.0,nM,CHEMBL896481,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1149528,KI,O=C(OCc1ccccc1)N1CCC(c2ccccc2)(c2nccn2Cc2ccccc2)CC1
CHEMBL392266,CHEMBL237,Kappa opioid receptor,Ki,=,84.0,nM,CHEMBL896481,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1149528,KI,CC(C)(C)OC(=O)N1CCC(c2ccccc2)(c2nccn2Cc2ccccc2)CC1
CHEMBL233143,CHEMBL237,Kappa opioid receptor,Ki,=,121.0,nM,CHEMBL896481,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1149528,KI,O=C(OC1CCCCC1)N1CCC(c2ccccc2)(c2nccn2Cc2ccccc2)CC1
CHEMBL400436,CHEMBL237,Kappa opioid receptor,Ki,=,201.0,nM,CHEMBL896481,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1149528,KI,CC(C)OC(=O)N1CCC(c2ccccc2)(c2nccn2Cc2ccccc2)CC1
CHEMBL232937,CHEMBL237,Kappa opioid receptor,Ki,=,188.0,nM,CHEMBL896481,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1149528,KI,CCCCOC(=O)N1CCC(c2ccccc2)(c2nccn2Cc2ccccc2)CC1
CHEMBL232740,CHEMBL237,Kappa opioid receptor,Ki,=,171.0,nM,CHEMBL896481,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1149528,KI,CCOC(=O)N1CCC(c2ccccc2)(c2nccn2Cc2ccccc2)CC1
CHEMBL232548,CHEMBL237,Kappa opioid receptor,Ki,=,88.0,nM,CHEMBL896481,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1149528,KI,COC(=O)c1ccc(Cn2ccnc2C2(c3ccccc3)CCN(C(=O)c3ccccc3)CC2)cc1
CHEMBL437397,CHEMBL237,Kappa opioid receptor,Ki,=,334.0,nM,CHEMBL896481,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1149528,KI,CC(c1ccccc1)n1ccnc1C1(c2ccccc2)CCN(C(=O)c2ccccc2)CC1
CHEMBL232137,CHEMBL237,Kappa opioid receptor,Ki,=,65.0,nM,CHEMBL896481,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1149528,KI,COCC(=O)N1CCC(c2ccccc2)(c2nccn2Cc2ccc(C(=O)OC)cc2)CC1
CHEMBL392478,CHEMBL237,Kappa opioid receptor,Ki,=,284.0,nM,CHEMBL896481,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1149528,KI,Cc1cc(C)cc(C(=O)N2CCC(c3ccccc3)(c3nccn3Cc3ccccc3)CC2)c1
CHEMBL232583,CHEMBL237,Kappa opioid receptor,Ki,=,124.0,nM,CHEMBL896481,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1149528,KI,O=C(c1ccccc1)N1CCC(c2ccccc2)(c2nccn2Cc2ccccc2)CC1
CHEMBL392477,CHEMBL237,Kappa opioid receptor,Ki,=,622.0,nM,CHEMBL896481,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1149528,KI,COCC(=O)N1CCC(c2ccccc2)(c2nccn2Cc2ccccc2)CC1
CHEMBL392476,CHEMBL237,Kappa opioid receptor,Ki,=,621.0,nM,CHEMBL896481,B,Displacement of [3H]U-69593 from cloned human kappa opioid receptor,CHEMBL1149528,KI,CC(C)C(=O)N1CCC(c2ccccc2)(c2nccn2Cc2ccccc2)CC1
CHEMBL401245,CHEMBL237,Kappa opioid receptor,Ki,=,26.0,nM,CHEMBL896541,B,Displacement of [3H]U-69593 from cloned kappa opioid receptor expressed in CHO cell membrane,CHEMBL1149641,KI,CO[C@]12C(O)C[C@@]3(C[C@@H]1[C@@H](C)O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL235239,CHEMBL237,Kappa opioid receptor,Ki,=,230.0,nM,CHEMBL896541,B,Displacement of [3H]U-69593 from cloned kappa opioid receptor expressed in CHO cell membrane,CHEMBL1149641,KI,CO[C@]12CC(O)[C@@]3(C[C@@H]1[C@@H](C)O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL392269,CHEMBL237,Kappa opioid receptor,Ki,=,170.0,nM,CHEMBL896541,B,Displacement of [3H]U-69593 from cloned kappa opioid receptor expressed in CHO cell membrane,CHEMBL1149641,KI,CO[C@]12CC(O)[C@@]3(C[C@@H]1[C@H](C)O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL238017,CHEMBL237,Kappa opioid receptor,Ki,=,64.0,nM,CHEMBL896541,B,Displacement of [3H]U-69593 from cloned kappa opioid receptor expressed in CHO cell membrane,CHEMBL1149641,KI,CO[C@]12C(O)C[C@@]3(C[C@@H]1[C@H](C)O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL238283,CHEMBL237,Kappa opioid receptor,Ki,=,2808.74,nM,CHEMBL899319,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells in presence of high sodium by SPA,CHEMBL1149707,KI,CCNC(=O)c1ccc(Oc2ccc(CNCCc3ccccc3)cc2)nc1
CHEMBL238361,CHEMBL237,Kappa opioid receptor,Ki,=,8.38,nM,CHEMBL899319,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells in presence of high sodium by SPA,CHEMBL1149707,KI,NC(=O)c1ccc(Oc2ccc(CNCCc3ccccc3)cc2)nc1
CHEMBL238280,CHEMBL237,Kappa opioid receptor,Ki,=,1147.5,nM,CHEMBL899319,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells in presence of high sodium by SPA,CHEMBL1149707,KI,N=C(N)c1ccc(Oc2ccc(CNCCc3ccccc3)cc2)nc1
CHEMBL237066,CHEMBL237,Kappa opioid receptor,Ki,=,136.26,nM,CHEMBL899319,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells in presence of high sodium by SPA,CHEMBL1149707,KI,NC(=O)c1ccc(Oc2ccc(CCNCc3ccccc3)cc2)nc1
CHEMBL238317,CHEMBL237,Kappa opioid receptor,Ki,=,15.04,nM,CHEMBL899319,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells in presence of high sodium by SPA,CHEMBL1149707,KI,NC(=O)c1ccc(Oc2ccc(CNCCc3ccccc3)cc2)cc1
CHEMBL19019,CHEMBL237,Kappa opioid receptor,Ki,=,5.28,nM,CHEMBL899319,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells in presence of high sodium by SPA,CHEMBL1149707,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL300662,CHEMBL237,Kappa opioid receptor,Ki,=,4.68,nM,CHEMBL899319,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells in presence of high sodium by SPA,CHEMBL1149707,KI,C[C@H]1CN(CC[C@H](O)C2CCCCC2)CC[C@@]1(C)c1cccc(O)c1
CHEMBL236376,CHEMBL237,Kappa opioid receptor,Ki,=,69.27,nM,CHEMBL899319,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells in presence of high sodium by SPA,CHEMBL1149707,KI,NC(=O)c1ccc(Oc2ccc(CNCCc3ccccc3)cc2)cn1
CHEMBL237066,CHEMBL237,Kappa opioid receptor,Ki,=,136.26,nM,CHEMBL901090,B,Displacement of [3H]diprenorphine from cloned human kappa opioid receptor expressed in CHO cells,CHEMBL1138307,KI,NC(=O)c1ccc(Oc2ccc(CCNCc3ccccc3)cc2)nc1
CHEMBL19019,CHEMBL237,Kappa opioid receptor,Ki,=,5.28,nM,CHEMBL901090,B,Displacement of [3H]diprenorphine from cloned human kappa opioid receptor expressed in CHO cells,CHEMBL1138307,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL300662,CHEMBL237,Kappa opioid receptor,Ki,=,4.68,nM,CHEMBL901090,B,Displacement of [3H]diprenorphine from cloned human kappa opioid receptor expressed in CHO cells,CHEMBL1138307,KI,C[C@H]1CN(CC[C@H](O)C2CCCCC2)CC[C@@]1(C)c1cccc(O)c1
CHEMBL238361,CHEMBL237,Kappa opioid receptor,Ki,=,8.38,nM,CHEMBL901090,B,Displacement of [3H]diprenorphine from cloned human kappa opioid receptor expressed in CHO cells,CHEMBL1138307,KI,NC(=O)c1ccc(Oc2ccc(CNCCc3ccccc3)cc2)nc1
CHEMBL238364,CHEMBL237,Kappa opioid receptor,Ki,=,3254.0,nM,CHEMBL901090,B,Displacement of [3H]diprenorphine from cloned human kappa opioid receptor expressed in CHO cells,CHEMBL1138307,KI,NC(=O)c1ccc(Oc2ccc3c(c2)CCCN(CCCN2CCOCC2)C3)nc1
CHEMBL238363,CHEMBL237,Kappa opioid receptor,Ki,=,359.89,nM,CHEMBL901090,B,Displacement of [3H]diprenorphine from cloned human kappa opioid receptor expressed in CHO cells,CHEMBL1138307,KI,NC(=O)c1ccc(Oc2ccc3c(c2)CCCN(CCN2CCOCC2)C3)nc1
CHEMBL238157,CHEMBL237,Kappa opioid receptor,Ki,=,703.78,nM,CHEMBL901090,B,Displacement of [3H]diprenorphine from cloned human kappa opioid receptor expressed in CHO cells,CHEMBL1138307,KI,NC(=O)c1ccc(Oc2ccc3c(c2)CCCN(CCCC2CCCCC2)C3)nc1
CHEMBL238156,CHEMBL237,Kappa opioid receptor,Ki,=,61.65,nM,CHEMBL901090,B,Displacement of [3H]diprenorphine from cloned human kappa opioid receptor expressed in CHO cells,CHEMBL1138307,KI,CCC(CC)CN1CCCc2cc(Oc3ccc(C(N)=O)cn3)ccc2C1
CHEMBL396637,CHEMBL237,Kappa opioid receptor,Ki,=,71.62,nM,CHEMBL901090,B,Displacement of [3H]diprenorphine from cloned human kappa opioid receptor expressed in CHO cells,CHEMBL1138307,KI,CC(C)(C)CCN1CCCc2cc(Oc3ccc(C(N)=O)cn3)ccc2C1
CHEMBL237934,CHEMBL237,Kappa opioid receptor,Ki,=,318.95,nM,CHEMBL901090,B,Displacement of [3H]diprenorphine from cloned human kappa opioid receptor expressed in CHO cells,CHEMBL1138307,KI,CC(C)CCCCN1CCCc2cc(Oc3ccc(C(N)=O)cn3)ccc2C1
CHEMBL396636,CHEMBL237,Kappa opioid receptor,Ki,=,105.95,nM,CHEMBL901090,B,Displacement of [3H]diprenorphine from cloned human kappa opioid receptor expressed in CHO cells,CHEMBL1138307,KI,CC(C)CCCN1CCCc2cc(Oc3ccc(C(N)=O)cn3)ccc2C1
CHEMBL237718,CHEMBL237,Kappa opioid receptor,Ki,=,78.09,nM,CHEMBL901090,B,Displacement of [3H]diprenorphine from cloned human kappa opioid receptor expressed in CHO cells,CHEMBL1138307,KI,CC(C)CCN1CCCc2cc(Oc3ccc(C(N)=O)cn3)ccc2C1
CHEMBL237716,CHEMBL237,Kappa opioid receptor,Ki,=,116.41,nM,CHEMBL901090,B,Displacement of [3H]diprenorphine from cloned human kappa opioid receptor expressed in CHO cells,CHEMBL1138307,KI,CCCCCCN1CCCc2cc(Oc3ccc(C(N)=O)cn3)ccc2C1
CHEMBL237506,CHEMBL237,Kappa opioid receptor,Ki,=,105.88,nM,CHEMBL901090,B,Displacement of [3H]diprenorphine from cloned human kappa opioid receptor expressed in CHO cells,CHEMBL1138307,KI,CCCCCN1CCCc2cc(Oc3ccc(C(N)=O)cn3)ccc2C1
CHEMBL237295,CHEMBL237,Kappa opioid receptor,Ki,=,187.97,nM,CHEMBL901090,B,Displacement of [3H]diprenorphine from cloned human kappa opioid receptor expressed in CHO cells,CHEMBL1138307,KI,NC(=O)c1ccc(Oc2ccc(CCN3CCc4ccccc4C3)cc2)nc1
CHEMBL237293,CHEMBL237,Kappa opioid receptor,Ki,=,2873.0,nM,CHEMBL901090,B,Displacement of [3H]diprenorphine from cloned human kappa opioid receptor expressed in CHO cells,CHEMBL1138307,KI,NC(=O)c1ccc(Oc2ccc3c(c2)CCN(Cc2ccccc2)CC3)nc1
CHEMBL237073,CHEMBL237,Kappa opioid receptor,Ki,=,360.6,nM,CHEMBL901090,B,Displacement of [3H]diprenorphine from cloned human kappa opioid receptor expressed in CHO cells,CHEMBL1138307,KI,NC(=O)c1ccc(Oc2ccc3c(c2)CCCN(CCc2ccccc2)C3)nc1
CHEMBL237072,CHEMBL237,Kappa opioid receptor,Ki,=,3606.0,nM,CHEMBL901090,B,Displacement of [3H]diprenorphine from cloned human kappa opioid receptor expressed in CHO cells,CHEMBL1138307,KI,NC(=O)c1ccc(Oc2ccc3c(c2)CN(CCc2ccccc2)CC3)nc1
CHEMBL398089,CHEMBL237,Kappa opioid receptor,Ki,=,2428.17,nM,CHEMBL901090,B,Displacement of [3H]diprenorphine from cloned human kappa opioid receptor expressed in CHO cells,CHEMBL1138307,KI,NC(=O)c1ccc(Oc2ccc3c(c2)CN(Cc2ccccc2)CC3)nc1
CHEMBL237071,CHEMBL237,Kappa opioid receptor,Ki,=,555.9,nM,CHEMBL901090,B,Displacement of [3H]diprenorphine from cloned human kappa opioid receptor expressed in CHO cells,CHEMBL1138307,KI,NC(=O)c1ccc(Oc2ccc3c(c2)CCN(CCCc2ccccc2)C3)nc1
CHEMBL397148,CHEMBL237,Kappa opioid receptor,Ki,=,1221.0,nM,CHEMBL901090,B,Displacement of [3H]diprenorphine from cloned human kappa opioid receptor expressed in CHO cells,CHEMBL1138307,KI,NC(=O)c1ccc(Oc2ccc3c(c2)CCN(CCc2ccccc2)C3)nc1
CHEMBL235155,CHEMBL237,Kappa opioid receptor,Ki,=,2150.0,nM,CHEMBL901090,B,Displacement of [3H]diprenorphine from cloned human kappa opioid receptor expressed in CHO cells,CHEMBL1138307,KI,NC(=O)c1ccc(Oc2ccc3c(c2)CCN(Cc2ccccc2)C3)nc1
CHEMBL203356,CHEMBL237,Kappa opioid receptor,Ki,=,196.0,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(Cc1ccccc1)CC2
CHEMBL393980,CHEMBL237,Kappa opioid receptor,Ki,=,938.0,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,CC1(C)CCC(N2CCC3(CC2)C(=O)NCN3c2ccccc2)c2cc(Cl)c(Cl)cc21
CHEMBL241087,CHEMBL237,Kappa opioid receptor,Ki,=,169.0,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,CC1(C)CCC(N2CCC3(CC2)C(=O)NCN3c2ccccc2)c2ccc(F)cc21
CHEMBL393807,CHEMBL237,Kappa opioid receptor,Ki,=,282.0,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,CC1(C)CCC(N2CCC3(CC2)C(=O)NCN3c2ccccc2)c2ccc(Cl)cc21
CHEMBL241086,CHEMBL237,Kappa opioid receptor,Ki,=,94.5,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCCc3c(Cl)cccc31)CC2
CHEMBL241085,CHEMBL237,Kappa opioid receptor,Ki,=,66.5,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCCc3ccc(Cl)cc31)CC2
CHEMBL393781,CHEMBL237,Kappa opioid receptor,Ki,=,143.0,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCCc3cccc(Cl)c31)CC2
CHEMBL240005,CHEMBL237,Kappa opioid receptor,Ki,=,13.7,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCCc3c(F)cccc31)CC2
CHEMBL239824,CHEMBL237,Kappa opioid receptor,Ki,=,33.5,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCCc3ccc(F)cc31)CC2
CHEMBL392798,CHEMBL237,Kappa opioid receptor,Ki,=,145.0,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCCc3cccc(F)c31)CC2
CHEMBL239822,CHEMBL237,Kappa opioid receptor,Ki,=,540.0,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,CC1(C)CCC(N2CCC3(CC2)C(=O)NCN3c2ccccc2)c2ccccc21
CHEMBL442090,CHEMBL237,Kappa opioid receptor,Ki,=,203.0,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCCCc3ccccc31)CC2
CHEMBL27460,CHEMBL237,Kappa opioid receptor,Ki,=,65.0,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCCc3ccccc31)CC2
CHEMBL284414,CHEMBL237,Kappa opioid receptor,Ki,=,32.0,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C1CCc3ccccc31)CC2
CHEMBL391703,CHEMBL237,Kappa opioid receptor,Ki,=,2009.0,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C(c1ccc(F)cc1)c1ccc(F)cc1)CC2
CHEMBL239821,CHEMBL237,Kappa opioid receptor,Ki,=,1448.0,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C(c1cccc(F)c1)c1cccc(F)c1)CC2
CHEMBL239820,CHEMBL237,Kappa opioid receptor,Ki,=,858.0,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C(c1ccccc1F)c1ccccc1F)CC2
CHEMBL239819,CHEMBL237,Kappa opioid receptor,Ki,=,4628.0,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C(c1cccc(Cl)c1)c1cccc(Cl)c1)CC2
CHEMBL241272,CHEMBL237,Kappa opioid receptor,Ki,=,5887.0,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C(c1ccccc1Cl)c1ccccc1Cl)CC2
CHEMBL439212,CHEMBL237,Kappa opioid receptor,Ki,=,1602.0,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,Cc1ccccc1C(c1ccccc1C)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL241080,CHEMBL237,Kappa opioid receptor,Ki,=,3529.0,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C(c1ccccc1)c1ccc(Cl)cc1)CC2
CHEMBL241079,CHEMBL237,Kappa opioid receptor,Ki,=,579.0,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,Cc1ccccc1C(c1ccccc1)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL428563,CHEMBL237,Kappa opioid receptor,Ki,=,1086.0,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C(c1ccccc1)c1ccccc1Cl)CC2
CHEMBL392969,CHEMBL237,Kappa opioid receptor,Ki,=,1183.0,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C(c1ccccc1)c1ccccc1F)CC2
CHEMBL241067,CHEMBL237,Kappa opioid receptor,Ki,=,776.0,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C1c3ccccc3C=Cc3ccccc31)CC2
CHEMBL240870,CHEMBL237,Kappa opioid receptor,Ki,=,1672.0,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C1c3ccccc3CCc3ccccc31)CC2
CHEMBL240657,CHEMBL237,Kappa opioid receptor,Ki,=,137.0,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C(c1ccccc1)c1ccccc1)CC2
CHEMBL391083,CHEMBL237,Kappa opioid receptor,Ki,=,26.0,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(C(c1ccccc1)C1CCCC1)CC2
CHEMBL428033,CHEMBL237,Kappa opioid receptor,Ki,=,25.5,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,CC(C)CCC(c1ccccc1)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL391082,CHEMBL237,Kappa opioid receptor,Ki,=,13.0,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,CCCCC(c1ccccc1)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL241112,CHEMBL237,Kappa opioid receptor,Ki,=,22.5,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,CCCC(c1ccccc1)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL240216,CHEMBL237,Kappa opioid receptor,Ki,=,60.5,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,CCC(c1ccccc1)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL392893,CHEMBL237,Kappa opioid receptor,Ki,=,50.0,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,CC(c1ccccc1)N1CCC2(CC1)C(=O)NCN2c1ccccc1
CHEMBL240215,CHEMBL237,Kappa opioid receptor,Ki,=,52.3,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(Cc1c(Cl)cccc1Cl)CC2
CHEMBL401451,CHEMBL237,Kappa opioid receptor,Ki,=,16.4,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(Cc1ccccc1Cl)CC2
CHEMBL240033,CHEMBL237,Kappa opioid receptor,Ki,=,26.2,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(Cc1ccsc1)CC2
CHEMBL240896,CHEMBL237,Kappa opioid receptor,Ki,=,252.0,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(Cc1cccnc1)CC2
CHEMBL240895,CHEMBL237,Kappa opioid receptor,Ki,=,321.0,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(Cc1ccccn1)CC2
CHEMBL240001,CHEMBL237,Kappa opioid receptor,Ki,=,517.0,nM,CHEMBL886504,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1139143,KI,O=C1NCN(c2ccccc2)C12CCN(CC1CCCCC1)CC2
CHEMBL246739,CHEMBL237,Kappa opioid receptor,Ki,=,1300.0,nM,CHEMBL887070,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1139195,KI,Cc1cc(C(N)=O)cc(C)c1C[C@H](N)C(=O)NCC(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)O
CHEMBL247758,CHEMBL237,Kappa opioid receptor,Ki,=,2400.0,nM,CHEMBL887070,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1139195,KI,Cc1cc(C(N)=O)cc(C)c1C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)O
CHEMBL246956,CHEMBL237,Kappa opioid receptor,Ki,=,460.0,nM,CHEMBL887070,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1139195,KI,CSCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(C(N)=O)cc1)C(N)=O
CHEMBL247368,CHEMBL237,Kappa opioid receptor,Ki,=,210.0,nM,CHEMBL887070,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1139195,KI,CSCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL391580,CHEMBL237,Kappa opioid receptor,Ki,=,1030.0,nM,CHEMBL887070,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1139195,KI,CSCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(C(N)=O)cc1)C(=O)O
CHEMBL247933,CHEMBL237,Kappa opioid receptor,Ki,=,74.0,nM,CHEMBL922969,B,Binding affinity to kappa opioid receptor,CHEMBL1140667,KI,c1cncc([C@@H]2CN3CCC[C@@H]3c3cc(OCCCN4CCCCC4)ccc32)c1
CHEMBL246002,CHEMBL237,Kappa opioid receptor,Ki,=,79.0,nM,CHEMBL924482,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1139774,KI,COc1c(O)ccc2c1[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)Cc1c([nH]c2ccccc12)C3
CHEMBL400157,CHEMBL237,Kappa opioid receptor,Ki,=,1440.0,nM,CHEMBL924482,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1139774,KI,COc1ccc2c(c1OC)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)Cc1c([nH]c2ccccc12)C3
CHEMBL557978,CHEMBL237,Kappa opioid receptor,Ki,=,515.0,nM,CHEMBL924482,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1139774,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccccc4c2C[C@@]3(O)[C@H]1C5.Cl
CHEMBL246003,CHEMBL237,Kappa opioid receptor,Ki,=,582.0,nM,CHEMBL924482,B,Displacement of [3H]U-69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1139774,KI,COc1c(O)ccc2c1[C@]13CCN(C)[C@H](C2)[C@]1(O)Cc1c([nH]c2ccccc12)C3
CHEMBL401093,CHEMBL237,Kappa opioid receptor,Ki,=,515.0,nM,CHEMBL922769,B,Displacement of [3H]U-69593 from cloned kappa opioid receptor,CHEMBL1140452,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccccc4c2C[C@@]3(O)[C@H]1C5
CHEMBL427706,CHEMBL237,Kappa opioid receptor,Ki,=,160.0,nM,CHEMBL922769,B,Displacement of [3H]U-69593 from cloned kappa opioid receptor,CHEMBL1140452,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccc(I)cc4c2C[C@@]3(O)[C@H]1C5
CHEMBL401094,CHEMBL237,Kappa opioid receptor,Ki,=,250.0,nM,CHEMBL922769,B,Displacement of [3H]U-69593 from cloned kappa opioid receptor,CHEMBL1140452,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccc(Br)cc4c2C[C@@]3(O)[C@H]1C5
CHEMBL248840,CHEMBL237,Kappa opioid receptor,Ki,=,360.0,nM,CHEMBL922769,B,Displacement of [3H]U-69593 from cloned kappa opioid receptor,CHEMBL1140452,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccc(Cl)cc4c2C[C@@]3(O)[C@H]1C5
CHEMBL248839,CHEMBL237,Kappa opioid receptor,Ki,=,310.0,nM,CHEMBL922769,B,Displacement of [3H]U-69593 from cloned kappa opioid receptor,CHEMBL1140452,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccc(F)cc4c2C[C@@]3(O)[C@H]1C5
CHEMBL377789,CHEMBL237,Kappa opioid receptor,Ki,=,1.8,nM,CHEMBL941714,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in CHO cells,CHEMBL1140563,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccccc5)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL428055,CHEMBL237,Kappa opioid receptor,Ki,=,1.9,nM,CHEMBL941714,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in CHO cells,CHEMBL1140563,KI,C[C@H]1C2Cc3ccc(C(=O)NCCCc4cccc5ccccc45)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL251161,CHEMBL237,Kappa opioid receptor,Ki,=,2.4,nM,CHEMBL941714,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in CHO cells,CHEMBL1140563,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4cccc5ccccc45)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL251160,CHEMBL237,Kappa opioid receptor,Ki,=,18.0,nM,CHEMBL941714,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in CHO cells,CHEMBL1140563,KI,C[C@H]1C2Cc3ccc(C(=O)NCc4cccc5ccccc45)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL430397,CHEMBL237,Kappa opioid receptor,Ki,=,0.18,nM,CHEMBL941714,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in CHO cells,CHEMBL1140563,KI,C[C@H]1C2Cc3ccc(C(=O)NCCCc4ccc5ccccc5c4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL399344,CHEMBL237,Kappa opioid receptor,Ki,=,0.2,nM,CHEMBL941714,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in CHO cells,CHEMBL1140563,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc5ccccc5c4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL250388,CHEMBL237,Kappa opioid receptor,Ki,=,19.0,nM,CHEMBL941714,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in CHO cells,CHEMBL1140563,KI,C[C@H]1C2Cc3ccc(C(=O)NCc4ccc5ccccc5c4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL250387,CHEMBL237,Kappa opioid receptor,Ki,=,3.3,nM,CHEMBL941714,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in CHO cells,CHEMBL1140563,KI,Cc1ccc(-c2ccc(CCNC(=O)c3ccc4c(c3)[C@@]3(C)CCN(CC5CC5)C(C4)[C@@H]3C)cc2)cc1
CHEMBL250186,CHEMBL237,Kappa opioid receptor,Ki,=,1.1,nM,CHEMBL941714,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in CHO cells,CHEMBL1140563,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccc(Cl)c(Cl)c5)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL438871,CHEMBL237,Kappa opioid receptor,Ki,=,3.2,nM,CHEMBL941714,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in CHO cells,CHEMBL1140563,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccc(Cl)cc5)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL249985,CHEMBL237,Kappa opioid receptor,Ki,=,1.5,nM,CHEMBL941714,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in CHO cells,CHEMBL1140563,KI,COc1ccc(-c2ccc(CCNC(=O)c3ccc4c(c3)[C@@]3(C)CCN(CC5CC5)C(C4)[C@@H]3C)cc2)cc1
CHEMBL398294,CHEMBL237,Kappa opioid receptor,Ki,=,19.0,nM,CHEMBL941714,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in CHO cells,CHEMBL1140563,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccccc4Br)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL250993,CHEMBL237,Kappa opioid receptor,Ki,=,0.063,nM,CHEMBL941714,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in CHO cells,CHEMBL1140563,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4cccc(Br)c4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL249567,CHEMBL237,Kappa opioid receptor,Ki,=,0.38,nM,CHEMBL941714,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in CHO cells,CHEMBL1140563,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc(Br)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL399465,CHEMBL237,Kappa opioid receptor,Ki,=,2.4,nM,CHEMBL941714,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in CHO cells,CHEMBL1140563,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccccc4-c4ccccc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL401278,CHEMBL237,Kappa opioid receptor,Ki,=,2.2,nM,CHEMBL941714,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in CHO cells,CHEMBL1140563,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4cccc(-c5ccccc5)c4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL3085528,CHEMBL237,Kappa opioid receptor,Ki,=,0.07,nM,CHEMBL941714,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in CHO cells,CHEMBL1140563,KI,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL58646,CHEMBL237,Kappa opioid receptor,Ki,=,0.06,nM,CHEMBL941714,B,Displacement of [3H]U-69593 from kappa opioid receptor expressed in CHO cells,CHEMBL1140563,KI,C[C@H]1C2Cc3ccc(C(N)=O)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL253597,CHEMBL237,Kappa opioid receptor,Ki,=,2200.0,nM,CHEMBL924982,B,Binding affinity to kappa opioid receptor,CHEMBL1140697,KI,CC(=O)N(Cc1ccccc1O[11CH3])c1cnccc1Oc1ccccc1
CHEMBL429026,CHEMBL237,Kappa opioid receptor,Ki,=,72.0,nM,CHEMBL946804,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1143255,KI,COC(=O)[C@@H]1C[C@H](OC(C)(C)OC)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL403137,CHEMBL237,Kappa opioid receptor,Ki,=,4.0,nM,CHEMBL946804,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1143255,KI,COC(=O)[C@@H]1C[C@H](OC2CCCCO2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL255139,CHEMBL237,Kappa opioid receptor,Ki,=,5.3,nM,CHEMBL946804,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1143255,KI,CCCCOCO[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL445332,CHEMBL237,Kappa opioid receptor,Ki,=,2.4,nM,CHEMBL946804,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1143255,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL556996,CHEMBL237,Kappa opioid receptor,Ki,=,6.6,nM,CHEMBL946804,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1143255,KI,CCOC(C)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O.Cl
CHEMBL257922,CHEMBL237,Kappa opioid receptor,Ki,=,11.0,nM,CHEMBL946804,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1143255,KI,CCOC(C)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL270844,CHEMBL237,Kappa opioid receptor,Ki,=,50.0,nM,CHEMBL946804,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1143255,KI,COC(=O)[C@@H]1C[C@H](OCF)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL403658,CHEMBL237,Kappa opioid receptor,Ki,=,13.0,nM,CHEMBL946804,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1143255,KI,COC(=O)[C@@H]1C[C@H](OCSC)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL271061,CHEMBL237,Kappa opioid receptor,Ki,=,147.0,nM,CHEMBL946804,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1143255,KI,COC(=O)[C@@H]1C[C@H](OCOCc2ccccc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL272483,CHEMBL237,Kappa opioid receptor,Ki,=,141.0,nM,CHEMBL946804,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1143255,KI,COCCOCO[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL272482,CHEMBL237,Kappa opioid receptor,Ki,=,31.0,nM,CHEMBL946804,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1143255,KI,COC(=O)[C@@H]1C[C@H](OCOCC(F)(F)F)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL271077,CHEMBL237,Kappa opioid receptor,Ki,=,1.9,nM,CHEMBL946804,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1143255,KI,COC(=O)[C@@H]1C[C@H](OCOCCF)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL271285,CHEMBL237,Kappa opioid receptor,Ki,=,35.0,nM,CHEMBL946804,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1143255,KI,COC(=O)[C@@H]1C[C@H](OCOC(C)(C)C)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL271078,CHEMBL237,Kappa opioid receptor,Ki,=,1.6,nM,CHEMBL946804,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1143255,KI,COC(=O)[C@@H]1C[C@H](OCOC(C)C)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL258285,CHEMBL237,Kappa opioid receptor,Ki,=,2.2,nM,CHEMBL946804,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1143255,KI,CCCOCO[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL272939,CHEMBL237,Kappa opioid receptor,Ki,=,0.32,nM,CHEMBL946804,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1143255,KI,CCOCO[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL258098,CHEMBL237,Kappa opioid receptor,Ki,=,0.6,nM,CHEMBL946804,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1143255,KI,COCO[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL441765,CHEMBL237,Kappa opioid receptor,Ki,=,2.2,nM,CHEMBL946804,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1143255,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL412098,CHEMBL237,Kappa opioid receptor,Ki,=,89.0,nM,CHEMBL930989,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1141567,KI,O=C1NCN(c2ccccc2)C12CCN([C@@H]1CC[C@H]3CCCc4cccc1c43)CC2
CHEMBL272592,CHEMBL237,Kappa opioid receptor,Ki,=,3641.0,nM,CHEMBL930989,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1141567,KI,CC(C)(C)C1CCC(N2CCC3(CC2)C(=O)NCc2cc(F)ccc23)CC1
CHEMBL272640,CHEMBL237,Kappa opioid receptor,Ki,=,3844.0,nM,CHEMBL930989,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1141567,KI,CC(C)(C)C1CCC(N2CCC3(CC2)C(=O)NCc2ccccc23)CC1
CHEMBL407846,CHEMBL237,Kappa opioid receptor,Ki,=,3977.0,nM,CHEMBL930989,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1141567,KI,CC(C)C1CCC(N2CCC3(CC2)C(=O)NCc2cc(F)ccc23)CC1
CHEMBL271590,CHEMBL237,Kappa opioid receptor,Ki,=,3827.0,nM,CHEMBL930989,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1141567,KI,CC(C)C1CCC(N2CCC3(CC2)C(=O)NCc2ccccc23)CC1
CHEMBL259681,CHEMBL237,Kappa opioid receptor,Ki,=,1104.0,nM,CHEMBL930989,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1141567,KI,CC(C)(C)C1CCC(N2CCC3(CC2)C(=O)N(Cc2ccccc2)Cc2cc(F)ccc23)CC1
CHEMBL259473,CHEMBL237,Kappa opioid receptor,Ki,=,190.0,nM,CHEMBL930989,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1141567,KI,CC(C)(C)C1CCC(N2CCC3(CC2)C(=O)N(Cc2ccccc2)Cc2cccc(F)c23)CC1
CHEMBL272805,CHEMBL237,Kappa opioid receptor,Ki,=,97.0,nM,CHEMBL930989,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1141567,KI,CC(C)(C)C1CCC(N2CCC3(CC2)C(=O)N(Cc2ccccc2)Cc2ccccc23)CC1
CHEMBL412290,CHEMBL237,Kappa opioid receptor,Ki,=,1920.0,nM,CHEMBL930989,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1141567,KI,CC(C)C1CCC(N2CCC3(CC2)C(=O)N(Cc2ccccc2)Cc2cc(F)ccc23)CC1
CHEMBL270756,CHEMBL237,Kappa opioid receptor,Ki,=,123.0,nM,CHEMBL930989,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1141567,KI,CC(C)C1CCC(N2CCC3(CC2)C(=O)N(Cc2ccccc2)Cc2cccc(F)c23)CC1
CHEMBL409621,CHEMBL237,Kappa opioid receptor,Ki,=,928.0,nM,CHEMBL930989,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1141567,KI,CC(C)C1CCC(N2CCC3(CC2)C(=O)N(Cc2ccccc2)Cc2ccccc23)CC1
CHEMBL407275,CHEMBL237,Kappa opioid receptor,Ki,=,1150.0,nM,CHEMBL930989,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1141567,KI,CN1Cc2cc(F)ccc2C2(CCN(C3CCC(C(C)(C)C)CC3)CC2)C1=O
CHEMBL272600,CHEMBL237,Kappa opioid receptor,Ki,=,3600.0,nM,CHEMBL930989,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1141567,KI,CN1Cc2cccc(F)c2C2(CCN(C3CCC(C(C)(C)C)CC3)CC2)C1=O
CHEMBL272390,CHEMBL237,Kappa opioid receptor,Ki,=,178.0,nM,CHEMBL930989,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1141567,KI,CN1Cc2ccccc2C2(CCN(C3CCC(C(C)(C)C)CC3)CC2)C1=O
CHEMBL272601,CHEMBL237,Kappa opioid receptor,Ki,=,103.0,nM,CHEMBL930989,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1141567,KI,CC(C)C1CCC(N2CCC3(CC2)C(=O)N(C)Cc2cc(F)ccc23)CC1
CHEMBL270133,CHEMBL237,Kappa opioid receptor,Ki,=,412.0,nM,CHEMBL930989,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1141567,KI,CC(C)C1CCC(N2CCC3(CC2)C(=O)N(C)Cc2cccc(F)c23)CC1
CHEMBL272852,CHEMBL237,Kappa opioid receptor,Ki,=,557.0,nM,CHEMBL930989,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1141567,KI,CC(C)C1CCC(N2CCC3(CC2)C(=O)N(C)Cc2ccccc23)CC1
CHEMBL19019,CHEMBL237,Kappa opioid receptor,Ki,=,0.81,nM,CHEMBL950283,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL429588,CHEMBL237,Kappa opioid receptor,Ki,=,2.74,nM,CHEMBL950283,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C(Cc1cccs1)N[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL443326,CHEMBL237,Kappa opioid receptor,Ki,=,1.2,nM,CHEMBL950283,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C(Cc1cccs1)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL270918,CHEMBL237,Kappa opioid receptor,Ki,=,0.42,nM,CHEMBL950283,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1142345,KI,COc1ccc(CC(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)cc1
CHEMBL411927,CHEMBL237,Kappa opioid receptor,Ki,=,0.43,nM,CHEMBL950283,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C(Cc1ccccc1)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL273105,CHEMBL237,Kappa opioid receptor,Ki,=,0.45,nM,CHEMBL950283,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1142345,KI,COc1cccc(CC(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)c1
CHEMBL412050,CHEMBL237,Kappa opioid receptor,Ki,=,0.09,nM,CHEMBL950283,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C(CCc1ccccc1)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL438413,CHEMBL237,Kappa opioid receptor,Ki,=,0.91,nM,CHEMBL950283,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C(/C=C/Cc1ccccc1)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL272021,CHEMBL237,Kappa opioid receptor,Ki,=,150.61,nM,CHEMBL950283,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C(O)c1ccc(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)cc1
CHEMBL411916,CHEMBL237,Kappa opioid receptor,Ki,=,1.7,nM,CHEMBL950283,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1142345,KI,CN(C)c1cccc(C(=O)NC2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)c1
CHEMBL271755,CHEMBL237,Kappa opioid receptor,Ki,=,0.79,nM,CHEMBL950283,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1142345,KI,CC(C)(C)OC(=O)Nc1ccc(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)cc1
CHEMBL410526,CHEMBL237,Kappa opioid receptor,Ki,=,0.24,nM,CHEMBL950283,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1142345,KI,COc1cccc(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)c1
CHEMBL272051,CHEMBL237,Kappa opioid receptor,Ki,=,0.4,nM,CHEMBL950283,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1142345,KI,Nc1ccc(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)cc1
CHEMBL260528,CHEMBL237,Kappa opioid receptor,Ki,=,0.39,nM,CHEMBL950283,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccccn1
CHEMBL271811,CHEMBL237,Kappa opioid receptor,Ki,=,0.29,nM,CHEMBL950283,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1142345,KI,COc1cc(OC)cc(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)c1
CHEMBL410884,CHEMBL237,Kappa opioid receptor,Ki,=,0.73,nM,CHEMBL950283,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1142345,KI,COC(=O)c1ccc(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)cc1
CHEMBL271797,CHEMBL237,Kappa opioid receptor,Ki,=,0.78,nM,CHEMBL950283,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C(N[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccccc1
CHEMBL411738,CHEMBL237,Kappa opioid receptor,Ki,=,2.41,nM,CHEMBL950283,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1142345,KI,COc1cc(OC)cc(C(=O)N[C@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)c1
CHEMBL407466,CHEMBL237,Kappa opioid receptor,Ki,=,0.28,nM,CHEMBL950283,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1cccc([N+](=O)[O-])c1
CHEMBL271815,CHEMBL237,Kappa opioid receptor,Ki,=,0.16,nM,CHEMBL950283,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccccc1
CHEMBL429929,CHEMBL237,Kappa opioid receptor,Ki,=,0.72,nM,CHEMBL950283,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1142345,KI,COc1cccc(C(=O)N[C@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)c1
CHEMBL410122,CHEMBL237,Kappa opioid receptor,Ki,=,0.06,nM,CHEMBL950283,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1cccc(O)c1
CHEMBL272215,CHEMBL237,Kappa opioid receptor,Ki,=,0.1,nM,CHEMBL950283,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccc(Cl)c(Cl)c1
CHEMBL409458,CHEMBL237,Kappa opioid receptor,Ki,=,0.37,nM,CHEMBL950283,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccc(Cl)cc1
CHEMBL409036,CHEMBL237,Kappa opioid receptor,Ki,=,4.5,nM,CHEMBL950283,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C(C[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL272181,CHEMBL237,Kappa opioid receptor,Ki,=,2.03,nM,CHEMBL950283,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C(C[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)N[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL406116,CHEMBL237,Kappa opioid receptor,Ki,=,0.51,nM,CHEMBL950283,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1142345,KI,O=C(C[C@@H]1O[C@H](COCc2ccccc2)[C@@H](OCc2ccccc2)[C@H](OCc2ccccc2)[C@H]1OCc1ccccc1)N[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL982,CHEMBL237,Kappa opioid receptor,Ki,=,1.03,nM,CHEMBL950283,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1142345,KI,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL2364732,CHEMBL237,Kappa opioid receptor,Ki,=,8.33,nM,CHEMBL950326,B,Binding affinity to kappa opioid receptor,CHEMBL1144030,KI,[11CH3]n1c2c(c3ccccc31)C[C@@]1(O)[C@H]3Cc4ccc(O)c5c4[C@@]1(CCN3CC1CC1)[C@H]2O5
CHEMBL80,CHEMBL237,Kappa opioid receptor,Ki,=,9.2,nM,CHEMBL933967,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1144033,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL401615,CHEMBL237,Kappa opioid receptor,Ki,=,580.0,nM,CHEMBL933967,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)N[C@@H](CCCCN)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL437983,CHEMBL237,Kappa opioid receptor,Ki,=,200.0,nM,CHEMBL933967,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)N[C@@H](CCCN)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL256010,CHEMBL237,Kappa opioid receptor,Ki,=,510.0,nM,CHEMBL933967,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)N[C@@H](CCc2ccccc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL270401,CHEMBL237,Kappa opioid receptor,Ki,=,720.0,nM,CHEMBL933967,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)N[C@@H](CC2CCCCC2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL270187,CHEMBL237,Kappa opioid receptor,Ki,=,240.0,nM,CHEMBL933967,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL404303,CHEMBL237,Kappa opioid receptor,Ki,=,83.0,nM,CHEMBL933967,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL402964,CHEMBL237,Kappa opioid receptor,Ki,=,160.0,nM,CHEMBL933967,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(-c3ccccc3)cc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL403190,CHEMBL237,Kappa opioid receptor,Ki,=,250.0,nM,CHEMBL933967,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL255354,CHEMBL237,Kappa opioid receptor,Ki,=,910.0,nM,CHEMBL933967,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1144033,KI,C[C@@H](NC(=O)[C@@H](Cc1ccccc1)CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)C(=O)O
CHEMBL403633,CHEMBL237,Kappa opioid receptor,Ki,=,67.0,nM,CHEMBL933967,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1144033,KI,C[C@H](NC(=O)[C@@H](Cc1ccccc1)CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)C(=O)O
CHEMBL271662,CHEMBL237,Kappa opioid receptor,Ki,=,460.0,nM,CHEMBL933967,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(CCC(=O)N(Cc2cccc(Cl)c2)[C@@H](Cc2ccccc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL270833,CHEMBL237,Kappa opioid receptor,Ki,=,230.0,nM,CHEMBL933967,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(CCC(=O)N(Cc2ccc(-c3ccccc3)cc2)[C@@H](Cc2ccccc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL403191,CHEMBL237,Kappa opioid receptor,Ki,=,1200.0,nM,CHEMBL933967,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(CCC(=O)N(CCc2ccccc2)[C@@H](Cc2ccccc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL255555,CHEMBL237,Kappa opioid receptor,Ki,=,550.0,nM,CHEMBL933967,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(CCC(=O)N(Cc2ccccc2)[C@@H](Cc2ccccc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL404583,CHEMBL237,Kappa opioid receptor,Ki,=,1400.0,nM,CHEMBL933967,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(CCC(=O)N(c2ccccc2)[C@@H](Cc2ccccc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL258294,CHEMBL237,Kappa opioid receptor,Ki,=,2200.0,nM,CHEMBL933967,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(CCC(=O)N(CC2CC2)[C@@H](Cc2ccccc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL258115,CHEMBL237,Kappa opioid receptor,Ki,=,2200.0,nM,CHEMBL933967,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1144033,KI,CC(C)CN(C(=O)CCN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)[C@@H](Cc1ccccc1)C(=O)O
CHEMBL403325,CHEMBL237,Kappa opioid receptor,Ki,=,690.0,nM,CHEMBL933967,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(CCC(=O)N[C@@H](CCc2ccccc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL441899,CHEMBL237,Kappa opioid receptor,Ki,=,1100.0,nM,CHEMBL933967,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(CCC(=O)N[C@@H](Cc2ccc(-c3ccccc3)cc2)C(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL270190,CHEMBL237,Kappa opioid receptor,Ki,=,100.0,nM,CHEMBL933967,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor,CHEMBL1144033,KI,C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(=O)O)CC[C@@]1(C)c1cccc(O)c1
CHEMBL69018,CHEMBL237,Kappa opioid receptor,Ki,=,2515.0,nM,CHEMBL932681,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1143918,KI,C=C[C@@H](O)C#CC#C[C@@H](O)/C=C\CCCCCCC
CHEMBL408980,CHEMBL237,Kappa opioid receptor,Ki,=,2600.0,nM,CHEMBL932681,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1143918,KI,CC(C)=CC(O)C/C(C)=C/COc1ccc2ccc(=O)oc2c1
CHEMBL260521,CHEMBL237,Kappa opioid receptor,Ki,=,890.0,nM,CHEMBL940229,B,Displacement of [3H]C1-977 from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1143969,KI,C=CCN1C[C@@H]2C(c3ccccc3)=CC[C@H]1CN2Cc1ccc(C(=O)N(CC)CC)cc1
CHEMBL409266,CHEMBL237,Kappa opioid receptor,Ki,=,2400.0,nM,CHEMBL940229,B,Displacement of [3H]C1-977 from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1143969,KI,CCCN1C[C@@H]2[C@H](c3ccccc3)CC[C@H]1CN2Cc1ccc(C(=O)N(CC)CC)cc1
CHEMBL258791,CHEMBL237,Kappa opioid receptor,Ki,=,1700.0,nM,CHEMBL940229,B,Displacement of [3H]C1-977 from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1143969,KI,C=CCN1C[C@@H]2[C@H](c3ccccc3)CC[C@H]1CN2Cc1ccc(C(=O)N(CC)CC)cc1
CHEMBL407728,CHEMBL237,Kappa opioid receptor,Ki,=,1100.0,nM,CHEMBL940229,B,Displacement of [3H]C1-977 from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1143969,KI,C=CCN1C[C@@H]2[C@@H](c3ccccc3)CC[C@H]1CN2Cc1ccc(C(=O)N(CC)CC)cc1
CHEMBL261048,CHEMBL237,Kappa opioid receptor,Ki,=,589.0,nM,CHEMBL922698,B,Displacement of [3H]diprenorphine from recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144851,KI,CN1CC[C@]23c4c5cccc4O[C@H]2CCC[C@H]3[C@H]1C5
CHEMBL408422,CHEMBL237,Kappa opioid receptor,Ki,=,3090.0,nM,CHEMBL922698,B,Displacement of [3H]diprenorphine from recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144851,KI,COc1ccc2c3c1O[C@H]1CC=C[C@H]4[C@@H](C2)N(C)CC[C@]314
CHEMBL410907,CHEMBL237,Kappa opioid receptor,Ki,=,45.5,nM,CHEMBL922698,B,Displacement of [3H]diprenorphine from recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144851,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2CC=C[C@H]3[C@H]1C5
CHEMBL409743,CHEMBL237,Kappa opioid receptor,Ki,=,11600.0,nM,CHEMBL922698,B,Displacement of [3H]diprenorphine from recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144851,KI,CO[C@H]1CC[C@H]2[C@H]3Cc4cccc5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL412301,CHEMBL237,Kappa opioid receptor,Ki,=,5430.0,nM,CHEMBL922698,B,Displacement of [3H]diprenorphine from recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144851,KI,COc1ccc2c3c1O[C@H]1[C@@H](OC)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341
CHEMBL358043,CHEMBL237,Kappa opioid receptor,Ki,=,22.8,nM,CHEMBL922698,B,Displacement of [3H]diprenorphine from recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144851,KI,CO[C@H]1C=C[C@H]2[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL258669,CHEMBL237,Kappa opioid receptor,Ki,=,4910.0,nM,CHEMBL922698,B,Displacement of [3H]diprenorphine from recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144851,KI,CN1CC[C@]23c4c5cccc4O[C@H]2[C@@H](O)CC[C@H]3[C@H]1C5
CHEMBL485,CHEMBL237,Kappa opioid receptor,Ki,=,25411.0,nM,CHEMBL922698,B,Displacement of [3H]diprenorphine from recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144851,KI,COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341
CHEMBL70,CHEMBL237,Kappa opioid receptor,Ki,=,65.5,nM,CHEMBL922698,B,Displacement of [3H]diprenorphine from recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144851,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL445332,CHEMBL237,Kappa opioid receptor,Ki,=,1.9,nM,CHEMBL923552,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL262346,CHEMBL237,Kappa opioid receptor,Ki,=,1410.0,nM,CHEMBL923552,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](SC(=O)c2ccccc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL445332,CHEMBL237,Kappa opioid receptor,Ki,=,5.7,nM,CHEMBL923552,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL438561,CHEMBL237,Kappa opioid receptor,Ki,=,1400.0,nM,CHEMBL923552,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](NS(=O)(=O)c2ccccc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL409414,CHEMBL237,Kappa opioid receptor,Ki,=,260.0,nM,CHEMBL923552,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](NS(C)(=O)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL259658,CHEMBL237,Kappa opioid receptor,Ki,=,7430.0,nM,CHEMBL923552,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](NC(=O)c2ccccc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL213155,CHEMBL237,Kappa opioid receptor,Ki,=,30.0,nM,CHEMBL923552,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](NC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL258754,CHEMBL237,Kappa opioid receptor,Ki,=,2010.0,nM,CHEMBL923552,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(=O)C2CCCCC2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL410436,CHEMBL237,Kappa opioid receptor,Ki,=,80.0,nM,CHEMBL923552,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccsc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL264967,CHEMBL237,Kappa opioid receptor,Ki,=,260.0,nM,CHEMBL923552,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2cccs2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL260121,CHEMBL237,Kappa opioid receptor,Ki,=,70.0,nM,CHEMBL923552,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2cc3ccccc3o2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL261807,CHEMBL237,Kappa opioid receptor,Ki,=,5490.0,nM,CHEMBL923552,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccc3ccccc3c2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL408900,CHEMBL237,Kappa opioid receptor,Ki,=,410.0,nM,CHEMBL923552,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2cccc3ccccc23)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL265195,CHEMBL237,Kappa opioid receptor,Ki,=,570.0,nM,CHEMBL923552,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccc([N+](=O)[O-])cc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL260809,CHEMBL237,Kappa opioid receptor,Ki,=,800.0,nM,CHEMBL923552,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2cccc([N+](=O)[O-])c2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL408775,CHEMBL237,Kappa opioid receptor,Ki,=,900.0,nM,CHEMBL923552,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccccc2[N+](=O)[O-])C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL260286,CHEMBL237,Kappa opioid receptor,Ki,=,540.0,nM,CHEMBL923552,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccc(OC)cc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL260485,CHEMBL237,Kappa opioid receptor,Ki,=,550.0,nM,CHEMBL923552,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2cccc(OC)c2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL429685,CHEMBL237,Kappa opioid receptor,Ki,=,230.0,nM,CHEMBL923552,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccccc2OC)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL259299,CHEMBL237,Kappa opioid receptor,Ki,=,740.0,nM,CHEMBL923552,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccc(Br)cc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL261024,CHEMBL237,Kappa opioid receptor,Ki,=,70.0,nM,CHEMBL923552,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2cccc(Br)c2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL407155,CHEMBL237,Kappa opioid receptor,Ki,=,90.0,nM,CHEMBL923552,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccccc2Br)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL363324,CHEMBL237,Kappa opioid receptor,Ki,=,90.0,nM,CHEMBL923552,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccccc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL424698,CHEMBL237,Kappa opioid receptor,Ki,=,280.0,nM,CHEMBL923552,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1144846,KI,COC(=O)[C@@H]1C[C@H](O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL38576,CHEMBL237,Kappa opioid receptor,Ki,=,0.044,nM,CHEMBL927004,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO-K1 cells,CHEMBL1145560,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@H](CN1CCCC1)c1ccccc1
CHEMBL257140,CHEMBL237,Kappa opioid receptor,Ki,=,0.19,nM,CHEMBL927004,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO-K1 cells,CHEMBL1145560,KI,CN(C(=O)Cc1cc2c(cc1S(=O)(=O)N(C)Cc1ccccc1)OCO2)[C@H](CN1CCCC1)c1ccccc1
CHEMBL257139,CHEMBL237,Kappa opioid receptor,Ki,=,0.54,nM,CHEMBL927004,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO-K1 cells,CHEMBL1145560,KI,CN(C(=O)Cc1cc2c(cc1S(=O)(=O)N(C)C)OCO2)[C@H](CN1CC[C@H](O)C1)c1ccccc1
CHEMBL402135,CHEMBL237,Kappa opioid receptor,Ki,=,0.22,nM,CHEMBL927004,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO-K1 cells,CHEMBL1145560,KI,CN(C(=O)Cc1cc2c(cc1S(=O)(=O)N(C)C)OCO2)[C@H](CN1CCCC1)c1ccccc1
CHEMBL403273,CHEMBL237,Kappa opioid receptor,Ki,=,0.7,nM,CHEMBL927004,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO-K1 cells,CHEMBL1145560,KI,CN(C(=O)Cc1ccc2c(c1)OCO2)[C@H](CN1CCCC1)c1ccccc1
CHEMBL429677,CHEMBL237,Kappa opioid receptor,Ki,=,1.4,nM,CHEMBL927004,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO-K1 cells,CHEMBL1145560,KI,COc1cc(CC(=O)N(C)[C@H](CN2CC[C@H](O)C2)c2ccccc2)c(S(=O)(=O)N2CCOCC2)cc1OC
CHEMBL402189,CHEMBL237,Kappa opioid receptor,Ki,=,0.55,nM,CHEMBL927004,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO-K1 cells,CHEMBL1145560,KI,COc1cc(CC(=O)N(C)[C@H](CN2CCCC2)c2ccccc2)c(S(=O)(=O)N2CCOCC2)cc1OC
CHEMBL254754,CHEMBL237,Kappa opioid receptor,Ki,=,3.8,nM,CHEMBL927004,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO-K1 cells,CHEMBL1145560,KI,COc1cc(CC(=O)N(C)[C@H](CN2CC[C@H](O)C2)c2ccccc2)c(S(=O)(=O)N2CCN(C)CC2)cc1OC
CHEMBL437784,CHEMBL237,Kappa opioid receptor,Ki,=,1.3,nM,CHEMBL927004,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO-K1 cells,CHEMBL1145560,KI,COc1cc(CC(=O)N(C)[C@H](CN2CCCC2)c2ccccc2)c(S(=O)(=O)N2CCN(C)CC2)cc1OC
CHEMBL257355,CHEMBL237,Kappa opioid receptor,Ki,=,1.1,nM,CHEMBL927004,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO-K1 cells,CHEMBL1145560,KI,COc1cc(CC(=O)N(C)[C@H](CN2CC[C@H](O)C2)c2ccccc2)c(S(=O)(=O)N2CCCC2)cc1OC
CHEMBL402820,CHEMBL237,Kappa opioid receptor,Ki,=,0.31,nM,CHEMBL927004,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO-K1 cells,CHEMBL1145560,KI,COc1cc(CC(=O)N(C)[C@H](CN2CCCC2)c2ccccc2)c(S(=O)(=O)N2CCCC2)cc1OC
CHEMBL401594,CHEMBL237,Kappa opioid receptor,Ki,=,0.68,nM,CHEMBL927004,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO-K1 cells,CHEMBL1145560,KI,COc1cc(CC(=O)N(C)[C@H](CN2CCCC2)c2ccccc2)c(S(=O)(=O)N(C)Cc2ccccc2)cc1OC
CHEMBL254960,CHEMBL237,Kappa opioid receptor,Ki,=,1.6,nM,CHEMBL927004,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO-K1 cells,CHEMBL1145560,KI,COc1cc(CC(=O)N(C)[C@H](CN2CC[C@H](O)C2)c2ccccc2)c(S(=O)(=O)N(C)C)cc1OC
CHEMBL254959,CHEMBL237,Kappa opioid receptor,Ki,=,0.5,nM,CHEMBL927004,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO-K1 cells,CHEMBL1145560,KI,COc1cc(CC(=O)N(C)[C@H](CN2CCCC2)c2ccccc2)c(S(=O)(=O)N(C)C)cc1OC
CHEMBL258172,CHEMBL237,Kappa opioid receptor,Ki,=,2.8,nM,CHEMBL927004,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO-K1 cells,CHEMBL1145560,KI,COc1ccc(CC(=O)N(C)[C@H](CN2CCCC2)c2ccccc2)cc1OC
CHEMBL411557,CHEMBL237,Kappa opioid receptor,Ki,=,0.21,nM,CHEMBL927004,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO-K1 cells,CHEMBL1145560,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)O
CHEMBL592,CHEMBL237,Kappa opioid receptor,Ki,=,2.3,nM,CHEMBL1005605,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1156604,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13
CHEMBL499868,CHEMBL237,Kappa opioid receptor,Ki,=,5.2,nM,CHEMBL1005605,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1156604,KI,Cl.Nc1ccc(Oc2ccc3c(c2)[C@@]24CCCC[C@@]2(O)[C@@H](C3)N(CC2CCC2)CC4)cc1
CHEMBL526362,CHEMBL237,Kappa opioid receptor,Ki,=,28.0,nM,CHEMBL1005605,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1156604,KI,Cl.O=[N+]([O-])c1ccc(Oc2ccc3c(c2)[C@@]24CCCC[C@@]2(O)[C@@H](C3)N(CC2CCC2)CC4)cc1
CHEMBL501447,CHEMBL237,Kappa opioid receptor,Ki,=,9.0,nM,CHEMBL1005605,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1156604,KI,Cl.O[C@@]12CCCC[C@@]13CCN(CC1CCC1)[C@@H]2Cc1ccc(OCCc2ccccc2)cc13
CHEMBL524505,CHEMBL237,Kappa opioid receptor,Ki,=,28.0,nM,CHEMBL1005605,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1156604,KI,Cl.O[C@@]12CCCC[C@@]13CCN(CC1CCC1)[C@@H]2Cc1ccc(OCc2ccccc2)cc13
CHEMBL500123,CHEMBL237,Kappa opioid receptor,Ki,=,8.6,nM,CHEMBL1005605,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1156604,KI,Cl.OCCCOc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3
CHEMBL497108,CHEMBL237,Kappa opioid receptor,Ki,=,67.0,nM,CHEMBL1005605,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1156604,KI,Cl.NC(=O)COc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3
CHEMBL521543,CHEMBL237,Kappa opioid receptor,Ki,=,0.21,nM,CHEMBL1005605,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1156604,KI,COc1ccc(CC(=O)Oc2ccc3c(c2)[C@@]24CCCC[C@@]2(O)[C@@H](C3)N(CC2CCC2)CC4)cc1.Cl
CHEMBL451320,CHEMBL237,Kappa opioid receptor,Ki,=,18.0,nM,CHEMBL1005605,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1156604,KI,Cl.O=C(Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3)c1ccc(-c2ccccc2)cc1
CHEMBL500419,CHEMBL237,Kappa opioid receptor,Ki,=,0.048,nM,CHEMBL1005605,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1156604,KI,Cl.O=C(COc1ccccc1)Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3
CHEMBL500154,CHEMBL237,Kappa opioid receptor,Ki,=,1.3,nM,CHEMBL1005605,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1156604,KI,Cc1ccc(C(C)C(=O)Oc2ccc3c(c2)[C@@]24CCCC[C@@]2(O)[C@@H](C3)N(CC2CCC2)CC4)cc1.Cl
CHEMBL501739,CHEMBL237,Kappa opioid receptor,Ki,=,0.48,nM,CHEMBL1005605,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1156604,KI,Cl.O=C(Cc1ccccc1)Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3
CHEMBL503457,CHEMBL237,Kappa opioid receptor,Ki,=,0.87,nM,CHEMBL1005605,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1156604,KI,Cl.O=C(Cc1ccc(-c2ccccc2)cc1)Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3
CHEMBL33986,CHEMBL237,Kappa opioid receptor,Ki,=,0.12,nM,CHEMBL1005605,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1156604,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3
CHEMBL301160,CHEMBL237,Kappa opioid receptor,Ki,=,0.079,nM,CHEMBL1005605,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1156604,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL499884,CHEMBL237,Kappa opioid receptor,Ki,=,11.0,nM,CHEMBL1005605,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL1156604,KI,C[C@H]1[C@H]2Cc3ccc(C(=O)N(C)CCc4ccc(-c5ccccc5)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL1237044,CHEMBL237,Kappa opioid receptor,Ki,=,14.0,nM,CHEMBL1019878,B,Displacement of [3H]U69593 form human kappa opioid receptor expressed in CHO cells,CHEMBL1139291,KI,COc1cccc(C2(O)CCCCC2CN(C)C)c1
CHEMBL443601,CHEMBL237,Kappa opioid receptor,Ki,=,350.0,nM,CHEMBL1019878,B,Displacement of [3H]U69593 form human kappa opioid receptor expressed in CHO cells,CHEMBL1139291,KI,CN(C)C[C@H]1CCCC[C@]1(O)c1cccc(C(N)=O)c1
CHEMBL1400,CHEMBL237,Kappa opioid receptor,Ki,=,450.0,nM,CHEMBL1019878,B,Displacement of [3H]U69593 form human kappa opioid receptor expressed in CHO cells,CHEMBL1139291,KI,CN(C)C[C@H]1CCCC[C@]1(O)c1cccc(O)c1
CHEMBL506457,CHEMBL237,Kappa opioid receptor,Ki,=,21.0,nM,CHEMBL1019878,B,Displacement of [3H]U69593 form human kappa opioid receptor expressed in CHO cells,CHEMBL1139291,KI,NC(=O)c1ccc2c3c1O[C@H]1C4NC5C(C[C@@]6(O)[C@H]7Cc8ccc(C(N)=O)c9c8[C@@]6(CCN7CC6CC6)[C@H]5O9)C4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL573214,CHEMBL237,Kappa opioid receptor,Ki,=,0.027,nM,CHEMBL1019878,B,Displacement of [3H]U69593 form human kappa opioid receptor expressed in CHO cells,CHEMBL1139291,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL517567,CHEMBL237,Kappa opioid receptor,Ki,=,2.1,nM,CHEMBL1019878,B,Displacement of [3H]U69593 form human kappa opioid receptor expressed in CHO cells,CHEMBL1139291,KI,CO[C@@]12CC[C@@]3(C[C@@H]1[C@@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(C(N)=O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL511142,CHEMBL237,Kappa opioid receptor,Ki,=,0.62,nM,CHEMBL1019878,B,Displacement of [3H]U69593 form human kappa opioid receptor expressed in CHO cells,CHEMBL1139291,KI,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL516552,CHEMBL237,Kappa opioid receptor,Ki,=,100.0,nM,CHEMBL1019878,B,Displacement of [3H]U69593 form human kappa opioid receptor expressed in CHO cells,CHEMBL1139291,KI,C=CCN1CC[C@]23c4c5ccc(C(N)=O)c4O[C@@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL415284,CHEMBL237,Kappa opioid receptor,Ki,=,0.38,nM,CHEMBL1019878,B,Displacement of [3H]U69593 form human kappa opioid receptor expressed in CHO cells,CHEMBL1139291,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL56585,CHEMBL237,Kappa opioid receptor,Ki,=,0.07,nM,CHEMBL1019878,B,Displacement of [3H]U69593 form human kappa opioid receptor expressed in CHO cells,CHEMBL1139291,KI,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@]1(C)CCN2CC1CC1
CHEMBL297428,CHEMBL237,Kappa opioid receptor,Ki,=,0.06,nM,CHEMBL1019878,B,Displacement of [3H]U69593 form human kappa opioid receptor expressed in CHO cells,CHEMBL1139291,KI,CC1C2Cc3ccc(C(N)=O)cc3C1(C)CCN2CC1CC1
CHEMBL19019,CHEMBL237,Kappa opioid receptor,Ki,=,0.19,nM,CHEMBL1019878,B,Displacement of [3H]U69593 form human kappa opioid receptor expressed in CHO cells,CHEMBL1139291,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL56695,CHEMBL237,Kappa opioid receptor,Ki,=,0.36,nM,CHEMBL1019878,B,Displacement of [3H]U69593 form human kappa opioid receptor expressed in CHO cells,CHEMBL1139291,KI,NC(=O)c1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL397705,CHEMBL237,Kappa opioid receptor,Ki,=,3.0,nM,CHEMBL1019878,B,Displacement of [3H]U69593 form human kappa opioid receptor expressed in CHO cells,CHEMBL1139291,KI,CC(C)=CCN1CC[C@@]2(C)c3cc(O)ccc3C[C@@H]1[C@H]2C
CHEMBL461227,CHEMBL237,Kappa opioid receptor,Ki,=,5.6,nM,CHEMBL1019878,B,Displacement of [3H]U69593 form human kappa opioid receptor expressed in CHO cells,CHEMBL1139291,KI,CC(C)=CCN1CC[C@@]2(C)c3cc(C(N)=O)ccc3C[C@@H]1[C@@H]2C
CHEMBL257661,CHEMBL237,Kappa opioid receptor,Ki,=,9.9,nM,CHEMBL1019878,B,Displacement of [3H]U69593 form human kappa opioid receptor expressed in CHO cells,CHEMBL1139291,KI,C[C@H]1[C@@H]2Cc3ccc(O)cc3[C@]1(C)CCN2C
CHEMBL511884,CHEMBL237,Kappa opioid receptor,Ki,=,19.0,nM,CHEMBL1019878,B,Displacement of [3H]U69593 form human kappa opioid receptor expressed in CHO cells,CHEMBL1139291,KI,CC1C2Cc3ccc(C(N)=O)cc3C1(C)CCN2C
CHEMBL3275494,CHEMBL237,Kappa opioid receptor,Ki,=,2.0,nM,CHEMBL1019878,B,Displacement of [3H]U69593 form human kappa opioid receptor expressed in CHO cells,CHEMBL1139291,KI,C[C@H]1C2Cc3ccc(O)cc3[C@@]1(C)CCN2CCc1ccccc1
CHEMBL464230,CHEMBL237,Kappa opioid receptor,Ki,=,0.55,nM,CHEMBL1019878,B,Displacement of [3H]U69593 form human kappa opioid receptor expressed in CHO cells,CHEMBL1139291,KI,CC1C2Cc3ccc(C(N)=O)cc3C1(C)CCN2CCc1ccccc1
CHEMBL33986,CHEMBL237,Kappa opioid receptor,Ki,=,0.22,nM,CHEMBL1019878,B,Displacement of [3H]U69593 form human kappa opioid receptor expressed in CHO cells,CHEMBL1139291,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3
CHEMBL517779,CHEMBL237,Kappa opioid receptor,Ki,=,0.39,nM,CHEMBL1019878,B,Displacement of [3H]U69593 form human kappa opioid receptor expressed in CHO cells,CHEMBL1139291,KI,NC(=O)c1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3
CHEMBL80,CHEMBL237,Kappa opioid receptor,Ki,=,1.2,nM,CHEMBL1019878,B,Displacement of [3H]U69593 form human kappa opioid receptor expressed in CHO cells,CHEMBL1139291,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL464250,CHEMBL237,Kappa opioid receptor,Ki,=,46.0,nM,CHEMBL1019878,B,Displacement of [3H]U69593 form human kappa opioid receptor expressed in CHO cells,CHEMBL1139291,KI,C=CCN1CC[C@]23c4c5ccc(C(N)=O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL140278,CHEMBL237,Kappa opioid receptor,Ki,=,0.48,nM,CHEMBL1019878,B,Displacement of [3H]U69593 form human kappa opioid receptor expressed in CHO cells,CHEMBL1139291,KI,Oc1ccc2c3c1O[C@H]1[C@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL442719,CHEMBL237,Kappa opioid receptor,Ki,=,30.0,nM,CHEMBL1019878,B,Displacement of [3H]U69593 form human kappa opioid receptor expressed in CHO cells,CHEMBL1139291,KI,NC(=O)c1ccc2c3c1O[C@H]1[C@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL468469,CHEMBL237,Kappa opioid receptor,Ki,=,0.56,nM,CHEMBL1019878,B,Displacement of [3H]U69593 form human kappa opioid receptor expressed in CHO cells,CHEMBL1139291,KI,Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL511588,CHEMBL237,Kappa opioid receptor,Ki,=,100.0,nM,CHEMBL1019878,B,Displacement of [3H]U69593 form human kappa opioid receptor expressed in CHO cells,CHEMBL1139291,KI,NC(=O)c1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL982,CHEMBL237,Kappa opioid receptor,Ki,=,0.12,nM,CHEMBL1019878,B,Displacement of [3H]U69593 form human kappa opioid receptor expressed in CHO cells,CHEMBL1139291,KI,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL518083,CHEMBL237,Kappa opioid receptor,Ki,=,2.1,nM,CHEMBL1019878,B,Displacement of [3H]U69593 form human kappa opioid receptor expressed in CHO cells,CHEMBL1139291,KI,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(C(N)=O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL482496,CHEMBL237,Kappa opioid receptor,Ki,=,288.0,nM,CHEMBL959801,B,Binding affinity to kappa opioid receptor,CHEMBL1150367,KI,[3H]C([3H])([3H])Oc1cc(I)c(OC)cc1CCNCc1ccccc1OC([3H])([3H])[3H]
CHEMBL58646,CHEMBL237,Kappa opioid receptor,Ki,=,0.06,nM,CHEMBL973305,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1150274,KI,C[C@H]1C2Cc3ccc(C(N)=O)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL213880,CHEMBL237,Kappa opioid receptor,Ki,=,36.0,nM,CHEMBL973305,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1150274,KI,C[C@H]1C2Cc3ccc(C(=O)NCc4ccccc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL377789,CHEMBL237,Kappa opioid receptor,Ki,=,1.8,nM,CHEMBL973305,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1150274,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccccc5)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL495462,CHEMBL237,Kappa opioid receptor,Ki,=,32.0,nM,CHEMBL973305,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1150274,KI,C[C@H]1C2Cc3cc(N)c(C(N)=O)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL522375,CHEMBL237,Kappa opioid receptor,Ki,=,0.7,nM,CHEMBL973305,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1150274,KI,C[C@H]1C2Cc3ccc(C(N)=O)c(N)c3[C@@]1(C)CCN2CC1CC1
CHEMBL495461,CHEMBL237,Kappa opioid receptor,Ki,=,110.0,nM,CHEMBL973305,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1150274,KI,C[C@H]1C2Cc3cc([N+](=O)[O-])c(C(N)=O)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL494614,CHEMBL237,Kappa opioid receptor,Ki,=,34.0,nM,CHEMBL973305,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1150274,KI,C[C@H]1C2Cc3ccc(C(N)=O)c([N+](=O)[O-])c3[C@@]1(C)CCN2CC1CC1
CHEMBL494613,CHEMBL237,Kappa opioid receptor,Ki,=,580.0,nM,CHEMBL973305,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1150274,KI,C[C@H]1C2Cc3cc([N+](=O)[O-])c(O)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL509054,CHEMBL237,Kappa opioid receptor,Ki,=,3.2,nM,CHEMBL973305,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1150274,KI,C[C@H]1C2Cc3ccc(O)c([N+](=O)[O-])c3[C@@]1(C)CCN2CC1CC1
CHEMBL468182,CHEMBL237,Kappa opioid receptor,Ki,=,48.0,nM,CHEMBL973305,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1150274,KI,C[C@H]1C2Cc3cc4ncnc(NCc5ccccc5)c4cc3[C@@]1(C)CCN2CC1CC1
CHEMBL463518,CHEMBL237,Kappa opioid receptor,Ki,=,140.0,nM,CHEMBL973305,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1150274,KI,C[C@H]1C2Cc3cc4ncnc(NCCc5ccc(-c6ccccc6)cc5)c4cc3[C@@]1(C)CCN2CC1CC1
CHEMBL511243,CHEMBL237,Kappa opioid receptor,Ki,=,240.0,nM,CHEMBL973305,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1150274,KI,C[C@H]1C2Cc3ccc4c(NCc5ccccc5)ncnc4c3[C@@]1(C)CCN2CC1CC1
CHEMBL468857,CHEMBL237,Kappa opioid receptor,Ki,=,8.6,nM,CHEMBL973305,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1150274,KI,C[C@H]1C2Cc3ccc4c(NCCc5ccc(-c6ccccc6)cc5)ncnc4c3[C@@]1(C)CCN2CC1CC1
CHEMBL502583,CHEMBL237,Kappa opioid receptor,Ki,=,560.0,nM,CHEMBL973305,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1150274,KI,C[C@H]1C2Cc3cc4ncnc(N)c4cc3[C@@]1(C)CCN2CC1CC1
CHEMBL469189,CHEMBL237,Kappa opioid receptor,Ki,=,1.0,nM,CHEMBL973305,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1150274,KI,C[C@H]1C2Cc3ccc4c(N)ncnc4c3[C@@]1(C)CCN2CC1CC1
CHEMBL512474,CHEMBL237,Kappa opioid receptor,Ki,=,160.0,nM,CHEMBL973305,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1150274,KI,C[C@H]1C2Cc3ccc4c(=O)[nH]cnc4c3[C@@]1(C)CCN2CC1CC1
CHEMBL469188,CHEMBL237,Kappa opioid receptor,Ki,=,12.0,nM,CHEMBL973305,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1150274,KI,C[C@H]1C2Cc3cc4nc[nH]c(=O)c4cc3[C@@]1(C)CCN2CC1CC1
CHEMBL493621,CHEMBL237,Kappa opioid receptor,Ki,=,0.74,nM,CHEMBL973305,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1150274,KI,C[C@H]1C2Cc3cc4cc[nH]c(=O)c4cc3[C@@]1(C)CCN2CC1CC1
CHEMBL25230,CHEMBL237,Kappa opioid receptor,Ki,=,130.0,nM,CHEMBL989029,B,Displacement of [3H]diprenorphine from human kappa opioid receptor in CHO cells at 10 uM,CHEMBL1140111,KI,C=CCN1C[C@H](C)N([C@H](c2ccc(C(=O)N(CC)CC)cc2)c2cccc(O)c2)C[C@H]1C
CHEMBL25230,CHEMBL237,Kappa opioid receptor,Ki,=,3400.0,nM,CHEMBL993333,B,Displacement of [3H]diprenorphine from human kappa opioid receptor in CHO cells,CHEMBL1140111,KI,C=CCN1C[C@H](C)N([C@H](c2ccc(C(=O)N(CC)CC)cc2)c2cccc(O)c2)C[C@H]1C
CHEMBL494479,CHEMBL237,Kappa opioid receptor,Ki,=,830.0,nM,CHEMBL993333,B,Displacement of [3H]diprenorphine from human kappa opioid receptor in CHO cells,CHEMBL1140111,KI,CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccc(O)cc32)cc1
CHEMBL494265,CHEMBL237,Kappa opioid receptor,Ki,=,520.0,nM,CHEMBL993333,B,Displacement of [3H]diprenorphine from human kappa opioid receptor in CHO cells,CHEMBL1140111,KI,COC(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1
CHEMBL492447,CHEMBL237,Kappa opioid receptor,Ki,=,3400.0,nM,CHEMBL993333,B,Displacement of [3H]diprenorphine from human kappa opioid receptor in CHO cells,CHEMBL1140111,KI,C1=C(c2ccccc2)c2ccccc2OC12CCNCC2
CHEMBL492449,CHEMBL237,Kappa opioid receptor,Ki,=,2000.0,nM,CHEMBL993333,B,Displacement of [3H]diprenorphine from human kappa opioid receptor in CHO cells,CHEMBL1140111,KI,FC(F)(F)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1
CHEMBL441765,CHEMBL237,Kappa opioid receptor,Ki,=,1.7,nM,CHEMBL947369,B,Displacement of radiolabeled U50488 from human kappa-type opioid receptor,CHEMBL1140203,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL493846,CHEMBL237,Kappa opioid receptor,Ki,=,65.26,nM,CHEMBL1006332,B,Displacement of [3H]norBNI from monocloned kappa opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccc2ccccc2c1
CHEMBL495058,CHEMBL237,Kappa opioid receptor,Ki,=,608.76,nM,CHEMBL1006332,B,Displacement of [3H]norBNI from monocloned kappa opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C(N[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccc2ccccc2c1
CHEMBL495057,CHEMBL237,Kappa opioid receptor,Ki,=,0.57,nM,CHEMBL1006332,B,Displacement of [3H]norBNI from monocloned kappa opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1cnc2ccccc2c1
CHEMBL523382,CHEMBL237,Kappa opioid receptor,Ki,=,1.81,nM,CHEMBL1006332,B,Displacement of [3H]norBNI from monocloned kappa opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C(N[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1cnc2ccccc2c1
CHEMBL494854,CHEMBL237,Kappa opioid receptor,Ki,=,5.04,nM,CHEMBL1006332,B,Displacement of [3H]norBNI from monocloned kappa opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccc2ccccc2n1
CHEMBL494853,CHEMBL237,Kappa opioid receptor,Ki,=,9.84,nM,CHEMBL1006332,B,Displacement of [3H]norBNI from monocloned kappa opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C(N[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccc2ccccc2n1
CHEMBL521854,CHEMBL237,Kappa opioid receptor,Ki,=,1.58,nM,CHEMBL1006332,B,Displacement of [3H]norBNI from monocloned kappa opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1cc2ccccc2cn1
CHEMBL522201,CHEMBL237,Kappa opioid receptor,Ki,=,26.45,nM,CHEMBL1006332,B,Displacement of [3H]norBNI from monocloned kappa opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C(N[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1cc2ccccc2cn1
CHEMBL271815,CHEMBL237,Kappa opioid receptor,Ki,=,7.79,nM,CHEMBL1006332,B,Displacement of [3H]norBNI from monocloned kappa opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccccc1
CHEMBL271797,CHEMBL237,Kappa opioid receptor,Ki,=,41.69,nM,CHEMBL1006332,B,Displacement of [3H]norBNI from monocloned kappa opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C(N[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccccc1
CHEMBL522143,CHEMBL237,Kappa opioid receptor,Ki,=,60.72,nM,CHEMBL1006332,B,Displacement of [3H]norBNI from monocloned kappa opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccncc1
CHEMBL515864,CHEMBL237,Kappa opioid receptor,Ki,=,19.56,nM,CHEMBL1006332,B,Displacement of [3H]norBNI from monocloned kappa opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C(N[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccncc1
CHEMBL472937,CHEMBL237,Kappa opioid receptor,Ki,=,5.42,nM,CHEMBL1006332,B,Displacement of [3H]norBNI from monocloned kappa opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1cccnc1
CHEMBL514769,CHEMBL237,Kappa opioid receptor,Ki,=,77.23,nM,CHEMBL1006332,B,Displacement of [3H]norBNI from monocloned kappa opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C(N[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1cccnc1
CHEMBL260528,CHEMBL237,Kappa opioid receptor,Ki,=,277.96,nM,CHEMBL1006332,B,Displacement of [3H]norBNI from monocloned kappa opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccccn1
CHEMBL514781,CHEMBL237,Kappa opioid receptor,Ki,=,222.58,nM,CHEMBL1006332,B,Displacement of [3H]norBNI from monocloned kappa opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C(N[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccccn1
CHEMBL525046,CHEMBL237,Kappa opioid receptor,Ki,=,1012.7,nM,CHEMBL1006332,B,Displacement of [3H]norBNI from monocloned kappa opioid receptor expressed in CHO cells,CHEMBL1140920,KI,C[C@@H](O)[C@H](NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H]2Cc3ccccc3CN2)CSSC1(C)C)C(N)=O
CHEMBL473136,CHEMBL237,Kappa opioid receptor,Ki,=,0.94,nM,CHEMBL1006332,B,Displacement of [3H]norBNI from monocloned kappa opioid receptor expressed in CHO cells,CHEMBL1140920,KI,COC(=O)/C=C/C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL19019,CHEMBL237,Kappa opioid receptor,Ki,=,5.15,nM,CHEMBL1006332,B,Displacement of [3H]norBNI from monocloned kappa opioid receptor expressed in CHO cells,CHEMBL1140920,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL398707,CHEMBL237,Kappa opioid receptor,Ki,=,2.8,nM,CHEMBL955071,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL1153960,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5
CHEMBL19019,CHEMBL237,Kappa opioid receptor,Ki,=,0.19,nM,CHEMBL955071,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL1153960,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL567175,CHEMBL237,Kappa opioid receptor,Ki,=,2.9,nM,CHEMBL955071,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL1153960,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL511795,CHEMBL237,Kappa opioid receptor,Ki,=,47.0,nM,CHEMBL955071,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL1153960,KI,NC(=O)c1ccc2c3c1O[C@H]1c4[nH]c5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL469815,CHEMBL237,Kappa opioid receptor,Ki,=,0.81,nM,CHEMBL955071,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL1153960,KI,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)Cc1c([nH]c2ccccc12)C3
CHEMBL471049,CHEMBL237,Kappa opioid receptor,Ki,=,19.0,nM,CHEMBL955071,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL1153960,KI,CN1CC[C@]23c4c5ccc(C(N)=O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5
CHEMBL471048,CHEMBL237,Kappa opioid receptor,Ki,=,2.3,nM,CHEMBL955071,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL1153960,KI,CN1CC[C@]23CC(=O)CC[C@H]2[C@H]1Cc1ccc(C(N)=O)c(O)c13
CHEMBL511816,CHEMBL237,Kappa opioid receptor,Ki,=,0.24,nM,CHEMBL955071,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL1153960,KI,Oc1ccc2c3c1O[C@H]1CCC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL511621,CHEMBL237,Kappa opioid receptor,Ki,=,16.0,nM,CHEMBL955071,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL1153960,KI,NC(=O)c1ccc2c3c1O[C@H]1CCC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL470005,CHEMBL237,Kappa opioid receptor,Ki,=,0.29,nM,CHEMBL955071,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL1153960,KI,NC(=O)c1ccc2c(c1O)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CC1)CC3
CHEMBL470617,CHEMBL237,Kappa opioid receptor,Ki,=,6.3,nM,CHEMBL955071,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL1153960,KI,C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.[I-]
CHEMBL511461,CHEMBL237,Kappa opioid receptor,Ki,=,210.0,nM,CHEMBL955071,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL1153960,KI,C[N+]1(CC2CC2)CC[C@]23c4c5ccc(C(N)=O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.[I-]
CHEMBL511302,CHEMBL237,Kappa opioid receptor,Ki,=,7.7,nM,CHEMBL955071,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL1153960,KI,C[N+]1(CC2CC2)CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(N)=O)c(O)c13.[I-]
CHEMBL511645,CHEMBL237,Kappa opioid receptor,Ki,=,0.34,nM,CHEMBL955071,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL1153960,KI,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CCC4)[C@H](C2)[C@]1(O)CC[C@@H](O)C3
CHEMBL895,CHEMBL237,Kappa opioid receptor,Ki,=,3.0,nM,CHEMBL955071,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL1153960,KI,Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
CHEMBL513762,CHEMBL237,Kappa opioid receptor,Ki,=,0.46,nM,CHEMBL955071,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL1153960,KI,NC(=O)c1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
CHEMBL512150,CHEMBL237,Kappa opioid receptor,Ki,=,9.0,nM,CHEMBL955071,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL1153960,KI,NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CCC4)[C@H](C2)[C@]1(O)CC[C@H](O)C3
CHEMBL56695,CHEMBL237,Kappa opioid receptor,Ki,=,11.0,nM,CHEMBL955071,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL1153960,KI,NC(=O)c1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL471243,CHEMBL237,Kappa opioid receptor,Ki,=,0.23,nM,CHEMBL955071,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL1153960,KI,Cl.NC(=O)c1ccc2c(c1O)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCC(=O)C3
CHEMBL140050,CHEMBL237,Kappa opioid receptor,Ki,=,0.5,nM,CHEMBL992672,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1153907,KI,CCC[C@@](C)(O)[C@H]1C[C@@]23C=C[C@]1(OC)[C@@H]1Oc4c(O)ccc5c4[C@@]12CCN(C)[C@@H]3C5
CHEMBL19019,CHEMBL237,Kappa opioid receptor,Ki,=,5.15,nM,CHEMBL993515,B,Displacement of [3H]norBNI from kappa opioid receptor expressed in CHO cells,CHEMBL1153911,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL473136,CHEMBL237,Kappa opioid receptor,Ki,=,0.94,nM,CHEMBL993515,B,Displacement of [3H]norBNI from kappa opioid receptor expressed in CHO cells,CHEMBL1153911,KI,COC(=O)/C=C/C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL500766,CHEMBL237,Kappa opioid receptor,Ki,=,1012.7,nM,CHEMBL993515,B,Displacement of [3H]norBNI from kappa opioid receptor expressed in CHO cells,CHEMBL1153911,KI,C[C@@H](O)[C@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](Cc1ccc(O)cc1)NC(=O)[C@H](CS)NC(=O)[C@H](N)Cc1ccccc1)[C@@H](C)O)C(C)(C)S)C(=O)O
CHEMBL476600,CHEMBL237,Kappa opioid receptor,Ki,=,25.5,nM,CHEMBL993515,B,Displacement of [3H]norBNI from kappa opioid receptor expressed in CHO cells,CHEMBL1153911,KI,O=C(O[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccccn1
CHEMBL476603,CHEMBL237,Kappa opioid receptor,Ki,=,47.81,nM,CHEMBL993515,B,Displacement of [3H]norBNI from kappa opioid receptor expressed in CHO cells,CHEMBL1153911,KI,O=C(O[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1cccnc1
CHEMBL515621,CHEMBL237,Kappa opioid receptor,Ki,=,49.21,nM,CHEMBL993515,B,Displacement of [3H]norBNI from kappa opioid receptor expressed in CHO cells,CHEMBL1153911,KI,O=C(O[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccncc1
CHEMBL516263,CHEMBL237,Kappa opioid receptor,Ki,=,586.42,nM,CHEMBL993515,B,Displacement of [3H]norBNI from kappa opioid receptor expressed in CHO cells,CHEMBL1153911,KI,O=C(O[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccccc1
CHEMBL472843,CHEMBL237,Kappa opioid receptor,Ki,=,67.15,nM,CHEMBL993515,B,Displacement of [3H]norBNI from kappa opioid receptor expressed in CHO cells,CHEMBL1153911,KI,O=C(O[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccc2ccccc2n1
CHEMBL473253,CHEMBL237,Kappa opioid receptor,Ki,=,148.23,nM,CHEMBL993515,B,Displacement of [3H]norBNI from kappa opioid receptor expressed in CHO cells,CHEMBL1153911,KI,O=C(O[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1cnc2ccccc2c1
CHEMBL513990,CHEMBL237,Kappa opioid receptor,Ki,=,46.57,nM,CHEMBL993515,B,Displacement of [3H]norBNI from kappa opioid receptor expressed in CHO cells,CHEMBL1153911,KI,O=C(O[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccc2ccccc2c1
CHEMBL56585,CHEMBL237,Kappa opioid receptor,Ki,=,0.2,nM,CHEMBL1016592,B,Displacement of [3H]U-69593 from kappa opioid receptor,CHEMBL1147348,KI,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@]1(C)CCN2CC1CC1
CHEMBL445332,CHEMBL237,Kappa opioid receptor,Ki,=,2.5,nM,CHEMBL988701,B,Displacement of [3H]diprenorphine from human KOPR expressed in CHO cells,CHEMBL1143388,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL390935,CHEMBL237,Kappa opioid receptor,Ki,=,2.9,nM,CHEMBL988701,B,Displacement of [3H]diprenorphine from human KOPR expressed in CHO cells,CHEMBL1143388,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3Br)C[C@]21C
CHEMBL458234,CHEMBL237,Kappa opioid receptor,Ki,=,7.1,nM,CHEMBL988701,B,Displacement of [3H]diprenorphine from human KOPR expressed in CHO cells,CHEMBL1143388,KI,C=Cc1occc1[C@@H]1C[C@]2(C)[C@H]3C(=O)[C@@H](OC(C)=O)C[C@@H](C(=O)OC)[C@]3(C)CC[C@H]2C(=O)O1
CHEMBL458235,CHEMBL237,Kappa opioid receptor,Ki,=,41.0,nM,CHEMBL988701,B,Displacement of [3H]diprenorphine from human KOPR expressed in CHO cells,CHEMBL1143388,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](c3ccoc3)C[C@]21C
CHEMBL458890,CHEMBL237,Kappa opioid receptor,Ki,=,55.0,nM,CHEMBL988701,B,Displacement of [3H]diprenorphine from human KOPR expressed in CHO cells,CHEMBL1143388,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C(=O)O)C[C@]21C
CHEMBL456695,CHEMBL237,Kappa opioid receptor,Ki,=,498.0,nM,CHEMBL988701,B,Displacement of [3H]diprenorphine from human KOPR expressed in CHO cells,CHEMBL1143388,KI,COC[C@@H]1C[C@]2(C)[C@H]3C(=O)[C@@H](OC(C)=O)C[C@@H](C(=O)OC)[C@]3(C)CC[C@H]2C(=O)O1
CHEMBL458869,CHEMBL237,Kappa opioid receptor,Ki,=,497.0,nM,CHEMBL988701,B,Displacement of [3H]diprenorphine from human KOPR expressed in CHO cells,CHEMBL1143388,KI,CCOC[C@@H]1C[C@]2(C)[C@H]3C(=O)[C@@H](OC(C)=O)C[C@@H](C(=O)OC)[C@]3(C)CC[C@H]2C(=O)O1
CHEMBL514597,CHEMBL237,Kappa opioid receptor,Ki,=,555.0,nM,CHEMBL988701,B,Displacement of [3H]diprenorphine from human KOPR expressed in CHO cells,CHEMBL1143388,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](COC(C)=O)C[C@]21C
CHEMBL458870,CHEMBL237,Kappa opioid receptor,Ki,=,38.0,nM,CHEMBL988701,B,Displacement of [3H]diprenorphine from human KOPR expressed in CHO cells,CHEMBL1143388,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C(=O)c3cccs3)C[C@]21C
CHEMBL457341,CHEMBL237,Kappa opioid receptor,Ki,=,83.0,nM,CHEMBL988701,B,Displacement of [3H]diprenorphine from human KOPR expressed in CHO cells,CHEMBL1143388,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C(=O)c3cnccn3)C[C@]21C
CHEMBL456055,CHEMBL237,Kappa opioid receptor,Ki,=,20.0,nM,CHEMBL988701,B,Displacement of [3H]diprenorphine from human KOPR expressed in CHO cells,CHEMBL1143388,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C(O)c3ccco3)C[C@]21C
CHEMBL456056,CHEMBL237,Kappa opioid receptor,Ki,=,154.0,nM,CHEMBL988701,B,Displacement of [3H]diprenorphine from human KOPR expressed in CHO cells,CHEMBL1143388,KI,COC(=O)[C@@H]1C[C@]2(C)[C@H]3C(=O)[C@@H](OC(C)=O)C[C@@H](C(=O)OC)[C@]3(C)CC[C@H]2C(=O)O1
CHEMBL456057,CHEMBL237,Kappa opioid receptor,Ki,=,196.0,nM,CHEMBL988701,B,Displacement of [3H]diprenorphine from human KOPR expressed in CHO cells,CHEMBL1143388,KI,CCOC(=O)[C@@H]1C[C@]2(C)[C@H]3C(=O)[C@@H](OC(C)=O)C[C@@H](C(=O)OC)[C@]3(C)CC[C@H]2C(=O)O1
CHEMBL456923,CHEMBL237,Kappa opioid receptor,Ki,=,109.0,nM,CHEMBL988701,B,Displacement of [3H]diprenorphine from human KOPR expressed in CHO cells,CHEMBL1143388,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C(=O)OC(C)C)C[C@]21C
CHEMBL441765,CHEMBL237,Kappa opioid receptor,Ki,=,1.6,nM,CHEMBL988701,B,Displacement of [3H]diprenorphine from human KOPR expressed in CHO cells,CHEMBL1143388,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL481512,CHEMBL237,Kappa opioid receptor,Ki,=,23.1,nM,CHEMBL993918,B,Displacement of [3H]enadoline from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1143349,KI,CC1(N2CCC(n3c([C@@H]4CCCNC4)nc4ccccc43)CC2)CCCCCCC1
CHEMBL518950,CHEMBL237,Kappa opioid receptor,Ki,=,25.0,nM,CHEMBL993918,B,Displacement of [3H]enadoline from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1143349,KI,CN1CCC[C@@H](c2nc3ccccc3n2C2CCN(C3(C)CCCCCCC3)CC2)C1
CHEMBL481366,CHEMBL237,Kappa opioid receptor,Ki,=,9.2,nM,CHEMBL993918,B,Displacement of [3H]enadoline from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1143349,KI,CC1(N2CCC(n3c([C@H]4CCCNC4)nc4ccccc43)CC2)CCCCCCC1
CHEMBL501331,CHEMBL237,Kappa opioid receptor,Ki,=,10.0,nM,CHEMBL993918,B,Displacement of [3H]enadoline from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1143349,KI,CN1CCC[C@H](c2nc3ccccc3n2C2CCN(C3(C)CCCCCCC3)CC2)C1
CHEMBL519100,CHEMBL237,Kappa opioid receptor,Ki,=,352.0,nM,CHEMBL993918,B,Displacement of [3H]enadoline from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1143349,KI,CC1(N2CCC(n3c(-c4cccc(C(F)(F)F)c4)nc4ccccc43)CC2)CCCCCCC1
CHEMBL480425,CHEMBL237,Kappa opioid receptor,Ki,=,43.0,nM,CHEMBL993918,B,Displacement of [3H]enadoline from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1143349,KI,CC1(N2CCC(n3c(-c4cccc(OCCO)c4)nc4ccccc43)CC2)CCCCCCC1
CHEMBL480426,CHEMBL237,Kappa opioid receptor,Ki,=,72.0,nM,CHEMBL993918,B,Displacement of [3H]enadoline from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1143349,KI,CC1(N2CCC(n3c(-c4cccc(CN)c4)nc4ccccc43)CC2)CCCCCCC1
CHEMBL519925,CHEMBL237,Kappa opioid receptor,Ki,=,15.0,nM,CHEMBL993918,B,Displacement of [3H]enadoline from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1143349,KI,CC1CN(c2nc3ccccc3n2C2CCN(C3(C)CCCCCCC3)CC2)CC(C)N1
CHEMBL3084529,CHEMBL237,Kappa opioid receptor,Ki,=,1610.0,nM,CHEMBL1009679,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1138605,KI,NC(=O)[C@]1(c2ccc(F)cn2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL228690,CHEMBL237,Kappa opioid receptor,Ki,=,364.0,nM,CHEMBL966895,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1138606,KI,OC1(c2ccccc2)CCN(C(c2ccccc2)c2ccccc2)CC1
CHEMBL466921,CHEMBL237,Kappa opioid receptor,Ki,=,752.0,nM,CHEMBL966895,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1138606,KI,NC(=O)C1(c2ccc(F)cc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL466847,CHEMBL237,Kappa opioid receptor,Ki,=,109.0,nM,CHEMBL966895,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1138606,KI,OC1(c2ccccc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL513136,CHEMBL237,Kappa opioid receptor,Ki,=,131.0,nM,CHEMBL966895,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1138606,KI,Cc1ccccc1C(c1ccccc1C)N1C2CCC1CC(O)(c1ccccc1)C2
CHEMBL512414,CHEMBL237,Kappa opioid receptor,Ki,=,268.0,nM,CHEMBL966895,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1138606,KI,NC(=O)C1(c2ccccc2)CC2CCC(C1)N2C(c1ccccc1Cl)c1ccccc1Cl
CHEMBL445332,CHEMBL237,Kappa opioid receptor,Ki,=,1.9,nM,CHEMBL968095,B,Displacement of [125]OXY from kappa opioid receptor,CHEMBL1157966,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL500122,CHEMBL237,Kappa opioid receptor,Ki,=,50.0,nM,CHEMBL968095,B,Displacement of [125]OXY from kappa opioid receptor,CHEMBL1157966,KI,COC(=O)[C@@H]1C[C@H](OS(=O)(=O)c2ccc(C)cc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL526700,CHEMBL237,Kappa opioid receptor,Ki,=,60.0,nM,CHEMBL968095,B,Displacement of [125]OXY from kappa opioid receptor,CHEMBL1157966,KI,COC(=O)[C@@H]1C[C@H](OS(=O)(=O)c2ccccc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL264967,CHEMBL237,Kappa opioid receptor,Ki,=,260.0,nM,CHEMBL968095,B,Displacement of [125]OXY from kappa opioid receptor,CHEMBL1157966,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2cccs2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL259299,CHEMBL237,Kappa opioid receptor,Ki,=,740.0,nM,CHEMBL968095,B,Displacement of [125]OXY from kappa opioid receptor,CHEMBL1157966,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccc(Br)cc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL261024,CHEMBL237,Kappa opioid receptor,Ki,=,70.0,nM,CHEMBL968095,B,Displacement of [125]OXY from kappa opioid receptor,CHEMBL1157966,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2cccc(Br)c2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL407155,CHEMBL237,Kappa opioid receptor,Ki,=,90.0,nM,CHEMBL968095,B,Displacement of [125]OXY from kappa opioid receptor,CHEMBL1157966,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccccc2Br)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL526686,CHEMBL237,Kappa opioid receptor,Ki,=,180.0,nM,CHEMBL968095,B,Displacement of [125]OXY from kappa opioid receptor,CHEMBL1157966,KI,COC(=O)[C@@H]1C[C@H](OC(=O)CCc2ccccc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL499315,CHEMBL237,Kappa opioid receptor,Ki,=,290.0,nM,CHEMBL968095,B,Displacement of [125]OXY from kappa opioid receptor,CHEMBL1157966,KI,COC(=O)[C@@H]1C[C@H](OC(=O)Cc2ccccc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL524522,CHEMBL237,Kappa opioid receptor,Ki,=,90.0,nM,CHEMBL968095,B,Displacement of [125]OXY from kappa opioid receptor,CHEMBL1157966,KI,COC(=O)[C@@H]1C[C@H](OC(=O)CNC(=O)OC(C)(C)C)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL498116,CHEMBL237,Kappa opioid receptor,Ki,=,70.0,nM,CHEMBL968095,B,Displacement of [125]OXY from kappa opioid receptor,CHEMBL1157966,KI,CCCCCC(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL498442,CHEMBL237,Kappa opioid receptor,Ki,=,15.0,nM,CHEMBL968095,B,Displacement of [125]OXY from kappa opioid receptor,CHEMBL1157966,KI,CCCCC(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL379138,CHEMBL237,Kappa opioid receptor,Ki,=,4.0,nM,CHEMBL968095,B,Displacement of [125]OXY from kappa opioid receptor,CHEMBL1157966,KI,CCCC(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL365216,CHEMBL237,Kappa opioid receptor,Ki,=,2.3,nM,CHEMBL968095,B,Displacement of [125]OXY from kappa opioid receptor,CHEMBL1157966,KI,COC(=O)[C@@H]1C[C@H](OS(C)(=O)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL363324,CHEMBL237,Kappa opioid receptor,Ki,=,90.0,nM,CHEMBL968095,B,Displacement of [125]OXY from kappa opioid receptor,CHEMBL1157966,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccccc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL370272,CHEMBL237,Kappa opioid receptor,Ki,=,1.8,nM,CHEMBL968095,B,Displacement of [125]OXY from kappa opioid receptor,CHEMBL1157966,KI,CCC(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL455906,CHEMBL237,Kappa opioid receptor,Ki,=,560.0,nM,CHEMBL1021468,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1151739,KI,Oc1ccc2c(c1)[C@]13CCC[C@H](C1)N(CCc1ccccc1)C[C@@H]3O2
CHEMBL509260,CHEMBL237,Kappa opioid receptor,Ki,=,620.0,nM,CHEMBL1021468,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1151739,KI,CN1C[C@@H]2Oc3ccc(O)cc3[C@@]23CCC[C@@H]1C3
CHEMBL515842,CHEMBL237,Kappa opioid receptor,Ki,=,26.0,nM,CHEMBL1021468,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1151739,KI,Oc1cccc2c1O[C@@H]1CC[C@H]3C[C@@]21CCN3CCc1ccccc1
CHEMBL517866,CHEMBL237,Kappa opioid receptor,Ki,=,10000.0,nM,CHEMBL1021468,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1151739,KI,CN1CC[C@@]23C[C@@H]1CC[C@H]2Oc1ccc(O)cc13
CHEMBL455905,CHEMBL237,Kappa opioid receptor,Ki,=,200.0,nM,CHEMBL1021468,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1151739,KI,Oc1cccc2c1O[C@H]1CN(CCc3ccccc3)[C@@H]3CCC[C@]21C3
CHEMBL450850,CHEMBL237,Kappa opioid receptor,Ki,=,910.0,nM,CHEMBL1021468,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1151739,KI,CN1CC[C@@]23C[C@@H]1CC[C@H]2Oc1c(O)cccc13
CHEMBL457389,CHEMBL237,Kappa opioid receptor,Ki,=,4820.0,nM,CHEMBL1021468,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1151739,KI,CN1C[C@@H]2Oc3c(O)cccc3[C@@]23CCC[C@@H]1C3
CHEMBL515681,CHEMBL237,Kappa opioid receptor,Ki,=,78.0,nM,CHEMBL1021468,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1151739,KI,Oc1ccc2c(c1)[C@@]13CCN(CCc4ccccc4)[C@@H](CC[C@H]1O2)C3
CHEMBL475108,CHEMBL237,Kappa opioid receptor,Ki,=,0.23,nM,CHEMBL1030606,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1136834,KI,C[C@H]1C2Cc3ccc4[nH]nnc4c3[C@@]1(C)CCN2CC1CC1
CHEMBL506290,CHEMBL237,Kappa opioid receptor,Ki,=,0.51,nM,CHEMBL1030606,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1136834,KI,Cc1nc2c3c(ccc2[nH]1)CC1[C@H](C)[C@]3(C)CCN1CC1CC1
CHEMBL475107,CHEMBL237,Kappa opioid receptor,Ki,=,0.92,nM,CHEMBL1030606,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1136834,KI,C[C@H]1C2Cc3ccc4[nH]cnc4c3[C@@]1(C)CCN2CC1CC1
CHEMBL515593,CHEMBL237,Kappa opioid receptor,Ki,=,0.81,nM,CHEMBL1030606,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1136834,KI,C[C@H]1C2Cc3cc4nn[nH]c4cc3[C@@]1(C)CCN2CC1CC1
CHEMBL515257,CHEMBL237,Kappa opioid receptor,Ki,=,12.0,nM,CHEMBL1030606,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1136834,KI,C[C@H]1C2Cc3cc4nc(O)[nH]c4cc3[C@@]1(C)CCN2CC1CC1
CHEMBL473699,CHEMBL237,Kappa opioid receptor,Ki,=,0.05,nM,CHEMBL1030606,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1136834,KI,Cc1nc2cc3c(cc2[nH]1)[C@@]1(C)CCN(CC2CC2)C(C3)[C@@H]1C
CHEMBL518712,CHEMBL237,Kappa opioid receptor,Ki,=,0.063,nM,CHEMBL1030606,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1136834,KI,C[C@H]1C2Cc3cc4nc[nH]c4cc3[C@@]1(C)CCN2CC1CC1
CHEMBL170384,CHEMBL237,Kappa opioid receptor,Ki,=,7.0,nM,CHEMBL1030606,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1136834,KI,C[C@H]1C2Cc3cc4cc[nH]c4cc3[C@@]1(C)CCN2CC1CC1
CHEMBL56585,CHEMBL237,Kappa opioid receptor,Ki,=,0.07,nM,CHEMBL1030606,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1136834,KI,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@]1(C)CCN2CC1CC1
CHEMBL240657,CHEMBL237,Kappa opioid receptor,Ki,=,137.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,O=C1NCN(c2ccccc2)C12CCN(C(c1ccccc1)c1ccccc1)CC2
CHEMBL510201,CHEMBL237,Kappa opioid receptor,Ki,=,150.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CN1CN(c2ccccc2)C2(CCN(C(c3ccccc3)c3ccccc3)CC2)C1=O
CHEMBL474091,CHEMBL237,Kappa opioid receptor,Ki,=,506.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CCN1CN(c2ccccc2)C2(CCN(C(c3ccccc3)c3ccccc3)CC2)C1=O
CHEMBL475308,CHEMBL237,Kappa opioid receptor,Ki,=,1342.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CCCN1CN(c2ccccc2)C2(CCN(C(c3ccccc3)c3ccccc3)CC2)C1=O
CHEMBL514606,CHEMBL237,Kappa opioid receptor,Ki,=,773.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CCCCN1CN(c2ccccc2)C2(CCN(C(c3ccccc3)c3ccccc3)CC2)C1=O
CHEMBL472676,CHEMBL237,Kappa opioid receptor,Ki,=,543.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CC(C)N1CN(c2ccccc2)C2(CCN(C(c3ccccc3)c3ccccc3)CC2)C1=O
CHEMBL472677,CHEMBL237,Kappa opioid receptor,Ki,=,633.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,O=C1N(CC2CC2)CN(c2ccccc2)C12CCN(C(c1ccccc1)c1ccccc1)CC2
CHEMBL515901,CHEMBL237,Kappa opioid receptor,Ki,=,1846.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,O=C1N(CC2CCC2)CN(c2ccccc2)C12CCN(C(c1ccccc1)c1ccccc1)CC2
CHEMBL515554,CHEMBL237,Kappa opioid receptor,Ki,=,2316.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,O=C1N(CC2CCCCC2)CN(c2ccccc2)C12CCN(C(c1ccccc1)c1ccccc1)CC2
CHEMBL474708,CHEMBL237,Kappa opioid receptor,Ki,=,1268.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,C#CCN1CN(c2ccccc2)C2(CCN(C(c3ccccc3)c3ccccc3)CC2)C1=O
CHEMBL514965,CHEMBL237,Kappa opioid receptor,Ki,=,694.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,C=CCN1CN(c2ccccc2)C2(CCN(C(c3ccccc3)c3ccccc3)CC2)C1=O
CHEMBL241272,CHEMBL237,Kappa opioid receptor,Ki,=,5887.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,O=C1NCN(c2ccccc2)C12CCN(C(c1ccccc1Cl)c1ccccc1Cl)CC2
CHEMBL475496,CHEMBL237,Kappa opioid receptor,Ki,=,81010.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CCCCN1CN(c2ccccc2)C2(CCN(C(c3ccccc3Cl)c3ccccc3Cl)CC2)C1=O
CHEMBL475497,CHEMBL237,Kappa opioid receptor,Ki,=,46515.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CC(C)CCN1CN(c2ccccc2)C2(CCN(C(c3ccccc3Cl)c3ccccc3Cl)CC2)C1=O
CHEMBL516077,CHEMBL237,Kappa opioid receptor,Ki,=,2274.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,COC(=O)CN1CN(c2ccccc2)C2(CCN(C(c3ccccc3Cl)c3ccccc3Cl)CC2)C1=O
CHEMBL473884,CHEMBL237,Kappa opioid receptor,Ki,=,1747.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,O=C1N(CCO)CN(c2ccccc2)C12CCN(C(c1ccccc1Cl)c1ccccc1Cl)CC2
CHEMBL516024,CHEMBL237,Kappa opioid receptor,Ki,=,1830.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,COCCN1CN(c2ccccc2)C2(CCN(C(c3ccccc3Cl)c3ccccc3Cl)CC2)C1=O
CHEMBL472867,CHEMBL237,Kappa opioid receptor,Ki,=,852.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,NCCN1CN(c2ccccc2)C2(CCN(C(c3ccccc3Cl)c3ccccc3Cl)CC2)C1=O
CHEMBL473068,CHEMBL237,Kappa opioid receptor,Ki,=,871.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CNCCN1CN(c2ccccc2)C2(CCN(C(c3ccccc3Cl)c3ccccc3Cl)CC2)C1=O
CHEMBL475096,CHEMBL237,Kappa opioid receptor,Ki,=,497.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CCNCCN1CN(c2ccccc2)C2(CCN(C(c3ccccc3Cl)c3ccccc3Cl)CC2)C1=O
CHEMBL518325,CHEMBL237,Kappa opioid receptor,Ki,=,469.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CC(C)NCCN1CN(c2ccccc2)C2(CCN(C(c3ccccc3Cl)c3ccccc3Cl)CC2)C1=O
CHEMBL456225,CHEMBL237,Kappa opioid receptor,Ki,=,247.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,O=C1N(CCNC2CCCC2)CN(c2ccccc2)C12CCN(C(c1ccccc1Cl)c1ccccc1Cl)CC2
CHEMBL510745,CHEMBL237,Kappa opioid receptor,Ki,=,224.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,O=C1N(CCNC2CCCCC2)CN(c2ccccc2)C12CCN(C(c1ccccc1Cl)c1ccccc1Cl)CC2
CHEMBL460636,CHEMBL237,Kappa opioid receptor,Ki,=,320.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CN(C)CCN1CN(c2ccccc2)C2(CCN(C(c3ccccc3Cl)c3ccccc3Cl)CC2)C1=O
CHEMBL517265,CHEMBL237,Kappa opioid receptor,Ki,=,1014.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,O=C1N(CCNC2CC2)CN(c2ccccc2)C12CCN(C(c1ccccc1Cl)c1ccccc1Cl)CC2
CHEMBL499169,CHEMBL237,Kappa opioid receptor,Ki,=,674.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CC(C)N(CCN1CN(c2ccccc2)C2(CCN(C(c3ccccc3Cl)c3ccccc3Cl)CC2)C1=O)C(C)C
CHEMBL515829,CHEMBL237,Kappa opioid receptor,Ki,=,165.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CCCCNCCN1CN(c2ccccc2)C2(CCN(C(c3ccccc3Cl)c3ccccc3Cl)CC2)C1=O
CHEMBL457244,CHEMBL237,Kappa opioid receptor,Ki,=,238.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CC(C)CNCCN1CN(c2ccccc2)C2(CCN(C(c3ccccc3Cl)c3ccccc3Cl)CC2)C1=O
CHEMBL501088,CHEMBL237,Kappa opioid receptor,Ki,=,271.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,O=C1N(CCNCC2CCCCC2)CN(c2ccccc2)C12CCN(C(c1ccccc1Cl)c1ccccc1Cl)CC2
CHEMBL457451,CHEMBL237,Kappa opioid receptor,Ki,=,254.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,O=C1N(CCN2CCCC2)CN(c2ccccc2)C12CCN(C(c1ccccc1Cl)c1ccccc1Cl)CC2
CHEMBL464191,CHEMBL237,Kappa opioid receptor,Ki,=,64.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,O=C1N(CCCN2CCCC2)CN(c2ccccc2)C12CCN(C(c1ccccc1Cl)c1ccccc1Cl)CC2
CHEMBL464192,CHEMBL237,Kappa opioid receptor,Ki,=,279.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,O=C1N(CCN2CCCCC2)CN(c2ccccc2)C12CCN(C(c1ccccc1Cl)c1ccccc1Cl)CC2
CHEMBL240215,CHEMBL237,Kappa opioid receptor,Ki,=,52.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,O=C1NCN(c2ccccc2)C12CCN(Cc1c(Cl)cccc1Cl)CC2
CHEMBL517167,CHEMBL237,Kappa opioid receptor,Ki,=,68.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CNCCN1CN(c2ccccc2)C2(CCN(Cc3c(Cl)cccc3Cl)CC2)C1=O
CHEMBL515142,CHEMBL237,Kappa opioid receptor,Ki,=,54.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CCNCCN1CN(c2ccccc2)C2(CCN(Cc3c(Cl)cccc3Cl)CC2)C1=O
CHEMBL475707,CHEMBL237,Kappa opioid receptor,Ki,=,40.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CC(C)NCCN1CN(c2ccccc2)C2(CCN(Cc3c(Cl)cccc3Cl)CC2)C1=O
CHEMBL472669,CHEMBL237,Kappa opioid receptor,Ki,=,25.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,O=C1N(CCNCC2CC2)CN(c2ccccc2)C12CCN(Cc1c(Cl)cccc1Cl)CC2
CHEMBL516389,CHEMBL237,Kappa opioid receptor,Ki,=,29.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,O=C1N(CCNC2CCC2)CN(c2ccccc2)C12CCN(Cc1c(Cl)cccc1Cl)CC2
CHEMBL514662,CHEMBL237,Kappa opioid receptor,Ki,=,13.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CCCNCCN1CN(c2ccccc2)C2(CCN(Cc3c(Cl)cccc3Cl)CC2)C1=O
CHEMBL475310,CHEMBL237,Kappa opioid receptor,Ki,=,8.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CC(C)CNCCN1CN(c2ccccc2)C2(CCN(Cc3c(Cl)cccc3Cl)CC2)C1=O
CHEMBL473700,CHEMBL237,Kappa opioid receptor,Ki,=,10.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CCCCNCCN1CN(c2ccccc2)C2(CCN(Cc3c(Cl)cccc3Cl)CC2)C1=O
CHEMBL473701,CHEMBL237,Kappa opioid receptor,Ki,=,56.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CCN(CC)CCN1CN(c2ccccc2)C2(CCN(Cc3c(Cl)cccc3Cl)CC2)C1=O
CHEMBL473904,CHEMBL237,Kappa opioid receptor,Ki,=,15.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,O=C1N(CCN2CCCC2)CN(c2ccccc2)C12CCN(Cc1c(Cl)cccc1Cl)CC2
CHEMBL239822,CHEMBL237,Kappa opioid receptor,Ki,=,540.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CC1(C)CCC(N2CCC3(CC2)C(=O)NCN3c2ccccc2)c2ccccc21
CHEMBL471262,CHEMBL237,Kappa opioid receptor,Ki,=,1392.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CCCN1CN(c2ccccc2)C2(CCN(C3CCC(C)(C)c4ccccc43)CC2)C1=O
CHEMBL511649,CHEMBL237,Kappa opioid receptor,Ki,=,56.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CC(=O)CN1CN(c2ccccc2)C2(CCN(C3CCC(C)(C)c4ccccc43)CC2)C1=O
CHEMBL474283,CHEMBL237,Kappa opioid receptor,Ki,=,655.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CC1(C)CCC(N2CCC3(CC2)C(=O)N(CCO)CN3c2ccccc2)c2ccccc21
CHEMBL474485,CHEMBL237,Kappa opioid receptor,Ki,=,48.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CNCCN1CN(c2ccccc2)C2(CCN(C3CCC(C)(C)c4ccccc43)CC2)C1=O
CHEMBL474687,CHEMBL237,Kappa opioid receptor,Ki,=,39.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CCNCCN1CN(c2ccccc2)C2(CCN(C3CCC(C)(C)c4ccccc43)CC2)C1=O
CHEMBL514489,CHEMBL237,Kappa opioid receptor,Ki,=,68.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CC(C)NCCN1CN(c2ccccc2)C2(CCN(C3CCC(C)(C)c4ccccc43)CC2)C1=O
CHEMBL515091,CHEMBL237,Kappa opioid receptor,Ki,=,49.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CC1(C)CCC(N2CCC3(CC2)C(=O)N(CCNC2CCCC2)CN3c2ccccc2)c2ccccc21
CHEMBL514463,CHEMBL237,Kappa opioid receptor,Ki,=,33.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CC1(C)CCC(N2CCC3(CC2)C(=O)N(CCNC2CCCCC2)CN3c2ccccc2)c2ccccc21
CHEMBL473272,CHEMBL237,Kappa opioid receptor,Ki,=,45.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CCCNCCN1CN(c2ccccc2)C2(CCN(C3CCC(C)(C)c4ccccc43)CC2)C1=O
CHEMBL475094,CHEMBL237,Kappa opioid receptor,Ki,=,208.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,C=CCNCCN1CN(c2ccccc2)C2(CCN(C3CCC(C)(C)c4ccccc43)CC2)C1=O
CHEMBL474092,CHEMBL237,Kappa opioid receptor,Ki,=,45.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CC1(C)CCC(N2CCC3(CC2)C(=O)N(CCNC2CCC2)CN3c2ccccc2)c2ccccc21
CHEMBL473278,CHEMBL237,Kappa opioid receptor,Ki,=,174.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CC1(C)CCC(N2CCC3(CC2)C(=O)N(CCNCC2CC2)CN3c2ccccc2)c2ccccc21
CHEMBL473279,CHEMBL237,Kappa opioid receptor,Ki,=,65.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CC(C)CNCCN1CN(c2ccccc2)C2(CCN(C3CCC(C)(C)c4ccccc43)CC2)C1=O
CHEMBL473280,CHEMBL237,Kappa opioid receptor,Ki,=,86.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CC(C)N(CCN1CN(c2ccccc2)C2(CCN(C3CCC(C)(C)c4ccccc43)CC2)C1=O)C(C)C
CHEMBL473898,CHEMBL237,Kappa opioid receptor,Ki,=,169.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CC1(C)CCC(N2CCC3(CC2)C(=O)N(CCN2CCCC2)CN3c2ccccc2)c2ccccc21
CHEMBL474096,CHEMBL237,Kappa opioid receptor,Ki,=,138.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CCCCNCCN1CN(c2ccccc2)C2(CCN(C3CCC(C)(C)c4ccccc43)CC2)C1=O
CHEMBL515575,CHEMBL237,Kappa opioid receptor,Ki,=,82.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CC(C)CCNCCN1CN(c2ccccc2)C2(CCN(C3CCC(C)(C)c4ccccc43)CC2)C1=O
CHEMBL471882,CHEMBL237,Kappa opioid receptor,Ki,=,26.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CC1(C)CCC(N2CCC3(CC2)C(=O)N(CCNCC2CCCCC2)CN3c2ccccc2)c2ccccc21
CHEMBL511162,CHEMBL237,Kappa opioid receptor,Ki,=,151.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CC1(C)CCC(N2CCC3(CC2)C(=O)N(CCNCc2ccccc2)CN3c2ccccc2)c2ccccc21
CHEMBL516187,CHEMBL237,Kappa opioid receptor,Ki,=,11.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CCCCNCCN1CN(c2ccccc2)C2(CCN(C3CCCc4ccc(Cl)cc43)CC2)C1=O
CHEMBL511161,CHEMBL237,Kappa opioid receptor,Ki,=,14.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CCCCNCCN1CN(c2ccccc2)C2(CCN(C3CCCc4c(Cl)cccc43)CC2)C1=O
CHEMBL471880,CHEMBL237,Kappa opioid receptor,Ki,=,25.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CCCCNCCN1CN(c2ccccc2)C2(CCN(C3CCC(C)(C)c4cc(Cl)ccc43)CC2)C1=O
CHEMBL472086,CHEMBL237,Kappa opioid receptor,Ki,=,158.0,nM,CHEMBL1030624,B,Displacement of [125I]diprenorphine from human KOP expressed in CHO cells,CHEMBL1136855,KI,CCCCNCCN1CN(c2ccccc2)C2(CCN(C3CCC(C)(C)c4cc(Cl)c(Cl)cc43)CC2)C1=O
CHEMBL503017,CHEMBL237,Kappa opioid receptor,Ki,=,0.26,nM,CHEMBL1019446,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane by liquid scintillation and luminescence counter,CHEMBL1152799,KI,O=C(/C=C/c1ccccc1)N[C@@H]1CC[C@@]2(OC(=O)Cc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL468871,CHEMBL237,Kappa opioid receptor,Ki,=,1.1,nM,CHEMBL1019446,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane by liquid scintillation and luminescence counter,CHEMBL1152799,KI,O=C(/C=C/c1ccccc1)N[C@@H]1CC[C@@]2(OC(=O)c3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL472583,CHEMBL237,Kappa opioid receptor,Ki,=,0.59,nM,CHEMBL1019446,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane by liquid scintillation and luminescence counter,CHEMBL1152799,KI,CC(=O)O[C@@]12CC[C@@H](NC(=O)/C=C/c3ccccc3)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL472410,CHEMBL237,Kappa opioid receptor,Ki,=,0.12,nM,CHEMBL1019446,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane by liquid scintillation and luminescence counter,CHEMBL1152799,KI,C=CCO[C@@]12CC[C@@H](NC(=O)/C=C/c3ccccc3)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL509552,CHEMBL237,Kappa opioid receptor,Ki,=,0.86,nM,CHEMBL1019446,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane by liquid scintillation and luminescence counter,CHEMBL1152799,KI,O=C(/C=C/c1ccccc1)N[C@@H]1CC[C@@]2(OCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL513598,CHEMBL237,Kappa opioid receptor,Ki,=,0.34,nM,CHEMBL1019446,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane by liquid scintillation and luminescence counter,CHEMBL1152799,KI,COc1ccccc1/C=C/C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL511655,CHEMBL237,Kappa opioid receptor,Ki,=,0.27,nM,CHEMBL1019446,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane by liquid scintillation and luminescence counter,CHEMBL1152799,KI,O=C(/C=C/c1ccccc1Cl)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL454018,CHEMBL237,Kappa opioid receptor,Ki,=,0.36,nM,CHEMBL1019446,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane by liquid scintillation and luminescence counter,CHEMBL1152799,KI,O=C(/C=C/c1cccc([N+](=O)[O-])c1)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL448145,CHEMBL237,Kappa opioid receptor,Ki,=,0.3,nM,CHEMBL1019446,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane by liquid scintillation and luminescence counter,CHEMBL1152799,KI,O=C(/C=C/c1ccccc1[N+](=O)[O-])N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL473362,CHEMBL237,Kappa opioid receptor,Ki,=,0.043,nM,CHEMBL1019446,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane by liquid scintillation and luminescence counter,CHEMBL1152799,KI,O=C(/C=C/c1ccccc1)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL474755,CHEMBL237,Kappa opioid receptor,Ki,=,4.3,nM,CHEMBL1022994,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1152801,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(OC(=O)/C=C/c5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL514774,CHEMBL237,Kappa opioid receptor,Ki,=,0.41,nM,CHEMBL1022994,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1152801,KI,O=C1CC[C@@]2(OCCCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL386492,CHEMBL237,Kappa opioid receptor,Ki,=,1.4,nM,CHEMBL1022994,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1152801,KI,O=C(/C=C/c1ccc(Cl)cc1)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL386272,CHEMBL237,Kappa opioid receptor,Ki,=,16.0,nM,CHEMBL1022994,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1152801,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)/C=C/c5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL19019,CHEMBL237,Kappa opioid receptor,Ki,=,0.4,nM,CHEMBL1022994,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1152801,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL471543,CHEMBL237,Kappa opioid receptor,Ki,=,36.0,nM,CHEMBL1022994,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1152801,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(OC(=O)/C=C/c5ccc(C)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL512526,CHEMBL237,Kappa opioid receptor,Ki,=,52.0,nM,CHEMBL1022994,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL1152801,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(OC(=O)/C=C/c5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL506616,CHEMBL237,Kappa opioid receptor,Ki,=,29.0,nM,CHEMBL1000644,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor by cell based assay,CHEMBL1136971,KI,O=C1N[C@@H](Cc2ccccc2)C(=O)N2CCC[C@@H]2C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H]1Cc1c[nH]c2ccccc12
CHEMBL502411,CHEMBL237,Kappa opioid receptor,Ki,=,3.8,nM,CHEMBL1000644,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor by cell based assay,CHEMBL1136971,KI,O=C1N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCC[C@@H]2C(=O)N[C@H]1Cc1ccccc1
CHEMBL506217,CHEMBL237,Kappa opioid receptor,Ki,=,220.0,nM,CHEMBL1000644,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor by cell based assay,CHEMBL1136971,KI,O=C1N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N2CCC[C@@H]2C(=O)N[C@H]1Cc1ccccc1
CHEMBL486388,CHEMBL237,Kappa opioid receptor,Ki,=,140.0,nM,CHEMBL1000644,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor by cell based assay,CHEMBL1136971,KI,O=C1N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCC[C@@H]2C(=O)N[C@H]1Cc1ccc(O)cc1
CHEMBL510506,CHEMBL237,Kappa opioid receptor,Ki,=,78.0,nM,CHEMBL1000644,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor by cell based assay,CHEMBL1136971,KI,O=C1N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2cccc(O)c2)C(=O)N2CCC[C@@H]2C(=O)N[C@H]1Cc1ccccc1
CHEMBL509201,CHEMBL237,Kappa opioid receptor,Ki,=,20.0,nM,CHEMBL1000644,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor by cell based assay,CHEMBL1136971,KI,O=C1N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCC[C@@H]2C(=O)N[C@H]1Cc1cccc(O)c1
CHEMBL507127,CHEMBL237,Kappa opioid receptor,Ki,=,66.0,nM,CHEMBL1000644,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor by cell based assay,CHEMBL1136971,KI,COc1ccc(C[C@@H]2NC(=O)[C@@H](Cc3c[nH]c4ccccc34)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H]3CCCN3C2=O)cc1
CHEMBL506211,CHEMBL237,Kappa opioid receptor,Ki,=,14.0,nM,CHEMBL1000644,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor by cell based assay,CHEMBL1136971,KI,COc1ccc(C[C@@H]2NC(=O)[C@H]3CCCN3C(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H](Cc3c[nH]c4ccccc34)NC2=O)cc1
CHEMBL446754,CHEMBL237,Kappa opioid receptor,Ki,=,28.0,nM,CHEMBL1000644,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor by cell based assay,CHEMBL1136971,KI,O=C1N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)N2CCC[C@@H]2C(=O)N[C@H]1Cc1ccccc1
CHEMBL501888,CHEMBL237,Kappa opioid receptor,Ki,=,21.0,nM,CHEMBL1000644,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor by cell based assay,CHEMBL1136971,KI,O=C1N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCC[C@@H]2C(=O)N[C@H]1Cc1ccc(F)cc1
CHEMBL525580,CHEMBL237,Kappa opioid receptor,Ki,=,1300.0,nM,CHEMBL1000644,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor by cell based assay,CHEMBL1136971,KI,C[C@@H]1NC(=O)[C@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC1=O
CHEMBL499595,CHEMBL237,Kappa opioid receptor,Ki,=,5.2,nM,CHEMBL1000644,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor by cell based assay,CHEMBL1136971,KI,C[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]2CCCN2C1=O
CHEMBL522071,CHEMBL237,Kappa opioid receptor,Ki,=,270.0,nM,CHEMBL1000644,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor by cell based assay,CHEMBL1136971,KI,O=C1N[C@H](Cc2c[nH]c3ccccc23)C(=O)NCC(=O)N2CCC[C@@H]2C(=O)N[C@H]1Cc1ccccc1
CHEMBL3084634,CHEMBL237,Kappa opioid receptor,Ki,=,518.0,nM,CHEMBL1063068,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells by Topcount microplate scintillation counting,CHEMBL1152437,KI,Clc1ccccc1C(c1ccccc1Cl)N1[C@@H]2CC[C@H]1C[C@@H](c1ccccn1)C2
CHEMBL551412,CHEMBL237,Kappa opioid receptor,Ki,=,800.0,nM,CHEMBL1056547,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1153522,KI,CCNC(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1
CHEMBL550063,CHEMBL237,Kappa opioid receptor,Ki,=,560.0,nM,CHEMBL1056547,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1153522,KI,NC(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1
CHEMBL551413,CHEMBL237,Kappa opioid receptor,Ki,=,1600.0,nM,CHEMBL1056547,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1153522,KI,CNC(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1
CHEMBL551613,CHEMBL237,Kappa opioid receptor,Ki,=,890.0,nM,CHEMBL1056547,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1153522,KI,O=C(c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)cc1)N1Cc2ccccc2C1
CHEMBL562478,CHEMBL237,Kappa opioid receptor,Ki,=,390.0,nM,CHEMBL1056547,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1153522,KI,CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)c(C)c1
CHEMBL567175,CHEMBL237,Kappa opioid receptor,Ki,=,75.0,nM,CHEMBL1052525,B,Displacement of [3H]U50488 from human kappa opioid receptor expressed in CHO cells,CHEMBL1153456,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL416647,CHEMBL237,Kappa opioid receptor,Ki,=,3160.0,nM,CHEMBL1052525,B,Displacement of [3H]U50488 from human kappa opioid receptor expressed in CHO cells,CHEMBL1153456,KI,COc1ccc2c(c1O)[C@]13CCN(C)[C@H](C2)[C@]1(O)Cc1c([nH]c2ccccc12)C3
CHEMBL246003,CHEMBL237,Kappa opioid receptor,Ki,=,582.0,nM,CHEMBL1052525,B,Displacement of [3H]U50488 from human kappa opioid receptor expressed in CHO cells,CHEMBL1153456,KI,COc1c(O)ccc2c1[C@]13CCN(C)[C@H](C2)[C@]1(O)Cc1c([nH]c2ccccc12)C3
CHEMBL551072,CHEMBL237,Kappa opioid receptor,Ki,=,5120.0,nM,CHEMBL1052525,B,Displacement of [3H]U50488 from human kappa opioid receptor expressed in CHO cells,CHEMBL1153456,KI,COc1ccc2c(c1)[C@]13CCN(C)C[C@@]1(C2)Cc1c([nH]c2ccccc12)C3
CHEMBL557252,CHEMBL237,Kappa opioid receptor,Ki,=,3810.0,nM,CHEMBL1052525,B,Displacement of [3H]U50488 from human kappa opioid receptor expressed in CHO cells,CHEMBL1153456,KI,COc1ccc2c(c1)[C@]13CCN(C)C[C@@]1(C2)Cc1c(n(C)c2ccccc12)C3
CHEMBL554292,CHEMBL237,Kappa opioid receptor,Ki,=,2550.0,nM,CHEMBL1052525,B,Displacement of [3H]U50488 from human kappa opioid receptor expressed in CHO cells,CHEMBL1153456,KI,COc1ccc2c(c1)[C@]13CCN(CC4CC4)C[C@@]1(C2)Cc1c([nH]c2ccccc12)C3
CHEMBL562139,CHEMBL237,Kappa opioid receptor,Ki,=,1190.0,nM,CHEMBL1052525,B,Displacement of [3H]U50488 from human kappa opioid receptor expressed in CHO cells,CHEMBL1153456,KI,CN1CC[C@]23Cc4[nH]c5ccccc5c4C[C@]2(Cc2ccc(O)cc23)C1
CHEMBL557937,CHEMBL237,Kappa opioid receptor,Ki,=,1120.0,nM,CHEMBL1052525,B,Displacement of [3H]U50488 from human kappa opioid receptor expressed in CHO cells,CHEMBL1153456,KI,CN1CC[C@]23Cc4c(c5ccccc5n4C)C[C@]2(Cc2ccc(O)cc23)C1
CHEMBL562340,CHEMBL237,Kappa opioid receptor,Ki,=,704.0,nM,CHEMBL1052525,B,Displacement of [3H]U50488 from human kappa opioid receptor expressed in CHO cells,CHEMBL1153456,KI,Oc1ccc2c(c1)[C@]13CCN(CC4CC4)C[C@@]1(C2)Cc1c([nH]c2ccccc12)C3
CHEMBL558135,CHEMBL237,Kappa opioid receptor,Ki,=,1520.0,nM,CHEMBL1052525,B,Displacement of [3H]U50488 from human kappa opioid receptor expressed in CHO cells,CHEMBL1153456,KI,Cn1c2c(c3ccccc31)C[C@@]13Cc4ccc(O)cc4[C@@]1(CCN(CC1CC1)C3)C2
CHEMBL554617,CHEMBL237,Kappa opioid receptor,Ki,=,14.7,nM,CHEMBL1063597,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells by liquid scintillation counting",CHEMBL1153596,KI,O=C(O[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)N(c1ccccc1)c1ccccc1
CHEMBL560200,CHEMBL237,Kappa opioid receptor,Ki,=,28.2,nM,CHEMBL1063597,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells by liquid scintillation counting",CHEMBL1153596,KI,CN(C)C(=O)O[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL563988,CHEMBL237,Kappa opioid receptor,Ki,=,1.66,nM,CHEMBL1063597,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells by liquid scintillation counting",CHEMBL1153596,KI,Cc1ccc(S(=O)(=O)O[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)cc1
CHEMBL551074,CHEMBL237,Kappa opioid receptor,Ki,=,6.75,nM,CHEMBL1063597,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells by liquid scintillation counting",CHEMBL1153596,KI,CS(=O)(=O)O[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL558140,CHEMBL237,Kappa opioid receptor,Ki,=,7.42,nM,CHEMBL1063597,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells by liquid scintillation counting",CHEMBL1153596,KI,Cl.Oc1ccc2c3c1O[C@H]1[C@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL578629,CHEMBL237,Kappa opioid receptor,Ki,=,0.12,nM,CHEMBL1047526,B,Displacement of [3H]diprenorphine from human cloned kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL1155180,KI,CO[C@]12C=C[C@@]3(C[C@@H]1[C@@](C)(O)CCc1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL572525,CHEMBL237,Kappa opioid receptor,Ki,=,1.3,nM,CHEMBL1046753,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1154182,KI,NC(=O)[C@@H]1CSCSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N1
CHEMBL583278,CHEMBL237,Kappa opioid receptor,Ki,=,5.9,nM,CHEMBL1046753,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1154182,KI,NC(=O)[C@@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N1
CHEMBL583277,CHEMBL237,Kappa opioid receptor,Ki,=,6.0,nM,CHEMBL1046753,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1154182,KI,NC(=O)[C@@H]1CSCSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1
CHEMBL583276,CHEMBL237,Kappa opioid receptor,Ki,=,11.0,nM,CHEMBL1046753,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1154182,KI,NC(=O)[C@@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1
CHEMBL583275,CHEMBL237,Kappa opioid receptor,Ki,=,69.0,nM,CHEMBL1046753,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1154182,KI,NC(=O)[C@@H]1CSCSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1
CHEMBL572524,CHEMBL237,Kappa opioid receptor,Ki,=,145.0,nM,CHEMBL1046753,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1154182,KI,NC(=O)[C@@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1
CHEMBL583274,CHEMBL237,Kappa opioid receptor,Ki,=,5.8,nM,CHEMBL1046753,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1154182,KI,NC(=O)[C@@H]1CSCSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1
CHEMBL583067,CHEMBL237,Kappa opioid receptor,Ki,=,21.0,nM,CHEMBL1046753,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1154182,KI,NC(=O)[C@@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1
CHEMBL583066,CHEMBL237,Kappa opioid receptor,Ki,=,2.5,nM,CHEMBL1046753,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1154182,KI,NC(=O)[C@@H]1CSCSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1
CHEMBL575994,CHEMBL237,Kappa opioid receptor,Ki,=,344.0,nM,CHEMBL1051419,B,Binding affinity to kappa opioid receptor,CHEMBL1154191,KI,FCCCC1OC2(CCN(Cc3ccccc3)CC2)c2ccccc21
CHEMBL566557,CHEMBL237,Kappa opioid receptor,Ki,=,9500.0,nM,CHEMBL1056134,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1154776,KI,CC[C@]12CCN(C[C@H](O)c3ccccc3)C[C@H]1Oc1ccc(O)cc12
CHEMBL567213,CHEMBL237,Kappa opioid receptor,Ki,=,5870.0,nM,CHEMBL1056134,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1154776,KI,CC[C@]12CCN(C[C@@H](O)c3ccccc3)C[C@H]1Oc1ccc(O)cc12
CHEMBL568076,CHEMBL237,Kappa opioid receptor,Ki,=,2325.0,nM,CHEMBL1056134,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1154776,KI,CC[C@]12CCN(CCc3ccccc3)C[C@H]1Oc1ccc(O)cc12
CHEMBL566527,CHEMBL237,Kappa opioid receptor,Ki,=,1090.0,nM,CHEMBL1056134,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1154776,KI,CC[C@@]12CCN(C[C@H](O)c3ccccc3)C[C@@H]1Oc1ccc(O)cc12
CHEMBL568309,CHEMBL237,Kappa opioid receptor,Ki,=,413.0,nM,CHEMBL1056134,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1154776,KI,CC[C@@]12CCN(C[C@@H](O)c3ccccc3)C[C@@H]1Oc1ccc(O)cc12
CHEMBL72180,CHEMBL237,Kappa opioid receptor,Ki,=,88.0,nM,CHEMBL1056134,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1154776,KI,CC[C@@]12CCN(CCc3ccccc3)C[C@@H]1Oc1ccc(O)cc12
CHEMBL430441,CHEMBL237,Kappa opioid receptor,Ki,=,450.0,nM,CHEMBL1056134,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1154776,KI,CC[C@@]12CCN(C)C[C@@H]1Oc1ccc(O)cc12
CHEMBL301160,CHEMBL237,Kappa opioid receptor,Ki,=,0.079,nM,CHEMBL1056142,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by liquid scintillation counting,CHEMBL1154777,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL566346,CHEMBL237,Kappa opioid receptor,Ki,=,0.29,nM,CHEMBL1056142,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by liquid scintillation counting,CHEMBL1154777,KI,O=C(O)CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL565679,CHEMBL237,Kappa opioid receptor,Ki,=,0.42,nM,CHEMBL1056142,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by liquid scintillation counting,CHEMBL1154777,KI,CC(CCCCCCC(C)C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)C(=O)O
CHEMBL566762,CHEMBL237,Kappa opioid receptor,Ki,=,0.94,nM,CHEMBL1056142,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by liquid scintillation counting,CHEMBL1154777,KI,COC(=O)C(C)CCCCCCC(C)C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL573918,CHEMBL237,Kappa opioid receptor,Ki,=,18.0,nM,CHEMBL1056142,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by liquid scintillation counting,CHEMBL1154777,KI,CC(C)(CCCCCCC(C)(C)C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)C(=O)O
CHEMBL575647,CHEMBL237,Kappa opioid receptor,Ki,=,4.7,nM,CHEMBL1056142,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by liquid scintillation counting,CHEMBL1154777,KI,CC(C)(CCCCCCC(C)(C)C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)C(=O)OCc1ccccc1
CHEMBL147511,CHEMBL237,Kappa opioid receptor,Ki,=,0.049,nM,CHEMBL1056142,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by liquid scintillation counting,CHEMBL1154777,KI,O=C(CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL582930,CHEMBL237,Kappa opioid receptor,Ki,=,0.62,nM,CHEMBL1056142,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by liquid scintillation counting,CHEMBL1154777,KI,CC(CCCCCCC(C)C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL584790,CHEMBL237,Kappa opioid receptor,Ki,=,0.47,nM,CHEMBL1056142,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by liquid scintillation counting,CHEMBL1154777,KI,CC(C)(CCCCCCC(C)(C)C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL575031,CHEMBL237,Kappa opioid receptor,Ki,=,2.2,nM,CHEMBL1056142,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by liquid scintillation counting,CHEMBL1154777,KI,CC(CCCCC(C)C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL584791,CHEMBL237,Kappa opioid receptor,Ki,=,0.13,nM,CHEMBL1056142,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by liquid scintillation counting,CHEMBL1154777,KI,C=CCN1CC[C@]23c4c5ccc(OC(=O)CCCCCCCCC(=O)Oc6ccc7c(c6)[C@@]68CCCC[C@H]6C(C7)N(CC6CCC6)CC8)c4O[C@H]2CCC[C@H]3[C@H]1C5
CHEMBL584792,CHEMBL237,Kappa opioid receptor,Ki,=,3.4,nM,CHEMBL1056142,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by liquid scintillation counting,CHEMBL1154777,KI,C=CCN1CC[C@]23c4c5ccc(OC(=O)C(C)CCCCCCC(C)C(=O)Oc6ccc7c(c6)[C@@]68CCCC[C@H]6C(C7)N(CC6CCC6)CC8)c4O[C@H]2CCC[C@H]3C1C5
CHEMBL385482,CHEMBL237,Kappa opioid receptor,Ki,=,0.91,nM,CHEMBL1061222,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1154638,KI,O=C1CC[C@@]2(NC/C=C/c3ccc(Cl)cc3)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL575682,CHEMBL237,Kappa opioid receptor,Ki,=,1.12,nM,CHEMBL1061222,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1154638,KI,O=C(C#Cc1ccccc1)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL386492,CHEMBL237,Kappa opioid receptor,Ki,=,1.41,nM,CHEMBL1061222,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1154638,KI,O=C(/C=C/c1ccc(Cl)cc1)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL574397,CHEMBL237,Kappa opioid receptor,Ki,=,2.73,nM,CHEMBL1061222,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1154638,KI,O=C(C#Cc1ccc(Cl)cc1)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL574175,CHEMBL237,Kappa opioid receptor,Ki,=,2.89,nM,CHEMBL1061222,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1154638,KI,O=C1CC[C@@]2(NCC#Cc3ccc(Cl)cc3)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL575451,CHEMBL237,Kappa opioid receptor,Ki,=,7.86,nM,CHEMBL1061222,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1154638,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)C#Cc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL578422,CHEMBL237,Kappa opioid receptor,Ki,=,13.7,nM,CHEMBL1061222,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1154638,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)C#Cc5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL386272,CHEMBL237,Kappa opioid receptor,Ki,=,16.4,nM,CHEMBL1061222,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1154638,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC(=O)/C=C/c5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL216251,CHEMBL237,Kappa opioid receptor,Ki,=,53.6,nM,CHEMBL1061222,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1154638,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NC/C=C/c5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL577168,CHEMBL237,Kappa opioid receptor,Ki,=,74.4,nM,CHEMBL1061222,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1154638,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(NCC#Cc5ccc(Cl)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL577786,CHEMBL237,Kappa opioid receptor,Ki,=,6176.0,nM,CHEMBL1058548,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1154594,KI,CCN(CC)C(=O)c1ccc(N(c2ccc(C(N)=O)cc2)C2CCN(Cc3ccccc3)CC2)cc1
CHEMBL583331,CHEMBL237,Kappa opioid receptor,Ki,=,3556.0,nM,CHEMBL1058548,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1154594,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(NS(C)(=O)=O)c2)C2CCN(Cc3ccccc3)CC2)cc1
CHEMBL574640,CHEMBL237,Kappa opioid receptor,Ki,=,576.0,nM,CHEMBL1058548,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1154594,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(NC(=O)OC)c2)C2CCN(Cc3ccccc3)CC2)cc1
CHEMBL573757,CHEMBL237,Kappa opioid receptor,Ki,=,4249.0,nM,CHEMBL1058548,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1154594,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(N)c2)C2CCN(Cc3ccccc3)CC2)cc1
CHEMBL577615,CHEMBL237,Kappa opioid receptor,Ki,=,725.0,nM,CHEMBL1058548,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1154594,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(C(N)=O)c2)C2CCN(Cc3ccccc3)CC2)cc1
CHEMBL575926,CHEMBL237,Kappa opioid receptor,Ki,=,5543.0,nM,CHEMBL1058548,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1154594,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(C(=O)OC)c2)C2CCN(Cc3ccccc3)CC2)cc1
CHEMBL577359,CHEMBL237,Kappa opioid receptor,Ki,=,1747.0,nM,CHEMBL1058548,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1154594,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(CN(C)C)c2)C2CCN(Cc3ccccc3)CC2)cc1
CHEMBL577394,CHEMBL237,Kappa opioid receptor,Ki,=,6666.0,nM,CHEMBL1058548,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1154594,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(CO)c2)C2CCN(Cc3ccccc3)CC2)cc1
CHEMBL577356,CHEMBL237,Kappa opioid receptor,Ki,=,2928.0,nM,CHEMBL1058548,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1154594,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(CN)c2)C2CCN(Cc3ccccc3)CC2)cc1
CHEMBL576740,CHEMBL237,Kappa opioid receptor,Ki,=,4542.0,nM,CHEMBL1058548,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1154594,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(C(C)=O)c2)C2CCN(Cc3ccccc3)CC2)cc1
CHEMBL572669,CHEMBL237,Kappa opioid receptor,Ki,=,4742.0,nM,CHEMBL1058548,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1154594,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(C(C)O)c2)C2CCN(Cc3ccccc3)CC2)cc1
CHEMBL567818,CHEMBL237,Kappa opioid receptor,Ki,=,4796.0,nM,CHEMBL1058548,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1154594,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(C=O)c2)C2CCN(Cc3ccccc3)CC2)cc1
CHEMBL567604,CHEMBL237,Kappa opioid receptor,Ki,=,744.0,nM,CHEMBL1058548,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1154594,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(Cc3ccccc3)CC2)cc1
CHEMBL301160,CHEMBL237,Kappa opioid receptor,Ki,=,0.079,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL49269,CHEMBL237,Kappa opioid receptor,Ki,=,0.034,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL568876,CHEMBL237,Kappa opioid receptor,Ki,=,0.79,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,Ic1ccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CC2)CC4)cc1
CHEMBL576273,CHEMBL237,Kappa opioid receptor,Ki,=,5.8,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,Ic1ccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)cc1
CHEMBL568877,CHEMBL237,Kappa opioid receptor,Ki,=,0.51,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,COc1ccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CC2)CC4)cc1
CHEMBL568988,CHEMBL237,Kappa opioid receptor,Ki,=,3.9,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,COc1ccc(CN(Cc2ccc(OC)cc2)c2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CC2)CC4)cc1
CHEMBL568813,CHEMBL237,Kappa opioid receptor,Ki,=,16.0,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,Ic1ccc(CN(Cc2ccc(I)cc2)c2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)cc1
CHEMBL571998,CHEMBL237,Kappa opioid receptor,Ki,=,0.34,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,c1ccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CC2)CC4)cc1
CHEMBL571767,CHEMBL237,Kappa opioid receptor,Ki,=,0.03,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,COc1ccc(Nc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CC2)CC4)cc1
CHEMBL568757,CHEMBL237,Kappa opioid receptor,Ki,=,0.047,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,c1ccc(Nc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CC2)CC4)cc1
CHEMBL571560,CHEMBL237,Kappa opioid receptor,Ki,=,2.8,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,c1ccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)cc1
CHEMBL571990,CHEMBL237,Kappa opioid receptor,Ki,=,0.59,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,COc1ccc(Nc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)cc1
CHEMBL570225,CHEMBL237,Kappa opioid receptor,Ki,=,1.5,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,c1ccc(Nc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)cc1
CHEMBL568989,CHEMBL237,Kappa opioid receptor,Ki,=,5.2,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(OC(=O)Nc2ccc(I)cc2)cc13
CHEMBL570429,CHEMBL237,Kappa opioid receptor,Ki,=,0.6,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,O=C(Nc1ccc(I)cc1)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL570654,CHEMBL237,Kappa opioid receptor,Ki,=,0.99,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,O=C(Nc1ccc(I)cc1)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL568829,CHEMBL237,Kappa opioid receptor,Ki,=,340.0,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(NC(=O)Nc2ccccc2)cc13
CHEMBL571561,CHEMBL237,Kappa opioid receptor,Ki,=,1.6,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,O=C(Nc1ccccc1)Nc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL569724,CHEMBL237,Kappa opioid receptor,Ki,=,280.0,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(NC(=O)Nc2ccc(I)cc2)cc13
CHEMBL569725,CHEMBL237,Kappa opioid receptor,Ki,=,12.0,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,O=C(Nc1ccc(I)cc1)Nc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL572216,CHEMBL237,Kappa opioid receptor,Ki,=,28.0,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,O=C(Nc1ccc(I)cc1)Nc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL570449,CHEMBL237,Kappa opioid receptor,Ki,=,40.0,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1cc(CO)c(O)cc13
CHEMBL568878,CHEMBL237,Kappa opioid receptor,Ki,=,86.0,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,OCc1cc2c(cc1O)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL578173,CHEMBL237,Kappa opioid receptor,Ki,=,380.0,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1cc(CNCc2ccccc2)c(O)cc13
CHEMBL576065,CHEMBL237,Kappa opioid receptor,Ki,=,310.0,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1cc2c(cc13)OCN(Cc1ccccc1)C2
CHEMBL585901,CHEMBL237,Kappa opioid receptor,Ki,=,0.62,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,O/N=C\c1cc2c(cc1O)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL568830,CHEMBL237,Kappa opioid receptor,Ki,=,140.0,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,NCc1cc2c(cc1O)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL583265,CHEMBL237,Kappa opioid receptor,Ki,=,350.0,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,CCCNCc1cc2c(cc1O)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL569215,CHEMBL237,Kappa opioid receptor,Ki,=,4.9,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,Oc1cc2c(cc1CNCCCCNCc1cc3c(cc1O)[C@@]14CCCC[C@H]1[C@@H](C3)N(CC1CCC1)CC4)C[C@@H]1[C@@H]3CCCC[C@]23CCN1CC1CCC1
CHEMBL569313,CHEMBL237,Kappa opioid receptor,Ki,=,37.0,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,Oc1cc2c(cc1CNCCCCCCNCc1cc3c(cc1O)[C@@]14CCCC[C@H]1[C@@H](C3)N(CC1CCC1)CC4)C[C@@H]1[C@@H]3CCCC[C@]23CCN1CC1CCC1
CHEMBL569448,CHEMBL237,Kappa opioid receptor,Ki,=,40.0,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,Oc1cc2c(cc1CNCCCCCCCCNCc1cc3c(cc1O)[C@@]14CCCC[C@H]1[C@@H](C3)N(CC1CCC1)CC4)C[C@@H]1[C@@H]3CCCC[C@]23CCN1CC1CCC1
CHEMBL568071,CHEMBL237,Kappa opioid receptor,Ki,=,44.0,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,CCN(CCCCN(CC)Cc1cc2c(cc1O)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Cc1cc2c(cc1O)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL566128,CHEMBL237,Kappa opioid receptor,Ki,=,54.0,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,CCN(CCCCCCN(CC)Cc1cc2c(cc1O)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Cc1cc2c(cc1O)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL584530,CHEMBL237,Kappa opioid receptor,Ki,=,72.0,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,CCC(O)c1cc2c(cc1O)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL567170,CHEMBL237,Kappa opioid receptor,Ki,=,67.0,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,Oc1cc2c(cc1C(O)CCCCC(O)c1cc3c(cc1O)[C@@]14CCCC[C@H]1[C@@H](C3)N(CC1CCC1)CC4)C[C@@H]1[C@@H]3CCCC[C@]23CCN1CC1CCC1
CHEMBL568758,CHEMBL237,Kappa opioid receptor,Ki,=,31.0,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,Oc1cc2c(cc1C(O)CCCCCCCCCCC(O)c1cc3c(cc1O)[C@@]14CCCC[C@H]1[C@@H](C3)N(CC1CCC1)CC4)C[C@@H]1[C@@H]3CCCC[C@]23CCN1CC1CCC1
CHEMBL571322,CHEMBL237,Kappa opioid receptor,Ki,=,13.0,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,CCCCC(O)c1cc2c(cc1O)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL570428,CHEMBL237,Kappa opioid receptor,Ki,=,26.0,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,CCCCCCCCCC(O)c1cc2c(cc1O)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL572217,CHEMBL237,Kappa opioid receptor,Ki,=,26.0,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,OCCCCCCCCCCC(O)c1cc2c(cc1O)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL569009,CHEMBL237,Kappa opioid receptor,Ki,=,30.0,nM,CHEMBL1050690,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL1156775,KI,O=C(CCCCC(=O)NCc1cc2c(cc1O)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)NCc1cc2c(cc1O)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL80,CHEMBL237,Kappa opioid receptor,Ki,=,3.0,nM,CHEMBL1038965,B,Displacement of [125I]OXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1156815,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL104042,CHEMBL237,Kappa opioid receptor,Ki,=,0.1,nM,CHEMBL1038965,B,Displacement of [125I]OXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1156815,KI,Oc1cccc2c1O[C@H]1CCC[C@H]3CN(CC4CC4)CC[C@@]231
CHEMBL397705,CHEMBL237,Kappa opioid receptor,Ki,=,2.2,nM,CHEMBL1038965,B,Displacement of [125I]OXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1156815,KI,CC(C)=CCN1CC[C@@]2(C)c3cc(O)ccc3C[C@@H]1[C@H]2C
CHEMBL585721,CHEMBL237,Kappa opioid receptor,Ki,=,15.0,nM,CHEMBL1038965,B,Displacement of [125I]OXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1156815,KI,Oc1cccc2c1O[C@H]1CCC[C@H]3CN(CCc4ccccc4)CC[C@@]231
CHEMBL571843,CHEMBL237,Kappa opioid receptor,Ki,=,14.0,nM,CHEMBL1038965,B,Displacement of [125I]OXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1156815,KI,CN1CC[C@]23c4cccc(O)c4O[C@H]2CCC[C@H]3C1
CHEMBL583881,CHEMBL237,Kappa opioid receptor,Ki,=,41.0,nM,CHEMBL1038965,B,Displacement of [125I]OXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1156815,KI,COc1cccc2c1O[C@H]1CCC[C@H]3CN(CC4CC4)CC[C@@]231
CHEMBL104042,CHEMBL237,Kappa opioid receptor,Ki,=,699.0,nM,CHEMBL1038965,B,Displacement of [125I]OXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1156815,KI,Oc1cccc2c1O[C@H]1CCC[C@H]3CN(CC4CC4)CC[C@@]231
CHEMBL585536,CHEMBL237,Kappa opioid receptor,Ki,=,565.0,nM,CHEMBL1038965,B,Displacement of [125I]OXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1156815,KI,COc1cccc2c1O[C@H]1CCC[C@@H]3CN(C)CC[C@@]231
CHEMBL571862,CHEMBL237,Kappa opioid receptor,Ki,=,1140.0,nM,CHEMBL1038965,B,Displacement of [125I]OXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1156815,KI,COc1cccc2c1O[C@H]1CCC[C@H]3CN(CCc4ccccc4)CC[C@@]231
CHEMBL571862,CHEMBL237,Kappa opioid receptor,Ki,=,1850.0,nM,CHEMBL1038965,B,Displacement of [125I]OXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1156815,KI,COc1cccc2c1O[C@H]1CCC[C@H]3CN(CCc4ccccc4)CC[C@@]231
CHEMBL585721,CHEMBL237,Kappa opioid receptor,Ki,=,1240.0,nM,CHEMBL1038965,B,Displacement of [125I]OXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1156815,KI,Oc1cccc2c1O[C@H]1CCC[C@H]3CN(CCc4ccccc4)CC[C@@]231
CHEMBL585536,CHEMBL237,Kappa opioid receptor,Ki,=,1850.0,nM,CHEMBL1038965,B,Displacement of [125I]OXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1156815,KI,COc1cccc2c1O[C@H]1CCC[C@@H]3CN(C)CC[C@@]231
CHEMBL571610,CHEMBL237,Kappa opioid receptor,Ki,=,3470.0,nM,CHEMBL1038965,B,Displacement of [125I]OXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1156815,KI,COc1cccc2c1O[C@H]1CCC[C@H]3CN(C)CC[C@@]231
CHEMBL571610,CHEMBL237,Kappa opioid receptor,Ki,=,7230.0,nM,CHEMBL1038965,B,Displacement of [125I]OXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1156815,KI,COc1cccc2c1O[C@H]1CCC[C@H]3CN(C)CC[C@@]231
CHEMBL571843,CHEMBL237,Kappa opioid receptor,Ki,=,6900.0,nM,CHEMBL1038965,B,Displacement of [125I]OXY from human kappa opioid receptor expressed in CHO cells,CHEMBL1156815,KI,CN1CC[C@]23c4cccc(O)c4O[C@H]2CCC[C@H]3C1
CHEMBL569316,CHEMBL237,Kappa opioid receptor,Ki,=,2043.0,nM,CHEMBL1043620,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(CCc3ccccn3)CC2)cc1
CHEMBL569956,CHEMBL237,Kappa opioid receptor,Ki,=,1189.0,nM,CHEMBL1043620,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(CCc3ncc[nH]3)CC2)cc1
CHEMBL568803,CHEMBL237,Kappa opioid receptor,Ki,=,453.0,nM,CHEMBL1043620,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(CCc3cccs3)CC2)cc1
CHEMBL570000,CHEMBL237,Kappa opioid receptor,Ki,=,263.0,nM,CHEMBL1043620,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(CCc3ccco3)CC2)cc1
CHEMBL584941,CHEMBL237,Kappa opioid receptor,Ki,=,495.0,nM,CHEMBL1043620,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(CCc3ccsc3)CC2)cc1
CHEMBL568818,CHEMBL237,Kappa opioid receptor,Ki,=,121.0,nM,CHEMBL1043620,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(CCc3ccoc3)CC2)cc1
CHEMBL569006,CHEMBL237,Kappa opioid receptor,Ki,=,1358.0,nM,CHEMBL1043620,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(CCc3cccc(F)c3)CC2)cc1
CHEMBL576267,CHEMBL237,Kappa opioid receptor,Ki,=,967.0,nM,CHEMBL1043620,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(CCc3ccccc3F)CC2)cc1
CHEMBL569728,CHEMBL237,Kappa opioid receptor,Ki,=,726.0,nM,CHEMBL1043620,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(CCc3ccc(C)cc3)CC2)cc1
CHEMBL568865,CHEMBL237,Kappa opioid receptor,Ki,=,2191.0,nM,CHEMBL1043620,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(CC(C)c3ccccc3)CC2)cc1
CHEMBL569755,CHEMBL237,Kappa opioid receptor,Ki,=,744.0,nM,CHEMBL1043620,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(CCc3ccccc3)CC2)cc1
CHEMBL585900,CHEMBL237,Kappa opioid receptor,Ki,=,508.0,nM,CHEMBL1043620,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(CCC3CC3)CC2)cc1
CHEMBL570233,CHEMBL237,Kappa opioid receptor,Ki,=,726.0,nM,CHEMBL1043620,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(CCC3CCCCC3)CC2)cc1
CHEMBL570232,CHEMBL237,Kappa opioid receptor,Ki,=,98.0,nM,CHEMBL1043620,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1156083,KI,C=CCCN1CCC(N(c2ccc(C(=O)N(CC)CC)cc2)c2cccc(O)c2)CC1
CHEMBL571324,CHEMBL237,Kappa opioid receptor,Ki,=,901.0,nM,CHEMBL1043620,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(C)CC2)cc1
CHEMBL569704,CHEMBL237,Kappa opioid receptor,Ki,=,4985.0,nM,CHEMBL1043620,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(OC)c2)C2CCN(CCc3ccoc3)CC2)cc1
CHEMBL570446,CHEMBL237,Kappa opioid receptor,Ki,=,7081.0,nM,CHEMBL1043620,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(OC)c2)C2CCN(CCc3ccco3)CC2)cc1
CHEMBL570645,CHEMBL237,Kappa opioid receptor,Ki,=,6405.0,nM,CHEMBL1043620,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(OC)c2)C2CCN(CCc3cccs3)CC2)cc1
CHEMBL569945,CHEMBL237,Kappa opioid receptor,Ki,=,2549.0,nM,CHEMBL1043620,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(OC)c2)C2CCN(CCc3ccsc3)CC2)cc1
CHEMBL569084,CHEMBL237,Kappa opioid receptor,Ki,=,3606.0,nM,CHEMBL1043620,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(OC)c2)C2CCN(CCc3ccccc3)CC2)cc1
CHEMBL13470,CHEMBL237,Kappa opioid receptor,Ki,=,4169.0,nM,CHEMBL1043620,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1156083,KI,C=CCN1C[C@H](C)N([C@H](c2ccc(C(=O)N(CC)CC)cc2)c2cccc(OC)c2)C[C@H]1C
CHEMBL584727,CHEMBL237,Kappa opioid receptor,Ki,=,1451.0,nM,CHEMBL1043620,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(CCc3c[nH]cn3)CC2)cc1
CHEMBL569529,CHEMBL237,Kappa opioid receptor,Ki,=,4568.0,nM,CHEMBL1043620,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(CCc3ccncc3)CC2)cc1
CHEMBL570448,CHEMBL237,Kappa opioid receptor,Ki,=,4595.0,nM,CHEMBL1043620,B,Displacement of [125I]D-pro10-dynorphin from human cloned kappa opioid receptor,CHEMBL1156083,KI,CCN(CC)C(=O)c1ccc(N(c2cccc(O)c2)C2CCN(CCc3nccn3C)CC2)cc1
CHEMBL19019,CHEMBL237,Kappa opioid receptor,Ki,=,0.81,nM,CHEMBL1071835,B,Displacement of [3H]U69593 from kappa opioid receptor expressed in HEK293 cells by visible spectrophotometry,CHEMBL1152554,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL982,CHEMBL237,Kappa opioid receptor,Ki,=,1.03,nM,CHEMBL1071835,B,Displacement of [3H]U69593 from kappa opioid receptor expressed in HEK293 cells by visible spectrophotometry,CHEMBL1152554,KI,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL593214,CHEMBL237,Kappa opioid receptor,Ki,=,0.11,nM,CHEMBL1071835,B,Displacement of [3H]U69593 from kappa opioid receptor expressed in HEK293 cells by visible spectrophotometry,CHEMBL1152554,KI,Cc1ccc(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)cc1.O=C(O)C(=O)O
CHEMBL611929,CHEMBL237,Kappa opioid receptor,Ki,=,0.34,nM,CHEMBL1071835,B,Displacement of [3H]U69593 from kappa opioid receptor expressed in HEK293 cells by visible spectrophotometry,CHEMBL1152554,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccc(C(F)(F)F)cc1.O=C(O)C(=O)O
CHEMBL611930,CHEMBL237,Kappa opioid receptor,Ki,=,0.29,nM,CHEMBL1071835,B,Displacement of [3H]U69593 from kappa opioid receptor expressed in HEK293 cells by visible spectrophotometry,CHEMBL1152554,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccc(Br)cc1.O=C(O)C(=O)O
CHEMBL611931,CHEMBL237,Kappa opioid receptor,Ki,=,0.37,nM,CHEMBL1071835,B,Displacement of [3H]U69593 from kappa opioid receptor expressed in HEK293 cells by visible spectrophotometry,CHEMBL1152554,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccc(I)cc1.O=C(O)C(=O)O
CHEMBL611932,CHEMBL237,Kappa opioid receptor,Ki,=,0.37,nM,CHEMBL1071835,B,Displacement of [3H]U69593 from kappa opioid receptor expressed in HEK293 cells by visible spectrophotometry,CHEMBL1152554,KI,CC(C)(C)c1ccc(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)cc1.O=C(O)C(=O)O
CHEMBL593215,CHEMBL237,Kappa opioid receptor,Ki,=,0.34,nM,CHEMBL1071835,B,Displacement of [3H]U69593 from kappa opioid receptor expressed in HEK293 cells by visible spectrophotometry,CHEMBL1152554,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccc(Cl)c(Cl)c1.O=C(O)C(=O)O
CHEMBL611933,CHEMBL237,Kappa opioid receptor,Ki,=,0.23,nM,CHEMBL1071835,B,Displacement of [3H]U69593 from kappa opioid receptor expressed in HEK293 cells by visible spectrophotometry,CHEMBL1152554,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccc(Cl)cc1.O=C(O)C(=O)O
CHEMBL445332,CHEMBL237,Kappa opioid receptor,Ki,=,0.8,nM,CHEMBL1071835,B,Displacement of [3H]U69593 from kappa opioid receptor expressed in HEK293 cells by visible spectrophotometry,CHEMBL1152554,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL594828,CHEMBL237,Kappa opioid receptor,Ki,=,3000.0,nM,CHEMBL1050383,B,Binding affinity to kappa opioid receptor,CHEMBL1153191,KI,COCc1nnc(N2CC(Oc3ccc(F)cc3Cl)C2)n1-c1ccc(OC)nc1
CHEMBL595245,CHEMBL237,Kappa opioid receptor,Ki,=,440.0,nM,CHEMBL1074667,B,Displacement of [125I]diprenorphine from human kappa opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1153251,KI,CCN(CC)C(=O)c1ccc(C2(c3cccc(O)c3)CCN(CC3CC3)CC2)cc1
CHEMBL605931,CHEMBL237,Kappa opioid receptor,Ki,=,347.0,nM,CHEMBL1074667,B,Displacement of [125I]diprenorphine from human kappa opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1153251,KI,C=CCN1CCC(c2ccc(C(=O)N(CC)CC)cc2)(c2cccc(O)c2)CC1
CHEMBL595472,CHEMBL237,Kappa opioid receptor,Ki,=,95.0,nM,CHEMBL1074667,B,Displacement of [125I]diprenorphine from human kappa opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1153251,KI,CCN(CC)C(=O)c1ccc(C2(c3cccc(O)c3)CCN(CCc3ccccc3)CC2)cc1
CHEMBL603428,CHEMBL237,Kappa opioid receptor,Ki,=,150.0,nM,CHEMBL1074667,B,Displacement of [125I]diprenorphine from human kappa opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1153251,KI,CCCC(C)CN1CCC(c2ccc(C(=O)N(C)C)cc2)(c2cccc(O)c2)CC1
CHEMBL593583,CHEMBL237,Kappa opioid receptor,Ki,=,79.0,nM,CHEMBL1074667,B,Displacement of [125I]diprenorphine from human kappa opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1153251,KI,CCC(O)(CC)c1ccc(C2(c3cccc(C(N)=O)c3)CCN(CC3CC3)CC2)cc1
CHEMBL593824,CHEMBL237,Kappa opioid receptor,Ki,=,45.0,nM,CHEMBL1074667,B,Displacement of [125I]diprenorphine from human kappa opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1153251,KI,CCCC(C)CN1CCC(c2ccc(C(O)(CC)CC)cc2)(c2cccc(C(N)=O)c2)CC1
CHEMBL605293,CHEMBL237,Kappa opioid receptor,Ki,=,24.0,nM,CHEMBL1074667,B,Displacement of [125I]diprenorphine from human kappa opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1153251,KI,CCN(CC)C(=O)c1ccc(C2(c3cccc(O)c3)CCCN(CC3CC3)C2)cc1
CHEMBL592908,CHEMBL237,Kappa opioid receptor,Ki,=,66.0,nM,CHEMBL1074667,B,Displacement of [125I]diprenorphine from human kappa opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1153251,KI,CCN(C)C(=O)c1ccc(C2(c3cccc(O)c3)CCCN(CC3CC3)C2)cc1
CHEMBL595714,CHEMBL237,Kappa opioid receptor,Ki,=,24.0,nM,CHEMBL1074667,B,Displacement of [125I]diprenorphine from human kappa opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1153251,KI,CCN(CC)C(=O)c1ccc(C2(c3cccc(O)c3)CCCN(CC(F)(F)F)C2)cc1
CHEMBL605735,CHEMBL237,Kappa opioid receptor,Ki,=,163.0,nM,CHEMBL1074667,B,Displacement of [125I]diprenorphine from human kappa opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1153251,KI,CCN(CC)C(=O)c1ccc(C2(c3cccc(O)c3)CCCN(Cc3nccs3)C2)cc1
CHEMBL595233,CHEMBL237,Kappa opioid receptor,Ki,=,41.0,nM,CHEMBL1074667,B,Displacement of [125I]diprenorphine from human kappa opioid receptor expressed in CHO cells by liquid scintillation counting,CHEMBL1153251,KI,CC(C)(O)c1ccc(C2(c3cccc(O)c3)CCCN(CC3CC3)C2)cc1
CHEMBL594787,CHEMBL237,Kappa opioid receptor,Ki,=,22.0,nM,CHEMBL1048559,B,Displacement of [3H]diprenorphine from human kappa receptor expressed in CHO cells by scintillation counting,CHEMBL1153149,KI,COc1ccc2c3c1O[C@@H]1[C@]34CCN(C)[C@H](C2)[C@]42C=C[C@]1(OC)C[C@H]2c1cccc([N+](=O)[O-])c1
CHEMBL606343,CHEMBL237,Kappa opioid receptor,Ki,=,10000.0,nM,CHEMBL1048559,B,Displacement of [3H]diprenorphine from human kappa receptor expressed in CHO cells by scintillation counting,CHEMBL1153149,KI,COc1ccc2c3c1O[C@H]1[C@]4(OC)C=C[C@@]5(C[C@@H]4c4ccc([N+](=O)[O-])cc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL604476,CHEMBL237,Kappa opioid receptor,Ki,=,674.0,nM,CHEMBL1048559,B,Displacement of [3H]diprenorphine from human kappa receptor expressed in CHO cells by scintillation counting,CHEMBL1153149,KI,COc1ccc2c3c1O[C@@H]1[C@]34CCN(C)[C@H](C2)[C@]42C=C[C@]1(OC)C[C@H]2c1ccc([N+](=O)[O-])cc1
CHEMBL70,CHEMBL237,Kappa opioid receptor,Ki,=,6.9,nM,CHEMBL1048559,B,Displacement of [3H]diprenorphine from human kappa receptor expressed in CHO cells by scintillation counting,CHEMBL1153149,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL72180,CHEMBL237,Kappa opioid receptor,Ki,=,88.0,nM,CHEMBL1065783,B,Displacement of [3H]U69593 from kappa opioid receptor expressed in CHO cells,CHEMBL1157715,KI,CC[C@@]12CCN(CCc3ccccc3)C[C@@H]1Oc1ccc(O)cc12
CHEMBL592300,CHEMBL237,Kappa opioid receptor,Ki,=,720.0,nM,CHEMBL1065783,B,Displacement of [3H]U69593 from kappa opioid receptor expressed in CHO cells,CHEMBL1157715,KI,CC[C@@]12CCN(CCc3ccc([N+](=O)[O-])cc3)C[C@@H]1Oc1c(O)cccc12
CHEMBL592302,CHEMBL237,Kappa opioid receptor,Ki,=,935.0,nM,CHEMBL1065783,B,Displacement of [3H]U69593 from kappa opioid receptor expressed in CHO cells,CHEMBL1157715,KI,CC[C@@]12CCN(CCc3ccc(F)cc3)C[C@@H]1Oc1c(O)cccc12
CHEMBL592301,CHEMBL237,Kappa opioid receptor,Ki,=,3380.0,nM,CHEMBL1065783,B,Displacement of [3H]U69593 from kappa opioid receptor expressed in CHO cells,CHEMBL1157715,KI,CC[C@@]12CCN(Cc3ccc(F)cc3)C[C@@H]1Oc1c(O)cccc12
CHEMBL598977,CHEMBL237,Kappa opioid receptor,Ki,=,2880.0,nM,CHEMBL1065783,B,Displacement of [3H]U69593 from kappa opioid receptor expressed in CHO cells,CHEMBL1157715,KI,CN1CC[C@@]2(CCc3ccccc3)c3cccc(O)c3O[C@H]2C1
CHEMBL599175,CHEMBL237,Kappa opioid receptor,Ki,=,2220.0,nM,CHEMBL1065783,B,Displacement of [3H]U69593 from kappa opioid receptor expressed in CHO cells,CHEMBL1157715,KI,CC[C@@]12CCN(CCc3ccccc3)C[C@@H]1Oc1c(O)cccc12
CHEMBL589260,CHEMBL237,Kappa opioid receptor,Ki,=,10000.0,nM,CHEMBL1065783,B,Displacement of [3H]U69593 from kappa opioid receptor expressed in CHO cells,CHEMBL1157715,KI,CC[C@@]12CCN(CC3CC3)C[C@@H]1Oc1c(O)cccc12
CHEMBL301160,CHEMBL237,Kappa opioid receptor,Ki,=,0.079,nM,CHEMBL1100234,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting",CHEMBL1154976,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL151872,CHEMBL237,Kappa opioid receptor,Ki,=,120.0,nM,CHEMBL1100234,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting",CHEMBL1154976,KI,c1cc2c(cc1OCCCCCCCCCCOc1ccc3c(c1)[C@@]14CCCC[C@H]1[C@@H](C3)N(CC1CCC1)CC4)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL348023,CHEMBL237,Kappa opioid receptor,Ki,=,18.0,nM,CHEMBL1100234,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting",CHEMBL1154976,KI,c1cc2c(cc1OCCCCOc1ccc3c(c1)[C@@]14CCCC[C@H]1[C@@H](C3)N(CC1CCC1)CC4)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1075629,CHEMBL237,Kappa opioid receptor,Ki,=,6.2,nM,CHEMBL1100234,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting",CHEMBL1154976,KI,c1cc2c(cc1OCCCOc1ccc3c(c1)[C@@]14CCCC[C@H]1[C@@H](C3)N(CC1CCC1)CC4)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1076572,CHEMBL237,Kappa opioid receptor,Ki,=,0.99,nM,CHEMBL1100234,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting",CHEMBL1154976,KI,OC(COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1076573,CHEMBL237,Kappa opioid receptor,Ki,=,0.17,nM,CHEMBL1100234,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting",CHEMBL1154976,KI,OC(COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)CC(O)COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1076574,CHEMBL237,Kappa opioid receptor,Ki,=,12.0,nM,CHEMBL1100234,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting",CHEMBL1154976,KI,OC(CCC(O)COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1076575,CHEMBL237,Kappa opioid receptor,Ki,=,9.8,nM,CHEMBL1100234,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting",CHEMBL1154976,KI,OC(CCCC(O)COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1076576,CHEMBL237,Kappa opioid receptor,Ki,=,3.3,nM,CHEMBL1100234,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting",CHEMBL1154976,KI,OC(CCCCC(O)COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1076577,CHEMBL237,Kappa opioid receptor,Ki,=,3.9,nM,CHEMBL1100234,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting",CHEMBL1154976,KI,OC(CCCCCC(O)COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1076578,CHEMBL237,Kappa opioid receptor,Ki,=,1.4,nM,CHEMBL1100234,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting",CHEMBL1154976,KI,OC(CCCCCCC(O)COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1076579,CHEMBL237,Kappa opioid receptor,Ki,=,0.34,nM,CHEMBL1100234,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting",CHEMBL1154976,KI,OC(COc1ccc(Cc2ccc(OCC(O)COc3ccc4c(c3)[C@@]35CCCC[C@H]3[C@@H](C4)N(CC3CCC3)CC5)cc2)cc1)COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1081084,CHEMBL237,Kappa opioid receptor,Ki,=,36.0,nM,CHEMBL1100234,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting",CHEMBL1154976,KI,c1cc2c(cc1OCC1CO1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1081250,CHEMBL237,Kappa opioid receptor,Ki,=,8.3,nM,CHEMBL1100234,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting",CHEMBL1154976,KI,CCCCCCCCC(O)COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1080925,CHEMBL237,Kappa opioid receptor,Ki,=,0.2,nM,CHEMBL1100234,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting",CHEMBL1154976,KI,CCCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1081093,CHEMBL237,Kappa opioid receptor,Ki,=,52.0,nM,CHEMBL1100234,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting",CHEMBL1154976,KI,CCCCCCCCCCOc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1081608,CHEMBL237,Kappa opioid receptor,Ki,=,22.0,nM,CHEMBL1100234,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting",CHEMBL1154976,KI,OC(COc1ccccc1)COc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1079079,CHEMBL237,Kappa opioid receptor,Ki,=,1477.0,nM,CHEMBL1111403,B,Displacement of [3H]U69593 from kappa opioid receptor at 10 uM by scintillation counting,CHEMBL1154290,KI,COc1ccc(-c2c(C#N)c(C(=O)NN3CCCCC3)nn2-c2ccccc2[125I])cc1
CHEMBL1091995,CHEMBL237,Kappa opioid receptor,Ki,=,363.0,nM,CHEMBL1112645,B,Binding affinity to kappa opioid receptor,CHEMBL1156939,KI,O=CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL80,CHEMBL237,Kappa opioid receptor,Ki,=,14.7,nM,CHEMBL1104716,B,Displacement of [3H]Cl977 from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1157818,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL441765,CHEMBL237,Kappa opioid receptor,Ki,=,1.5,nM,CHEMBL1104716,B,Displacement of [3H]Cl977 from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1157818,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL573214,CHEMBL237,Kappa opioid receptor,Ki,=,0.34,nM,CHEMBL1104716,B,Displacement of [3H]Cl977 from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1157818,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL1094237,CHEMBL237,Kappa opioid receptor,Ki,=,120.0,nM,CHEMBL1104716,B,Displacement of [3H]Cl977 from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1157818,KI,CCC(=O)N1C[C@H]2[C@H](N3CCCC3)CC[C@@H]1CN2C(=O)Cc1ccc(Cl)c(Cl)c1
CHEMBL1096475,CHEMBL237,Kappa opioid receptor,Ki,=,850.0,nM,CHEMBL1104716,B,Displacement of [3H]Cl977 from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1157818,KI,COC(=O)N1C[C@H]2[C@@H](N3CCCC3)CC[C@@H]1CN2C(=O)Cc1ccc(Cl)c(Cl)c1
CHEMBL1094880,CHEMBL237,Kappa opioid receptor,Ki,=,6.0,nM,CHEMBL1104716,B,Displacement of [3H]Cl977 from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1157818,KI,COC(=O)N1C[C@H]2[C@H](N3CCCC3)CC[C@@H]1CN2C(=O)Cc1ccc(Cl)c(Cl)c1
CHEMBL1096474,CHEMBL237,Kappa opioid receptor,Ki,=,1510.0,nM,CHEMBL1104716,B,Displacement of [3H]Cl977 from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1157818,KI,O=C(Cc1ccc(Cl)c(Cl)c1)N1C[C@H]2CC[C@H](N3CCCC3)[C@@H]1CN2Cc1ccccc1
CHEMBL1096473,CHEMBL237,Kappa opioid receptor,Ki,=,920.0,nM,CHEMBL1104716,B,Displacement of [3H]Cl977 from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1157818,KI,O=C(Cc1ccc(Cl)c(Cl)c1)N1C[C@@H]2CC[C@@H](N3CCCC3)[C@H]1CN2Cc1ccccc1
CHEMBL1095521,CHEMBL237,Kappa opioid receptor,Ki,=,70.0,nM,CHEMBL1104716,B,Displacement of [3H]Cl977 from human kappa opioid receptor expressed in HEK293 cells,CHEMBL1157818,KI,O=C(Cc1ccc(Cl)c(Cl)c1)N1C[C@H]2CC[C@@H](N3CCCC3)[C@@H]1CN2Cc1ccccc1
CHEMBL440765,CHEMBL237,Kappa opioid receptor,Ki,=,0.475,nM,CHEMBL1168405,B,Binding affinity to kappa opioid receptor,CHEMBL1165960,KI,CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL441765,CHEMBL237,Kappa opioid receptor,Ki,=,0.69,nM,CHEMBL1168405,B,Binding affinity to kappa opioid receptor,CHEMBL1165960,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL445332,CHEMBL237,Kappa opioid receptor,Ki,=,1.9,nM,CHEMBL1168405,B,Binding affinity to kappa opioid receptor,CHEMBL1165960,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL1163522,CHEMBL237,Kappa opioid receptor,Ki,=,15.0,nM,CHEMBL1168405,B,Binding affinity to kappa opioid receptor,CHEMBL1165960,KI,COC(=O)[C@]12CN(C)C[C@](C(=O)OC)(C1=O)[C@@H](c1ccccn1)N(C)[C@H]2c1ccccn1
CHEMBL350384,CHEMBL237,Kappa opioid receptor,Ki,=,0.04,nM,CHEMBL1168405,B,Binding affinity to kappa opioid receptor,CHEMBL1165960,KI,CCC12CCN(CC3(O)CC3)C(Cc3ccc(O)cc31)C2(C)C
CHEMBL169703,CHEMBL237,Kappa opioid receptor,Ki,=,0.17,nM,CHEMBL1168405,B,Binding affinity to kappa opioid receptor,CHEMBL1165960,KI,CN1c2ccccc2C(c2ccccc2F)=NCC1CNC(=O)c1ccsc1
CHEMBL485605,CHEMBL237,Kappa opioid receptor,Ki,=,0.195,nM,CHEMBL1168405,B,Binding affinity to kappa opioid receptor,CHEMBL1165960,KI,CN(C(=O)/C=C/c1ccco1)[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL2016680,CHEMBL237,Kappa opioid receptor,Ki,=,0.111,nM,CHEMBL1168405,B,Binding affinity to kappa opioid receptor,CHEMBL1165960,KI,O=C(Nc1ccccc1)[C@H]1O[C@@]23CC[C@]1(O)[C@@H]1Oc4c(O)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5
CHEMBL1165548,CHEMBL237,Kappa opioid receptor,Ki,=,0.152,nM,CHEMBL1168405,B,Binding affinity to kappa opioid receptor,CHEMBL1165960,KI,O=C(Nc1ccccc1)[C@@H]1O[C@@]23CC[C@@]1(O)[C@@H]1Oc4c(O)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5
CHEMBL1163923,CHEMBL237,Kappa opioid receptor,Ki,=,0.279,nM,CHEMBL1168405,B,Binding affinity to kappa opioid receptor,CHEMBL1165960,KI,CN(CCc1ccccc1)C(=O)[C@H]1C[C@@]23C=C[C@]1(O)[C@@H]1Oc4c(O)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5
CHEMBL1163924,CHEMBL237,Kappa opioid receptor,Ki,=,0.135,nM,CHEMBL1168405,B,Binding affinity to kappa opioid receptor,CHEMBL1165960,KI,O=C(NC[C@H]1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@]3(O)CO1)c1ccccc1
CHEMBL70,CHEMBL237,Kappa opioid receptor,Ki,=,33.7,nM,CHEMBL1168405,B,Binding affinity to kappa opioid receptor,CHEMBL1165960,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL1164183,CHEMBL237,Kappa opioid receptor,Ki,=,38.7,nM,CHEMBL1168405,B,Binding affinity to kappa opioid receptor,CHEMBL1165960,KI,NC(=O)[C@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1
CHEMBL1164269,CHEMBL237,Kappa opioid receptor,Ki,=,39.0,nM,CHEMBL1168405,B,Binding affinity to kappa opioid receptor,CHEMBL1165960,KI,COc1ccc([C@H]2CN3C(=NC[C@@H]3C)N2CCCc2ccccc2)cc1
CHEMBL1224527,CHEMBL237,Kappa opioid receptor,Ki,=,820000.0,nM,CHEMBL1225587,B,Binding affinity to adrenergic kappa opioid receptor,CHEMBL1221364,KI,Oc1ccc2c(c1O)C[C@@H](c1ccccc1)[C@@H]1CCNC[C@@H]21
CHEMBL1241328,CHEMBL237,Kappa opioid receptor,Ki,=,1800.0,nM,CHEMBL1247782,B,Binding affinity to kappa opioid receptor,CHEMBL1240486,KI,Cl.Cn1c(=O)[nH]c2c([nH]c(=O)n2C)c1=N
CHEMBL573214,CHEMBL237,Kappa opioid receptor,Ki,=,0.9,nM,CHEMBL1259488,B,Binding affinity to kappa opioid receptor,CHEMBL1255514,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL10872,CHEMBL237,Kappa opioid receptor,Ki,=,0.3,nM,CHEMBL1259488,B,Binding affinity to kappa opioid receptor,CHEMBL1255514,KI,CC(C)[C@@H](CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)NC(=O)[C@H]1Cc2ccccc2CN1
CHEMBL1257346,CHEMBL237,Kappa opioid receptor,Ki,=,0.5,nM,CHEMBL1259488,B,Binding affinity to kappa opioid receptor,CHEMBL1255514,KI,O=C(Nc1cccc(NC(=O)c2cccc(N3CCOCC3)c2)c1)c1cccc(OC2CCN(CC3CC3)CC2)c1
CHEMBL1256487,CHEMBL237,Kappa opioid receptor,Ki,=,146.0,nM,CHEMBL1259488,B,Binding affinity to kappa opioid receptor,CHEMBL1255514,KI,NC(=O)c1cccc(OC2CCN(CC3CC3)CC2)c1
CHEMBL1257457,CHEMBL237,Kappa opioid receptor,Ki,=,75.0,nM,CHEMBL1259488,B,Binding affinity to kappa opioid receptor,CHEMBL1255514,KI,NC(=O)c1cccc(OC2CCN(Cc3ccccc3)CC2)c1
CHEMBL1223951,CHEMBL237,Kappa opioid receptor,Ki,=,40.0,nM,CHEMBL1259488,B,Binding affinity to kappa opioid receptor,CHEMBL1255514,KI,NC(=O)c1cccc(O[C@@H]2C[C@H]3CC[C@@H](C2)N3Cc2ccccc2)c1
CHEMBL441765,CHEMBL237,Kappa opioid receptor,Ki,=,1.2,nM,CHEMBL1260358,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1255551,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL1257853,CHEMBL237,Kappa opioid receptor,Ki,=,51.6,nM,CHEMBL1260358,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1255551,KI,COC(=O)[C@@H]1CCC(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL1257852,CHEMBL237,Kappa opioid receptor,Ki,=,245.0,nM,CHEMBL1260358,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1255551,KI,COC(=O)[C@@H]1C[C@@H](I)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL1257731,CHEMBL237,Kappa opioid receptor,Ki,=,198.0,nM,CHEMBL1260358,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1255551,KI,COC(=O)[C@@H]1C[C@H](I)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL1257610,CHEMBL237,Kappa opioid receptor,Ki,=,42.3,nM,CHEMBL1260358,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1255551,KI,COC(=O)[C@@H]1C[C@@H](Br)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL1257609,CHEMBL237,Kappa opioid receptor,Ki,=,422.0,nM,CHEMBL1260358,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1255551,KI,COC(=O)[C@@H]1C[C@H](Br)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL1257489,CHEMBL237,Kappa opioid receptor,Ki,=,24.3,nM,CHEMBL1260358,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1255551,KI,COC(=O)[C@@H]1CC(C(=O)O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL1257488,CHEMBL237,Kappa opioid receptor,Ki,=,167.0,nM,CHEMBL1260358,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1255551,KI,COC(=O)[C@@H]1C[C@@H](Cl)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL1257378,CHEMBL237,Kappa opioid receptor,Ki,=,197.0,nM,CHEMBL1260358,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells,CHEMBL1255551,KI,COC(=O)[C@@H]1C[C@@H](F)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL1644773,CHEMBL237,Kappa opioid receptor,Ki,=,3784.0,nM,CHEMBL1648968,B,Displacement of [3H]U69593 from kappa opioid receptor expressed in HEK293 cells,CHEMBL1641545,KI,COC(=O)[C@@H]1C[C@H](OC(=O)[C@H](C)N)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL1644775,CHEMBL237,Kappa opioid receptor,Ki,=,42.0,nM,CHEMBL1648968,B,Displacement of [3H]U69593 from kappa opioid receptor expressed in HEK293 cells,CHEMBL1641545,KI,COC(=O)[C@@H]1C[C@H](OC(=O)[C@@H](N)C(C)C)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL445332,CHEMBL237,Kappa opioid receptor,Ki,=,0.75,nM,CHEMBL1648968,B,Displacement of [3H]U69593 from kappa opioid receptor expressed in HEK293 cells,CHEMBL1641545,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL1645202,CHEMBL237,Kappa opioid receptor,Ki,=,372.0,nM,CHEMBL1646515,B,Displacement of radioligand from kappa opioid receptor,CHEMBL1641560,KI,FCCC1OC2(CCN(Cc3ccccc3)CC2)c2ccccc21
CHEMBL1650845,CHEMBL237,Kappa opioid receptor,Ki,=,39.0,nM,CHEMBL1659155,B,Displacement of [3H]enadoline from human KOP receptor expressed in HEK-293 cells after 45 mins,CHEMBL1649335,KI,OCC1(N2CCC(n3c(N4CC5CN(Cc6ccccc6)CC5C4)nc4ccccc43)CC2)CCCCCCC1
CHEMBL1650847,CHEMBL237,Kappa opioid receptor,Ki,=,333.0,nM,CHEMBL1659155,B,Displacement of [3H]enadoline from human KOP receptor expressed in HEK-293 cells after 45 mins,CHEMBL1649335,KI,CN1CCN(c2nc3ccccc3n2C2CCN(C3(CO)CCCCCCC3)CC2)CC1
CHEMBL1650841,CHEMBL237,Kappa opioid receptor,Ki,=,387.0,nM,CHEMBL1659155,B,Displacement of [3H]enadoline from human KOP receptor expressed in HEK-293 cells after 45 mins,CHEMBL1649335,KI,CC1(C)CN(c2nc3ccccc3n2C2CCN(C3(CO)CCCCCCC3)CC2)CCN1
CHEMBL1650848,CHEMBL237,Kappa opioid receptor,Ki,=,275.0,nM,CHEMBL1659155,B,Displacement of [3H]enadoline from human KOP receptor expressed in HEK-293 cells after 45 mins,CHEMBL1649335,KI,CC1CN(c2nc3ccccc3n2C2CCN(C3(CO)CCCCCCC3)CC2)CCN1
CHEMBL1650851,CHEMBL237,Kappa opioid receptor,Ki,=,239.0,nM,CHEMBL1659155,B,Displacement of [3H]enadoline from human KOP receptor expressed in HEK-293 cells after 45 mins,CHEMBL1649335,KI,O=c1[nH]c2ccccc2n1C1CCN(C2(CO)CCCCCCC2)CC1
CHEMBL1743605,CHEMBL237,Kappa opioid receptor,Ki,=,1.4,nM,CHEMBL1670101,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1667791,KI,Cc1cc(O)cc(C)c1C[C@@H](C(=O)N1Cc2ccccc2C[C@H]1C(=O)NCCC(=O)OC1=C2O[C@H]3[C@@H](O)C=C[C@H]4[C@H]5CC(C=C1)C2[C@]43CCN5C)N(C)C.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
CHEMBL1743604,CHEMBL237,Kappa opioid receptor,Ki,=,12.0,nM,CHEMBL1670101,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1667791,KI,Cc1cc(O)cc(C)c1C[C@@H](C(=O)N1Cc2ccccc2C[C@H]1C(=O)OC1=C2O[C@H]3[C@@H](O)C=C[C@H]4[C@H]5CC(C=C1)C2[C@]43CCN5C)N(C)C.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
CHEMBL1672177,CHEMBL237,Kappa opioid receptor,Ki,=,125.0,nM,CHEMBL1678428,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1671786,KI,Cl.Oc1cccc([C@]23CCC[C@H](C2)N(C/C=C/c2ccccc2)CC3)c1
CHEMBL1672178,CHEMBL237,Kappa opioid receptor,Ki,=,225.0,nM,CHEMBL1678428,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1671786,KI,Cl.Oc1cccc([C@@]23CCC[C@@H](C2)N(C/C=C/c2ccccc2)CC3)c1
CHEMBL1672179,CHEMBL237,Kappa opioid receptor,Ki,=,123.0,nM,CHEMBL1678428,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1671786,KI,Cl.Oc1cccc([C@]23CCC[C@H](C2)N(C/C=C\c2ccccc2)CC3)c1
CHEMBL1672180,CHEMBL237,Kappa opioid receptor,Ki,=,367.0,nM,CHEMBL1678428,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1671786,KI,Cl.Oc1cccc([C@@]23CCC[C@@H](C2)N(C/C=C\c2ccccc2)CC3)c1
CHEMBL1672181,CHEMBL237,Kappa opioid receptor,Ki,=,390.0,nM,CHEMBL1678428,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1671786,KI,Cl.Oc1cccc([C@]23CCC[C@H](C2)N(C[C@@H]2C[C@H]2c2ccccc2)CC3)c1
CHEMBL1672182,CHEMBL237,Kappa opioid receptor,Ki,=,72.0,nM,CHEMBL1678428,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1671786,KI,Cl.Oc1cccc([C@@]23CCC[C@@H](C2)N(C[C@H]2C[C@@H]2c2ccccc2)CC3)c1
CHEMBL1672183,CHEMBL237,Kappa opioid receptor,Ki,=,323.0,nM,CHEMBL1678428,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1671786,KI,Cl.Oc1cccc([C@]23CCC[C@H](C2)N(C[C@H]2C[C@@H]2c2ccccc2)CC3)c1
CHEMBL1672184,CHEMBL237,Kappa opioid receptor,Ki,=,210.0,nM,CHEMBL1678428,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1671786,KI,Cl.Oc1cccc([C@@]23CCC[C@@H](C2)N(C[C@@H]2C[C@H]2c2ccccc2)CC3)c1
CHEMBL1672185,CHEMBL237,Kappa opioid receptor,Ki,=,153.0,nM,CHEMBL1678428,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1671786,KI,Cl.Oc1cccc([C@]23CCC[C@H](C2)N(C[C@@H]2C[C@@H]2c2ccccc2)CC3)c1
CHEMBL1672186,CHEMBL237,Kappa opioid receptor,Ki,=,475.0,nM,CHEMBL1678428,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1671786,KI,Cl.Oc1cccc([C@@]23CCC[C@@H](C2)N(C[C@H]2C[C@H]2c2ccccc2)CC3)c1
CHEMBL1672187,CHEMBL237,Kappa opioid receptor,Ki,=,174.0,nM,CHEMBL1678428,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1671786,KI,Cl.Oc1cccc([C@]23CCC[C@H](C2)N(C[C@H]2C[C@H]2c2ccccc2)CC3)c1
CHEMBL1672188,CHEMBL237,Kappa opioid receptor,Ki,=,322.0,nM,CHEMBL1678428,B,Displacement of [125I]IOXY from human recombinant kappa opioid receptor expressed in CHO cells,CHEMBL1671786,KI,Cl.Oc1cccc([C@@]23CCC[C@@H](C2)N(C[C@@H]2C[C@@H]2c2ccccc2)CC3)c1
CHEMBL1765684,CHEMBL237,Kappa opioid receptor,Ki,=,597.0,nM,CHEMBL1767922,B,Binding affinity to kappa opioid receptor by radioligand binding assay,CHEMBL1764973,KI,COc1ccc(-c2c(C)c(C(=O)NC3(C#N)CCCCC3)nn2-c2ccccc2Br)cc1
CHEMBL1765683,CHEMBL237,Kappa opioid receptor,Ki,=,798.0,nM,CHEMBL1767922,B,Binding affinity to kappa opioid receptor by radioligand binding assay,CHEMBL1764973,KI,COc1ccc(-c2c(C)c(C(=O)NC3(C#N)CCOCC3)nn2-c2ccccc2Br)cc1
CHEMBL301160,CHEMBL237,Kappa opioid receptor,Ki,=,0.079,nM,CHEMBL1769426,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL49269,CHEMBL237,Kappa opioid receptor,Ki,=,0.034,nM,CHEMBL1769426,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL299220,CHEMBL237,Kappa opioid receptor,Ki,=,0.18,nM,CHEMBL1769426,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,Nc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL242756,CHEMBL237,Kappa opioid receptor,Ki,=,0.049,nM,CHEMBL1769426,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1
CHEMBL390911,CHEMBL237,Kappa opioid receptor,Ki,=,52.0,nM,CHEMBL1769426,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,Nc1nc2cc3c(cc2o1)[C@@]12CCCC[C@H]1[C@@H](C3)N(CC1CC1)CC2
CHEMBL1766021,CHEMBL237,Kappa opioid receptor,Ki,=,6.4,nM,CHEMBL1769426,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1cc2sc(N)nc2cc13
CHEMBL390866,CHEMBL237,Kappa opioid receptor,Ki,=,0.79,nM,CHEMBL1769426,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CCC1
CHEMBL1766022,CHEMBL237,Kappa opioid receptor,Ki,=,0.3,nM,CHEMBL1769426,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CCCF
CHEMBL1766023,CHEMBL237,Kappa opioid receptor,Ki,=,0.83,nM,CHEMBL1769426,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1C[C@@H]1CCCO1
CHEMBL1766024,CHEMBL237,Kappa opioid receptor,Ki,=,0.066,nM,CHEMBL1769426,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,CNc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1
CHEMBL1766025,CHEMBL237,Kappa opioid receptor,Ki,=,0.151,nM,CHEMBL1769426,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,CCNc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1
CHEMBL1766026,CHEMBL237,Kappa opioid receptor,Ki,=,0.84,nM,CHEMBL1769426,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,FC(F)(F)CNc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1
CHEMBL1766027,CHEMBL237,Kappa opioid receptor,Ki,=,1.6,nM,CHEMBL1769426,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,CCCNc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1
CHEMBL1766028,CHEMBL237,Kappa opioid receptor,Ki,=,13.0,nM,CHEMBL1769426,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,CC(=O)Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1
CHEMBL1766029,CHEMBL237,Kappa opioid receptor,Ki,=,21.0,nM,CHEMBL1769426,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,c1ccc(Nc2nc3cc4c(cc3s2)C[C@@H]2[C@@H]3CCCC[C@]43CCN2CC2CC2)cc1
CHEMBL1766030,CHEMBL237,Kappa opioid receptor,Ki,=,2.1,nM,CHEMBL1769426,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,c1ccc(CNc2nc3cc4c(cc3s2)C[C@@H]2[C@@H]3CCCC[C@]43CCN2CC2CC2)cc1
CHEMBL1766031,CHEMBL237,Kappa opioid receptor,Ki,=,4.8,nM,CHEMBL1769426,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,COc1cccc(CNc2nc3cc4c(cc3s2)C[C@@H]2[C@@H]3CCCC[C@]43CCN2CC2CC2)c1
CHEMBL1766032,CHEMBL237,Kappa opioid receptor,Ki,=,3.5,nM,CHEMBL1769426,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,Oc1cccc(CNc2nc3cc4c(cc3s2)C[C@@H]2[C@@H]3CCCC[C@]43CCN2CC2CC2)c1
CHEMBL1766033,CHEMBL237,Kappa opioid receptor,Ki,=,18.0,nM,CHEMBL1769426,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,CCNC(=S)Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1
CHEMBL1766034,CHEMBL237,Kappa opioid receptor,Ki,=,95.0,nM,CHEMBL1769426,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,c1ccc(Nc2nc3cc4c(cc3s2)C[C@@H]2[C@@H]3CCCC[C@]43CCN2CC2CC2)nc1
CHEMBL1766035,CHEMBL237,Kappa opioid receptor,Ki,=,110.0,nM,CHEMBL1769426,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,c1c2c(cc3sc(NN4CCNCC4)nc13)C[C@@H]1[C@@H]3CCCC[C@]23CCN1CC1CC1
CHEMBL1766036,CHEMBL237,Kappa opioid receptor,Ki,=,0.45,nM,CHEMBL1769426,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,CN(C)c1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1
CHEMBL1766037,CHEMBL237,Kappa opioid receptor,Ki,=,6.9,nM,CHEMBL1769426,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,CC(=O)N(C)c1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1
CHEMBL1766038,CHEMBL237,Kappa opioid receptor,Ki,=,13.0,nM,CHEMBL1769426,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,CCN(C(C)=O)c1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1
CHEMBL1766039,CHEMBL237,Kappa opioid receptor,Ki,=,2.4,nM,CHEMBL1769426,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,CNc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CCC1
CHEMBL1766040,CHEMBL237,Kappa opioid receptor,Ki,=,3.7,nM,CHEMBL1769426,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,CCNc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CCC1
CHEMBL1766041,CHEMBL237,Kappa opioid receptor,Ki,=,0.71,nM,CHEMBL1769426,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,CNc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CCCF
CHEMBL1766042,CHEMBL237,Kappa opioid receptor,Ki,=,1.2,nM,CHEMBL1769426,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,CC(=O)Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CCCF
CHEMBL1766043,CHEMBL237,Kappa opioid receptor,Ki,=,0.94,nM,CHEMBL1769426,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,CCNc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CCCF
CHEMBL1766044,CHEMBL237,Kappa opioid receptor,Ki,=,5.8,nM,CHEMBL1769426,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,CCCNc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CCCF
CHEMBL1766045,CHEMBL237,Kappa opioid receptor,Ki,=,11.0,nM,CHEMBL1769426,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1765082,KI,CN(C)c1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CCCF
CHEMBL445332,CHEMBL237,Kappa opioid receptor,Ki,=,7.4,nM,CHEMBL1775888,B,Displacement of [3H]U69593 from kappa opioid receptor,CHEMBL1773062,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL1773747,CHEMBL237,Kappa opioid receptor,Ki,=,120.0,nM,CHEMBL1775888,B,Displacement of [3H]U69593 from kappa opioid receptor,CHEMBL1773062,KI,CCOC(=O)C1=C(C(=O)OCC)C2OC1C=C2[C@@H]1C[C@]2(C)[C@H]3C(=O)[C@@H](OC(C)=O)C[C@@H](C(=O)OC)[C@]3(C)CC[C@H]2C(=O)O1
CHEMBL1773748,CHEMBL237,Kappa opioid receptor,Ki,=,60.0,nM,CHEMBL1775888,B,Displacement of [3H]U69593 from kappa opioid receptor,CHEMBL1773062,KI,COC(=O)C1=C(C(=O)OC)C2OC1C=C2[C@@H]1C[C@]2(C)[C@H]3C(=O)[C@@H](OC(C)=O)C[C@@H](C(=O)OC)[C@]3(C)CC[C@H]2C(=O)O1
CHEMBL1773749,CHEMBL237,Kappa opioid receptor,Ki,=,790.0,nM,CHEMBL1775888,B,Displacement of [3H]U69593 from kappa opioid receptor,CHEMBL1773062,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C3=CC4OC3c3ccccc34)C[C@]21C
CHEMBL1773751,CHEMBL237,Kappa opioid receptor,Ki,=,290.0,nM,CHEMBL1775888,B,Displacement of [3H]U69593 from kappa opioid receptor,CHEMBL1773062,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C3=CC4OC3C3C4C4OC3(C)c3c4c4ccccc4c(=O)c4ccccc34)C[C@]21C
CHEMBL1773752,CHEMBL237,Kappa opioid receptor,Ki,=,228.0,nM,CHEMBL1775888,B,Displacement of [3H]U69593 from kappa opioid receptor,CHEMBL1773062,KI,CCOC(=O)c1ccc([C@@H]2C[C@]3(C)[C@H]4C(=O)[C@@H](OC(C)=O)C[C@@H](C(=O)OC)[C@]4(C)CC[C@H]3C(=O)O2)cc1C(=O)OCC
CHEMBL1773753,CHEMBL237,Kappa opioid receptor,Ki,=,286.0,nM,CHEMBL1775888,B,Displacement of [3H]U69593 from kappa opioid receptor,CHEMBL1773062,KI,COC(=O)c1ccc([C@@H]2C[C@]3(C)[C@H]4C(=O)[C@@H](OC(C)=O)C[C@@H](C(=O)OC)[C@]4(C)CC[C@H]3C(=O)O2)cc1C(=O)OC
CHEMBL1774952,CHEMBL237,Kappa opioid receptor,Ki,=,0.27,nM,CHEMBL1776828,B,Displacement of [3H]U69563 from human kappa-opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1772956,KI,c1c2c(cc3sc(NCCCCCCCCCCNc4nc5cc6c(cc5s4)C[C@@H]4[C@@H]5CCCC[C@]65CCN4CC4CC4)nc13)C[C@@H]1[C@@H]3CCCC[C@]23CCN1CC1CC1
CHEMBL1774951,CHEMBL237,Kappa opioid receptor,Ki,=,0.37,nM,CHEMBL1776828,B,Displacement of [3H]U69563 from human kappa-opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1772956,KI,O=C(CCCCCCCCC(=O)Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1)Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1
CHEMBL242756,CHEMBL237,Kappa opioid receptor,Ki,=,0.049,nM,CHEMBL1776828,B,Displacement of [3H]U69563 from human kappa-opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1772956,KI,Nc1nc2cc3c(cc2s1)C[C@@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1
CHEMBL1774950,CHEMBL237,Kappa opioid receptor,Ki,=,0.28,nM,CHEMBL1776828,B,Displacement of [3H]U69563 from human kappa-opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1772956,KI,C=CCN1CC[C@]23c4c5ccc(OC(=O)CCCCCCCCC(=O)Oc6ccc7c(c6)[C@@]68CCCC[C@@]6(O)[C@@H](C7)N(CC6CCC6)CC8)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL1774949,CHEMBL237,Kappa opioid receptor,Ki,=,0.073,nM,CHEMBL1776828,B,Displacement of [3H]U69563 from human kappa-opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1772956,KI,O=C(CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1774948,CHEMBL237,Kappa opioid receptor,Ki,=,0.14,nM,CHEMBL1776828,B,Displacement of [3H]U69563 from human kappa-opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1772956,KI,C=CCN1CC[C@]23c4c5ccc(OC(=O)CCCCCCCCC(=O)Oc6ccc7c(c6)[C@@]68CCCC[C@@]6(OC)[C@@H](C7)N(CC6CCC6)CC8)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL1773091,CHEMBL237,Kappa opioid receptor,Ki,=,0.23,nM,CHEMBL1776828,B,Displacement of [3H]U69563 from human kappa-opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1772956,KI,CO[C@@]12CCCC[C@@]13CCN(CC1CCC1)[C@@H]2Cc1ccc(OC(=O)CCCCCCCCC(=O)OCc2ccccc2)cc13
CHEMBL1774947,CHEMBL237,Kappa opioid receptor,Ki,=,0.37,nM,CHEMBL1776828,B,Displacement of [3H]U69563 from human kappa-opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1772956,KI,CO[C@@]12CCCC[C@@]13CCN(CC1CCC1)[C@@H]2Cc1ccc(OC(=O)CCCCCCCCC(=O)Oc2ccc4c(c2)[C@@]25CCCC[C@@]2(OC)[C@@H](C4)N(CC2CCC2)CC5)cc13
CHEMBL146756,CHEMBL237,Kappa opioid receptor,Ki,=,0.08,nM,CHEMBL1776828,B,Displacement of [3H]U69563 from human kappa-opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1772956,KI,O=C(/C=C/C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL147511,CHEMBL237,Kappa opioid receptor,Ki,=,0.049,nM,CHEMBL1776828,B,Displacement of [3H]U69563 from human kappa-opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1772956,KI,O=C(CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL1774946,CHEMBL237,Kappa opioid receptor,Ki,=,0.2,nM,CHEMBL1776828,B,Displacement of [3H]U69563 from human kappa-opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1772956,KI,CO[C@@]12CCCC[C@@]13CCN(CC1CCC1)[C@@H]2Cc1ccc(O)cc13
CHEMBL33986,CHEMBL237,Kappa opioid receptor,Ki,=,0.12,nM,CHEMBL1776828,B,Displacement of [3H]U69563 from human kappa-opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1772956,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3
CHEMBL301160,CHEMBL237,Kappa opioid receptor,Ki,=,0.079,nM,CHEMBL1776828,B,Displacement of [3H]U69563 from human kappa-opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1772956,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL80,CHEMBL237,Kappa opioid receptor,Ki,=,0.25,nM,CHEMBL1776828,B,Displacement of [3H]U69563 from human kappa-opioid receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1772956,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL80,CHEMBL237,Kappa opioid receptor,Ki,=,4.467,nM,CHEMBL1786448,B,Displacement of [3H]DPN from human recombinant kappa-type opioid receptor expressed in CHO cell membranes,CHEMBL1781947,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL1783826,CHEMBL237,Kappa opioid receptor,Ki,=,316.23,nM,CHEMBL1786448,B,Displacement of [3H]DPN from human recombinant kappa-type opioid receptor expressed in CHO cell membranes,CHEMBL1781947,KI,O=C(NCCCN1CCC(c2c(Cl)cccc2Cl)CC1)[C@H]1CCCN1Cc1ccccc1
CHEMBL603370,CHEMBL237,Kappa opioid receptor,Ki,=,0.45,nM,CHEMBL1785787,B,Displacement of [3H]U69593 from kappa opioid receptor,CHEMBL1781976,KI,COC(=O)N1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)C(CN2CCCC2)C1
CHEMBL1095519,CHEMBL237,Kappa opioid receptor,Ki,=,0.31,nM,CHEMBL1785787,B,Displacement of [3H]U69593 from kappa opioid receptor,CHEMBL1781976,KI,COC(=O)N1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)[C@@H]([C@@H](C)N2CCCC2)C1
CHEMBL1795711,CHEMBL237,Kappa opioid receptor,Ki,=,0.23,nM,CHEMBL1799267,B,Displacement of [3H]-U69593 from KOR-1 expressed in CHO cells after 60 mins,CHEMBL1795226,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1cccc(I)c1
CHEMBL1795712,CHEMBL237,Kappa opioid receptor,Ki,=,0.08,nM,CHEMBL1799267,B,Displacement of [3H]-U69593 from KOR-1 expressed in CHO cells after 60 mins,CHEMBL1795226,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@H](NC(=O)c2cccc(I)c2)CC[C@@]3(O)[C@H]1C5
CHEMBL1795713,CHEMBL237,Kappa opioid receptor,Ki,=,9.0,nM,CHEMBL1799267,B,Displacement of [3H]-U69593 from KOR-1 expressed in CHO cells after 60 mins,CHEMBL1795226,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@H](NC(=O)c2cccc(I)c2)CC[C@@]3(O)[C@H]1C5
CHEMBL573214,CHEMBL237,Kappa opioid receptor,Ki,=,0.23,nM,CHEMBL1799277,B,Displacement of [125I]-IBNtxA from KOR-1 expressed in CHO cells,CHEMBL1795226,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL485832,CHEMBL237,Kappa opioid receptor,Ki,=,0.15,nM,CHEMBL1799277,B,Displacement of [125I]-IBNtxA from KOR-1 expressed in CHO cells,CHEMBL1795226,KI,N=C(N)Nc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL482811,CHEMBL237,Kappa opioid receptor,Ki,=,0.73,nM,CHEMBL1799277,B,Displacement of [125I]-IBNtxA from KOR-1 expressed in CHO cells,CHEMBL1795226,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1.CS(=O)(=O)O
CHEMBL573214,CHEMBL237,Kappa opioid receptor,Ki,=,0.19,nM,CHEMBL1799278,B,Displacement of [125I]-IBNalA from KOR-1 expressed in CHO cells,CHEMBL1795226,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL485832,CHEMBL237,Kappa opioid receptor,Ki,=,0.19,nM,CHEMBL1799278,B,Displacement of [125I]-IBNalA from KOR-1 expressed in CHO cells,CHEMBL1795226,KI,N=C(N)Nc1ccc2[nH]c3c(c2c1)C[C@@]1(O)[C@H]2Cc4ccc(O)c5c4[C@@]1(CCN2CC1CC1)[C@H]3O5
CHEMBL482811,CHEMBL237,Kappa opioid receptor,Ki,=,0.95,nM,CHEMBL1799278,B,Displacement of [125I]-IBNalA from KOR-1 expressed in CHO cells,CHEMBL1795226,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1.CS(=O)(=O)O
CHEMBL1808299,CHEMBL237,Kappa opioid receptor,Ki,=,7500.0,nM,CHEMBL1809751,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells coexpressing human recombinant KOP after 2 hrs by liquid scintillation counting,CHEMBL1806350,KI,CN1CC[C@]23C[C@H]1CC[C@H]2Oc1c(O)cccc13
CHEMBL1808300,CHEMBL237,Kappa opioid receptor,Ki,=,171.0,nM,CHEMBL1809751,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells coexpressing human recombinant KOP after 2 hrs by liquid scintillation counting,CHEMBL1806350,KI,Oc1cccc2c1O[C@@H]1CC[C@@H]3C[C@]21CCN3CCc1ccccc1
CHEMBL1808302,CHEMBL237,Kappa opioid receptor,Ki,=,98.0,nM,CHEMBL1809751,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells coexpressing human recombinant KOP after 2 hrs by liquid scintillation counting,CHEMBL1806350,KI,Oc1ccc2c(c1)[C@]13CCN(CCc4ccccc4)[C@H](CC[C@H]1O2)C3
CHEMBL1808303,CHEMBL237,Kappa opioid receptor,Ki,=,199.0,nM,CHEMBL1809751,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells coexpressing human recombinant KOP after 2 hrs by liquid scintillation counting,CHEMBL1806350,KI,Oc1ccc2c(c1)[C@]13CCN(CCc4ccccc4)[C@H](CC[C@@H]1O2)C3
CHEMBL515681,CHEMBL237,Kappa opioid receptor,Ki,=,102.0,nM,CHEMBL1809751,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells coexpressing human recombinant KOP after 2 hrs by liquid scintillation counting,CHEMBL1806350,KI,Oc1ccc2c(c1)[C@@]13CCN(CCc4ccccc4)[C@@H](CC[C@H]1O2)C3
CHEMBL1808304,CHEMBL237,Kappa opioid receptor,Ki,=,367.0,nM,CHEMBL1809751,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells coexpressing human recombinant KOP after 2 hrs by liquid scintillation counting,CHEMBL1806350,KI,Oc1cccc2c1O[C@H]1CC[C@@H]3C[C@]21CCN3CCc1ccccc1
CHEMBL515842,CHEMBL237,Kappa opioid receptor,Ki,=,42.0,nM,CHEMBL1809751,B,Displacement of [125I]IOXY from human kappa opioid receptor expressed in CHO cells coexpressing human recombinant KOP after 2 hrs by liquid scintillation counting,CHEMBL1806350,KI,Oc1cccc2c1O[C@@H]1CC[C@H]3C[C@@]21CCN3CCc1ccccc1
CHEMBL1814703,CHEMBL237,Kappa opioid receptor,Ki,=,1080.0,nM,CHEMBL1816054,B,"Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting",CHEMBL1811836,KI,CN1C[C@H]2Oc3ccc(O)cc3[C@@]23CCC[C@@H]1C3
CHEMBL1814704,CHEMBL237,Kappa opioid receptor,Ki,=,1230.0,nM,CHEMBL1816054,B,"Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting",CHEMBL1811836,KI,Oc1ccc2c(c1)[C@]13CCC[C@H](C1)N(CCc1ccccc1)C[C@H]3O2
CHEMBL1814705,CHEMBL237,Kappa opioid receptor,Ki,=,51.0,nM,CHEMBL1816054,B,"Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting",CHEMBL1811836,KI,Oc1cccc2c1O[C@@H]1CN(CCc3ccccc3)[C@@H]3CCC[C@]21C3
CHEMBL573214,CHEMBL237,Kappa opioid receptor,Ki,=,0.85,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL1818336,CHEMBL237,Kappa opioid receptor,Ki,=,4.7,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CO[C@@H]1CCCN1S(=O)(=O)c1ccccc1-c1ccc(CNCC(C)C)cc1
CHEMBL1818337,CHEMBL237,Kappa opioid receptor,Ki,=,3.5,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CC(C)CNCc1ccc(-c2ccccc2S(=O)(=O)N2CCOC[C@H]2C)cc1
CHEMBL1818338,CHEMBL237,Kappa opioid receptor,Ki,=,62.0,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CC(C)CNCc1ccc(-c2ccccc2S(=O)(=O)NC(C)C)cc1
CHEMBL1818339,CHEMBL237,Kappa opioid receptor,Ki,=,7.5,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CC(C)N(C)S(=O)(=O)c1ccccc1-c1ccc(CNC2CCCC2)cc1
CHEMBL1818340,CHEMBL237,Kappa opioid receptor,Ki,=,10.0,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CC(C)N(C)S(=O)(=O)c1ccccc1-c1ccc(CN2CCCCC2)cc1
CHEMBL1818341,CHEMBL237,Kappa opioid receptor,Ki,=,3.0,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CC(C)CNCc1ccc(-c2ccccc2S(=O)(=O)N2CCCC2)cc1
CHEMBL1818342,CHEMBL237,Kappa opioid receptor,Ki,=,25.0,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CC(C)CNCc1ccc(-c2ccccc2S(=O)(=O)N2CCC(F)(F)C2)cc1
CHEMBL1818222,CHEMBL237,Kappa opioid receptor,Ki,=,75.0,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CC(C)CN(C)Cc1ccc(-c2ccccc2S(=O)(=O)N2CCCC2)cc1
CHEMBL1818326,CHEMBL237,Kappa opioid receptor,Ki,=,33.0,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,O=S(=O)(c1ccccc1-c1ccc(CNC2CCOCC2)cc1)N1CCC(F)(F)C1
CHEMBL1818327,CHEMBL237,Kappa opioid receptor,Ki,=,14.0,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,C[C@@H]1COCCN1S(=O)(=O)c1ccccc1-c1ccc(CNC2CCOCC2)cc1
CHEMBL1818328,CHEMBL237,Kappa opioid receptor,Ki,=,11.0,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,O=S(=O)(c1ccccc1-c1ccc(CNC2CCOCC2)cc1)N1CCCC1
CHEMBL1818329,CHEMBL237,Kappa opioid receptor,Ki,=,8.6,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,COC[C@H](C)NCc1ccc(-c2ccccc2S(=O)(=O)N2CCCC2)cc1
CHEMBL1818330,CHEMBL237,Kappa opioid receptor,Ki,=,2.2,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,COC1CCN(Cc2ccc(-c3ccccc3S(=O)(=O)N3CCCC3)cc2)CC1
CHEMBL1818331,CHEMBL237,Kappa opioid receptor,Ki,=,5.8,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CN(C)CCNCc1ccc(-c2ccccc2S(=O)(=O)N2CCCC2)cc1
CHEMBL1818332,CHEMBL237,Kappa opioid receptor,Ki,=,2.6,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CC1(CNCc2ccc(-c3ccccc3S(=O)(=O)N3CCCC3)cc2)COC1
CHEMBL1818333,CHEMBL237,Kappa opioid receptor,Ki,=,13.0,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,C[C@@H]1COCCN1S(=O)(=O)c1ccccc1-c1ccc(CN2CCN(C)CC2)cc1
CHEMBL1818233,CHEMBL237,Kappa opioid receptor,Ki,=,0.5,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CC1(O)CCN(Cc2ccc(-c3ccccc3S(=O)(=O)N3CCCC3)cc2)CC1
CHEMBL1818234,CHEMBL237,Kappa opioid receptor,Ki,=,1.8,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,O=S(=O)(c1ccccc1-c1ccc(CN2C[C@@H]3CCC[C@H]2C3)cc1)N1CCCC1
CHEMBL1818235,CHEMBL237,Kappa opioid receptor,Ki,=,3.7,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,COC[C@@H]1CCCN1S(=O)(=O)c1ccccc1-c1ccc(CN2C[C@@H]3CCC[C@H]2C3)cc1
CHEMBL1818236,CHEMBL237,Kappa opioid receptor,Ki,=,1.1,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,O=S(=O)(c1ccccc1-c1ccc(CN2CCC(CCO)CC2)cc1)N1CCCC[C@H]1CO
CHEMBL1818237,CHEMBL237,Kappa opioid receptor,Ki,=,54.0,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CC(C)CNCc1ccc(-c2ccccc2S(=O)(=O)N2CCCC2)cn1
CHEMBL1818238,CHEMBL237,Kappa opioid receptor,Ki,=,72.0,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,O=S(=O)(c1ccccc1-c1ccc(CN2C[C@@H]3CCC[C@H]2C3)nc1)N1CCCC1
CHEMBL1818324,CHEMBL237,Kappa opioid receptor,Ki,=,10.0,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CC(C)CNCc1ccc(-c2ccccc2S(=O)(=O)N2CCOC[C@H]2C)cc1F
CHEMBL1818325,CHEMBL237,Kappa opioid receptor,Ki,=,8.8,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,O=S(=O)(c1ccccc1-c1ccc(CN2CCC(CCO)CC2)c(F)c1)N1CCCCC1
CHEMBL1818223,CHEMBL237,Kappa opioid receptor,Ki,=,157.0,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CC(C)CNCc1ccc(-c2ccccc2S(=O)(=O)N2CCCC2)nc1
CHEMBL1818224,CHEMBL237,Kappa opioid receptor,Ki,=,84.0,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,O=S(=O)(c1ccccc1-c1ccc(CN2C[C@@H]3CCC[C@H]2C3)cn1)N1CCCC1
CHEMBL1818225,CHEMBL237,Kappa opioid receptor,Ki,=,66.0,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CC(C)CNCc1ccc(-c2ncccc2S(=O)(=O)N2CCCC2)cc1
CHEMBL1818226,CHEMBL237,Kappa opioid receptor,Ki,=,26.0,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,O=S(=O)(c1cccnc1-c1ccc(CN2C[C@@H]3CCC[C@H]2C3)cc1)N1CCCC1
CHEMBL1818227,CHEMBL237,Kappa opioid receptor,Ki,=,584.0,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CC(C)CNCc1ccc(-c2cnccc2S(=O)(=O)N2CCCC2)cc1
CHEMBL1818228,CHEMBL237,Kappa opioid receptor,Ki,=,75.0,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CC(C)(C)CCNCc1ccc(-c2cnccc2S(=O)(=O)N2CCCC2)cc1
CHEMBL1818230,CHEMBL237,Kappa opioid receptor,Ki,=,54.0,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CC(C)CNCc1ccc(-c2cccnc2S(=O)(=O)N2CCCC2)cc1
CHEMBL1818231,CHEMBL237,Kappa opioid receptor,Ki,=,53.0,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,O=S(=O)(c1ncccc1-c1ccc(CN2C[C@@H]3CCC[C@H]2C3)cc1)N1CCCC1
CHEMBL1818232,CHEMBL237,Kappa opioid receptor,Ki,=,8.4,nM,CHEMBL1820178,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr by liquid scintillation counting,CHEMBL1817540,KI,CC(C)(C)CCNCc1ccc(-c2cccnc2S(=O)(=O)N2CCCC2)cc1
CHEMBL1818334,CHEMBL237,Kappa opioid receptor,Ki,=,2.49,nM,CHEMBL1820306,B,Agonist activity at human kappa opioid receptor by GTPgamma S binding assay,CHEMBL1817540,KI,CC(C)C[C@]1(c2cccc(O)c2)CCN(CC2CC2)C1
CHEMBL1818335,CHEMBL237,Kappa opioid receptor,Ki,=,9.0,nM,CHEMBL1820306,B,Agonist activity at human kappa opioid receptor by GTPgamma S binding assay,CHEMBL1817540,KI,O=S(=O)(c1ccccc1-c1ccc(CN[C@H]2c3ccccc3C[C@H]2O)cc1)N1CCCCC1
CHEMBL1818341,CHEMBL237,Kappa opioid receptor,Ki,=,1.2,nM,CHEMBL1820306,B,Agonist activity at human kappa opioid receptor by GTPgamma S binding assay,CHEMBL1817540,KI,CC(C)CNCc1ccc(-c2ccccc2S(=O)(=O)N2CCCC2)cc1
CHEMBL1824777,CHEMBL237,Kappa opioid receptor,Ki,=,662.4,nM,CHEMBL1826475,B,Inhibition of kappa opioid receptor by NIMH PDSP,CHEMBL1821607,KI,Cl.OC12CC3CC(CC(C3)N1Cc1ccccc1)C2
CHEMBL1824778,CHEMBL237,Kappa opioid receptor,Ki,=,1203.0,nM,CHEMBL1826475,B,Inhibition of kappa opioid receptor by NIMH PDSP,CHEMBL1821607,KI,Cl.OC12CC3CC(CC(C3)N1Cc1cccc(F)c1)C2
CHEMBL1824509,CHEMBL237,Kappa opioid receptor,Ki,=,0.15,nM,CHEMBL1828462,B,Displacement of [3H]-norBNI from kappa opioid receptor expressed in CHO cells after 1 hr,CHEMBL1821548,KI,Cl.O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccnc(Cl)c1
CHEMBL1824510,CHEMBL237,Kappa opioid receptor,Ki,=,0.18,nM,CHEMBL1828462,B,Displacement of [3H]-norBNI from kappa opioid receptor expressed in CHO cells after 1 hr,CHEMBL1821548,KI,Cl.O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccnc(Br)c1
CHEMBL1824512,CHEMBL237,Kappa opioid receptor,Ki,=,0.58,nM,CHEMBL1828462,B,Displacement of [3H]-norBNI from kappa opioid receptor expressed in CHO cells after 1 hr,CHEMBL1821548,KI,Cc1cc(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)ccn1.Cl
CHEMBL1824514,CHEMBL237,Kappa opioid receptor,Ki,=,19.93,nM,CHEMBL1828462,B,Displacement of [3H]-norBNI from kappa opioid receptor expressed in CHO cells after 1 hr,CHEMBL1821548,KI,Cl.O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccncc1Cl
CHEMBL1824513,CHEMBL237,Kappa opioid receptor,Ki,=,2.83,nM,CHEMBL1828462,B,Displacement of [3H]-norBNI from kappa opioid receptor expressed in CHO cells after 1 hr,CHEMBL1821548,KI,Cl.O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccncc1Br
CHEMBL1824515,CHEMBL237,Kappa opioid receptor,Ki,=,96.7,nM,CHEMBL1828462,B,Displacement of [3H]-norBNI from kappa opioid receptor expressed in CHO cells after 1 hr,CHEMBL1821548,KI,Cc1cnccc1C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5.Cl
CHEMBL1824516,CHEMBL237,Kappa opioid receptor,Ki,=,9.01,nM,CHEMBL1828462,B,Displacement of [3H]-norBNI from kappa opioid receptor expressed in CHO cells after 1 hr,CHEMBL1821548,KI,Cl.O=C(Cc1ccncc1)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL1824511,CHEMBL237,Kappa opioid receptor,Ki,=,1.65,nM,CHEMBL1828462,B,Displacement of [3H]-norBNI from kappa opioid receptor expressed in CHO cells after 1 hr,CHEMBL1821548,KI,Cl.O=C(CCc1ccncc1)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL1824517,CHEMBL237,Kappa opioid receptor,Ki,=,203.2,nM,CHEMBL1828462,B,Displacement of [3H]-norBNI from kappa opioid receptor expressed in CHO cells after 1 hr,CHEMBL1821548,KI,Cl.O=C(CNC(=O)c1ccncc1)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL1824518,CHEMBL237,Kappa opioid receptor,Ki,=,6.49,nM,CHEMBL1828462,B,Displacement of [3H]-norBNI from kappa opioid receptor expressed in CHO cells after 1 hr,CHEMBL1821548,KI,CN1CCC(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)CC1.Cl
CHEMBL511142,CHEMBL237,Kappa opioid receptor,Ki,=,2.5,nM,CHEMBL1839054,B,Displacement of [3H]U69593 from human KOP receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1833948,KI,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL1834409,CHEMBL237,Kappa opioid receptor,Ki,=,5.63,nM,CHEMBL1839054,B,Displacement of [3H]U69593 from human KOP receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1833948,KI,CCC(C)(C)[C@](C)(O)[C@H]1C[C@@]23CC[C@]1(OC)[C@@H]1Oc4c(O)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5
CHEMBL1834410,CHEMBL237,Kappa opioid receptor,Ki,=,1.59,nM,CHEMBL1839054,B,Displacement of [3H]U69593 from human KOP receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1833948,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)CC(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL1834411,CHEMBL237,Kappa opioid receptor,Ki,=,4.15,nM,CHEMBL1839054,B,Displacement of [3H]U69593 from human KOP receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1833948,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)CC(C)(C)c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL1834412,CHEMBL237,Kappa opioid receptor,Ki,=,8.92,nM,CHEMBL1839054,B,Displacement of [3H]U69593 from human KOP receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1833948,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@@](C)(O)c1ccc(C(C)(C)C)cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL1834413,CHEMBL237,Kappa opioid receptor,Ki,=,9.87,nM,CHEMBL1839054,B,Displacement of [3H]U69593 from human KOP receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1833948,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)CC1CC4CCC1C4)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL1834414,CHEMBL237,Kappa opioid receptor,Ki,=,9.93,nM,CHEMBL1839054,B,Displacement of [3H]U69593 from human KOP receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1833948,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@@](C)(O)C(C)(C)C)[C@H]1Cc4c(Br)cc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL1834415,CHEMBL237,Kappa opioid receptor,Ki,=,45.6,nM,CHEMBL1839054,B,Displacement of [3H]U69593 from human KOP receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1833948,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@@](C)(O)C(C)(C)C)[C@H]1Cc4c(Cl)cc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL1834416,CHEMBL237,Kappa opioid receptor,Ki,=,35.5,nM,CHEMBL1839054,B,Displacement of [3H]U69593 from human KOP receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1833948,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@@](C)(O)C(C)(C)C)[C@H]1Cc4cc(Br)c(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL396460,CHEMBL237,Kappa opioid receptor,Ki,=,147.0,nM,CHEMBL1839054,B,Displacement of [3H]U69593 from human KOP receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1833948,KI,CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)O
CHEMBL38874,CHEMBL237,Kappa opioid receptor,Ki,=,306.0,nM,CHEMBL1839054,B,Displacement of [3H]U69593 from human KOP receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1833948,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL440765,CHEMBL237,Kappa opioid receptor,Ki,=,1.6,nM,CHEMBL1839054,B,Displacement of [3H]U69593 from human KOP receptor expressed in CHO cells after 60 mins by scintillation counting,CHEMBL1833948,KI,CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL942,CHEMBL237,Kappa opioid receptor,Ki,=,975.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,CC(=O)Oc1ccc(C(c2ccc(OC(C)=O)cc2)c2ccccn2)cc1
CHEMBL508112,CHEMBL237,Kappa opioid receptor,Ki,=,497.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,c1ccc2sc(SSc3nc4ccccc4s3)nc2c1
CHEMBL296419,CHEMBL237,Kappa opioid receptor,Ki,=,2646.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1
CHEMBL633,CHEMBL237,Kappa opioid receptor,Ki,=,6672.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1
CHEMBL1289,CHEMBL237,Kappa opioid receptor,Ki,=,459.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,Clc1cc(Cl)c(OCC#CI)cc1Cl
CHEMBL64894,CHEMBL237,Kappa opioid receptor,Ki,=,616.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1.[Cl-]
CHEMBL808,CHEMBL237,Kappa opioid receptor,Ki,=,3446.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1
CHEMBL726,CHEMBL237,Kappa opioid receptor,Ki,=,9891.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
CHEMBL691,CHEMBL237,Kappa opioid receptor,Ki,=,10358.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C
CHEMBL104,CHEMBL237,Kappa opioid receptor,Ki,=,2521.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1
CHEMBL964,CHEMBL237,Kappa opioid receptor,Ki,=,2441.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,CCN(CC)C(=S)SSC(=S)N(CC)CC
CHEMBL411,CHEMBL237,Kappa opioid receptor,Ki,=,1825.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1
CHEMBL71,CHEMBL237,Kappa opioid receptor,Ki,=,4433.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21
CHEMBL219916,CHEMBL237,Kappa opioid receptor,Ki,=,2798.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1
CHEMBL1479,CHEMBL237,Kappa opioid receptor,Ki,=,6207.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C
CHEMBL584,CHEMBL237,Kappa opioid receptor,Ki,=,14398.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
CHEMBL19019,CHEMBL237,Kappa opioid receptor,Ki,=,7.175,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL1618305,CHEMBL237,Kappa opioid receptor,Ki,=,34.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2/C(=N/N=C2\CC[C@@]4(O)[C@H]6Cc7ccc(O)c8c7[C@@]4(CCN6CC=C)[C@H]2O8)CC[C@@]3(O)[C@H]1C5
CHEMBL91,CHEMBL237,Kappa opioid receptor,Ki,=,2637.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
CHEMBL80,CHEMBL237,Kappa opioid receptor,Ki,=,30.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL1276308,CHEMBL237,Kappa opioid receptor,Ki,=,8038.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C
CHEMBL841,CHEMBL237,Kappa opioid receptor,Ki,=,1250.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1
CHEMBL895,CHEMBL237,Kappa opioid receptor,Ki,=,44.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
CHEMBL479,CHEMBL237,Kappa opioid receptor,Ki,=,996.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2
CHEMBL83,CHEMBL237,Kappa opioid receptor,Ki,=,6252.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1
CHEMBL163,CHEMBL237,Kappa opioid receptor,Ki,=,5462.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
CHEMBL114,CHEMBL237,Kappa opioid receptor,Ki,=,2780.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1
CHEMBL81,CHEMBL237,Kappa opioid receptor,Ki,=,641.0,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12
CHEMBL118865,CHEMBL237,Kappa opioid receptor,Ki,=,3.32,nM,CHEMBL1909181,B,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",CHEMBL1909046,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)C1CCC2(CCCO2)CC1N1CCCC1
CHEMBL415247,CHEMBL237,Kappa opioid receptor,Ki,=,0.0591,nM,CHEMBL1924792,B,Displacement of [3H]diprenorphine from human opioid kappa receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,CC(C)[C@@H](CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1
CHEMBL573214,CHEMBL237,Kappa opioid receptor,Ki,=,0.153,nM,CHEMBL1924792,B,Displacement of [3H]diprenorphine from human opioid kappa receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL575508,CHEMBL237,Kappa opioid receptor,Ki,=,0.153,nM,CHEMBL1924792,B,Displacement of [3H]diprenorphine from human opioid kappa receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,CC(C)[C@@H](CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1C
CHEMBL277863,CHEMBL237,Kappa opioid receptor,Ki,=,0.502,nM,CHEMBL1924792,B,Displacement of [3H]diprenorphine from human opioid kappa receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,COC(=O)N1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)[C@H](CN2CCCC2)C1
CHEMBL238316,CHEMBL237,Kappa opioid receptor,Ki,=,1.78,nM,CHEMBL1924792,B,Displacement of [3H]diprenorphine from human opioid kappa receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,NC(=O)c1ccc(Oc2ccc(CNCc3ccccc3)cc2)nc1
CHEMBL1921839,CHEMBL237,Kappa opioid receptor,Ki,=,9.21,nM,CHEMBL1924792,B,Displacement of [3H]diprenorphine from human opioid kappa receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,NC(=O)c1ccc(Oc2ccc(CN3CCCC3c3ccccc3)cc2)nc1
CHEMBL1921840,CHEMBL237,Kappa opioid receptor,Ki,=,1.49,nM,CHEMBL1924792,B,Displacement of [3H]diprenorphine from human opioid kappa receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,NC(=O)c1ccc(Oc2ccc(CN3CCCC3c3cccnc3)cc2)nc1
CHEMBL1921841,CHEMBL237,Kappa opioid receptor,Ki,=,0.622,nM,CHEMBL1924792,B,Displacement of [3H]diprenorphine from human opioid kappa receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,NC(=O)c1ccc(Oc2ccc(CN3CCCC3c3cccnc3)cc2)c(Cl)c1
CHEMBL1921842,CHEMBL237,Kappa opioid receptor,Ki,=,0.722,nM,CHEMBL1924792,B,Displacement of [3H]diprenorphine from human opioid kappa receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,NC(=O)c1ccc(Oc2ccc(CN3CCC[C@H]3c3cccnc3)cc2)c(Cl)c1
CHEMBL1921843,CHEMBL237,Kappa opioid receptor,Ki,=,44.9,nM,CHEMBL1924792,B,Displacement of [3H]diprenorphine from human opioid kappa receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,NC(=O)c1ccc(Oc2ccc(CN3CCC[C@@H]3c3cccnc3)cc2)c(Cl)c1
CHEMBL1921844,CHEMBL237,Kappa opioid receptor,Ki,=,0.617,nM,CHEMBL1924792,B,Displacement of [3H]diprenorphine from human opioid kappa receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,NC(=O)c1ccc(Oc2ccc(CN3CCCC3c3cccc(F)c3)cc2)c(F)c1
CHEMBL1921845,CHEMBL237,Kappa opioid receptor,Ki,=,0.565,nM,CHEMBL1924792,B,Displacement of [3H]diprenorphine from human opioid kappa receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,NC(=O)c1ccc(Oc2ccc(CN3CCC[C@H]3c3cccc(F)c3)cc2)c(F)c1
CHEMBL1921846,CHEMBL237,Kappa opioid receptor,Ki,=,53.7,nM,CHEMBL1924792,B,Displacement of [3H]diprenorphine from human opioid kappa receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,NC(=O)c1ccc(Oc2ccc(CN3CCC[C@@H]3c3cccc(F)c3)cc2)c(F)c1
CHEMBL1921847,CHEMBL237,Kappa opioid receptor,Ki,=,0.949,nM,CHEMBL1924792,B,Displacement of [3H]diprenorphine from human opioid kappa receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,Cc1cc(C)cc([C@@H]2CCCN2Cc2ccc(Oc3ccc(C(N)=O)cc3F)cc2)c1
CHEMBL1921848,CHEMBL237,Kappa opioid receptor,Ki,=,14.0,nM,CHEMBL1924792,B,Displacement of [3H]diprenorphine from human opioid kappa receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,Cc1cc(C)cc([C@H]2CCCN2Cc2ccc(Oc3ccc(C(N)=O)cc3F)cc2)c1
CHEMBL1921849,CHEMBL237,Kappa opioid receptor,Ki,=,1.41,nM,CHEMBL1924792,B,Displacement of [3H]diprenorphine from human opioid kappa receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,CC1(C)CN(Cc2ccc(Oc3ccc(C(N)=O)cn3)cc2)C1c1ccccc1
CHEMBL1921850,CHEMBL237,Kappa opioid receptor,Ki,=,1.05,nM,CHEMBL1924792,B,Displacement of [3H]diprenorphine from human opioid kappa receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,CC1(C)CN(Cc2ccc(Oc3ccc(C(N)=O)cn3)cc2)[C@@H]1c1ccccc1
CHEMBL1921851,CHEMBL237,Kappa opioid receptor,Ki,=,26.7,nM,CHEMBL1924792,B,Displacement of [3H]diprenorphine from human opioid kappa receptor expressed in CHO cells after 120 mins by scintillation counting,CHEMBL1921714,KI,CC1(C)CN(Cc2ccc(Oc3ccc(C(N)=O)cn3)cc2)[C@H]1c1ccccc1
CHEMBL1939698,CHEMBL237,Kappa opioid receptor,Ki,=,918.0,nM,CHEMBL1941654,B,Binding affinity to kappa opioid receptor,CHEMBL1938297,KI,FCC1OC2(CCN(Cc3ccccc3)CC2)c2ccccc21
CHEMBL1645202,CHEMBL237,Kappa opioid receptor,Ki,=,372.0,nM,CHEMBL1941654,B,Binding affinity to kappa opioid receptor,CHEMBL1938297,KI,FCCC1OC2(CCN(Cc3ccccc3)CC2)c2ccccc21
CHEMBL575994,CHEMBL237,Kappa opioid receptor,Ki,=,368.0,nM,CHEMBL1941654,B,Binding affinity to kappa opioid receptor,CHEMBL1938297,KI,FCCCC1OC2(CCN(Cc3ccccc3)CC2)c2ccccc21
CHEMBL1939699,CHEMBL237,Kappa opioid receptor,Ki,=,419.0,nM,CHEMBL1941654,B,Binding affinity to kappa opioid receptor,CHEMBL1938297,KI,FCCCCC1OC2(CCN(Cc3ccccc3)CC2)c2ccccc21
CHEMBL1941030,CHEMBL237,Kappa opioid receptor,Ki,=,4.4,nM,CHEMBL1942560,B,Displacement of [3H]diprenorphine from human KOPR expressed in CHO cells,CHEMBL1938260,KI,COCO[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL1941031,CHEMBL237,Kappa opioid receptor,Ki,=,2.5,nM,CHEMBL1942560,B,Displacement of [3H]diprenorphine from human KOPR expressed in CHO cells,CHEMBL1938260,KI,CCOCO[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL1941032,CHEMBL237,Kappa opioid receptor,Ki,=,63.0,nM,CHEMBL1942560,B,Displacement of [3H]diprenorphine from human KOPR expressed in CHO cells,CHEMBL1938260,KI,COC(=O)[C@@H]1C[C@H](O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](c3ccoc3)C[C@]21C
CHEMBL1941033,CHEMBL237,Kappa opioid receptor,Ki,=,18.0,nM,CHEMBL1942560,B,Displacement of [3H]diprenorphine from human KOPR expressed in CHO cells,CHEMBL1938260,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](c3ccoc3Br)C[C@]21C
CHEMBL1941034,CHEMBL237,Kappa opioid receptor,Ki,=,40.0,nM,CHEMBL1942560,B,Displacement of [3H]diprenorphine from human KOPR expressed in CHO cells,CHEMBL1938260,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](c3cc(Br)oc3Br)C[C@]21C
CHEMBL445332,CHEMBL237,Kappa opioid receptor,Ki,=,3.0,nM,CHEMBL1942560,B,Displacement of [3H]diprenorphine from human KOPR expressed in CHO cells,CHEMBL1938260,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL441765,CHEMBL237,Kappa opioid receptor,Ki,=,4.5,nM,CHEMBL1942560,B,Displacement of [3H]diprenorphine from human KOPR expressed in CHO cells,CHEMBL1938260,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL1951699,CHEMBL237,Kappa opioid receptor,Ki,=,3800.0,nM,CHEMBL1955137,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells membrane after 2 hrs by liquid scintillation counting,CHEMBL1949670,KI,CN1C[C@H](O)[C@]2(c3cccc(O)c3)CCC[C@H]1C2
CHEMBL1951701,CHEMBL237,Kappa opioid receptor,Ki,=,751.0,nM,CHEMBL1955137,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells membrane after 2 hrs by liquid scintillation counting,CHEMBL1949670,KI,Oc1cccc([C@@]23CCC[C@@H](C2)N(CCc2ccccc2)C[C@@H]3O)c1
CHEMBL1951700,CHEMBL237,Kappa opioid receptor,Ki,=,8300.0,nM,CHEMBL1955137,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells membrane after 2 hrs by liquid scintillation counting,CHEMBL1949670,KI,CN1C[C@@H](O)[C@]2(c3cccc(O)c3)CCC[C@H]1C2
CHEMBL1951702,CHEMBL237,Kappa opioid receptor,Ki,=,604.0,nM,CHEMBL1955137,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells membrane after 2 hrs by liquid scintillation counting,CHEMBL1949670,KI,Oc1cccc([C@@]23CCC[C@@H](C2)N(CCc2ccccc2)C[C@H]3O)c1
CHEMBL1951704,CHEMBL237,Kappa opioid receptor,Ki,=,483.0,nM,CHEMBL1955137,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells membrane after 2 hrs by liquid scintillation counting,CHEMBL1949670,KI,CN1C2CCC[C@@](c3cccc(O)c3)(C2)[C@@H]1CO
CHEMBL1951705,CHEMBL237,Kappa opioid receptor,Ki,=,140.0,nM,CHEMBL1955137,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells membrane after 2 hrs by liquid scintillation counting,CHEMBL1949670,KI,CN1CC2(OCCO2)[C@]2(c3cccc(O)c3)CCC[C@H]1C2
CHEMBL70,CHEMBL237,Kappa opioid receptor,Ki,=,299.0,nM,CHEMBL1955137,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells membrane after 2 hrs by liquid scintillation counting,CHEMBL1949670,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL440765,CHEMBL237,Kappa opioid receptor,Ki,=,3.5,nM,CHEMBL1955137,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells membrane after 2 hrs by liquid scintillation counting,CHEMBL1949670,KI,CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL267495,CHEMBL237,Kappa opioid receptor,Ki,=,0.23,nM,CHEMBL2020487,B,Binding affinity to kappa opioid receptor,CHEMBL2016571,KI,CN(C(=O)/C=C/c1ccoc1)[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL2016680,CHEMBL237,Kappa opioid receptor,Ki,=,0.11,nM,CHEMBL2020487,B,Binding affinity to kappa opioid receptor,CHEMBL2016571,KI,O=C(Nc1ccccc1)[C@H]1O[C@@]23CC[C@]1(O)[C@@H]1Oc4c(O)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5
CHEMBL445332,CHEMBL237,Kappa opioid receptor,Ki,=,7.4,nM,CHEMBL2026571,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2021813,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL458235,CHEMBL237,Kappa opioid receptor,Ki,=,17.0,nM,CHEMBL2026571,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2021813,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@@H](c3ccoc3)C[C@]21C
CHEMBL2022017,CHEMBL237,Kappa opioid receptor,Ki,=,1120.0,nM,CHEMBL2026571,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2021813,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](/C=C/c3ccoc3)C[C@]21C
CHEMBL2022018,CHEMBL237,Kappa opioid receptor,Ki,=,30.0,nM,CHEMBL2026571,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2021813,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](/C=C\c3ccoc3)C[C@]21C
CHEMBL2022019,CHEMBL237,Kappa opioid receptor,Ki,=,70.0,nM,CHEMBL2026571,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2021813,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C(=O)c3ccccc3)C[C@]21C
CHEMBL2022020,CHEMBL237,Kappa opioid receptor,Ki,=,1070.0,nM,CHEMBL2026571,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2021813,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C(=O)c3ccccc3OC)C[C@]21C
CHEMBL2022021,CHEMBL237,Kappa opioid receptor,Ki,=,290.0,nM,CHEMBL2026571,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2021813,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C(=O)c3cccc(OC)c3)C[C@]21C
CHEMBL2022293,CHEMBL237,Kappa opioid receptor,Ki,=,500.0,nM,CHEMBL2026571,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2021813,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C(=O)c3ccccc3O)C[C@]21C
CHEMBL2022294,CHEMBL237,Kappa opioid receptor,Ki,=,110.0,nM,CHEMBL2026571,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2021813,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C(=O)c3cccc(O)c3)C[C@]21C
CHEMBL2022295,CHEMBL237,Kappa opioid receptor,Ki,=,8470.0,nM,CHEMBL2026571,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2021813,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C(=O)c3ccc(O)cc3)C[C@]21C
CHEMBL2022296,CHEMBL237,Kappa opioid receptor,Ki,=,40.0,nM,CHEMBL2026571,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2021813,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C(=O)c3cccc(C(N)=O)c3)C[C@]21C
CHEMBL2022297,CHEMBL237,Kappa opioid receptor,Ki,=,220.0,nM,CHEMBL2026571,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2021813,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C(=O)c3cccc(C#N)c3)C[C@]21C
CHEMBL2022299,CHEMBL237,Kappa opioid receptor,Ki,=,2260.0,nM,CHEMBL2026571,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2021813,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C(=O)c3cccc(C(F)(F)F)c3)C[C@]21C
CHEMBL2022300,CHEMBL237,Kappa opioid receptor,Ki,=,80.0,nM,CHEMBL2026571,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2021813,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C(=O)c3ccco3)C[C@]21C
CHEMBL2022301,CHEMBL237,Kappa opioid receptor,Ki,=,150.0,nM,CHEMBL2026571,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2021813,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C(=O)c3ccoc3)C[C@]21C
CHEMBL458870,CHEMBL237,Kappa opioid receptor,Ki,=,36.0,nM,CHEMBL2026571,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2021813,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C(=O)c3cccs3)C[C@]21C
CHEMBL2022302,CHEMBL237,Kappa opioid receptor,Ki,=,31.0,nM,CHEMBL2026571,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2021813,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C(=O)c3ccsc3)C[C@]21C
CHEMBL2022304,CHEMBL237,Kappa opioid receptor,Ki,=,9210.0,nM,CHEMBL2026571,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2021813,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C(=O)c3cc4ccccc4s3)C[C@]21C
CHEMBL2022307,CHEMBL237,Kappa opioid receptor,Ki,=,30.0,nM,CHEMBL2026571,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2021813,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccco3)C[C@]21C
CHEMBL2022306,CHEMBL237,Kappa opioid receptor,Ki,=,320.0,nM,CHEMBL2026571,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting,CHEMBL2021813,KI,C/C=C\C(=O)[C@@H]1C[C@]2(C)[C@H]3C(=O)[C@@H](OC(C)=O)C[C@@H](C(=O)OC)[C@]3(C)CC[C@H]2C(=O)O1
CHEMBL2048787,CHEMBL237,Kappa opioid receptor,Ki,=,560.0,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,CN1CC[C@]23c4c5ccc(NCc6ccc(O)cc6)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL2048786,CHEMBL237,Kappa opioid receptor,Ki,=,910.0,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,CN1CC[C@]23c4c5ccc(NCc6cccc(O)c6)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL2048785,CHEMBL237,Kappa opioid receptor,Ki,=,370.0,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,CN1CC[C@]23c4c5ccc(NCc6ccccc6O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL2048783,CHEMBL237,Kappa opioid receptor,Ki,=,500.0,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,COc1cccc(CNc2ccc3c4c2O[C@H]2[C@@H](O)C=C[C@H]5[C@@H](C3)N(C)CC[C@@]452)c1
CHEMBL2048782,CHEMBL237,Kappa opioid receptor,Ki,=,220.0,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,COc1ccccc1CNc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@@]341
CHEMBL1457,CHEMBL237,Kappa opioid receptor,Ki,=,260.0,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,COc1ccc2c3c1O[C@H]1C(=O)CC[C@H]4[C@@H](C2)N(C)CC[C@]314
CHEMBL70,CHEMBL237,Kappa opioid receptor,Ki,=,24.0,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL2048781,CHEMBL237,Kappa opioid receptor,Ki,=,0.99,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,Oc1cccc(CNc2ccc3c(c2)C[C@@H]2[C@@H]4CCCC[C@]34CCN2CC2CC2)c1
CHEMBL2048780,CHEMBL237,Kappa opioid receptor,Ki,=,4.1,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,CN(Cc1ccc(O)cc1)c1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL2048779,CHEMBL237,Kappa opioid receptor,Ki,=,23.0,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,CN(Cc1cccc(O)c1)c1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL2048778,CHEMBL237,Kappa opioid receptor,Ki,=,27.0,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,CN(Cc1ccc(Cl)cc1)c1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL2048777,CHEMBL237,Kappa opioid receptor,Ki,=,8.5,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,COc1ccc(CN(C)c2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)cc1
CHEMBL2048776,CHEMBL237,Kappa opioid receptor,Ki,=,25.0,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,COc1cccc(CN(C)c2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)c1
CHEMBL2048775,CHEMBL237,Kappa opioid receptor,Ki,=,19.0,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,COc1ccccc1CN(C)c1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL2048774,CHEMBL237,Kappa opioid receptor,Ki,=,10.0,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(NCc2cccc(O)c2)cc13
CHEMBL2048773,CHEMBL237,Kappa opioid receptor,Ki,=,0.27,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,Oc1ccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CC2)CC4)cc1
CHEMBL2048772,CHEMBL237,Kappa opioid receptor,Ki,=,0.36,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,Oc1cccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CC2)CC4)c1
CHEMBL2048771,CHEMBL237,Kappa opioid receptor,Ki,=,0.26,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,Oc1ccccc1CNc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL2048770,CHEMBL237,Kappa opioid receptor,Ki,=,2.3,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,Oc1ccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)cc1
CHEMBL2048769,CHEMBL237,Kappa opioid receptor,Ki,=,1.9,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,Oc1cccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)c1
CHEMBL2048768,CHEMBL237,Kappa opioid receptor,Ki,=,1.7,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,Oc1ccccc1CNc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL2048767,CHEMBL237,Kappa opioid receptor,Ki,=,1.1,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,O=[N+]([O-])c1cccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)c1
CHEMBL2048766,CHEMBL237,Kappa opioid receptor,Ki,=,0.53,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,c1cc2c(cc1CNc1ccc3c(c1)[C@@]14CCCC[C@H]1[C@@H](C3)N(CC1CC1)CC4)OCO2
CHEMBL568877,CHEMBL237,Kappa opioid receptor,Ki,=,0.51,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,COc1ccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CC2)CC4)cc1
CHEMBL2048765,CHEMBL237,Kappa opioid receptor,Ki,=,1.5,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,COc1cccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CC2)CC4)c1
CHEMBL2046467,CHEMBL237,Kappa opioid receptor,Ki,=,1.3,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,COc1ccccc1CNc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL2048764,CHEMBL237,Kappa opioid receptor,Ki,=,1.1,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,c1cc2c(cc1CNc1ccc3c(c1)[C@@]14CCCC[C@H]1[C@@H](C3)N(CC1CCC1)CC4)OCO2
CHEMBL2048763,CHEMBL237,Kappa opioid receptor,Ki,=,4.5,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,Clc1ccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)cc1
CHEMBL2048762,CHEMBL237,Kappa opioid receptor,Ki,=,4.5,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,COc1ccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)cc1
CHEMBL2048761,CHEMBL237,Kappa opioid receptor,Ki,=,3.5,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,COc1cccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)c1
CHEMBL2048760,CHEMBL237,Kappa opioid receptor,Ki,=,2.2,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,COc1ccccc1CNc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL571560,CHEMBL237,Kappa opioid receptor,Ki,=,2.8,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,c1ccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CCC2)CC4)cc1
CHEMBL571998,CHEMBL237,Kappa opioid receptor,Ki,=,0.34,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,c1ccc(CNc2ccc3c(c2)[C@@]24CCCC[C@H]2[C@@H](C3)N(CC2CC2)CC4)cc1
CHEMBL299220,CHEMBL237,Kappa opioid receptor,Ki,=,0.18,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,Nc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL49143,CHEMBL237,Kappa opioid receptor,Ki,=,1.8,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,Nc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL48420,CHEMBL237,Kappa opioid receptor,Ki,=,110.0,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(N)cc13
CHEMBL49269,CHEMBL237,Kappa opioid receptor,Ki,=,0.034,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL301160,CHEMBL237,Kappa opioid receptor,Ki,=,0.079,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL592,CHEMBL237,Kappa opioid receptor,Ki,=,2.3,nM,CHEMBL2050633,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2046406,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13
CHEMBL316446,CHEMBL237,Kappa opioid receptor,Ki,=,2048.0,nM,CHEMBL2161189,B,Displacement of [3H]diprenorphine from kappa-opioid receptor expressed in CHOK1 cells after overnight incubation by scintillation proximity assay,CHEMBL2157939,KI,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL2158990,CHEMBL237,Kappa opioid receptor,Ki,=,1566.0,nM,CHEMBL2161189,B,Displacement of [3H]diprenorphine from kappa-opioid receptor expressed in CHOK1 cells after overnight incubation by scintillation proximity assay,CHEMBL2157939,KI,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CCC(=O)N[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O
CHEMBL70,CHEMBL237,Kappa opioid receptor,Ki,=,13.3,nM,CHEMBL2161189,B,Displacement of [3H]diprenorphine from kappa-opioid receptor expressed in CHOK1 cells after overnight incubation by scintillation proximity assay,CHEMBL2157939,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL2178724,CHEMBL237,Kappa opioid receptor,Ki,=,33000.0,nM,CHEMBL2183871,B,"Displacement of [3H]U69,593 from human KOR expressed in HEK293 cells after 90 mins by liquid scintillation counting",CHEMBL2177066,KI,CC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(N)=O
CHEMBL441765,CHEMBL237,Kappa opioid receptor,Ki,=,2.9,nM,CHEMBL2183871,B,"Displacement of [3H]U69,593 from human KOR expressed in HEK293 cells after 90 mins by liquid scintillation counting",CHEMBL2177066,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL611438,CHEMBL237,Kappa opioid receptor,Ki,=,468.0,nM,CHEMBL2187196,B,Binding affinity to kappa opioid receptor by radioligand binding assay,CHEMBL2177065,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2ncc(-c4ccc(Cl)cc4)cc2C[C@@]3(O)[C@H]1C5
CHEMBL610261,CHEMBL237,Kappa opioid receptor,Ki,=,20.0,nM,CHEMBL2187196,B,Binding affinity to kappa opioid receptor by radioligand binding assay,CHEMBL2177065,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccc(Cl)cc5)cc4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL2179663,CHEMBL237,Kappa opioid receptor,Ki,=,5.97,nM,CHEMBL2187201,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells by scintillation counting analysis",CHEMBL2177065,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccc(Cl)cc5)cc4C=C4[C@@H](C2)N(CC2CC2)CC[C@]431
CHEMBL2179662,CHEMBL237,Kappa opioid receptor,Ki,=,4.41,nM,CHEMBL2187201,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells by scintillation counting analysis",CHEMBL2177065,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2ncc(-c4ccc(Cl)cc4)cc2C[C@@]3(OC(=O)CCc2ccccc2)[C@H]1C5
CHEMBL2179661,CHEMBL237,Kappa opioid receptor,Ki,=,17.0,nM,CHEMBL2187201,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells by scintillation counting analysis",CHEMBL2177065,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2ncc(-c4ccc(Cl)cc4)cc2C[C@@]3(OC(=O)Cc2ccccc2)[C@H]1C5
CHEMBL2179660,CHEMBL237,Kappa opioid receptor,Ki,=,112.0,nM,CHEMBL2187201,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells by scintillation counting analysis",CHEMBL2177065,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2ncc(-c4ccc(Cl)cc4)cc2C[C@@]3(OC(=O)c2ccccc2)[C@H]1C5
CHEMBL2179659,CHEMBL237,Kappa opioid receptor,Ki,=,12.0,nM,CHEMBL2187201,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells by scintillation counting analysis",CHEMBL2177065,KI,O=C(CCc1ccccc1)O[C@@]12Cc3cc(-c4ccc(Cl)cc4)cnc3[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL2179658,CHEMBL237,Kappa opioid receptor,Ki,=,3.1,nM,CHEMBL2187201,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells by scintillation counting analysis",CHEMBL2177065,KI,O=C(Cc1ccccc1)O[C@@]12Cc3cc(-c4ccc(Cl)cc4)cnc3[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL2179657,CHEMBL237,Kappa opioid receptor,Ki,=,117.0,nM,CHEMBL2187201,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells by scintillation counting analysis",CHEMBL2177065,KI,O=C(O[C@@]12Cc3cc(-c4ccc(Cl)cc4)cnc3[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccccc1
CHEMBL2179656,CHEMBL237,Kappa opioid receptor,Ki,=,1.53,nM,CHEMBL2187201,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells by scintillation counting analysis",CHEMBL2177065,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2ncc(-c4ccc(Cl)cc4)cc2C[C@@]3(OCCCc2ccccc2)[C@H]1C5
CHEMBL2179655,CHEMBL237,Kappa opioid receptor,Ki,=,1.55,nM,CHEMBL2187201,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells by scintillation counting analysis",CHEMBL2177065,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2ncc(-c4ccc(Cl)cc4)cc2C[C@@]3(OC/C=C/c2ccccc2)[C@H]1C5
CHEMBL2179654,CHEMBL237,Kappa opioid receptor,Ki,=,49.0,nM,CHEMBL2187201,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells by scintillation counting analysis",CHEMBL2177065,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2ncc(-c4ccc(Cl)cc4)cc2C[C@@]3(OCc2ccccc2)[C@H]1C5
CHEMBL2179653,CHEMBL237,Kappa opioid receptor,Ki,=,27.99,nM,CHEMBL2187201,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells by scintillation counting analysis",CHEMBL2177065,KI,CO[C@@]12Cc3cc(-c4ccc(Cl)cc4)cnc3[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL2179652,CHEMBL237,Kappa opioid receptor,Ki,=,1.82,nM,CHEMBL2187201,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells by scintillation counting analysis",CHEMBL2177065,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccc(Cl)cc5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL2179651,CHEMBL237,Kappa opioid receptor,Ki,=,3.31,nM,CHEMBL2187201,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells by scintillation counting analysis",CHEMBL2177065,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccc(Cl)cc5)cc4C[C@@]4(OC/C=C/c5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL2179650,CHEMBL237,Kappa opioid receptor,Ki,=,5.33,nM,CHEMBL2187201,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells by scintillation counting analysis",CHEMBL2177065,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccc(Cl)cc5)cc4C[C@@]4(OCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL2179649,CHEMBL237,Kappa opioid receptor,Ki,=,5.37,nM,CHEMBL2187201,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells by scintillation counting analysis",CHEMBL2177065,KI,CO[C@@]12Cc3cc(-c4ccc(Cl)cc4)cnc3[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL2178341,CHEMBL237,Kappa opioid receptor,Ki,=,1.21,nM,CHEMBL2184588,B,Displacement of [3H]DPN from kappa opioid receptor expressed in CHO cells after 1 hr,CHEMBL2176919,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccncn1
CHEMBL2178340,CHEMBL237,Kappa opioid receptor,Ki,=,1.57,nM,CHEMBL2184588,B,Displacement of [3H]DPN from kappa opioid receptor expressed in CHO cells after 1 hr,CHEMBL2176919,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccnnc1
CHEMBL2178339,CHEMBL237,Kappa opioid receptor,Ki,=,4.28,nM,CHEMBL2184588,B,Displacement of [3H]DPN from kappa opioid receptor expressed in CHO cells after 1 hr,CHEMBL2176919,KI,COc1cnccc1C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL2178338,CHEMBL237,Kappa opioid receptor,Ki,=,0.46,nM,CHEMBL2184588,B,Displacement of [3H]DPN from kappa opioid receptor expressed in CHO cells after 1 hr,CHEMBL2176919,KI,COc1cc(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)ccn1
CHEMBL2177697,CHEMBL237,Kappa opioid receptor,Ki,=,0.13,nM,CHEMBL2184588,B,Displacement of [3H]DPN from kappa opioid receptor expressed in CHO cells after 1 hr,CHEMBL2176919,KI,N#Cc1cc(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)ccn1
CHEMBL1852475,CHEMBL237,Kappa opioid receptor,Ki,=,6.49,nM,CHEMBL2184594,B,Displacement of [3H]norBNI from kappa opioid receptor expressed in CHO cells after 1 hr,CHEMBL2176919,KI,CN1CCC(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)CC1
CHEMBL1852458,CHEMBL237,Kappa opioid receptor,Ki,=,203.2,nM,CHEMBL2184594,B,Displacement of [3H]norBNI from kappa opioid receptor expressed in CHO cells after 1 hr,CHEMBL2176919,KI,O=C(CNC(=O)c1ccncc1)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL1852555,CHEMBL237,Kappa opioid receptor,Ki,=,1.65,nM,CHEMBL2184594,B,Displacement of [3H]norBNI from kappa opioid receptor expressed in CHO cells after 1 hr,CHEMBL2176919,KI,O=C(CCc1ccncc1)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL1852814,CHEMBL237,Kappa opioid receptor,Ki,=,9.01,nM,CHEMBL2184594,B,Displacement of [3H]norBNI from kappa opioid receptor expressed in CHO cells after 1 hr,CHEMBL2176919,KI,O=C(Cc1ccncc1)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL1852393,CHEMBL237,Kappa opioid receptor,Ki,=,96.7,nM,CHEMBL2184594,B,Displacement of [3H]norBNI from kappa opioid receptor expressed in CHO cells after 1 hr,CHEMBL2176919,KI,Cc1cnccc1C(=O)N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL1852602,CHEMBL237,Kappa opioid receptor,Ki,=,2.83,nM,CHEMBL2184594,B,Displacement of [3H]norBNI from kappa opioid receptor expressed in CHO cells after 1 hr,CHEMBL2176919,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccncc1Br
CHEMBL1852672,CHEMBL237,Kappa opioid receptor,Ki,=,19.9,nM,CHEMBL2184594,B,Displacement of [3H]norBNI from kappa opioid receptor expressed in CHO cells after 1 hr,CHEMBL2176919,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccncc1Cl
CHEMBL1852558,CHEMBL237,Kappa opioid receptor,Ki,=,0.58,nM,CHEMBL2184594,B,Displacement of [3H]norBNI from kappa opioid receptor expressed in CHO cells after 1 hr,CHEMBL2176919,KI,Cc1cc(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)ccn1
CHEMBL1852385,CHEMBL237,Kappa opioid receptor,Ki,=,0.18,nM,CHEMBL2184594,B,Displacement of [3H]norBNI from kappa opioid receptor expressed in CHO cells after 1 hr,CHEMBL2176919,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccnc(Br)c1
CHEMBL1852788,CHEMBL237,Kappa opioid receptor,Ki,=,0.15,nM,CHEMBL2184594,B,Displacement of [3H]norBNI from kappa opioid receptor expressed in CHO cells after 1 hr,CHEMBL2176919,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccnc(Cl)c1
CHEMBL440765,CHEMBL237,Kappa opioid receptor,Ki,=,0.3,nM,CHEMBL2182842,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes incubated for 60 mins by liquid scintillation counting",CHEMBL2177058,KI,CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL441765,CHEMBL237,Kappa opioid receptor,Ki,=,0.2,nM,CHEMBL2182842,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes incubated for 60 mins by liquid scintillation counting",CHEMBL2177058,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL2180641,CHEMBL237,Kappa opioid receptor,Ki,=,141.0,nM,CHEMBL2182842,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes incubated for 60 mins by liquid scintillation counting",CHEMBL2177058,KI,CCCCCCN(CCc1ccccc1)CCc1cccc(O)c1
CHEMBL2180640,CHEMBL237,Kappa opioid receptor,Ki,=,10.9,nM,CHEMBL2182842,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes incubated for 60 mins by liquid scintillation counting",CHEMBL2177058,KI,CCCCN(CCc1ccccc1)CCc1cccc(O)c1
CHEMBL2180639,CHEMBL237,Kappa opioid receptor,Ki,=,0.49,nM,CHEMBL2182842,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes incubated for 60 mins by liquid scintillation counting",CHEMBL2177058,KI,Oc1cccc(CCN(CCc2ccccc2)CC2CCC2)c1
CHEMBL2180638,CHEMBL237,Kappa opioid receptor,Ki,=,5.9,nM,CHEMBL2182842,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes incubated for 60 mins by liquid scintillation counting",CHEMBL2177058,KI,Oc1cccc(CCN(CCc2ccccc2)CC2CC2)c1
CHEMBL2180637,CHEMBL237,Kappa opioid receptor,Ki,=,12.6,nM,CHEMBL2182842,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes incubated for 60 mins by liquid scintillation counting",CHEMBL2177058,KI,CCCCCN(CCc1ccccc1)CCc1cccc(O)c1
CHEMBL1188090,CHEMBL237,Kappa opioid receptor,Ki,=,8.13,nM,CHEMBL2182842,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes incubated for 60 mins by liquid scintillation counting",CHEMBL2177058,KI,CCCN(CCc1ccccc1)CCc1cccc(O)c1
CHEMBL2205813,CHEMBL237,Kappa opioid receptor,Ki,=,2080.0,nM,CHEMBL2215558,B,Binding affinity to kappa opioid receptor,CHEMBL2203059,KI,COc1cccc(CCN2C3C4C5CC6C7C5C3C7C2(O)C64)c1OC
CHEMBL2205812,CHEMBL237,Kappa opioid receptor,Ki,=,1575.0,nM,CHEMBL2215558,B,Binding affinity to kappa opioid receptor,CHEMBL2203059,KI,COc1ccc(CCN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1
CHEMBL2205811,CHEMBL237,Kappa opioid receptor,Ki,=,1420.0,nM,CHEMBL2215558,B,Binding affinity to kappa opioid receptor,CHEMBL2203059,KI,COc1cccc(CCN2C3C4C5CC6C7C5C3C7C2(O)C64)c1
CHEMBL2205836,CHEMBL237,Kappa opioid receptor,Ki,=,1107.0,nM,CHEMBL2215558,B,Binding affinity to kappa opioid receptor,CHEMBL2203059,KI,COc1ccccc1CCN1C2C3C4CC5C6C4C2C6C1(O)C53
CHEMBL2205832,CHEMBL237,Kappa opioid receptor,Ki,=,2688.0,nM,CHEMBL2215558,B,Binding affinity to kappa opioid receptor,CHEMBL2203059,KI,OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccccn1
CHEMBL2205829,CHEMBL237,Kappa opioid receptor,Ki,=,1426.0,nM,CHEMBL2215558,B,Binding affinity to kappa opioid receptor,CHEMBL2203059,KI,OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccc2c(c1)OCO2
CHEMBL2205827,CHEMBL237,Kappa opioid receptor,Ki,=,1147.0,nM,CHEMBL2215558,B,Binding affinity to kappa opioid receptor,CHEMBL2203059,KI,COc1ccc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1OC
CHEMBL2205825,CHEMBL237,Kappa opioid receptor,Ki,=,617.0,nM,CHEMBL2215558,B,Binding affinity to kappa opioid receptor,CHEMBL2203059,KI,COc1ccc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1
CHEMBL2205823,CHEMBL237,Kappa opioid receptor,Ki,=,1094.0,nM,CHEMBL2215558,B,Binding affinity to kappa opioid receptor,CHEMBL2203059,KI,COc1ccccc1CN1C2C3C4CC5C6C4C2C6C1(O)C53
CHEMBL1189234,CHEMBL237,Kappa opioid receptor,Ki,=,488.0,nM,CHEMBL2215558,B,Binding affinity to kappa opioid receptor,CHEMBL2203059,KI,OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccccc1
CHEMBL2208355,CHEMBL237,Kappa opioid receptor,Ki,=,0.2,nM,CHEMBL2213839,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2203245,KI,CC1C2Cc3ccc(C(=O)NCCc4ccc5ccccc5c4)cc3C1(C)CCN2CC1CC1
CHEMBL2208354,CHEMBL237,Kappa opioid receptor,Ki,=,0.45,nM,CHEMBL2213839,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2203245,KI,COc1ccc2cc(CCNC(=O)c3ccc4c(c3)C3(C)CCN(CC5CC5)C(C4)C3C)ccc2c1
CHEMBL2208353,CHEMBL237,Kappa opioid receptor,Ki,=,1.3,nM,CHEMBL2213839,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2203245,KI,COc1ccc(-c2ccc(CCNC(=O)c3ccc4c(c3)C3(C)CCN(CC5CC5)C(C4)C3C)cc2)c(C)c1
CHEMBL2208352,CHEMBL237,Kappa opioid receptor,Ki,=,1.7,nM,CHEMBL2213839,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2203245,KI,COc1ccc(-c2ccc(CCNC(=O)c3ccc4c(c3)C3(C)CCN(CC5CC5)C(C4)C3C)cc2)cc1C
CHEMBL2208351,CHEMBL237,Kappa opioid receptor,Ki,=,0.73,nM,CHEMBL2213839,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2203245,KI,CC1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccc6c(c5)OCO6)cc4)cc3C1(C)CCN2CC1CC1
CHEMBL2208350,CHEMBL237,Kappa opioid receptor,Ki,=,1.3,nM,CHEMBL2213839,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2203245,KI,COc1ccc(-c2ccc(CCNC(=O)c3ccc4c(c3)C3(C)CCN(CC5CC5)C(C4)C3C)cc2)cc1OC
CHEMBL2208349,CHEMBL237,Kappa opioid receptor,Ki,=,2.1,nM,CHEMBL2213839,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2203245,KI,CC1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccccc5O)cc4)cc3C1(C)CCN2CC1CC1
CHEMBL2208348,CHEMBL237,Kappa opioid receptor,Ki,=,1.3,nM,CHEMBL2213839,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2203245,KI,CC1C2Cc3ccc(C(=O)NCCc4ccc(-c5cccc(O)c5)cc4)cc3C1(C)CCN2CC1CC1
CHEMBL2208347,CHEMBL237,Kappa opioid receptor,Ki,=,0.36,nM,CHEMBL2213839,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2203245,KI,C[C@H]1[C@H]2Cc3ccc(C(=O)NCCc4ccc(-c5ccc(O)cc5)cc4)cc3[C@]1(C)CCN2CC1CC1
CHEMBL2203338,CHEMBL237,Kappa opioid receptor,Ki,=,0.49,nM,CHEMBL2213839,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2203245,KI,CC1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccc(O)cc5)cc4)cc3C1(C)CCN2CC1CC1
CHEMBL2208346,CHEMBL237,Kappa opioid receptor,Ki,=,2.7,nM,CHEMBL2213839,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2203245,KI,CC1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccc(OC(F)F)cc5)cc4)cc3C1(C)CCN2CC1CC1
CHEMBL2208345,CHEMBL237,Kappa opioid receptor,Ki,=,5.2,nM,CHEMBL2213839,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2203245,KI,CC1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccc(OC(F)(F)F)cc5)cc4)cc3C1(C)CCN2CC1CC1
CHEMBL2208363,CHEMBL237,Kappa opioid receptor,Ki,=,1.8,nM,CHEMBL2213839,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2203245,KI,CC(C)Oc1ccccc1-c1ccc(CCNC(=O)c2ccc3c(c2)C2(C)CCN(CC4CC4)C(C3)C2C)cc1
CHEMBL2208362,CHEMBL237,Kappa opioid receptor,Ki,=,2.4,nM,CHEMBL2213839,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2203245,KI,CC(C)Oc1cccc(-c2ccc(CCNC(=O)c3ccc4c(c3)C3(C)CCN(CC5CC5)C(C4)C3C)cc2)c1
CHEMBL2208361,CHEMBL237,Kappa opioid receptor,Ki,=,1.6,nM,CHEMBL2213839,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2203245,KI,CC(C)Oc1ccc(-c2ccc(CCNC(=O)c3ccc4c(c3)C3(C)CCN(CC5CC5)C(C4)C3C)cc2)cc1
CHEMBL2208360,CHEMBL237,Kappa opioid receptor,Ki,=,3.3,nM,CHEMBL2213839,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2203245,KI,CCOc1ccc(-c2ccc(CCNC(=O)c3ccc4c(c3)C3(C)CCN(CC5CC5)C(C4)C3C)cc2)cc1
CHEMBL2208359,CHEMBL237,Kappa opioid receptor,Ki,=,0.38,nM,CHEMBL2213839,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2203245,KI,COc1ccccc1-c1ccc(CCNC(=O)c2ccc3c(c2)C2(C)CCN(CC4CC4)C(C3)C2C)cc1
CHEMBL2208358,CHEMBL237,Kappa opioid receptor,Ki,=,0.22,nM,CHEMBL2213839,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2203245,KI,COc1cccc(-c2ccc(CCNC(=O)c3ccc4c(c3)C3(C)CCN(CC5CC5)C(C4)C3C)cc2)c1
CHEMBL377789,CHEMBL237,Kappa opioid receptor,Ki,=,1.8,nM,CHEMBL2213839,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2203245,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccccc5)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL289683,CHEMBL237,Kappa opioid receptor,Ki,=,0.07,nM,CHEMBL2213839,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2203245,KI,CC1C2Cc3ccc(O)cc3C1(C)CCN2CC1CC1
CHEMBL297428,CHEMBL237,Kappa opioid receptor,Ki,=,0.06,nM,CHEMBL2213839,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2203245,KI,CC1C2Cc3ccc(C(N)=O)cc3C1(C)CCN2CC1CC1
CHEMBL2208356,CHEMBL237,Kappa opioid receptor,Ki,=,1.5,nM,CHEMBL2213839,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting",CHEMBL2203245,KI,COc1ccc(-c2ccc(CCNC(=O)c3ccc4c(c3)C3(C)CCN(CC5CC5)C(C4)C3C)cc2)cc1
CHEMBL2261249,CHEMBL237,Kappa opioid receptor,Ki,=,16000.0,nM,CHEMBL3054593,B,Displacement of [3H]-diprenorphine from kappa opioid receptor (unknown origin) expressed in CHO cells after 30 min by liquid scintillation counting,CHEMBL3046915,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)C=C[C@@]5(C[C@@H]4c4cccc(N)c4)[C@@H](C2)N(C)CC[C@]315
CHEMBL2261250,CHEMBL237,Kappa opioid receptor,Ki,=,9910.0,nM,CHEMBL3054593,B,Displacement of [3H]-diprenorphine from kappa opioid receptor (unknown origin) expressed in CHO cells after 30 min by liquid scintillation counting,CHEMBL3046915,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)C=C[C@@]5(C[C@@H]4c4ccccc4N)[C@@H](C2)N(C)CC[C@]315
CHEMBL2261248,CHEMBL237,Kappa opioid receptor,Ki,=,7890.0,nM,CHEMBL3054593,B,Displacement of [3H]-diprenorphine from kappa opioid receptor (unknown origin) expressed in CHO cells after 30 min by liquid scintillation counting,CHEMBL3046915,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)C=C[C@@]5(C[C@@H]4c4ccc(N)cc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL2260849,CHEMBL237,Kappa opioid receptor,Ki,=,418.0,nM,CHEMBL3056599,B,Binding affinity to Kappa opioid receptor (unknown origin),CHEMBL3044919,KI,CN(C[C@@H]1C[C@@]1(CO)c1ccccc1)C12CC3CC(CC(C3)C1)C2
CHEMBL2322511,CHEMBL237,Kappa opioid receptor,Ki,=,0.5,nM,CHEMBL2327117,B,Binding affinity to KOR (unknown origin),CHEMBL2321730,KI,O=C(Nc1cccc(NC(=O)c2cccc(N3CCCCC3)c2)c1)c1cccc(OC2CCN(CC3CC3)CC2)c1
CHEMBL1921847,CHEMBL237,Kappa opioid receptor,Ki,=,0.597,nM,CHEMBL2327121,B,Binding affinity to human cloned KOR in presence of Na+/GDP,CHEMBL2321730,KI,Cc1cc(C)cc([C@@H]2CCCN2Cc2ccc(Oc3ccc(C(N)=O)cc3F)cc2)c1
CHEMBL2372399,CHEMBL237,Kappa opioid receptor,Ki,=,30.3,nM,CHEMBL2327850,B,Displacement of [3H]diprenorphine from KOR (unknown origin) expressed in CHO cells,CHEMBL2321730,KI,CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)CNC(=O)[C@H](Cc2ccc(O)cc2)NCc2ccccc2)CC(=O)NC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)NC1=O
CHEMBL2322568,CHEMBL237,Kappa opioid receptor,Ki,=,68.0,nM,CHEMBL2330682,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cells after 1 hr by liquid scintillation counting analysis,CHEMBL2321843,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCNc2ccc(Cc3ccccc3)cc21
CHEMBL2322560,CHEMBL237,Kappa opioid receptor,Ki,=,25.0,nM,CHEMBL2330682,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cells after 1 hr by liquid scintillation counting analysis,CHEMBL2321843,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCNc2ccc(CCc3ccccc3)cc21
CHEMBL2322561,CHEMBL237,Kappa opioid receptor,Ki,=,17.0,nM,CHEMBL2330682,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cells after 1 hr by liquid scintillation counting analysis,CHEMBL2321843,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCNc2ccc(Cc3cccc4ccccc34)cc21
CHEMBL2322562,CHEMBL237,Kappa opioid receptor,Ki,=,54.0,nM,CHEMBL2330682,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cells after 1 hr by liquid scintillation counting analysis,CHEMBL2321843,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCNc2ccc(Cc3ccc4ccccc4c3)cc21
CHEMBL2322563,CHEMBL237,Kappa opioid receptor,Ki,=,1.2,nM,CHEMBL2330682,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cells after 1 hr by liquid scintillation counting analysis,CHEMBL2321843,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCNc2ccc(CC3Cc4ccccc4C3)cc21
CHEMBL70,CHEMBL237,Kappa opioid receptor,Ki,=,60.9,nM,CHEMBL2330682,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cells after 1 hr by liquid scintillation counting analysis,CHEMBL2321843,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL2322564,CHEMBL237,Kappa opioid receptor,Ki,=,220.0,nM,CHEMBL2330682,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cells after 1 hr by liquid scintillation counting analysis,CHEMBL2321843,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H]1CCNc2ccc(Cc3ccccc3)cc21
CHEMBL2322565,CHEMBL237,Kappa opioid receptor,Ki,=,1200.0,nM,CHEMBL2330682,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cells after 1 hr by liquid scintillation counting analysis,CHEMBL2321843,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H]1CCNc2ccc(CCc3ccccc3)cc21
CHEMBL2322566,CHEMBL237,Kappa opioid receptor,Ki,=,130.0,nM,CHEMBL2330682,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cells after 1 hr by liquid scintillation counting analysis,CHEMBL2321843,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H]1CCNc2ccc(Cc3ccc4ccccc4c3)cc21
CHEMBL2322567,CHEMBL237,Kappa opioid receptor,Ki,=,110.0,nM,CHEMBL2330682,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cells after 1 hr by liquid scintillation counting analysis,CHEMBL2321843,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H]1CCNc2ccc(CC3Cc4ccccc4C3)cc21
CHEMBL2334774,CHEMBL237,Kappa opioid receptor,Ki,=,240.0,nM,CHEMBL2341880,B,"Displacement of [3H]U69,593 from kappa-type opioid receptor (unknown origin) expressed in HEK293 cells after 60 mins by liquid scintillation counting analysis",CHEMBL2331515,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H]1CCN(C(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C1)c1ccccc1
CHEMBL2335120,CHEMBL237,Kappa opioid receptor,Ki,=,205.0,nM,CHEMBL2341880,B,"Displacement of [3H]U69,593 from kappa-type opioid receptor (unknown origin) expressed in HEK293 cells after 60 mins by liquid scintillation counting analysis",CHEMBL2331515,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCN(C(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C1)c1ccco1
CHEMBL2334773,CHEMBL237,Kappa opioid receptor,Ki,=,200.0,nM,CHEMBL2341880,B,"Displacement of [3H]U69,593 from kappa-type opioid receptor (unknown origin) expressed in HEK293 cells after 60 mins by liquid scintillation counting analysis",CHEMBL2331515,KI,C=C(C(=O)O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1c(C)cc(O)cc1C)c1ccco1
CHEMBL2334772,CHEMBL237,Kappa opioid receptor,Ki,=,192.0,nM,CHEMBL2341880,B,"Displacement of [3H]U69,593 from kappa-type opioid receptor (unknown origin) expressed in HEK293 cells after 60 mins by liquid scintillation counting analysis",CHEMBL2331515,KI,C=C(C(=O)O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1c(C)cc(O)cc1C)c1ccccc1
CHEMBL2334775,CHEMBL237,Kappa opioid receptor,Ki,=,180.0,nM,CHEMBL2341880,B,"Displacement of [3H]U69,593 from kappa-type opioid receptor (unknown origin) expressed in HEK293 cells after 60 mins by liquid scintillation counting analysis",CHEMBL2331515,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H]1CCN(C(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C1)c1ccco1
CHEMBL2334776,CHEMBL237,Kappa opioid receptor,Ki,=,174.0,nM,CHEMBL2341880,B,"Displacement of [3H]U69,593 from kappa-type opioid receptor (unknown origin) expressed in HEK293 cells after 60 mins by liquid scintillation counting analysis",CHEMBL2331515,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCN(C(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C1)c1ccccc1
CHEMBL2338715,CHEMBL237,Kappa opioid receptor,Ki,=,0.39,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CC[C@@]12CCN(CC3CC3)[C@@H](C(=O)c3ccc(O)cc31)[C@H]2C
CHEMBL2338714,CHEMBL237,Kappa opioid receptor,Ki,=,0.082,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12C=C[C@@]3(C[C@@H]1[C@](C)(O)CCC(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338729,CHEMBL237,Kappa opioid receptor,Ki,=,0.047,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@@H](O)CCc1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338728,CHEMBL237,Kappa opioid receptor,Ki,=,0.041,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@@H](O)Cc1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338727,CHEMBL237,Kappa opioid receptor,Ki,=,0.086,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@@H](O)CCC1CCCCC1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338726,CHEMBL237,Kappa opioid receptor,Ki,=,0.12,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@@H](O)CC1CCCCC1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338725,CHEMBL237,Kappa opioid receptor,Ki,=,0.12,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@@H](O)C1CCCCC1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338724,CHEMBL237,Kappa opioid receptor,Ki,=,0.062,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@@H](O)CCC1CCCC1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338723,CHEMBL237,Kappa opioid receptor,Ki,=,0.086,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@@H](O)CC1CCCC1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338722,CHEMBL237,Kappa opioid receptor,Ki,=,0.086,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@@H](O)C1CCCC1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338721,CHEMBL237,Kappa opioid receptor,Ki,=,0.067,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@@H](O)CCC(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338720,CHEMBL237,Kappa opioid receptor,Ki,=,0.057,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@@H](O)CC(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338719,CHEMBL237,Kappa opioid receptor,Ki,=,0.16,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@@H](O)C(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338718,CHEMBL237,Kappa opioid receptor,Ki,=,0.025,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@H](O)CCc1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338717,CHEMBL237,Kappa opioid receptor,Ki,=,0.02,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@H](O)Cc1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338716,CHEMBL237,Kappa opioid receptor,Ki,=,0.019,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@H](O)CCC1CCCCC1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338742,CHEMBL237,Kappa opioid receptor,Ki,=,0.015,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@H](O)CC1CCCCC1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338741,CHEMBL237,Kappa opioid receptor,Ki,=,0.09,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@H](O)C1CCCCC1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338740,CHEMBL237,Kappa opioid receptor,Ki,=,0.078,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@H](O)C1CCCC1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338739,CHEMBL237,Kappa opioid receptor,Ki,=,0.033,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@H](O)CCC(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338738,CHEMBL237,Kappa opioid receptor,Ki,=,0.059,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@H](O)CC(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338737,CHEMBL237,Kappa opioid receptor,Ki,=,0.067,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@H](O)C(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338734,CHEMBL237,Kappa opioid receptor,Ki,=,0.16,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@@](C)(O)CCC1CCCCC1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338733,CHEMBL237,Kappa opioid receptor,Ki,=,0.22,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@@](C)(O)CC1CCCCC1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338732,CHEMBL237,Kappa opioid receptor,Ki,=,0.15,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@@](C)(O)C1CCCC1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338731,CHEMBL237,Kappa opioid receptor,Ki,=,0.15,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@@](C)(O)CCC(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338730,CHEMBL237,Kappa opioid receptor,Ki,=,0.11,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@@](C)(O)CC(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338756,CHEMBL237,Kappa opioid receptor,Ki,=,0.11,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@@](C)(O)C(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL511142,CHEMBL237,Kappa opioid receptor,Ki,=,0.067,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338753,CHEMBL237,Kappa opioid receptor,Ki,=,0.065,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)CCc1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338752,CHEMBL237,Kappa opioid receptor,Ki,=,0.082,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)Cc1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338751,CHEMBL237,Kappa opioid receptor,Ki,=,0.18,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)CCC1CCCCC1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338750,CHEMBL237,Kappa opioid receptor,Ki,=,0.051,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)CC1CCCCC1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338749,CHEMBL237,Kappa opioid receptor,Ki,=,0.1,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C1CCCCC1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338748,CHEMBL237,Kappa opioid receptor,Ki,=,0.12,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)CCC1CCCC1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338747,CHEMBL237,Kappa opioid receptor,Ki,=,0.069,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)CC1CCCC1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338746,CHEMBL237,Kappa opioid receptor,Ki,=,0.074,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C1CCCC1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338745,CHEMBL237,Kappa opioid receptor,Ki,=,0.06,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)CCC(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338744,CHEMBL237,Kappa opioid receptor,Ki,=,0.092,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)CC(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2338743,CHEMBL237,Kappa opioid receptor,Ki,=,0.051,nM,CHEMBL2340175,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cells,CHEMBL2331145,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL2347239,CHEMBL237,Kappa opioid receptor,Ki,=,1.4,nM,CHEMBL2353046,B,Displacement of [3H]DAMGO from human kappa opioid receptor expressed in CHO cell membrane after 60 mins by liquid scintillation counting,CHEMBL2346652,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccccc5)cn4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL2347238,CHEMBL237,Kappa opioid receptor,Ki,=,2.6,nM,CHEMBL2353046,B,Displacement of [3H]DAMGO from human kappa opioid receptor expressed in CHO cell membrane after 60 mins by liquid scintillation counting,CHEMBL2346652,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccccc5)nc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL2347237,CHEMBL237,Kappa opioid receptor,Ki,=,3.3,nM,CHEMBL2353046,B,Displacement of [3H]DAMGO from human kappa opioid receptor expressed in CHO cell membrane after 60 mins by liquid scintillation counting,CHEMBL2346652,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccccn5)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL2347236,CHEMBL237,Kappa opioid receptor,Ki,=,2.2,nM,CHEMBL2353046,B,Displacement of [3H]DAMGO from human kappa opioid receptor expressed in CHO cell membrane after 60 mins by liquid scintillation counting,CHEMBL2346652,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc(-c5cccnc5)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL2347235,CHEMBL237,Kappa opioid receptor,Ki,=,1.8,nM,CHEMBL2353046,B,Displacement of [3H]DAMGO from human kappa opioid receptor expressed in CHO cell membrane after 60 mins by liquid scintillation counting,CHEMBL2346652,KI,C[C@H]1C2Cc3ccc(C(=O)NCCc4ccc(-c5ccncc5)cc4)cc3[C@@]1(C)CCN2CC1CC1
CHEMBL2381590,CHEMBL237,Kappa opioid receptor,Ki,=,4070.0,nM,CHEMBL2383888,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin),CHEMBL2380279,KI,COC(=O)[C@@H]1C[C@H](OC(=O)CCC(=O)O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL2381595,CHEMBL237,Kappa opioid receptor,Ki,=,2291.0,nM,CHEMBL2383888,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin),CHEMBL2380279,KI,COC(=O)[C@@H]1C[C@H](OC(=O)c2ccccc2C(=O)O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL2380325,CHEMBL237,Kappa opioid receptor,Ki,=,575.0,nM,CHEMBL2383888,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin),CHEMBL2380279,KI,COC(=O)CCCCC(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL2381588,CHEMBL237,Kappa opioid receptor,Ki,=,437.0,nM,CHEMBL2383888,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin),CHEMBL2380279,KI,CCOC(=O)CCC(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL2381594,CHEMBL237,Kappa opioid receptor,Ki,=,427.0,nM,CHEMBL2383888,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin),CHEMBL2380279,KI,CCOC(=O)/C=C/C(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL2381589,CHEMBL237,Kappa opioid receptor,Ki,=,302.0,nM,CHEMBL2383888,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin),CHEMBL2380279,KI,COC(=O)CCCC(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL2381591,CHEMBL237,Kappa opioid receptor,Ki,=,263.0,nM,CHEMBL2383888,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin),CHEMBL2380279,KI,COC(=O)[C@@H]1C[C@H](OC(=O)CCCC(=O)O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL2381586,CHEMBL237,Kappa opioid receptor,Ki,=,148.0,nM,CHEMBL2383888,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin),CHEMBL2380279,KI,COC(=O)[C@@H]1C[C@H](OC(=O)CC(=O)OC(C)(C)C)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL2381593,CHEMBL237,Kappa opioid receptor,Ki,=,39.0,nM,CHEMBL2383888,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin),CHEMBL2380279,KI,COC(=O)/C=C/C(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL2381587,CHEMBL237,Kappa opioid receptor,Ki,=,36.0,nM,CHEMBL2383888,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin),CHEMBL2380279,KI,COC(=O)CCC(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL2381585,CHEMBL237,Kappa opioid receptor,Ki,=,21.0,nM,CHEMBL2383888,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin),CHEMBL2380279,KI,CCOC(=O)CC(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL445332,CHEMBL237,Kappa opioid receptor,Ki,=,6.2,nM,CHEMBL2383888,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin),CHEMBL2380279,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL2381584,CHEMBL237,Kappa opioid receptor,Ki,=,2.0,nM,CHEMBL2383888,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin),CHEMBL2380279,KI,COC(=O)CC(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL2381583,CHEMBL237,Kappa opioid receptor,Ki,=,0.6,nM,CHEMBL2383888,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin),CHEMBL2380279,KI,COC(=O)[C@@H]1C[C@H](OC(=O)CSC#N)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL267495,CHEMBL237,Kappa opioid receptor,Ki,=,0.23,nM,CHEMBL2388585,B,Binding affinity to kappa opioid receptor (unknown origin),CHEMBL2384951,KI,CN(C(=O)/C=C/c1ccoc1)[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL1196093,CHEMBL237,Kappa opioid receptor,Ki,=,34.0,nM,CHEMBL2390020,B,Binding affinity to kappa opioid receptor (unknown origin),CHEMBL2384966,KI,CC[C@@]12CCN(CC3CC3)C[C@@H]1Oc1ccc(O)cc12
CHEMBL440765,CHEMBL237,Kappa opioid receptor,Ki,=,3.5,nM,CHEMBL2390777,B,"Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis",CHEMBL2384966,KI,CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL70,CHEMBL237,Kappa opioid receptor,Ki,=,299.0,nM,CHEMBL2390777,B,"Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis",CHEMBL2384966,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL2386904,CHEMBL237,Kappa opioid receptor,Ki,=,541.0,nM,CHEMBL2390777,B,"Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis",CHEMBL2384966,KI,Oc1ccc2c(c1)[C@]1(CCc3ccccc3)CCN(CCc3cccc(C(F)(F)F)c3)C[C@@H]1O2
CHEMBL2386903,CHEMBL237,Kappa opioid receptor,Ki,=,1922.0,nM,CHEMBL2390777,B,"Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis",CHEMBL2384966,KI,Oc1ccc2c(c1)[C@]1(CCc3ccccc3)CCN(CCc3ccccc3C(F)(F)F)C[C@@H]1O2
CHEMBL2386902,CHEMBL237,Kappa opioid receptor,Ki,=,80.0,nM,CHEMBL2390777,B,"Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis",CHEMBL2384966,KI,C=CCN1CC[C@@]2(CCc3ccccc3)c3cc(O)ccc3O[C@H]2C1
CHEMBL2386901,CHEMBL237,Kappa opioid receptor,Ki,=,16.0,nM,CHEMBL2390777,B,"Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis",CHEMBL2384966,KI,Oc1ccc2c(c1)[C@]1(CCc3ccccc3)CCN(CC3CC3)C[C@@H]1O2
CHEMBL2386900,CHEMBL237,Kappa opioid receptor,Ki,=,2459.0,nM,CHEMBL2390777,B,"Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis",CHEMBL2384966,KI,Oc1ccc2c(c1)[C@]1(CCc3ccccc3)CCN(CCc3ccc(C(F)(F)F)cc3)C[C@@H]1O2
CHEMBL2386899,CHEMBL237,Kappa opioid receptor,Ki,=,826.0,nM,CHEMBL2390777,B,"Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis",CHEMBL2384966,KI,Oc1ccc2c(c1)[C@]1(CCc3ccccc3)CCN(CCc3ccccc3F)C[C@@H]1O2
CHEMBL2386898,CHEMBL237,Kappa opioid receptor,Ki,=,721.0,nM,CHEMBL2390777,B,"Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis",CHEMBL2384966,KI,Oc1ccc2c(c1)[C@]1(CCc3ccccc3)CCN(CCc3ccc(F)cc3)C[C@@H]1O2
CHEMBL2386897,CHEMBL237,Kappa opioid receptor,Ki,=,670.0,nM,CHEMBL2390777,B,"Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis",CHEMBL2384966,KI,Oc1ccc2c(c1)[C@]1(CCc3ccccc3)CCN(CCCc3ccccc3)C[C@@H]1O2
CHEMBL2386896,CHEMBL237,Kappa opioid receptor,Ki,=,730.0,nM,CHEMBL2390777,B,"Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis",CHEMBL2384966,KI,Oc1ccc2c(c1)[C@]1(CCc3ccccc3)CCN(CCc3ccccc3)C[C@@H]1O2
CHEMBL2386895,CHEMBL237,Kappa opioid receptor,Ki,=,2217.0,nM,CHEMBL2390777,B,"Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis",CHEMBL2384966,KI,CN1CC[C@@]2(CCc3ccccc3F)c3cc(O)ccc3O[C@H]2C1
CHEMBL2386894,CHEMBL237,Kappa opioid receptor,Ki,=,2879.0,nM,CHEMBL2390777,B,"Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis",CHEMBL2384966,KI,CN1CC[C@@]2(CCc3ccc(F)cc3)c3cc(O)ccc3O[C@H]2C1
CHEMBL2386893,CHEMBL237,Kappa opioid receptor,Ki,=,971.0,nM,CHEMBL2390777,B,"Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis",CHEMBL2384966,KI,CCCCC[C@@]12CCN(C)C[C@@H]1Oc1ccc(O)cc12
CHEMBL2386892,CHEMBL237,Kappa opioid receptor,Ki,=,1913.0,nM,CHEMBL2390777,B,"Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis",CHEMBL2384966,KI,CCCC[C@@]12CCN(C)C[C@@H]1Oc1ccc(O)cc12
CHEMBL2386891,CHEMBL237,Kappa opioid receptor,Ki,=,1651.0,nM,CHEMBL2390777,B,"Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis",CHEMBL2384966,KI,CCC[C@@]12CCN(C)C[C@@H]1Oc1ccc(O)cc12
CHEMBL2386824,CHEMBL237,Kappa opioid receptor,Ki,=,4182.0,nM,CHEMBL2390777,B,"Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis",CHEMBL2384966,KI,CN1CC[C@@]2(C)c3cc(O)ccc3O[C@H]2C1
CHEMBL2386823,CHEMBL237,Kappa opioid receptor,Ki,=,71.0,nM,CHEMBL2390777,B,"Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis",CHEMBL2384966,KI,CN1CC[C@@]2(CCCCCc3ccccc3)c3cc(O)ccc3O[C@H]2C1
CHEMBL2386822,CHEMBL237,Kappa opioid receptor,Ki,=,163.0,nM,CHEMBL2390777,B,"Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis",CHEMBL2384966,KI,CN1CC[C@@]2(CCCCc3ccccc3)c3cc(O)ccc3O[C@H]2C1
CHEMBL2386821,CHEMBL237,Kappa opioid receptor,Ki,=,238.0,nM,CHEMBL2390777,B,"Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis",CHEMBL2384966,KI,CN1CC[C@@]2(CCCc3ccccc3)c3cc(O)ccc3O[C@H]2C1
CHEMBL2386820,CHEMBL237,Kappa opioid receptor,Ki,=,3544.0,nM,CHEMBL2390777,B,"Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis",CHEMBL2384966,KI,CN1CC[C@@]2(CCc3ccccc3)c3cc(O)ccc3O[C@H]2C1
CHEMBL2386819,CHEMBL237,Kappa opioid receptor,Ki,=,2882.0,nM,CHEMBL2390777,B,"Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting analysis",CHEMBL2384966,KI,CN1CC[C@@]2(Cc3ccccc3)c3cc(O)ccc3O[C@H]2C1
CHEMBL2387193,CHEMBL237,Kappa opioid receptor,Ki,=,681.3,nM,CHEMBL2389092,B,Displacement of [3H] U69593 from human kappa opioid receptor transfected in CHO cells,CHEMBL2385080,KI,O=C1Cc2ccccc2N1C1CCN(C2CC[C@H]3CCCc4cccc2c43)CC1
CHEMBL2387188,CHEMBL237,Kappa opioid receptor,Ki,=,190.2,nM,CHEMBL2389092,B,Displacement of [3H] U69593 from human kappa opioid receptor transfected in CHO cells,CHEMBL2385080,KI,CCC[C@H]1CC[C@@H](N2CCC(N3C(=O)Cc4ccccc43)CC2)CC1
CHEMBL2387189,CHEMBL237,Kappa opioid receptor,Ki,=,159.7,nM,CHEMBL2389092,B,Displacement of [3H] U69593 from human kappa opioid receptor transfected in CHO cells,CHEMBL2385080,KI,CCC(C)(C)[C@H]1CC[C@@H](N2CCC(N3C(=O)Cc4ccccc43)CC2)CC1
CHEMBL2387187,CHEMBL237,Kappa opioid receptor,Ki,=,148.7,nM,CHEMBL2389092,B,Displacement of [3H] U69593 from human kappa opioid receptor transfected in CHO cells,CHEMBL2385080,KI,CC(C)C1CCC(N2CCC(N3C(=O)Cc4ccccc43)CC2)CC1
CHEMBL320874,CHEMBL237,Kappa opioid receptor,Ki,=,84.5,nM,CHEMBL2389092,B,Displacement of [3H] U69593 from human kappa opioid receptor transfected in CHO cells,CHEMBL2385080,KI,O=C1Cc2ccccc2N1C1CCN(Cc2ccccc2)CC1
CHEMBL2387196,CHEMBL237,Kappa opioid receptor,Ki,=,82.4,nM,CHEMBL2389092,B,Displacement of [3H] U69593 from human kappa opioid receptor transfected in CHO cells,CHEMBL2385080,KI,CCC1C(=O)N(C2CCN([C@H]3CC[C@@H](C(C)C)CC3)CC2)c2ccccc21
CHEMBL2387198,CHEMBL237,Kappa opioid receptor,Ki,=,70.04,nM,CHEMBL2389092,B,Displacement of [3H] U69593 from human kappa opioid receptor transfected in CHO cells,CHEMBL2385080,KI,CC(C)C1CCC(N2CCC(N3C(=O)CCc4ccccc43)CC2)CC1
CHEMBL2387191,CHEMBL237,Kappa opioid receptor,Ki,=,43.9,nM,CHEMBL2389092,B,Displacement of [3H] U69593 from human kappa opioid receptor transfected in CHO cells,CHEMBL2385080,KI,CC(C1CCCCC1)N1CCC(N2C(=O)Cc3ccccc32)CC1
CHEMBL2387197,CHEMBL237,Kappa opioid receptor,Ki,=,43.4,nM,CHEMBL2389092,B,Displacement of [3H] U69593 from human kappa opioid receptor transfected in CHO cells,CHEMBL2385080,KI,CCC1C(=O)N(C2CCN(C3CCCCCCC3)CC2)c2ccccc21
CHEMBL101454,CHEMBL237,Kappa opioid receptor,Ki,=,42.7,nM,CHEMBL2389092,B,Displacement of [3H] U69593 from human kappa opioid receptor transfected in CHO cells,CHEMBL2385080,KI,O=C1Cc2ccccc2N1C1CCN(C2CCCCCCC2)CC1
CHEMBL2387194,CHEMBL237,Kappa opioid receptor,Ki,=,41.77,nM,CHEMBL2389092,B,Displacement of [3H] U69593 from human kappa opioid receptor transfected in CHO cells,CHEMBL2385080,KI,CC1C(=O)N(C2CCN([C@H]3CC[C@@H](C(C)C)CC3)CC2)c2ccccc21
CHEMBL2387195,CHEMBL237,Kappa opioid receptor,Ki,=,39.2,nM,CHEMBL2389092,B,Displacement of [3H] U69593 from human kappa opioid receptor transfected in CHO cells,CHEMBL2385080,KI,CC1C(=O)N(C2CCN(C3CCCCCCC3)CC2)c2ccccc21
CHEMBL2387199,CHEMBL237,Kappa opioid receptor,Ki,=,37.92,nM,CHEMBL2389092,B,Displacement of [3H] U69593 from human kappa opioid receptor transfected in CHO cells,CHEMBL2385080,KI,O=C1CCc2ccccc2N1C1CCN(C2CCCCCCC2)CC1
CHEMBL102900,CHEMBL237,Kappa opioid receptor,Ki,=,31.74,nM,CHEMBL2389092,B,Displacement of [3H] U69593 from human kappa opioid receptor transfected in CHO cells,CHEMBL2385080,KI,O=C1Cc2ccccc2N1C1CCN(C2C3CCCC2CCC3)CC1
CHEMBL2387192,CHEMBL237,Kappa opioid receptor,Ki,=,29.2,nM,CHEMBL2389092,B,Displacement of [3H] U69593 from human kappa opioid receptor transfected in CHO cells,CHEMBL2385080,KI,CC(c1ccccc1)N1CCC(N2C(=O)Cc3ccccc32)CC1
CHEMBL2387200,CHEMBL237,Kappa opioid receptor,Ki,=,27.69,nM,CHEMBL2389092,B,Displacement of [3H] U69593 from human kappa opioid receptor transfected in CHO cells,CHEMBL2385080,KI,CC1CC(=O)N(C2CCN(C3CCCCCCC3)CC2)c2ccccc21
CHEMBL2390967,CHEMBL237,Kappa opioid receptor,Ki,=,6.4,nM,CHEMBL2395089,B,Displacement of [3H]Diprenorphine from human recombinant kappa opioid receptor expressed in HEK293 cells after 60 mins,CHEMBL2390918,KI,CN(C(=O)Cc1ccccc1)[C@H]1C[C@]2(CCCO2)CC[C@@H]1N1CCCC1
CHEMBL441765,CHEMBL237,Kappa opioid receptor,Ki,=,0.5,nM,CHEMBL2394940,B,Binding affinity to human kappa-type opioid receptor by radioligand displacement assay,CHEMBL2390830,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL58362,CHEMBL237,Kappa opioid receptor,Ki,=,79.0,nM,CHEMBL2399174,B,Binding affinity to kappa opioid receptor (unknown origin),CHEMBL2396537,KI,CC[C@@H]1CN2CC[C@]3(Nc4cccc(OC)c4C3=O)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL2396991,CHEMBL237,Kappa opioid receptor,Ki,=,7.0,nM,CHEMBL2399174,B,Binding affinity to kappa opioid receptor (unknown origin),CHEMBL2396537,KI,CC[C@@H]1CN2CC[C@@]34OCCO[C@@]3(Nc3ccc(F)c(OC)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL2397019,CHEMBL237,Kappa opioid receptor,Ki,=,0.33,nM,CHEMBL2399075,B,Displacement of [3H]DPN from kappa opioid receptor (unknown origin) after 1.5 hrs,CHEMBL2396652,KI,O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccc2ccccc2c1
CHEMBL2397018,CHEMBL237,Kappa opioid receptor,Ki,=,0.13,nM,CHEMBL2399075,B,Displacement of [3H]DPN from kappa opioid receptor (unknown origin) after 1.5 hrs,CHEMBL2396652,KI,O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1cnc2ccccc2c1
CHEMBL2397017,CHEMBL237,Kappa opioid receptor,Ki,=,0.26,nM,CHEMBL2399075,B,Displacement of [3H]DPN from kappa opioid receptor (unknown origin) after 1.5 hrs,CHEMBL2396652,KI,O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccc2ccccc2n1
CHEMBL2397016,CHEMBL237,Kappa opioid receptor,Ki,=,0.27,nM,CHEMBL2399075,B,Displacement of [3H]DPN from kappa opioid receptor (unknown origin) after 1.5 hrs,CHEMBL2396652,KI,O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1cc2ccccc2cn1
CHEMBL2397015,CHEMBL237,Kappa opioid receptor,Ki,=,0.12,nM,CHEMBL2399075,B,Displacement of [3H]DPN from kappa opioid receptor (unknown origin) after 1.5 hrs,CHEMBL2396652,KI,O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccccc1
CHEMBL2397022,CHEMBL237,Kappa opioid receptor,Ki,=,0.33,nM,CHEMBL2399075,B,Displacement of [3H]DPN from kappa opioid receptor (unknown origin) after 1.5 hrs,CHEMBL2396652,KI,O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccncc1
CHEMBL2397021,CHEMBL237,Kappa opioid receptor,Ki,=,0.16,nM,CHEMBL2399075,B,Displacement of [3H]DPN from kappa opioid receptor (unknown origin) after 1.5 hrs,CHEMBL2396652,KI,O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1cccnc1
CHEMBL2397020,CHEMBL237,Kappa opioid receptor,Ki,=,0.36,nM,CHEMBL2399075,B,Displacement of [3H]DPN from kappa opioid receptor (unknown origin) after 1.5 hrs,CHEMBL2396652,KI,O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccccn1
CHEMBL19019,CHEMBL237,Kappa opioid receptor,Ki,=,0.9,nM,CHEMBL2399075,B,Displacement of [3H]DPN from kappa opioid receptor (unknown origin) after 1.5 hrs,CHEMBL2396652,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL2409225,CHEMBL237,Kappa opioid receptor,Ki,=,14.0,nM,CHEMBL2410567,B,Displacement of [125]IBNtxA from KOR-1 (unknown origin) transfected in CHO cells after 90 mins by competitive binding assay,CHEMBL2407029,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(I)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O
CHEMBL2409224,CHEMBL237,Kappa opioid receptor,Ki,=,13.0,nM,CHEMBL2410567,B,Displacement of [125]IBNtxA from KOR-1 (unknown origin) transfected in CHO cells after 90 mins by competitive binding assay,CHEMBL2407029,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O
CHEMBL2409223,CHEMBL237,Kappa opioid receptor,Ki,=,3.5,nM,CHEMBL2410567,B,Displacement of [125]IBNtxA from KOR-1 (unknown origin) transfected in CHO cells after 90 mins by competitive binding assay,CHEMBL2407029,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(I)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O
CHEMBL2409222,CHEMBL237,Kappa opioid receptor,Ki,=,2.4,nM,CHEMBL2410567,B,Displacement of [125]IBNtxA from KOR-1 (unknown origin) transfected in CHO cells after 90 mins by competitive binding assay,CHEMBL2407029,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O
CHEMBL2413522,CHEMBL237,Kappa opioid receptor,Ki,=,320.0,nM,CHEMBL2416547,B,Binding affinity to kappa opioid receptor (unknown origin),CHEMBL2412971,KI,COc1c(F)cccc1C(=O)N1C[C@@H](C)CC[C@H]1CNc1ccc(Br)cn1
CHEMBL2413879,CHEMBL237,Kappa opioid receptor,Ki,=,2200.0,nM,CHEMBL2416893,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 120 mins by liquid scintillation counting",CHEMBL2412978,KI,CN(CCCc1ccccc1)[C@H]1CCCC[C@@H]1OCCCc1ccccc1
CHEMBL2413877,CHEMBL237,Kappa opioid receptor,Ki,=,21000.0,nM,CHEMBL2416893,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 120 mins by liquid scintillation counting",CHEMBL2412978,KI,CN(CCc1ccccc1)[C@H]1CCCC[C@@H]1OCCCc1ccccc1
CHEMBL2418736,CHEMBL237,Kappa opioid receptor,Ki,=,1229.0,nM,CHEMBL2423612,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting",CHEMBL2417511,KI,CN1CC[C@]2(c3cccc(O)c3)C[C@H](O)C[C@@H]1C2
CHEMBL2418729,CHEMBL237,Kappa opioid receptor,Ki,=,302.0,nM,CHEMBL2423612,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting",CHEMBL2417511,KI,C[C@H]1C[C@H]2C[C@](c3cccc(O)c3)(CCN2C)C1
CHEMBL70,CHEMBL237,Kappa opioid receptor,Ki,=,299.0,nM,CHEMBL2423612,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting",CHEMBL2417511,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL2418735,CHEMBL237,Kappa opioid receptor,Ki,=,198.0,nM,CHEMBL2423612,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting",CHEMBL2417511,KI,O=C1C[C@H]2C[C@](c3cccc(O)c3)(CCN2CCc2ccccc2)C1
CHEMBL2418731,CHEMBL237,Kappa opioid receptor,Ki,=,136.0,nM,CHEMBL2423612,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting",CHEMBL2417511,KI,CN1CC[C@]2(c3cccc(O)c3)C[C@@H](c3ccccc3)C[C@H]1C2
CHEMBL2418737,CHEMBL237,Kappa opioid receptor,Ki,=,135.0,nM,CHEMBL2423612,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting",CHEMBL2417511,KI,Oc1cccc([C@@]23CCN(CCc4ccccc4)[C@H](C[C@@H](O)C2)C3)c1
CHEMBL2418730,CHEMBL237,Kappa opioid receptor,Ki,=,91.0,nM,CHEMBL2423612,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting",CHEMBL2417511,KI,C[C@H]1C[C@H]2C[C@](c3cccc(O)c3)(CCN2CCc2ccccc2)C1
CHEMBL2418734,CHEMBL237,Kappa opioid receptor,Ki,=,82.0,nM,CHEMBL2423612,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting",CHEMBL2417511,KI,Oc1cccc([C@]23CCN(CCc4ccccc4)[C@H](C2)[C@H]2CCCC[C@@H]2C3)c1
CHEMBL2418572,CHEMBL237,Kappa opioid receptor,Ki,=,54.0,nM,CHEMBL2423612,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting",CHEMBL2417511,KI,C[C@H]1CC[C@@]2(c3cccc(O)c3)CCN(CCc3ccccc3)[C@@H]1C2
CHEMBL2418571,CHEMBL237,Kappa opioid receptor,Ki,=,39.0,nM,CHEMBL2423612,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting",CHEMBL2417511,KI,C[C@H]1CC[C@@]2(c3cccc(O)c3)CCN(C)[C@@H]1C2
CHEMBL2418733,CHEMBL237,Kappa opioid receptor,Ki,=,22.0,nM,CHEMBL2423612,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting",CHEMBL2417511,KI,CN1CC[C@]2(c3cccc(O)c3)C[C@H]3CCCC[C@@H]3[C@H]1C2
CHEMBL2418732,CHEMBL237,Kappa opioid receptor,Ki,=,4.05,nM,CHEMBL2423612,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting",CHEMBL2417511,KI,Oc1cccc([C@@]23CCN(CCc4ccccc4)[C@@H](C[C@H](c4ccccc4)C2)C3)c1
CHEMBL440765,CHEMBL237,Kappa opioid receptor,Ki,=,3.5,nM,CHEMBL2423612,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cells after 2 hrs by liquid scintillation counting",CHEMBL2417511,KI,CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL2432039,CHEMBL237,Kappa opioid receptor,Ki,=,809.0,nM,CHEMBL2432433,B,Inhibition of kappa opioid receptor (unknown origin) by PDSP assay,CHEMBL2429832,KI,C1C2C3CC4C2C2C1C3[C@H](NCC13C5C6C7C5C1C7C63)C42
CHEMBL2432051,CHEMBL237,Kappa opioid receptor,Ki,=,1977.0,nM,CHEMBL2432433,B,Inhibition of kappa opioid receptor (unknown origin) by PDSP assay,CHEMBL2429832,KI,COc1cc(CN[C@H]2C3C4CC5C6C4CC3C6C52)cc(OC)c1OC
CHEMBL2432045,CHEMBL237,Kappa opioid receptor,Ki,=,4864.0,nM,CHEMBL2432433,B,Inhibition of kappa opioid receptor (unknown origin) by PDSP assay,CHEMBL2429832,KI,c1ccc(CN[C@H]2C3C4CC5C6C4CC3C6C52)cc1
CHEMBL2205829,CHEMBL237,Kappa opioid receptor,Ki,=,1426.0,nM,CHEMBL2432433,B,Inhibition of kappa opioid receptor (unknown origin) by PDSP assay,CHEMBL2429832,KI,OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccc2c(c1)OCO2
CHEMBL2205827,CHEMBL237,Kappa opioid receptor,Ki,=,1147.0,nM,CHEMBL2432433,B,Inhibition of kappa opioid receptor (unknown origin) by PDSP assay,CHEMBL2429832,KI,COc1ccc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1OC
CHEMBL2432059,CHEMBL237,Kappa opioid receptor,Ki,=,934.0,nM,CHEMBL2432433,B,Inhibition of kappa opioid receptor (unknown origin) by PDSP assay,CHEMBL2429832,KI,CN(CCc1ccccn1)[C@H]1C2C3CC4C5C3CC2C5C41
CHEMBL2432057,CHEMBL237,Kappa opioid receptor,Ki,=,1662.0,nM,CHEMBL2432433,B,Inhibition of kappa opioid receptor (unknown origin) by PDSP assay,CHEMBL2429832,KI,CN(Cc1cccnc1)[C@H]1C2C3CC4C5C3CC2C5C41
CHEMBL1189234,CHEMBL237,Kappa opioid receptor,Ki,=,488.0,nM,CHEMBL2432433,B,Inhibition of kappa opioid receptor (unknown origin) by PDSP assay,CHEMBL2429832,KI,OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccccc1
CHEMBL3217271,CHEMBL237,Kappa opioid receptor,Ki,=,0.92,nM,CHEMBL3088917,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL3085655,KI,C[C@@H]1CN(CCCc2ccccc2)[C@H]2C[C@H](N(C)CC3CC3)C[C@]1(c1cccc(O)c1)C2.Cl.Cl
CHEMBL3216613,CHEMBL237,Kappa opioid receptor,Ki,=,9.9,nM,CHEMBL3088917,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL3085655,KI,C[C@@H]1CN(CCCc2ccccc2)[C@H]2C[C@H](N(C)C)C[C@]1(c1cccc(O)c1)C2.Cl.Cl
CHEMBL3217273,CHEMBL237,Kappa opioid receptor,Ki,=,13.67,nM,CHEMBL3088917,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL3085655,KI,C[C@@H]1CN(CCCc2ccccc2)[C@H]2C[C@H](NCC3CC3)C[C@]1(c1cccc(O)c1)C2.Cl.Cl
CHEMBL3215960,CHEMBL237,Kappa opioid receptor,Ki,=,1.4,nM,CHEMBL3088917,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL3085655,KI,CCCN[C@H]1C[C@H]2C[C@@](c3cccc(O)c3)(C1)[C@H](C)CN2CCCc1ccccc1.Cl.Cl
CHEMBL3217051,CHEMBL237,Kappa opioid receptor,Ki,=,8.22,nM,CHEMBL3088917,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL3085655,KI,CCN[C@H]1C[C@H]2C[C@@](c3cccc(O)c3)(C1)[C@H](C)CN2CCCc1ccccc1.Cl.Cl
CHEMBL3217272,CHEMBL237,Kappa opioid receptor,Ki,=,20.92,nM,CHEMBL3088917,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL3085655,KI,CN[C@H]1C[C@H]2C[C@@](c3cccc(O)c3)(C1)[C@H](C)CN2CCCc1ccccc1.Cl.Cl
CHEMBL3086466,CHEMBL237,Kappa opioid receptor,Ki,=,7.79,nM,CHEMBL3088917,B,Displacement of [3H]U-69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL3085655,KI,C[C@@H]1CN(CCCc2ccccc2)[C@@H]2CCC[C@]1(c1cccc(O)c1)C2.Cl
CHEMBL3086756,CHEMBL237,Kappa opioid receptor,Ki,=,0.14,nM,CHEMBL3089528,B,Displacement of [3H]DPN from kappa opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(CNC(=O)c1ccccn1)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL3086755,CHEMBL237,Kappa opioid receptor,Ki,=,0.17,nM,CHEMBL3089528,B,Displacement of [3H]DPN from kappa opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(CCc1ccccn1)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL3086754,CHEMBL237,Kappa opioid receptor,Ki,=,0.19,nM,CHEMBL3089528,B,Displacement of [3H]DPN from kappa opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(Cc1ccccn1)N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL3086753,CHEMBL237,Kappa opioid receptor,Ki,=,0.33,nM,CHEMBL3089528,B,Displacement of [3H]DPN from kappa opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccc2ccccc2c1
CHEMBL3086752,CHEMBL237,Kappa opioid receptor,Ki,=,0.13,nM,CHEMBL3089528,B,Displacement of [3H]DPN from kappa opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1cnc2ccccc2c1
CHEMBL3086751,CHEMBL237,Kappa opioid receptor,Ki,=,0.26,nM,CHEMBL3089528,B,Displacement of [3H]DPN from kappa opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccc2ccccc2n1
CHEMBL3086750,CHEMBL237,Kappa opioid receptor,Ki,=,0.27,nM,CHEMBL3089528,B,Displacement of [3H]DPN from kappa opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1cc2ccccc2cn1
CHEMBL3086749,CHEMBL237,Kappa opioid receptor,Ki,=,0.12,nM,CHEMBL3089528,B,Displacement of [3H]DPN from kappa opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccccc1
CHEMBL3086748,CHEMBL237,Kappa opioid receptor,Ki,=,0.33,nM,CHEMBL3089528,B,Displacement of [3H]DPN from kappa opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccncc1
CHEMBL3086747,CHEMBL237,Kappa opioid receptor,Ki,=,0.16,nM,CHEMBL3089528,B,Displacement of [3H]DPN from kappa opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1cccnc1
CHEMBL3086746,CHEMBL237,Kappa opioid receptor,Ki,=,0.36,nM,CHEMBL3089528,B,Displacement of [3H]DPN from kappa opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(N[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccccn1
CHEMBL3086745,CHEMBL237,Kappa opioid receptor,Ki,=,46.6,nM,CHEMBL3089528,B,Displacement of [3H]DPN from kappa opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(O[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccc2ccccc2c1
CHEMBL3086744,CHEMBL237,Kappa opioid receptor,Ki,=,148.2,nM,CHEMBL3089528,B,Displacement of [3H]DPN from kappa opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(O[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1cnc2ccccc2c1
CHEMBL3086762,CHEMBL237,Kappa opioid receptor,Ki,=,67.2,nM,CHEMBL3089528,B,Displacement of [3H]DPN from kappa opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(O[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccc2ccccc2n1
CHEMBL3086760,CHEMBL237,Kappa opioid receptor,Ki,=,586.4,nM,CHEMBL3089528,B,Displacement of [3H]DPN from kappa opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(O[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccccc1
CHEMBL3086759,CHEMBL237,Kappa opioid receptor,Ki,=,49.2,nM,CHEMBL3089528,B,Displacement of [3H]DPN from kappa opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(O[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccncc1
CHEMBL3086758,CHEMBL237,Kappa opioid receptor,Ki,=,47.8,nM,CHEMBL3089528,B,Displacement of [3H]DPN from kappa opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(O[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1cccnc1
CHEMBL3086757,CHEMBL237,Kappa opioid receptor,Ki,=,25.5,nM,CHEMBL3089528,B,Displacement of [3H]DPN from kappa opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,Cl.O=C(O[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5)c1ccccn1
CHEMBL19019,CHEMBL237,Kappa opioid receptor,Ki,=,0.9,nM,CHEMBL3089528,B,Displacement of [3H]DPN from kappa opioid receptor (unknown origin) expressed in CHO cell membranes after 1.5 hrs,CHEMBL3085727,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL3086308,CHEMBL237,Kappa opioid receptor,Ki,=,0.084,nM,CHEMBL3090462,B,Displacement of [3H]-U69593 from human kappa opioid receptor transfected in CHO cells after 60 mins,CHEMBL3085732,KI,Br.CNc1nc2c(s1)C[C@H]1[C@H]3Cc4ccc(O)cc4[C@@]1(CCN3CC1CC1)C2
CHEMBL3086307,CHEMBL237,Kappa opioid receptor,Ki,=,3.6,nM,CHEMBL3090462,B,Displacement of [3H]-U69593 from human kappa opioid receptor transfected in CHO cells after 60 mins,CHEMBL3085732,KI,CNc1nc2c(s1)C[C@H]1[C@H]3Cc4ccc(OC)cc4[C@@]1(CCN3CC1CC1)C2
CHEMBL3086306,CHEMBL237,Kappa opioid receptor,Ki,=,9.0,nM,CHEMBL3090462,B,Displacement of [3H]-U69593 from human kappa opioid receptor transfected in CHO cells after 60 mins,CHEMBL3085732,KI,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@@H]1Cc1sc(NC(C)=O)nc1C3
CHEMBL3086305,CHEMBL237,Kappa opioid receptor,Ki,=,0.17,nM,CHEMBL3090462,B,Displacement of [3H]-U69593 from human kappa opioid receptor transfected in CHO cells after 60 mins,CHEMBL3085732,KI,CC(=O)Nc1nc2c(s1)C[C@H]1[C@H]3Cc4ccc(O)cc4[C@@]1(CCN3CC1CC1)C2
CHEMBL3086303,CHEMBL237,Kappa opioid receptor,Ki,=,1.9,nM,CHEMBL3090462,B,Displacement of [3H]-U69593 from human kappa opioid receptor transfected in CHO cells after 60 mins,CHEMBL3085732,KI,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@@H]1Cc1sc(N)nc1C3
CHEMBL301160,CHEMBL237,Kappa opioid receptor,Ki,=,0.079,nM,CHEMBL3090462,B,Displacement of [3H]-U69593 from human kappa opioid receptor transfected in CHO cells after 60 mins,CHEMBL3085732,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL445332,CHEMBL237,Kappa opioid receptor,Ki,=,3.162,nM,CHEMBL3106112,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin),CHEMBL3102773,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL445332,CHEMBL237,Kappa opioid receptor,Ki,=,3.2,nM,CHEMBL3106112,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin),CHEMBL3102773,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL3104091,CHEMBL237,Kappa opioid receptor,Ki,=,2179.0,nM,CHEMBL3106112,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin),CHEMBL3102773,KI,CN1CCc2c(c3cccc4c3n2-c2ccccc2CC4)C1
CHEMBL3104091,CHEMBL237,Kappa opioid receptor,Ki,=,1995.26,nM,CHEMBL3106112,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin),CHEMBL3102773,KI,CN1CCc2c(c3cccc4c3n2-c2ccccc2CC4)C1
CHEMBL3104104,CHEMBL237,Kappa opioid receptor,Ki,=,36.5,nM,CHEMBL3106325,B,Binding affinity to kappa opioid receptor (unknown origin),CHEMBL3102699,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1CCCc2ccccc21
CHEMBL3104103,CHEMBL237,Kappa opioid receptor,Ki,=,39.0,nM,CHEMBL3106317,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes after 1 hr by liquid scintillation counting analysis,CHEMBL3102699,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1CCN(CCCCCc2ccccc2)CC1
CHEMBL3104102,CHEMBL237,Kappa opioid receptor,Ki,=,54.0,nM,CHEMBL3106317,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes after 1 hr by liquid scintillation counting analysis,CHEMBL3102699,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1CCN(C/C=C\Cc2ccccc2)CC1
CHEMBL3104101,CHEMBL237,Kappa opioid receptor,Ki,=,89.0,nM,CHEMBL3106317,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes after 1 hr by liquid scintillation counting analysis,CHEMBL3102699,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1CCN(C/C=C/Cc2ccccc2)CC1
CHEMBL3104100,CHEMBL237,Kappa opioid receptor,Ki,=,78.0,nM,CHEMBL3106317,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes after 1 hr by liquid scintillation counting analysis,CHEMBL3102699,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1CCN(CCCCc2ccccc2)CC1
CHEMBL3104099,CHEMBL237,Kappa opioid receptor,Ki,=,150.0,nM,CHEMBL3106317,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes after 1 hr by liquid scintillation counting analysis,CHEMBL3102699,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1CCN(CCC(c2ccccc2)c2ccccc2)CC1
CHEMBL3104110,CHEMBL237,Kappa opioid receptor,Ki,=,330.0,nM,CHEMBL3106317,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes after 1 hr by liquid scintillation counting analysis,CHEMBL3102699,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1CCN(C/C=C/c2cccc3ccccc23)CC1
CHEMBL3104109,CHEMBL237,Kappa opioid receptor,Ki,=,78.0,nM,CHEMBL3106317,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes after 1 hr by liquid scintillation counting analysis,CHEMBL3102699,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1CCN(CCCc2cccc3ccccc23)CC1
CHEMBL3104108,CHEMBL237,Kappa opioid receptor,Ki,=,250.0,nM,CHEMBL3106317,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes after 1 hr by liquid scintillation counting analysis,CHEMBL3102699,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1CCN(CCCc2ccccc2)CC1
CHEMBL3104107,CHEMBL237,Kappa opioid receptor,Ki,=,110.0,nM,CHEMBL3106317,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes after 1 hr by liquid scintillation counting analysis,CHEMBL3102699,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1CCC(CCCc2ccccc2)CC1
CHEMBL3104106,CHEMBL237,Kappa opioid receptor,Ki,=,140.0,nM,CHEMBL3106317,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes after 1 hr by liquid scintillation counting analysis,CHEMBL3102699,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1CCC(Cc2ccccc2)CC1
CHEMBL3104105,CHEMBL237,Kappa opioid receptor,Ki,=,310.0,nM,CHEMBL3106317,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes after 1 hr by liquid scintillation counting analysis,CHEMBL3102699,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1CCC(Cc2ccccc2)c2ccccc21
CHEMBL2307889,CHEMBL237,Kappa opioid receptor,Ki,=,948.0,nM,CHEMBL3107077,B,Binding affinity to kappa opioid receptor (unknown origin),CHEMBL3102719,KI,N=C(N)NCCC[C@@H](NC(=O)CC1(CC(=O)N2CCN(C3c4ccccc4NC(=O)c4ccccc43)CC2)CCCC1)C(=O)NCCn1c(=O)n(-c2ccccc2)n(-c2ccccc2)c1=O
CHEMBL445332,CHEMBL237,Kappa opioid receptor,Ki,=,16.0,nM,CHEMBL3131491,B,Binding affinity to kappa opioid receptor (unknown origin) expressed in HEK293 cells by radioligand displacement assay,CHEMBL3124851,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL3220706,CHEMBL237,Kappa opioid receptor,Ki,=,142.0,nM,CHEMBL3223626,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells by liquid scintillation counting analysis,CHEMBL3217747,KI,CCC[C@@H](C)CN1CCC(c2cccc(O)c2)(c2ncc(C(=O)N(CC)CC)cn2)CC1
CHEMBL3220707,CHEMBL237,Kappa opioid receptor,Ki,=,65.0,nM,CHEMBL3223626,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells by liquid scintillation counting analysis,CHEMBL3217747,KI,CCCC(C)CN1CCC(c2cccc(C(N)=O)c2)(c2ncc(C(=O)N(CC)CC)cn2)CC1
CHEMBL603428,CHEMBL237,Kappa opioid receptor,Ki,=,150.0,nM,CHEMBL3223626,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cells by liquid scintillation counting analysis,CHEMBL3217747,KI,CCCC(C)CN1CCC(c2ccc(C(=O)N(C)C)cc2)(c2cccc(O)c2)CC1
CHEMBL3219614,CHEMBL237,Kappa opioid receptor,Ki,=,16.0,nM,CHEMBL3225965,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in cells after 1 hr by liquid scintillation counting analysis,CHEMBL3217574,KI,CC[C@]1(c2cccc(NS(C)(=O)=O)c2)[C@@H]2CN(CCCC3(O)CCCCC3)C[C@@H]21
CHEMBL3219615,CHEMBL237,Kappa opioid receptor,Ki,=,60.0,nM,CHEMBL3225965,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in cells after 1 hr by liquid scintillation counting analysis,CHEMBL3217574,KI,CC[C@]1(c2cccc(C(N)=O)c2)[C@@H]2CN(CC3(O)Cc4ccccc4C3)C[C@@H]21
CHEMBL3219616,CHEMBL237,Kappa opioid receptor,Ki,=,42.0,nM,CHEMBL3225965,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in cells after 1 hr by liquid scintillation counting analysis,CHEMBL3217574,KI,CC[C@]1(c2cccc(NS(C)(=O)=O)c2)[C@@H]2CN(CC3(O)Cc4ccccc4C3)C[C@@H]21
CHEMBL258098,CHEMBL237,Kappa opioid receptor,Ki,=,1.9,nM,CHEMBL3224075,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane after 2 hrs by scintillation counting analysis,CHEMBL3217531,KI,COCO[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL272939,CHEMBL237,Kappa opioid receptor,Ki,=,3.13,nM,CHEMBL3224075,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane after 2 hrs by scintillation counting analysis,CHEMBL3217531,KI,CCOCO[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL3219933,CHEMBL237,Kappa opioid receptor,Ki,=,6.21,nM,CHEMBL3224075,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane after 2 hrs by scintillation counting analysis,CHEMBL3217531,KI,COC(=O)[C@@H]1C[C@H](O[C@@H]2CCCCO2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL3219934,CHEMBL237,Kappa opioid receptor,Ki,=,300.0,nM,CHEMBL3224075,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane after 2 hrs by scintillation counting analysis,CHEMBL3217531,KI,COC(=O)[C@@H]1C[C@H](O[C@H]2CCCCO2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL3219935,CHEMBL237,Kappa opioid receptor,Ki,=,75.0,nM,CHEMBL3224075,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane after 2 hrs by scintillation counting analysis,CHEMBL3217531,KI,COC(=O)[C@@H]1C[C@H](O[C@@H]2CCCO2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL3219936,CHEMBL237,Kappa opioid receptor,Ki,=,81.0,nM,CHEMBL3224075,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane after 2 hrs by scintillation counting analysis,CHEMBL3217531,KI,COC(=O)[C@@H]1C[C@H](O[C@H]2CCCO2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL3219937,CHEMBL237,Kappa opioid receptor,Ki,=,6.7,nM,CHEMBL3224075,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane after 2 hrs by scintillation counting analysis,CHEMBL3217531,KI,CCO[C@@H](C)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL3219938,CHEMBL237,Kappa opioid receptor,Ki,=,1233.0,nM,CHEMBL3224075,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane after 2 hrs by scintillation counting analysis,CHEMBL3217531,KI,CCO[C@H](C)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL3219939,CHEMBL237,Kappa opioid receptor,Ki,=,5261.0,nM,CHEMBL3224075,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane after 2 hrs by scintillation counting analysis,CHEMBL3217531,KI,CCO[C@@H](CBr)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL3219940,CHEMBL237,Kappa opioid receptor,Ki,=,7438.0,nM,CHEMBL3224075,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane after 2 hrs by scintillation counting analysis,CHEMBL3217531,KI,CCO[C@H](CBr)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL370680,CHEMBL237,Kappa opioid receptor,Ki,=,41.0,nM,CHEMBL3224075,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane after 2 hrs by scintillation counting analysis,CHEMBL3217531,KI,COC(=O)[C@@H]1C[C@H](OC=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL3219941,CHEMBL237,Kappa opioid receptor,Ki,=,171.0,nM,CHEMBL3224075,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane after 2 hrs by scintillation counting analysis,CHEMBL3217531,KI,CCOC(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL3219943,CHEMBL237,Kappa opioid receptor,Ki,=,59.0,nM,CHEMBL3224075,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane after 2 hrs by scintillation counting analysis,CHEMBL3217531,KI,COCO[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](C(=O)N4CCCCC4)C[C@]3(C)[C@H]2C1=O
CHEMBL3219944,CHEMBL237,Kappa opioid receptor,Ki,=,140.0,nM,CHEMBL3224075,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane after 2 hrs by scintillation counting analysis,CHEMBL3217531,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C(=O)N3CCCCC3)C[C@]21C
CHEMBL3219942,CHEMBL237,Kappa opioid receptor,Ki,=,462.0,nM,CHEMBL3224078,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL3217531,KI,CCNC(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL3237720,CHEMBL237,Kappa opioid receptor,Ki,=,776.0,nM,CHEMBL3242765,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes after 1 hr by liquid scintillation counting analysis,CHEMBL3232873,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CSCCSC(C)(C)[C@H](C(=O)O)NC(=O)C2(Cc3ccccc3C2)NC1=O
CHEMBL3237721,CHEMBL237,Kappa opioid receptor,Ki,=,7100.0,nM,CHEMBL3242765,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes after 1 hr by liquid scintillation counting analysis,CHEMBL3232873,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CSCCSC(C)(C)[C@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)C2(Cc3ccccc3C2)NC1=O
CHEMBL3237722,CHEMBL237,Kappa opioid receptor,Ki,=,93.4,nM,CHEMBL3242765,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes after 1 hr by liquid scintillation counting analysis,CHEMBL3232873,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CSCCSC(C)(C)[C@H](C(=O)N[C@@H](CO)C(N)=O)NC(=O)C2(Cc3ccccc3C2)NC1=O
CHEMBL3237723,CHEMBL237,Kappa opioid receptor,Ki,=,420.0,nM,CHEMBL3242765,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes after 1 hr by liquid scintillation counting analysis,CHEMBL3232873,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CSCCSC(C)(C)[C@H](C(=O)N[C@@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C(N)=O)NC(=O)C2(Cc3ccccc3C2)NC1=O
CHEMBL3264439,CHEMBL237,Kappa opioid receptor,Ki,=,158.6,nM,CHEMBL3268183,B,Displacement of [3H]diprenorphine from kappa opioid receptor (unknown origin) expressed in CHO cells membranes,CHEMBL3259577,KI,C[C@H]1CN(CCOC(=O)[C@H]2Cc3ccc(O)cc3CN2)CC[C@@]1(C)c1cccc(O)c1
CHEMBL3264440,CHEMBL237,Kappa opioid receptor,Ki,=,25.2,nM,CHEMBL3268183,B,Displacement of [3H]diprenorphine from kappa opioid receptor (unknown origin) expressed in CHO cells membranes,CHEMBL3259577,KI,C[C@H]1CN(CCCOC(=O)[C@H]2Cc3ccc(O)cc3CN2)CC[C@@]1(C)c1cccc(O)c1
CHEMBL3264441,CHEMBL237,Kappa opioid receptor,Ki,=,1.72,nM,CHEMBL3268183,B,Displacement of [3H]diprenorphine from kappa opioid receptor (unknown origin) expressed in CHO cells membranes,CHEMBL3259577,KI,CCOC(=O)C(CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)OC(=O)[C@H]1Cc2ccc(O)cc2CN1
CHEMBL2372399,CHEMBL237,Kappa opioid receptor,Ki,=,30.0,nM,CHEMBL3268183,B,Displacement of [3H]diprenorphine from kappa opioid receptor (unknown origin) expressed in CHO cells membranes,CHEMBL3259577,KI,CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)CNC(=O)[C@H](Cc2ccc(O)cc2)NCc2ccccc2)CC(=O)NC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)NC1=O
CHEMBL3262542,CHEMBL237,Kappa opioid receptor,Ki,=,516.0,nM,CHEMBL3270913,B,"Displacement of [3H]U69,593 from human kappa opioid receptor transfected in CHO cell membranes after 60 mins",CHEMBL3259735,KI,O=C1Cc2ccccc2N1C1CCN([C@H]2CC[C@@H]3CCCc4cccc2c43)CC1
CHEMBL3262543,CHEMBL237,Kappa opioid receptor,Ki,=,814.0,nM,CHEMBL3270913,B,"Displacement of [3H]U69,593 from human kappa opioid receptor transfected in CHO cell membranes after 60 mins",CHEMBL3259735,KI,O=C1Cc2ccccc2N1C1CCN([C@@H]2CC[C@@H]3CCCc4cccc2c43)CC1
CHEMBL3262544,CHEMBL237,Kappa opioid receptor,Ki,=,152.0,nM,CHEMBL3270913,B,"Displacement of [3H]U69,593 from human kappa opioid receptor transfected in CHO cell membranes after 60 mins",CHEMBL3259735,KI,CCC1C(=O)N(C2CCN([C@H]3CC[C@@H]4CCCc5cccc3c54)CC2)c2ccccc21
CHEMBL3262545,CHEMBL237,Kappa opioid receptor,Ki,=,184.0,nM,CHEMBL3270913,B,"Displacement of [3H]U69,593 from human kappa opioid receptor transfected in CHO cell membranes after 60 mins",CHEMBL3259735,KI,CCC1C(=O)N(C2CCN([C@@H]3CC[C@@H]4CCCc5cccc3c54)CC2)c2ccccc21
CHEMBL3262546,CHEMBL237,Kappa opioid receptor,Ki,=,56.3,nM,CHEMBL3270913,B,"Displacement of [3H]U69,593 from human kappa opioid receptor transfected in CHO cell membranes after 60 mins",CHEMBL3259735,KI,CCC1C(=O)N(C2CCN(C3CCCc4ccccc43)CC2)c2ccccc21
CHEMBL3262547,CHEMBL237,Kappa opioid receptor,Ki,=,15.13,nM,CHEMBL3270913,B,"Displacement of [3H]U69,593 from human kappa opioid receptor transfected in CHO cell membranes after 60 mins",CHEMBL3259735,KI,CCC1C(=O)N(C2CCN(C3CCc4ccccc4C3)CC2)c2ccccc21
CHEMBL3262548,CHEMBL237,Kappa opioid receptor,Ki,=,12.82,nM,CHEMBL3270913,B,"Displacement of [3H]U69,593 from human kappa opioid receptor transfected in CHO cell membranes after 60 mins",CHEMBL3259735,KI,CCC1C(=O)N(C2CCN(Cc3cccc4[nH]ccc34)CC2)c2ccccc21
CHEMBL3262549,CHEMBL237,Kappa opioid receptor,Ki,=,88.4,nM,CHEMBL3270913,B,"Displacement of [3H]U69,593 from human kappa opioid receptor transfected in CHO cell membranes after 60 mins",CHEMBL3259735,KI,CCC1C(=O)N(C2CCN(CCC(c3ccccc3)c3ccccc3)CC2)c2ccccc21
CHEMBL3262550,CHEMBL237,Kappa opioid receptor,Ki,=,4171.0,nM,CHEMBL3270913,B,"Displacement of [3H]U69,593 from human kappa opioid receptor transfected in CHO cell membranes after 60 mins",CHEMBL3259735,KI,CCC1C(=O)N(C2CCN(C(C)CC(c3ccccc3)c3ccccc3)CC2)c2ccccc21
CHEMBL3262551,CHEMBL237,Kappa opioid receptor,Ki,=,467.7,nM,CHEMBL3270913,B,"Displacement of [3H]U69,593 from human kappa opioid receptor transfected in CHO cell membranes after 60 mins",CHEMBL3259735,KI,CCC1C(=O)N(C2CCN(CCCc3ccccc3)CC2)c2ccccc21
CHEMBL3262552,CHEMBL237,Kappa opioid receptor,Ki,=,1367.0,nM,CHEMBL3270913,B,"Displacement of [3H]U69,593 from human kappa opioid receptor transfected in CHO cell membranes after 60 mins",CHEMBL3259735,KI,CCC1C(=O)N(C2CCN(C/C=C/c3ccccc3)CC2)c2ccccc21
CHEMBL440765,CHEMBL237,Kappa opioid receptor,Ki,=,1.05,nM,CHEMBL3270913,B,"Displacement of [3H]U69,593 from human kappa opioid receptor transfected in CHO cell membranes after 60 mins",CHEMBL3259735,KI,CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL3262088,CHEMBL237,Kappa opioid receptor,Ki,=,0.56,nM,CHEMBL3267130,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor transfected in CHO cells after 60 mins by beta-plate liquid scintillation counting analysis",CHEMBL3259633,KI,CC[C@](O)([C@H]1C[C@@]23CC[C@]1(OC)[C@@H]1Oc4c(O)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5)C(C)(C)C
CHEMBL511142,CHEMBL237,Kappa opioid receptor,Ki,=,0.089,nM,CHEMBL3269120,B,Displacement of [3H]diprenorphine from recombinant human kappa opioid receptor expressed in CHO cells,CHEMBL3259633,KI,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3262377,CHEMBL237,Kappa opioid receptor,Ki,=,0.39,nM,CHEMBL3269120,B,Displacement of [3H]diprenorphine from recombinant human kappa opioid receptor expressed in CHO cells,CHEMBL3259633,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@@](C)(O)c1ccncc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3262092,CHEMBL237,Kappa opioid receptor,Ki,=,0.88,nM,CHEMBL3267130,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor transfected in CHO cells after 60 mins by beta-plate liquid scintillation counting analysis",CHEMBL3259633,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@@H](O)c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3262363,CHEMBL237,Kappa opioid receptor,Ki,=,0.16,nM,CHEMBL3269120,B,Displacement of [3H]diprenorphine from recombinant human kappa opioid receptor expressed in CHO cells,CHEMBL3259633,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)c1ccccc1C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3262091,CHEMBL237,Kappa opioid receptor,Ki,=,0.36,nM,CHEMBL3267130,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor transfected in CHO cells after 60 mins by beta-plate liquid scintillation counting analysis",CHEMBL3259633,KI,CC[C@@](O)(c1ccccc1)[C@H]1C[C@@]23CC[C@]1(OC)[C@@H]1Oc4c(O)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5
CHEMBL3262089,CHEMBL237,Kappa opioid receptor,Ki,=,0.49,nM,CHEMBL3267130,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor transfected in CHO cells after 60 mins by beta-plate liquid scintillation counting analysis",CHEMBL3259633,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3262089,CHEMBL237,Kappa opioid receptor,Ki,=,0.044,nM,CHEMBL3269120,B,Displacement of [3H]diprenorphine from recombinant human kappa opioid receptor expressed in CHO cells,CHEMBL3259633,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3262372,CHEMBL237,Kappa opioid receptor,Ki,=,2.8,nM,CHEMBL3269120,B,Displacement of [3H]diprenorphine from recombinant human kappa opioid receptor expressed in CHO cells,CHEMBL3259633,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)c1cccs1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3262362,CHEMBL237,Kappa opioid receptor,Ki,=,0.75,nM,CHEMBL3267130,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor transfected in CHO cells after 60 mins by beta-plate liquid scintillation counting analysis",CHEMBL3259633,KI,CC[C@](O)([C@H]1C[C@@]23C=C[C@]1(OC)[C@@H]1Oc4c(O)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5)C(C)(C)C
CHEMBL3262361,CHEMBL237,Kappa opioid receptor,Ki,=,0.95,nM,CHEMBL3267130,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor transfected in CHO cells after 60 mins by beta-plate liquid scintillation counting analysis",CHEMBL3259633,KI,CC[C@@](O)(c1ccccc1)[C@H]1C[C@@]23C=C[C@]1(OC)[C@@H]1Oc4c(O)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5
CHEMBL3262093,CHEMBL237,Kappa opioid receptor,Ki,=,3.8,nM,CHEMBL3267130,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor transfected in CHO cells after 60 mins by beta-plate liquid scintillation counting analysis",CHEMBL3259633,KI,CO[C@]12C=C[C@@]3(C[C@@H]1[C@H](O)c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3262367,CHEMBL237,Kappa opioid receptor,Ki,=,0.1,nM,CHEMBL3269120,B,Displacement of [3H]diprenorphine from recombinant human kappa opioid receptor expressed in CHO cells,CHEMBL3259633,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)c1cc(C)cc(C)c1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL511142,CHEMBL237,Kappa opioid receptor,Ki,=,2.5,nM,CHEMBL3267130,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor transfected in CHO cells after 60 mins by beta-plate liquid scintillation counting analysis",CHEMBL3259633,KI,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3262090,CHEMBL237,Kappa opioid receptor,Ki,=,4.4,nM,CHEMBL3267130,B,"Displacement of [3H]-U69,593 from human kappa opioid receptor transfected in CHO cells after 60 mins by beta-plate liquid scintillation counting analysis",CHEMBL3259633,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@H](O)c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3291216,CHEMBL237,Kappa opioid receptor,Ki,=,0.08,nM,CHEMBL3293117,B,Binding affinity to human cloned kappa opioid receptor expressed in HEK293 cells by radioligand displacement assay,CHEMBL3286325,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@]2(OCCF)C=C[C@@]3(C[C@@H]2[C@@](C)(O)CCc2ccccc2)[C@H]1C5
CHEMBL281786,CHEMBL237,Kappa opioid receptor,Ki,=,0.02,nM,CHEMBL3293117,B,Binding affinity to human cloned kappa opioid receptor expressed in HEK293 cells by radioligand displacement assay,CHEMBL3286325,KI,CO[C@]12CC[C@@]3(C[C@@H]1C(C)(C)O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL511142,CHEMBL237,Kappa opioid receptor,Ki,=,0.07,nM,CHEMBL3293117,B,Binding affinity to human cloned kappa opioid receptor expressed in HEK293 cells by radioligand displacement assay,CHEMBL3286325,KI,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3291214,CHEMBL237,Kappa opioid receptor,Ki,=,0.2,nM,CHEMBL3293117,B,Binding affinity to human cloned kappa opioid receptor expressed in HEK293 cells by radioligand displacement assay,CHEMBL3286325,KI,CC(C)(O)[C@H]1C[C@@]23CC[C@@]1(OCCF)[C@@H]1Oc4c(O)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5
CHEMBL3291215,CHEMBL237,Kappa opioid receptor,Ki,=,0.12,nM,CHEMBL3293117,B,Binding affinity to human cloned kappa opioid receptor expressed in HEK293 cells by radioligand displacement assay,CHEMBL3286325,KI,CC(C)(C)[C@@](C)(O)[C@H]1C[C@@]23CC[C@]1(OCCF)[C@@H]1Oc4c(O)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5
CHEMBL3287466,CHEMBL237,Kappa opioid receptor,Ki,=,17.4,nM,CHEMBL3292385,B,Displacement of [3H]U-69593 from kappa-opioid receptor (unknown origin),CHEMBL3286318,KI,O=C1CC[C@@]23Cc4ccc(O)cc4[C@@]2(CCN(CC2CC2)C3)C1
CHEMBL3287467,CHEMBL237,Kappa opioid receptor,Ki,=,84.6,nM,CHEMBL3292385,B,Displacement of [3H]U-69593 from kappa-opioid receptor (unknown origin),CHEMBL3286318,KI,Oc1ccc2c(c1)[C@]13CCN(CC4CC4)C[C@@]1(C2)Cc1cc2ccccc2nc1C3
CHEMBL3287468,CHEMBL237,Kappa opioid receptor,Ki,=,879.0,nM,CHEMBL3292385,B,Displacement of [3H]U-69593 from kappa-opioid receptor (unknown origin),CHEMBL3286318,KI,Oc1ccc2c(c1)[C@]13CCN(CC4(O)CC4)C[C@@]1(C2)Cc1cc2ccccc2nc1C3
CHEMBL3287469,CHEMBL237,Kappa opioid receptor,Ki,=,594.0,nM,CHEMBL3292385,B,Displacement of [3H]U-69593 from kappa-opioid receptor (unknown origin),CHEMBL3286318,KI,Oc1ccc2c(c1)[C@]13CCN(Cc4ccccc4)C[C@@]1(C2)Cc1cc2ccccc2nc1C3
CHEMBL3287470,CHEMBL237,Kappa opioid receptor,Ki,=,195.0,nM,CHEMBL3292385,B,Displacement of [3H]U-69593 from kappa-opioid receptor (unknown origin),CHEMBL3286318,KI,CN1CC[C@]23Cc4nc5ccccc5cc4C[C@]2(Cc2ccc(O)cc23)C1
CHEMBL3309506,CHEMBL237,Kappa opioid receptor,Ki,=,20.4,nM,CHEMBL3361832,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,CN1C(=O)CCC2=C1[C@@H]1Oc3c(O)ccc4c3[C@@]13CCN(C)[C@H](C4)[C@]3(O)C2
CHEMBL3309507,CHEMBL237,Kappa opioid receptor,Ki,=,1.98,nM,CHEMBL3361832,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C2=C(CCC(=O)N2Cc2ccccc2)C[C@@]3(O)[C@H]1C5
CHEMBL3309508,CHEMBL237,Kappa opioid receptor,Ki,=,48.7,nM,CHEMBL3361832,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,CN1C(=O)[C@H](CCO)CC2=C1[C@@H]1Oc3c(O)ccc4c3[C@@]13CCN(C)[C@H](C4)[C@]3(O)C2
CHEMBL3309509,CHEMBL237,Kappa opioid receptor,Ki,=,182.0,nM,CHEMBL3361832,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,CN1C(=O)[C@@H](CCO)CC2=C1[C@@H]1Oc3c(O)ccc4c3[C@@]13CCN(C)[C@H](C4)[C@]3(O)C2
CHEMBL3309264,CHEMBL237,Kappa opioid receptor,Ki,=,4.68,nM,CHEMBL3361832,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C2=C(C[C@@H](CCO)C(=O)N2Cc2ccccc2)C[C@@]3(O)[C@H]1C5
CHEMBL3309510,CHEMBL237,Kappa opioid receptor,Ki,=,15.6,nM,CHEMBL3361832,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C2=C(C[C@H](CCO)C(=O)N2Cc2ccccc2)C[C@@]3(O)[C@H]1C5
CHEMBL3309511,CHEMBL237,Kappa opioid receptor,Ki,=,0.95,nM,CHEMBL3361832,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,C[C@@H]1CC2=C([C@@H]3Oc4c(O)ccc5c4[C@@]34CCN(CC3CC3)[C@H](C5)[C@]4(O)C2)N(Cc2ccccc2)C1=O
CHEMBL3309512,CHEMBL237,Kappa opioid receptor,Ki,=,0.71,nM,CHEMBL3361832,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,C[C@H]1CC2=C([C@@H]3Oc4c(O)ccc5c4[C@@]34CCN(CC3CC3)[C@H](C5)[C@]4(O)C2)N(Cc2ccccc2)C1=O
CHEMBL3309513,CHEMBL237,Kappa opioid receptor,Ki,=,1.29,nM,CHEMBL3361832,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,O=C1[C@H](CCO)CC2=C([C@@H]3Oc4c(O)ccc5c4[C@@]34CCN(CC3CC3)[C@H](C5)[C@]4(O)C2)N1Cc1ccccc1
CHEMBL3309514,CHEMBL237,Kappa opioid receptor,Ki,=,2.76,nM,CHEMBL3361832,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,O=C1[C@@H](CCO)CC2=C([C@@H]3Oc4c(O)ccc5c4[C@@]34CCN(CC3CC3)[C@H](C5)[C@]4(O)C2)N1Cc1ccccc1
CHEMBL3309515,CHEMBL237,Kappa opioid receptor,Ki,=,0.15,nM,CHEMBL3361832,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,O=C1CCC2=C([C@@H]3Oc4c(O)ccc5c4[C@@]34CCN(CC3CC3)[C@H](C5)[C@]4(O)C2)N1Cc1ccccc1
CHEMBL3309518,CHEMBL237,Kappa opioid receptor,Ki,=,0.33,nM,CHEMBL3361832,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,O=C1CCC2=C([C@@H]3Oc4c(O)ccc5c4[C@@]34CCN(CC3CC3)[C@H](C5)[C@]4(O)C2)N1CC1CCCCC1
CHEMBL3357966,CHEMBL237,Kappa opioid receptor,Ki,=,159.0,nM,CHEMBL3361832,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,CCOC(=O)Cc1c2c(n(Cc3ccccc3)c1O)[C@@H]1Oc3c(O)ccc4c3[C@@]13CCN(C)[C@H](C4)[C@]3(O)C2
CHEMBL3357967,CHEMBL237,Kappa opioid receptor,Ki,=,4.79,nM,CHEMBL3361832,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,CCOC(=O)Cc1c2c(n(Cc3ccccc3)c1O)[C@@H]1Oc3c(O)ccc4c3[C@@]13CCN(CC1CC1)[C@H](C4)[C@]3(O)C2
CHEMBL19019,CHEMBL237,Kappa opioid receptor,Ki,=,0.4,nM,CHEMBL3361832,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL567175,CHEMBL237,Kappa opioid receptor,Ki,=,10.1,nM,CHEMBL3361832,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL573214,CHEMBL237,Kappa opioid receptor,Ki,=,0.2,nM,CHEMBL3361832,B,Displacement of [3H]U69593 from human recombinant kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting method,CHEMBL3352469,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL441765,CHEMBL237,Kappa opioid receptor,Ki,=,2.9,nM,CHEMBL3366387,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in HEK293 cells by scintillation counting,CHEMBL3351525,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL445332,CHEMBL237,Kappa opioid receptor,Ki,=,2.9,nM,CHEMBL3385055,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin) expressed in HEK293T cells after 1.5 hrs by radioligand binding assay,CHEMBL3351980,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL3330663,CHEMBL237,Kappa opioid receptor,Ki,=,18.1,nM,CHEMBL3385055,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin) expressed in HEK293T cells after 1.5 hrs by radioligand binding assay,CHEMBL3351980,KI,C=CC(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL370912,CHEMBL237,Kappa opioid receptor,Ki,=,34.0,nM,CHEMBL3385055,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin) expressed in HEK293T cells after 1.5 hrs by radioligand binding assay,CHEMBL3351980,KI,C=C(C)C(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL3330664,CHEMBL237,Kappa opioid receptor,Ki,=,385.0,nM,CHEMBL3385055,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin) expressed in HEK293T cells after 1.5 hrs by radioligand binding assay,CHEMBL3351980,KI,COC(=O)[C@@H]1C[C@H](OC(=O)C=C(C)C)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL3330665,CHEMBL237,Kappa opioid receptor,Ki,=,6.0,nM,CHEMBL3385055,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin) expressed in HEK293T cells after 1.5 hrs by radioligand binding assay,CHEMBL3351980,KI,C=C(C)CC(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL3330666,CHEMBL237,Kappa opioid receptor,Ki,=,25.3,nM,CHEMBL3385055,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin) expressed in HEK293T cells after 1.5 hrs by radioligand binding assay,CHEMBL3351980,KI,C/C=C/C(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL3330667,CHEMBL237,Kappa opioid receptor,Ki,=,10.0,nM,CHEMBL3385055,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin) expressed in HEK293T cells after 1.5 hrs by radioligand binding assay,CHEMBL3351980,KI,C=CCC(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL3330668,CHEMBL237,Kappa opioid receptor,Ki,=,153.0,nM,CHEMBL3385055,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin) expressed in HEK293T cells after 1.5 hrs by radioligand binding assay,CHEMBL3351980,KI,C/C=C(\C)C(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL3330669,CHEMBL237,Kappa opioid receptor,Ki,=,28.8,nM,CHEMBL3385055,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin) expressed in HEK293T cells after 1.5 hrs by radioligand binding assay,CHEMBL3351980,KI,C=CC(C)C(=O)O[C@H]1C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL3330670,CHEMBL237,Kappa opioid receptor,Ki,=,9.6,nM,CHEMBL3385055,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin) expressed in HEK293T cells after 1.5 hrs by radioligand binding assay,CHEMBL3351980,KI,COC(=O)[C@@H]1C[C@H](OC(=O)/C=C/c2ccccc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL3330671,CHEMBL237,Kappa opioid receptor,Ki,=,64.9,nM,CHEMBL3385055,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin) expressed in HEK293T cells after 1.5 hrs by radioligand binding assay,CHEMBL3351980,KI,COC(=O)[C@@H]1C[C@H](OC(=O)/C=C/c2ccccc2OC)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL3330672,CHEMBL237,Kappa opioid receptor,Ki,=,134.8,nM,CHEMBL3385055,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin) expressed in HEK293T cells after 1.5 hrs by radioligand binding assay,CHEMBL3351980,KI,COC(=O)[C@@H]1C[C@H](OC(=O)/C=C/c2ccc(OC)cc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL3330673,CHEMBL237,Kappa opioid receptor,Ki,=,581.0,nM,CHEMBL3385055,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin) expressed in HEK293T cells after 1.5 hrs by radioligand binding assay,CHEMBL3351980,KI,COC(=O)[C@@H]1C[C@H](OC(=O)/C=C/c2cc(OC)ccc2OC)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL3330674,CHEMBL237,Kappa opioid receptor,Ki,=,161.5,nM,CHEMBL3385055,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin) expressed in HEK293T cells after 1.5 hrs by radioligand binding assay,CHEMBL3351980,KI,COC(=O)[C@@H]1C[C@H](OC(=O)/C=C/c2ccc(OC)cc2OC)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL3330676,CHEMBL237,Kappa opioid receptor,Ki,=,323.0,nM,CHEMBL3385055,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin) expressed in HEK293T cells after 1.5 hrs by radioligand binding assay,CHEMBL3351980,KI,COC(=O)[C@@H]1C[C@H](OC(=O)/C=C/c2ccc3c(c2)OCO3)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL3330677,CHEMBL237,Kappa opioid receptor,Ki,=,148.3,nM,CHEMBL3385055,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin) expressed in HEK293T cells after 1.5 hrs by radioligand binding assay,CHEMBL3351980,KI,COC(=O)[C@@H]1C[C@H](OC(=O)/C=C/c2ccccc2[N+](=O)[O-])C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL3330678,CHEMBL237,Kappa opioid receptor,Ki,=,280.5,nM,CHEMBL3385055,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin) expressed in HEK293T cells after 1.5 hrs by radioligand binding assay,CHEMBL3351980,KI,COC(=O)[C@@H]1C[C@H](OC(=O)/C=C/c2ccc([N+](=O)[O-])cc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL3330679,CHEMBL237,Kappa opioid receptor,Ki,=,129.5,nM,CHEMBL3385055,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin) expressed in HEK293T cells after 1.5 hrs by radioligand binding assay,CHEMBL3351980,KI,COC(=O)[C@@H]1C[C@H](OC(=O)/C=C/c2ccccc2C(F)(F)F)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL3330683,CHEMBL237,Kappa opioid receptor,Ki,=,304.0,nM,CHEMBL3385055,B,Displacement of [3H]U69593 from kappa opioid receptor (unknown origin) expressed in HEK293T cells after 1.5 hrs by radioligand binding assay,CHEMBL3351980,KI,COC(=O)[C@@H]1C[C@H](OC(=O)/C=C/c2ccsc2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL3326224,CHEMBL237,Kappa opioid receptor,Ki,=,2.3,nM,CHEMBL3362478,B,Binding affinity to human kappa opioid receptor,CHEMBL3351750,KI,CN(C)[C@]1(c2ccccc2)CC[C@]2(CC1)OCCc1c3ccccc3[nH]c12.Cl
CHEMBL300662,CHEMBL237,Kappa opioid receptor,Ki,=,4.7,nM,CHEMBL3369357,B,Binding affinity to human kappa opioid receptor expressed in CHO cells,CHEMBL3352410,KI,C[C@H]1CN(CC[C@H](O)C2CCCCC2)CC[C@@]1(C)c1cccc(O)c1
CHEMBL3326796,CHEMBL237,Kappa opioid receptor,Ki,=,749.0,nM,CHEMBL3369357,B,Binding affinity to human kappa opioid receptor expressed in CHO cells,CHEMBL3352410,KI,C[C@H]1CN(CC[C@H](O)C2CCCCC2)CC[C@@]1(C)c1ccccc1
CHEMBL3325957,CHEMBL237,Kappa opioid receptor,Ki,=,2.6,nM,CHEMBL3366611,B,Binding affinity to human kappa opioid receptor,CHEMBL3352090,KI,CN(C)[C@]1(c2ccccc2)CC[C@]2(CC1)OCCc1c3cc(F)ccc3[nH]c12.O=C(O)CC(O)(CC(=O)O)C(=O)O
CHEMBL3360832,CHEMBL237,Kappa opioid receptor,Ki,=,4.83,nM,CHEMBL3387191,B,Displacement of [3H]U-69593 from human KOR expressed in HEK293 cells after 60 mins by scintillation counting analysis,CHEMBL3351542,KI,N=C(N)NCCC[C@H](N)C(=O)NCC1(Nc2ccccc2)CCN(Cc2ccccc2)CC1
CHEMBL3361416,CHEMBL237,Kappa opioid receptor,Ki,=,1233.0,nM,CHEMBL3387191,B,Displacement of [3H]U-69593 from human KOR expressed in HEK293 cells after 60 mins by scintillation counting analysis,CHEMBL3351542,KI,N=C(N)NCC(=O)NCC1(Nc2ccccc2)CCN(Cc2ccccc2)CC1
CHEMBL3361418,CHEMBL237,Kappa opioid receptor,Ki,=,705.0,nM,CHEMBL3387191,B,Displacement of [3H]U-69593 from human KOR expressed in HEK293 cells after 60 mins by scintillation counting analysis,CHEMBL3351542,KI,N=C(N)NCC(=O)NCC1(Nc2cccc3ccccc23)CCN(Cc2ccccc2)CC1
CHEMBL3361419,CHEMBL237,Kappa opioid receptor,Ki,=,3678.0,nM,CHEMBL3387191,B,Displacement of [3H]U-69593 from human KOR expressed in HEK293 cells after 60 mins by scintillation counting analysis,CHEMBL3351542,KI,COc1cc(NC2(CNC(=O)CNC(=N)N)CCN(Cc3ccccc3)CC2)cc(OC)c1
CHEMBL3361423,CHEMBL237,Kappa opioid receptor,Ki,=,4247.0,nM,CHEMBL3387191,B,Displacement of [3H]U-69593 from human KOR expressed in HEK293 cells after 60 mins by scintillation counting analysis,CHEMBL3351542,KI,N=C(N)NCC(=O)NCC1(Cc2ccccc2)CCN(Cc2ccccc2)CC1
CHEMBL3361425,CHEMBL237,Kappa opioid receptor,Ki,=,224.0,nM,CHEMBL3387191,B,Displacement of [3H]U-69593 from human KOR expressed in HEK293 cells after 60 mins by scintillation counting analysis,CHEMBL3351542,KI,N=C(N)NCCNC(=O)C1(Nc2ccccc2)CCN(Cc2ccccc2)CC1
CHEMBL3361433,CHEMBL237,Kappa opioid receptor,Ki,=,1470.0,nM,CHEMBL3387191,B,Displacement of [3H]U-69593 from human KOR expressed in HEK293 cells after 60 mins by scintillation counting analysis,CHEMBL3351542,KI,N=C(N)NCC(=O)NCC1(Cc2cccc3ccccc23)CCN(Cc2ccccc2)CC1
CHEMBL80,CHEMBL237,Kappa opioid receptor,Ki,=,362.0,nM,CHEMBL3387191,B,Displacement of [3H]U-69593 from human KOR expressed in HEK293 cells after 60 mins by scintillation counting analysis,CHEMBL3351542,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL1921847,CHEMBL237,Kappa opioid receptor,Ki,=,0.8,nM,CHEMBL3399793,B,Antagonist activity at kappa opioid receptor (unknown origin),CHEMBL3396991,KI,Cc1cc(C)cc([C@@H]2CCCN2Cc2ccc(Oc3ccc(C(N)=O)cc3F)cc2)c1
CHEMBL573214,CHEMBL237,Kappa opioid receptor,Ki,=,0.15,nM,CHEMBL3399793,B,Antagonist activity at kappa opioid receptor (unknown origin),CHEMBL3396991,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL415247,CHEMBL237,Kappa opioid receptor,Ki,=,0.03,nM,CHEMBL3399793,B,Antagonist activity at kappa opioid receptor (unknown origin),CHEMBL3396991,KI,CC(C)[C@@H](CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)NC(=O)[C@H]1Cc2ccc(O)cc2CN1
CHEMBL70,CHEMBL237,Kappa opioid receptor,Ki,=,299.0,nM,CHEMBL3413015,B,"Displacement of [3H]U69,593 from human recombinant opioid kappa receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method",CHEMBL3407384,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL440765,CHEMBL237,Kappa opioid receptor,Ki,=,3.5,nM,CHEMBL3413015,B,"Displacement of [3H]U69,593 from human recombinant opioid kappa receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method",CHEMBL3407384,KI,CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL3409100,CHEMBL237,Kappa opioid receptor,Ki,=,110.0,nM,CHEMBL3413015,B,"Displacement of [3H]U69,593 from human recombinant opioid kappa receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method",CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCc3ccccc3)CCN(CCc3ccccc3)C[C@@H]1O2
CHEMBL3409101,CHEMBL237,Kappa opioid receptor,Ki,=,110.0,nM,CHEMBL3413015,B,"Displacement of [3H]U69,593 from human recombinant opioid kappa receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method",CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCc3ccccc3)CCN(CCc3ccc(F)cc3)C[C@@H]1O2
CHEMBL3409102,CHEMBL237,Kappa opioid receptor,Ki,=,160.0,nM,CHEMBL3413015,B,"Displacement of [3H]U69,593 from human recombinant opioid kappa receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method",CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCc3ccccc3)CCN(CCc3ccccc3F)C[C@@H]1O2
CHEMBL3409103,CHEMBL237,Kappa opioid receptor,Ki,=,88.0,nM,CHEMBL3413015,B,"Displacement of [3H]U69,593 from human recombinant opioid kappa receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method",CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCc3ccccc3)CCN(CCCc3ccccc3)C[C@@H]1O2
CHEMBL3409104,CHEMBL237,Kappa opioid receptor,Ki,=,139.0,nM,CHEMBL3413015,B,"Displacement of [3H]U69,593 from human recombinant opioid kappa receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method",CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCc3ccccc3)CCN(CCc3ccc(C(F)(F)F)cc3)C[C@@H]1O2
CHEMBL3409105,CHEMBL237,Kappa opioid receptor,Ki,=,5.1,nM,CHEMBL3413015,B,"Displacement of [3H]U69,593 from human recombinant opioid kappa receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method",CHEMBL3407384,KI,C=CCN1CC[C@@]2(CCCc3ccccc3)c3cc(O)ccc3O[C@H]2C1
CHEMBL3409106,CHEMBL237,Kappa opioid receptor,Ki,=,1.4,nM,CHEMBL3413015,B,"Displacement of [3H]U69,593 from human recombinant opioid kappa receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method",CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCc3ccccc3)CCN(CC3CC3)C[C@@H]1O2
CHEMBL3409107,CHEMBL237,Kappa opioid receptor,Ki,=,795.0,nM,CHEMBL3413015,B,"Displacement of [3H]U69,593 from human recombinant opioid kappa receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method",CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCc3ccccc3)CCN(CCc3ccccc3C(F)(F)F)C[C@@H]1O2
CHEMBL3409108,CHEMBL237,Kappa opioid receptor,Ki,=,923.0,nM,CHEMBL3413015,B,"Displacement of [3H]U69,593 from human recombinant opioid kappa receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method",CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCc3ccccc3)CCN(CCc3cccc(C(F)(F)F)c3)C[C@@H]1O2
CHEMBL3409109,CHEMBL237,Kappa opioid receptor,Ki,=,117.0,nM,CHEMBL3413015,B,"Displacement of [3H]U69,593 from human recombinant opioid kappa receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method",CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCCc3ccccc3)CCN(CCc3ccccc3)C[C@@H]1O2
CHEMBL3409110,CHEMBL237,Kappa opioid receptor,Ki,=,147.0,nM,CHEMBL3413015,B,"Displacement of [3H]U69,593 from human recombinant opioid kappa receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method",CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCCc3ccccc3)CCN(CCc3ccc(F)cc3)C[C@@H]1O2
CHEMBL3409111,CHEMBL237,Kappa opioid receptor,Ki,=,230.0,nM,CHEMBL3413015,B,"Displacement of [3H]U69,593 from human recombinant opioid kappa receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method",CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCCc3ccccc3)CCN(CCc3ccccc3F)C[C@@H]1O2
CHEMBL3409112,CHEMBL237,Kappa opioid receptor,Ki,=,424.0,nM,CHEMBL3413015,B,"Displacement of [3H]U69,593 from human recombinant opioid kappa receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method",CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCCc3ccccc3)CCN(CCCc3ccccc3)C[C@@H]1O2
CHEMBL3409113,CHEMBL237,Kappa opioid receptor,Ki,=,163.0,nM,CHEMBL3413015,B,"Displacement of [3H]U69,593 from human recombinant opioid kappa receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method",CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCCc3ccccc3)CCN(CCc3ccc(C(F)(F)F)cc3)C[C@@H]1O2
CHEMBL3409114,CHEMBL237,Kappa opioid receptor,Ki,=,1.6,nM,CHEMBL3413015,B,"Displacement of [3H]U69,593 from human recombinant opioid kappa receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method",CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCCc3ccccc3)CCN(CC3CC3)C[C@@H]1O2
CHEMBL3409115,CHEMBL237,Kappa opioid receptor,Ki,=,1769.0,nM,CHEMBL3413015,B,"Displacement of [3H]U69,593 from human recombinant opioid kappa receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method",CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCCc3ccccc3)CCN(CCc3ccccc3C(F)(F)F)C[C@@H]1O2
CHEMBL3409116,CHEMBL237,Kappa opioid receptor,Ki,=,410.0,nM,CHEMBL3413015,B,"Displacement of [3H]U69,593 from human recombinant opioid kappa receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method",CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCCc3ccccc3)CCN(CCCCc3ccccc3)C[C@@H]1O2
CHEMBL3409117,CHEMBL237,Kappa opioid receptor,Ki,=,3184.0,nM,CHEMBL3413015,B,"Displacement of [3H]U69,593 from human recombinant opioid kappa receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method",CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCCc3ccccc3)CCN(CCc3cccc(C(F)(F)F)c3)C[C@@H]1O2
CHEMBL3409118,CHEMBL237,Kappa opioid receptor,Ki,=,82.0,nM,CHEMBL3413015,B,"Displacement of [3H]U69,593 from human recombinant opioid kappa receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method",CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCCCc3ccccc3)CCN(CCc3ccccc3)C[C@@H]1O2
CHEMBL3409119,CHEMBL237,Kappa opioid receptor,Ki,=,130.0,nM,CHEMBL3413015,B,"Displacement of [3H]U69,593 from human recombinant opioid kappa receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method",CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCCCc3ccccc3)CCN(CCc3ccc(F)cc3)C[C@@H]1O2
CHEMBL3409120,CHEMBL237,Kappa opioid receptor,Ki,=,177.0,nM,CHEMBL3413015,B,"Displacement of [3H]U69,593 from human recombinant opioid kappa receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method",CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCCCc3ccccc3)CCN(CCc3ccccc3F)C[C@@H]1O2
CHEMBL3409121,CHEMBL237,Kappa opioid receptor,Ki,=,297.0,nM,CHEMBL3413015,B,"Displacement of [3H]U69,593 from human recombinant opioid kappa receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method",CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCCCc3ccccc3)CCN(CCc3ccc(C(F)(F)F)cc3)C[C@@H]1O2
CHEMBL3409122,CHEMBL237,Kappa opioid receptor,Ki,=,3.7,nM,CHEMBL3413015,B,"Displacement of [3H]U69,593 from human recombinant opioid kappa receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method",CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCCCc3ccccc3)CCN(CC3CC3)C[C@@H]1O2
CHEMBL3409123,CHEMBL237,Kappa opioid receptor,Ki,=,1119.0,nM,CHEMBL3413015,B,"Displacement of [3H]U69,593 from human recombinant opioid kappa receptor expressed in CHO cell membranes after 2 hrs by liquid scintillation counting method",CHEMBL3407384,KI,Oc1ccc2c(c1)[C@]1(CCCCCc3ccccc3)CCN(CCc3ccccc3C(F)(F)F)C[C@@H]1O2
CHEMBL511142,CHEMBL237,Kappa opioid receptor,Ki,=,0.089,nM,CHEMBL3583931,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by beta counting method,CHEMBL3580663,KI,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3262089,CHEMBL237,Kappa opioid receptor,Ki,=,0.044,nM,CHEMBL3583931,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by beta counting method,CHEMBL3580663,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3581740,CHEMBL237,Kappa opioid receptor,Ki,=,0.08,nM,CHEMBL3583931,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by beta counting method,CHEMBL3580663,KI,CO[C@]12C=C[C@@]3(C[C@]1(C)[C@H](O)c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3581741,CHEMBL237,Kappa opioid receptor,Ki,=,0.04,nM,CHEMBL3583931,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by beta counting method,CHEMBL3580663,KI,CO[C@]12C=C[C@@]3(C[C@]1(C)[C@H](O)c1cccc(C)c1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3581743,CHEMBL237,Kappa opioid receptor,Ki,=,0.05,nM,CHEMBL3583931,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by beta counting method,CHEMBL3580663,KI,CO[C@]12C=C[C@@]3(C[C@]1(C)[C@H](O)c1ccc(F)cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3581750,CHEMBL237,Kappa opioid receptor,Ki,=,0.04,nM,CHEMBL3583931,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by beta counting method,CHEMBL3580663,KI,CO[C@]12CC[C@@]3(C[C@]1(C)[C@H](O)c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3581751,CHEMBL237,Kappa opioid receptor,Ki,=,0.12,nM,CHEMBL3583931,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by beta counting method,CHEMBL3580663,KI,CO[C@]12CC[C@@]3(C[C@]1(C)[C@H](O)c1ccccc1C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3581752,CHEMBL237,Kappa opioid receptor,Ki,=,0.11,nM,CHEMBL3583931,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by beta counting method,CHEMBL3580663,KI,CO[C@]12CC[C@@]3(C[C@]1(C)[C@H](O)c1cccc(C)c1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3581753,CHEMBL237,Kappa opioid receptor,Ki,=,0.16,nM,CHEMBL3583931,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by beta counting method,CHEMBL3580663,KI,CO[C@]12CC[C@@]3(C[C@]1(C)[C@H](O)c1ccc(C)cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3581754,CHEMBL237,Kappa opioid receptor,Ki,=,0.1,nM,CHEMBL3583931,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by beta counting method,CHEMBL3580663,KI,CO[C@]12CC[C@@]3(C[C@]1(C)[C@H](O)c1ccc(F)cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3581756,CHEMBL237,Kappa opioid receptor,Ki,=,0.094,nM,CHEMBL3583931,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by beta counting method,CHEMBL3580663,KI,CO[C@]12CC[C@@]3(C[C@]1(C)[C@H](O)c1cccc(Cl)c1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3581757,CHEMBL237,Kappa opioid receptor,Ki,=,0.13,nM,CHEMBL3583931,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by beta counting method,CHEMBL3580663,KI,CO[C@]12CC[C@@]3(C[C@]1(C)[C@H](O)c1cccc(F)c1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3581762,CHEMBL237,Kappa opioid receptor,Ki,=,0.14,nM,CHEMBL3583931,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by beta counting method,CHEMBL3580663,KI,CO[C@]12CC[C@@]3(C[C@]1(C)[C@H](O)c1ccoc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3596365,CHEMBL237,Kappa opioid receptor,Ki,=,397.0,nM,CHEMBL3598352,B,"Displacement of [3H]U-69,593 from human KOR expressed in CHO cells",CHEMBL3596130,KI,Cl.Oc1ccc2c3c1O[C@H]1c4[nH]c5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CCF)CC[C@]314
CHEMBL3596364,CHEMBL237,Kappa opioid receptor,Ki,=,74.3,nM,CHEMBL3598352,B,"Displacement of [3H]U-69,593 from human KOR expressed in CHO cells",CHEMBL3596130,KI,CCCN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccccc4c2C[C@@]3(O)[C@H]1C5.Cl
CHEMBL3596363,CHEMBL237,Kappa opioid receptor,Ki,=,468.0,nM,CHEMBL3598352,B,"Displacement of [3H]U-69,593 from human KOR expressed in CHO cells",CHEMBL3596130,KI,CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccccc4c2C[C@@]3(O)[C@H]1C5.Cl
CHEMBL567175,CHEMBL237,Kappa opioid receptor,Ki,=,14.7,nM,CHEMBL3598352,B,"Displacement of [3H]U-69,593 from human KOR expressed in CHO cells",CHEMBL3596130,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL610012,CHEMBL237,Kappa opioid receptor,Ki,=,11.0,nM,CHEMBL3598352,B,"Displacement of [3H]U-69,593 from human KOR expressed in CHO cells",CHEMBL3596130,KI,Oc1ccc2c3c1O[C@H]1c4nc5ccccc5cc4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL3596368,CHEMBL237,Kappa opioid receptor,Ki,=,477.0,nM,CHEMBL3598352,B,"Displacement of [3H]U-69,593 from human KOR expressed in CHO cells",CHEMBL3596130,KI,CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2nc4ccccc4cc2C[C@@]3(O)[C@H]1C5.Cl
CHEMBL3596369,CHEMBL237,Kappa opioid receptor,Ki,=,313.0,nM,CHEMBL3598352,B,"Displacement of [3H]U-69,593 from human KOR expressed in CHO cells",CHEMBL3596130,KI,CCCN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2nc4ccccc4cc2C[C@@]3(O)[C@H]1C5.Cl
CHEMBL3596370,CHEMBL237,Kappa opioid receptor,Ki,=,854.0,nM,CHEMBL3598352,B,"Displacement of [3H]U-69,593 from human KOR expressed in CHO cells",CHEMBL3596130,KI,Cl.Oc1ccc2c3c1O[C@H]1c4nc5ccccc5cc4C[C@@]4(O)[C@@H](C2)N(CCF)CC[C@]314
CHEMBL3597074,CHEMBL237,Kappa opioid receptor,Ki,=,100.0,nM,CHEMBL3599489,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)CCNC(=O)[C@H](Cc1ccccc1)N(C)C(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL3597073,CHEMBL237,Kappa opioid receptor,Ki,=,45.0,nM,CHEMBL3599489,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccccc1)N(C)C(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL3597072,CHEMBL237,Kappa opioid receptor,Ki,=,340.0,nM,CHEMBL3599489,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)N(C)C(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL3597071,CHEMBL237,Kappa opioid receptor,Ki,=,200.0,nM,CHEMBL3599489,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CCNC(=O)[C@H](Cc1ccccc1)N(C)C(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL38874,CHEMBL237,Kappa opioid receptor,Ki,=,270.0,nM,CHEMBL3599489,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL3597075,CHEMBL237,Kappa opioid receptor,Ki,=,19.0,nM,CHEMBL3599489,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)N(C)C(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL3597076,CHEMBL237,Kappa opioid receptor,Ki,=,59.0,nM,CHEMBL3599489,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccccc1)N(C)C(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL3597077,CHEMBL237,Kappa opioid receptor,Ki,=,430.0,nM,CHEMBL3599489,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccccc1)N(C)C(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL3597078,CHEMBL237,Kappa opioid receptor,Ki,=,11.0,nM,CHEMBL3599489,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccccc1)N(C)C(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL3597082,CHEMBL237,Kappa opioid receptor,Ki,=,340.0,nM,CHEMBL3599489,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccccc1)N(C)C(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL3597083,CHEMBL237,Kappa opioid receptor,Ki,=,42.0,nM,CHEMBL3599489,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)[C@@H](C)O)C(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)C(N)=O
CHEMBL3597084,CHEMBL237,Kappa opioid receptor,Ki,=,2.3,nM,CHEMBL3599489,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)[C@@H](C)O)C(N)=O
CHEMBL3597085,CHEMBL237,Kappa opioid receptor,Ki,=,14.0,nM,CHEMBL3599489,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)[C@@H](C)O)C(N)=O
CHEMBL3597086,CHEMBL237,Kappa opioid receptor,Ki,=,9.7,nM,CHEMBL3599489,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)[C@@H](C)O)C(N)=O
CHEMBL3597087,CHEMBL237,Kappa opioid receptor,Ki,=,78.0,nM,CHEMBL3599489,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)[C@@H](C)O)C(N)=O
CHEMBL3597088,CHEMBL237,Kappa opioid receptor,Ki,=,39.0,nM,CHEMBL3599489,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO)NC(=O)CCCNC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)[C@@H](C)O)C(N)=O
CHEMBL3597150,CHEMBL237,Kappa opioid receptor,Ki,=,71.0,nM,CHEMBL3599489,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)CCCNC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)[C@@H](C)O)C(N)=O
CHEMBL3597151,CHEMBL237,Kappa opioid receptor,Ki,=,11.0,nM,CHEMBL3599489,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CCCNC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)[C@@H](C)O)C(N)=O
CHEMBL3597152,CHEMBL237,Kappa opioid receptor,Ki,=,52.0,nM,CHEMBL3599489,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CCCNC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)[C@@H](C)O)C(N)=O
CHEMBL3597153,CHEMBL237,Kappa opioid receptor,Ki,=,12.0,nM,CHEMBL3599489,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting analysis,CHEMBL3596173,KI,CC(C)C[C@H](NC(=O)[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CCCCNC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)[C@@H](C)O)C(N)=O
CHEMBL3597154,CHEMBL237,Kappa opioid receptor,Ki,=,2000.0,nM,CHEMBL3599495,B,Binding affinity to kappa opioid receptor (unknown origin),CHEMBL3596173,KI,CC1(C)SCCSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H]1C(N)=O
CHEMBL482811,CHEMBL237,Kappa opioid receptor,Ki,=,2.7,nM,CHEMBL3626670,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes,CHEMBL3621128,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1.CS(=O)(=O)O
CHEMBL424698,CHEMBL237,Kappa opioid receptor,Ki,=,0.73,nM,CHEMBL3626670,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes,CHEMBL3621128,KI,COC(=O)[C@@H]1C[C@H](O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL445332,CHEMBL237,Kappa opioid receptor,Ki,=,1.3,nM,CHEMBL3626670,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes,CHEMBL3621128,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL140050,CHEMBL237,Kappa opioid receptor,Ki,=,0.5,nM,CHEMBL3626670,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes,CHEMBL3621128,KI,CCC[C@@](C)(O)[C@H]1C[C@@]23C=C[C@]1(OC)[C@@H]1Oc4c(O)ccc5c4[C@@]12CCN(C)[C@@H]3C5
CHEMBL3622718,CHEMBL237,Kappa opioid receptor,Ki,=,316.0,nM,CHEMBL3626670,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes,CHEMBL3621128,KI,COC[C@@]1(CCOCCI)C[C@@H](C(=O)OC)[C@]2(C)CC[C@@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL3622717,CHEMBL237,Kappa opioid receptor,Ki,=,108.0,nM,CHEMBL3626670,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes,CHEMBL3621128,KI,COC[C@@]1(CCOCCI)C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL3622715,CHEMBL237,Kappa opioid receptor,Ki,=,250.0,nM,CHEMBL3626670,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes,CHEMBL3621128,KI,C=CC[C@]1(COC)C[C@@H](C(=O)OC)[C@]2(C)CC[C@@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL3622714,CHEMBL237,Kappa opioid receptor,Ki,=,48.0,nM,CHEMBL3626670,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes,CHEMBL3621128,KI,C=CC[C@]1(COC)C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL3622710,CHEMBL237,Kappa opioid receptor,Ki,=,210.0,nM,CHEMBL3626670,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes,CHEMBL3621128,KI,CC[C@]1(COC)C[C@@H](C(=O)OC)[C@]2(C)CC[C@@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL3622711,CHEMBL237,Kappa opioid receptor,Ki,=,301.0,nM,CHEMBL3626670,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes,CHEMBL3621128,KI,CC[C@]1(COC)C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL3622712,CHEMBL237,Kappa opioid receptor,Ki,=,20.5,nM,CHEMBL3626670,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes,CHEMBL3621128,KI,COC[C@@]1(C)C[C@@H](C(=O)OC)[C@]2(C)CC[C@@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL3622713,CHEMBL237,Kappa opioid receptor,Ki,=,4.7,nM,CHEMBL3626670,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes,CHEMBL3621128,KI,COC[C@@]1(C)C[C@@H](C(=O)OC)[C@]2(C)CC[C@H]3C(=O)O[C@H](c4ccoc4)C[C@]3(C)[C@H]2C1=O
CHEMBL3634396,CHEMBL237,Kappa opioid receptor,Ki,=,1200.0,nM,CHEMBL3637629,B,Binding affinity to kappa opioid receptor (unknown origin),CHEMBL3632621,KI,COC(=O)N1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)[C@@H]2[C@H]1CCC[C@@H]2N1CCCC1
CHEMBL267495,CHEMBL237,Kappa opioid receptor,Ki,=,170.0,nM,CHEMBL3637629,B,Binding affinity to kappa opioid receptor (unknown origin),CHEMBL3632621,KI,CN(C(=O)/C=C/c1ccoc1)[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL58033,CHEMBL237,Kappa opioid receptor,Ki,=,340.0,nM,CHEMBL3637629,B,Binding affinity to kappa opioid receptor (unknown origin),CHEMBL3632621,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@H]1CCCC[C@@H]1N1CCCC1
CHEMBL603370,CHEMBL237,Kappa opioid receptor,Ki,=,360.0,nM,CHEMBL3637629,B,Binding affinity to kappa opioid receptor (unknown origin),CHEMBL3632621,KI,COC(=O)N1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)C(CN2CCCC2)C1
CHEMBL3299005,CHEMBL237,Kappa opioid receptor,Ki,=,9.4,nM,CHEMBL3637629,B,Binding affinity to kappa opioid receptor (unknown origin),CHEMBL3632621,KI,COC(=O)N1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)[C@H]2[C@H]1CCC[C@@H]2N1CCCC1
CHEMBL3634252,CHEMBL237,Kappa opioid receptor,Ki,=,48.0,nM,CHEMBL3636125,B,Displacement of [3H]diprenorphine from human kappa-opioid receptor expressed in CHO cell membrane for 1 hr by liquid scintillation counting analysis,CHEMBL3632584,KI,CC(=O)N1CC[C@@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)c2cc(Cc3ccc4ccccc4c3)ccc21
CHEMBL3634253,CHEMBL237,Kappa opioid receptor,Ki,=,92.0,nM,CHEMBL3636125,B,Displacement of [3H]diprenorphine from human kappa-opioid receptor expressed in CHO cell membrane for 1 hr by liquid scintillation counting analysis,CHEMBL3632584,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCCc2ccc(Cc3ccc4ccccc4c3)cc21
CHEMBL2322561,CHEMBL237,Kappa opioid receptor,Ki,=,17.0,nM,CHEMBL3636125,B,Displacement of [3H]diprenorphine from human kappa-opioid receptor expressed in CHO cell membrane for 1 hr by liquid scintillation counting analysis,CHEMBL3632584,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCNc2ccc(Cc3cccc4ccccc34)cc21
CHEMBL3634254,CHEMBL237,Kappa opioid receptor,Ki,=,4.3,nM,CHEMBL3636125,B,Displacement of [3H]diprenorphine from human kappa-opioid receptor expressed in CHO cell membrane for 1 hr by liquid scintillation counting analysis,CHEMBL3632584,KI,CC(=O)N1CC[C@@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)c2cc(Cc3cccc4ccccc34)ccc21
CHEMBL3634255,CHEMBL237,Kappa opioid receptor,Ki,=,63.0,nM,CHEMBL3636125,B,Displacement of [3H]diprenorphine from human kappa-opioid receptor expressed in CHO cell membrane for 1 hr by liquid scintillation counting analysis,CHEMBL3632584,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCCc2ccc(Cc3cccc4ccccc34)cc21
CHEMBL2322563,CHEMBL237,Kappa opioid receptor,Ki,=,1.2,nM,CHEMBL3636125,B,Displacement of [3H]diprenorphine from human kappa-opioid receptor expressed in CHO cell membrane for 1 hr by liquid scintillation counting analysis,CHEMBL3632584,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCNc2ccc(CC3Cc4ccccc4C3)cc21
CHEMBL3634256,CHEMBL237,Kappa opioid receptor,Ki,=,12.0,nM,CHEMBL3636125,B,Displacement of [3H]diprenorphine from human kappa-opioid receptor expressed in CHO cell membrane for 1 hr by liquid scintillation counting analysis,CHEMBL3632584,KI,CC(=O)N1CC[C@@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)c2cc(CC3Cc4ccccc4C3)ccc21
CHEMBL3634257,CHEMBL237,Kappa opioid receptor,Ki,=,19.0,nM,CHEMBL3636125,B,Displacement of [3H]diprenorphine from human kappa-opioid receptor expressed in CHO cell membrane for 1 hr by liquid scintillation counting analysis,CHEMBL3632584,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCNc2ccc(CC3CCc4ccccc43)cc21
CHEMBL3634258,CHEMBL237,Kappa opioid receptor,Ki,=,15.0,nM,CHEMBL3636125,B,Displacement of [3H]diprenorphine from human kappa-opioid receptor expressed in CHO cell membrane for 1 hr by liquid scintillation counting analysis,CHEMBL3632584,KI,CC(=O)N1CC[C@@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)c2cc(CC3CCc4ccccc43)ccc21
CHEMBL2322562,CHEMBL237,Kappa opioid receptor,Ki,=,54.0,nM,CHEMBL3636125,B,Displacement of [3H]diprenorphine from human kappa-opioid receptor expressed in CHO cell membrane for 1 hr by liquid scintillation counting analysis,CHEMBL3632584,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCNc2ccc(Cc3ccc4ccccc4c3)cc21
CHEMBL3634251,CHEMBL237,Kappa opioid receptor,Ki,=,20.0,nM,CHEMBL3636125,B,Displacement of [3H]diprenorphine from human kappa-opioid receptor expressed in CHO cell membrane for 1 hr by liquid scintillation counting analysis,CHEMBL3632584,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCCc2ccc(CC3CCCCC3)cc21
CHEMBL3634250,CHEMBL237,Kappa opioid receptor,Ki,=,8.4,nM,CHEMBL3636125,B,Displacement of [3H]diprenorphine from human kappa-opioid receptor expressed in CHO cell membrane for 1 hr by liquid scintillation counting analysis,CHEMBL3632584,KI,CC(=O)N1CC[C@@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)c2cc(CC3CCCCC3)ccc21
CHEMBL3634249,CHEMBL237,Kappa opioid receptor,Ki,=,6.2,nM,CHEMBL3636125,B,Displacement of [3H]diprenorphine from human kappa-opioid receptor expressed in CHO cell membrane for 1 hr by liquid scintillation counting analysis,CHEMBL3632584,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCNc2ccc(CC3CCCCC3)cc21
CHEMBL3634248,CHEMBL237,Kappa opioid receptor,Ki,=,19.0,nM,CHEMBL3636125,B,Displacement of [3H]diprenorphine from human kappa-opioid receptor expressed in CHO cell membrane for 1 hr by liquid scintillation counting analysis,CHEMBL3632584,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCCc2ccc(Cc3ccccc3)cc21
CHEMBL3634247,CHEMBL237,Kappa opioid receptor,Ki,=,87.0,nM,CHEMBL3636125,B,Displacement of [3H]diprenorphine from human kappa-opioid receptor expressed in CHO cell membrane for 1 hr by liquid scintillation counting analysis,CHEMBL3632584,KI,CC(=O)N1CC[C@@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)c2cc(Cc3ccccc3)ccc21
CHEMBL2322568,CHEMBL237,Kappa opioid receptor,Ki,=,68.0,nM,CHEMBL3636125,B,Displacement of [3H]diprenorphine from human kappa-opioid receptor expressed in CHO cell membrane for 1 hr by liquid scintillation counting analysis,CHEMBL3632584,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCNc2ccc(Cc3ccccc3)cc21
CHEMBL3667199,CHEMBL237,Kappa opioid receptor,Ki,=,140.0,nM,CHEMBL3707891,B,"Competitive Displacement Assay: Receptor Binding (in vitro Assay) The Ki (binding affinity) for mu-, delta-, and kippa-receptors was determined with a previously described method using a competitive displacement assay (Neumeyer, 2003). Membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed one type of the cloned human opioid receptor were incubated with 12 different concentrations of the compound in the presence of 0.25 nM [3H]DAMGO, 0.2 nM [3H]naltrindole or 1 nM [3H]U69,593 in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25 C. Incubation times of 60 min were used for [3H]DAMGO and [3H]U69,593. Because of a slower association of [3H]naltrindole with the receptor, a 3 h incubation was used with this radioligand. Samples incubated with [3H]naltrindole also contained 10 mM MgCl2 and 0.5 mM phenylmethylsulfonyl fluoride. Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass.",CHEMBL3638770,KI,CN1CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(=O)NCCc2ccc(-c4cc[nH]c(=O)c4)cc2)c(O)c13
CHEMBL3647958,CHEMBL237,Kappa opioid receptor,Ki,=,4763.0,nM,CHEMBL3707516,B,"ORL-1 Receptor Binding Assay: Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 g membrane protein in a final volume of 500 L binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Non-specific binding was determined in the presence of 10 nM unlabeled nociceptin (American Peptide Company). All reactions were performed in 96-deep well polypropylene plates for 1 h at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by three filtration washes with 5004 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty L/well scintillation cocktail (BetaScint; Wallac) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3638658,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C2CC3CCCC(C3)C2)c1=O
CHEMBL219495,CHEMBL237,Kappa opioid receptor,Ki,=,112.0,nM,CHEMBL3707655,B,"Binding Assay: The receptor binding method (DeHaven and DeHaven-Hudkins, 1998) was a modification of the method of Raynor et al. (1994).",CHEMBL3638450,KI,C[C@H]1CN2CCN(CCc3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL3695678,CHEMBL237,Kappa opioid receptor,Ki,=,2.52,nM,CHEMBL3707541,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3639236,KI,O=C(O)CN1CC[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@@H]3C1
CHEMBL426523,CHEMBL237,Kappa opioid receptor,Ki,=,8.9,nM,CHEMBL3707655,B,"Binding Assay: The receptor binding method (DeHaven and DeHaven-Hudkins, 1998) was a modification of the method of Raynor et al. (1994).",CHEMBL3638450,KI,C[C@H]1CN2C[C@H](c3ccccc3)CC[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL376690,CHEMBL237,Kappa opioid receptor,Ki,=,44.0,nM,CHEMBL3707655,B,"Binding Assay: The receptor binding method (DeHaven and DeHaven-Hudkins, 1998) was a modification of the method of Raynor et al. (1994).",CHEMBL3638450,KI,C[C@H]1CN2CCN(Cc3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL3647958,CHEMBL237,Kappa opioid receptor,Ki,=,2280.0,nM,CHEMBL3707516,B,"ORL-1 Receptor Binding Assay: Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 g membrane protein in a final volume of 500 L binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Non-specific binding was determined in the presence of 10 nM unlabeled nociceptin (American Peptide Company). All reactions were performed in 96-deep well polypropylene plates for 1 h at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by three filtration washes with 5004 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty L/well scintillation cocktail (BetaScint; Wallac) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3638658,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C2CC3CCCC(C3)C2)c1=O
CHEMBL3695677,CHEMBL237,Kappa opioid receptor,Ki,=,0.09,nM,CHEMBL3707541,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3639236,KI,C[C@H](N)C(=O)N1CC[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@@H]3C1
CHEMBL3647962,CHEMBL237,Kappa opioid receptor,Ki,=,75.4,nM,CHEMBL3707516,B,"ORL-1 Receptor Binding Assay: Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 g membrane protein in a final volume of 500 L binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Non-specific binding was determined in the presence of 10 nM unlabeled nociceptin (American Peptide Company). All reactions were performed in 96-deep well polypropylene plates for 1 h at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by three filtration washes with 5004 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty L/well scintillation cocktail (BetaScint; Wallac) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3638658,KI,C[C@@H]1C[C@@H]2C[C@H](C1)C[C@@H](N1[C@@H]3CCC[C@H]1C[C@@H](n1c(=O)c(C(=O)O)nc4ccccc41)C3)C2
CHEMBL3667197,CHEMBL237,Kappa opioid receptor,Ki,=,19.0,nM,CHEMBL3707891,B,"Competitive Displacement Assay: Receptor Binding (in vitro Assay) The Ki (binding affinity) for mu-, delta-, and kippa-receptors was determined with a previously described method using a competitive displacement assay (Neumeyer, 2003). Membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed one type of the cloned human opioid receptor were incubated with 12 different concentrations of the compound in the presence of 0.25 nM [3H]DAMGO, 0.2 nM [3H]naltrindole or 1 nM [3H]U69,593 in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25 C. Incubation times of 60 min were used for [3H]DAMGO and [3H]U69,593. Because of a slower association of [3H]naltrindole with the receptor, a 3 h incubation was used with this radioligand. Samples incubated with [3H]naltrindole also contained 10 mM MgCl2 and 0.5 mM phenylmethylsulfonyl fluoride. Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass.",CHEMBL3638770,KI,CN1CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(=O)NCCc2ccc(-c4cn[nH]c4)cc2)c(O)c13
CHEMBL3647961,CHEMBL237,Kappa opioid receptor,Ki,=,5345.0,nM,CHEMBL3707516,B,"ORL-1 Receptor Binding Assay: Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 g membrane protein in a final volume of 500 L binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Non-specific binding was determined in the presence of 10 nM unlabeled nociceptin (American Peptide Company). All reactions were performed in 96-deep well polypropylene plates for 1 h at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by three filtration washes with 5004 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty L/well scintillation cocktail (BetaScint; Wallac) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3638658,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C23CCCC(CCC2)C3)c1=O
CHEMBL218404,CHEMBL237,Kappa opioid receptor,Ki,=,190.0,nM,CHEMBL3707655,B,"Binding Assay: The receptor binding method (DeHaven and DeHaven-Hudkins, 1998) was a modification of the method of Raynor et al. (1994).",CHEMBL3638450,KI,C[C@H]1CN2CCN(C(=O)c3ccccc3)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL3647959,CHEMBL237,Kappa opioid receptor,Ki,=,2691.0,nM,CHEMBL3707516,B,"ORL-1 Receptor Binding Assay: Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 g membrane protein in a final volume of 500 L binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Non-specific binding was determined in the presence of 10 nM unlabeled nociceptin (American Peptide Company). All reactions were performed in 96-deep well polypropylene plates for 1 h at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by three filtration washes with 5004 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty L/well scintillation cocktail (BetaScint; Wallac) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3638658,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CC3CCCC(C3)C2)c1=O
CHEMBL3695668,CHEMBL237,Kappa opioid receptor,Ki,=,6.27,nM,CHEMBL3707541,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3639236,KI,O=C1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@@H]3CN1Cc1ccc(O)cc1
CHEMBL218520,CHEMBL237,Kappa opioid receptor,Ki,=,12.0,nM,CHEMBL3707655,B,"Binding Assay: The receptor binding method (DeHaven and DeHaven-Hudkins, 1998) was a modification of the method of Raynor et al. (1994).",CHEMBL3638450,KI,C[C@H]1CN2C[C@H](c3ccccc3)N(C)C[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL3695676,CHEMBL237,Kappa opioid receptor,Ki,=,0.21,nM,CHEMBL3707541,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3639236,KI,Oc1ccc2c(c1)[C@@]13CCNC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL3667196,CHEMBL237,Kappa opioid receptor,Ki,=,860.0,nM,CHEMBL3707891,B,"Competitive Displacement Assay: Receptor Binding (in vitro Assay) The Ki (binding affinity) for mu-, delta-, and kippa-receptors was determined with a previously described method using a competitive displacement assay (Neumeyer, 2003). Membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed one type of the cloned human opioid receptor were incubated with 12 different concentrations of the compound in the presence of 0.25 nM [3H]DAMGO, 0.2 nM [3H]naltrindole or 1 nM [3H]U69,593 in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25 C. Incubation times of 60 min were used for [3H]DAMGO and [3H]U69,593. Because of a slower association of [3H]naltrindole with the receptor, a 3 h incubation was used with this radioligand. Samples incubated with [3H]naltrindole also contained 10 mM MgCl2 and 0.5 mM phenylmethylsulfonyl fluoride. Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass.",CHEMBL3638770,KI,CO[C@@]12CCC(=O)C[C@@]13CCN(C)[C@@H]2Cc1ccc(C(=O)NCCc2ccc(-c4c[nH]c(=O)[nH]c4=O)cc2)c(O)c13
CHEMBL3695675,CHEMBL237,Kappa opioid receptor,Ki,=,0.98,nM,CHEMBL3707541,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3639236,KI,Oc1ccc(CN2CC[C@]34CCN(CC5CC5)[C@H](Cc5ccc(O)cc53)[C@@H]4C2)cc1
CHEMBL3695666,CHEMBL237,Kappa opioid receptor,Ki,=,5.84,nM,CHEMBL3707541,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3639236,KI,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@@H]1CNC(=O)C3
CHEMBL3695664,CHEMBL237,Kappa opioid receptor,Ki,=,410.89,nM,CHEMBL3707541,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3639236,KI,COc1ccc(CN2C[C@H]3[C@H]4Cc5ccc(OC)cc5[C@@]3(CCN4CC3CC3)CC2=O)cc1
CHEMBL3695665,CHEMBL237,Kappa opioid receptor,Ki,=,13.06,nM,CHEMBL3707541,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3639236,KI,COc1ccc(CN2C=C3[C@H]4Cc5ccc(OC)cc5[C@@]3(CCN4CC3CC3)CC2=O)cc1
CHEMBL3667198,CHEMBL237,Kappa opioid receptor,Ki,=,400.0,nM,CHEMBL3707891,B,"Competitive Displacement Assay: Receptor Binding (in vitro Assay) The Ki (binding affinity) for mu-, delta-, and kippa-receptors was determined with a previously described method using a competitive displacement assay (Neumeyer, 2003). Membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed one type of the cloned human opioid receptor were incubated with 12 different concentrations of the compound in the presence of 0.25 nM [3H]DAMGO, 0.2 nM [3H]naltrindole or 1 nM [3H]U69,593 in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25 C. Incubation times of 60 min were used for [3H]DAMGO and [3H]U69,593. Because of a slower association of [3H]naltrindole with the receptor, a 3 h incubation was used with this radioligand. Samples incubated with [3H]naltrindole also contained 10 mM MgCl2 and 0.5 mM phenylmethylsulfonyl fluoride. Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass.",CHEMBL3638770,KI,CN1CC[C@]23CC(=O)CCC2[C@H]1Cc1ccc(C(=O)NCCc2nc4ccccc4[nH]2)c(O)c13
CHEMBL3667190,CHEMBL237,Kappa opioid receptor,Ki,=,0.71,nM,CHEMBL3707891,B,"Competitive Displacement Assay: Receptor Binding (in vitro Assay) The Ki (binding affinity) for mu-, delta-, and kippa-receptors was determined with a previously described method using a competitive displacement assay (Neumeyer, 2003). Membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed one type of the cloned human opioid receptor were incubated with 12 different concentrations of the compound in the presence of 0.25 nM [3H]DAMGO, 0.2 nM [3H]naltrindole or 1 nM [3H]U69,593 in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25 C. Incubation times of 60 min were used for [3H]DAMGO and [3H]U69,593. Because of a slower association of [3H]naltrindole with the receptor, a 3 h incubation was used with this radioligand. Samples incubated with [3H]naltrindole also contained 10 mM MgCl2 and 0.5 mM phenylmethylsulfonyl fluoride. Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass.",CHEMBL3638770,KI,CN1CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(=O)NCCc2ccc(-c4ccccc4)cc2)c(O)c13
CHEMBL3667194,CHEMBL237,Kappa opioid receptor,Ki,=,190.0,nM,CHEMBL3707891,B,"Competitive Displacement Assay: Receptor Binding (in vitro Assay) The Ki (binding affinity) for mu-, delta-, and kippa-receptors was determined with a previously described method using a competitive displacement assay (Neumeyer, 2003). Membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed one type of the cloned human opioid receptor were incubated with 12 different concentrations of the compound in the presence of 0.25 nM [3H]DAMGO, 0.2 nM [3H]naltrindole or 1 nM [3H]U69,593 in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25 C. Incubation times of 60 min were used for [3H]DAMGO and [3H]U69,593. Because of a slower association of [3H]naltrindole with the receptor, a 3 h incubation was used with this radioligand. Samples incubated with [3H]naltrindole also contained 10 mM MgCl2 and 0.5 mM phenylmethylsulfonyl fluoride. Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass.",CHEMBL3638770,KI,CN1CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(=O)NCCc2ccc(-c4cnc(O)nc4O)cc2)c(O)c13
CHEMBL3695667,CHEMBL237,Kappa opioid receptor,Ki,=,0.55,nM,CHEMBL3707541,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3639236,KI,NC(=O)CN1C[C@H]2[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL3695674,CHEMBL237,Kappa opioid receptor,Ki,=,0.26,nM,CHEMBL3707541,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3639236,KI,NC(=O)CN1CC[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@@H]3C1
CHEMBL3695672,CHEMBL237,Kappa opioid receptor,Ki,=,204.49,nM,CHEMBL3707541,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3639236,KI,COc1ccc(CN2CC[C@]34CCN(CC5CC5)[C@H](Cc5ccc(OC)cc53)[C@@H]4C2)cc1
CHEMBL409938,CHEMBL237,Kappa opioid receptor,Ki,=,230.0,nM,CHEMBL3707891,B,"Competitive Displacement Assay: Receptor Binding (in vitro Assay) The Ki (binding affinity) for mu-, delta-, and kippa-receptors was determined with a previously described method using a competitive displacement assay (Neumeyer, 2003). Membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed one type of the cloned human opioid receptor were incubated with 12 different concentrations of the compound in the presence of 0.25 nM [3H]DAMGO, 0.2 nM [3H]naltrindole or 1 nM [3H]U69,593 in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25 C. Incubation times of 60 min were used for [3H]DAMGO and [3H]U69,593. Because of a slower association of [3H]naltrindole with the receptor, a 3 h incubation was used with this radioligand. Samples incubated with [3H]naltrindole also contained 10 mM MgCl2 and 0.5 mM phenylmethylsulfonyl fluoride. Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass.",CHEMBL3638770,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=CC3C1C5
CHEMBL3647962,CHEMBL237,Kappa opioid receptor,Ki,=,691.0,nM,CHEMBL3707516,B,"ORL-1 Receptor Binding Assay: Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 g membrane protein in a final volume of 500 L binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Non-specific binding was determined in the presence of 10 nM unlabeled nociceptin (American Peptide Company). All reactions were performed in 96-deep well polypropylene plates for 1 h at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by three filtration washes with 5004 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty L/well scintillation cocktail (BetaScint; Wallac) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3638658,KI,C[C@@H]1C[C@@H]2C[C@H](C1)C[C@@H](N1[C@@H]3CCC[C@H]1C[C@@H](n1c(=O)c(C(=O)O)nc4ccccc41)C3)C2
CHEMBL435746,CHEMBL237,Kappa opioid receptor,Ki,=,85.0,nM,CHEMBL3707655,B,"Binding Assay: The receptor binding method (DeHaven and DeHaven-Hudkins, 1998) was a modification of the method of Raynor et al. (1994).",CHEMBL3638450,KI,C[C@H]1CN2C[C@H](Cc3ccccc3)NC[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL219319,CHEMBL237,Kappa opioid receptor,Ki,=,18.0,nM,CHEMBL3707655,B,"Binding Assay: The receptor binding method (DeHaven and DeHaven-Hudkins, 1998) was a modification of the method of Raynor et al. (1994).",CHEMBL3638450,KI,C[C@H]1CN2C[C@H](c3ccccc3)NC[C@H]2C[C@@]1(C)c1cccc(O)c1
CHEMBL3667195,CHEMBL237,Kappa opioid receptor,Ki,=,1000.0,nM,CHEMBL3707891,B,"Competitive Displacement Assay: Receptor Binding (in vitro Assay) The Ki (binding affinity) for mu-, delta-, and kippa-receptors was determined with a previously described method using a competitive displacement assay (Neumeyer, 2003). Membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed one type of the cloned human opioid receptor were incubated with 12 different concentrations of the compound in the presence of 0.25 nM [3H]DAMGO, 0.2 nM [3H]naltrindole or 1 nM [3H]U69,593 in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25 C. Incubation times of 60 min were used for [3H]DAMGO and [3H]U69,593. Because of a slower association of [3H]naltrindole with the receptor, a 3 h incubation was used with this radioligand. Samples incubated with [3H]naltrindole also contained 10 mM MgCl2 and 0.5 mM phenylmethylsulfonyl fluoride. Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass.",CHEMBL3638770,KI,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(C(=O)NCCc5ccc(-c6c[nH]c(=O)[nH]c6=O)cc5)c(O)c4[C@@]2(CCN3C)C1
CHEMBL3647963,CHEMBL237,Kappa opioid receptor,Ki,=,18180.0,nM,CHEMBL3707516,B,"ORL-1 Receptor Binding Assay: Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 g membrane protein in a final volume of 500 L binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Non-specific binding was determined in the presence of 10 nM unlabeled nociceptin (American Peptide Company). All reactions were performed in 96-deep well polypropylene plates for 1 h at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by three filtration washes with 5004 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty L/well scintillation cocktail (BetaScint; Wallac) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3638658,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCCCCCC2)c1=O
CHEMBL3647959,CHEMBL237,Kappa opioid receptor,Ki,=,6143.0,nM,CHEMBL3707516,B,"ORL-1 Receptor Binding Assay: Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 g membrane protein in a final volume of 500 L binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Non-specific binding was determined in the presence of 10 nM unlabeled nociceptin (American Peptide Company). All reactions were performed in 96-deep well polypropylene plates for 1 h at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by three filtration washes with 5004 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty L/well scintillation cocktail (BetaScint; Wallac) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3638658,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CC3CCCC(C3)C2)c1=O
CHEMBL3695670,CHEMBL237,Kappa opioid receptor,Ki,=,0.18,nM,CHEMBL3707541,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3639236,KI,O=C1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@@H]3CN1
CHEMBL3695671,CHEMBL237,Kappa opioid receptor,Ki,=,4.03,nM,CHEMBL3707541,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3639236,KI,O=C(O)CN1C[C@H]2[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL3647960,CHEMBL237,Kappa opioid receptor,Ki,=,8900.0,nM,CHEMBL3707516,B,"ORL-1 Receptor Binding Assay: Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 g membrane protein in a final volume of 500 L binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Non-specific binding was determined in the presence of 10 nM unlabeled nociceptin (American Peptide Company). All reactions were performed in 96-deep well polypropylene plates for 1 h at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by three filtration washes with 5004 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty L/well scintillation cocktail (BetaScint; Wallac) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3638658,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCCCCC2)c1=O
CHEMBL3667193,CHEMBL237,Kappa opioid receptor,Ki,=,180.0,nM,CHEMBL3707891,B,"Competitive Displacement Assay: Receptor Binding (in vitro Assay) The Ki (binding affinity) for mu-, delta-, and kippa-receptors was determined with a previously described method using a competitive displacement assay (Neumeyer, 2003). Membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed one type of the cloned human opioid receptor were incubated with 12 different concentrations of the compound in the presence of 0.25 nM [3H]DAMGO, 0.2 nM [3H]naltrindole or 1 nM [3H]U69,593 in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25 C. Incubation times of 60 min were used for [3H]DAMGO and [3H]U69,593. Because of a slower association of [3H]naltrindole with the receptor, a 3 h incubation was used with this radioligand. Samples incubated with [3H]naltrindole also contained 10 mM MgCl2 and 0.5 mM phenylmethylsulfonyl fluoride. Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass.",CHEMBL3638770,KI,CN1CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(=O)NCCc2ccc(-c4ccc(=O)[nH]c4)cc2)c(O)c13
CHEMBL3647963,CHEMBL237,Kappa opioid receptor,Ki,=,76.0,nM,CHEMBL3707516,B,"ORL-1 Receptor Binding Assay: Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 g membrane protein in a final volume of 500 L binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Non-specific binding was determined in the presence of 10 nM unlabeled nociceptin (American Peptide Company). All reactions were performed in 96-deep well polypropylene plates for 1 h at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by three filtration washes with 5004 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty L/well scintillation cocktail (BetaScint; Wallac) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3638658,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCCCCCC2)c1=O
CHEMBL3695673,CHEMBL237,Kappa opioid receptor,Ki,=,37.0,nM,CHEMBL3707541,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3639236,KI,COc1ccc2c(c1)[C@@]13CCNC[C@H]1[C@@H](C2)N(CC1CC1)CC3
CHEMBL3667194,CHEMBL237,Kappa opioid receptor,Ki,=,680.0,nM,CHEMBL3707891,B,"Competitive Displacement Assay: Receptor Binding (in vitro Assay) The Ki (binding affinity) for mu-, delta-, and kippa-receptors was determined with a previously described method using a competitive displacement assay (Neumeyer, 2003). Membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed one type of the cloned human opioid receptor were incubated with 12 different concentrations of the compound in the presence of 0.25 nM [3H]DAMGO, 0.2 nM [3H]naltrindole or 1 nM [3H]U69,593 in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25 C. Incubation times of 60 min were used for [3H]DAMGO and [3H]U69,593. Because of a slower association of [3H]naltrindole with the receptor, a 3 h incubation was used with this radioligand. Samples incubated with [3H]naltrindole also contained 10 mM MgCl2 and 0.5 mM phenylmethylsulfonyl fluoride. Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass.",CHEMBL3638770,KI,CN1CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(=O)NCCc2ccc(-c4cnc(O)nc4O)cc2)c(O)c13
CHEMBL3695669,CHEMBL237,Kappa opioid receptor,Ki,=,1.27,nM,CHEMBL3707541,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose-displacement binding assays for u-opioid receptors used 0.3 nM [3H]-diprenorphine (Perkin Elmer, Shelton, Conn.), with 5 mg membrane protein/well in a final volume of 500 ul binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Reactions were carried out in the absence or presence of increasing concentrations of unlabeled naloxone. All reactions were conducted in 96-deep well polypropylene plates for 2 hours at room temperature. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.), presoaked in 0.5% polyethylenimine using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by performing three filtration washes with 500 ul of ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. BetaScint scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added (50 ul/well), and plates were counted using a Packard Top-Counter.",CHEMBL3639236,KI,O=C1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)C3=CN1Cc1ccc(O)cc1
CHEMBL3667191,CHEMBL237,Kappa opioid receptor,Ki,=,850.0,nM,CHEMBL3707891,B,"Competitive Displacement Assay: Receptor Binding (in vitro Assay) The Ki (binding affinity) for mu-, delta-, and kippa-receptors was determined with a previously described method using a competitive displacement assay (Neumeyer, 2003). Membrane protein from CHO (Chinese Hamster Ovarian) cells that stably expressed one type of the cloned human opioid receptor were incubated with 12 different concentrations of the compound in the presence of 0.25 nM [3H]DAMGO, 0.2 nM [3H]naltrindole or 1 nM [3H]U69,593 in a final volume of 1 mL of 50 mM Tris-HCl, pH 7.5 at 25 C. Incubation times of 60 min were used for [3H]DAMGO and [3H]U69,593. Because of a slower association of [3H]naltrindole with the receptor, a 3 h incubation was used with this radioligand. Samples incubated with [3H]naltrindole also contained 10 mM MgCl2 and 0.5 mM phenylmethylsulfonyl fluoride. Nonspecific binding was measured by inclusion of 10 uM naloxone. The binding was terminated by filtering the samples through Schleicher & Schuell No. 32 glass.",CHEMBL3638770,KI,CN1CC[C@]23CC(=O)CC[C@@]2(O)[C@H]1Cc1ccc(C(=O)NCCc2nc4ccccc4[nH]2)c(O)c13
CHEMBL3647960,CHEMBL237,Kappa opioid receptor,Ki,=,640.0,nM,CHEMBL3707516,B,"ORL-1 Receptor Binding Assay: Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 g membrane protein in a final volume of 500 L binding buffer (10 mM MgCl2, 1 mM EDTA, 5% DMSO, 50 mM HEPES, pH 7.4). Non-specific binding was determined in the presence of 10 nM unlabeled nociceptin (American Peptide Company). All reactions were performed in 96-deep well polypropylene plates for 1 h at about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by three filtration washes with 5004 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty L/well scintillation cocktail (BetaScint; Wallac) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3638658,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCCCCC2)c1=O
CHEMBL3735756,CHEMBL237,Kappa opioid receptor,Ki,=,363.0,nM,CHEMBL3736712,B,Displacement of [3H]U69593 from human kappa-opioid receptor stably expressed in HEK cell membrane after 90 mins by scintillation counting method,CHEMBL3734659,KI,COc1ccc(CCN(CCCc2ccccc2)CCc2ccc3c(c2)OCO3)cc1OC
CHEMBL3754166,CHEMBL237,Kappa opioid receptor,Ki,=,891.25,nM,CHEMBL3756494,B,Binding affinity to kappa type opioid receptor (unknown origin) by competition binding assay,CHEMBL3751848,KI,C=CCN(CC=C)CCc1c[nH]c2ccc(Br)cc12
CHEMBL3753318,CHEMBL237,Kappa opioid receptor,Ki,=,1230.27,nM,CHEMBL3756494,B,Binding affinity to kappa type opioid receptor (unknown origin) by competition binding assay,CHEMBL3751848,KI,C=CCN(CC=C)CCc1c[nH]c2ccc(C)cc12
CHEMBL2391541,CHEMBL237,Kappa opioid receptor,Ki,=,1122.02,nM,CHEMBL3756494,B,Binding affinity to kappa type opioid receptor (unknown origin) by competition binding assay,CHEMBL3751848,KI,C=CCN(CC=C)CCc1c[nH]c2ccc(OC)cc12
CHEMBL3752900,CHEMBL237,Kappa opioid receptor,Ki,=,812.83,nM,CHEMBL3756494,B,Binding affinity to kappa type opioid receptor (unknown origin) by competition binding assay,CHEMBL3751848,KI,C=CCN(CC=C)CCc1c[nH]c2ccc(Cl)cc12
CHEMBL3752576,CHEMBL237,Kappa opioid receptor,Ki,=,2454.71,nM,CHEMBL3756494,B,Binding affinity to kappa type opioid receptor (unknown origin) by competition binding assay,CHEMBL3751848,KI,C=CCN(CC=C)CCc1c[nH]c2ccccc12
CHEMBL3754496,CHEMBL237,Kappa opioid receptor,Ki,=,2187.76,nM,CHEMBL3756494,B,Binding affinity to kappa type opioid receptor (unknown origin) by competition binding assay,CHEMBL3751848,KI,C=CCN(CC=C)CCc1c[nH]c2ccc(F)cc12
CHEMBL3758259,CHEMBL237,Kappa opioid receptor,Ki,=,1.3,nM,CHEMBL3762584,B,Binding affinity to kappa opioid receptor (unknown origin),CHEMBL3758122,KI,NC(=O)[C@H]1CSCSC[C@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N1
CHEMBL326684,CHEMBL237,Kappa opioid receptor,Ki,=,25.2,nM,CHEMBL3762584,B,Binding affinity to kappa opioid receptor (unknown origin),CHEMBL3758122,KI,CO[C@@]12CCC(=O)[C@]3(C)Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL146756,CHEMBL237,Kappa opioid receptor,Ki,=,0.078,nM,CHEMBL3762594,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL3758122,KI,O=C(/C=C/C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL301160,CHEMBL237,Kappa opioid receptor,Ki,=,0.073,nM,CHEMBL3762584,B,Binding affinity to kappa opioid receptor (unknown origin),CHEMBL3758122,KI,Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL3759238,CHEMBL237,Kappa opioid receptor,Ki,=,0.18,nM,CHEMBL3762584,B,Binding affinity to kappa opioid receptor (unknown origin),CHEMBL3758122,KI,O=C1c2ccc(O)cc2[C@@]23CCCC[C@H]2[C@@H]1N(CC1CCCO1)CC3
CHEMBL147511,CHEMBL237,Kappa opioid receptor,Ki,=,0.049,nM,CHEMBL3762594,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane,CHEMBL3758122,KI,O=C(CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL3759660,CHEMBL237,Kappa opioid receptor,Ki,=,0.049,nM,CHEMBL3760683,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membrane",CHEMBL3758122,KI,Nc1nc2cc3c(cc2s1)C[C@H]1[C@@H]2CCCC[C@]32CCN1CC1CC1
CHEMBL583066,CHEMBL237,Kappa opioid receptor,Ki,=,2.5,nM,CHEMBL3762584,B,Binding affinity to kappa opioid receptor (unknown origin),CHEMBL3758122,KI,NC(=O)[C@@H]1CSCSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1
CHEMBL3770284,CHEMBL237,Kappa opioid receptor,Ki,=,2500.0,nM,CHEMBL3771799,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cells after 1 hr by liquid scintillation counting method,CHEMBL3769345,KI,N[C@@H](Cc1ccc2cccc(O)c2c1)C(=O)N[C@@H]1CCNc2ccc(Cc3ccccc3)cc21
CHEMBL3770024,CHEMBL237,Kappa opioid receptor,Ki,=,130.0,nM,CHEMBL3771799,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cells after 1 hr by liquid scintillation counting method,CHEMBL3769345,KI,Cc1cccc(C)c1C[C@H](N)C(=O)N[C@@H]1CCNc2ccc(Cc3ccccc3)cc21
CHEMBL3770643,CHEMBL237,Kappa opioid receptor,Ki,=,35.0,nM,CHEMBL3771799,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cells after 1 hr by liquid scintillation counting method,CHEMBL3769345,KI,N[C@@H](Cc1c(Cl)cc(O)cc1Cl)C(=O)N[C@@H]1CCNc2ccc(Cc3ccccc3)cc21
CHEMBL3770677,CHEMBL237,Kappa opioid receptor,Ki,=,730.0,nM,CHEMBL3771799,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cells after 1 hr by liquid scintillation counting method,CHEMBL3769345,KI,Cc1cc(C[C@H](N)C(=O)N[C@@H]2CCNc3ccc(Cc4ccccc4)cc32)c(C)cc1O
CHEMBL3770668,CHEMBL237,Kappa opioid receptor,Ki,=,96.0,nM,CHEMBL3771799,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cells after 1 hr by liquid scintillation counting method,CHEMBL3769345,KI,Cc1cc(O)ccc1C[C@H](N)C(=O)N[C@@H]1CCNc2ccc(Cc3ccccc3)cc21
CHEMBL415284,CHEMBL237,Kappa opioid receptor,Ki,=,2.0,nM,CHEMBL3777305,B,Binding affinity to human kappa opioid receptor,CHEMBL3774335,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL70,CHEMBL237,Kappa opioid receptor,Ki,=,120.0,nM,CHEMBL3777305,B,Binding affinity to human kappa opioid receptor,CHEMBL3774335,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL3785955,CHEMBL237,Kappa opioid receptor,Ki,=,22.0,nM,CHEMBL3790688,B,Displacement of [3H]Cl-977 from human kappa opioid receptor expressed on HEK-293 cells by liquid scintillation counting method,CHEMBL3785048,KI,O=C(Cc1ccc(Cl)c(Cl)c1)N1CCN(Cc2cccnc2)C2CCCC(N3CCCC3)C21
CHEMBL3786545,CHEMBL237,Kappa opioid receptor,Ki,=,31.0,nM,CHEMBL3790688,B,Displacement of [3H]Cl-977 from human kappa opioid receptor expressed on HEK-293 cells by liquid scintillation counting method,CHEMBL3785048,KI,O=C(Cc1ccc(Cl)c(Cl)c1)N1CCN(Cc2cccnc2)C2CCCC(N3CCC(O)C3)C21
CHEMBL80,CHEMBL237,Kappa opioid receptor,Ki,=,15.0,nM,CHEMBL3790688,B,Displacement of [3H]Cl-977 from human kappa opioid receptor expressed on HEK-293 cells by liquid scintillation counting method,CHEMBL3785048,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL1797689,CHEMBL237,Kappa opioid receptor,Ki,=,0.648,nM,CHEMBL3787928,B,"Displacement of [3H]U-69,593 from human kappa opioid receptor expressed in CHO cell membranes",CHEMBL3785070,KI,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)C1
CHEMBL3786675,CHEMBL237,Kappa opioid receptor,Ki,=,0.748,nM,CHEMBL3787928,B,"Displacement of [3H]U-69,593 from human kappa opioid receptor expressed in CHO cell membranes",CHEMBL3785070,KI,O=C1CCC[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)C1
CHEMBL3785854,CHEMBL237,Kappa opioid receptor,Ki,=,2.97,nM,CHEMBL3787928,B,"Displacement of [3H]U-69,593 from human kappa opioid receptor expressed in CHO cell membranes",CHEMBL3785070,KI,Oc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@@H](C2)[C@]1(O)Cc1c([nH]c2ccccc12)C3
CHEMBL3787016,CHEMBL237,Kappa opioid receptor,Ki,=,6.63,nM,CHEMBL3787928,B,"Displacement of [3H]U-69,593 from human kappa opioid receptor expressed in CHO cell membranes",CHEMBL3785070,KI,Oc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCc1c([nH]c2ccccc12)C3
CHEMBL3787263,CHEMBL237,Kappa opioid receptor,Ki,=,3.22,nM,CHEMBL3787928,B,"Displacement of [3H]U-69,593 from human kappa opioid receptor expressed in CHO cell membranes",CHEMBL3785070,KI,Oc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@@H](C2)[C@]1(O)Cc1cc2ccccc2nc1C3
CHEMBL3787663,CHEMBL237,Kappa opioid receptor,Ki,=,4.3,nM,CHEMBL3787928,B,"Displacement of [3H]U-69,593 from human kappa opioid receptor expressed in CHO cell membranes",CHEMBL3785070,KI,Oc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)CCc1cc2ccccc2nc1C3
CHEMBL3786970,CHEMBL237,Kappa opioid receptor,Ki,=,39.1,nM,CHEMBL3787928,B,"Displacement of [3H]U-69,593 from human kappa opioid receptor expressed in CHO cell membranes",CHEMBL3785070,KI,O=C1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@]3(O)C/C1=C\c1ccccc1
CHEMBL3786218,CHEMBL237,Kappa opioid receptor,Ki,=,9.11,nM,CHEMBL3787928,B,"Displacement of [3H]U-69,593 from human kappa opioid receptor expressed in CHO cell membranes",CHEMBL3785070,KI,O=C1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@]3(O)CC/C1=C\c1ccccc1
CHEMBL3785265,CHEMBL237,Kappa opioid receptor,Ki,=,9.65,nM,CHEMBL3787928,B,"Displacement of [3H]U-69,593 from human kappa opioid receptor expressed in CHO cell membranes",CHEMBL3785070,KI,O=C1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@]3(O)C/C1=C/c1ccccc1
CHEMBL3786083,CHEMBL237,Kappa opioid receptor,Ki,=,17.5,nM,CHEMBL3787928,B,"Displacement of [3H]U-69,593 from human kappa opioid receptor expressed in CHO cell membranes",CHEMBL3785070,KI,O=C1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@]3(O)CC/C1=C/c1ccccc1
CHEMBL252172,CHEMBL237,Kappa opioid receptor,Ki,=,28.3,nM,CHEMBL3787928,B,"Displacement of [3H]U-69,593 from human kappa opioid receptor expressed in CHO cell membranes",CHEMBL3785070,KI,O=C1/C(=C/c2ccccc2)C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL3759092,CHEMBL237,Kappa opioid receptor,Ki,=,7500.0,nM,CHEMBL3802783,B,Displacement of [3H]-DPN from human KOR expressed in EE-HEK293 cell membranes by liquid scintillation counting,CHEMBL3797063,KI,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@]1(C)CCN2CCC(=O)Nc1ccccc1
CHEMBL3798175,CHEMBL237,Kappa opioid receptor,Ki,=,230.0,nM,CHEMBL3802783,B,Displacement of [3H]-DPN from human KOR expressed in EE-HEK293 cell membranes by liquid scintillation counting,CHEMBL3797063,KI,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@]1(C)CCN2CCC(=O)Nc1cccc2cccnc12
CHEMBL3799570,CHEMBL237,Kappa opioid receptor,Ki,=,4400.0,nM,CHEMBL3802783,B,Displacement of [3H]-DPN from human KOR expressed in EE-HEK293 cell membranes by liquid scintillation counting,CHEMBL3797063,KI,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@]1(C)CCN2CCC(=O)Nc1ccc2ncccc2c1
CHEMBL3797616,CHEMBL237,Kappa opioid receptor,Ki,=,1540.0,nM,CHEMBL3802783,B,Displacement of [3H]-DPN from human KOR expressed in EE-HEK293 cell membranes by liquid scintillation counting,CHEMBL3797063,KI,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@]1(C)CCN2CCC(=O)Nc1cccc2ncccc12
CHEMBL3800620,CHEMBL237,Kappa opioid receptor,Ki,=,6470.0,nM,CHEMBL3802783,B,Displacement of [3H]-DPN from human KOR expressed in EE-HEK293 cell membranes by liquid scintillation counting,CHEMBL3797063,KI,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@]1(C)CCN2CCC(=O)Nc1cnc2ccccc2c1
CHEMBL3797702,CHEMBL237,Kappa opioid receptor,Ki,=,2900.0,nM,CHEMBL3802783,B,Displacement of [3H]-DPN from human KOR expressed in EE-HEK293 cell membranes by liquid scintillation counting,CHEMBL3797063,KI,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@]1(C)CCN2CCC(=O)Nc1cccc2cnccc12
CHEMBL3797228,CHEMBL237,Kappa opioid receptor,Ki,=,800.0,nM,CHEMBL3802783,B,Displacement of [3H]-DPN from human KOR expressed in EE-HEK293 cell membranes by liquid scintillation counting,CHEMBL3797063,KI,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@]1(C)CCN2CCC(=O)Nc1cccc2ccccc12
CHEMBL3809091,CHEMBL237,Kappa opioid receptor,Ki,=,140.0,nM,CHEMBL3812005,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes after 60 mins,CHEMBL3808393,KI,CN(C)C[C@H]1CCc2cc(-c3ccccc3)ccc2[C@]1(O)c1cccc(O)c1
CHEMBL3408737,CHEMBL237,Kappa opioid receptor,Ki,=,29.9,nM,CHEMBL3810905,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in HEK293 cell membrane incubated for 1 hr by TopCount scintillation counting method,CHEMBL3808291,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(N)=O)C1=O
CHEMBL3809510,CHEMBL237,Kappa opioid receptor,Ki,=,732.0,nM,CHEMBL3810905,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in HEK293 cell membrane incubated for 1 hr by TopCount scintillation counting method,CHEMBL3808291,KI,CC[C@H](C)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL3808415,CHEMBL237,Kappa opioid receptor,Ki,=,33.0,nM,CHEMBL3810905,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in HEK293 cell membrane incubated for 1 hr by TopCount scintillation counting method,CHEMBL3808291,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CCN1Cc2ccccc2C[C@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C1=O)C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL3808398,CHEMBL237,Kappa opioid receptor,Ki,=,84.0,nM,CHEMBL3810905,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in HEK293 cell membrane incubated for 1 hr by TopCount scintillation counting method,CHEMBL3808291,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)C1=O
CHEMBL3810104,CHEMBL237,Kappa opioid receptor,Ki,=,22.0,nM,CHEMBL3810905,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in HEK293 cell membrane incubated for 1 hr by TopCount scintillation counting method,CHEMBL3808291,KI,Cc1cc(O)cc(C)c1C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CCN1Cc2ccccc2C[C@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C1=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O
CHEMBL3808523,CHEMBL237,Kappa opioid receptor,Ki,=,47.0,nM,CHEMBL3810905,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in HEK293 cell membrane incubated for 1 hr by TopCount scintillation counting method,CHEMBL3808291,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)C1=O
CHEMBL3810101,CHEMBL237,Kappa opioid receptor,Ki,=,1900.0,nM,CHEMBL3810905,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in HEK293 cell membrane incubated for 1 hr by TopCount scintillation counting method,CHEMBL3808291,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL3808514,CHEMBL237,Kappa opioid receptor,Ki,=,231.3,nM,CHEMBL3813455,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis,CHEMBL3808316,KI,C[N+]1(CC2c3ccc(O)cc3CCN2C(=O)C2CC(=O)c3ccc(Cl)cc32)CCCC1.[I-]
CHEMBL3809031,CHEMBL237,Kappa opioid receptor,Ki,=,138.3,nM,CHEMBL3813455,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis,CHEMBL3808316,KI,C[N+]1(CC2c3cc(F)ccc3CCN2C(=O)C2CC(=O)c3ccc(Cl)cc32)CCCC1.[I-]
CHEMBL3808824,CHEMBL237,Kappa opioid receptor,Ki,=,0.94,nM,CHEMBL3813455,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis,CHEMBL3808316,KI,CCCC[N+]1(CC2c3ccccc3CCN2C(=O)C2CC(=O)c3ccc(Cl)cc32)CCCC1.[I-]
CHEMBL3809310,CHEMBL237,Kappa opioid receptor,Ki,=,1.86,nM,CHEMBL3813455,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis,CHEMBL3808316,KI,C=CC[N+]1(CC2c3ccccc3CCN2C(=O)C2CC(=O)c3ccc(Cl)cc32)CCCC1.[Br-]
CHEMBL3809782,CHEMBL237,Kappa opioid receptor,Ki,=,3.56,nM,CHEMBL3813455,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis,CHEMBL3808316,KI,O=C1CC(C(=O)N2CCc3ccccc3C2C[N+]2(CC3CC3)CCCC2)c2cc(Cl)ccc21.[Br-]
CHEMBL3808477,CHEMBL237,Kappa opioid receptor,Ki,=,0.033,nM,CHEMBL3813455,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis,CHEMBL3808316,KI,O=C1CC(C(=O)N2CCc3ccccc3C2CN2CCCC2)c2cc(Cl)ccc21
CHEMBL441765,CHEMBL237,Kappa opioid receptor,Ki,=,6.08,nM,CHEMBL3813455,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis,CHEMBL3808316,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL3822956,CHEMBL237,Kappa opioid receptor,Ki,=,40.0,nM,CHEMBL3825886,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cell membranes after 1 hr by liquid scintillation counting,CHEMBL3822362,KI,CCC(=O)N1CC[C@@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)c2cc(Cc3ccccc3)ccc21
CHEMBL3824052,CHEMBL237,Kappa opioid receptor,Ki,=,50.0,nM,CHEMBL3825886,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cell membranes after 1 hr by liquid scintillation counting,CHEMBL3822362,KI,CCCC(=O)N1CC[C@@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)c2cc(Cc3ccccc3)ccc21
CHEMBL3824042,CHEMBL237,Kappa opioid receptor,Ki,=,76.0,nM,CHEMBL3825886,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cell membranes after 1 hr by liquid scintillation counting,CHEMBL3822362,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCN(C(=O)C(C)C)c2ccc(Cc3ccccc3)cc21
CHEMBL3823231,CHEMBL237,Kappa opioid receptor,Ki,=,25.0,nM,CHEMBL3825886,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cell membranes after 1 hr by liquid scintillation counting,CHEMBL3822362,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCN(C(=O)C2CC2)c2ccc(Cc3ccccc3)cc21
CHEMBL3823787,CHEMBL237,Kappa opioid receptor,Ki,=,56.0,nM,CHEMBL3825886,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cell membranes after 1 hr by liquid scintillation counting,CHEMBL3822362,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCN(C(=O)C2CCC2)c2ccc(Cc3ccccc3)cc21
CHEMBL3823830,CHEMBL237,Kappa opioid receptor,Ki,=,29.0,nM,CHEMBL3825886,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cell membranes after 1 hr by liquid scintillation counting,CHEMBL3822362,KI,COC(=O)N1CC[C@@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)c2cc(Cc3ccccc3)ccc21
CHEMBL3822963,CHEMBL237,Kappa opioid receptor,Ki,=,34.0,nM,CHEMBL3825886,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cell membranes after 1 hr by liquid scintillation counting,CHEMBL3822362,KI,COCC(=O)N1CC[C@@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)c2cc(Cc3ccccc3)ccc21
CHEMBL3823958,CHEMBL237,Kappa opioid receptor,Ki,=,39.0,nM,CHEMBL3825886,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cell membranes after 1 hr by liquid scintillation counting,CHEMBL3822362,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCN(C(=O)c2ccccc2)c2ccc(Cc3ccccc3)cc21
CHEMBL3824309,CHEMBL237,Kappa opioid receptor,Ki,=,4.3,nM,CHEMBL3825886,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cell membranes after 1 hr by liquid scintillation counting,CHEMBL3822362,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCN(CC(N)=O)c2ccc(Cc3ccccc3)cc21
CHEMBL3823815,CHEMBL237,Kappa opioid receptor,Ki,=,15.0,nM,CHEMBL3825886,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cell membranes after 1 hr by liquid scintillation counting,CHEMBL3822362,KI,CCOC(=O)CN1CC[C@@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)c2cc(Cc3ccccc3)ccc21
CHEMBL3824013,CHEMBL237,Kappa opioid receptor,Ki,=,280.0,nM,CHEMBL3825886,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cell membranes after 1 hr by liquid scintillation counting,CHEMBL3822362,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCN(CC(=O)O)c2ccc(Cc3ccccc3)cc21
CHEMBL3823186,CHEMBL237,Kappa opioid receptor,Ki,=,58.0,nM,CHEMBL3825886,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cell membranes after 1 hr by liquid scintillation counting,CHEMBL3822362,KI,CCC(=O)N1CC[C@@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)c2cc(Cc3ccc4ccccc4c3)ccc21
CHEMBL3823891,CHEMBL237,Kappa opioid receptor,Ki,=,64.0,nM,CHEMBL3825886,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cell membranes after 1 hr by liquid scintillation counting,CHEMBL3822362,KI,CCCC(=O)N1CC[C@@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)c2cc(Cc3ccc4ccccc4c3)ccc21
CHEMBL3824356,CHEMBL237,Kappa opioid receptor,Ki,=,190.0,nM,CHEMBL3825886,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cell membranes after 1 hr by liquid scintillation counting,CHEMBL3822362,KI,COC(=O)N1CC[C@@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)c2cc(Cc3ccc4ccccc4c3)ccc21
CHEMBL982,CHEMBL237,Kappa opioid receptor,Ki,=,0.083,nM,CHEMBL3857936,B,"Displacement of [3H]U69,593 from human kappa-opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting",CHEMBL3856219,KI,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL3923010,CHEMBL237,Kappa opioid receptor,Ki,=,211.0,nM,CHEMBL3858678,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting",CHEMBL3856240,KI,Oc1cccc(CCN(CCc2ccccc2)CCc2ccccc2)c1
CHEMBL3890511,CHEMBL237,Kappa opioid receptor,Ki,=,36.3,nM,CHEMBL3858678,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting",CHEMBL3856240,KI,Oc1ccc(CCN(CCc2ccccc2)CC2CCC2)cc1
CHEMBL3950863,CHEMBL237,Kappa opioid receptor,Ki,=,218.0,nM,CHEMBL3858678,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting",CHEMBL3856240,KI,Oc1ccc(CCN(CCc2ccccc2)CC2CC2)cc1
CHEMBL3897499,CHEMBL237,Kappa opioid receptor,Ki,=,416.0,nM,CHEMBL3869797,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEKT cells measured after 90 mins by microbeta scintillation counting method,CHEMBL3868615,KI,CCCN1CC[C@H]2c3cc4ccc(C(F)(F)F)cc4nc3[C@H](CC)[C@H]3CCC[C@@H]1[C@@H]32
CHEMBL3959852,CHEMBL237,Kappa opioid receptor,Ki,=,1695.0,nM,CHEMBL3869797,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEKT cells measured after 90 mins by microbeta scintillation counting method,CHEMBL3868615,KI,CCCN1CC[C@H]2c3cc4cccc(OC)c4nc3[C@H](CC)[C@H]3CCC[C@@H]1[C@@H]32
CHEMBL3951093,CHEMBL237,Kappa opioid receptor,Ki,=,372.0,nM,CHEMBL3869797,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEKT cells measured after 90 mins by microbeta scintillation counting method,CHEMBL3868615,KI,CCCN1CC[C@H]2c3cc4cc(Cl)ccc4nc3[C@H](CC)[C@H]3CCC[C@@H]1[C@@H]32
CHEMBL3970903,CHEMBL237,Kappa opioid receptor,Ki,=,493.0,nM,CHEMBL3869797,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEKT cells measured after 90 mins by microbeta scintillation counting method,CHEMBL3868615,KI,CCCN1CC[C@H]2c3cc4ccccc4nc3[C@H](CC)[C@H]3CCC[C@@H]1[C@@H]32
CHEMBL3952259,CHEMBL237,Kappa opioid receptor,Ki,=,3488.0,nM,CHEMBL3869797,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEKT cells measured after 90 mins by microbeta scintillation counting method,CHEMBL3868615,KI,CC[C@H]1c2nc3ccccc3cc2[C@@H]2CCN(C)[C@@H]3CCC[C@H]1[C@H]32
CHEMBL3889749,CHEMBL237,Kappa opioid receptor,Ki,=,1602.0,nM,CHEMBL3869797,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEKT cells measured after 90 mins by microbeta scintillation counting method,CHEMBL3868615,KI,COc1ccc(C[C@H]2C(=O)C[C@@H]3CCN(CC4CCCCC4)[C@@H]4CCC[C@H]2[C@@H]34)cc1
CHEMBL3910552,CHEMBL237,Kappa opioid receptor,Ki,=,1396.0,nM,CHEMBL3869797,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEKT cells measured after 90 mins by microbeta scintillation counting method,CHEMBL3868615,KI,O=C1C[C@@H]2CCN(Cc3nccs3)[C@@H]3CCC[C@@H]([C@@H]23)[C@H]1Cc1ccccc1
CHEMBL3980626,CHEMBL237,Kappa opioid receptor,Ki,=,638.0,nM,CHEMBL3869797,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEKT cells measured after 90 mins by microbeta scintillation counting method,CHEMBL3868615,KI,O=C1C[C@@H]2CCN(Cc3cccs3)[C@@H]3CCC[C@@H]([C@@H]23)[C@H]1Cc1ccccc1
CHEMBL3945203,CHEMBL237,Kappa opioid receptor,Ki,=,1229.0,nM,CHEMBL3869797,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEKT cells measured after 90 mins by microbeta scintillation counting method,CHEMBL3868615,KI,O=C1C[C@@H]2CCN(CC3CCCCC3)[C@@H]3CCC[C@@H]([C@@H]23)[C@H]1Cc1ccccc1
CHEMBL3948140,CHEMBL237,Kappa opioid receptor,Ki,=,711.0,nM,CHEMBL3869797,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEKT cells measured after 90 mins by microbeta scintillation counting method,CHEMBL3868615,KI,CC(C)CCN1CC[C@H]2CC(=O)[C@H](Cc3ccccc3)[C@H]3CCC[C@@H]1[C@H]23
CHEMBL3954961,CHEMBL237,Kappa opioid receptor,Ki,=,3624.0,nM,CHEMBL3869797,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEKT cells measured after 90 mins by microbeta scintillation counting method,CHEMBL3868615,KI,CCCN1CC[C@H]2CC(=O)[C@H](Cc3ccccc3)[C@H]3CCC[C@@H]1[C@H]23
CHEMBL3946273,CHEMBL237,Kappa opioid receptor,Ki,=,1474.0,nM,CHEMBL3869797,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEKT cells measured after 90 mins by microbeta scintillation counting method,CHEMBL3868615,KI,CC[C@H]1C(=O)C[C@@H]2CCN(Cc3cccs3)[C@@H]3CCC[C@H]1[C@@H]23
CHEMBL3890935,CHEMBL237,Kappa opioid receptor,Ki,=,278.0,nM,CHEMBL3869797,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEKT cells measured after 90 mins by microbeta scintillation counting method,CHEMBL3868615,KI,CC[C@H]1C(=O)C[C@@H]2CCN(CC3CCCCC3)[C@@H]3CCC[C@H]1[C@@H]23
CHEMBL3918997,CHEMBL237,Kappa opioid receptor,Ki,=,1276.0,nM,CHEMBL3869797,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEKT cells measured after 90 mins by microbeta scintillation counting method,CHEMBL3868615,KI,CC[C@H]1C(=O)C[C@@H]2CCN(CCC(C)C)[C@@H]3CCC[C@H]1[C@@H]23
CHEMBL3695216,CHEMBL237,Kappa opioid receptor,Ki,=,135.8,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(C)(C)OC(=O)N1CC2CN(c3nc4ccccc4n(C4CCN(C5CCCCCCC5)CC4)c3=O)CC2C1
CHEMBL3695217,CHEMBL237,Kappa opioid receptor,Ki,=,224.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(NCC(O)CO)nc2ccccc2n1[C@H]1C[C@H]2CC[C@@H](C1)N2C1CCCCCCC1
CHEMBL3695218,CHEMBL237,Kappa opioid receptor,Ki,=,154.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC(=O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3695219,CHEMBL237,Kappa opioid receptor,Ki,=,657.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)C1CCN(c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)CC1
CHEMBL3695221,CHEMBL237,Kappa opioid receptor,Ki,=,14.9,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,N[C@@H]1CCN(c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)C1
CHEMBL3695222,CHEMBL237,Kappa opioid receptor,Ki,=,5350.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC(=O)[C@H](CO)Nc1nc2ccccc2n([C@@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3695224,CHEMBL237,Kappa opioid receptor,Ki,=,2840.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)CNc1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3695228,CHEMBL237,Kappa opioid receptor,Ki,=,19250.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)Cc1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3695229,CHEMBL237,Kappa opioid receptor,Ki,=,1203.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)CC1CCN(c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)C1
CHEMBL3695230,CHEMBL237,Kappa opioid receptor,Ki,=,998.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)[C@@H](CO)Nc1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3695234,CHEMBL237,Kappa opioid receptor,Ki,=,381.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C1CCN(c2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)N1
CHEMBL3695235,CHEMBL237,Kappa opioid receptor,Ki,=,55.8,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,COc1ccc(NC(=O)c2nc3ccccc3n([C@@]3(C)C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)cn1
CHEMBL3695236,CHEMBL237,Kappa opioid receptor,Ki,=,460.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CONC(=O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3695237,CHEMBL237,Kappa opioid receptor,Ki,=,161.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(Nc1ccc(=O)[nH]c1)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3695238,CHEMBL237,Kappa opioid receptor,Ki,=,743.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,COc1ccc(NC(=O)c2nc3ccccc3n([C@@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)cn1
CHEMBL3695239,CHEMBL237,Kappa opioid receptor,Ki,=,2600.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(Nc1ccc(=O)[nH]c1)c1nc2ccccc2n([C@@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3695240,CHEMBL237,Kappa opioid receptor,Ki,=,380.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(NCC(O)CO)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3898898,CHEMBL237,Kappa opioid receptor,Ki,=,422.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,C[C@]12CC[C@H](C[C@H](N3C(=O)C(N[C@@H](CO)C(=O)O)Nc4ccccc43)C1)N2C1CCCCCCC1
CHEMBL3695242,CHEMBL237,Kappa opioid receptor,Ki,=,480.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(NO)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3695243,CHEMBL237,Kappa opioid receptor,Ki,=,250.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,C[C@@]12CC[C@@H](C[C@@H](n3c(=O)c(C(=O)NCC(=O)O)nc4ccccc43)C1)N2C1CCCCCCC1
CHEMBL3695244,CHEMBL237,Kappa opioid receptor,Ki,=,180.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(NC(CO)C(=O)O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3695245,CHEMBL237,Kappa opioid receptor,Ki,=,2430.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C23CC4CC(CC(C4)C2)C3)c1=O
CHEMBL3639941,CHEMBL237,Kappa opioid receptor,Ki,=,707.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)CNCCNc1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3695249,CHEMBL237,Kappa opioid receptor,Ki,=,3320.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)CN(CCNc1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O)CC(=O)O
CHEMBL3695251,CHEMBL237,Kappa opioid receptor,Ki,=,346.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)[C@@H](Nc1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O)c1ccccc1
CHEMBL3695252,CHEMBL237,Kappa opioid receptor,Ki,=,534.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)[C@H](Cc1ccccc1)Nc1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3695253,CHEMBL237,Kappa opioid receptor,Ki,=,871.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)C1(O)CCN(c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)CC1
CHEMBL3695254,CHEMBL237,Kappa opioid receptor,Ki,=,67.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C1NC(=O)C2(CCN(c3nc4ccccc4n([C@H]4C[C@H]5CC[C@@H](C4)N5C4CCCCCCC4)c3=O)CC2)N1
CHEMBL3939135,CHEMBL237,Kappa opioid receptor,Ki,=,568.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)C1CCN(CCNc2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)CC1
CHEMBL3695255,CHEMBL237,Kappa opioid receptor,Ki,=,1493.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)CNC(=O)CNc1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3695256,CHEMBL237,Kappa opioid receptor,Ki,=,224.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC1(C(=O)O)CCN(c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)CC1
CHEMBL3698861,CHEMBL237,Kappa opioid receptor,Ki,=,25.9,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C1CN(c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)CCN1
CHEMBL3698862,CHEMBL237,Kappa opioid receptor,Ki,=,863.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)C(CO)NCCNc1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698863,CHEMBL237,Kappa opioid receptor,Ki,=,256.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(=O)NC1(C(=O)O)CCN(c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)CC1
CHEMBL3698864,CHEMBL237,Kappa opioid receptor,Ki,=,1650.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)C1(O)CCN(c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)C1
CHEMBL3698865,CHEMBL237,Kappa opioid receptor,Ki,=,740.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC(=O)CN(CCNc1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O)CC(=O)O
CHEMBL3698866,CHEMBL237,Kappa opioid receptor,Ki,=,890.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(C)(Nc1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O)C(=O)O
CHEMBL3698867,CHEMBL237,Kappa opioid receptor,Ki,=,920.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)C1(Nc2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)CCCCC1
CHEMBL3698868,CHEMBL237,Kappa opioid receptor,Ki,=,1360.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)N1CCN(c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)CC1=O
CHEMBL3698869,CHEMBL237,Kappa opioid receptor,Ki,=,134.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)CN1CC2CN(c3nc4ccccc4n([C@H]4C[C@H]5CC[C@@H](C4)N5C4CCCCCCC4)c3=O)CC2C1
CHEMBL3698870,CHEMBL237,Kappa opioid receptor,Ki,=,750.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)C1CCCN1C(=O)CNc1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698872,CHEMBL237,Kappa opioid receptor,Ki,=,488.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)C(=O)N1CC2CN(c3nc4ccccc4n(C4CCN(C5CCCCCCC5)CC4)c3=O)CC2C1
CHEMBL3698873,CHEMBL237,Kappa opioid receptor,Ki,=,1153.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)CC1CCN(c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)CC1
CHEMBL3698874,CHEMBL237,Kappa opioid receptor,Ki,=,429.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC1(C(=O)O)CCN(c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)C1
CHEMBL3698876,CHEMBL237,Kappa opioid receptor,Ki,=,2032.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)CN(CCO)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698877,CHEMBL237,Kappa opioid receptor,Ki,=,46.3,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CCOC(=O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698878,CHEMBL237,Kappa opioid receptor,Ki,=,440.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698879,CHEMBL237,Kappa opioid receptor,Ki,=,2055.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(C)C1CCC(N2[C@@H]3CC[C@H]2C[C@@H](n2c(=O)c(C(=O)O)nc4ccccc42)C3)CC1
CHEMBL3698882,CHEMBL237,Kappa opioid receptor,Ki,=,6000.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3COC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698884,CHEMBL237,Kappa opioid receptor,Ki,=,66.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CCOC(=O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3695245,CHEMBL237,Kappa opioid receptor,Ki,=,3500.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C23CC4CC(CC(C4)C2)C3)c1=O
CHEMBL3698889,CHEMBL237,Kappa opioid receptor,Ki,=,1600.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2Cc3cccc4cccc2c34)c1=O
CHEMBL3698890,CHEMBL237,Kappa opioid receptor,Ki,=,1116.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC1(N2CCC(n3c(=O)c(C(=O)O)nc4ccccc43)CC2)CCCCCCC1
CHEMBL3698892,CHEMBL237,Kappa opioid receptor,Ki,=,1430.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC12CC3CC(C)(C1)CC(N1[C@@H]4CC[C@H]1C[C@@H](n1c(=O)c(C(=O)O)nc5ccccc51)C4)(C3)C2
CHEMBL3698893,CHEMBL237,Kappa opioid receptor,Ki,=,5625.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C23CC4CC(CC(C4)C2)C3)c1=O
CHEMBL3889570,CHEMBL237,Kappa opioid receptor,Ki,=,2473.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CCC1(N2CCC(n3c(=O)c(C(=O)O)nc4ccccc43)CC2)CCCCCCC1
CHEMBL3698894,CHEMBL237,Kappa opioid receptor,Ki,=,3272.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CCCC1(N2CCC(n3c(=O)c(C(=O)O)nc4ccccc43)CC2)CCCCCCC1
CHEMBL3698895,CHEMBL237,Kappa opioid receptor,Ki,=,447.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)N[C@@H]1CCN(c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)C1
CHEMBL3698896,CHEMBL237,Kappa opioid receptor,Ki,=,64.2,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1ccncc1Nc1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698897,CHEMBL237,Kappa opioid receptor,Ki,=,223.4,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CN(C(=O)O)[C@@H]1CCN(c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)C1
CHEMBL3698893,CHEMBL237,Kappa opioid receptor,Ki,=,5035.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C23CC4CC(CC(C4)C2)C3)c1=O
CHEMBL3698892,CHEMBL237,Kappa opioid receptor,Ki,=,6866.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC12CC3CC(C)(C1)CC(N1[C@@H]4CC[C@H]1C[C@@H](n1c(=O)c(C(=O)O)nc5ccccc51)C4)(C3)C2
CHEMBL3698898,CHEMBL237,Kappa opioid receptor,Ki,=,16760.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(C)(C)CC(C)(C)N1[C@@H]2CC[C@H]1C[C@@H](n1c(=O)c(C(=O)O)nc3ccccc31)C2
CHEMBL3698899,CHEMBL237,Kappa opioid receptor,Ki,=,565.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C2CCCCCCCCC2)c1=O
CHEMBL3698900,CHEMBL237,Kappa opioid receptor,Ki,=,375.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C2CCCCCCCC2)c1=O
CHEMBL3698901,CHEMBL237,Kappa opioid receptor,Ki,=,4470.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C2C3CCCC2CCC3)c1=O
CHEMBL3698902,CHEMBL237,Kappa opioid receptor,Ki,=,425.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCCCC2)c1=O
CHEMBL3698903,CHEMBL237,Kappa opioid receptor,Ki,=,1547.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2C3CCCC2CCC3)c1=O
CHEMBL3698904,CHEMBL237,Kappa opioid receptor,Ki,=,469.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCCC2)c1=O
CHEMBL3698906,CHEMBL237,Kappa opioid receptor,Ki,=,129.5,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(NC(Cc1c[nH]cn1)C(=O)O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698907,CHEMBL237,Kappa opioid receptor,Ki,=,49.7,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(NC(Cc1ccccc1)C(=O)O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3647963,CHEMBL237,Kappa opioid receptor,Ki,=,76.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCCCCCC2)c1=O
CHEMBL3647958,CHEMBL237,Kappa opioid receptor,Ki,=,2280.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C2CC3CCCC(C3)C2)c1=O
CHEMBL3647958,CHEMBL237,Kappa opioid receptor,Ki,=,5345.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C2CC3CCCC(C3)C2)c1=O
CHEMBL3664217,CHEMBL237,Kappa opioid receptor,Ki,=,41.0,nM,CHEMBL3705280,B,Competitive Inhibition Assay: In vitro binding assay: The affinities of compounds for opioid receptors were determined by competitive inhibition of [3H]diprenorphine binding to kappa opioid receptors (KOPR).,CHEMBL3638558,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CCC1C(=O)O[C@@H](c3ccoc3)C[C@@]12C
CHEMBL3664216,CHEMBL237,Kappa opioid receptor,Ki,=,55.0,nM,CHEMBL3705280,B,Competitive Inhibition Assay: In vitro binding assay: The affinities of compounds for opioid receptors were determined by competitive inhibition of [3H]diprenorphine binding to kappa opioid receptors (KOPR).,CHEMBL3638558,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CCC1C(=O)O[C@H](C(=O)O)C[C@@]12C
CHEMBL456695,CHEMBL237,Kappa opioid receptor,Ki,=,498.0,nM,CHEMBL3705280,B,Competitive Inhibition Assay: In vitro binding assay: The affinities of compounds for opioid receptors were determined by competitive inhibition of [3H]diprenorphine binding to kappa opioid receptors (KOPR).,CHEMBL3638558,KI,COC[C@@H]1C[C@]2(C)[C@H]3C(=O)[C@@H](OC(C)=O)C[C@@H](C(=O)OC)[C@]3(C)CC[C@H]2C(=O)O1
CHEMBL458869,CHEMBL237,Kappa opioid receptor,Ki,=,497.0,nM,CHEMBL3705280,B,Competitive Inhibition Assay: In vitro binding assay: The affinities of compounds for opioid receptors were determined by competitive inhibition of [3H]diprenorphine binding to kappa opioid receptors (KOPR).,CHEMBL3638558,KI,CCOC[C@@H]1C[C@]2(C)[C@H]3C(=O)[C@@H](OC(C)=O)C[C@@H](C(=O)OC)[C@]3(C)CC[C@H]2C(=O)O1
CHEMBL514597,CHEMBL237,Kappa opioid receptor,Ki,=,555.0,nM,CHEMBL3705280,B,Competitive Inhibition Assay: In vitro binding assay: The affinities of compounds for opioid receptors were determined by competitive inhibition of [3H]diprenorphine binding to kappa opioid receptors (KOPR).,CHEMBL3638558,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](COC(C)=O)C[C@]21C
CHEMBL458870,CHEMBL237,Kappa opioid receptor,Ki,=,38.0,nM,CHEMBL3705280,B,Competitive Inhibition Assay: In vitro binding assay: The affinities of compounds for opioid receptors were determined by competitive inhibition of [3H]diprenorphine binding to kappa opioid receptors (KOPR).,CHEMBL3638558,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C(=O)c3cccs3)C[C@]21C
CHEMBL457341,CHEMBL237,Kappa opioid receptor,Ki,=,83.0,nM,CHEMBL3705280,B,Competitive Inhibition Assay: In vitro binding assay: The affinities of compounds for opioid receptors were determined by competitive inhibition of [3H]diprenorphine binding to kappa opioid receptors (KOPR).,CHEMBL3638558,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C(=O)c3cnccn3)C[C@]21C
CHEMBL456055,CHEMBL237,Kappa opioid receptor,Ki,=,20.0,nM,CHEMBL3705280,B,Competitive Inhibition Assay: In vitro binding assay: The affinities of compounds for opioid receptors were determined by competitive inhibition of [3H]diprenorphine binding to kappa opioid receptors (KOPR).,CHEMBL3638558,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C(O)c3ccco3)C[C@]21C
CHEMBL456056,CHEMBL237,Kappa opioid receptor,Ki,=,154.0,nM,CHEMBL3705280,B,Competitive Inhibition Assay: In vitro binding assay: The affinities of compounds for opioid receptors were determined by competitive inhibition of [3H]diprenorphine binding to kappa opioid receptors (KOPR).,CHEMBL3638558,KI,COC(=O)[C@@H]1C[C@]2(C)[C@H]3C(=O)[C@@H](OC(C)=O)C[C@@H](C(=O)OC)[C@]3(C)CC[C@H]2C(=O)O1
CHEMBL456057,CHEMBL237,Kappa opioid receptor,Ki,=,196.0,nM,CHEMBL3705280,B,Competitive Inhibition Assay: In vitro binding assay: The affinities of compounds for opioid receptors were determined by competitive inhibition of [3H]diprenorphine binding to kappa opioid receptors (KOPR).,CHEMBL3638558,KI,CCOC(=O)[C@@H]1C[C@]2(C)[C@H]3C(=O)[C@@H](OC(C)=O)C[C@@H](C(=O)OC)[C@]3(C)CC[C@H]2C(=O)O1
CHEMBL456923,CHEMBL237,Kappa opioid receptor,Ki,=,109.0,nM,CHEMBL3705280,B,Competitive Inhibition Assay: In vitro binding assay: The affinities of compounds for opioid receptors were determined by competitive inhibition of [3H]diprenorphine binding to kappa opioid receptors (KOPR).,CHEMBL3638558,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C(=O)OC(C)C)C[C@]21C
CHEMBL3665423,CHEMBL237,Kappa opioid receptor,Ki,=,439.0,nM,CHEMBL3706203,B,"-Opioid Receptor Binding Assays: -Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kappa opioid receptor (kappa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000g for 15 min at 4 C. and pellets resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL.",CHEMBL3638667,KI,O=c1[nH]c2ccccc2n(C2CCN(C3Cc4cccc5cccc3c45)CC2)c1=O
CHEMBL3665424,CHEMBL237,Kappa opioid receptor,Ki,=,6950.0,nM,CHEMBL3706203,B,"-Opioid Receptor Binding Assays: -Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kappa opioid receptor (kappa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000g for 15 min at 4 C. and pellets resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL.",CHEMBL3638667,KI,NC(=O)Cn1c(=O)c(=O)n(C2CCN(C3Cc4cccc5cccc3c45)CC2)c2ccccc21
CHEMBL3665433,CHEMBL237,Kappa opioid receptor,Ki,=,4232.0,nM,CHEMBL3706203,B,"-Opioid Receptor Binding Assays: -Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kappa opioid receptor (kappa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000g for 15 min at 4 C. and pellets resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL.",CHEMBL3638667,KI,N#CCn1c(=O)c(=O)n(C2CCN(C3CCCCCCC3)CC2)c2ccccc21
CHEMBL3665436,CHEMBL237,Kappa opioid receptor,Ki,=,559.0,nM,CHEMBL3706203,B,"-Opioid Receptor Binding Assays: -Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kappa opioid receptor (kappa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000g for 15 min at 4 C. and pellets resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL.",CHEMBL3638667,KI,O=c1[nH]c2ccc(N3CCOCC3)cc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3665440,CHEMBL237,Kappa opioid receptor,Ki,=,170.0,nM,CHEMBL3706203,B,"-Opioid Receptor Binding Assays: -Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kappa opioid receptor (kappa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000g for 15 min at 4 C. and pellets resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL.",CHEMBL3638667,KI,O=c1[nH]c2ccccc2n([C@@H]2C[C@H]3CCC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3665443,CHEMBL237,Kappa opioid receptor,Ki,=,119.0,nM,CHEMBL3706203,B,"-Opioid Receptor Binding Assays: -Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kappa opioid receptor (kappa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000g for 15 min at 4 C. and pellets resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL.",CHEMBL3638667,KI,O=c1[nH]c2ccccc2n([C@H]2C[C@H]3C=C[C@@H](C2)N3C2/C=C\CCCCC2)c1=O
CHEMBL3665444,CHEMBL237,Kappa opioid receptor,Ki,=,682.0,nM,CHEMBL3706203,B,"-Opioid Receptor Binding Assays: -Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kappa opioid receptor (kappa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000g for 15 min at 4 C. and pellets resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL.",CHEMBL3638667,KI,O=c1[nH]c2ccccc2n([C@@H]2C[C@H]3C=C[C@@H](C2)N3C2/C=C\CCCCC2)c1=O
CHEMBL3665435,CHEMBL237,Kappa opioid receptor,Ki,=,1317.0,nM,CHEMBL3706203,B,"-Opioid Receptor Binding Assays: -Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kappa opioid receptor (kappa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000g for 15 min at 4 C. and pellets resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL.",CHEMBL3638667,KI,O=c1[nH]c2ncccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3665425,CHEMBL237,Kappa opioid receptor,Ki,=,355.0,nM,CHEMBL3706203,B,"-Opioid Receptor Binding Assays: -Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kappa opioid receptor (kappa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000g for 15 min at 4 C. and pellets resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL.",CHEMBL3638667,KI,O=C1CC(=O)N(C2CCN(C3CCCCCCC3)CC2)c2ccccc2N1
CHEMBL3665419,CHEMBL237,Kappa opioid receptor,Ki,=,167.0,nM,CHEMBL3706203,B,"-Opioid Receptor Binding Assays: -Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kappa opioid receptor (kappa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000g for 15 min at 4 C. and pellets resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL.",CHEMBL3638667,KI,O=c1[nH]c2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3665422,CHEMBL237,Kappa opioid receptor,Ki,=,880.0,nM,CHEMBL3706203,B,"-Opioid Receptor Binding Assays: -Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kappa opioid receptor (kappa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000g for 15 min at 4 C. and pellets resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL.",CHEMBL3638667,KI,CC(C)C1CCC(N2CCC(n3c(=O)c(=O)[nH]c4ccccc43)CC2)CC1
CHEMBL3698834,CHEMBL237,Kappa opioid receptor,Ki,=,257.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CN(C)c1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698835,CHEMBL237,Kappa opioid receptor,Ki,=,888.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(NCCO)nc2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3698836,CHEMBL237,Kappa opioid receptor,Ki,=,22.5,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(N2CC3CNCC3C2)nc2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3698837,CHEMBL237,Kappa opioid receptor,Ki,=,165.2,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(NCc2ccccc2)nc2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3698838,CHEMBL237,Kappa opioid receptor,Ki,=,296.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(C)(C)OC(=O)NCCNc1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698840,CHEMBL237,Kappa opioid receptor,Ki,=,167.6,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NCCNc1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698841,CHEMBL237,Kappa opioid receptor,Ki,=,73.5,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(N2CCNCC2)nc2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3698842,CHEMBL237,Kappa opioid receptor,Ki,=,905.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CS(=O)(=O)NCCNc1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698843,CHEMBL237,Kappa opioid receptor,Ki,=,15.1,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CN1CC2CN(c3nc4ccccc4n(C4CCN(C5CCCCCCC5)CC4)c3=O)CC2C1
CHEMBL3698844,CHEMBL237,Kappa opioid receptor,Ki,=,283.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(=O)N1CC2CN(c3nc4ccccc4n(C4CCN(C5CCCCCCC5)CC4)c3=O)CC2C1
CHEMBL3698846,CHEMBL237,Kappa opioid receptor,Ki,=,92.9,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,Nc1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3695257,CHEMBL237,Kappa opioid receptor,Ki,=,328.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,COC(=O)C1CCN(c2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)CC1
CHEMBL3698847,CHEMBL237,Kappa opioid receptor,Ki,=,622.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(=O)Nc1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698848,CHEMBL237,Kappa opioid receptor,Ki,=,303.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C1CN(c2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)CCN1
CHEMBL3698849,CHEMBL237,Kappa opioid receptor,Ki,=,11500.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(N2Cc3ccccc3C2)nc2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3695259,CHEMBL237,Kappa opioid receptor,Ki,=,151.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(C)(C)OC(=O)NC1CCN(c2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)CC1
CHEMBL3695260,CHEMBL237,Kappa opioid receptor,Ki,=,30.4,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC1CCN(c2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)CC1
CHEMBL3695261,CHEMBL237,Kappa opioid receptor,Ki,=,514.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(=O)NC1CCN(c2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)CC1
CHEMBL3698850,CHEMBL237,Kappa opioid receptor,Ki,=,852.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,C=CCNc1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698851,CHEMBL237,Kappa opioid receptor,Ki,=,1300.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(NCC(O)CO)nc2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3695262,CHEMBL237,Kappa opioid receptor,Ki,=,191.4,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,N=C(N)NCCNc1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3695263,CHEMBL237,Kappa opioid receptor,Ki,=,583.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,COC(=O)[C@@H]1CCCN1c1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3695264,CHEMBL237,Kappa opioid receptor,Ki,=,1038.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,COC(=O)[C@@H]1C[C@@H](O)CN1c1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3695265,CHEMBL237,Kappa opioid receptor,Ki,=,481.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC(=O)C1CCN(c2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)CC1
CHEMBL3695266,CHEMBL237,Kappa opioid receptor,Ki,=,378.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CS(=O)(=O)NC1CCN(c2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)CC1
CHEMBL3695267,CHEMBL237,Kappa opioid receptor,Ki,=,67.5,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(NC2CCNCC2)nc2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3695268,CHEMBL237,Kappa opioid receptor,Ki,=,354.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC(=O)CNc1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3695269,CHEMBL237,Kappa opioid receptor,Ki,=,1282.6,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC(=O)[C@H](CO)Nc1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3695270,CHEMBL237,Kappa opioid receptor,Ki,=,46.34,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,COc1ccc(Nc2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)cn1
CHEMBL3695271,CHEMBL237,Kappa opioid receptor,Ki,=,222.01,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(=O)N[C@@H]1CCN(c2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)C1
CHEMBL3695272,CHEMBL237,Kappa opioid receptor,Ki,=,375.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(N2CCc3ccccc32)nc2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3695273,CHEMBL237,Kappa opioid receptor,Ki,=,57.3,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,N[C@H]1CCN(c2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)C1
CHEMBL3695276,CHEMBL237,Kappa opioid receptor,Ki,=,611.9,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC(=O)[C@@H]1CCCN1c1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3695277,CHEMBL237,Kappa opioid receptor,Ki,=,544.2,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(N2CCc3ccccc3C2)nc2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3695278,CHEMBL237,Kappa opioid receptor,Ki,=,301.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,COC(=O)c1ccc2c(c1)CN(c1nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c1=O)CC2
CHEMBL3695279,CHEMBL237,Kappa opioid receptor,Ki,=,805.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1ccc(Nc2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)c[nH]1
CHEMBL3695280,CHEMBL237,Kappa opioid receptor,Ki,=,191.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,COC(=O)C(CO)Nc1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3695281,CHEMBL237,Kappa opioid receptor,Ki,=,731.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC(=O)CCNc1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3695283,CHEMBL237,Kappa opioid receptor,Ki,=,971.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(=O)N1CCC(Nc2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)CC1
CHEMBL3695285,CHEMBL237,Kappa opioid receptor,Ki,=,22.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,N[C@@H]1CCN(c2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)C1
CHEMBL3695286,CHEMBL237,Kappa opioid receptor,Ki,=,712.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(N2CCC(O)CC2)nc2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3695288,CHEMBL237,Kappa opioid receptor,Ki,=,1195.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(NC[C@@H](O)CO)nc2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3698750,CHEMBL237,Kappa opioid receptor,Ki,=,929.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(NC[C@H](O)CO)nc2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3698751,CHEMBL237,Kappa opioid receptor,Ki,=,544.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)[C@H](CO)Nc1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698752,CHEMBL237,Kappa opioid receptor,Ki,=,379.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CCOC(=O)CNc1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698753,CHEMBL237,Kappa opioid receptor,Ki,=,175.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NCC(O)CNc1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698754,CHEMBL237,Kappa opioid receptor,Ki,=,457.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(=O)N[C@H]1CCN(c2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)C1
CHEMBL3698755,CHEMBL237,Kappa opioid receptor,Ki,=,510.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC(=O)C1CCCN(c2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)C1
CHEMBL3698756,CHEMBL237,Kappa opioid receptor,Ki,=,810.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CCOC(=O)CN(C)c1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698759,CHEMBL237,Kappa opioid receptor,Ki,=,4359.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC(=O)CNc1nc2ccccc2n(C2CCN(C34CC5CC(CC(C5)C3)C4)CC2)c1=O
CHEMBL3698760,CHEMBL237,Kappa opioid receptor,Ki,=,1149.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CN(CC(O)CO)c1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698761,CHEMBL237,Kappa opioid receptor,Ki,=,587.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CS(=O)(=O)N[C@@H]1CCN(c2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)C1
CHEMBL3698762,CHEMBL237,Kappa opioid receptor,Ki,=,666.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(NC(CO)CO)nc2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3698763,CHEMBL237,Kappa opioid receptor,Ki,=,1486.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(N2CC[C@H](O)C2)nc2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3698764,CHEMBL237,Kappa opioid receptor,Ki,=,161.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,COc1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698852,CHEMBL237,Kappa opioid receptor,Ki,=,141.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CCOC(=O)c1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698853,CHEMBL237,Kappa opioid receptor,Ki,=,1034.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698854,CHEMBL237,Kappa opioid receptor,Ki,=,23.4,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(C)(C)OC(=O)N1CC2CN(C(=O)c3nc4ccccc4n(C4CCN(C5CCCCCCC5)CC4)c3=O)CC2C1
CHEMBL3698765,CHEMBL237,Kappa opioid receptor,Ki,=,630.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698768,CHEMBL237,Kappa opioid receptor,Ki,=,418.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC(=O)c1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698769,CHEMBL237,Kappa opioid receptor,Ki,=,618.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CNC(=O)c1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698770,CHEMBL237,Kappa opioid receptor,Ki,=,994.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(NCC(O)CO)c1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698771,CHEMBL237,Kappa opioid receptor,Ki,=,132.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,COc1ccc(NC(=O)c2nc3ccccc3n(C3CCN(C4CCCCCCC4)CC3)c2=O)cn1
CHEMBL3698772,CHEMBL237,Kappa opioid receptor,Ki,=,669.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CN(C)C(=O)c1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698773,CHEMBL237,Kappa opioid receptor,Ki,=,391.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(Nc1ccc(=O)[nH]c1)c1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698774,CHEMBL237,Kappa opioid receptor,Ki,=,586.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CONC(=O)c1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698775,CHEMBL237,Kappa opioid receptor,Ki,=,245.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(NOCc1ccccc1)c1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698856,CHEMBL237,Kappa opioid receptor,Ki,=,182.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C1CNc2ccccc2N1C1CCN(C2CCCCCCC2)CC1
CHEMBL3698857,CHEMBL237,Kappa opioid receptor,Ki,=,83.5,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C1CN(C2CCN(C3CCCCCCC3)CC2)c2ccccc2N1
CHEMBL3698776,CHEMBL237,Kappa opioid receptor,Ki,=,536.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,N#Cc1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698777,CHEMBL237,Kappa opioid receptor,Ki,=,4490.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(NC[C@@H](O)CO)nc2ccccc2n1C1CCN(C23CC4CC(CC(C4)C2)C3)CC1
CHEMBL3698778,CHEMBL237,Kappa opioid receptor,Ki,=,253.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC(=O)CNc1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3695217,CHEMBL237,Kappa opioid receptor,Ki,=,224.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(NCC(O)CO)nc2ccccc2n1[C@H]1C[C@H]2CC[C@@H](C1)N2C1CCCCCCC1
CHEMBL3698779,CHEMBL237,Kappa opioid receptor,Ki,=,688.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(N2CC[C@@H](O)C2)nc2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3695218,CHEMBL237,Kappa opioid receptor,Ki,=,154.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC(=O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698781,CHEMBL237,Kappa opioid receptor,Ki,=,2728.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(NO)c1nc2ccccc2n(C2CCN(C3CCCCCCC3)CC2)c1=O
CHEMBL3698858,CHEMBL237,Kappa opioid receptor,Ki,=,130.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(N2CC3CNCC3C2)nc2ncccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3698782,CHEMBL237,Kappa opioid receptor,Ki,=,156.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=c1c(NC[C@@H](O)CO)nc2ccccc2n1[C@H]1C[C@H]2CC[C@@H](C1)N2C1CCCCCCC1
CHEMBL3698783,CHEMBL237,Kappa opioid receptor,Ki,=,4330.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,NC(=O)CNc1nc2ccccc2n([C@@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698785,CHEMBL237,Kappa opioid receptor,Ki,=,501.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccc(F)cc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698786,CHEMBL237,Kappa opioid receptor,Ki,=,220.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)CN1CCN(c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)CC1
CHEMBL3698787,CHEMBL237,Kappa opioid receptor,Ki,=,780.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1cccc(CNc2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)c1
CHEMBL3698788,CHEMBL237,Kappa opioid receptor,Ki,=,350.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)C1CCCN1C(=O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698789,CHEMBL237,Kappa opioid receptor,Ki,=,478.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CN(CC(=O)O)C(=O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698790,CHEMBL237,Kappa opioid receptor,Ki,=,144.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(C)(NC(=O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O)C(=O)O
CHEMBL3698791,CHEMBL237,Kappa opioid receptor,Ki,=,210.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CSCCC(NC(=O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O)C(=O)O
CHEMBL3698792,CHEMBL237,Kappa opioid receptor,Ki,=,229.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)CC(NC(=O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O)C(=O)O
CHEMBL3698793,CHEMBL237,Kappa opioid receptor,Ki,=,49.3,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(N[C@H](C(=O)O)c1ccccc1)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698794,CHEMBL237,Kappa opioid receptor,Ki,=,172.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(NC(=O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O)C(=O)O
CHEMBL3698795,CHEMBL237,Kappa opioid receptor,Ki,=,35.3,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(C)CC(NC(=O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O)C(=O)O
CHEMBL3698796,CHEMBL237,Kappa opioid receptor,Ki,=,909.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1ccc(CNC(=O)c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)cc1
CHEMBL3698798,CHEMBL237,Kappa opioid receptor,Ki,=,1720.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(NCc1nn[nH]n1)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698799,CHEMBL237,Kappa opioid receptor,Ki,=,835.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1ccc(CNC(=O)c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)nc1
CHEMBL3698801,CHEMBL237,Kappa opioid receptor,Ki,=,3090.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C23CC4CC(CC2C4)C3)c1=O
CHEMBL3698807,CHEMBL237,Kappa opioid receptor,Ki,=,16.2,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CCOC(=O)[C@@H]1CN(CCNc2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)C[C@H]1C(=O)OCC
CHEMBL3698808,CHEMBL237,Kappa opioid receptor,Ki,=,672.5,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)[C@@H]1CN(CCNc2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)C[C@H]1C(=O)O
CHEMBL3698809,CHEMBL237,Kappa opioid receptor,Ki,=,102.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CN(C)C1(C(=O)O)CCN(c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)CC1
CHEMBL3698810,CHEMBL237,Kappa opioid receptor,Ki,=,31.2,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CCOC(=O)C1CN(CCNc2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4C3CCCCCCC3)c2=O)C[C@H]1C(=O)OCC
CHEMBL3698813,CHEMBL237,Kappa opioid receptor,Ki,=,5154.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC1(N2[C@@H]3CCC[C@H]2C[C@@H](n2c(=O)c(C(=O)O)nc4ccccc42)C3)CCCCCCC1
CHEMBL3698814,CHEMBL237,Kappa opioid receptor,Ki,=,365.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C2/C=C\CCCCC2)c1=O
CHEMBL3698816,CHEMBL237,Kappa opioid receptor,Ki,=,63.4,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(N[C@H](C(=O)O)c1ccccc1)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C2CCCCCCC2)c1=O
CHEMBL3698817,CHEMBL237,Kappa opioid receptor,Ki,=,162.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CCOC(=O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C(C)CCC(C)C)c1=O
CHEMBL3698818,CHEMBL237,Kappa opioid receptor,Ki,=,85.4,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CCOC(=O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C(C)CC(C)C)c1=O
CHEMBL3698819,CHEMBL237,Kappa opioid receptor,Ki,=,1582.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(C)CCC(C)N1[C@@H]2CCC[C@H]1C[C@@H](n1c(=O)c(C(=O)O)nc3ccccc31)C2
CHEMBL3698820,CHEMBL237,Kappa opioid receptor,Ki,=,523.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(C)CC(C)N1[C@@H]2CCC[C@H]1C[C@@H](n1c(=O)c(C(=O)O)nc3ccccc31)C2
CHEMBL3647961,CHEMBL237,Kappa opioid receptor,Ki,=,2889.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C23CCCC(CCC2)C3)c1=O
CHEMBL3698821,CHEMBL237,Kappa opioid receptor,Ki,=,589.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CN(CC(=O)O)[C@H]1CCN(c2nc3ccccc3n([C@H]3C[C@H]4CCC[C@@H](C3)N4C3CCCCCCC3)c2=O)C1
CHEMBL3984664,CHEMBL237,Kappa opioid receptor,Ki,=,20.6,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CCOC(=O)c1nc2ccccc2n([C@@H]2C[C@H]3CCC[C@@H](C2)N3C/C=C2\CCC3CC2C3(C)C)c1=O
CHEMBL3698823,CHEMBL237,Kappa opioid receptor,Ki,=,3891.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C23CCC(CC2)C3)c1=O
CHEMBL3647963,CHEMBL237,Kappa opioid receptor,Ki,=,76.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCCCCCC2)c1=O
CHEMBL3647960,CHEMBL237,Kappa opioid receptor,Ki,=,640.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCCCCC2)c1=O
CHEMBL3698825,CHEMBL237,Kappa opioid receptor,Ki,=,1756.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CCCC[C@@H](C2)N3C2/C=C\CCCCC2)c1=O
CHEMBL3647959,CHEMBL237,Kappa opioid receptor,Ki,=,2691.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CC3CCCC(C3)C2)c1=O
CHEMBL3647959,CHEMBL237,Kappa opioid receptor,Ki,=,6143.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CC3CCCC(C3)C2)c1=O
CHEMBL3698826,CHEMBL237,Kappa opioid receptor,Ki,=,10240.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C2C3CC4CC(C3)CC2C4)c1=O
CHEMBL3698827,CHEMBL237,Kappa opioid receptor,Ki,=,63.0,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC1(C)[C@H]2CC[C@@H](CCN3[C@@H]4CC[C@H]3C[C@@H](n3c(=O)c(C(=O)O)nc5ccccc53)C4)[C@@H]1C2
CHEMBL3698828,CHEMBL237,Kappa opioid receptor,Ki,=,480.5,nM,CHEMBL3887032,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 uL binding buffer (5% DMSO, 50mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200uL ice-cold binding buffer. Filter plates were subsequently dried at 50C for 1-2 hours. Fifty uL/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886144,KI,CC(C)CC(C)N1[C@@H]2CC[C@H]1C[C@@H](n1c(=O)c(C(=O)O)nc3ccccc31)C2
CHEMBL3965826,CHEMBL237,Kappa opioid receptor,Ki,=,13.8,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4CNC(=O)[C@H](C)N)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3691854,CHEMBL237,Kappa opioid receptor,Ki,=,0.06,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNC(=O)[C@@H](N)Cc1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691855,CHEMBL237,Kappa opioid receptor,Ki,=,0.09,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,CC[C@H](C)[C@H](N)C(=O)NC[C@H]1C[C@@]23CC[C@]1(OC)[C@@H]1Oc4c(O)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5
CHEMBL3691856,CHEMBL237,Kappa opioid receptor,Ki,=,0.14,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNC(=O)[C@H](C)N)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691857,CHEMBL237,Kappa opioid receptor,Ki,=,0.18,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNC(=O)[C@@H](N)CO)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691858,CHEMBL237,Kappa opioid receptor,Ki,=,0.06,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNC(=O)[C@@H](N)CC(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691859,CHEMBL237,Kappa opioid receptor,Ki,=,0.07,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNC(=O)C1CCCN1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691860,CHEMBL237,Kappa opioid receptor,Ki,=,0.13,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNC(=O)[C@@H](N)Cc1ccc(O)cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691861,CHEMBL237,Kappa opioid receptor,Ki,=,3.05,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNC(=O)[C@@H](N)CC(=O)O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691862,CHEMBL237,Kappa opioid receptor,Ki,=,0.25,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNC(=O)[C@@H](N)Cc1c[nH]cn1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691863,CHEMBL237,Kappa opioid receptor,Ki,=,0.35,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNC(=O)[C@H](C)NC(C)=O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691864,CHEMBL237,Kappa opioid receptor,Ki,=,0.16,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNC(=O)[C@H](Cc1ccccc1)NC(C)=O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691865,CHEMBL237,Kappa opioid receptor,Ki,=,0.07,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNC(=O)CN)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691866,CHEMBL237,Kappa opioid receptor,Ki,=,0.13,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNC(=O)[C@H](Cc1ccc(O)cc1)NC(C)=O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691867,CHEMBL237,Kappa opioid receptor,Ki,=,0.4,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,CC[C@H](C)[C@H](NC(C)=O)C(=O)NC[C@H]1C[C@@]23CC[C@]1(OC)[C@@H]1Oc4c(O)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5
CHEMBL3691868,CHEMBL237,Kappa opioid receptor,Ki,=,0.16,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNC(=O)[C@@H]1CCCN1C(C)=O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691869,CHEMBL237,Kappa opioid receptor,Ki,=,0.95,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNC(=O)[C@H](Cc1c[nH]cn1)NC(C)=O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691870,CHEMBL237,Kappa opioid receptor,Ki,=,0.22,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNC(=O)CNC(C)=O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691871,CHEMBL237,Kappa opioid receptor,Ki,=,7.1,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNC(=O)[C@H](CC(=O)O)NC(C)=O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691872,CHEMBL237,Kappa opioid receptor,Ki,=,0.62,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNC(=O)[C@H](CC(N)=O)NC(C)=O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691873,CHEMBL237,Kappa opioid receptor,Ki,=,0.35,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNC(=O)[C@H](CC(C)C)NC(C)=O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691874,CHEMBL237,Kappa opioid receptor,Ki,=,0.09,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNC(=O)[C@@H](N)CC(N)=O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691875,CHEMBL237,Kappa opioid receptor,Ki,=,0.61,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNC(=O)[C@H](CO)NC(C)=O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691876,CHEMBL237,Kappa opioid receptor,Ki,=,0.11,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNC(=O)C1=CNC4C=CC=CC14)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691877,CHEMBL237,Kappa opioid receptor,Ki,=,0.07,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNS(=O)(=O)c1ccc(C)cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691878,CHEMBL237,Kappa opioid receptor,Ki,=,0.08,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNS(=O)(=O)c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691879,CHEMBL237,Kappa opioid receptor,Ki,=,0.37,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNS(=O)(=O)C(F)(F)F)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691880,CHEMBL237,Kappa opioid receptor,Ki,=,0.74,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNS(C)(=O)=O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691881,CHEMBL237,Kappa opioid receptor,Ki,=,2.62,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,COC12CC[C@@]3(C[C@@H]1CNC(=O)CCC(=O)O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691882,CHEMBL237,Kappa opioid receptor,Ki,=,0.17,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,COC12CC[C@@]3(C[C@@H]1CNC(=O)CCC(N)=O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3639907,CHEMBL237,Kappa opioid receptor,Ki,=,13.52,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,COC12CC[C@@]3(C[C@@H]1CNC(=O)CCCCC(=O)O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691883,CHEMBL237,Kappa opioid receptor,Ki,=,0.47,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,COC12CC[C@@]3(C[C@@H]1CNC(=O)CCCCC(N)=O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691884,CHEMBL237,Kappa opioid receptor,Ki,=,15.28,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,COC12CC[C@@]3(C[C@@H]1CNC(=O)c1nccnc1C(=O)O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691885,CHEMBL237,Kappa opioid receptor,Ki,=,0.48,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,COC12CC[C@@]3(C[C@@H]1CNC(=O)c1nccnc1C(N)=O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691886,CHEMBL237,Kappa opioid receptor,Ki,=,0.32,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,COC12CC[C@@]3(C[C@@H]1CNC(=O)c1ccccc1C(=O)O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691887,CHEMBL237,Kappa opioid receptor,Ki,=,1.15,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,COC12CC[C@@]3(C[C@@H]1CNC(=O)CCc1nnn[nH]1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691888,CHEMBL237,Kappa opioid receptor,Ki,=,0.08,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,COC12CC[C@@]3(C[C@@H]1CNC(=O)Nc1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3691889,CHEMBL237,Kappa opioid receptor,Ki,=,0.1,nM,CHEMBL3705986,B,"Binding Assay: Kippa-Opioid Receptor Binding Assay Procedures: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (kippa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 mM at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant lc opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3639331,KI,COC12CC[C@@]3(C[C@@H]1CNC(=O)Nc1cccc(C)c1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4115704,CHEMBL237,Kappa opioid receptor,Ki,=,8.87,nM,CHEMBL3705914,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant kippa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 ul ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3638713,KI,
CHEMBL4115705,CHEMBL237,Kappa opioid receptor,Ki,=,23.33,nM,CHEMBL3705914,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant kippa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 ul ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3638713,KI,
CHEMBL4115706,CHEMBL237,Kappa opioid receptor,Ki,=,3.04,nM,CHEMBL3705914,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant kippa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 ul ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3638713,KI,
CHEMBL4115707,CHEMBL237,Kappa opioid receptor,Ki,=,2.19,nM,CHEMBL3705914,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant kippa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 ul ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3638713,KI,
CHEMBL4115708,CHEMBL237,Kappa opioid receptor,Ki,=,125.99,nM,CHEMBL3705914,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant kippa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 ul ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3638713,KI,
CHEMBL4115772,CHEMBL237,Kappa opioid receptor,Ki,=,37.62,nM,CHEMBL3706234,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3638455,KI,
CHEMBL4115773,CHEMBL237,Kappa opioid receptor,Ki,=,3.85,nM,CHEMBL3706234,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3638455,KI,
CHEMBL4115774,CHEMBL237,Kappa opioid receptor,Ki,=,292.2,nM,CHEMBL3706234,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3638455,KI,
CHEMBL4115775,CHEMBL237,Kappa opioid receptor,Ki,=,0.58,nM,CHEMBL3706234,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3638455,KI,
CHEMBL4115776,CHEMBL237,Kappa opioid receptor,Ki,=,35.68,nM,CHEMBL3706234,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3638455,KI,
CHEMBL4115777,CHEMBL237,Kappa opioid receptor,Ki,=,0.19,nM,CHEMBL3706234,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3638455,KI,
CHEMBL4115774,CHEMBL237,Kappa opioid receptor,Ki,=,728.34,nM,CHEMBL3706234,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3638455,KI,
CHEMBL4115749,CHEMBL237,Kappa opioid receptor,Ki,=,1.52,nM,CHEMBL3706234,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3638455,KI,
CHEMBL4115750,CHEMBL237,Kappa opioid receptor,Ki,=,182.83,nM,CHEMBL3706234,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3638455,KI,
CHEMBL4115751,CHEMBL237,Kappa opioid receptor,Ki,=,18.53,nM,CHEMBL3706234,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3638455,KI,
CHEMBL4115752,CHEMBL237,Kappa opioid receptor,Ki,=,467.11,nM,CHEMBL3706234,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3638455,KI,
CHEMBL4115753,CHEMBL237,Kappa opioid receptor,Ki,=,1.53,nM,CHEMBL3706234,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3638455,KI,
CHEMBL4115754,CHEMBL237,Kappa opioid receptor,Ki,=,1.05,nM,CHEMBL3706234,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3638455,KI,
CHEMBL4115756,CHEMBL237,Kappa opioid receptor,Ki,=,0.85,nM,CHEMBL3706234,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3638455,KI,
CHEMBL4115757,CHEMBL237,Kappa opioid receptor,Ki,=,1.09,nM,CHEMBL3706234,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3638455,KI,
CHEMBL4115758,CHEMBL237,Kappa opioid receptor,Ki,=,0.97,nM,CHEMBL3706234,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3638455,KI,
CHEMBL4115759,CHEMBL237,Kappa opioid receptor,Ki,=,2.59,nM,CHEMBL3706234,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3638455,KI,
CHEMBL4115768,CHEMBL237,Kappa opioid receptor,Ki,=,0.31,nM,CHEMBL3706234,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3638455,KI,
CHEMBL4115769,CHEMBL237,Kappa opioid receptor,Ki,=,0.96,nM,CHEMBL3706234,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3638455,KI,
CHEMBL4115770,CHEMBL237,Kappa opioid receptor,Ki,=,0.32,nM,CHEMBL3706234,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3638455,KI,
CHEMBL4115771,CHEMBL237,Kappa opioid receptor,Ki,=,0.86,nM,CHEMBL3706234,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3638455,KI,
CHEMBL4115778,CHEMBL237,Kappa opioid receptor,Ki,=,3075.07,nM,CHEMBL3706234,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3638455,KI,
CHEMBL4115779,CHEMBL237,Kappa opioid receptor,Ki,=,12268.59,nM,CHEMBL3706234,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3638455,KI,
CHEMBL4115780,CHEMBL237,Kappa opioid receptor,Ki,=,25.3,nM,CHEMBL3706234,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3638455,KI,
CHEMBL4115781,CHEMBL237,Kappa opioid receptor,Ki,=,599.3,nM,CHEMBL3706234,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3638455,KI,
CHEMBL4115782,CHEMBL237,Kappa opioid receptor,Ki,=,1582.0,nM,CHEMBL3706234,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3638455,KI,
CHEMBL4115784,CHEMBL237,Kappa opioid receptor,Ki,=,130.4,nM,CHEMBL3706296,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant kippa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 ul ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty ul/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added.",CHEMBL3638576,KI,
CHEMBL4115785,CHEMBL237,Kappa opioid receptor,Ki,=,0.6,nM,CHEMBL3706296,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant kippa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 ul ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty ul/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added.",CHEMBL3638576,KI,
CHEMBL4115709,CHEMBL237,Kappa opioid receptor,Ki,=,134.63,nM,CHEMBL3706296,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant kippa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 ul ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty ul/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added.",CHEMBL3638576,KI,
CHEMBL4115710,CHEMBL237,Kappa opioid receptor,Ki,=,0.94,nM,CHEMBL3706296,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant kippa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 ul ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty ul/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added.",CHEMBL3638576,KI,
CHEMBL4115711,CHEMBL237,Kappa opioid receptor,Ki,=,12.25,nM,CHEMBL3706296,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant kippa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 ul ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty ul/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added.",CHEMBL3638576,KI,
CHEMBL4115712,CHEMBL237,Kappa opioid receptor,Ki,=,0.23,nM,CHEMBL3706296,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant kippa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 ul ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty ul/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added.",CHEMBL3638576,KI,
CHEMBL4115712,CHEMBL237,Kappa opioid receptor,Ki,=,0.2,nM,CHEMBL3706296,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant kippa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 ul ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty ul/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added.",CHEMBL3638576,KI,
CHEMBL4115714,CHEMBL237,Kappa opioid receptor,Ki,=,155.2,nM,CHEMBL3706296,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant kippa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 ul ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty ul/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added.",CHEMBL3638576,KI,
CHEMBL4115735,CHEMBL237,Kappa opioid receptor,Ki,=,0.47,nM,CHEMBL3706296,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant kippa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 ul ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty ul/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added.",CHEMBL3638576,KI,
CHEMBL4115736,CHEMBL237,Kappa opioid receptor,Ki,=,0.3,nM,CHEMBL3706296,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant kippa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 ul ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty ul/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added.",CHEMBL3638576,KI,
CHEMBL3688135,CHEMBL237,Kappa opioid receptor,Ki,=,64.47,nM,CHEMBL3705818,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant kippa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 ul ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty ul/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added.",CHEMBL3638511,KI,O=C(O)CCC[C@]12CCN(CC3CC3)[C@H](Cc3ccc(O)cc31)[C@@H]2CC(=O)O
CHEMBL4114012,CHEMBL237,Kappa opioid receptor,Ki,=,33.15,nM,CHEMBL3705818,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant kippa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 ul ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty ul/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added.",CHEMBL3638511,KI,O=C(O)/C=C1\[C@H]2Cc3ccc(O)cc3[C@]1(CCCC(=O)O)CCN2CC1CC1
CHEMBL4106660,CHEMBL237,Kappa opioid receptor,Ki,=,42.53,nM,CHEMBL3705818,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant kippa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 ul ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty ul/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added.",CHEMBL3638511,KI,CN(C)C(=O)CCC[C@]12CCN(CC3CC3)[C@H](Cc3ccc(O)cc31)/C2=C\C(=O)O
CHEMBL4114012,CHEMBL237,Kappa opioid receptor,Ki,=,66.82,nM,CHEMBL3705818,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant kippa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 ul ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty ul/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added.",CHEMBL3638511,KI,O=C(O)/C=C1\[C@H]2Cc3ccc(O)cc3[C@]1(CCCC(=O)O)CCN2CC1CC1
CHEMBL3688138,CHEMBL237,Kappa opioid receptor,Ki,=,89.61,nM,CHEMBL3705818,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant kippa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 ul ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty ul/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added.",CHEMBL3638511,KI,COc1ccc2c(c1)[C@@]1(CCO)CCN(CC3CC3)[C@H](C2)[C@@H]1CO
CHEMBL3688139,CHEMBL237,Kappa opioid receptor,Ki,=,79.08,nM,CHEMBL3705818,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant kippa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 uM unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 ul ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty ul/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added.",CHEMBL3638511,KI,COc1ccc2c(c1)[C@@]1(CC(N)=O)CCN(CC3CC3)[C@H](C2)[C@@H]1CO
CHEMBL3704576,CHEMBL237,Kappa opioid receptor,Ki,=,353.0,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,O=C(O)CN1CCC[C@H](c2nc3ccccc3n2[C@H]2C[C@H]3CCC[C@@H](C2)N3[C@H]2C[C@@H]3CCC[C@@H](C3)C2)C1
CHEMBL3704583,CHEMBL237,Kappa opioid receptor,Ki,=,150.0,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,O=C(O)CN1CCC[C@H]1c1nc2ccccc2n1[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@@H]1C[C@@H]2CCCC[C@@H](C2)C1
CHEMBL3704584,CHEMBL237,Kappa opioid receptor,Ki,=,65.2,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,O=C(O)CN1CCC[C@@H]1c1nc2ccccc2n1[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@@H]1C[C@@H]2CCCC[C@@H](C2)C1
CHEMBL3704586,CHEMBL237,Kappa opioid receptor,Ki,=,828.0,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,O=C(O)CCN1CCC[C@@H]1c1nc2ccccc2n1[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@@H]1C[C@@H]2CCCC[C@@H](C2)C1
CHEMBL3704588,CHEMBL237,Kappa opioid receptor,Ki,=,123.0,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,NC(=O)CN1CCC[C@H]1c1nc2ccccc2n1[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@@H]1C[C@@H]2CCCC[C@@H](C2)C1
CHEMBL3704589,CHEMBL237,Kappa opioid receptor,Ki,=,108.0,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,O=C(O)CN1CCCC[C@H]1c1nc2ccccc2n1[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@@H]1C[C@@H]2CCCC[C@@H](C2)C1
CHEMBL3704590,CHEMBL237,Kappa opioid receptor,Ki,=,16.3,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,O=C(O)CN1CCCC[C@@H]1c1nc2ccccc2n1[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@@H]1C[C@@H]2CCCC[C@@H](C2)C1
CHEMBL3704591,CHEMBL237,Kappa opioid receptor,Ki,=,700.0,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,O=C(O)CN1CCC[C@H](c2nc3ccccc3n2[C@H]2C[C@H]3CCC[C@@H](C2)N3[C@@H]2C[C@@H]3CCCC[C@@H](C3)C2)C1
CHEMBL3704592,CHEMBL237,Kappa opioid receptor,Ki,=,254.0,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,O=C(O)CCN1CCC[C@H](c2nc3ccccc3n2[C@H]2C[C@H]3CCC[C@@H](C2)N3[C@@H]2C[C@@H]3CCCC[C@@H](C3)C2)C1
CHEMBL3704594,CHEMBL237,Kappa opioid receptor,Ki,=,41.3,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,O=C(O)CN1CCC/C(=C2/N(CC(=O)O)c3ccccc3N2[C@H]2C[C@H]3CCC[C@@H](C2)N3[C@@H]2C[C@@H]3CCCC[C@@H](C3)C2)C1
CHEMBL3704598,CHEMBL237,Kappa opioid receptor,Ki,=,822.0,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,O=C(O)CCN1CCC(Cc2nc3ccccc3n2[C@H]2C[C@H]3CCC[C@@H](C2)N3[C@@H]2C[C@@H]3CCCC[C@@H](C3)C2)CC1
CHEMBL3704606,CHEMBL237,Kappa opioid receptor,Ki,=,6800.0,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,O=C(O)CN1CCN(Cc2nc3ccccc3n2[C@H]2C[C@H]3CCC[C@@H](C2)N3[C@H]2C[C@@H]3CCC[C@@H](C3)C2)CC1
CHEMBL3704607,CHEMBL237,Kappa opioid receptor,Ki,=,59.0,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,CCOC(=N)/N=c1\[nH]c2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3704608,CHEMBL237,Kappa opioid receptor,Ki,=,33.7,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,NC(=O)/N=c1\[nH]c2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3704609,CHEMBL237,Kappa opioid receptor,Ki,=,26.2,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,CONC(=N)/N=c1\[nH]c2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3704610,CHEMBL237,Kappa opioid receptor,Ki,=,594.0,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,COC(=O)/N=c1\n(CC(N)=O)c2ccccc2n1C1CCN(C2CCCCCCC2)CC1
CHEMBL3704612,CHEMBL237,Kappa opioid receptor,Ki,=,265.0,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,O=C(O)CNc1nc2ccccc2n1C1C[C@H]2CCC[C@@H](C1)N2C1CCCCCCCCC1
CHEMBL3704613,CHEMBL237,Kappa opioid receptor,Ki,=,246.0,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,OCc1nc2ccccc2n1C1C[C@H]2CCC[C@@H](C1)N2[C@H]1C[C@@H]2CCC[C@@H](C2)C1
CHEMBL3704614,CHEMBL237,Kappa opioid receptor,Ki,=,1543.0,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,O=C(O)CO/N=C/c1nc2ccccc2n1[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@H]1C[C@@H]2CCC[C@@H](C2)C1
CHEMBL3704616,CHEMBL237,Kappa opioid receptor,Ki,=,566.0,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,c1ccc2c(c1)nc(-c1nnn[nH]1)n2[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@@H]1C[C@@H]2CCCC[C@@H](C2)C1
CHEMBL3704620,CHEMBL237,Kappa opioid receptor,Ki,=,43.7,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,CS(=O)(=O)NCCN1CCC[C@H]1Cc1nc2ccccc2n1[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@@H]1C[C@@H]2CCCC[C@@H](C2)C1
CHEMBL3704623,CHEMBL237,Kappa opioid receptor,Ki,=,344.0,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,O=C(O)CN1CCC[C@H]1Cc1nc2ccccc2n1[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@@H]1C[C@@H]2CCCC[C@@H](C2)C1
CHEMBL3704625,CHEMBL237,Kappa opioid receptor,Ki,=,614.0,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,O=C(O)CCN1CC[C@@H](Cc2nc3ccccc3n2[C@H]2C[C@H]3CCC[C@@H](C2)N3[C@@H]2C[C@@H]3CCCC[C@@H](C3)C2)C1
CHEMBL3704627,CHEMBL237,Kappa opioid receptor,Ki,=,58.3,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,CS(=O)(=O)NCCN1CC[C@@H](Cc2nc3ccccc3n2[C@H]2C[C@H]3CCC[C@@H](C2)N3[C@@H]2C[C@@H]3CCCC[C@@H](C3)C2)C1
CHEMBL3704629,CHEMBL237,Kappa opioid receptor,Ki,=,30.4,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,CCN(CC)C(=O)CN1CC[C@@H](Cc2nc3ccccc3n2[C@H]2C[C@H]3CCC[C@@H](C2)N3[C@@H]2C[C@@H]3CCCC[C@@H](C3)C2)C1
CHEMBL3704623,CHEMBL237,Kappa opioid receptor,Ki,=,254.0,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,O=C(O)CN1CCC[C@H]1Cc1nc2ccccc2n1[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@@H]1C[C@@H]2CCCC[C@@H](C2)C1
CHEMBL3704631,CHEMBL237,Kappa opioid receptor,Ki,=,31.3,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,c1ccc2c(c1)nc(C[C@H]1COCCN1)n2[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@@H]1C[C@@H]2CCCC[C@@H](C2)C1
CHEMBL3704632,CHEMBL237,Kappa opioid receptor,Ki,=,50.1,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,c1ccc2c(c1)nc(C[C@@H]1COCCN1)n2[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@@H]1C[C@@H]2CCCC[C@@H](C2)C1
CHEMBL3704634,CHEMBL237,Kappa opioid receptor,Ki,=,444.0,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,O=C(O)CCN1CCC[C@H]1Cc1nc2ccccc2n1[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@@H]1C[C@@H]2CCCC[C@@H](C2)C1
CHEMBL3704635,CHEMBL237,Kappa opioid receptor,Ki,=,169.0,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,O=C(O)CN1CCCC[C@H]1Cc1nc2ccccc2n1[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@@H]1C[C@@H]2CCCC[C@@H](C2)C1
CHEMBL3704636,CHEMBL237,Kappa opioid receptor,Ki,=,114.8,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,c1ccc2c(c1)nc(Cc1cnccn1)n2[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@@H]1C[C@@H]2CCCC[C@@H](C2)C1
CHEMBL3704637,CHEMBL237,Kappa opioid receptor,Ki,=,130.0,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,Cc1nnc(Cc2nc3ccccc3n2[C@H]2C[C@H]3CCC[C@@H](C2)N3[C@@H]2C[C@@H]3CCCC[C@@H](C3)C2)[nH]1
CHEMBL3704644,CHEMBL237,Kappa opioid receptor,Ki,=,89.6,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,c1ccc2c(c1)nc(-c1c[nH]cn1)n2[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@@H]1C[C@@H]2CCCC[C@@H](C2)C1
CHEMBL3704645,CHEMBL237,Kappa opioid receptor,Ki,=,51.0,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,c1ccc2c(c1)nc(-c1cc[nH]n1)n2[C@H]1C[C@H]2CCC[C@@H](C1)N2[C@@H]1C[C@@H]2CCCC[C@@H](C2)C1
CHEMBL3704646,CHEMBL237,Kappa opioid receptor,Ki,=,79.0,nM,CHEMBL3705776,B,"Radioligand Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hrs. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3639368,KI,Cn1cc(Cl)c(-c2nc3ccccc3n2[C@H]2C[C@H]3CCC[C@@H](C2)N3[C@@H]2C[C@@H]3CCCC[C@@H](C3)C2)n1
CHEMBL4112289,CHEMBL237,Kappa opioid receptor,Ki,=,5.02,nM,CHEMBL3705498,B,"Radioligand Dose-Displacement Binding Assay: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 min at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant K opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3638402,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(Cl)c(Cl)c4)[C@@H](C2)[N+](C)(CC2CC2)CC[C@]315
CHEMBL4106939,CHEMBL237,Kappa opioid receptor,Ki,=,66.73,nM,CHEMBL3705498,B,"Radioligand Dose-Displacement Binding Assay: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 min at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant K opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3638402,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4cc6c(cc4Cl)OCO6)[C@@H](C2)[N+](C)(CC2CC2)CC[C@]315
CHEMBL4108501,CHEMBL237,Kappa opioid receptor,Ki,=,117.13,nM,CHEMBL3705498,B,"Radioligand Dose-Displacement Binding Assay: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 min at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant K opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3638402,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(C)cc4)[C@@H](C2)[N+](C)(CC2CC2)CC[C@]315
CHEMBL3678964,CHEMBL237,Kappa opioid receptor,Ki,=,0.26,nM,CHEMBL3705498,B,"Radioligand Dose-Displacement Binding Assay: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 min at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant K opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3638402,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccc(F)cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CC[N+]1(C)CC1CC1)[C@H]2O5
CHEMBL3678965,CHEMBL237,Kappa opioid receptor,Ki,=,0.78,nM,CHEMBL3705498,B,"Radioligand Dose-Displacement Binding Assay: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 min at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant K opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3638402,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1cc4ccccc4s1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CC[N+]1(C)CC1CC1)[C@H]2O5
CHEMBL3678966,CHEMBL237,Kappa opioid receptor,Ki,=,1.06,nM,CHEMBL3705498,B,"Radioligand Dose-Displacement Binding Assay: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 min at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant K opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3638402,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccc(C)cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CC[N+]1(C)CC1CC1)[C@H]2O5
CHEMBL3678967,CHEMBL237,Kappa opioid receptor,Ki,=,0.55,nM,CHEMBL3705498,B,"Radioligand Dose-Displacement Binding Assay: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 min at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant K opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3638402,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CC[N+]1(C)CC1CC1)[C@H]2O5
CHEMBL3678968,CHEMBL237,Kappa opioid receptor,Ki,=,56.98,nM,CHEMBL3705498,B,"Radioligand Dose-Displacement Binding Assay: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 min at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant K opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3638402,KI,COc1ccc(COC[C@H]2C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(OC)ccc6c5[C@@]23CC[N+](C)(CC2CC2)[C@@H]4C6)cc1
CHEMBL4111313,CHEMBL237,Kappa opioid receptor,Ki,=,348.08,nM,CHEMBL3705498,B,"Radioligand Dose-Displacement Binding Assay: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 min at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant K opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3638402,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COc4ccccc4)[C@@H](C2)[N+](C)(CC2CC2)CC[C@]315
CHEMBL4108857,CHEMBL237,Kappa opioid receptor,Ki,=,35.04,nM,CHEMBL3705498,B,"Radioligand Dose-Displacement Binding Assay: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 min at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant K opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3638402,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccoc4)[C@@H](C2)[N+](C)(CC2CC2)CC[C@]315
CHEMBL3678971,CHEMBL237,Kappa opioid receptor,Ki,=,0.29,nM,CHEMBL3705498,B,"Radioligand Dose-Displacement Binding Assay: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 min at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant K opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3638402,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccoc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CC[N+]1(C)CC1CC1)[C@H]2O5
CHEMBL4108315,CHEMBL237,Kappa opioid receptor,Ki,=,17.31,nM,CHEMBL3705498,B,"Radioligand Dose-Displacement Binding Assay: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 min at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant K opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3638402,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4cc6ccccc6o4)[C@@H](C2)[N+](C)(CC2CC2)CC[C@]315
CHEMBL4106588,CHEMBL237,Kappa opioid receptor,Ki,=,165.12,nM,CHEMBL3705498,B,"Radioligand Dose-Displacement Binding Assay: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 min at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant K opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3638402,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc6ccccc6c4)[C@@H](C2)[N+](C)(CC2CC2)CC[C@]315
CHEMBL3678974,CHEMBL237,Kappa opioid receptor,Ki,=,0.59,nM,CHEMBL3705498,B,"Radioligand Dose-Displacement Binding Assay: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 min at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant K opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3638402,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccc(Cl)cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CC[N+]1(C)CC1CC1)[C@H]2O5
CHEMBL3678975,CHEMBL237,Kappa opioid receptor,Ki,=,0.2,nM,CHEMBL3705498,B,"Radioligand Dose-Displacement Binding Assay: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 min at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant K opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3638402,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccsc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CC[N+]1(C)CC1CC1)[C@H]2O5
CHEMBL3678976,CHEMBL237,Kappa opioid receptor,Ki,=,0.2,nM,CHEMBL3705498,B,"Radioligand Dose-Displacement Binding Assay: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 min at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant K opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3638402,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1F)[C@H]1Cc4ccc(O)c5c4[C@@]3(CC[N+]1(C)CC1CC1)[C@H]2O5
CHEMBL3678977,CHEMBL237,Kappa opioid receptor,Ki,=,0.29,nM,CHEMBL3705498,B,"Radioligand Dose-Displacement Binding Assay: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 min at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant K opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3638402,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1cccc(C)c1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CC[N+]1(C)CC1CC1)[C@H]2O5
CHEMBL4109521,CHEMBL237,Kappa opioid receptor,Ki,=,1031.97,nM,CHEMBL3705498,B,"Radioligand Dose-Displacement Binding Assay: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 min at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant K opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3638402,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(C(N)=O)cc4)[C@@H](C2)[N+](C)(CC2CC2)CC[C@]315
CHEMBL3678979,CHEMBL237,Kappa opioid receptor,Ki,=,0.25,nM,CHEMBL3705498,B,"Radioligand Dose-Displacement Binding Assay: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 min at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant K opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3638402,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1cccc(F)c1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CC[N+]1(C)CC1CC1)[C@H]2O5
CHEMBL3678980,CHEMBL237,Kappa opioid receptor,Ki,=,0.27,nM,CHEMBL3705498,B,"Radioligand Dose-Displacement Binding Assay: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 min at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant K opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3638402,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1cccc(Cl)c1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CC[N+]1(C)CC1CC1)[C@H]2O5
CHEMBL3678981,CHEMBL237,Kappa opioid receptor,Ki,=,0.19,nM,CHEMBL3705498,B,"Radioligand Dose-Displacement Binding Assay: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 min at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant K opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3638402,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1Cl)[C@H]1Cc4ccc(O)c5c4[C@@]3(CC[N+]1(C)CC1CC1)[C@H]2O5
CHEMBL3678982,CHEMBL237,Kappa opioid receptor,Ki,=,0.47,nM,CHEMBL3705498,B,"Radioligand Dose-Displacement Binding Assay: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 min at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant K opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3638402,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CC[N+]1(C)CC1CC1)[C@H]2O5
CHEMBL4108094,CHEMBL237,Kappa opioid receptor,Ki,=,112.07,nM,CHEMBL3705498,B,"Radioligand Dose-Displacement Binding Assay: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 min at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant K opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3638402,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(C(C)(F)F)cc4)[C@@H](C2)[N+](C)(CC2CC2)CC[C@]315
CHEMBL4113404,CHEMBL237,Kappa opioid receptor,Ki,=,10.57,nM,CHEMBL3705498,B,"Radioligand Dose-Displacement Binding Assay: Membranes from recombinant HEK-293 cells expressing the human kippa opioid receptor (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 min at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of kippa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 ug membrane protein (recombinant K opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 ul binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3638402,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccco4)[C@@H](C2)[N+](C)(CC2CC2)CC[C@]315
CHEMBL3647963,CHEMBL237,Kappa opioid receptor,Ki,=,76.0,nM,CHEMBL3887300,B,"Alpha-Opioid Receptor Binding Assay: Membranes from recombinant HEK-293 cells expressing the human kappa opioid receptor (kappa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 min at 4 C. and pellets resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as a standard. Aliquots of kappa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 2004 binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3886266,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCCCCCC2)c1=O
CHEMBL3647960,CHEMBL237,Kappa opioid receptor,Ki,=,640.0,nM,CHEMBL3887300,B,"Alpha-Opioid Receptor Binding Assay: Membranes from recombinant HEK-293 cells expressing the human kappa opioid receptor (kappa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 min at 4 C. and pellets resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as a standard. Aliquots of kappa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 2004 binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3886266,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CCCCCCCCCC2)c1=O
CHEMBL3906430,CHEMBL237,Kappa opioid receptor,Ki,=,2691.0,nM,CHEMBL3887300,B,"Alpha-Opioid Receptor Binding Assay: Membranes from recombinant HEK-293 cells expressing the human kappa opioid receptor (kappa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 min at 4 C. and pellets resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as a standard. Aliquots of kappa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 2004 binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3886266,KI,O=C(O)c1nc2ccccc2n(C2CC3CCC(C2)N3C2CC3CCCC(C3)C2)c1=O
CHEMBL3647959,CHEMBL237,Kappa opioid receptor,Ki,=,6143.0,nM,CHEMBL3887300,B,"Alpha-Opioid Receptor Binding Assay: Membranes from recombinant HEK-293 cells expressing the human kappa opioid receptor (kappa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 min at 4 C. and pellets resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as a standard. Aliquots of kappa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 2004 binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3886266,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3C2CC3CCCC(C3)C2)c1=O
CHEMBL3647958,CHEMBL237,Kappa opioid receptor,Ki,=,2280.0,nM,CHEMBL3887300,B,"Alpha-Opioid Receptor Binding Assay: Membranes from recombinant HEK-293 cells expressing the human kappa opioid receptor (kappa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 min at 4 C. and pellets resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as a standard. Aliquots of kappa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 2004 binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3886266,KI,O=C(O)c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3C2CC3CCCC(C3)C2)c1=O
CHEMBL4114883,CHEMBL237,Kappa opioid receptor,Ki,=,5345.0,nM,CHEMBL3887300,B,"Alpha-Opioid Receptor Binding Assay: Membranes from recombinant HEK-293 cells expressing the human kappa opioid receptor (kappa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 min at 4 C. and pellets resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as a standard. Aliquots of kappa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 2004 binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3886266,KI,N[C@]12CCC[C@H](C[C@H](n3c(=O)c(C(=O)O)nc4ccccc43)C1)N2C1CC2CCCC(C2)C1
CHEMBL3647962,CHEMBL237,Kappa opioid receptor,Ki,=,75.4,nM,CHEMBL3887300,B,"Alpha-Opioid Receptor Binding Assay: Membranes from recombinant HEK-293 cells expressing the human kappa opioid receptor (kappa) (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2, 50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000xg for 15 min at 4 C. and pellets resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as a standard. Aliquots of kappa receptor membranes were stored at -80 C.Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 ug membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 2004 binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3886266,KI,C[C@@H]1C[C@@H]2C[C@H](C1)C[C@@H](N1[C@@H]3CCC[C@H]1C[C@@H](n1c(=O)c(C(=O)O)nc4ccccc41)C3)C2
CHEMBL4107541,CHEMBL237,Kappa opioid receptor,Ki,=,12.89,nM,CHEMBL3887473,B,"Radioligand Dose-Displacement Binding Assays (kappa): Membranes from recombinant HEK-293 cells expressing the human  opioid receptor (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2,50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000g for 15 min at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of  receptor membranes were stored at 80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3886333,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4[C@](O)(CC(O)CO)c4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4115057,CHEMBL237,Kappa opioid receptor,Ki,=,52.21,nM,CHEMBL3887473,B,"Radioligand Dose-Displacement Binding Assays (kappa): Membranes from recombinant HEK-293 cells expressing the human  opioid receptor (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2,50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000g for 15 min at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of  receptor membranes were stored at 80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3886333,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4C(NCC(=O)O)c4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4110838,CHEMBL237,Kappa opioid receptor,Ki,=,138.42,nM,CHEMBL3887473,B,"Radioligand Dose-Displacement Binding Assays (kappa): Membranes from recombinant HEK-293 cells expressing the human  opioid receptor (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2,50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000g for 15 min at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of  receptor membranes were stored at 80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3886333,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4C(NC(C)C(=O)O)c4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4111934,CHEMBL237,Kappa opioid receptor,Ki,=,40.13,nM,CHEMBL3887473,B,"Radioligand Dose-Displacement Binding Assays (kappa): Membranes from recombinant HEK-293 cells expressing the human  opioid receptor (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2,50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000g for 15 min at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of  receptor membranes were stored at 80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3886333,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4C(NC(C)C(N)=O)c4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4108359,CHEMBL237,Kappa opioid receptor,Ki,=,51.34,nM,CHEMBL3887473,B,"Radioligand Dose-Displacement Binding Assays (kappa): Membranes from recombinant HEK-293 cells expressing the human  opioid receptor (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2,50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000g for 15 min at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of  receptor membranes were stored at 80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3886333,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4C(NC(C(=O)O)c4ccccc4)c4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4107606,CHEMBL237,Kappa opioid receptor,Ki,=,21.82,nM,CHEMBL3887473,B,"Radioligand Dose-Displacement Binding Assays (kappa): Membranes from recombinant HEK-293 cells expressing the human  opioid receptor (cloned in house) were prepared by lysing cells in ice cold hypotonic buffer (2.5 mM MgCl2,50 mM HEPES, pH 7.4) (10 mL/10 cm dish) followed by homogenization with a tissue grinder/Teflon pestle. Membranes were collected by centrifugation at 30,000g for 15 min at 4 C. and pellets were resuspended in hypotonic buffer to a final concentration of 1-3 mg/mL. Protein concentrations were determined using the BioRad protein assay reagent with bovine serum albumen as standard. Aliquots of  receptor membranes were stored at 80 C.Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4).",CHEMBL3886333,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4C(N[C@@H](C(N)=O)c4ccccc4)c4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4111224,CHEMBL237,Kappa opioid receptor,Ki,=,0.46,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1C)[C@H]1Cc4ccc(OCCO)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL4107680,CHEMBL237,Kappa opioid receptor,Ki,=,0.28,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(N)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL4115338,CHEMBL237,Kappa opioid receptor,Ki,=,0.23,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,C=Cc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccccc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL4107906,CHEMBL237,Kappa opioid receptor,Ki,=,0.19,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(F)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL4113804,CHEMBL237,Kappa opioid receptor,Ki,=,31.23,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COc4ccc(-n6ccnc6)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4107470,CHEMBL237,Kappa opioid receptor,Ki,=,45.49,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4CSc4nc6ccccc6s4)[C@@H](C2)N(C)CC[C@]315
CHEMBL4106544,CHEMBL237,Kappa opioid receptor,Ki,=,8.03,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4CSc4nc6ccccc6s4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4115091,CHEMBL237,Kappa opioid receptor,Ki,=,4.18,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COc1ccc(-n4ccnc4)cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL4111378,CHEMBL237,Kappa opioid receptor,Ki,=,15.02,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4CSc4nc(C)ns4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3916122,CHEMBL237,Kappa opioid receptor,Ki,=,0.09,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4110639,CHEMBL237,Kappa opioid receptor,Ki,=,0.09,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COc1ccc(-n4ccnc4)cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4110417,CHEMBL237,Kappa opioid receptor,Ki,=,399.88,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4CSc4nc(C)ns4)[C@@H](C2)N(C)CC[C@]315
CHEMBL4113984,CHEMBL237,Kappa opioid receptor,Ki,=,461.98,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4CSc4nncs4)[C@@H](C2)N(C)CC[C@]315
CHEMBL4108301,CHEMBL237,Kappa opioid receptor,Ki,=,2.43,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4CSc4nncs4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4108017,CHEMBL237,Kappa opioid receptor,Ki,=,0.02,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(F)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4111233,CHEMBL237,Kappa opioid receptor,Ki,=,0.53,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(NS(C)(=O)=O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL4110440,CHEMBL237,Kappa opioid receptor,Ki,=,15.18,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(NC(C)=O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL4112656,CHEMBL237,Kappa opioid receptor,Ki,=,0.08,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccccc4)[C@@H](C2)NCC[C@]315
CHEMBL4109652,CHEMBL237,Kappa opioid receptor,Ki,=,0.24,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(Br)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4107210,CHEMBL237,Kappa opioid receptor,Ki,=,1.76,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(C#N)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL4114477,CHEMBL237,Kappa opioid receptor,Ki,=,0.15,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(C(N)=O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL4111231,CHEMBL237,Kappa opioid receptor,Ki,=,0.08,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1)[C@H]2O5
CHEMBL4109258,CHEMBL237,Kappa opioid receptor,Ki,=,5.49,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(C(=O)O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL4114002,CHEMBL237,Kappa opioid receptor,Ki,=,5.74,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4c(C)noc4C)[C@@H](C2)N(C)CC[C@]315
CHEMBL4106985,CHEMBL237,Kappa opioid receptor,Ki,=,2.51,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1cc4ccccc4s1)[C@H]1Cc4ccc(OCCO)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4112472,CHEMBL237,Kappa opioid receptor,Ki,=,0.15,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4c(C)noc4C)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4112358,CHEMBL237,Kappa opioid receptor,Ki,=,6.69,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1CNCc1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4113058,CHEMBL237,Kappa opioid receptor,Ki,=,0.04,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4CNCc4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4112051,CHEMBL237,Kappa opioid receptor,Ki,=,0.43,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4CN(Cc4ccccc4)S(C)(=O)=O)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4112771,CHEMBL237,Kappa opioid receptor,Ki,=,0.14,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4CN(Cc4ccccc4)C(C)=O)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4107918,CHEMBL237,Kappa opioid receptor,Ki,=,0.14,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4CSCc4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4108066,CHEMBL237,Kappa opioid receptor,Ki,=,0.43,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4C[S+]([O-])Cc4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4113830,CHEMBL237,Kappa opioid receptor,Ki,=,37.04,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COCCOCCOCCOC[C@H]1C[C@@]23CC[C@]1(OC)[C@@H]1Oc4c(OC)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5
CHEMBL4106700,CHEMBL237,Kappa opioid receptor,Ki,=,47.06,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COCCOCCOCCOCCOCCOC[C@H]1C[C@@]23CC[C@]1(OC)[C@@H]1Oc4c(OC)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5
CHEMBL4111124,CHEMBL237,Kappa opioid receptor,Ki,=,2.55,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COCCOCCOCCOc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4110312,CHEMBL237,Kappa opioid receptor,Ki,=,10.13,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COCCOCCOCCOCCOCCOc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4109389,CHEMBL237,Kappa opioid receptor,Ki,=,47.27,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COCCOCCOCCOc1ccc(COC[C@H]2C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(OC)ccc6c5[C@@]23CCN(CC2CC2)[C@@H]4C6)cc1
CHEMBL4115652,CHEMBL237,Kappa opioid receptor,Ki,=,42.46,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COCCOCCOCCOCCOCCOc1ccc(COC[C@H]2C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(OC)ccc6c5[C@@]23CCN(CC2CC2)[C@@H]4C6)cc1
CHEMBL4111803,CHEMBL237,Kappa opioid receptor,Ki,=,12.07,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COC(=O)COc1ccc(COC[C@H]2C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(OC)ccc6c5[C@@]23CCN(CC2CC2)[C@@H]4C6)cc1
CHEMBL4111244,CHEMBL237,Kappa opioid receptor,Ki,=,31.61,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(OCC(=O)O)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4112155,CHEMBL237,Kappa opioid receptor,Ki,=,1.71,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccccc4)[C@@H](C2)N(CCC(N)=O)CC[C@]315
CHEMBL4111763,CHEMBL237,Kappa opioid receptor,Ki,=,51.45,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4CNCC(=O)O)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4106505,CHEMBL237,Kappa opioid receptor,Ki,=,434.84,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(C(=O)NCC(=O)O)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4114486,CHEMBL237,Kappa opioid receptor,Ki,=,15.81,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4CNCC(N)=O)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4115536,CHEMBL237,Kappa opioid receptor,Ki,=,20.48,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCC(N)=O)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4115119,CHEMBL237,Kappa opioid receptor,Ki,=,516.58,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(CC(=O)O)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4109818,CHEMBL237,Kappa opioid receptor,Ki,=,2.76,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(C(O)CO)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4111717,CHEMBL237,Kappa opioid receptor,Ki,=,1.37,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4cccc(NC(N)=O)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4107627,CHEMBL237,Kappa opioid receptor,Ki,=,4.39,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COC(=O)[C@@H](N)Cc4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4107681,CHEMBL237,Kappa opioid receptor,Ki,=,9.8,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4cccc(NCC(=O)O)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4110146,CHEMBL237,Kappa opioid receptor,Ki,=,1.07,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(c5ccccc5)CC[C@@]5(C[C@@H]4COCc4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4111263,CHEMBL237,Kappa opioid receptor,Ki,=,180.85,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(Cc6nn[nH]n6)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4107537,CHEMBL237,Kappa opioid receptor,Ki,=,16.18,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CCCc1cc(COC[C@H]2C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(OC)ccc6c5[C@@]23CCN(C)[C@@H]4C6)on1
CHEMBL4114011,CHEMBL237,Kappa opioid receptor,Ki,=,64.53,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccccc4)[C@@H](C2)N(CCC(=O)O)CC[C@]315
CHEMBL4114882,CHEMBL237,Kappa opioid receptor,Ki,=,29.43,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccccc4)[C@@H](C2)N(CC(=O)O)CC[C@]315
CHEMBL4106487,CHEMBL237,Kappa opioid receptor,Ki,=,16.03,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccccc4)[C@@H](C2)N(CC(N)=O)CC[C@]315
CHEMBL4109778,CHEMBL237,Kappa opioid receptor,Ki,=,19.8,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(OCC(=O)O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4109142,CHEMBL237,Kappa opioid receptor,Ki,=,32.67,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(OCc5nn[nH]n5)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4109061,CHEMBL237,Kappa opioid receptor,Ki,=,0.29,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(OCC(N)=O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4110163,CHEMBL237,Kappa opioid receptor,Ki,=,20.61,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(N(S(C)(=O)=O)S(C)(=O)=O)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4114584,CHEMBL237,Kappa opioid receptor,Ki,=,10.06,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(CC(O)CO)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4110967,CHEMBL237,Kappa opioid receptor,Ki,=,0.7,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4cccc(NS(C)(=O)=O)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4112287,CHEMBL237,Kappa opioid receptor,Ki,=,0.93,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4C(C)(C)OCc4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4110056,CHEMBL237,Kappa opioid receptor,Ki,=,2.86,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4cccc(C(=N)N)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4111594,CHEMBL237,Kappa opioid receptor,Ki,=,1.39,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4CS(=O)(=O)Cc4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4113221,CHEMBL237,Kappa opioid receptor,Ki,=,1.57,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCC(O)CO)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4109954,CHEMBL237,Kappa opioid receptor,Ki,=,0.07,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(C#N)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4108808,CHEMBL237,Kappa opioid receptor,Ki,=,5.02,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(-c5nn[nH]n5)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4114523,CHEMBL237,Kappa opioid receptor,Ki,=,1.58,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(C(=O)O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4112241,CHEMBL237,Kappa opioid receptor,Ki,=,0.05,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1cccc(NC(C)=O)c1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4110449,CHEMBL237,Kappa opioid receptor,Ki,=,0.2,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COC(=O)COc1cccc(COC[C@H]2C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(O)ccc6c5[C@@]23CCN(CC2CC2)[C@@H]4C6)c1
CHEMBL4115153,CHEMBL237,Kappa opioid receptor,Ki,=,0.15,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1cccc(NC(=O)c4ccccc4)c1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4109154,CHEMBL237,Kappa opioid receptor,Ki,=,0.014,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccc(C(N)=O)cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4106746,CHEMBL237,Kappa opioid receptor,Ki,=,0.1,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1ccccc1)[C@H]1Cc4ccc(C(N)=O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3930597,CHEMBL237,Kappa opioid receptor,Ki,=,6.63,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COC(=O)[C@H](C)N)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4110981,CHEMBL237,Kappa opioid receptor,Ki,=,26.28,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COC(=O)[C@@H](N)CO)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4108290,CHEMBL237,Kappa opioid receptor,Ki,=,1.02,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COC(=O)[C@@H](N)C(C)O)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3908063,CHEMBL237,Kappa opioid receptor,Ki,=,0.73,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CC[C@H](C)[C@H](N)C(=O)OC[C@H]1C[C@@]23CC[C@]1(OC)[C@@H]1Oc4c(OC)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5
CHEMBL3965826,CHEMBL237,Kappa opioid receptor,Ki,=,13.8,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4CNC(=O)[C@H](C)N)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4107821,CHEMBL237,Kappa opioid receptor,Ki,=,1.16,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COC(=O)[C@@H](N)CC(C)C)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4113588,CHEMBL237,Kappa opioid receptor,Ki,=,12.67,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COC(=O)[C@@H](N)CCC(N)=O)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4115222,CHEMBL237,Kappa opioid receptor,Ki,=,0.07,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COC(=O)[C@@H](N)Cc1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3927136,CHEMBL237,Kappa opioid receptor,Ki,=,0.06,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CC[C@H](C)[C@H](N)C(=O)OC[C@H]1C[C@@]23CC[C@]1(OC)[C@@H]1Oc4c(O)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5
CHEMBL3939745,CHEMBL237,Kappa opioid receptor,Ki,=,0.14,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COC(=O)[C@H](C)N)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3969293,CHEMBL237,Kappa opioid receptor,Ki,=,8.33,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CCOC(=O)CC[C@H]1[C@H](COCc2ccccc2)[C@]2(OC)CC[C@]13[C@H]1Cc4ccc(OC)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4114384,CHEMBL237,Kappa opioid receptor,Ki,=,6.75,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5([C@@H](CC#N)[C@@H]4COCc4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3956140,CHEMBL237,Kappa opioid receptor,Ki,=,19.26,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5([C@@H](CCC(=O)O)[C@@H]4COCc4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4106873,CHEMBL237,Kappa opioid receptor,Ki,=,1.11,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CO[C@]12CC[C@@]3(C[C@@H]1COCc1cccc(OCC(=O)O)c1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4112294,CHEMBL237,Kappa opioid receptor,Ki,=,0.11,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CNC(=O)Nc1cccc(COC[C@H]2C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(O)ccc6c5[C@@]23CCN(CC2CC2)[C@@H]4C6)c1
CHEMBL3930729,CHEMBL237,Kappa opioid receptor,Ki,=,2.55,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,CCOC(=O)CC[C@H]1[C@H](COCc2ccccc2)[C@@]23CC[C@]1(OC)[C@@H]1Oc4c(OC)ccc5c4[C@@]12CCN(CC1CC1)[C@@H]3C5
CHEMBL4106647,CHEMBL237,Kappa opioid receptor,Ki,=,38.44,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(NC(C)=O)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4113890,CHEMBL237,Kappa opioid receptor,Ki,=,43.67,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccccc4)[C@@H](C2)N(Cc2nn[nH]n2)CC[C@]315
CHEMBL4112393,CHEMBL237,Kappa opioid receptor,Ki,=,87.27,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4cccc(CC(=O)O)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4109220,CHEMBL237,Kappa opioid receptor,Ki,=,2.75,nM,CHEMBL3887790,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hr at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 2001 ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886452,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4COCc4ccc(C(O)CO)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3262089,CHEMBL237,Kappa opioid receptor,Ki,=,0.49,nM,CHEMBL3887967,B,"Ligand Binding Assays: As Alt et al., 2002. Membranes (20 ug) are incubated in 50 mM Tris-HCl, pH 7.4 with [3H]diprenorphine or [3H]nociceptin in the absence or presence of varying concentrations of test compounds for 60 min in a shaking water bath at 25 C. Nonspecific binding is measured using 10 uM naloxone (MOR, DOR, KOR) or N/OFQ (NOP). Samples are filtered through GF/C glass-fiber filtermats mounted on a Brandel cell harvester and rinsed four times with 4 C. 50 mM Tris-HCl, pH 7.4 buffer. Filtermats are dried and 0.1 ml EcoLume scintillation cocktail added to each sample area to soak the filter. Each filtermat in a heat-sealed bag, is counted in a Wallac 1450 MicroBeta Liquid Scintillation and Luminescence Counter.",CHEMBL3886520,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3262090,CHEMBL237,Kappa opioid receptor,Ki,=,4.4,nM,CHEMBL3887967,B,"Ligand Binding Assays: As Alt et al., 2002. Membranes (20 ug) are incubated in 50 mM Tris-HCl, pH 7.4 with [3H]diprenorphine or [3H]nociceptin in the absence or presence of varying concentrations of test compounds for 60 min in a shaking water bath at 25 C. Nonspecific binding is measured using 10 uM naloxone (MOR, DOR, KOR) or N/OFQ (NOP). Samples are filtered through GF/C glass-fiber filtermats mounted on a Brandel cell harvester and rinsed four times with 4 C. 50 mM Tris-HCl, pH 7.4 buffer. Filtermats are dried and 0.1 ml EcoLume scintillation cocktail added to each sample area to soak the filter. Each filtermat in a heat-sealed bag, is counted in a Wallac 1450 MicroBeta Liquid Scintillation and Luminescence Counter.",CHEMBL3886520,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@H](O)c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3581740,CHEMBL237,Kappa opioid receptor,Ki,=,0.08,nM,CHEMBL3887967,B,"Ligand Binding Assays: As Alt et al., 2002. Membranes (20 ug) are incubated in 50 mM Tris-HCl, pH 7.4 with [3H]diprenorphine or [3H]nociceptin in the absence or presence of varying concentrations of test compounds for 60 min in a shaking water bath at 25 C. Nonspecific binding is measured using 10 uM naloxone (MOR, DOR, KOR) or N/OFQ (NOP). Samples are filtered through GF/C glass-fiber filtermats mounted on a Brandel cell harvester and rinsed four times with 4 C. 50 mM Tris-HCl, pH 7.4 buffer. Filtermats are dried and 0.1 ml EcoLume scintillation cocktail added to each sample area to soak the filter. Each filtermat in a heat-sealed bag, is counted in a Wallac 1450 MicroBeta Liquid Scintillation and Luminescence Counter.",CHEMBL3886520,KI,CO[C@]12C=C[C@@]3(C[C@]1(C)[C@H](O)c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3581745,CHEMBL237,Kappa opioid receptor,Ki,=,3.02,nM,CHEMBL3887967,B,"Ligand Binding Assays: As Alt et al., 2002. Membranes (20 ug) are incubated in 50 mM Tris-HCl, pH 7.4 with [3H]diprenorphine or [3H]nociceptin in the absence or presence of varying concentrations of test compounds for 60 min in a shaking water bath at 25 C. Nonspecific binding is measured using 10 uM naloxone (MOR, DOR, KOR) or N/OFQ (NOP). Samples are filtered through GF/C glass-fiber filtermats mounted on a Brandel cell harvester and rinsed four times with 4 C. 50 mM Tris-HCl, pH 7.4 buffer. Filtermats are dried and 0.1 ml EcoLume scintillation cocktail added to each sample area to soak the filter. Each filtermat in a heat-sealed bag, is counted in a Wallac 1450 MicroBeta Liquid Scintillation and Luminescence Counter.",CHEMBL3886520,KI,CO[C@]12C=C[C@@]3(C[C@]1(C)[C@@H](O)c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3262093,CHEMBL237,Kappa opioid receptor,Ki,=,3.84,nM,CHEMBL3887967,B,"Ligand Binding Assays: As Alt et al., 2002. Membranes (20 ug) are incubated in 50 mM Tris-HCl, pH 7.4 with [3H]diprenorphine or [3H]nociceptin in the absence or presence of varying concentrations of test compounds for 60 min in a shaking water bath at 25 C. Nonspecific binding is measured using 10 uM naloxone (MOR, DOR, KOR) or N/OFQ (NOP). Samples are filtered through GF/C glass-fiber filtermats mounted on a Brandel cell harvester and rinsed four times with 4 C. 50 mM Tris-HCl, pH 7.4 buffer. Filtermats are dried and 0.1 ml EcoLume scintillation cocktail added to each sample area to soak the filter. Each filtermat in a heat-sealed bag, is counted in a Wallac 1450 MicroBeta Liquid Scintillation and Luminescence Counter.",CHEMBL3886520,KI,CO[C@]12C=C[C@@]3(C[C@@H]1[C@H](O)c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3262367,CHEMBL237,Kappa opioid receptor,Ki,=,0.1,nM,CHEMBL3887967,B,"Ligand Binding Assays: As Alt et al., 2002. Membranes (20 ug) are incubated in 50 mM Tris-HCl, pH 7.4 with [3H]diprenorphine or [3H]nociceptin in the absence or presence of varying concentrations of test compounds for 60 min in a shaking water bath at 25 C. Nonspecific binding is measured using 10 uM naloxone (MOR, DOR, KOR) or N/OFQ (NOP). Samples are filtered through GF/C glass-fiber filtermats mounted on a Brandel cell harvester and rinsed four times with 4 C. 50 mM Tris-HCl, pH 7.4 buffer. Filtermats are dried and 0.1 ml EcoLume scintillation cocktail added to each sample area to soak the filter. Each filtermat in a heat-sealed bag, is counted in a Wallac 1450 MicroBeta Liquid Scintillation and Luminescence Counter.",CHEMBL3886520,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)c1cc(C)cc(C)c1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3262363,CHEMBL237,Kappa opioid receptor,Ki,=,0.16,nM,CHEMBL3887967,B,"Ligand Binding Assays: As Alt et al., 2002. Membranes (20 ug) are incubated in 50 mM Tris-HCl, pH 7.4 with [3H]diprenorphine or [3H]nociceptin in the absence or presence of varying concentrations of test compounds for 60 min in a shaking water bath at 25 C. Nonspecific binding is measured using 10 uM naloxone (MOR, DOR, KOR) or N/OFQ (NOP). Samples are filtered through GF/C glass-fiber filtermats mounted on a Brandel cell harvester and rinsed four times with 4 C. 50 mM Tris-HCl, pH 7.4 buffer. Filtermats are dried and 0.1 ml EcoLume scintillation cocktail added to each sample area to soak the filter. Each filtermat in a heat-sealed bag, is counted in a Wallac 1450 MicroBeta Liquid Scintillation and Luminescence Counter.",CHEMBL3886520,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)c1ccccc1C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3581741,CHEMBL237,Kappa opioid receptor,Ki,=,0.04,nM,CHEMBL3887967,B,"Ligand Binding Assays: As Alt et al., 2002. Membranes (20 ug) are incubated in 50 mM Tris-HCl, pH 7.4 with [3H]diprenorphine or [3H]nociceptin in the absence or presence of varying concentrations of test compounds for 60 min in a shaking water bath at 25 C. Nonspecific binding is measured using 10 uM naloxone (MOR, DOR, KOR) or N/OFQ (NOP). Samples are filtered through GF/C glass-fiber filtermats mounted on a Brandel cell harvester and rinsed four times with 4 C. 50 mM Tris-HCl, pH 7.4 buffer. Filtermats are dried and 0.1 ml EcoLume scintillation cocktail added to each sample area to soak the filter. Each filtermat in a heat-sealed bag, is counted in a Wallac 1450 MicroBeta Liquid Scintillation and Luminescence Counter.",CHEMBL3886520,KI,CO[C@]12C=C[C@@]3(C[C@]1(C)[C@H](O)c1cccc(C)c1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3581750,CHEMBL237,Kappa opioid receptor,Ki,=,0.04,nM,CHEMBL3887967,B,"Ligand Binding Assays: As Alt et al., 2002. Membranes (20 ug) are incubated in 50 mM Tris-HCl, pH 7.4 with [3H]diprenorphine or [3H]nociceptin in the absence or presence of varying concentrations of test compounds for 60 min in a shaking water bath at 25 C. Nonspecific binding is measured using 10 uM naloxone (MOR, DOR, KOR) or N/OFQ (NOP). Samples are filtered through GF/C glass-fiber filtermats mounted on a Brandel cell harvester and rinsed four times with 4 C. 50 mM Tris-HCl, pH 7.4 buffer. Filtermats are dried and 0.1 ml EcoLume scintillation cocktail added to each sample area to soak the filter. Each filtermat in a heat-sealed bag, is counted in a Wallac 1450 MicroBeta Liquid Scintillation and Luminescence Counter.",CHEMBL3886520,KI,CO[C@]12CC[C@@]3(C[C@]1(C)[C@H](O)c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3581743,CHEMBL237,Kappa opioid receptor,Ki,=,0.05,nM,CHEMBL3887967,B,"Ligand Binding Assays: As Alt et al., 2002. Membranes (20 ug) are incubated in 50 mM Tris-HCl, pH 7.4 with [3H]diprenorphine or [3H]nociceptin in the absence or presence of varying concentrations of test compounds for 60 min in a shaking water bath at 25 C. Nonspecific binding is measured using 10 uM naloxone (MOR, DOR, KOR) or N/OFQ (NOP). Samples are filtered through GF/C glass-fiber filtermats mounted on a Brandel cell harvester and rinsed four times with 4 C. 50 mM Tris-HCl, pH 7.4 buffer. Filtermats are dried and 0.1 ml EcoLume scintillation cocktail added to each sample area to soak the filter. Each filtermat in a heat-sealed bag, is counted in a Wallac 1450 MicroBeta Liquid Scintillation and Luminescence Counter.",CHEMBL3886520,KI,CO[C@]12C=C[C@@]3(C[C@]1(C)[C@H](O)c1ccc(F)cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3923831,CHEMBL237,Kappa opioid receptor,Ki,=,118.38,nM,CHEMBL3888045,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,CO[C@H]1C=CC2C3Cc4ccc(O)c5c4[C@@]2(CCN3C)C1O5
CHEMBL4110373,CHEMBL237,Kappa opioid receptor,Ki,=,444.54,nM,CHEMBL3888045,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCO[C@H]1CC[C@@]2(O)C3Cc4ccc(O)c5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL4107642,CHEMBL237,Kappa opioid receptor,Ki,=,404.33,nM,CHEMBL3888045,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCO[C@H]1CC[C@@]2(O)C3Cc4ccc(O)c5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL4112562,CHEMBL237,Kappa opioid receptor,Ki,=,575.98,nM,CHEMBL3888045,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCOCCO[C@H]1CC[C@@]2(O)C3Cc4ccc(O)c5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL4106506,CHEMBL237,Kappa opioid receptor,Ki,=,438.88,nM,CHEMBL3888045,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCOCCOCCO[C@H]1CC[C@@]2(O)C3Cc4ccc(O)c5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL4108649,CHEMBL237,Kappa opioid receptor,Ki,=,557.54,nM,CHEMBL3888045,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)C3Cc4ccc(O)c5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL4112722,CHEMBL237,Kappa opioid receptor,Ki,=,773.56,nM,CHEMBL3888045,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)C3Cc4ccc(O)c5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL4110642,CHEMBL237,Kappa opioid receptor,Ki,=,669.56,nM,CHEMBL3888045,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)C3Cc4ccc(O)c5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL4108525,CHEMBL237,Kappa opioid receptor,Ki,=,1253.71,nM,CHEMBL3888045,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCOCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)C3Cc4ccc(O)c5c4[C@@]2(CCN3C)[C@H]1O5
CHEMBL2448883,CHEMBL237,Kappa opioid receptor,Ki,=,28067.0,nM,CHEMBL3888045,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COc1ccc2c3c1O[C@H]1[C@@H](O)C=CC4[C@@H](C2)N(C)CC[C@@]341
CHEMBL3895828,CHEMBL237,Kappa opioid receptor,Ki,=,54669.89,nM,CHEMBL3888045,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCO[C@H]1C=CC2C3Cc4ccc(OC)c5c4[C@@]2(CCN3C)C1O5
CHEMBL3937789,CHEMBL237,Kappa opioid receptor,Ki,=,22603.05,nM,CHEMBL3888045,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCO[C@H]1C=CC2C3Cc4ccc(OC)c5c4[C@@]2(CCN3C)C1O5
CHEMBL3934684,CHEMBL237,Kappa opioid receptor,Ki,=,36539.78,nM,CHEMBL3888045,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCOCCO[C@H]1C=CC2C3Cc4ccc(OC)c5c4[C@@]2(CCN3C)C1O5
CHEMBL3967811,CHEMBL237,Kappa opioid receptor,Ki,=,96978.61,nM,CHEMBL3888045,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCOCCOCCO[C@H]1C=CC2C3Cc4ccc(OC)c5c4[C@@]2(CCN3C)C1O5
CHEMBL3933053,CHEMBL237,Kappa opioid receptor,Ki,=,59138.22,nM,CHEMBL3888045,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCOCCOCCOCCO[C@H]1C=CC2C3Cc4ccc(OC)c5c4[C@@]2(CCN3C)C1O5
CHEMBL3984515,CHEMBL237,Kappa opioid receptor,Ki,=,108317.5,nM,CHEMBL3888045,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCOCCOCCOCCOCCOCCO[C@H]1C=CC2C3Cc4ccc(OC)c5c4[C@@]2(CCN3C)C1O5
CHEMBL3911284,CHEMBL237,Kappa opioid receptor,Ki,=,72246.23,nM,CHEMBL3888045,B,"Scintillation Proximity Assay (SPA): Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay conditions for each opioid receptor subtype are described in Table 10 below. The plates were incubated for 8 hours-overnight at room temperature, spun at 1000 rpm to pellet the SPA beads, and radioactivity was measured using the TopCount microplate Scintillation counter. Specific binding at each concentration of test compound was calculated by subtracting the non-specific binding measured in the presence of excess cold ligand. IC50 values were obtained by non-linear regression of specific binding versus concentration curves and Ki values were calculated using Kd values that were experimentally pre-determined for each lot of membrane preparations.",CHEMBL3886551,KI,COCCOCCOCCOCCOCCOCCOCCOCCOCCO[C@H]1C=CC2C3Cc4ccc(OC)c5c4[C@@]2(CCN3C)C1O5
CHEMBL895,CHEMBL237,Kappa opioid receptor,Ki,=,29.95,nM,CHEMBL3888050,B,Binding of PEG-Nalbuphine assays: Specific binding is determined by subtraction of the cpm bound in the presence of 50-100 excess of cold ligand. Binding data assays were analyzed using GraphPad Prism 4.0 and IC50 is generated by non-linear regression from dose-response curves. Ki values were calculated using the Cheng Prusoff equation using the Kd values from saturation isotherms as follows: Ki=IC50/(1+[Ligand]/Kd).,CHEMBL3886551,KI,Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
CHEMBL3954154,CHEMBL237,Kappa opioid receptor,Ki,=,218.1,nM,CHEMBL3888050,B,Binding of PEG-Nalbuphine assays: Specific binding is determined by subtraction of the cpm bound in the presence of 50-100 excess of cold ligand. Binding data assays were analyzed using GraphPad Prism 4.0 and IC50 is generated by non-linear regression from dose-response curves. Ki values were calculated using the Cheng Prusoff equation using the Kd values from saturation isotherms as follows: Ki=IC50/(1+[Ligand]/Kd).,CHEMBL3886551,KI,COCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CCC2)C1O5
CHEMBL3901176,CHEMBL237,Kappa opioid receptor,Ki,=,35.56,nM,CHEMBL3888050,B,Binding of PEG-Nalbuphine assays: Specific binding is determined by subtraction of the cpm bound in the presence of 50-100 excess of cold ligand. Binding data assays were analyzed using GraphPad Prism 4.0 and IC50 is generated by non-linear regression from dose-response curves. Ki values were calculated using the Cheng Prusoff equation using the Kd values from saturation isotherms as follows: Ki=IC50/(1+[Ligand]/Kd).,CHEMBL3886551,KI,COCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CCC2)C1O5
CHEMBL3947626,CHEMBL237,Kappa opioid receptor,Ki,=,246.9,nM,CHEMBL3888050,B,Binding of PEG-Nalbuphine assays: Specific binding is determined by subtraction of the cpm bound in the presence of 50-100 excess of cold ligand. Binding data assays were analyzed using GraphPad Prism 4.0 and IC50 is generated by non-linear regression from dose-response curves. Ki values were calculated using the Cheng Prusoff equation using the Kd values from saturation isotherms as follows: Ki=IC50/(1+[Ligand]/Kd).,CHEMBL3886551,KI,COCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CCC2)C1O5
CHEMBL3966308,CHEMBL237,Kappa opioid receptor,Ki,=,346.1,nM,CHEMBL3888050,B,Binding of PEG-Nalbuphine assays: Specific binding is determined by subtraction of the cpm bound in the presence of 50-100 excess of cold ligand. Binding data assays were analyzed using GraphPad Prism 4.0 and IC50 is generated by non-linear regression from dose-response curves. Ki values were calculated using the Cheng Prusoff equation using the Kd values from saturation isotherms as follows: Ki=IC50/(1+[Ligand]/Kd).,CHEMBL3886551,KI,COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CCC2)C1O5
CHEMBL3953339,CHEMBL237,Kappa opioid receptor,Ki,=,282.2,nM,CHEMBL3888050,B,Binding of PEG-Nalbuphine assays: Specific binding is determined by subtraction of the cpm bound in the presence of 50-100 excess of cold ligand. Binding data assays were analyzed using GraphPad Prism 4.0 and IC50 is generated by non-linear regression from dose-response curves. Ki values were calculated using the Cheng Prusoff equation using the Kd values from saturation isotherms as follows: Ki=IC50/(1+[Ligand]/Kd).,CHEMBL3886551,KI,COCCOCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CCC2)C1O5
CHEMBL3919846,CHEMBL237,Kappa opioid receptor,Ki,=,186.1,nM,CHEMBL3888050,B,Binding of PEG-Nalbuphine assays: Specific binding is determined by subtraction of the cpm bound in the presence of 50-100 excess of cold ligand. Binding data assays were analyzed using GraphPad Prism 4.0 and IC50 is generated by non-linear regression from dose-response curves. Ki values were calculated using the Cheng Prusoff equation using the Kd values from saturation isotherms as follows: Ki=IC50/(1+[Ligand]/Kd).,CHEMBL3886551,KI,COCCOCCOCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CCC2)C1O5
CHEMBL4111642,CHEMBL237,Kappa opioid receptor,Ki,=,323.0,nM,CHEMBL3888261,B,"In Vitro Kappa-Opioid Receptor Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,C[C@@H]1C[C@@H]2C[C@H](C1)C[C@@H](N1[C@@H]3CC[C@H]1C[C@@H](n1c(=O)c(N4CC[C@@H]4C(=O)O)nc4ccccc41)C3)C2
CHEMBL3942346,CHEMBL237,Kappa opioid receptor,Ki,=,116.0,nM,CHEMBL3888261,B,"In Vitro Kappa-Opioid Receptor Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,C[C@@H]1C[C@@H]2C[C@H](C1)C[C@@H](N1[C@@H]3CC[C@H]1C[C@@H](n1c(=O)c(N4CC[C@H]4C(=O)O)nc4ccccc41)C3)C2
CHEMBL3970857,CHEMBL237,Kappa opioid receptor,Ki,=,289.0,nM,CHEMBL3888261,B,"In Vitro Kappa-Opioid Receptor Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,O=C(O)[C@@H]1CCN1c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3[C@H]2C[C@@H]3CCC[C@@H](C3)C2)c1=O
CHEMBL3894621,CHEMBL237,Kappa opioid receptor,Ki,=,40.8,nM,CHEMBL3888261,B,"In Vitro Kappa-Opioid Receptor Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,C[C@@H]1C[C@@H]2C[C@H](C1)C[C@@H](N1[C@@H]3CCC[C@H]1C[C@@H](n1c(=O)c(N4CC[C@H]4C(=O)O)nc4ccccc41)C3)C2
CHEMBL3986914,CHEMBL237,Kappa opioid receptor,Ki,=,113.0,nM,CHEMBL3888261,B,"In Vitro Kappa-Opioid Receptor Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,C[C@@H]1C[C@@H]2C[C@H](C1)C[C@@H](N1[C@@H]3CCC[C@H]1C[C@@H](n1c(=O)c(N4CC(C(=O)O)C4)nc4ccccc41)C3)C2
CHEMBL4115318,CHEMBL237,Kappa opioid receptor,Ki,=,137.0,nM,CHEMBL3888261,B,"In Vitro Kappa-Opioid Receptor Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,CC12C[C@H]3C[C@@H](N4[C@@H]5CCC[C@H]4C[C@@H](n4c(=O)c(N6CC[C@@H]6C(=O)O)nc6ccccc64)C5)C[C@@H]1C[C@@H]2C3
CHEMBL4114020,CHEMBL237,Kappa opioid receptor,Ki,=,159.0,nM,CHEMBL3888261,B,"In Vitro Kappa-Opioid Receptor Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,CC12C[C@H]3C[C@@H](N4[C@@H]5CCC[C@H]4C[C@@H](n4c(=O)c(N6CC[C@H]6C(=O)O)nc6ccccc64)C5)C[C@@H]1C[C@@H]2C3
CHEMBL4113014,CHEMBL237,Kappa opioid receptor,Ki,=,111.4,nM,CHEMBL3888261,B,"In Vitro Kappa-Opioid Receptor Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,CC12C[C@H]3C[C@@H](N4[C@@H]5CCC[C@H]4C[C@@H](n4c(=O)c(N6CC(C(=O)O)C6)nc6ccccc64)C5)C[C@@H]1C[C@@H]2C3
CHEMBL3903565,CHEMBL237,Kappa opioid receptor,Ki,=,72.3,nM,CHEMBL3888261,B,"In Vitro Kappa-Opioid Receptor Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,C[C@@H]1C[C@@H]2C[C@H](C1)C[C@@H](N1[C@@H]3CCC[C@H]1C[C@@H](n1c(=O)c(N4CC(CC(=O)O)C4)nc4ccccc41)C3)C2
CHEMBL4112220,CHEMBL237,Kappa opioid receptor,Ki,=,7050.0,nM,CHEMBL3888261,B,"In Vitro Kappa-Opioid Receptor Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,CC12C[C@H]3C[C@@H](N4[C@@H]5COC[C@H]4C[C@@H](n4c(=O)c(N6CC[C@H]6C(=O)O)nc6ccccc64)C5)C[C@@H]1C[C@@H]2C3
CHEMBL3920823,CHEMBL237,Kappa opioid receptor,Ki,=,128.0,nM,CHEMBL3888261,B,"In Vitro Kappa-Opioid Receptor Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,CC1(C)[C@H]2CC[C@@H](CCN3[C@@H]4CCC[C@H]3C[C@@H](n3c(=O)c(N5CC[C@@H]5C(=O)O)nc5ccccc53)C4)[C@@H]1C2
CHEMBL3957299,CHEMBL237,Kappa opioid receptor,Ki,=,274.0,nM,CHEMBL3888261,B,"In Vitro Kappa-Opioid Receptor Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,CC1(C)[C@H]2CC[C@@H](CCN3[C@@H]4CCC[C@H]3C[C@@H](n3c(=O)c(N5CC[C@H]5C(=O)O)nc5ccccc53)C4)[C@@H]1C2
CHEMBL3926298,CHEMBL237,Kappa opioid receptor,Ki,=,1770.0,nM,CHEMBL3888261,B,"In Vitro Kappa-Opioid Receptor Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,CC1(C)[C@H]2CC[C@@H](CCN3[C@@H]4CCC[C@H]3C[C@@H](n3c(=O)c(N5CC(C(=O)O)C5)nc5ccccc53)C4)[C@@H]1C2
CHEMBL3935191,CHEMBL237,Kappa opioid receptor,Ki,=,223.0,nM,CHEMBL3888261,B,"In Vitro Kappa-Opioid Receptor Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,O=C(O)[C@@H]1CCN1c1nc2ccccc2n([C@H]2C[C@H]3CC[C@@H](C2)N3[C@@H]2C[C@@H]3CCCC[C@@H](C3)C2)c1=O
CHEMBL3973642,CHEMBL237,Kappa opioid receptor,Ki,=,135.0,nM,CHEMBL3888261,B,"In Vitro Kappa-Opioid Receptor Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,O=C(O)CC1CN(c2nc3ccccc3n([C@H]3C[C@H]4CC[C@@H](C3)N4[C@@H]3C[C@@H]4CCCC[C@@H](C4)C3)c2=O)C1
CHEMBL4107594,CHEMBL237,Kappa opioid receptor,Ki,=,188.0,nM,CHEMBL3888261,B,"In Vitro Kappa-Opioid Receptor Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,O=C(O)[C@H]1CCN1c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3[C@@H]2C[C@@H]3CCCC[C@@H](C3)C2)c1=O
CHEMBL3941054,CHEMBL237,Kappa opioid receptor,Ki,=,86.0,nM,CHEMBL3888261,B,"In Vitro Kappa-Opioid Receptor Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,O=C(O)[C@@H]1CCN1c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3[C@@H]2C[C@@H]3CCCC[C@@H](C3)C2)c1=O
CHEMBL4107295,CHEMBL237,Kappa opioid receptor,Ki,=,11.6,nM,CHEMBL3888261,B,"In Vitro Kappa-Opioid Receptor Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,N[C@@H]1CN(c2nc3ccccc3n([C@H]3C[C@H]4CCC[C@@H](C3)N4[C@@H]3C[C@@H]4CCCC[C@@H](C4)C3)c2=O)[C@@H]1C(=O)O
CHEMBL4110144,CHEMBL237,Kappa opioid receptor,Ki,=,7.4,nM,CHEMBL3888261,B,"In Vitro Kappa-Opioid Receptor Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,CN(C)[C@@H]1CN(c2nc3ccccc3n([C@H]3C[C@H]4CCC[C@@H](C3)N4[C@@H]3C[C@@H]4CCCC[C@@H](C4)C3)c2=O)[C@@H]1C(=O)O
CHEMBL3895142,CHEMBL237,Kappa opioid receptor,Ki,=,38.0,nM,CHEMBL3888261,B,"In Vitro Kappa-Opioid Receptor Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,O=C(O)[C@@H]1CCCN1c1nc2ccccc2n([C@H]2C[C@H]3CCC[C@@H](C2)N3[C@H]2C[C@@H]3CCC[C@@H](C3)C2)c1=O
CHEMBL4112615,CHEMBL237,Kappa opioid receptor,Ki,=,51.0,nM,CHEMBL3888261,B,"In Vitro Kappa-Opioid Receptor Binding Assay: Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 g membrane protein (recombinant kappa opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 L binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 h at a temperature of about 25 C. Binding reactions were determined by rapid filtration onto 96-well Unifilter GF/C filter plates (Packard) presoaked in 0.5% polyethylenimine (Sigma-Aldrich). Harvesting was performed using a 96-well tissue harvester (Packard) followed by five filtration washes with 200 L ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty L/well scintillation cocktail (MicroScint20, Packard) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886630,KI,CC12C[C@H]3C[C@@H](N4[C@@H]5CCC[C@H]4C[C@@H](n4c(=O)c(N6CCC[C@H]6C(=O)O)nc6ccccc64)C5)C[C@@H]1C[C@@H]2C3
CHEMBL511142,CHEMBL237,Kappa opioid receptor,Ki,=,0.04,nM,CHEMBL3888319,B,"-Opioid Receptor Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886656,KI,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4107585,CHEMBL237,Kappa opioid receptor,Ki,=,0.12,nM,CHEMBL3888319,B,"-Opioid Receptor Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886656,KI,CC(C)(C)[C@@]1(C)OCO[C@]23CC[C@@]4(C[C@@H]21)[C@H]1Cc2ccc(O)c5c2[C@@]4(CCN1CC1CC1)[C@H]3O5
CHEMBL4113162,CHEMBL237,Kappa opioid receptor,Ki,=,0.19,nM,CHEMBL3888319,B,"-Opioid Receptor Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886656,KI,CCC1O[C@]23CC[C@@]4(C[C@@H]2[C@@](C)(C(C)(C)C)O1)[C@H]1Cc2ccc(O)c5c2[C@@]4(CCN1CC1CC1)[C@H]3O5
CHEMBL4111049,CHEMBL237,Kappa opioid receptor,Ki,=,0.72,nM,CHEMBL3888319,B,"-Opioid Receptor Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886656,KI,CCCC1O[C@]23CC[C@@]4(C[C@@H]2[C@@](C)(C(C)(C)C)O1)[C@H]1Cc2ccc(O)c5c2[C@@]4(CCN1CC1CC1)[C@H]3O5
CHEMBL4113900,CHEMBL237,Kappa opioid receptor,Ki,=,4.61,nM,CHEMBL3888319,B,"-Opioid Receptor Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886656,KI,CC(C)(C)[C@@]1(C)OC(c2ccccc2)O[C@]23CC[C@@]4(C[C@@H]21)[C@H]1Cc2ccc(O)c5c2[C@@]4(CCN1CC1CC1)[C@H]3O5
CHEMBL4109805,CHEMBL237,Kappa opioid receptor,Ki,=,0.44,nM,CHEMBL3888319,B,"-Opioid Receptor Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886656,KI,CC(C)(C)[C@@]1(C)OCO[C@]23C=C[C@@]4(C[C@@H]21)[C@H]1Cc2ccc(O)c5c2[C@@]4(CCN1CC1CC1)[C@H]3O5
CHEMBL4115892,CHEMBL237,Kappa opioid receptor,Ki,=,30.1,nM,CHEMBL3888319,B,"-Opioid Receptor Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886656,KI,
CHEMBL4115893,CHEMBL237,Kappa opioid receptor,Ki,=,7.22,nM,CHEMBL3888319,B,"-Opioid Receptor Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886656,KI,
CHEMBL4115381,CHEMBL237,Kappa opioid receptor,Ki,=,757.0,nM,CHEMBL3888319,B,"-Opioid Receptor Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886656,KI,CC(C)(C)[C@@]1(C)OCO[C@]23CC[C@@]4(C[C@@H]21)[C@H]1Cc2ccc(OCc5ccccc5)c5c2[C@@]4(CCN1CC1CC1)[C@H]3O5
CHEMBL3944286,CHEMBL237,Kappa opioid receptor,Ki,=,4758.0,nM,CHEMBL3888407,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886698,KI,COc1ccc2c(c1)[C@]13CCN(CC4CC4)C[C@]1(CC[C@@]1(C3)NC(=O)NC1=O)C2
CHEMBL3986032,CHEMBL237,Kappa opioid receptor,Ki,=,8406.0,nM,CHEMBL3888407,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886698,KI,COc1ccc2c(c1)[C@]13CCN(CC4CC4)C[C@]1(CC[C@]1(C3)NC(=O)NC1=O)C2
CHEMBL4113236,CHEMBL237,Kappa opioid receptor,Ki,=,3602.0,nM,CHEMBL3888407,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886698,KI,COC(=O)c1cc2c([nH]c1=O)C[C@@]13CCN(CC4CC4)C[C@@]1(Cc1ccc(OC)cc13)C2
CHEMBL4113521,CHEMBL237,Kappa opioid receptor,Ki,=,4285.0,nM,CHEMBL3888407,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886698,KI,COc1ccc2c(c1)[C@]13CCN(CC4CC4)C[C@@]1(C2)Cc1cc(C(N)=O)c(=O)[nH]c1C3
CHEMBL4108929,CHEMBL237,Kappa opioid receptor,Ki,=,147.6,nM,CHEMBL3888407,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886698,KI,NC(=O)c1cc2c([nH]c1=O)C[C@@]13CCN(CC4CC4)C[C@@]1(Cc1ccc(O)cc13)C2
CHEMBL3916263,CHEMBL237,Kappa opioid receptor,Ki,=,72.5,nM,CHEMBL3888407,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886698,KI,O=C1NC(=O)[C@@]2(CC[C@@]34Cc5ccc(O)cc5[C@@]3(CCN(CC3CC3)C4)C2)N1
CHEMBL3981333,CHEMBL237,Kappa opioid receptor,Ki,=,147.8,nM,CHEMBL3888407,B,"Radioligand Dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours.",CHEMBL3886698,KI,O=C1NC(=O)[C@]2(CC[C@@]34Cc5ccc(O)cc5[C@@]3(CCN(CC3CC3)C4)C2)N1
CHEMBL4113753,CHEMBL237,Kappa opioid receptor,Ki,=,407.78,nM,CHEMBL3888718,B,"Radioligand dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,KI,CCOC(=O)C[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(OC)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL3935417,CHEMBL237,Kappa opioid receptor,Ki,=,260.85,nM,CHEMBL3888718,B,"Radioligand dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,KI,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)C[C@H](CC(=O)O)C(=O)C3
CHEMBL3890527,CHEMBL237,Kappa opioid receptor,Ki,=,0.97,nM,CHEMBL3888718,B,"Radioligand dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,KI,O=C(O)C[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL4107030,CHEMBL237,Kappa opioid receptor,Ki,=,3410.66,nM,CHEMBL3888718,B,"Radioligand dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,KI,O=C(O)CC1(CC(=O)O)C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL3923032,CHEMBL237,Kappa opioid receptor,Ki,=,190.65,nM,CHEMBL3888718,B,"Radioligand dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,KI,C[C@H](NC(=O)C[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O)C(=O)O
CHEMBL4110715,CHEMBL237,Kappa opioid receptor,Ki,=,128.06,nM,CHEMBL3888718,B,"Radioligand dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,KI,O=C1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@]3(O)C[C@@H]1CC(=O)N1CCC[C@H]1C(=O)O
CHEMBL3933752,CHEMBL237,Kappa opioid receptor,Ki,=,15905.72,nM,CHEMBL3888718,B,"Radioligand dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,KI,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)C[C@H](CC(=O)N[C@@H](CC(C)C)C(=O)O)C(=O)C3
CHEMBL3906641,CHEMBL237,Kappa opioid receptor,Ki,=,145.53,nM,CHEMBL3888718,B,"Radioligand dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,KI,CC(C)C[C@H](NC(=O)C[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O)C(=O)O
CHEMBL4115581,CHEMBL237,Kappa opioid receptor,Ki,=,249.2,nM,CHEMBL3888718,B,"Radioligand dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,KI,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)C1[C@@H](O)[C@H](OCc1ccccc1)C(=O)C3
CHEMBL3922780,CHEMBL237,Kappa opioid receptor,Ki,=,394.2,nM,CHEMBL3888718,B,"Radioligand dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,KI,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)C[C@H](CCO)C(=O)C3
CHEMBL4106563,CHEMBL237,Kappa opioid receptor,Ki,=,65.3,nM,CHEMBL3888718,B,"Radioligand dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,KI,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)C[C@H](CCOCc1ccccc1)C(=O)C3
CHEMBL3932459,CHEMBL237,Kappa opioid receptor,Ki,=,324.4,nM,CHEMBL3888718,B,"Radioligand dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,KI,COCC[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(OC)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL3976681,CHEMBL237,Kappa opioid receptor,Ki,=,82.9,nM,CHEMBL3888718,B,"Radioligand dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,KI,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@@H]1C[C@@H](C(C)C)C(=O)C3
CHEMBL3948713,CHEMBL237,Kappa opioid receptor,Ki,=,0.32,nM,CHEMBL3888718,B,"Radioligand dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,KI,CC(C)[C@@H]1C[C@H]2[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL4111936,CHEMBL237,Kappa opioid receptor,Ki,=,0.33,nM,CHEMBL3888718,B,"Radioligand dose-Displacement Binding Assay: Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 g membrane protein (recombinant  opioid receptor expressed in HEK 293 cells; in-house prep) in a final volume of 200 l binding buffer (5% DMSO, 50 mM Trizma base, pH 7.4). Non-specific binding was determined in the presence of 10 M unlabeled naloxone or U69,593. All reactions were performed in 96-well polypropylene plates for 1 hour at a temperature of about 25 C. Binding reactions were terminated by rapid filtration onto 96-well Unifilter GF/C filter plates (Perkin Elmer, Shelton, Conn.) presoaked in 0.5% polyethylenimine (Sigma). Harvesting was performed using a 96-well tissue harvester (Perkin Elmer, Shelton, Conn.) followed by five filtration washes with 200 l ice-cold binding buffer. Filter plates were subsequently dried at 50 C. for 1-2 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,KI,CC(C)[C@H]1C[C@H]2[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL3959941,CHEMBL237,Kappa opioid receptor,Ki,=,1170.0,nM,CHEMBL3888832,B,"Binding Assay: The determination occurred in a homogeneous batch in microtiter plates. For this, dilution series of the respective substances to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (7 g of protein per 250 l of incubation batch) of CHO-K 1 cells, which express the human -opiate receptor, in the presence of 1 nmol/l of the radioactive ligand [3H']Cl-977 and 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 l. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 100 mol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 500 rpm and the radioactivity measured in a -counter (Microbeta-Trilux 1450, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CNC1(c2ccccc2)CCC(c2ccccc2)(N(C)C)CC1
CHEMBL3935944,CHEMBL237,Kappa opioid receptor,Ki,=,1160.0,nM,CHEMBL3888832,B,"Binding Assay: The determination occurred in a homogeneous batch in microtiter plates. For this, dilution series of the respective substances to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (7 g of protein per 250 l of incubation batch) of CHO-K 1 cells, which express the human -opiate receptor, in the presence of 1 nmol/l of the radioactive ligand [3H']Cl-977 and 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 l. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 100 mol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 500 rpm and the radioactivity measured in a -counter (Microbeta-Trilux 1450, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(c2ccccc2)(N(C)C)CC1
CHEMBL3924824,CHEMBL237,Kappa opioid receptor,Ki,=,2240.0,nM,CHEMBL3888832,B,"Binding Assay: The determination occurred in a homogeneous batch in microtiter plates. For this, dilution series of the respective substances to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (7 g of protein per 250 l of incubation batch) of CHO-K 1 cells, which express the human -opiate receptor, in the presence of 1 nmol/l of the radioactive ligand [3H']Cl-977 and 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 l. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 100 mol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 500 rpm and the radioactivity measured in a -counter (Microbeta-Trilux 1450, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(c2ccccc2)CCC(O)(c2ccccc2)CC1
CHEMBL3951213,CHEMBL237,Kappa opioid receptor,Ki,=,3745.0,nM,CHEMBL3888832,B,"Binding Assay: The determination occurred in a homogeneous batch in microtiter plates. For this, dilution series of the respective substances to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (7 g of protein per 250 l of incubation batch) of CHO-K 1 cells, which express the human -opiate receptor, in the presence of 1 nmol/l of the radioactive ligand [3H']Cl-977 and 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 l. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 100 mol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 500 rpm and the radioactivity measured in a -counter (Microbeta-Trilux 1450, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,CN(C)C1(Cc2ccccc2)CCC(c2ccccc2)(N(C)C)CC1
CHEMBL3900292,CHEMBL237,Kappa opioid receptor,Ki,=,1460.0,nM,CHEMBL3888832,B,"Binding Assay: The determination occurred in a homogeneous batch in microtiter plates. For this, dilution series of the respective substances to be tested were incubated for 90 minutes at room temperature with a receptor membrane preparation (7 g of protein per 250 l of incubation batch) of CHO-K 1 cells, which express the human -opiate receptor, in the presence of 1 nmol/l of the radioactive ligand [3H']Cl-977 and 1 mg WGA-SPA beads (wheat germ agglutinin SPA beads from Amersham/Pharmacia, Freiburg, Germany) in a total volume of 250 l. 50 mmol/l of tris-HCl supplemented by 0.05% by wt. of sodium azide and 0.06% by wt. of bovine serum albumin was used as incubation buffer. 100 mol/l of naloxone were additionally added to determine the non-specific bond. After the ninety-minute incubation time had ended, the microtiter plates were centrifuged for 20 minutes at 500 rpm and the radioactivity measured in a -counter (Microbeta-Trilux 1450, PerkinElmer Wallac, Freiburg, Germany).",CHEMBL3886853,KI,Cc1ccc(C2(N(C)C)CCC(O)(c3ccccc3)CC2)cc1
CHEMBL3262089,CHEMBL237,Kappa opioid receptor,Ki,=,0.49,nM,CHEMBL3889194,B,"Ligand Binding Assay: As Alt et al., 2002. Membranes (20 g) are incubated in 50 mM Tris-HCl, pH 7.4 with [3H]diprenorphine or [3H]nociceptin in the absence or presence of varying concentrations of test compounds for 60 min in a shaking water bath at 25 C. Nonspecific binding is measured using 10 M naloxone (MOR, DOR, KOR) or N/OFQ (NOP). Samples are filtered through GF/C glass-fiber filtermats mounted on a Brandel cell harvester and rinsed four times with 4 C. 50 mM Tris-HCl, pH 7.4 buffer. Filtermats are dried and 0.1 ml EcoLume scintillation cocktail added to each sample area to soak the filter. Each filtermat in a heat-sealed bag, is counted in a Wallac 1450 MicroBeta Liquid Scintillation and Luminescence Counter.",CHEMBL3886987,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3262090,CHEMBL237,Kappa opioid receptor,Ki,=,4.4,nM,CHEMBL3889194,B,"Ligand Binding Assay: As Alt et al., 2002. Membranes (20 g) are incubated in 50 mM Tris-HCl, pH 7.4 with [3H]diprenorphine or [3H]nociceptin in the absence or presence of varying concentrations of test compounds for 60 min in a shaking water bath at 25 C. Nonspecific binding is measured using 10 M naloxone (MOR, DOR, KOR) or N/OFQ (NOP). Samples are filtered through GF/C glass-fiber filtermats mounted on a Brandel cell harvester and rinsed four times with 4 C. 50 mM Tris-HCl, pH 7.4 buffer. Filtermats are dried and 0.1 ml EcoLume scintillation cocktail added to each sample area to soak the filter. Each filtermat in a heat-sealed bag, is counted in a Wallac 1450 MicroBeta Liquid Scintillation and Luminescence Counter.",CHEMBL3886987,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@H](O)c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL95302,CHEMBL237,Kappa opioid receptor,Ki,=,0.08,nM,CHEMBL3889194,B,"Ligand Binding Assay: As Alt et al., 2002. Membranes (20 g) are incubated in 50 mM Tris-HCl, pH 7.4 with [3H]diprenorphine or [3H]nociceptin in the absence or presence of varying concentrations of test compounds for 60 min in a shaking water bath at 25 C. Nonspecific binding is measured using 10 M naloxone (MOR, DOR, KOR) or N/OFQ (NOP). Samples are filtered through GF/C glass-fiber filtermats mounted on a Brandel cell harvester and rinsed four times with 4 C. 50 mM Tris-HCl, pH 7.4 buffer. Filtermats are dried and 0.1 ml EcoLume scintillation cocktail added to each sample area to soak the filter. Each filtermat in a heat-sealed bag, is counted in a Wallac 1450 MicroBeta Liquid Scintillation and Luminescence Counter.",CHEMBL3886987,KI,CC(C)c1ccccc1Nc1ncnc2c1ncn2[C@H]1OC(CO)C(O)C1O
CHEMBL3935546,CHEMBL237,Kappa opioid receptor,Ki,=,3.02,nM,CHEMBL3889194,B,"Ligand Binding Assay: As Alt et al., 2002. Membranes (20 g) are incubated in 50 mM Tris-HCl, pH 7.4 with [3H]diprenorphine or [3H]nociceptin in the absence or presence of varying concentrations of test compounds for 60 min in a shaking water bath at 25 C. Nonspecific binding is measured using 10 M naloxone (MOR, DOR, KOR) or N/OFQ (NOP). Samples are filtered through GF/C glass-fiber filtermats mounted on a Brandel cell harvester and rinsed four times with 4 C. 50 mM Tris-HCl, pH 7.4 buffer. Filtermats are dried and 0.1 ml EcoLume scintillation cocktail added to each sample area to soak the filter. Each filtermat in a heat-sealed bag, is counted in a Wallac 1450 MicroBeta Liquid Scintillation and Luminescence Counter.",CHEMBL3886987,KI,CO[C@@]12C=C[C@]3(C[C@@]1(C)[C@H](O)c1ccccc1)[C@@H]1Cc4ccc(O)c5c4[C@]3(CCN1CC1CC1)[C@@H]2O5
CHEMBL3262093,CHEMBL237,Kappa opioid receptor,Ki,=,3.84,nM,CHEMBL3889194,B,"Ligand Binding Assay: As Alt et al., 2002. Membranes (20 g) are incubated in 50 mM Tris-HCl, pH 7.4 with [3H]diprenorphine or [3H]nociceptin in the absence or presence of varying concentrations of test compounds for 60 min in a shaking water bath at 25 C. Nonspecific binding is measured using 10 M naloxone (MOR, DOR, KOR) or N/OFQ (NOP). Samples are filtered through GF/C glass-fiber filtermats mounted on a Brandel cell harvester and rinsed four times with 4 C. 50 mM Tris-HCl, pH 7.4 buffer. Filtermats are dried and 0.1 ml EcoLume scintillation cocktail added to each sample area to soak the filter. Each filtermat in a heat-sealed bag, is counted in a Wallac 1450 MicroBeta Liquid Scintillation and Luminescence Counter.",CHEMBL3886987,KI,CO[C@]12C=C[C@@]3(C[C@@H]1[C@H](O)c1ccccc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3262367,CHEMBL237,Kappa opioid receptor,Ki,=,0.1,nM,CHEMBL3889194,B,"Ligand Binding Assay: As Alt et al., 2002. Membranes (20 g) are incubated in 50 mM Tris-HCl, pH 7.4 with [3H]diprenorphine or [3H]nociceptin in the absence or presence of varying concentrations of test compounds for 60 min in a shaking water bath at 25 C. Nonspecific binding is measured using 10 M naloxone (MOR, DOR, KOR) or N/OFQ (NOP). Samples are filtered through GF/C glass-fiber filtermats mounted on a Brandel cell harvester and rinsed four times with 4 C. 50 mM Tris-HCl, pH 7.4 buffer. Filtermats are dried and 0.1 ml EcoLume scintillation cocktail added to each sample area to soak the filter. Each filtermat in a heat-sealed bag, is counted in a Wallac 1450 MicroBeta Liquid Scintillation and Luminescence Counter.",CHEMBL3886987,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)c1cc(C)cc(C)c1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL3262363,CHEMBL237,Kappa opioid receptor,Ki,=,0.16,nM,CHEMBL3889194,B,"Ligand Binding Assay: As Alt et al., 2002. Membranes (20 g) are incubated in 50 mM Tris-HCl, pH 7.4 with [3H]diprenorphine or [3H]nociceptin in the absence or presence of varying concentrations of test compounds for 60 min in a shaking water bath at 25 C. Nonspecific binding is measured using 10 M naloxone (MOR, DOR, KOR) or N/OFQ (NOP). Samples are filtered through GF/C glass-fiber filtermats mounted on a Brandel cell harvester and rinsed four times with 4 C. 50 mM Tris-HCl, pH 7.4 buffer. Filtermats are dried and 0.1 ml EcoLume scintillation cocktail added to each sample area to soak the filter. Each filtermat in a heat-sealed bag, is counted in a Wallac 1450 MicroBeta Liquid Scintillation and Luminescence Counter.",CHEMBL3886987,KI,CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)c1ccccc1C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL266314,CHEMBL237,Kappa opioid receptor,Ki,=,0.04,nM,CHEMBL3889194,B,"Ligand Binding Assay: As Alt et al., 2002. Membranes (20 g) are incubated in 50 mM Tris-HCl, pH 7.4 with [3H]diprenorphine or [3H]nociceptin in the absence or presence of varying concentrations of test compounds for 60 min in a shaking water bath at 25 C. Nonspecific binding is measured using 10 M naloxone (MOR, DOR, KOR) or N/OFQ (NOP). Samples are filtered through GF/C glass-fiber filtermats mounted on a Brandel cell harvester and rinsed four times with 4 C. 50 mM Tris-HCl, pH 7.4 buffer. Filtermats are dried and 0.1 ml EcoLume scintillation cocktail added to each sample area to soak the filter. Each filtermat in a heat-sealed bag, is counted in a Wallac 1450 MicroBeta Liquid Scintillation and Luminescence Counter.",CHEMBL3886987,KI,CC(C)C[C@H](NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)C1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)NCC(N)=O
CHEMBL3907014,CHEMBL237,Kappa opioid receptor,Ki,=,0.04,nM,CHEMBL3889194,B,"Ligand Binding Assay: As Alt et al., 2002. Membranes (20 g) are incubated in 50 mM Tris-HCl, pH 7.4 with [3H]diprenorphine or [3H]nociceptin in the absence or presence of varying concentrations of test compounds for 60 min in a shaking water bath at 25 C. Nonspecific binding is measured using 10 M naloxone (MOR, DOR, KOR) or N/OFQ (NOP). Samples are filtered through GF/C glass-fiber filtermats mounted on a Brandel cell harvester and rinsed four times with 4 C. 50 mM Tris-HCl, pH 7.4 buffer. Filtermats are dried and 0.1 ml EcoLume scintillation cocktail added to each sample area to soak the filter. Each filtermat in a heat-sealed bag, is counted in a Wallac 1450 MicroBeta Liquid Scintillation and Luminescence Counter.",CHEMBL3886987,KI,CO[C@@]12CC[C@]3(C[C@@]1(C)[C@@H](O)c1ccccc1)[C@@H]1Cc4ccc(O)c5c4[C@]3(CCN1CC1CC1)[C@@H]2O5
CHEMBL3974294,CHEMBL237,Kappa opioid receptor,Ki,=,0.05,nM,CHEMBL3889194,B,"Ligand Binding Assay: As Alt et al., 2002. Membranes (20 g) are incubated in 50 mM Tris-HCl, pH 7.4 with [3H]diprenorphine or [3H]nociceptin in the absence or presence of varying concentrations of test compounds for 60 min in a shaking water bath at 25 C. Nonspecific binding is measured using 10 M naloxone (MOR, DOR, KOR) or N/OFQ (NOP). Samples are filtered through GF/C glass-fiber filtermats mounted on a Brandel cell harvester and rinsed four times with 4 C. 50 mM Tris-HCl, pH 7.4 buffer. Filtermats are dried and 0.1 ml EcoLume scintillation cocktail added to each sample area to soak the filter. Each filtermat in a heat-sealed bag, is counted in a Wallac 1450 MicroBeta Liquid Scintillation and Luminescence Counter.",CHEMBL3886987,KI,CO[C@@]12C=C[C@]3(C[C@@]1(C)[C@@H](O)c1ccc(F)cc1)[C@@H]1Cc4ccc(O)c5c4[C@]3(CCN1CC1CC1)[C@@H]2O5
CHEMBL440765,CHEMBL237,Kappa opioid receptor,Ki,=,1.1,nM,CHEMBL4001473,B,Displacement of [3H]U69593 from human KOR expressed in CHO cells,CHEMBL4000201,KI,CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL4073537,CHEMBL237,Kappa opioid receptor,Ki,=,793.0,nM,CHEMBL4001473,B,Displacement of [3H]U69593 from human KOR expressed in CHO cells,CHEMBL4000201,KI,O=C1/C(=C/c2ccccc2)C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CCCc2ccccc2)[C@H]1O5
CHEMBL4094170,CHEMBL237,Kappa opioid receptor,Ki,=,602.0,nM,CHEMBL4001473,B,Displacement of [3H]U69593 from human KOR expressed in CHO cells,CHEMBL4000201,KI,O=C1/C(=C/c2ccccc2)C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CCc2ccccc2)[C@H]1O5
CHEMBL4083911,CHEMBL237,Kappa opioid receptor,Ki,=,1067.0,nM,CHEMBL4001473,B,Displacement of [3H]U69593 from human KOR expressed in CHO cells,CHEMBL4000201,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)/C(=C/c2ccccc2)C[C@@]3(O)[C@H]1C5
CHEMBL4071862,CHEMBL237,Kappa opioid receptor,Ki,=,0.017,nM,CHEMBL4019244,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method",CHEMBL4017505,KI,Cl.Oc1cccc(CCN(CCc2ccccc2)CC2CCCC2)c1
CHEMBL4092640,CHEMBL237,Kappa opioid receptor,Ki,=,0.061,nM,CHEMBL4019244,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method",CHEMBL4017505,KI,Cl.Oc1cccc(CCN(CCc2ccccc2)CC2CCCCC2)c1
CHEMBL4063231,CHEMBL237,Kappa opioid receptor,Ki,=,0.71,nM,CHEMBL4019244,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method",CHEMBL4017505,KI,Cl.Oc1cccc(CCN(CCc2ccccc2)Cc2ccccc2)c1
CHEMBL4084881,CHEMBL237,Kappa opioid receptor,Ki,=,10.3,nM,CHEMBL4019244,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method",CHEMBL4017505,KI,Cl.Oc1cccc(CCN(CCc2ccccc2)C2CCC2)c1
CHEMBL4078954,CHEMBL237,Kappa opioid receptor,Ki,=,2.69,nM,CHEMBL4019244,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method",CHEMBL4017505,KI,CC(C)CCN(CCc1ccccc1)CCc1cccc(O)c1.Cl
CHEMBL4096973,CHEMBL237,Kappa opioid receptor,Ki,=,0.38,nM,CHEMBL4019244,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method",CHEMBL4017505,KI,Cl.Oc1cccc(CCN(CCc2cccc(O)c2)CC2CCC2)c1
CHEMBL4103205,CHEMBL237,Kappa opioid receptor,Ki,=,4.62,nM,CHEMBL4019244,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method",CHEMBL4017505,KI,Cl.Oc1cccc(CCN(CCc2cccc(O)c2)CC2CC2)c1
CHEMBL4078930,CHEMBL237,Kappa opioid receptor,Ki,=,19.1,nM,CHEMBL4019244,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method",CHEMBL4017505,KI,C=CCN(CCc1cccc(O)c1)CCc1cccc(O)c1.Cl
CHEMBL4065350,CHEMBL237,Kappa opioid receptor,Ki,=,0.14,nM,CHEMBL4019244,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method",CHEMBL4017505,KI,Cl.Oc1cccc(CCN(CCc2cccc(O)c2)CC2CCCCC2)c1
CHEMBL4086783,CHEMBL237,Kappa opioid receptor,Ki,=,0.31,nM,CHEMBL4019244,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method",CHEMBL4017505,KI,Cl.Oc1cccc(CCN(CCc2cccc(O)c2)CC2CCCC2)c1
CHEMBL4073963,CHEMBL237,Kappa opioid receptor,Ki,=,2.1,nM,CHEMBL4019244,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method",CHEMBL4017505,KI,CC(C)CCN(CCc1cccc(O)c1)CCc1cccc(O)c1.Cl
CHEMBL4094512,CHEMBL237,Kappa opioid receptor,Ki,=,3.43,nM,CHEMBL4019244,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method",CHEMBL4017505,KI,Cl.Oc1ccc(CCN(CCc2cccc(O)c2)CC2CCC2)cc1
CHEMBL4084291,CHEMBL237,Kappa opioid receptor,Ki,=,1.85,nM,CHEMBL4019244,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method",CHEMBL4017505,KI,Cl.Oc1ccc(CCN(CCc2cccc(O)c2)CC2CCCCC2)cc1
CHEMBL4102256,CHEMBL237,Kappa opioid receptor,Ki,=,43.5,nM,CHEMBL4019244,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method",CHEMBL4017505,KI,C=CCN(CCc1ccc(O)cc1)CCc1cccc(O)c1.Cl
CHEMBL4069115,CHEMBL237,Kappa opioid receptor,Ki,=,3.56,nM,CHEMBL4019244,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method",CHEMBL4017505,KI,Cl.Oc1ccc(CCN(CCc2cccc(O)c2)CC2CC2)cc1
CHEMBL4090181,CHEMBL237,Kappa opioid receptor,Ki,=,0.072,nM,CHEMBL4019244,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method",CHEMBL4017505,KI,Cl.Oc1cccc(CCN(CCc2ccccc2)CC2CCC2)c1F
CHEMBL4101576,CHEMBL237,Kappa opioid receptor,Ki,=,0.04,nM,CHEMBL4019244,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method",CHEMBL4017505,KI,Cl.Oc1cccc(CCN(CCc2ccccc2)CC2CCCCC2)c1F
CHEMBL4083571,CHEMBL237,Kappa opioid receptor,Ki,=,0.12,nM,CHEMBL4019244,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method",CHEMBL4017505,KI,Cl.Oc1cccc(CCN(CCc2cccc(O)c2F)CC2CCC2)c1
CHEMBL4093848,CHEMBL237,Kappa opioid receptor,Ki,=,3.37,nM,CHEMBL4019244,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method",CHEMBL4017505,KI,Cl.Oc1ccc(CCN(CCc2cccc(O)c2F)CC2CCC2)cc1
CHEMBL4073160,CHEMBL237,Kappa opioid receptor,Ki,=,79.1,nM,CHEMBL4019244,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method",CHEMBL4017505,KI,c1ccc(CCN(CCc2ccccc2)CC2CCC2)cc1
CHEMBL963,CHEMBL237,Kappa opioid receptor,Ki,=,25.3,nM,CHEMBL4032001,B,Displacement of [3H]-HS665 from recombinant human KOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting,CHEMBL4028881,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL4074110,CHEMBL237,Kappa opioid receptor,Ki,=,21.6,nM,CHEMBL4032001,B,Displacement of [3H]-HS665 from recombinant human KOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting,CHEMBL4028881,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2CCC[C@@]3(O)[C@H]1C5
CHEMBL607405,CHEMBL237,Kappa opioid receptor,Ki,=,10.1,nM,CHEMBL4032001,B,Displacement of [3H]-HS665 from recombinant human KOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting,CHEMBL4028881,KI,CO[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4065490,CHEMBL237,Kappa opioid receptor,Ki,=,3.99,nM,CHEMBL4032001,B,Displacement of [3H]-HS665 from recombinant human KOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting,CHEMBL4028881,KI,CO[C@@]12CCC[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL607351,CHEMBL237,Kappa opioid receptor,Ki,=,1.27,nM,CHEMBL4032001,B,Displacement of [3H]-HS665 from recombinant human KOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting,CHEMBL4028881,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(OCc2ccccc2)[C@H]1C5
CHEMBL4103328,CHEMBL237,Kappa opioid receptor,Ki,=,0.85,nM,CHEMBL4032001,B,Displacement of [3H]-HS665 from recombinant human KOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting,CHEMBL4028881,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2CCC[C@@]3(OCc2ccccc2)[C@H]1C5
CHEMBL326684,CHEMBL237,Kappa opioid receptor,Ki,=,15.1,nM,CHEMBL4032001,B,Displacement of [3H]-HS665 from recombinant human KOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting,CHEMBL4028881,KI,CO[C@@]12CCC(=O)[C@]3(C)Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4088589,CHEMBL237,Kappa opioid receptor,Ki,=,7.92,nM,CHEMBL4032001,B,Displacement of [3H]-HS665 from recombinant human KOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting,CHEMBL4028881,KI,CO[C@@]12CCC[C@]3(C)Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4066752,CHEMBL237,Kappa opioid receptor,Ki,=,1.05,nM,CHEMBL4035927,B,"Displacement of [3H]U-69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL4033703,KI,O=C(c1ccccc1)N1C[C@H]2OC34CCC1C2C31CCN(CC2CC2)C4Cc2ccc(O)cc21
CHEMBL4081856,CHEMBL237,Kappa opioid receptor,Ki,=,0.658,nM,CHEMBL4035927,B,"Displacement of [3H]U-69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL4033703,KI,O=S(=O)(c1ccccc1)N1C[C@H]2OC34CCC1C2C31CCN(CC2CC2)C4Cc2ccc(O)cc21
CHEMBL4100943,CHEMBL237,Kappa opioid receptor,Ki,=,1.38,nM,CHEMBL4035927,B,"Displacement of [3H]U-69,593 from human kappa opioid receptor expressed in CHO cells",CHEMBL4033703,KI,Oc1ccc2c(c1)C13CCN(CC4CC4)C(C2)C12CCC1C3[C@@H](CN1Cc1ccccc1)O2
CHEMBL4094845,CHEMBL237,Kappa opioid receptor,Ki,=,0.479,nM,CHEMBL4036554,B,"Displacement of [3H]U-69,593 from human recombinant KOR expressed in CHO cell membranes",CHEMBL4033739,KI,Oc1ccc2c(c1)C13CCN(CC4CC4)C(C2)C12CCC1C3[C@@H](CN1c1cnccn1)C2
CHEMBL4067629,CHEMBL237,Kappa opioid receptor,Ki,=,2.43,nM,CHEMBL4036554,B,"Displacement of [3H]U-69,593 from human recombinant KOR expressed in CHO cell membranes",CHEMBL4033739,KI,Oc1ccc2c(c1)C13CCN(CC4CC4)C(C2)C12CCC1C3[C@@H](CN1c1ccccc1)C2
CHEMBL4076681,CHEMBL237,Kappa opioid receptor,Ki,=,0.522,nM,CHEMBL4036554,B,"Displacement of [3H]U-69,593 from human recombinant KOR expressed in CHO cell membranes",CHEMBL4033739,KI,O=C(Oc1ccccc1)N1C[C@H]2CC34CCC1C2C31CCN(CC2CC2)C4Cc2ccc(O)cc21
CHEMBL4076632,CHEMBL237,Kappa opioid receptor,Ki,=,0.336,nM,CHEMBL4036554,B,"Displacement of [3H]U-69,593 from human recombinant KOR expressed in CHO cell membranes",CHEMBL4033739,KI,O=C(Nc1ccccc1)N1C[C@H]2CC34CCC1C2C31CCN(CC2CC2)C4Cc2ccc(O)cc21
CHEMBL4098662,CHEMBL237,Kappa opioid receptor,Ki,=,0.781,nM,CHEMBL4036554,B,"Displacement of [3H]U-69,593 from human recombinant KOR expressed in CHO cell membranes",CHEMBL4033739,KI,Oc1ccc2c(c1)C13CCN(CC4CC4)C(C2)C12CCC1C3[C@@H](CN1CC1CCCCC1)C2
CHEMBL4068691,CHEMBL237,Kappa opioid receptor,Ki,=,0.564,nM,CHEMBL4036554,B,"Displacement of [3H]U-69,593 from human recombinant KOR expressed in CHO cell membranes",CHEMBL4033739,KI,O=C(c1ccccn1)N1C[C@H]2CC34CCC1C2C31CCN(CC2CC2)C4Cc2ccc(O)cc21
CHEMBL4103044,CHEMBL237,Kappa opioid receptor,Ki,=,0.221,nM,CHEMBL4036554,B,"Displacement of [3H]U-69,593 from human recombinant KOR expressed in CHO cell membranes",CHEMBL4033739,KI,O=C(c1ccoc1)N1C[C@H]2CC34CCC1C2C31CCN(CC2CC2)C4Cc2ccc(O)cc21
CHEMBL4083940,CHEMBL237,Kappa opioid receptor,Ki,=,0.362,nM,CHEMBL4036554,B,"Displacement of [3H]U-69,593 from human recombinant KOR expressed in CHO cell membranes",CHEMBL4033739,KI,O=C(c1ccccc1)N1C[C@H]2CC34CCC1C2C31CCN(CC2CC2)C4Cc2ccc(O)cc21
CHEMBL4061334,CHEMBL237,Kappa opioid receptor,Ki,=,4.26,nM,CHEMBL4036554,B,"Displacement of [3H]U-69,593 from human recombinant KOR expressed in CHO cell membranes",CHEMBL4033739,KI,Oc1ccc2c(c1)C13CCN(CC4CC4)C(C2)C12CCC1C3[C@@H](CN1Cc1ccccc1)C2
CHEMBL1927270,CHEMBL237,Kappa opioid receptor,Ki,=,2.36,nM,CHEMBL4038748,B,Displacement of [3H]U-69593 from recombinant human kappa opioid receptor expressed in CHO cell membranes after 120 mins by liquid scintillation counter analysis,CHEMBL4038279,KI,NC(=O)[C@@H]1CC(=O)NCCCC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1
CHEMBL4083221,CHEMBL237,Kappa opioid receptor,Ki,=,884.0,nM,CHEMBL4038748,B,Displacement of [3H]U-69593 from recombinant human kappa opioid receptor expressed in CHO cell membranes after 120 mins by liquid scintillation counter analysis,CHEMBL4038279,KI,NC(=O)[C@@H]1CC(=O)NCCCC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCC[C@H]2C(=O)N1
CHEMBL4074931,CHEMBL237,Kappa opioid receptor,Ki,=,6717.0,nM,CHEMBL4038748,B,Displacement of [3H]U-69593 from recombinant human kappa opioid receptor expressed in CHO cell membranes after 120 mins by liquid scintillation counter analysis,CHEMBL4038279,KI,NC(=O)[C@@H]1CC(=O)NCCCC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCCC[C@H]2C(=O)N1
CHEMBL4095366,CHEMBL237,Kappa opioid receptor,Ki,=,4625.0,nM,CHEMBL4038748,B,Displacement of [3H]U-69593 from recombinant human kappa opioid receptor expressed in CHO cell membranes after 120 mins by liquid scintillation counter analysis,CHEMBL4038279,KI,NC(=O)[C@@H]1CC(=O)NCCCC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCC[C@H](C2)C(=O)N1
CHEMBL4085033,CHEMBL237,Kappa opioid receptor,Ki,=,5461.0,nM,CHEMBL4038748,B,Displacement of [3H]U-69593 from recombinant human kappa opioid receptor expressed in CHO cell membranes after 120 mins by liquid scintillation counter analysis,CHEMBL4038279,KI,NC(=O)[C@@H]1CC(=O)NCCCC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCC(CC2)C(=O)N1
CHEMBL252172,CHEMBL237,Kappa opioid receptor,Ki,=,32.8,nM,CHEMBL4044350,B,"Displacement of [3H]U-69,593 from human kappa opioid receptor expressed in CHO cell membranes by microbeta scintillation counting analysis",CHEMBL4043100,KI,O=C1/C(=C/c2ccccc2)C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL2059382,CHEMBL237,Kappa opioid receptor,Ki,=,27.8,nM,CHEMBL4044350,B,"Displacement of [3H]U-69,593 from human kappa opioid receptor expressed in CHO cell membranes by microbeta scintillation counting analysis",CHEMBL4043100,KI,COc1ccc(/C=C2\C[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@@H](O6)C2=O)cc1
CHEMBL2059381,CHEMBL237,Kappa opioid receptor,Ki,=,108.0,nM,CHEMBL4044350,B,"Displacement of [3H]U-69,593 from human kappa opioid receptor expressed in CHO cell membranes by microbeta scintillation counting analysis",CHEMBL4043100,KI,O=C1/C(=C/c2ccc(F)cc2)C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL3632690,CHEMBL237,Kappa opioid receptor,Ki,=,28.6,nM,CHEMBL4044350,B,"Displacement of [3H]U-69,593 from human kappa opioid receptor expressed in CHO cell membranes by microbeta scintillation counting analysis",CHEMBL4043100,KI,CN(C)c1ccc(/C=C2\C[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@@H](O6)C2=O)cc1
CHEMBL4070277,CHEMBL237,Kappa opioid receptor,Ki,=,78.6,nM,CHEMBL4044350,B,"Displacement of [3H]U-69,593 from human kappa opioid receptor expressed in CHO cell membranes by microbeta scintillation counting analysis",CHEMBL4043100,KI,O=C1/C(=C/c2ccc(Cl)cc2)C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL4071324,CHEMBL237,Kappa opioid receptor,Ki,=,70.4,nM,CHEMBL4044350,B,"Displacement of [3H]U-69,593 from human kappa opioid receptor expressed in CHO cell membranes by microbeta scintillation counting analysis",CHEMBL4043100,KI,O=C1/C(=C/c2ccc(Br)cc2)C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL4092119,CHEMBL237,Kappa opioid receptor,Ki,=,126.0,nM,CHEMBL4044350,B,"Displacement of [3H]U-69,593 from human kappa opioid receptor expressed in CHO cell membranes by microbeta scintillation counting analysis",CHEMBL4043100,KI,O=C1/C(=C/c2ccc(I)cc2)C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL4081053,CHEMBL237,Kappa opioid receptor,Ki,=,49.0,nM,CHEMBL4044350,B,"Displacement of [3H]U-69,593 from human kappa opioid receptor expressed in CHO cell membranes by microbeta scintillation counting analysis",CHEMBL4043100,KI,O=C1/C(=C/c2cccc(F)c2)C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL4105306,CHEMBL237,Kappa opioid receptor,Ki,=,35.1,nM,CHEMBL4044350,B,"Displacement of [3H]U-69,593 from human kappa opioid receptor expressed in CHO cell membranes by microbeta scintillation counting analysis",CHEMBL4043100,KI,O=C1/C(=C/c2ccccc2F)C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL4089193,CHEMBL237,Kappa opioid receptor,Ki,=,209.0,nM,CHEMBL4044350,B,"Displacement of [3H]U-69,593 from human kappa opioid receptor expressed in CHO cell membranes by microbeta scintillation counting analysis",CHEMBL4043100,KI,N#Cc1ccc(/C=C2\C[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@@H](O6)C2=O)cc1
CHEMBL4061882,CHEMBL237,Kappa opioid receptor,Ki,=,176.0,nM,CHEMBL4044350,B,"Displacement of [3H]U-69,593 from human kappa opioid receptor expressed in CHO cell membranes by microbeta scintillation counting analysis",CHEMBL4043100,KI,O=C1/C(=C/c2ccc(C(F)(F)F)cc2)C[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL4082214,CHEMBL237,Kappa opioid receptor,Ki,=,37.6,nM,CHEMBL4049836,B,Displacement of [3H]U69593 from recombinant human kappa-opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method,CHEMBL4049389,KI,Cc1cc(C)cc(C2CCCN2Cc2ccc(Oc3ccc(C(N)=O)cc3)c(Cl)c2)c1
CHEMBL4069892,CHEMBL237,Kappa opioid receptor,Ki,=,29.4,nM,CHEMBL4049836,B,Displacement of [3H]U69593 from recombinant human kappa-opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method,CHEMBL4049389,KI,Cc1cc(C)cc(C2CCCN2Cc2ccc(Oc3ccc(C(N)=O)cc3)c(F)c2)c1
CHEMBL4090064,CHEMBL237,Kappa opioid receptor,Ki,=,15.7,nM,CHEMBL4049836,B,Displacement of [3H]U69593 from recombinant human kappa-opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method,CHEMBL4049389,KI,Cc1cc(C)cc(C2CCCN2Cc2ccc(Oc3ccc(C(N)=O)cc3F)c(Cl)c2)c1
CHEMBL4062024,CHEMBL237,Kappa opioid receptor,Ki,=,42.7,nM,CHEMBL4049836,B,Displacement of [3H]U69593 from recombinant human kappa-opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method,CHEMBL4049389,KI,Cc1cc(C)cc(C2CCCN2Cc2ccc(Oc3ccc(C(N)=O)cc3F)c(F)c2)c1
CHEMBL4063074,CHEMBL237,Kappa opioid receptor,Ki,=,11.9,nM,CHEMBL4049836,B,Displacement of [3H]U69593 from recombinant human kappa-opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method,CHEMBL4049389,KI,Cc1cc(C)cc(C2CCCN2Cc2ccc(Oc3ccc(C(N)=O)cc3F)cc2)c1
CHEMBL4067922,CHEMBL237,Kappa opioid receptor,Ki,=,4603.0,nM,CHEMBL4049836,B,Displacement of [3H]U69593 from recombinant human kappa-opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method,CHEMBL4049389,KI,COc1ccc(C2CCCN2Cc2ccc(Oc3ccc(C(N)=O)c4ccccc34)cc2)cc1
CHEMBL4087860,CHEMBL237,Kappa opioid receptor,Ki,=,1738.0,nM,CHEMBL4049836,B,Displacement of [3H]U69593 from recombinant human kappa-opioid receptor expressed in CHO cell membranes after 60 mins by liquid scintillation counting method,CHEMBL4049389,KI,Cc1cccc(C2CCCN2Cc2ccc(Oc3ccc(C(N)=O)c4ccccc34)cc2)c1
CHEMBL4071661,CHEMBL237,Kappa opioid receptor,Ki,=,234.42,nM,CHEMBL4050974,B,Antagonist activity at KOR (unknown origin) expressed in HTLA cells assessed as inhibition of Sal A-induced beta-arrestin recruitment preincubated for overnight followed by Sal-A addition at 30 mins post compound treatment measured after 20 mins by Bright-Glo luminescence assay,CHEMBL4049419,KI,Oc1cccc(C(O)CNCc2ccc(Cl)cc2Cl)c1
CHEMBL4071661,CHEMBL237,Kappa opioid receptor,Ki,=,230.0,nM,CHEMBL4050974,B,Antagonist activity at KOR (unknown origin) expressed in HTLA cells assessed as inhibition of Sal A-induced beta-arrestin recruitment preincubated for overnight followed by Sal-A addition at 30 mins post compound treatment measured after 20 mins by Bright-Glo luminescence assay,CHEMBL4049419,KI,Oc1cccc(C(O)CNCc2ccc(Cl)cc2Cl)c1
CHEMBL4063789,CHEMBL237,Kappa opioid receptor,Ki,=,912.01,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,O=C(NC[C@@H](c1ccco1)N1CCCC1)c1cc2ccccc2o1
CHEMBL4083805,CHEMBL237,Kappa opioid receptor,Ki,=,707.95,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,COc1ccc2oc(C(=O)NCC(c3ccco3)N3CCCC3)c(C)c2c1
CHEMBL4101810,CHEMBL237,Kappa opioid receptor,Ki,=,676.08,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,Oc1cccc(CNCc2cc3ccccc3[nH]2)c1
CHEMBL4077345,CHEMBL237,Kappa opioid receptor,Ki,=,645.65,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,Cc1ccc(C(CNC(=O)c2oc3ccc(F)cc3c2C)N2CCCC2)o1
CHEMBL4104275,CHEMBL237,Kappa opioid receptor,Ki,=,562.34,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,CCN(Cc1csc(C)n1)C(C)c1cccc(O)c1
CHEMBL1701606,CHEMBL237,Kappa opioid receptor,Ki,=,512.86,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,Cc1c(C(=O)NCC(c2ccco2)N2CCCC2)oc2ccc(Cl)cc12
CHEMBL4078777,CHEMBL237,Kappa opioid receptor,Ki,=,363.08,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,Cc1ccc(C(CNC(=O)c2oc3ccccc3c2C)N2CCCC2)o1
CHEMBL4084706,CHEMBL237,Kappa opioid receptor,Ki,=,346.74,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,Cc1ncsc1CN1CCCCC1CCc1cccc(O)c1
CHEMBL3484893,CHEMBL237,Kappa opioid receptor,Ki,=,229.09,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,COc1ccc(CNCC(O)c2cccc(O)c2)cc1Br
CHEMBL4092454,CHEMBL237,Kappa opioid receptor,Ki,=,154.88,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,CC(NCc1nccn1C)c1cccc(O)c1
CHEMBL4071661,CHEMBL237,Kappa opioid receptor,Ki,=,83.18,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,Oc1cccc(C(O)CNCc2ccc(Cl)cc2Cl)c1
CHEMBL4100198,CHEMBL237,Kappa opioid receptor,Ki,=,9772.37,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,NC(=O)c1cc(S(=O)(=O)NC2CCN(Cc3ccccc3)CC2)cs1
CHEMBL144439,CHEMBL237,Kappa opioid receptor,Ki,=,8317.64,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,NC1CCc2cc(O)ccc2C1
CHEMBL4061999,CHEMBL237,Kappa opioid receptor,Ki,=,8128.31,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,Cc1nc(O)cc(C2CCN(Cc3ccc(C4CCCC4)s3)CC2)n1
CHEMBL4090036,CHEMBL237,Kappa opioid receptor,Ki,=,6606.93,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,CC(CCc1ccc(O)cc1)NCCc1ccccc1
CHEMBL4075479,CHEMBL237,Kappa opioid receptor,Ki,=,6456.54,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,Cc1cccc(C(O)CNC(C)Cn2cc(Br)cn2)c1
CHEMBL4100033,CHEMBL237,Kappa opioid receptor,Ki,=,6165.95,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,Cc1cc(S(=O)(=O)NCC(=O)NC2CCC2NC(C)C)ccc1F
CHEMBL4070528,CHEMBL237,Kappa opioid receptor,Ki,=,3019.95,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,Cc1ccc(-c2ccccc2CN2CC3CNCC3C2)o1
CHEMBL4091446,CHEMBL237,Kappa opioid receptor,Ki,=,3019.95,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,CSc1ccc(CN(CCO)Cc2ccc(-c3ccn[nH]3)s2)cc1
CHEMBL4081151,CHEMBL237,Kappa opioid receptor,Ki,=,2630.27,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,Oc1cccc(C(O)CNCc2c(Cl)cccc2Cl)c1
CHEMBL4099178,CHEMBL237,Kappa opioid receptor,Ki,=,2570.4,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,c1ccc(CN2CCC(Nc3nc4ccccc4o3)C2)cc1
CHEMBL4089032,CHEMBL237,Kappa opioid receptor,Ki,=,2290.87,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,CN(Cc1ccccc1NC(=O)NCc1ccoc1)C1CCCCC1
CHEMBL1875314,CHEMBL237,Kappa opioid receptor,Ki,=,1122.02,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,Cc1cc2oc(C(=O)NCC(c3ccco3)N3CCCC3)c(C)c2cc1C
CHEMBL4066432,CHEMBL237,Kappa opioid receptor,Ki,=,501.19,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,Oc1ccc(CCC2CCCCN2Cc2ccc(Cl)o2)cc1
CHEMBL4072651,CHEMBL237,Kappa opioid receptor,Ki,=,151.36,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,CC(c1cccc(O)c1)N(C)Cc1nccn1CC(F)(F)F
CHEMBL4063789,CHEMBL237,Kappa opioid receptor,Ki,=,950.0,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,O=C(NC[C@@H](c1ccco1)N1CCCC1)c1cc2ccccc2o1
CHEMBL4083805,CHEMBL237,Kappa opioid receptor,Ki,=,720.0,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,COc1ccc2oc(C(=O)NCC(c3ccco3)N3CCCC3)c(C)c2c1
CHEMBL4101810,CHEMBL237,Kappa opioid receptor,Ki,=,710.0,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,Oc1cccc(CNCc2cc3ccccc3[nH]2)c1
CHEMBL4077345,CHEMBL237,Kappa opioid receptor,Ki,=,660.0,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,Cc1ccc(C(CNC(=O)c2oc3ccc(F)cc3c2C)N2CCCC2)o1
CHEMBL4104275,CHEMBL237,Kappa opioid receptor,Ki,=,630.0,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,CCN(Cc1csc(C)n1)C(C)c1cccc(O)c1
CHEMBL1701606,CHEMBL237,Kappa opioid receptor,Ki,=,520.0,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,Cc1c(C(=O)NCC(c2ccco2)N2CCCC2)oc2ccc(Cl)cc12
CHEMBL4078777,CHEMBL237,Kappa opioid receptor,Ki,=,380.0,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,Cc1ccc(C(CNC(=O)c2oc3ccccc3c2C)N2CCCC2)o1
CHEMBL4084706,CHEMBL237,Kappa opioid receptor,Ki,=,350.0,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,Cc1ncsc1CN1CCCCC1CCc1cccc(O)c1
CHEMBL3484893,CHEMBL237,Kappa opioid receptor,Ki,=,230.0,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,COc1ccc(CNCC(O)c2cccc(O)c2)cc1Br
CHEMBL4092454,CHEMBL237,Kappa opioid receptor,Ki,=,160.0,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,CC(NCc1nccn1C)c1cccc(O)c1
CHEMBL4071661,CHEMBL237,Kappa opioid receptor,Ki,=,90.0,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,Oc1cccc(C(O)CNCc2ccc(Cl)cc2Cl)c1
CHEMBL4100198,CHEMBL237,Kappa opioid receptor,Ki,=,9800.0,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,NC(=O)c1cc(S(=O)(=O)NC2CCN(Cc3ccccc3)CC2)cs1
CHEMBL144439,CHEMBL237,Kappa opioid receptor,Ki,=,8300.0,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,NC1CCc2cc(O)ccc2C1
CHEMBL4061999,CHEMBL237,Kappa opioid receptor,Ki,=,8100.0,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,Cc1nc(O)cc(C2CCN(Cc3ccc(C4CCCC4)s3)CC2)n1
CHEMBL4090036,CHEMBL237,Kappa opioid receptor,Ki,=,6600.0,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,CC(CCc1ccc(O)cc1)NCCc1ccccc1
CHEMBL4075479,CHEMBL237,Kappa opioid receptor,Ki,=,6400.0,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,Cc1cccc(C(O)CNC(C)Cn2cc(Br)cn2)c1
CHEMBL4100033,CHEMBL237,Kappa opioid receptor,Ki,=,6200.0,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,Cc1cc(S(=O)(=O)NCC(=O)NC2CCC2NC(C)C)ccc1F
CHEMBL4070528,CHEMBL237,Kappa opioid receptor,Ki,=,3000.0,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,Cc1ccc(-c2ccccc2CN2CC3CNCC3C2)o1
CHEMBL4091446,CHEMBL237,Kappa opioid receptor,Ki,=,3000.0,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,CSc1ccc(CN(CCO)Cc2ccc(-c3ccn[nH]3)s2)cc1
CHEMBL4081151,CHEMBL237,Kappa opioid receptor,Ki,=,2600.0,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,Oc1cccc(C(O)CNCc2c(Cl)cccc2Cl)c1
CHEMBL4099178,CHEMBL237,Kappa opioid receptor,Ki,=,2600.0,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,c1ccc(CN2CCC(Nc3nc4ccccc4o3)C2)cc1
CHEMBL4089032,CHEMBL237,Kappa opioid receptor,Ki,=,2300.0,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,CN(Cc1ccccc1NC(=O)NCc1ccoc1)C1CCCCC1
CHEMBL1875314,CHEMBL237,Kappa opioid receptor,Ki,=,1100.0,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,Cc1cc2oc(C(=O)NCC(c3ccco3)N3CCCC3)c(C)c2cc1C
CHEMBL4066432,CHEMBL237,Kappa opioid receptor,Ki,=,500.0,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,Oc1ccc(CCC2CCCCN2Cc2ccc(Cl)o2)cc1
CHEMBL4072651,CHEMBL237,Kappa opioid receptor,Ki,=,200.0,nM,CHEMBL4050969,B,Displacement of 3H-U69593 from human KOR expressed in HEK293 cells after 90 mins by micro beta scintillation counting analysis,CHEMBL4049419,KI,CC(c1cccc(O)c1)N(C)Cc1nccn1CC(F)(F)F
CHEMBL4130303,CHEMBL237,Kappa opioid receptor,Ki,=,0.87,nM,CHEMBL4124511,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEK cells,CHEMBL4118237,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)NCCSSCCNC(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O
CHEMBL4129668,CHEMBL237,Kappa opioid receptor,Ki,=,18.0,nM,CHEMBL4124511,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEK cells,CHEMBL4118237,KI,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)NCCSSCCNC(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O
CHEMBL4128853,CHEMBL237,Kappa opioid receptor,Ki,=,5.6,nM,CHEMBL4124511,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEK cells,CHEMBL4118237,KI,CC1(C)SSC(C)(C)[C@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCN(CC2)C(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@H]1NC(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL4126803,CHEMBL237,Kappa opioid receptor,Ki,=,4.9,nM,CHEMBL4124511,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEK cells,CHEMBL4118237,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCN(CC2)C(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O
CHEMBL4130069,CHEMBL237,Kappa opioid receptor,Ki,=,19.0,nM,CHEMBL4124511,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEK cells,CHEMBL4118237,KI,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCN(CC2)C(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O
CHEMBL4130303,CHEMBL237,Kappa opioid receptor,Ki,=,0.871,nM,CHEMBL4124511,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEK cells,CHEMBL4118237,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)NCCSSCCNC(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O
CHEMBL4129668,CHEMBL237,Kappa opioid receptor,Ki,=,17.38,nM,CHEMBL4124511,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEK cells,CHEMBL4118237,KI,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)NCCSSCCNC(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O
CHEMBL4128853,CHEMBL237,Kappa opioid receptor,Ki,=,5.623,nM,CHEMBL4124511,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEK cells,CHEMBL4118237,KI,CC1(C)SSC(C)(C)[C@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCN(CC2)C(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@H]1NC(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL4130069,CHEMBL237,Kappa opioid receptor,Ki,=,18.62,nM,CHEMBL4124511,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEK cells,CHEMBL4118237,KI,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCN(CC2)C(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O
CHEMBL4126803,CHEMBL237,Kappa opioid receptor,Ki,=,4.898,nM,CHEMBL4124511,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEK cells,CHEMBL4118237,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCN(CC2)C(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O
CHEMBL200199,CHEMBL237,Kappa opioid receptor,Ki,=,270.0,nM,CHEMBL4124520,B,Binding affinity to KOR (unknown origin),CHEMBL4118237,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)NNC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL4160669,CHEMBL237,Kappa opioid receptor,Ki,=,14400.0,nM,CHEMBL4137920,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in membranes after 90 mins by scintillation counting method,CHEMBL4130639,KI,CN(Cc1cnn(C)c1)C(=O)NCCN1Cc2ccccc2C1
CHEMBL4171269,CHEMBL237,Kappa opioid receptor,Ki,=,2930.0,nM,CHEMBL4137920,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in membranes after 90 mins by scintillation counting method,CHEMBL4130639,KI,Nc1nc(Cl)cc(NC[C@@H](O)CN2CCc3ccccc3C2)n1
CHEMBL4176316,CHEMBL237,Kappa opioid receptor,Ki,=,4670.0,nM,CHEMBL4137920,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in membranes after 90 mins by scintillation counting method,CHEMBL4130639,KI,C[C@H](NC(C)(C)CN(C)C(=O)C1(C(N)=O)CC1)c1ccccc1
CHEMBL4165704,CHEMBL237,Kappa opioid receptor,Ki,=,1810.0,nM,CHEMBL4137920,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in membranes after 90 mins by scintillation counting method,CHEMBL4130639,KI,CN(C)[C@H](CNC(=O)Nc1ccc(C(N)=O)cc1)c1cccs1
CHEMBL4160217,CHEMBL237,Kappa opioid receptor,Ki,=,10500.0,nM,CHEMBL4137920,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in membranes after 90 mins by scintillation counting method,CHEMBL4130639,KI,CN(C)[C@H](CNC(=O)c1c[nH]nc1-c1ccccc1)c1cccs1
CHEMBL4172508,CHEMBL237,Kappa opioid receptor,Ki,=,3140.0,nM,CHEMBL4137920,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in membranes after 90 mins by scintillation counting method,CHEMBL4130639,KI,C[C@H](c1ccco1)N(C)CC(=O)N1CCC(C(N)=O)CC1
CHEMBL4161204,CHEMBL237,Kappa opioid receptor,Ki,=,2690.0,nM,CHEMBL4137920,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in membranes after 90 mins by scintillation counting method,CHEMBL4130639,KI,CN(C)[C@H](CNC(=O)C1CCN(C(N)=O)CC1)c1cccs1
CHEMBL4162636,CHEMBL237,Kappa opioid receptor,Ki,=,11100.0,nM,CHEMBL4137920,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in membranes after 90 mins by scintillation counting method,CHEMBL4130639,KI,NC(=O)c1ccc(N2CCCN(Cc3ccc(F)cc3)CC2)nc1
CHEMBL4172964,CHEMBL237,Kappa opioid receptor,Ki,=,5560.0,nM,CHEMBL4137920,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in membranes after 90 mins by scintillation counting method,CHEMBL4130639,KI,Nc1nc(Cl)cc(NC2CCN(Cc3ccccc3F)CC2)n1
CHEMBL441765,CHEMBL237,Kappa opioid receptor,Ki,=,2.9,nM,CHEMBL4150317,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in HEK293 cell membranes after 2 hrs by liquid scintillation spectrometry",CHEMBL4145618,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL4159127,CHEMBL237,Kappa opioid receptor,Ki,=,9.8,nM,CHEMBL4150317,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in HEK293 cell membranes after 2 hrs by liquid scintillation spectrometry",CHEMBL4145618,KI,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)N1C(=O)O[C@@H](CNC(=O)[C@@H](N)Cc2ccc(O)cc2)C1=O
CHEMBL4177061,CHEMBL237,Kappa opioid receptor,Ki,=,5430.0,nM,CHEMBL4150329,B,Displacement of [3H]-ethylketocyclazocine from kappa opioid receptor (unknown origin),CHEMBL4145618,KI,N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(=O)O
CHEMBL4167315,CHEMBL237,Kappa opioid receptor,Ki,=,3182.0,nM,CHEMBL4153426,B,Displacement of [3H]-U69593 from human KOR expressed in stable HEK cells after 90 mins by microbeta scintillation counting method,CHEMBL4152214,KI,COc1cccc(-c2ccc3c(c2)CN(Cc2ccccc2)C3)c1
CHEMBL4217398,CHEMBL237,Kappa opioid receptor,Ki,=,4060.0,nM,CHEMBL4189972,B,Displacement of [3H]-U69593 from human KOR expressed in HEK293 cell membranes after 90 mins by scintillation counting method,CHEMBL4184336,KI,CC(C)(C)OC(=O)NCCCCCCn1cc(CCCCN2CCC(c3ccc(-c4cc(C(=O)O)cc5cc(-c6ccc(C(F)(F)F)cc6)ccc45)cc3)CC2)nn1
CHEMBL4203753,CHEMBL237,Kappa opioid receptor,Ki,=,6.7,nM,CHEMBL4197661,B,"Displacement of [3H]U69,593 from KOR (unknown origin) expressed in CHO cell membranes",CHEMBL4196036,KI,C[C@H]1[C@H]2Cc3cc4sc(N)nc4cc3[C@@]1(C)CCN2CC1CC1
CHEMBL4211113,CHEMBL237,Kappa opioid receptor,Ki,=,0.49,nM,CHEMBL4197661,B,"Displacement of [3H]U69,593 from KOR (unknown origin) expressed in CHO cell membranes",CHEMBL4196036,KI,C[C@H]1[C@H]2Cc3cc4sc(N)nc4cc3[C@@]1(C)CCN2CC1CCC1
CHEMBL4210181,CHEMBL237,Kappa opioid receptor,Ki,=,4.33,nM,CHEMBL4197670,B,"Displacement of [3H]U69,593 from human KOR expressed in HEK293 cell membranes after 1 hr by scintillation counting method",CHEMBL4196036,KI,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@@]1(C)CC[N+]2(C)CC1CC1
CHEMBL4213336,CHEMBL237,Kappa opioid receptor,Ki,=,10.3,nM,CHEMBL4197670,B,"Displacement of [3H]U69,593 from human KOR expressed in HEK293 cell membranes after 1 hr by scintillation counting method",CHEMBL4196036,KI,C=CC[N+]1(C)CC[C@]2(C)c3cc(O)ccc3C[C@@H]1[C@@H]2C
CHEMBL55033,CHEMBL237,Kappa opioid receptor,Ki,=,0.62,nM,CHEMBL4197673,B,Binding affinity to KOR (unknown origin),CHEMBL4196036,KI,CCC12CCN(CC3CC3)C(C(=O)c3ccc(O)cc31)C2C
CHEMBL4217097,CHEMBL237,Kappa opioid receptor,Ki,=,6.7,nM,CHEMBL4197673,B,Binding affinity to KOR (unknown origin),CHEMBL4196036,KI,CCCCC(=N)NCCCCCNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@]1(c2ccccc2)C[C@H]1CN1CC[C@]2(C)c3cc(O)ccc3C[C@@H]1[C@@H]2C
CHEMBL4218284,CHEMBL237,Kappa opioid receptor,Ki,=,179.0,nM,CHEMBL4197673,B,Binding affinity to KOR (unknown origin),CHEMBL4196036,KI,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@@]1(C)CCN2C[C@@H]1C[C@@]1(CN1CCCCC1)c1ccccc1
CHEMBL4213351,CHEMBL237,Kappa opioid receptor,Ki,=,720.0,nM,CHEMBL4197673,B,Binding affinity to KOR (unknown origin),CHEMBL4196036,KI,C[C@H]1[C@H]2C(=O)c3ccc(O)cc3[C@@]1(C)CCN2CC1CCCO1
CHEMBL4208689,CHEMBL237,Kappa opioid receptor,Ki,=,5.3,nM,CHEMBL4197673,B,Binding affinity to KOR (unknown origin),CHEMBL4196036,KI,CCCCC(=N)NCCCCCCNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@]1(c2ccccc2)C[C@H]1CN1CC[C@]2(C)c3cc(O)ccc3C[C@@H]1[C@@H]2C
CHEMBL4213625,CHEMBL237,Kappa opioid receptor,Ki,=,35.0,nM,CHEMBL4197673,B,Binding affinity to KOR (unknown origin),CHEMBL4196036,KI,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@@]1(C)CCN2C[C@@H]1C[C@@]1(C(=O)NCc1ccccc1)c1ccccc1
CHEMBL4245818,CHEMBL237,Kappa opioid receptor,Ki,=,2.7,nM,CHEMBL4234964,B,"Displacement of [3H]U69,593 from human KOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis",CHEMBL4229484,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@]4(C)CO)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4241031,CHEMBL237,Kappa opioid receptor,Ki,=,9.0,nM,CHEMBL4234964,B,"Displacement of [3H]U69,593 from human KOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis",CHEMBL4229484,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@]4(C)OC(C)=O)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4237854,CHEMBL237,Kappa opioid receptor,Ki,=,28.0,nM,CHEMBL4234964,B,"Displacement of [3H]U69,593 from human KOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis",CHEMBL4229484,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@]4(C)OC(=O)C(C)C)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4243112,CHEMBL237,Kappa opioid receptor,Ki,=,1250.0,nM,CHEMBL4234964,B,"Displacement of [3H]U69,593 from human KOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis",CHEMBL4229484,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@]4(C)OC(=O)c4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4238309,CHEMBL237,Kappa opioid receptor,Ki,=,168.8,nM,CHEMBL4234964,B,"Displacement of [3H]U69,593 from human KOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis",CHEMBL4229484,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@]4(C)OC(=O)c4ccc(C(F)(F)F)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4248801,CHEMBL237,Kappa opioid receptor,Ki,=,4.6,nM,CHEMBL4234964,B,"Displacement of [3H]U69,593 from human KOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis",CHEMBL4229484,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@]4(C)C=O)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4237758,CHEMBL237,Kappa opioid receptor,Ki,=,38.0,nM,CHEMBL4234964,B,"Displacement of [3H]U69,593 from human KOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis",CHEMBL4229484,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@]4(C)C(O)c4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4242847,CHEMBL237,Kappa opioid receptor,Ki,=,2.1,nM,CHEMBL4234964,B,"Displacement of [3H]U69,593 from human KOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis",CHEMBL4229484,KI,COc1cccc(C(O)[C@@]2(C)C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(OC)ccc6c5[C@@]23CCN(CC2CC2)[C@@H]4C6)c1
CHEMBL4246433,CHEMBL237,Kappa opioid receptor,Ki,=,0.6,nM,CHEMBL4234964,B,"Displacement of [3H]U69,593 from human KOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis",CHEMBL4229484,KI,COc1ccc(C(O)[C@@]2(C)C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(OC)ccc6c5[C@@]23CCN(CC2CC2)[C@@H]4C6)cc1
CHEMBL4243463,CHEMBL237,Kappa opioid receptor,Ki,=,303.2,nM,CHEMBL4234964,B,"Displacement of [3H]U69,593 from human KOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis",CHEMBL4229484,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@]4(C)C(O)c4ccc(-c6ccccc6)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4239240,CHEMBL237,Kappa opioid receptor,Ki,=,9.1,nM,CHEMBL4234964,B,"Displacement of [3H]U69,593 from human KOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis",CHEMBL4229484,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@]4(C)C(O)c4ccc(C(F)(F)F)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4240426,CHEMBL237,Kappa opioid receptor,Ki,=,33.2,nM,CHEMBL4234964,B,"Displacement of [3H]U69,593 from human KOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis",CHEMBL4229484,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@]4(C)C(=O)c4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4243649,CHEMBL237,Kappa opioid receptor,Ki,=,11.3,nM,CHEMBL4234964,B,"Displacement of [3H]U69,593 from human KOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis",CHEMBL4229484,KI,COc1cccc(C(=O)[C@@]2(C)C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(OC)ccc6c5[C@@]23CCN(CC2CC2)[C@@H]4C6)c1
CHEMBL4238289,CHEMBL237,Kappa opioid receptor,Ki,=,48.5,nM,CHEMBL4234964,B,"Displacement of [3H]U69,593 from human KOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis",CHEMBL4229484,KI,COc1ccc(C(=O)[C@@]2(C)C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(OC)ccc6c5[C@@]23CCN(CC2CC2)[C@@H]4C6)cc1
CHEMBL4245987,CHEMBL237,Kappa opioid receptor,Ki,=,263.4,nM,CHEMBL4234964,B,"Displacement of [3H]U69,593 from human KOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis",CHEMBL4229484,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@]4(C)C(=O)c4ccc(-c6ccccc6)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4241369,CHEMBL237,Kappa opioid receptor,Ki,=,72.1,nM,CHEMBL4234964,B,"Displacement of [3H]U69,593 from human KOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis",CHEMBL4229484,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@]4(C)C(=O)c4ccc(C(F)(F)F)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4249256,CHEMBL237,Kappa opioid receptor,Ki,=,0.4,nM,CHEMBL4234964,B,"Displacement of [3H]U69,593 from human KOR expressed in CHO cell membranes after 30 mins by liquid scintillation counting analysis",CHEMBL4229484,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)C=C[C@@]5(C[C@@H]4C(=O)c4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL3264441,CHEMBL237,Kappa opioid receptor,Ki,=,2.39,nM,CHEMBL4252141,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr,CHEMBL4251556,KI,CCOC(=O)C(CN1CC[C@@](C)(c2cccc(O)c2)[C@@H](C)C1)OC(=O)[C@H]1Cc2ccc(O)cc2CN1
CHEMBL3264440,CHEMBL237,Kappa opioid receptor,Ki,=,173.8,nM,CHEMBL4252141,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr,CHEMBL4251556,KI,C[C@H]1CN(CCCOC(=O)[C@H]2Cc3ccc(O)cc3CN2)CC[C@@]1(C)c1cccc(O)c1
CHEMBL3264439,CHEMBL237,Kappa opioid receptor,Ki,=,134.9,nM,CHEMBL4252141,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cells after 1 hr,CHEMBL4251556,KI,C[C@H]1CN(CCOC(=O)[C@H]2Cc3ccc(O)cc3CN2)CC[C@@]1(C)c1cccc(O)c1
CHEMBL4287623,CHEMBL237,Kappa opioid receptor,Ki,=,1021.0,nM,CHEMBL4260829,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEK cells by radioligand binding assay,CHEMBL4257579,KI,OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCC=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1
CHEMBL4282702,CHEMBL237,Kappa opioid receptor,Ki,=,1705.0,nM,CHEMBL4260829,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEK cells by radioligand binding assay,CHEMBL4257579,KI,OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCCCc2ccc(F)cc2)CC1
CHEMBL4291048,CHEMBL237,Kappa opioid receptor,Ki,=,667.0,nM,CHEMBL4260829,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEK cells by radioligand binding assay,CHEMBL4257579,KI,OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCN(c2ccc(F)cc2)c2ccc(F)cc2)CC1
CHEMBL4278465,CHEMBL237,Kappa opioid receptor,Ki,=,10000.0,nM,CHEMBL4260829,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEK cells by radioligand binding assay,CHEMBL4257579,KI,OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCCN(c2ccc(F)cc2)c2ccc(F)cc2)CC1
CHEMBL1644978,CHEMBL237,Kappa opioid receptor,Ki,=,2669.0,nM,CHEMBL4260829,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEK cells by radioligand binding assay,CHEMBL4257579,KI,OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
CHEMBL1644980,CHEMBL237,Kappa opioid receptor,Ki,=,1328.0,nM,CHEMBL4260829,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEK cells by radioligand binding assay,CHEMBL4257579,KI,OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCC(c2ccccc2)c2ccccc2)CC1
CHEMBL4293307,CHEMBL237,Kappa opioid receptor,Ki,=,10000.0,nM,CHEMBL4260829,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEK cells by radioligand binding assay,CHEMBL4257579,KI,COc1ccc(N(CCCCN2CCC(O)(c3ccc(Cl)c(C(F)(F)F)c3)CC2)c2ccc(OC)cc2)cc1
CHEMBL47050,CHEMBL237,Kappa opioid receptor,Ki,=,1000.0,nM,CHEMBL4260829,B,Displacement of [3H]U69593 from KOR (unknown origin) expressed in HEK cells by radioligand binding assay,CHEMBL4257579,KI,OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
CHEMBL4472703,CHEMBL237,Kappa opioid receptor,Ki,=,316.23,nM,CHEMBL4308643,B,Displacement of [3H]-U69593 from human recombinant KOR receptor expressed in stable HEK cells after 90 mins by microbeta scintillation counting method,CHEMBL4304834,KI,CC[C@H]1c2cc(OC)ccc2CC[C@@]1(C)N
CHEMBL4442460,CHEMBL237,Kappa opioid receptor,Ki,=,3900.0,nM,CHEMBL4323492,B,Displacement of [3H] diprenorphine from kappa opioid receptor (unknown origin),CHEMBL4321823,KI,COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2ccccc2)c2ccccc2)CC1
CHEMBL4544086,CHEMBL237,Kappa opioid receptor,Ki,=,4300.0,nM,CHEMBL4323492,B,Displacement of [3H] diprenorphine from kappa opioid receptor (unknown origin),CHEMBL4321823,KI,COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2ccc(F)cc2)c2ccccc2)CC1
CHEMBL4461965,CHEMBL237,Kappa opioid receptor,Ki,=,7890.0,nM,CHEMBL4324691,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting,CHEMBL4321856,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)C=C[C@@]5(C[C@@H]4c4ccccc4)[C@@H](C2)N(C)CC[C@]315
CHEMBL4451186,CHEMBL237,Kappa opioid receptor,Ki,=,6.4,nM,CHEMBL4324691,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting,CHEMBL4321856,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4ccc(N)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4580549,CHEMBL237,Kappa opioid receptor,Ki,=,20.3,nM,CHEMBL4324691,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting,CHEMBL4321856,KI,CNc1ccc([C@H]2C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(OC)ccc6c5[C@@]23CCN(CC2CC2)[C@@H]4C6)cc1
CHEMBL4439183,CHEMBL237,Kappa opioid receptor,Ki,=,16.9,nM,CHEMBL4324691,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting,CHEMBL4321856,KI,CCNc1ccc([C@H]2C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(OC)ccc6c5[C@@]23CCN(CC2CC2)[C@@H]4C6)cc1
CHEMBL4449999,CHEMBL237,Kappa opioid receptor,Ki,=,16.8,nM,CHEMBL4324691,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting,CHEMBL4321856,KI,CCCNc1ccc([C@H]2C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(OC)ccc6c5[C@@]23CCN(CC2CC2)[C@@H]4C6)cc1
CHEMBL4570786,CHEMBL237,Kappa opioid receptor,Ki,=,19.5,nM,CHEMBL4324691,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting,CHEMBL4321856,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4ccc(NCC6CC6)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4447249,CHEMBL237,Kappa opioid receptor,Ki,=,17.2,nM,CHEMBL4324691,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting,CHEMBL4321856,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4ccc(NCc6ccccc6)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4469187,CHEMBL237,Kappa opioid receptor,Ki,=,13.0,nM,CHEMBL4324691,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting,CHEMBL4321856,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4ccc(NCCN(C)C)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4530660,CHEMBL237,Kappa opioid receptor,Ki,=,58.6,nM,CHEMBL4324691,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting,CHEMBL4321856,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4ccc(NCCCN(C)C)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4436473,CHEMBL237,Kappa opioid receptor,Ki,=,16.1,nM,CHEMBL4324691,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting,CHEMBL4321856,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4ccc(NCC(N)=O)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4474277,CHEMBL237,Kappa opioid receptor,Ki,=,20.8,nM,CHEMBL4324691,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting,CHEMBL4321856,KI,CCOC(=O)CCNc1ccc([C@H]2C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(OC)ccc6c5[C@@]23CCN(CC2CC2)[C@@H]4C6)cc1
CHEMBL4550514,CHEMBL237,Kappa opioid receptor,Ki,=,309.9,nM,CHEMBL4324691,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting,CHEMBL4321856,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4ccc(N6CCCC6)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4446668,CHEMBL237,Kappa opioid receptor,Ki,=,40.3,nM,CHEMBL4324691,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting,CHEMBL4321856,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4ccc(N6CCCCC6)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4530627,CHEMBL237,Kappa opioid receptor,Ki,=,80.0,nM,CHEMBL4324691,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting,CHEMBL4321856,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4ccc(N6CCNCC6)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4469788,CHEMBL237,Kappa opioid receptor,Ki,=,50.27,nM,CHEMBL4324691,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting,CHEMBL4321856,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4ccc(N6CCN(CC7CC7)CC6)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4483469,CHEMBL237,Kappa opioid receptor,Ki,=,120.9,nM,CHEMBL4324691,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting,CHEMBL4321856,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4ccc(N6CCN(C(C)=O)CC6)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4559381,CHEMBL237,Kappa opioid receptor,Ki,=,1551.0,nM,CHEMBL4324691,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting,CHEMBL4321856,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4ccc(N6CCN(S(=O)(=O)c7ccc(C)cc7)CC6)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4562400,CHEMBL237,Kappa opioid receptor,Ki,=,89.04,nM,CHEMBL4324691,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting,CHEMBL4321856,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4ccc(N6CCN(C(=O)c7ccccc7)CC6)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4546243,CHEMBL237,Kappa opioid receptor,Ki,=,4.3,nM,CHEMBL4324691,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting,CHEMBL4321856,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4ccc(NC=O)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4542404,CHEMBL237,Kappa opioid receptor,Ki,=,7.8,nM,CHEMBL4324691,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting,CHEMBL4321856,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4ccc(NC(C)=O)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4449252,CHEMBL237,Kappa opioid receptor,Ki,=,0.47,nM,CHEMBL4324691,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting,CHEMBL4321856,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4ccc(NC(=O)c6ccccc6)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4522335,CHEMBL237,Kappa opioid receptor,Ki,=,21.4,nM,CHEMBL4324691,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting,CHEMBL4321856,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4ccc(NC(=O)Cc6ccccc6)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4444964,CHEMBL237,Kappa opioid receptor,Ki,=,1588.0,nM,CHEMBL4324691,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting,CHEMBL4321856,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4ccc(/N=N/c6ccc(O)cc6)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4459592,CHEMBL237,Kappa opioid receptor,Ki,=,8.6,nM,CHEMBL4344748,B,Displacement of [3H]-diprenorphine from recombinant human KOR transiently expressed in HEK293 cell membranes measured after 60 mins,CHEMBL4342472,KI,CN1/C(=C/C=C/C2=[N+](CCCCCC(=O)NCCCNC(=N)Nc3ccc4[nH]c5c(c4c3)C[C@@]3(O)[C@H]4Cc6ccc(O)c7c6[C@@]3(CCN4CC3CC3)[C@H]5O7)c3ccc(S(=O)(=O)[O-])cc3C2(C)C)C(C)(C)c2cc(S(=O)(=O)O)ccc21
CHEMBL4463414,CHEMBL237,Kappa opioid receptor,Ki,=,1.4,nM,CHEMBL4344748,B,Displacement of [3H]-diprenorphine from recombinant human KOR transiently expressed in HEK293 cell membranes measured after 60 mins,CHEMBL4342472,KI,CN1/C(=C/C=C/C=C/C2=[N+](CCCCCC(=O)NCCCNC(=N)Nc3ccc4[nH]c5c(c4c3)C[C@@]3(O)[C@H]4Cc6ccc(O)c7c6[C@@]3(CCN4CC3CC3)[C@H]5O7)c3ccc(S(=O)(=O)[O-])cc3C2(C)C)C(C)(C)c2cc(S(=O)(=O)O)ccc21
CHEMBL4438046,CHEMBL237,Kappa opioid receptor,Ki,=,1.1,nM,CHEMBL4344748,B,Displacement of [3H]-diprenorphine from recombinant human KOR transiently expressed in HEK293 cell membranes measured after 60 mins,CHEMBL4342472,KI,CN1/C(=C/C=C/C=C/C2=[N+](CCCCCC(=O)NCC(=O)NCC(=O)NCCCNC(=N)Nc3ccc4[nH]c5c(c4c3)C[C@@]3(O)[C@H]4Cc6ccc(O)c7c6[C@@]3(CCN4CC3CC3)[C@H]5O7)c3ccc(S(=O)(=O)[O-])cc3C2(C)C)C(C)(C)c2cc(S(=O)(=O)O)ccc21
CHEMBL4577693,CHEMBL237,Kappa opioid receptor,Ki,=,1.8,nM,CHEMBL4344748,B,Displacement of [3H]-diprenorphine from recombinant human KOR transiently expressed in HEK293 cell membranes measured after 60 mins,CHEMBL4342472,KI,CN1/C(=C/C=C/C=C/C2=[N+](CCCCCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCCCNC(=N)Nc3ccc4[nH]c5c(c4c3)C[C@@]3(O)[C@H]4Cc6ccc(O)c7c6[C@@]3(CCN4CC3CC3)[C@H]5O7)c3ccc(S(=O)(=O)[O-])cc3C2(C)C)C(C)(C)c2cc(S(=O)(=O)O)ccc21
CHEMBL4514226,CHEMBL237,Kappa opioid receptor,Ki,=,3.2,nM,CHEMBL4344748,B,Displacement of [3H]-diprenorphine from recombinant human KOR transiently expressed in HEK293 cell membranes measured after 60 mins,CHEMBL4342472,KI,CN1/C(=C/C=C/C2=[N+](CCCCCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCCCNC(=N)Nc3ccc4[nH]c5c(c4c3)C[C@@]3(O)[C@H]4Cc6ccc(O)c7c6[C@@]3(CCN4CC3CC3)[C@H]5O7)c3ccc(S(=O)(=O)[O-])cc3C2(C)C)C(C)(C)c2cc(S(=O)(=O)O)ccc21
CHEMBL4570328,CHEMBL237,Kappa opioid receptor,Ki,=,562.0,nM,CHEMBL4358239,B,Displacement of [3H]U69593 from human KOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CC(C)[C@H]1CC[C@@H](N2CCC(N3CCc4ccccc43)CC2)CC1
CHEMBL4435280,CHEMBL237,Kappa opioid receptor,Ki,=,1594.0,nM,CHEMBL4358239,B,Displacement of [3H]U69593 from human KOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3ccc4ccccc43)CC2)CC1
CHEMBL4548515,CHEMBL237,Kappa opioid receptor,Ki,=,172.0,nM,CHEMBL4358239,B,Displacement of [3H]U69593 from human KOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(CN)c4ccccc43)CC2)CC1
CHEMBL4465668,CHEMBL237,Kappa opioid receptor,Ki,=,2750.0,nM,CHEMBL4358239,B,Displacement of [3H]U69593 from human KOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(CCN)c4ccccc43)CC2)CC1.Cl.Cl
CHEMBL4451073,CHEMBL237,Kappa opioid receptor,Ki,=,1320.0,nM,CHEMBL4358239,B,Displacement of [3H]U69593 from human KOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(CCCN)c4ccccc43)CC2)CC1.Cl.Cl
CHEMBL4541337,CHEMBL237,Kappa opioid receptor,Ki,=,461.0,nM,CHEMBL4358239,B,Displacement of [3H]U69593 from human KOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(CN4CCCC4)c4ccccc43)CC2)CC1
CHEMBL4590786,CHEMBL237,Kappa opioid receptor,Ki,=,3456.0,nM,CHEMBL4358239,B,Displacement of [3H]U69593 from human KOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(CN4CCC(N)CC4)c4ccccc43)CC2)CC1
CHEMBL4550088,CHEMBL237,Kappa opioid receptor,Ki,=,3840.0,nM,CHEMBL4358239,B,Displacement of [3H]U69593 from human KOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(CN4CCC(O)CC4)c4ccccc43)CC2)CC1
CHEMBL4518220,CHEMBL237,Kappa opioid receptor,Ki,=,1490.0,nM,CHEMBL4358239,B,Displacement of [3H]U69593 from human KOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(CNCCO)c4ccccc43)CC2)CC1
CHEMBL4460695,CHEMBL237,Kappa opioid receptor,Ki,=,1328.0,nM,CHEMBL4358239,B,Displacement of [3H]U69593 from human KOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(CNC(N)=S)c4ccccc43)CC2)CC1
CHEMBL4467156,CHEMBL237,Kappa opioid receptor,Ki,=,81.0,nM,CHEMBL4358239,B,Displacement of [3H]U69593 from human KOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(CCNC(N)=S)c4ccccc43)CC2)CC1
CHEMBL4591048,CHEMBL237,Kappa opioid receptor,Ki,=,830.0,nM,CHEMBL4358239,B,Displacement of [3H]U69593 from human KOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(CCCNC(N)=S)c4ccccc43)CC2)CC1
CHEMBL4594096,CHEMBL237,Kappa opioid receptor,Ki,=,674.0,nM,CHEMBL4358239,B,Displacement of [3H]U69593 from human KOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(CNC(=O)[C@@H](N)CCCNC(=N)N)c4ccccc43)CC2)CC1
CHEMBL4519453,CHEMBL237,Kappa opioid receptor,Ki,=,1440.0,nM,CHEMBL4358239,B,Displacement of [3H]U69593 from human KOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CCNCC(=O)NCc1cn(C2CCN([C@H]3CC[C@@H](C(C)C)CC3)CC2)c2ccccc12
CHEMBL4473383,CHEMBL237,Kappa opioid receptor,Ki,=,446.0,nM,CHEMBL4358239,B,Displacement of [3H]U69593 from human KOP expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4354845,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(C(N)=O)c4ccccc43)CC2)CC1
CHEMBL4579650,CHEMBL237,Kappa opioid receptor,Ki,=,2630.0,nM,CHEMBL4369940,B,Inhibition of KOR (unknown origin),CHEMBL4368904,KI,O=C(NCCO)[C@@]12C[C@@H]1[C@@H](n1cnc3c(N[C@H]4C[C@H]5CC[C@@H]4C5)nc(Cl)nc31)[C@H](O)[C@@H]2O
CHEMBL4483681,CHEMBL237,Kappa opioid receptor,Ki,=,18.0,nM,CHEMBL4372802,B,Displacement of [3H]diprenorphine from human KOR expressed in HEK293T cell membranes after 120 mins by scintillation counting method,CHEMBL4371059,KI,CC(C)(C)OC(=O)N1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)[C@@H]2[C@@H](N3CCCC3)CCC[C@@H]21
CHEMBL4069231,CHEMBL237,Kappa opioid receptor,Ki,=,4.8,nM,CHEMBL4372802,B,Displacement of [3H]diprenorphine from human KOR expressed in HEK293T cell membranes after 120 mins by scintillation counting method,CHEMBL4371059,KI,O=C(Cc1ccc(Cl)c(Cl)c1)N1CCN[C@H]2CCC[C@H](N3CCCC3)[C@H]21
CHEMBL4462000,CHEMBL237,Kappa opioid receptor,Ki,=,11.0,nM,CHEMBL4372802,B,Displacement of [3H]diprenorphine from human KOR expressed in HEK293T cell membranes after 120 mins by scintillation counting method,CHEMBL4371059,KI,CN1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)[C@H]2[C@@H]1CCC[C@@H]2N1CCCC1
CHEMBL4467644,CHEMBL237,Kappa opioid receptor,Ki,=,11.0,nM,CHEMBL4372802,B,Displacement of [3H]diprenorphine from human KOR expressed in HEK293T cell membranes after 120 mins by scintillation counting method,CHEMBL4371059,KI,CCN1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)[C@H]2[C@@H]1CCC[C@@H]2N1CCCC1
CHEMBL4582146,CHEMBL237,Kappa opioid receptor,Ki,=,9.2,nM,CHEMBL4372802,B,Displacement of [3H]diprenorphine from human KOR expressed in HEK293T cell membranes after 120 mins by scintillation counting method,CHEMBL4371059,KI,CCCN1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)[C@@H]2[C@@H](N3CCCC3)CCC[C@@H]21
CHEMBL4561040,CHEMBL237,Kappa opioid receptor,Ki,=,16.0,nM,CHEMBL4372802,B,Displacement of [3H]diprenorphine from human KOR expressed in HEK293T cell membranes after 120 mins by scintillation counting method,CHEMBL4371059,KI,CCCCN1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)[C@@H]2[C@@H](N3CCCC3)CCC[C@@H]21
CHEMBL4438714,CHEMBL237,Kappa opioid receptor,Ki,=,42.0,nM,CHEMBL4372802,B,Displacement of [3H]diprenorphine from human KOR expressed in HEK293T cell membranes after 120 mins by scintillation counting method,CHEMBL4371059,KI,O=C(Cc1ccc(Cl)c(Cl)c1)N1CCN(Cc2ccc(F)cc2)[C@H]2CCC[C@H](N3CCCC3)[C@H]21
CHEMBL4463652,CHEMBL237,Kappa opioid receptor,Ki,=,46.0,nM,CHEMBL4372802,B,Displacement of [3H]diprenorphine from human KOR expressed in HEK293T cell membranes after 120 mins by scintillation counting method,CHEMBL4371059,KI,O=C(Cc1ccc(Cl)c(Cl)c1)N1CCN(Cc2cn(CCF)nn2)[C@H]2CCC[C@H](N3CCCC3)[C@H]21
CHEMBL4555496,CHEMBL237,Kappa opioid receptor,Ki,=,77.0,nM,CHEMBL4372802,B,Displacement of [3H]diprenorphine from human KOR expressed in HEK293T cell membranes after 120 mins by scintillation counting method,CHEMBL4371059,KI,O=C(Cc1ccc(Cl)c(Cl)c1)N1CCN(C(=O)COCCF)[C@H]2CCC[C@H](N3CCCC3)[C@H]21
CHEMBL281786,CHEMBL237,Kappa opioid receptor,Ki,=,0.69,nM,CHEMBL4372802,B,Displacement of [3H]diprenorphine from human KOR expressed in HEK293T cell membranes after 120 mins by scintillation counting method,CHEMBL4371059,KI,CO[C@]12CC[C@@]3(C[C@@H]1C(C)(C)O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL60533,CHEMBL237,Kappa opioid receptor,Ki,=,1910.0,nM,CHEMBL4380083,B,"Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in rat RBL cell membranes incubated for 60 mins",CHEMBL4376854,KI,CC[C@@H]1CN2CCc3c([nH]c4ccccc34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL299031,CHEMBL237,Kappa opioid receptor,Ki,=,198.0,nM,CHEMBL4380083,B,"Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in rat RBL cell membranes incubated for 60 mins",CHEMBL4376854,KI,CC[C@@H]1CN2CCc3c([nH]c4cccc(OC)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL61630,CHEMBL237,Kappa opioid receptor,Ki,=,74.1,nM,CHEMBL4380083,B,"Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in rat RBL cell membranes incubated for 60 mins",CHEMBL4376854,KI,CC[C@@H]1CN2CC[C@@]3(O)C(=Nc4cccc(OC)c43)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL4546925,CHEMBL237,Kappa opioid receptor,Ki,=,116.0,nM,CHEMBL4380083,B,"Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in rat RBL cell membranes incubated for 60 mins",CHEMBL4376854,KI,CC[C@@H]1CN2CCc3c([nH]c4cccc(OC)c34)[C@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL441765,CHEMBL237,Kappa opioid receptor,Ki,=,0.3,nM,CHEMBL4380083,B,"Displacement of [3H]U69,593 from human recombinant kappa opioid receptor expressed in rat RBL cell membranes incubated for 60 mins",CHEMBL4376854,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL4440537,CHEMBL237,Kappa opioid receptor,Ki,=,44.2,nM,CHEMBL4381836,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cell membranes incubated for 1 hr by liquid scintillation counting assay,CHEMBL4376894,KI,CCOc1ccc(CN2CCc3ccccc3C2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F
CHEMBL4443716,CHEMBL237,Kappa opioid receptor,Ki,=,243.0,nM,CHEMBL4381836,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cell membranes incubated for 1 hr by liquid scintillation counting assay,CHEMBL4376894,KI,CCOc1ccc(CN2Cc3ccccc3C2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F
CHEMBL4437661,CHEMBL237,Kappa opioid receptor,Ki,=,247.0,nM,CHEMBL4381836,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cell membranes incubated for 1 hr by liquid scintillation counting assay,CHEMBL4376894,KI,CCOc1ccc(CN2CC3CC3C2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F
CHEMBL4482942,CHEMBL237,Kappa opioid receptor,Ki,=,101.0,nM,CHEMBL4381836,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cell membranes incubated for 1 hr by liquid scintillation counting assay,CHEMBL4376894,KI,CCOc1ccc(CN2CCCCC2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F
CHEMBL4564309,CHEMBL237,Kappa opioid receptor,Ki,=,430.0,nM,CHEMBL4381836,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cell membranes incubated for 1 hr by liquid scintillation counting assay,CHEMBL4376894,KI,CCOc1ccc(CN2CCCC2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F
CHEMBL4453368,CHEMBL237,Kappa opioid receptor,Ki,=,1200.0,nM,CHEMBL4381836,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cell membranes incubated for 1 hr by liquid scintillation counting assay,CHEMBL4376894,KI,CCOc1ccc(Cc2ccccc2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C
CHEMBL70,CHEMBL237,Kappa opioid receptor,Ki,=,36.8,nM,CHEMBL4381836,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cell membranes incubated for 1 hr by liquid scintillation counting assay,CHEMBL4376894,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL4592669,CHEMBL237,Kappa opioid receptor,Ki,=,23.2,nM,CHEMBL4381836,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cell membranes incubated for 1 hr by liquid scintillation counting assay,CHEMBL4376894,KI,CCOc1ccc(CNCc2ccccc2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F
CHEMBL4587201,CHEMBL237,Kappa opioid receptor,Ki,=,12.4,nM,CHEMBL4381836,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cell membranes incubated for 1 hr by liquid scintillation counting assay,CHEMBL4376894,KI,CCOc1ccc(CN(C)Cc2ccccc2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F
CHEMBL4443759,CHEMBL237,Kappa opioid receptor,Ki,=,261.0,nM,CHEMBL4381836,B,Displacement of [3H]diprenorphine from human KOR expressed in CHO cell membranes incubated for 1 hr by liquid scintillation counting assay,CHEMBL4376894,KI,CCOc1ccc(C(=O)N2Cc3ccccc3C2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F
CHEMBL4460430,CHEMBL237,Kappa opioid receptor,Ki,=,410.0,nM,CHEMBL4385882,B,Displacement of [3H]-diprenorphine from human kappa-type opioid receptor expressed in CHO cell membranes incubated for 1 hr in shaker by liquid scintillation counting method,CHEMBL4385600,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)NCc1cccc(Cc2ccccc2)c1.O=C(O)C(F)(F)F
CHEMBL4538540,CHEMBL237,Kappa opioid receptor,Ki,=,201.0,nM,CHEMBL4385882,B,Displacement of [3H]-diprenorphine from human kappa-type opioid receptor expressed in CHO cell membranes incubated for 1 hr in shaker by liquid scintillation counting method,CHEMBL4385600,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](C)c1cccc(Cc2ccccc2)c1.O=C(O)C(F)(F)F
CHEMBL4443946,CHEMBL237,Kappa opioid receptor,Ki,=,49.5,nM,CHEMBL4385882,B,Displacement of [3H]-diprenorphine from human kappa-type opioid receptor expressed in CHO cell membranes incubated for 1 hr in shaker by liquid scintillation counting method,CHEMBL4385600,KI,CC[C@@H](NC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C)c1cccc(Cc2ccccc2)c1.O=C(O)C(F)(F)F
CHEMBL4569796,CHEMBL237,Kappa opioid receptor,Ki,=,360.0,nM,CHEMBL4385882,B,Displacement of [3H]-diprenorphine from human kappa-type opioid receptor expressed in CHO cell membranes incubated for 1 hr in shaker by liquid scintillation counting method,CHEMBL4385600,KI,Cc1ccc(Cc2ccccc2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F
CHEMBL4437304,CHEMBL237,Kappa opioid receptor,Ki,=,528.0,nM,CHEMBL4385882,B,Displacement of [3H]-diprenorphine from human kappa-type opioid receptor expressed in CHO cell membranes incubated for 1 hr in shaker by liquid scintillation counting method,CHEMBL4385600,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)NCc1cc(Cc2ccccc2)ccc1Cl.O=C(O)C(F)(F)F
CHEMBL4475106,CHEMBL237,Kappa opioid receptor,Ki,=,307.0,nM,CHEMBL4385882,B,Displacement of [3H]-diprenorphine from human kappa-type opioid receptor expressed in CHO cell membranes incubated for 1 hr in shaker by liquid scintillation counting method,CHEMBL4385600,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)NCc1cc(Cc2ccccc2)ccc1O.O=C(O)C(F)(F)F
CHEMBL4473111,CHEMBL237,Kappa opioid receptor,Ki,=,1550.0,nM,CHEMBL4385882,B,Displacement of [3H]-diprenorphine from human kappa-type opioid receptor expressed in CHO cell membranes incubated for 1 hr in shaker by liquid scintillation counting method,CHEMBL4385600,KI,CC(=O)Nc1ccc(Cc2ccccc2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F
CHEMBL4440903,CHEMBL237,Kappa opioid receptor,Ki,=,408.0,nM,CHEMBL4385882,B,Displacement of [3H]-diprenorphine from human kappa-type opioid receptor expressed in CHO cell membranes incubated for 1 hr in shaker by liquid scintillation counting method,CHEMBL4385600,KI,CCNc1ccc(Cc2ccccc2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F
CHEMBL4573912,CHEMBL237,Kappa opioid receptor,Ki,=,1090.0,nM,CHEMBL4385882,B,Displacement of [3H]-diprenorphine from human kappa-type opioid receptor expressed in CHO cell membranes incubated for 1 hr in shaker by liquid scintillation counting method,CHEMBL4385600,KI,CCC(=O)Nc1ccc(Cc2ccccc2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F
CHEMBL4464497,CHEMBL237,Kappa opioid receptor,Ki,=,610.0,nM,CHEMBL4385882,B,Displacement of [3H]-diprenorphine from human kappa-type opioid receptor expressed in CHO cell membranes incubated for 1 hr in shaker by liquid scintillation counting method,CHEMBL4385600,KI,COc1ccc(Cc2ccccc2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F
CHEMBL4436450,CHEMBL237,Kappa opioid receptor,Ki,=,370.0,nM,CHEMBL4385882,B,Displacement of [3H]-diprenorphine from human kappa-type opioid receptor expressed in CHO cell membranes incubated for 1 hr in shaker by liquid scintillation counting method,CHEMBL4385600,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)NCc1cc(Cc2ccccc2)ccc1OC(F)(F)F.O=C(O)C(F)(F)F
CHEMBL4455826,CHEMBL237,Kappa opioid receptor,Ki,=,1180.0,nM,CHEMBL4385882,B,Displacement of [3H]-diprenorphine from human kappa-type opioid receptor expressed in CHO cell membranes incubated for 1 hr in shaker by liquid scintillation counting method,CHEMBL4385600,KI,CCOc1ccc(Cc2ccccc2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F
CHEMBL4451153,CHEMBL237,Kappa opioid receptor,Ki,=,390.0,nM,CHEMBL4385882,B,Displacement of [3H]-diprenorphine from human kappa-type opioid receptor expressed in CHO cell membranes incubated for 1 hr in shaker by liquid scintillation counting method,CHEMBL4385600,KI,CCCOc1ccc(Cc2ccccc2)cc1CNC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F
CHEMBL4448378,CHEMBL237,Kappa opioid receptor,Ki,=,319.0,nM,CHEMBL4385882,B,Displacement of [3H]-diprenorphine from human kappa-type opioid receptor expressed in CHO cell membranes incubated for 1 hr in shaker by liquid scintillation counting method,CHEMBL4385600,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)NCc1cc(Cc2ccccc2)ccc1OCC1CC1.O=C(O)C(F)(F)F
CHEMBL4459283,CHEMBL237,Kappa opioid receptor,Ki,=,575.0,nM,CHEMBL4385882,B,Displacement of [3H]-diprenorphine from human kappa-type opioid receptor expressed in CHO cell membranes incubated for 1 hr in shaker by liquid scintillation counting method,CHEMBL4385600,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)NCc1cc(Cc2ccccc2)ccc1OCc1ccccc1.O=C(O)C(F)(F)F
CHEMBL4450863,CHEMBL237,Kappa opioid receptor,Ki,=,330.0,nM,CHEMBL4385882,B,Displacement of [3H]-diprenorphine from human kappa-type opioid receptor expressed in CHO cell membranes incubated for 1 hr in shaker by liquid scintillation counting method,CHEMBL4385600,KI,COc1ccc(Cc2ccccc2)cc1[C@@H](C)NC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C.O=C(O)C(F)(F)F
CHEMBL70,CHEMBL237,Kappa opioid receptor,Ki,=,61.0,nM,CHEMBL4385884,B,Displacement of [3H]-diprenorphine from human kappa-type opioid receptor expressed in CHO cell membranes incubated for 1 hr by liquid scintillation counting method,CHEMBL4385600,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL4277264,CHEMBL237,Kappa opioid receptor,Ki,=,3100.0,nM,CHEMBL4392135,B,Displacement of [3H]-U69593 from KOR (unknown origin) measured after 90 mins by microbeta scintillation counting method,CHEMBL4390674,KI,Cc1cc(Oc2nccc3occc23)ccc1-c1c(C)ncc2nccn12
CHEMBL4572614,CHEMBL237,Kappa opioid receptor,Ki,=,7200.0,nM,CHEMBL4392135,B,Displacement of [3H]-U69593 from KOR (unknown origin) measured after 90 mins by microbeta scintillation counting method,CHEMBL4390674,KI,Cc1ncc2nccn2c1-c1ccc(Oc2nccc3occc23)cc1C(F)(F)F
CHEMBL4469848,CHEMBL237,Kappa opioid receptor,Ki,=,1500.0,nM,CHEMBL4392135,B,Displacement of [3H]-U69593 from KOR (unknown origin) measured after 90 mins by microbeta scintillation counting method,CHEMBL4390674,KI,FC(F)(F)c1cc(Oc2nccc3occc23)ccc1-c1cccc2nccn12
CHEMBL4466483,CHEMBL237,Kappa opioid receptor,Ki,=,3200.0,nM,CHEMBL4392135,B,Displacement of [3H]-U69593 from KOR (unknown origin) measured after 90 mins by microbeta scintillation counting method,CHEMBL4390674,KI,FC(F)(F)c1cc(Oc2nccc3ccsc23)ccc1-c1cccc2nccn12
CHEMBL333357,CHEMBL237,Kappa opioid receptor,Ki,=,1136.0,nM,CHEMBL4399059,B,Displacement of [3H]U-69593 from human recombinant KOR expressed in CHO cell membranes incubated for 2 hrs by liquid scintillation counting method,CHEMBL4396910,KI,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL4527584,CHEMBL237,Kappa opioid receptor,Ki,=,9150.0,nM,CHEMBL4399059,B,Displacement of [3H]U-69593 from human recombinant KOR expressed in CHO cell membranes incubated for 2 hrs by liquid scintillation counting method,CHEMBL4396910,KI,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1cccc(O)c1
CHEMBL331325,CHEMBL237,Kappa opioid receptor,Ki,=,520.0,nM,CHEMBL4399059,B,Displacement of [3H]U-69593 from human recombinant KOR expressed in CHO cell membranes incubated for 2 hrs by liquid scintillation counting method,CHEMBL4396910,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
CHEMBL4514319,CHEMBL237,Kappa opioid receptor,Ki,=,37.3,nM,CHEMBL4399059,B,Displacement of [3H]U-69593 from human recombinant KOR expressed in CHO cell membranes incubated for 2 hrs by liquid scintillation counting method,CHEMBL4396910,KI,Cc1cc(O)c(Cl)c(C)c1C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
CHEMBL4466953,CHEMBL237,Kappa opioid receptor,Ki,=,4650.0,nM,CHEMBL4399059,B,Displacement of [3H]U-69593 from human recombinant KOR expressed in CHO cell membranes incubated for 2 hrs by liquid scintillation counting method,CHEMBL4396910,KI,Cc1cc(C[C@H](N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(N)=O)cc(C)c1O
CHEMBL4475274,CHEMBL237,Kappa opioid receptor,Ki,=,4478.0,nM,CHEMBL4399059,B,Displacement of [3H]U-69593 from human recombinant KOR expressed in CHO cell membranes incubated for 2 hrs by liquid scintillation counting method,CHEMBL4396910,KI,COc1cc(C[C@H](N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(N)=O)cc(OC)c1O
CHEMBL441765,CHEMBL237,Kappa opioid receptor,Ki,=,31.2,nM,CHEMBL4403882,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cell membranes incubated for 1 hr by scintillation counting method,CHEMBL4402550,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL4473632,CHEMBL237,Kappa opioid receptor,Ki,=,120.7,nM,CHEMBL4403882,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cell membranes incubated for 1 hr by scintillation counting method,CHEMBL4402550,KI,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1CSCc2ccccc2CSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)N2CCN(CC2)C(=O)[C@H](Cc2ccc(F)cc2)NC(=O)CNC1=O.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
CHEMBL4551481,CHEMBL237,Kappa opioid receptor,Ki,=,137.7,nM,CHEMBL4403882,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cell membranes incubated for 1 hr by scintillation counting method,CHEMBL4402550,KI,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1CSSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)N2CCN(CC2)C(=O)[C@H](Cc2ccc(F)cc2)NC(=O)CNC1=O.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
CHEMBL4539430,CHEMBL237,Kappa opioid receptor,Ki,=,76.7,nM,CHEMBL4403882,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cell membranes incubated for 1 hr by scintillation counting method,CHEMBL4402550,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CSCc2ccccc2CSC[C@@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C(=O)NCC(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)NNC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)CNC1=O.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
CHEMBL4586954,CHEMBL237,Kappa opioid receptor,Ki,=,293.3,nM,CHEMBL4403882,B,Displacement of [3H]-diprenorphine from human KOR expressed in CHO cell membranes incubated for 1 hr by scintillation counting method,CHEMBL4402550,KI,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1CSCc2ccccc2CSC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)NNC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)CNC1=O.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
CHEMBL4514672,CHEMBL237,Kappa opioid receptor,Ki,=,1707.0,nM,CHEMBL4423342,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in HEK cells by radioligand binding assay,CHEMBL4422623,KI,CC1=NC2(CCN(C)CC2)C(=O)N(c2c(C)cccc2C)C1=O
CHEMBL4592045,CHEMBL237,Kappa opioid receptor,Ki,=,1.5,nM,CHEMBL4424354,B,Displacement of [3H]diprenorphine from human KOR,CHEMBL4422661,KI,CCc1cc(F)c2nc(N3CCC(NC4CCOCC4)CC3)c(-c3nc(C)no3)c(C)c2c1
CHEMBL506616,CHEMBL237,Kappa opioid receptor,Ki,=,32.0,nM,CHEMBL4430537,B,"Displacement of [3H]U69,593 from human KOR expressed in HEK293 cell membranes incubated for 90 mins by liquid scintillation counting",CHEMBL4428100,KI,O=C1N[C@@H](Cc2ccccc2)C(=O)N2CCC[C@@H]2C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H]1Cc1c[nH]c2ccccc12
CHEMBL441765,CHEMBL237,Kappa opioid receptor,Ki,=,2.9,nM,CHEMBL4430537,B,"Displacement of [3H]U69,593 from human KOR expressed in HEK293 cell membranes incubated for 90 mins by liquid scintillation counting",CHEMBL4428100,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL4444479,CHEMBL237,Kappa opioid receptor,Ki,=,68.0,nM,CHEMBL4433510,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes measured after 1 hr by liquid scintillation counting method,CHEMBL4433205,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCNc2ccc(Cc3ccccc3)cc21.O=C(O)C(F)(F)F
CHEMBL4473177,CHEMBL237,Kappa opioid receptor,Ki,=,16.0,nM,CHEMBL4433510,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes measured after 1 hr by liquid scintillation counting method,CHEMBL4433205,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCNc2ccc(Cc3cnc4ccccc4c3)cc21.O=C(O)C(F)(F)F
CHEMBL4467875,CHEMBL237,Kappa opioid receptor,Ki,=,2.2,nM,CHEMBL4433510,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes measured after 1 hr by liquid scintillation counting method,CHEMBL4433205,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCNc2ccc(CN3CCc4ccccc4C3)cc21.O=C(O)C(F)(F)F
CHEMBL4446196,CHEMBL237,Kappa opioid receptor,Ki,=,116.0,nM,CHEMBL4433510,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes measured after 1 hr by liquid scintillation counting method,CHEMBL4433205,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCNc2ccc(Cc3ccc4c(c3)OCCO4)cc21.O=C(O)C(F)(F)F
CHEMBL4529363,CHEMBL237,Kappa opioid receptor,Ki,=,40.0,nM,CHEMBL4433510,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes measured after 1 hr by liquid scintillation counting method,CHEMBL4433205,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCNc2ccc(Cc3cc4ccccc4o3)cc21.O=C(O)C(F)(F)F
CHEMBL4550332,CHEMBL237,Kappa opioid receptor,Ki,=,53.0,nM,CHEMBL4433510,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes measured after 1 hr by liquid scintillation counting method,CHEMBL4433205,KI,CC(=O)N1CC[C@@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)c2cc(Cc3cnc4ccccc4c3)ccc21.O=C(O)C(F)(F)F
CHEMBL4454102,CHEMBL237,Kappa opioid receptor,Ki,=,0.78,nM,CHEMBL4433510,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes measured after 1 hr by liquid scintillation counting method,CHEMBL4433205,KI,CC(=O)N1CC[C@@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)c2cc(CN3CCc4ccccc4C3)ccc21.O=C(O)C(F)(F)F
CHEMBL4593995,CHEMBL237,Kappa opioid receptor,Ki,=,142.0,nM,CHEMBL4433510,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes measured after 1 hr by liquid scintillation counting method,CHEMBL4433205,KI,CC(=O)N1CC[C@@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)c2cc(Cc3ccc4c(c3)OCCO4)ccc21.O=C(O)C(F)(F)F
CHEMBL4453526,CHEMBL237,Kappa opioid receptor,Ki,=,58.0,nM,CHEMBL4433510,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes measured after 1 hr by liquid scintillation counting method,CHEMBL4433205,KI,CC(=O)N1CC[C@@H](NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)c2cc(Cc3cc4ccccc4o3)ccc21.O=C(O)C(F)(F)F
CHEMBL4446945,CHEMBL237,Kappa opioid receptor,Ki,=,117.0,nM,CHEMBL4433510,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes measured after 1 hr by liquid scintillation counting method,CHEMBL4433205,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCN(C(=O)C2CC2)c2ccc(Cc3ccc4ccccc4c3)cc21.O=C(O)C(F)(F)F
CHEMBL4476818,CHEMBL237,Kappa opioid receptor,Ki,=,84.0,nM,CHEMBL4433510,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes measured after 1 hr by liquid scintillation counting method,CHEMBL4433205,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCN(C(=O)C2CC2)c2ccc(Cc3cnc4ccccc4c3)cc21.O=C(O)C(F)(F)F
CHEMBL4553931,CHEMBL237,Kappa opioid receptor,Ki,=,40.0,nM,CHEMBL4433510,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes measured after 1 hr by liquid scintillation counting method,CHEMBL4433205,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCN(C(=O)C2CC2)c2ccc(CN3CCc4ccccc4C3)cc21.O=C(O)C(F)(F)F
CHEMBL4463767,CHEMBL237,Kappa opioid receptor,Ki,=,412.0,nM,CHEMBL4433510,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes measured after 1 hr by liquid scintillation counting method,CHEMBL4433205,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCN(C(=O)C2CC2)c2ccc(Cc3ccc4c(c3)OCCO4)cc21.O=C(O)C(F)(F)F
CHEMBL4451910,CHEMBL237,Kappa opioid receptor,Ki,=,98.0,nM,CHEMBL4433510,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes measured after 1 hr by liquid scintillation counting method,CHEMBL4433205,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCN(C(=O)C2CC2)c2ccc(Cc3cc4ccccc4o3)cc21.O=C(O)C(F)(F)F
CHEMBL4521319,CHEMBL237,Kappa opioid receptor,Ki,=,8.0,nM,CHEMBL4433510,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes measured after 1 hr by liquid scintillation counting method,CHEMBL4433205,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCN(S(C)(=O)=O)c2ccc(Cc3ccccc3)cc21.O=C(O)C(F)(F)F
CHEMBL4588807,CHEMBL237,Kappa opioid receptor,Ki,=,27.0,nM,CHEMBL4433510,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes measured after 1 hr by liquid scintillation counting method,CHEMBL4433205,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCN(S(C)(=O)=O)c2ccc(Cc3ccc4ccccc4c3)cc21.O=C(O)C(F)(F)F
CHEMBL4471560,CHEMBL237,Kappa opioid receptor,Ki,=,7.0,nM,CHEMBL4433510,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes measured after 1 hr by liquid scintillation counting method,CHEMBL4433205,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCN(S(C)(=O)=O)c2ccc(Cc3cnc4ccccc4c3)cc21.O=C(O)C(F)(F)F
CHEMBL4548498,CHEMBL237,Kappa opioid receptor,Ki,=,1.1,nM,CHEMBL4433510,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes measured after 1 hr by liquid scintillation counting method,CHEMBL4433205,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCN(S(C)(=O)=O)c2ccc(CN3CCc4ccccc4C3)cc21.O=C(O)C(F)(F)F
CHEMBL4574998,CHEMBL237,Kappa opioid receptor,Ki,=,46.0,nM,CHEMBL4433510,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes measured after 1 hr by liquid scintillation counting method,CHEMBL4433205,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCN(S(C)(=O)=O)c2ccc(Cc3ccc4c(c3)OCCO4)cc21.O=C(O)C(F)(F)F
CHEMBL4459271,CHEMBL237,Kappa opioid receptor,Ki,=,8.0,nM,CHEMBL4433510,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes measured after 1 hr by liquid scintillation counting method,CHEMBL4433205,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCN(S(C)(=O)=O)c2ccc(Cc3cc4ccccc4o3)cc21.O=C(O)C(F)(F)F
CHEMBL4516240,CHEMBL237,Kappa opioid receptor,Ki,=,160.0,nM,CHEMBL4433510,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes measured after 1 hr by liquid scintillation counting method,CHEMBL4433205,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCN(C(=O)c2ccccc2)c2ccc(Cc3ccc4ccccc4c3)cc21.O=C(O)C(F)(F)F
CHEMBL4569709,CHEMBL237,Kappa opioid receptor,Ki,=,100.0,nM,CHEMBL4433510,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes measured after 1 hr by liquid scintillation counting method,CHEMBL4433205,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCN(C(=O)c2ccccc2)c2ccc(Cc3cnc4ccccc4c3)cc21.O=C(O)C(F)(F)F
CHEMBL4549639,CHEMBL237,Kappa opioid receptor,Ki,=,160.0,nM,CHEMBL4433510,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes measured after 1 hr by liquid scintillation counting method,CHEMBL4433205,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCN(C(=O)c2ccccc2)c2ccc(CN3CCc4ccccc4C3)cc21.O=C(O)C(F)(F)F
CHEMBL4468750,CHEMBL237,Kappa opioid receptor,Ki,=,240.0,nM,CHEMBL4433510,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes measured after 1 hr by liquid scintillation counting method,CHEMBL4433205,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCN(C(=O)c2ccccc2)c2ccc(Cc3ccc4c(c3)OCCO4)cc21.O=C(O)C(F)(F)F
CHEMBL4459439,CHEMBL237,Kappa opioid receptor,Ki,=,100.0,nM,CHEMBL4433510,B,Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO cell membranes measured after 1 hr by liquid scintillation counting method,CHEMBL4433205,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@@H]1CCN(C(=O)c2ccccc2)c2ccc(Cc3cc4ccccc4o3)cc21.O=C(O)C(F)(F)F
CHEMBL441765,CHEMBL237,Kappa opioid receptor,Ki,=,23.9,nM,CHEMBL4433606,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by micro beta2 scintillation counting method,CHEMBL4433209,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL4434948,CHEMBL237,Kappa opioid receptor,Ki,=,495.0,nM,CHEMBL4433606,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by micro beta2 scintillation counting method,CHEMBL4433209,KI,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1C/C=C\C[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)NNC(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
CHEMBL4473857,CHEMBL237,Kappa opioid receptor,Ki,=,686.0,nM,CHEMBL4433606,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by micro beta2 scintillation counting method,CHEMBL4433209,KI,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1C/C=C/C[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)NNC(=O)[C@H](Cc2ccccc2)NC(=O)CNC1=O.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
CHEMBL441765,CHEMBL237,Kappa opioid receptor,Ki,=,120.0,nM,CHEMBL4615752,B,Displacement of [3H]diprenorphine human kappa opioid receptor expressed in CHO cell membranes after 1 hr by micro beta2 scintillation counting method,CHEMBL4613286,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL4648915,CHEMBL237,Kappa opioid receptor,Ki,=,179.9,nM,CHEMBL4620844,B,Displacement of [3H]-U69593 from human kappa opiod receptor expressed in CHO cells incubated for 60 mins by liquid scintillation counting method,CHEMBL4619756,KI,COc1ccc(C2CCCN2Cc2ccc(Oc3ccc(C(=O)NO)cc3)cc2)cc1
CHEMBL4636535,CHEMBL237,Kappa opioid receptor,Ki,=,497.6,nM,CHEMBL4620844,B,Displacement of [3H]-U69593 from human kappa opiod receptor expressed in CHO cells incubated for 60 mins by liquid scintillation counting method,CHEMBL4619756,KI,O=C(NO)c1ccc(Oc2ccc(CN3CCCC3c3cccc(F)c3)cc2)c(F)c1
CHEMBL4644052,CHEMBL237,Kappa opioid receptor,Ki,=,2154.0,nM,CHEMBL4620844,B,Displacement of [3H]-U69593 from human kappa opiod receptor expressed in CHO cells incubated for 60 mins by liquid scintillation counting method,CHEMBL4619756,KI,COc1cccc(C2CCCN2Cc2ccc(Oc3ccc(C(=O)NO)cc3F)cc2)c1
CHEMBL4063074,CHEMBL237,Kappa opioid receptor,Ki,=,14.0,nM,CHEMBL4620844,B,Displacement of [3H]-U69593 from human kappa opiod receptor expressed in CHO cells incubated for 60 mins by liquid scintillation counting method,CHEMBL4619756,KI,Cc1cc(C)cc(C2CCCN2Cc2ccc(Oc3ccc(C(N)=O)cc3F)cc2)c1
CHEMBL4638966,CHEMBL237,Kappa opioid receptor,Ki,=,1411.0,nM,CHEMBL4620844,B,Displacement of [3H]-U69593 from human kappa opiod receptor expressed in CHO cells incubated for 60 mins by liquid scintillation counting method,CHEMBL4619756,KI,Cc1cc(C)cc(C2CCCN2Cc2ccc(Oc3ccc4c(=O)[nH]oc4c3)cc2)c1
CHEMBL567175,CHEMBL237,Kappa opioid receptor,Ki,=,14.7,nM,CHEMBL4629273,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL4627370,KI,Oc1ccc2c3c1O[C@H]1c4[nH]c5ccccc5c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4638693,CHEMBL237,Kappa opioid receptor,Ki,=,5989.0,nM,CHEMBL4629273,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL4627370,KI,O=C(Cc1ccccc1)N1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccccc4c2C[C@@]3(O)[C@H]1C5
CHEMBL4636799,CHEMBL237,Kappa opioid receptor,Ki,=,2150.0,nM,CHEMBL4629273,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells,CHEMBL4627370,KI,O=C(CCc1ccccc1)N1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccccc4c2C[C@@]3(O)[C@H]1C5
CHEMBL2179652,CHEMBL237,Kappa opioid receptor,Ki,=,60.9,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccc(Cl)cc5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4633209,CHEMBL237,Kappa opioid receptor,Ki,=,132.0,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccccc5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4641670,CHEMBL237,Kappa opioid receptor,Ki,=,75.9,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccc(Br)cc5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4644543,CHEMBL237,Kappa opioid receptor,Ki,=,6.69,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccc(F)cc5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4636305,CHEMBL237,Kappa opioid receptor,Ki,=,35.9,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccc(F)cc5F)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4645952,CHEMBL237,Kappa opioid receptor,Ki,=,71.2,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccc(F)c(F)c5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4633020,CHEMBL237,Kappa opioid receptor,Ki,=,152.0,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Cc1ccccc1-c1cnc2c(c1)C[C@@]1(OCCCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]1(CCN3CC1CC1)[C@H]2O5
CHEMBL4633223,CHEMBL237,Kappa opioid receptor,Ki,=,17.6,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Cc1cccc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)c1
CHEMBL4647696,CHEMBL237,Kappa opioid receptor,Ki,=,102.0,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Cc1ccc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)cc1
CHEMBL4638667,CHEMBL237,Kappa opioid receptor,Ki,=,129.0,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Cc1cc(F)ccc1-c1cnc2c(c1)C[C@@]1(OCCCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]1(CCN3CC1CC1)[C@H]2O5
CHEMBL4647353,CHEMBL237,Kappa opioid receptor,Ki,=,175.0,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccccc5C5CC5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4649820,CHEMBL237,Kappa opioid receptor,Ki,=,134.0,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Cc1cccc(C)c1-c1cnc2c(c1)C[C@@]1(OCCCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]1(CCN3CC1CC1)[C@H]2O5
CHEMBL4644691,CHEMBL237,Kappa opioid receptor,Ki,=,126.0,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,COc1ccccc1-c1cnc2c(c1)C[C@@]1(OCCCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]1(CCN3CC1CC1)[C@H]2O5
CHEMBL4633907,CHEMBL237,Kappa opioid receptor,Ki,=,103.0,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,COc1cccc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)c1
CHEMBL4636159,CHEMBL237,Kappa opioid receptor,Ki,=,140.0,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,COc1ccc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)cc1
CHEMBL4640139,CHEMBL237,Kappa opioid receptor,Ki,=,18.1,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1cccc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)c1
CHEMBL4649485,CHEMBL237,Kappa opioid receptor,Ki,=,7.96,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,CN(C)c1ccccc1-c1cnc2c(c1)C[C@@]1(OCCCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]1(CCN3CC1CC1)[C@H]2O5
CHEMBL4634021,CHEMBL237,Kappa opioid receptor,Ki,=,11.9,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,CN(C)c1cccc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)c1
CHEMBL4641271,CHEMBL237,Kappa opioid receptor,Ki,=,6.18,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,CN(C)c1ccc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)cc1
CHEMBL4648920,CHEMBL237,Kappa opioid receptor,Ki,=,22.7,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,CN(C)Cc1ccccc1-c1cnc2c(c1)C[C@@]1(OCCCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]1(CCN3CC1CC1)[C@H]2O5
CHEMBL4639005,CHEMBL237,Kappa opioid receptor,Ki,=,13.5,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,NC(=O)Nc1ccccc1-c1cnc2c(c1)C[C@@]1(OCCCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]1(CCN3CC1CC1)[C@H]2O5
CHEMBL4647851,CHEMBL237,Kappa opioid receptor,Ki,=,608.0,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,CC(=O)Nc1cccc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)c1
CHEMBL4634141,CHEMBL237,Kappa opioid receptor,Ki,=,15.1,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,CC(=O)Nc1ccc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)cc1
CHEMBL593781,CHEMBL237,Kappa opioid receptor,Ki,=,31.9,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@H]1CCCC[C@@H]1N1CCCC1.Cl
CHEMBL4634079,CHEMBL237,Kappa opioid receptor,Ki,=,13.8,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-n5cccc5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4648628,CHEMBL237,Kappa opioid receptor,Ki,=,19.2,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccccn5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4640141,CHEMBL237,Kappa opioid receptor,Ki,=,27.8,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5cccnc5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4640826,CHEMBL237,Kappa opioid receptor,Ki,=,15.8,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccncc5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4636598,CHEMBL237,Kappa opioid receptor,Ki,=,6.62,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,COc1cc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)ccn1
CHEMBL4649042,CHEMBL237,Kappa opioid receptor,Ki,=,30.8,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccncn5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4647357,CHEMBL237,Kappa opioid receptor,Ki,=,24.8,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5cncnc5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4649607,CHEMBL237,Kappa opioid receptor,Ki,=,19.8,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5cnccn5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4634007,CHEMBL237,Kappa opioid receptor,Ki,=,29.8,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5cn[nH]c5)cc4C[C@@]4(OCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4644731,CHEMBL237,Kappa opioid receptor,Ki,=,8.4,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Cn1cc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)cn1
CHEMBL4643256,CHEMBL237,Kappa opioid receptor,Ki,=,23.1,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Cc1nocc1-c1cnc2c(c1)C[C@@]1(OCCCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]1(CCN3CC1CC1)[C@H]2O5
CHEMBL4646678,CHEMBL237,Kappa opioid receptor,Ki,=,14.8,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Cc1nnc(-c2cnc3c(c2)C[C@@]2(OCCCc4ccccc4)[C@H]4Cc5ccc(O)c6c5[C@@]2(CCN4CC2CC2)[C@H]3O6)o1
CHEMBL4635711,CHEMBL237,Kappa opioid receptor,Ki,=,10.3,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccc(Cl)cc5)cc4C[C@@]4(OCCCc5ccncc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4647180,CHEMBL237,Kappa opioid receptor,Ki,=,21.3,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccc(Cl)cc5)cc4C[C@@]4(OCCOc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4640017,CHEMBL237,Kappa opioid receptor,Ki,=,31.0,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccc(Cl)cc5)cc4C[C@@]4(OCc5ccc6ccccc6n5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4646687,CHEMBL237,Kappa opioid receptor,Ki,=,5.3,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccccc5)cc4C[C@@]4(OCCCc5ccccn5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4644964,CHEMBL237,Kappa opioid receptor,Ki,=,21.9,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccccc5)cc4C[C@@]4(OCCCc5ccncc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4633348,CHEMBL237,Kappa opioid receptor,Ki,=,60.2,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccccc5)cc4C[C@@]4(OCCCc5ccc(F)cc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4646507,CHEMBL237,Kappa opioid receptor,Ki,=,57.9,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccccc5)cc4C[C@@]4(OCCCC5CCCCC5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4645533,CHEMBL237,Kappa opioid receptor,Ki,=,24.8,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccccc5)cc4C[C@@]4(OCCCC5CCOCC5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4634862,CHEMBL237,Kappa opioid receptor,Ki,=,57.1,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,Oc1ccc2c3c1O[C@H]1c4ncc(-c5ccccc5)cc4C[C@@]4(OCCCCc5ccccc5)[C@@H](C2)N(CC2CC2)CC[C@]314
CHEMBL4638709,CHEMBL237,Kappa opioid receptor,Ki,=,252.0,nM,CHEMBL4630063,B,Displacement of [3H]-diprenorphine from human kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by competition radioligand binding assay,CHEMBL4627399,KI,CCO[C@@]12Cc3cc(-c4ccccc4)cnc3[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(CC1CC1)[C@@H]2C5
CHEMBL4761627,CHEMBL237,Kappa opioid receptor,Ki,=,407.0,nM,CHEMBL4673763,B,Binding affinity to KOR (unknown origin),CHEMBL4673196,KI,c1ccc2c(c1)CCO[C@@]21CCC[C@H](NCC2CCCCC2)C1
CHEMBL4786173,CHEMBL237,Kappa opioid receptor,Ki,=,71.38,nM,CHEMBL4684595,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells incubated for 30 mins by liquid scintillation counting method,CHEMBL4680180,KI,CN(C)CC1CN(C(=O)Nc2ccccc2)CCC1(O)c1cccc(O)c1.Cl
CHEMBL4800532,CHEMBL237,Kappa opioid receptor,Ki,=,718.6,nM,CHEMBL4684595,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells incubated for 30 mins by liquid scintillation counting method,CHEMBL4680180,KI,CN(C)CC1CN(C(=O)Nc2cccc(Cl)c2)CCC1(O)c1ccccc1.Cl
CHEMBL441765,CHEMBL237,Kappa opioid receptor,Ki,=,0.91,nM,CHEMBL4684595,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells incubated for 30 mins by liquid scintillation counting method,CHEMBL4680180,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL4756256,CHEMBL237,Kappa opioid receptor,Ki,=,49.1,nM,CHEMBL4684595,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in CHO cells incubated for 30 mins by liquid scintillation counting method,CHEMBL4680180,KI,CN(C)CC1CN(C(=O)Nc2ccccc2)CCC1(O)c1ccccc1.Cl
CHEMBL190461,CHEMBL237,Kappa opioid receptor,Ki,=,2300.0,nM,CHEMBL4687693,B,Inhibition of kappa-type opioid receptor (unknown origin),CHEMBL4680278,KI,C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O
CHEMBL3408737,CHEMBL237,Kappa opioid receptor,Ki,=,16.6,nM,CHEMBL4701857,B,Displacement of [3H]-U69593 from recombinant human kappa opioid receptor expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4699489,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(N)=O)C1=O
CHEMBL4761165,CHEMBL237,Kappa opioid receptor,Ki,=,33.5,nM,CHEMBL4701857,B,Displacement of [3H]-U69593 from recombinant human kappa opioid receptor expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4699489,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C
CHEMBL4789659,CHEMBL237,Kappa opioid receptor,Ki,=,78.6,nM,CHEMBL4701857,B,Displacement of [3H]-U69593 from recombinant human kappa opioid receptor expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4699489,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C)C1=O
CHEMBL4744531,CHEMBL237,Kappa opioid receptor,Ki,=,201.0,nM,CHEMBL4701857,B,Displacement of [3H]-U69593 from recombinant human kappa opioid receptor expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4699489,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C)C1=O
CHEMBL4798887,CHEMBL237,Kappa opioid receptor,Ki,=,102.0,nM,CHEMBL4701857,B,Displacement of [3H]-U69593 from recombinant human kappa opioid receptor expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4699489,KI,Cc1cc(O)cc(C)c1C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CCN1Cc2ccccc2C[C@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C1=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C
CHEMBL4758754,CHEMBL237,Kappa opioid receptor,Ki,=,138.0,nM,CHEMBL4701857,B,Displacement of [3H]-U69593 from recombinant human kappa opioid receptor expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4699489,KI,Cc1cc(O)cc(C)c1C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CCN1Cc2ccccc2C[C@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C1=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C
CHEMBL4776986,CHEMBL237,Kappa opioid receptor,Ki,=,27.9,nM,CHEMBL4701857,B,Displacement of [3H]-U69593 from recombinant human kappa opioid receptor expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4699489,KI,Cc1cc(O)cc(C)c1C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)C[C@H](CCCNC(=N)N)NC(=O)CCN1Cc2ccccc2C[C@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C1=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C
CHEMBL4749016,CHEMBL237,Kappa opioid receptor,Ki,=,208.0,nM,CHEMBL4701857,B,Displacement of [3H]-U69593 from recombinant human kappa opioid receptor expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4699489,KI,Cc1cc(O)cc(C)c1C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)C[C@H](CCCCN)NC(=O)CCN1Cc2ccccc2C[C@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)C1=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C
CHEMBL4742666,CHEMBL237,Kappa opioid receptor,Ki,=,22.4,nM,CHEMBL4701857,B,Displacement of [3H]-U69593 from recombinant human kappa opioid receptor expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4699489,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N2Cc3ccc(O)cc3C[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C)C1=O
CHEMBL4750783,CHEMBL237,Kappa opioid receptor,Ki,=,150.0,nM,CHEMBL4701857,B,Displacement of [3H]-U69593 from recombinant human kappa opioid receptor expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4699489,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N2Cc3ccc(O)cc3C[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C)C1=O
CHEMBL4745899,CHEMBL237,Kappa opioid receptor,Ki,=,19.9,nM,CHEMBL4701857,B,Displacement of [3H]-U69593 from recombinant human kappa opioid receptor expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4699489,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc(O)c2)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C)C1=O
CHEMBL4747286,CHEMBL237,Kappa opioid receptor,Ki,=,70.9,nM,CHEMBL4701857,B,Displacement of [3H]-U69593 from recombinant human kappa opioid receptor expressed in CHO cell membrane incubated for 60 mins by liquid scintillation counting method,CHEMBL4699489,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H]1Cc2ccccc2CN(CCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc(O)c2)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)(C)C)C1=O
CHEMBL4797769,CHEMBL237,Kappa opioid receptor,Ki,=,220.0,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O
CHEMBL4750644,CHEMBL237,Kappa opioid receptor,Ki,=,51.0,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(C)=O)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O
CHEMBL4745486,CHEMBL237,Kappa opioid receptor,Ki,=,94.0,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](C)Cc1c(C)cc(O)cc1C)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O
CHEMBL4754961,CHEMBL237,Kappa opioid receptor,Ki,=,0.3,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O
CHEMBL4745504,CHEMBL237,Kappa opioid receptor,Ki,=,4300.0,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,KI,CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL4780433,CHEMBL237,Kappa opioid receptor,Ki,=,98.0,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,KI,CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL4788135,CHEMBL237,Kappa opioid receptor,Ki,=,3600.0,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,KI,CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL4755568,CHEMBL237,Kappa opioid receptor,Ki,=,5200.0,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,KI,CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL4761040,CHEMBL237,Kappa opioid receptor,Ki,=,730.0,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(C)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL4762413,CHEMBL237,Kappa opioid receptor,Ki,=,61.0,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL4787539,CHEMBL237,Kappa opioid receptor,Ki,=,230.0,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](C)Cc1c(C)cc(O)cc1C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O
CHEMBL4779988,CHEMBL237,Kappa opioid receptor,Ki,=,85.0,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(C)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL4754076,CHEMBL237,Kappa opioid receptor,Ki,=,63.0,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](C)Cc1c(C)cc(O)cc1C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL4784791,CHEMBL237,Kappa opioid receptor,Ki,=,0.07,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL4757601,CHEMBL237,Kappa opioid receptor,Ki,=,0.43,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O
CHEMBL4760958,CHEMBL237,Kappa opioid receptor,Ki,=,0.39,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O
CHEMBL216640,CHEMBL237,Kappa opioid receptor,Ki,=,0.1,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL438223,CHEMBL237,Kappa opioid receptor,Ki,=,0.12,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O
CHEMBL405618,CHEMBL237,Kappa opioid receptor,Ki,=,0.09,nM,CHEMBL4719712,B,"Displacement of [3H]U69,593 from human KOR expressed in mouse HN9.10 cell membranes incubated for 2 hrs by liquid scintillation counting based radioligand competition assay",CHEMBL4715797,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O
CHEMBL100116,CHEMBL237,Kappa opioid receptor,Ki,=,2.2,nM,CHEMBL4723560,B,Binding affinity to kappa opioid receptor (unknown origin),CHEMBL4715859,KI,CC(C)=CCN1CCC2(C)c3cc(O)ccc3CC1C2C
CHEMBL4871880,CHEMBL237,Kappa opioid receptor,Ki,=,1680.0,nM,CHEMBL4814798,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in U2OS cells by radioligand binding assay,CHEMBL4813924,KI,C/C=C1/CN2CC[C@@]34c5cc(O)ccc5N(C)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL4856018,CHEMBL237,Kappa opioid receptor,Ki,=,14200.0,nM,CHEMBL4814798,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in U2OS cells by radioligand binding assay,CHEMBL4813924,KI,C/C=C1/CN2[C@H]3Cc4c([nH]c5ccccc45)[C@@H]2C[C@@H]1[C@]3(CO)C(=O)OC
CHEMBL4846243,CHEMBL237,Kappa opioid receptor,Ki,=,2250.0,nM,CHEMBL4814798,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in U2OS cells by radioligand binding assay,CHEMBL4813924,KI,C/C=C1/CN2CC[C@@]34c5ccccc5N(C)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL508955,CHEMBL237,Kappa opioid receptor,Ki,=,89.0,nM,CHEMBL4814798,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in U2OS cells by radioligand binding assay,CHEMBL4813924,KI,C/C=C1/CN2CC[C@]34C(=C(C(=O)OC)[C@H]1C[C@H]23)Nc1ccccc14
CHEMBL4874877,CHEMBL237,Kappa opioid receptor,Ki,=,1110.0,nM,CHEMBL4814798,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in U2OS cells by radioligand binding assay,CHEMBL4813924,KI,C/C=C1/CN2CC[C@]34C(=Nc5ccccc53)[C@@H]2C[C@@H]1[C@@]4(COC(C)=O)C(=O)OC
CHEMBL4852987,CHEMBL237,Kappa opioid receptor,Ki,=,2380.0,nM,CHEMBL4814798,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in U2OS cells by radioligand binding assay,CHEMBL4813924,KI,C/C=C1/CN2[C@@H]3C[C@@]45c6ccccc6N[C@]4(O3)[C@@H]2C[C@@H]1[C@@]5(COC(C)=O)C(=O)OC
CHEMBL441765,CHEMBL237,Kappa opioid receptor,Ki,=,0.094,nM,CHEMBL4814798,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in U2OS cells by radioligand binding assay,CHEMBL4813924,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL4871880,CHEMBL237,Kappa opioid receptor,Ki,=,1584.89,nM,CHEMBL4814798,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in U2OS cells by radioligand binding assay,CHEMBL4813924,KI,C/C=C1/CN2CC[C@@]34c5cc(O)ccc5N(C)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL4856018,CHEMBL237,Kappa opioid receptor,Ki,=,15848.93,nM,CHEMBL4814798,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in U2OS cells by radioligand binding assay,CHEMBL4813924,KI,C/C=C1/CN2[C@H]3Cc4c([nH]c5ccccc45)[C@@H]2C[C@@H]1[C@]3(CO)C(=O)OC
CHEMBL4846243,CHEMBL237,Kappa opioid receptor,Ki,=,2511.89,nM,CHEMBL4814798,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in U2OS cells by radioligand binding assay,CHEMBL4813924,KI,C/C=C1/CN2CC[C@@]34c5ccccc5N(C)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL508955,CHEMBL237,Kappa opioid receptor,Ki,=,79.43,nM,CHEMBL4814798,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in U2OS cells by radioligand binding assay,CHEMBL4813924,KI,C/C=C1/CN2CC[C@]34C(=C(C(=O)OC)[C@H]1C[C@H]23)Nc1ccccc14
CHEMBL4874877,CHEMBL237,Kappa opioid receptor,Ki,=,1000.0,nM,CHEMBL4814798,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in U2OS cells by radioligand binding assay,CHEMBL4813924,KI,C/C=C1/CN2CC[C@]34C(=Nc5ccccc53)[C@@H]2C[C@@H]1[C@@]4(COC(C)=O)C(=O)OC
CHEMBL4852987,CHEMBL237,Kappa opioid receptor,Ki,=,2511.89,nM,CHEMBL4814798,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in U2OS cells by radioligand binding assay,CHEMBL4813924,KI,C/C=C1/CN2[C@@H]3C[C@@]45c6ccccc6N[C@]4(O3)[C@@H]2C[C@@H]1[C@@]5(COC(C)=O)C(=O)OC
CHEMBL441765,CHEMBL237,Kappa opioid receptor,Ki,=,0.1,nM,CHEMBL4814798,B,Displacement of [3H]-U69593 from human kappa opioid receptor expressed in U2OS cells by radioligand binding assay,CHEMBL4813924,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL80,CHEMBL237,Kappa opioid receptor,Ki,=,15.85,nM,CHEMBL4837566,B,Binding affinity to kappa-opioid receptor (unknown origin),CHEMBL4837182,KI,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL4870433,CHEMBL237,Kappa opioid receptor,Ki,=,13.7,nM,CHEMBL4841080,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membrane measured after 30 mins by liquid scintillation counting method",CHEMBL4840326,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4cccc(N)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4857175,CHEMBL237,Kappa opioid receptor,Ki,=,61.0,nM,CHEMBL4841080,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membrane measured after 30 mins by liquid scintillation counting method",CHEMBL4840326,KI,CNc1cccc([C@H]2C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(OC)ccc6c5[C@@]23CCN(CC2CC2)[C@@H]4C6)c1
CHEMBL4864911,CHEMBL237,Kappa opioid receptor,Ki,=,6.0,nM,CHEMBL4841080,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membrane measured after 30 mins by liquid scintillation counting method",CHEMBL4840326,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4cccc(NCC6CC6)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4860416,CHEMBL237,Kappa opioid receptor,Ki,=,7.2,nM,CHEMBL4841080,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membrane measured after 30 mins by liquid scintillation counting method",CHEMBL4840326,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4cccc(NCC6CCC6)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4861737,CHEMBL237,Kappa opioid receptor,Ki,=,206.5,nM,CHEMBL4841080,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membrane measured after 30 mins by liquid scintillation counting method",CHEMBL4840326,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4cccc(NCc6ccccc6)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4851681,CHEMBL237,Kappa opioid receptor,Ki,=,45.6,nM,CHEMBL4841080,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membrane measured after 30 mins by liquid scintillation counting method",CHEMBL4840326,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4cccc(NCc6ccc(C)cc6)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4848808,CHEMBL237,Kappa opioid receptor,Ki,=,7.1,nM,CHEMBL4841080,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membrane measured after 30 mins by liquid scintillation counting method",CHEMBL4840326,KI,COc1ccc(CNc2cccc([C@H]3C[C@@]45CC[C@]3(OC)[C@@H]3Oc6c(OC)ccc7c6[C@@]34CCN(CC3CC3)[C@@H]5C7)c2)cc1
CHEMBL4873458,CHEMBL237,Kappa opioid receptor,Ki,=,8.0,nM,CHEMBL4841080,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membrane measured after 30 mins by liquid scintillation counting method",CHEMBL4840326,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4cccc(NCc6ccc(Cl)nc6)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4851082,CHEMBL237,Kappa opioid receptor,Ki,=,242.7,nM,CHEMBL4841080,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membrane measured after 30 mins by liquid scintillation counting method",CHEMBL4840326,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4cccc(NC(=O)C6CC6)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4858515,CHEMBL237,Kappa opioid receptor,Ki,=,46.5,nM,CHEMBL4841080,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membrane measured after 30 mins by liquid scintillation counting method",CHEMBL4840326,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4cccc(NC(=O)c6ccccc6)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4870270,CHEMBL237,Kappa opioid receptor,Ki,=,268.1,nM,CHEMBL4841080,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membrane measured after 30 mins by liquid scintillation counting method",CHEMBL4840326,KI,COc1ccc(C(=O)Nc2cccc([C@H]3C[C@@]45CC[C@]3(OC)[C@@H]3Oc6c(OC)ccc7c6[C@@]34CCN(CC3CC3)[C@@H]5C7)c2)cc1
CHEMBL4857172,CHEMBL237,Kappa opioid receptor,Ki,=,37.4,nM,CHEMBL4841080,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membrane measured after 30 mins by liquid scintillation counting method",CHEMBL4840326,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4cccc(NC(=O)c6ccc(C)c(C)c6)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4870917,CHEMBL237,Kappa opioid receptor,Ki,=,93.8,nM,CHEMBL4841080,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membrane measured after 30 mins by liquid scintillation counting method",CHEMBL4840326,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4cccc(NCC(O)COc6cccc7[nH]c8ccccc8c67)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4449252,CHEMBL237,Kappa opioid receptor,Ki,=,0.47,nM,CHEMBL4841080,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membrane measured after 30 mins by liquid scintillation counting method",CHEMBL4840326,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4ccc(NC(=O)c6ccccc6)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4875933,CHEMBL237,Kappa opioid receptor,Ki,=,9.8,nM,CHEMBL4841080,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membrane measured after 30 mins by liquid scintillation counting method",CHEMBL4840326,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4cccc(NCc6ccc(F)cc6)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4863358,CHEMBL237,Kappa opioid receptor,Ki,=,56.2,nM,CHEMBL4841080,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membrane measured after 30 mins by liquid scintillation counting method",CHEMBL4840326,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4cccc(NCc6cccc(C)c6)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4860580,CHEMBL237,Kappa opioid receptor,Ki,=,11.7,nM,CHEMBL4841080,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membrane measured after 30 mins by liquid scintillation counting method",CHEMBL4840326,KI,COc1cccc(CNc2cccc([C@H]3C[C@@]45CC[C@]3(OC)[C@@H]3Oc6c(OC)ccc7c6[C@@]34CCN(CC3CC3)[C@@H]5C7)c2)c1
CHEMBL4879175,CHEMBL237,Kappa opioid receptor,Ki,=,423.3,nM,CHEMBL4841080,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membrane measured after 30 mins by liquid scintillation counting method",CHEMBL4840326,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4cccc(NCc6ccc(OC(F)(F)F)cc6)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4850589,CHEMBL237,Kappa opioid receptor,Ki,=,51.0,nM,CHEMBL4841080,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membrane measured after 30 mins by liquid scintillation counting method",CHEMBL4840326,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4cccc(NCc6ccc(C(F)(F)F)cc6)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4858270,CHEMBL237,Kappa opioid receptor,Ki,=,48.7,nM,CHEMBL4841080,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membrane measured after 30 mins by liquid scintillation counting method",CHEMBL4840326,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4cccc(NCc6ccc([N+](=O)[O-])cc6)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4876542,CHEMBL237,Kappa opioid receptor,Ki,=,6.6,nM,CHEMBL4841080,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membrane measured after 30 mins by liquid scintillation counting method",CHEMBL4840326,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4cccc(NCc6ccc(N)cc6)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4874064,CHEMBL237,Kappa opioid receptor,Ki,=,16.1,nM,CHEMBL4841080,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membrane measured after 30 mins by liquid scintillation counting method",CHEMBL4840326,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4cccc(NCc6ccc(O)cc6)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4862968,CHEMBL237,Kappa opioid receptor,Ki,=,13.9,nM,CHEMBL4841080,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membrane measured after 30 mins by liquid scintillation counting method",CHEMBL4840326,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4cccc(NCc6ccc(OC(C)=O)cc6)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4856092,CHEMBL237,Kappa opioid receptor,Ki,=,200.2,nM,CHEMBL4841080,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membrane measured after 30 mins by liquid scintillation counting method",CHEMBL4840326,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4cccc(NCc6ccc(OCC7CC7)cc6)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4876239,CHEMBL237,Kappa opioid receptor,Ki,=,224.5,nM,CHEMBL4841080,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membrane measured after 30 mins by liquid scintillation counting method",CHEMBL4840326,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@H]4c4cccc(NCc6ccc(OCC7CCC7)cc6)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL4859512,CHEMBL237,Kappa opioid receptor,Ki,=,0.016,nM,CHEMBL4841080,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membrane measured after 30 mins by liquid scintillation counting method",CHEMBL4840326,KI,COc1ccc(CNc2cccc([C@H]3C[C@@]45CC[C@]3(OC)[C@@H]3Oc6c(O)ccc7c6[C@@]34CCN(CC3CC3)[C@@H]5C7)c2)cc1
CHEMBL58033,CHEMBL237,Kappa opioid receptor,Ki,=,6.1,nM,CHEMBL4841080,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membrane measured after 30 mins by liquid scintillation counting method",CHEMBL4840326,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@H]1CCCC[C@@H]1N1CCCC1
CHEMBL70,CHEMBL237,Kappa opioid receptor,Ki,=,76.9,nM,CHEMBL4841080,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membrane measured after 30 mins by liquid scintillation counting method",CHEMBL4840326,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5
CHEMBL4867565,CHEMBL237,Kappa opioid receptor,Ki,=,3270.0,nM,CHEMBL4844556,B,Binding affinity to human kappa opioid receptor,CHEMBL4842371,KI,O=S(=O)(c1cccc(F)c1)n1ccc2c(N3CCNCC3)nc3ccccc3c21
CHEMBL4513786,CHEMBL237,Kappa opioid receptor,Ki,=,2784.5,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL4507258,KI,CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC
CHEMBL4513786,CHEMBL237,Kappa opioid receptor,Ki,=,2818.38,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL4507258,KI,CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC
CHEMBL3907057,CHEMBL237,Kappa opioid receptor,Ki,=,124.61,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL4507270,KI,Cc1cc(C)c(-n2ccn3nc(-c4cccnc4)cc23)cc1NC(=O)c1cc(C#N)cc(S(F)(F)(F)(F)F)c1
CHEMBL3907057,CHEMBL237,Kappa opioid receptor,Ki,=,112.2,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL4507270,KI,Cc1cc(C)c(-n2ccn3nc(-c4cccnc4)cc23)cc1NC(=O)c1cc(C#N)cc(S(F)(F)(F)(F)F)c1
CHEMBL4526351,CHEMBL237,Kappa opioid receptor,Ki,=,10000.0,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL4507270,KI,Cc1cc(NC(=O)c2cccc(S(F)(F)(F)(F)F)c2)cc(-n2ccn3nc(-c4cccnc4)cc23)c1
CHEMBL4526351,CHEMBL237,Kappa opioid receptor,Ki,=,10000.0,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL4507270,KI,Cc1cc(NC(=O)c2cccc(S(F)(F)(F)(F)F)c2)cc(-n2ccn3nc(-c4cccnc4)cc23)c1
CHEMBL4520788,CHEMBL237,Kappa opioid receptor,Ki,=,841.37,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL4507273,KI,CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1
CHEMBL4520788,CHEMBL237,Kappa opioid receptor,Ki,=,822.24,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL4507273,KI,CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1
CHEMBL1971943,CHEMBL237,Kappa opioid receptor,Ki,=,187.33,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL4507274,KI,Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12
CHEMBL1971943,CHEMBL237,Kappa opioid receptor,Ki,=,186.21,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL4507274,KI,Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12
CHEMBL4546802,CHEMBL237,Kappa opioid receptor,Ki,=,390.57,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL4507274,KI,Cn1cc(Cl)c2c(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)ccnc21
CHEMBL4546802,CHEMBL237,Kappa opioid receptor,Ki,=,389.05,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL4507274,KI,Cn1cc(Cl)c2c(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)ccnc21
CHEMBL4558518,CHEMBL237,Kappa opioid receptor,Ki,=,3305.0,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL4507288,KI,CC(C)(C)OC(=O)N1CCCC1CNC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1
CHEMBL4558518,CHEMBL237,Kappa opioid receptor,Ki,=,3311.31,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL4507288,KI,CC(C)(C)OC(=O)N1CCCC1CNC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1
CHEMBL1800685,CHEMBL237,Kappa opioid receptor,Ki,=,3210.0,nM,CHEMBL4880826,B,"Inhibition of Opiate kappa (OP2, KOP) at 10 M in the Eurofins-Panlabs radioligand binding assay (Eurofins_assay_260210)",CHEMBL4507292,KI,O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1
CHEMBL3480577,CHEMBL237,Kappa opioid receptor,Ki,=,2307.75,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL4507309,KI,Cc1ccc2nc(CNCCCOc3ccccc3)cc(O)c2c1
CHEMBL3480577,CHEMBL237,Kappa opioid receptor,Ki,=,2187.76,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL4507309,KI,Cc1ccc2nc(CNCCCOc3ccccc3)cc(O)c2c1
CHEMBL4458424,CHEMBL237,Kappa opioid receptor,Ki,=,7634.84,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL4507317,KI,O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1
CHEMBL4458424,CHEMBL237,Kappa opioid receptor,Ki,=,7585.78,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL4507317,KI,O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1
CHEMBL4592872,CHEMBL237,Kappa opioid receptor,Ki,=,3134.73,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL4507317,KI,O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@H]1c1ccc(F)cc1
CHEMBL4592872,CHEMBL237,Kappa opioid receptor,Ki,=,3162.28,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL4507317,KI,O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@H]1c1ccc(F)cc1
CHEMBL4638406,CHEMBL237,Kappa opioid receptor,Ki,=,3005.38,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL4630906,KI,CCOc1cc(N2C3COCC2CN(C(=O)[C@H]2C[C@H](O)CN2c2ccc(Cl)cc2)C3)ccc1Cl
CHEMBL4638406,CHEMBL237,Kappa opioid receptor,Ki,=,3019.95,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL4630906,KI,CCOc1cc(N2C3COCC2CN(C(=O)[C@H]2C[C@H](O)CN2c2ccc(Cl)cc2)C3)ccc1Cl
CHEMBL1186579,CHEMBL237,Kappa opioid receptor,Ki,=,32.1,nM,CHEMBL5049534,B,Displacement of [3H]-U69593 from human recombinant kappa opioid receptor by radioligand binding assay,CHEMBL5046294,KI,C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
CHEMBL5083183,CHEMBL237,Kappa opioid receptor,Ki,=,44.0,nM,CHEMBL5055010,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in mouse HN9.10 cells assessed as inhibition constant by radioligand binding assay",CHEMBL5053542,KI,CCC(=O)N(c1ccc(Cl)c(Cl)c1)C1CCN(C(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc2ccc(O)cc2)CC1
CHEMBL5081245,CHEMBL237,Kappa opioid receptor,Ki,=,47.0,nM,CHEMBL5055010,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in mouse HN9.10 cells assessed as inhibition constant by radioligand binding assay",CHEMBL5053542,KI,CCC(=O)N(c1ccc(Cl)c(Cl)c1)C1CCN(C(=O)[C@H](Cc2ccc(Cl)cc2)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc2ccc(O)cc2)CC1
CHEMBL5091642,CHEMBL237,Kappa opioid receptor,Ki,=,20.0,nM,CHEMBL5055010,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in mouse HN9.10 cells assessed as inhibition constant by radioligand binding assay",CHEMBL5053542,KI,CCCC[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](Cc1ccc(F)cc1)C(=O)N1CCC(N(C(=O)CC)c2ccc(Cl)c(Cl)c2)CC1
CHEMBL5078669,CHEMBL237,Kappa opioid receptor,Ki,=,5.8,nM,CHEMBL5055010,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in mouse HN9.10 cells assessed as inhibition constant by radioligand binding assay",CHEMBL5053542,KI,CCC(=O)N(c1ccc(Cl)c(Cl)c1)C1CCN(C(=O)[C@H](Cc2ccc(Cl)cc2)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)Cc2c(C)cc(O)cc2C)CC1
CHEMBL5086370,CHEMBL237,Kappa opioid receptor,Ki,=,1.5,nM,CHEMBL5055010,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in mouse HN9.10 cells assessed as inhibition constant by radioligand binding assay",CHEMBL5053542,KI,CCCC[C@@H](NC(=O)[C@@H](N)Cc1c(C)cc(O)cc1C)C(=O)NCC(=O)N[C@@H](Cc1ccc(F)cc1)C(=O)N1CCC(N(C(=O)CC)c2ccc(Cl)c(Cl)c2)CC1
CHEMBL5094499,CHEMBL237,Kappa opioid receptor,Ki,=,0.53,nM,CHEMBL5055010,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in mouse HN9.10 cells assessed as inhibition constant by radioligand binding assay",CHEMBL5053542,KI,CCC(=O)N(c1ccc(Cl)c(Cl)c1)C1CCN(C(=O)[C@H](Cc2ccc(Cl)cc2)NC(=O)CNC(=O)[C@H]2Cc3ccccc3CN2C(=O)[C@@H](N)Cc2cc(C)c(O)c(C)c2)CC1
CHEMBL5089012,CHEMBL237,Kappa opioid receptor,Ki,=,0.13,nM,CHEMBL5055010,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in mouse HN9.10 cells assessed as inhibition constant by radioligand binding assay",CHEMBL5053542,KI,CCC(=O)N(c1ccc(Cl)c(Cl)c1)C1CCN(C(=O)[C@H](Cc2ccc(F)cc2)NC(=O)CNC(=O)[C@H]2Cc3ccccc3CN2C(=O)[C@@H](N)Cc2cc(C)c(O)c(C)c2)CC1
CHEMBL5077561,CHEMBL237,Kappa opioid receptor,Ki,=,34.0,nM,CHEMBL5055010,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in mouse HN9.10 cells assessed as inhibition constant by radioligand binding assay",CHEMBL5053542,KI,CCC(=O)N(c1ccc(Cl)c(Cl)c1)C1CCN(C(=O)[C@H](Cc2ccc(Cl)cc2)NC(=O)[C@H]2Cc3ccccc3CN2C(=O)[C@@H](N)Cc2cc(C)c(O)c(C)c2)CC1
CHEMBL5090705,CHEMBL237,Kappa opioid receptor,Ki,=,28.0,nM,CHEMBL5055010,B,"Displacement of [3H]U69,593 from human kappa opioid receptor expressed in mouse HN9.10 cells assessed as inhibition constant by radioligand binding assay",CHEMBL5053542,KI,CCC(=O)N(c1ccc(Cl)c(Cl)c1)C1CCN(C(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H]2Cc3ccccc3CN2C(=O)[C@@H](N)Cc2cc(C)c(O)c(C)c2)CC1
CHEMBL5086847,CHEMBL237,Kappa opioid receptor,Ki,=,3.3,nM,CHEMBL5055736,B,Displacement of [3H]-Diprenorphine from kappa opiod receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,C=CCOc1cccc(C[C@H](NC(=O)[C@H](Cc2ccccc2)NC(C)=O)C(=O)N[C@@H](Cc2cccc(OCC=C)c2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)c1
CHEMBL5070938,CHEMBL237,Kappa opioid receptor,Ki,=,62.2,nM,CHEMBL5055736,B,Displacement of [3H]-Diprenorphine from kappa opiod receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,C=CCOc1ccc(C[C@H](NC(C)=O)C(=O)N[C@@H](Cc2cccc(OCC=C)c2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)cc1
CHEMBL5076040,CHEMBL237,Kappa opioid receptor,Ki,=,12.1,nM,CHEMBL5055736,B,Displacement of [3H]-Diprenorphine from kappa opiod receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,C=CCOc1ccc(C[C@H](NC(C)=O)C(=O)N[C@@H](Cc2ccc(OCC=C)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)cc1
CHEMBL5092332,CHEMBL237,Kappa opioid receptor,Ki,=,65.8,nM,CHEMBL5055736,B,Displacement of [3H]-Diprenorphine from kappa opiod receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,C=CCOc1cccc(C[C@H](NC(C)=O)C(=O)N[C@@H](Cc2cccc(OCC=C)c2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)c1
CHEMBL5094885,CHEMBL237,Kappa opioid receptor,Ki,=,43.2,nM,CHEMBL5055736,B,Displacement of [3H]-Diprenorphine from kappa opiod receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,C=CCOc1ccc(C[C@H](NC(=O)[C@H](Cc2cccc(OCC=C)c2)NC(C)=O)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)cc1
CHEMBL5089230,CHEMBL237,Kappa opioid receptor,Ki,=,18.9,nM,CHEMBL5055736,B,Displacement of [3H]-Diprenorphine from kappa opiod receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,C=CCOc1ccc(C[C@H](NC(=O)[C@H](Cc2ccccc2)NC(C)=O)C(=O)N[C@@H](Cc2ccc(OCC=C)cc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)cc1
CHEMBL4290635,CHEMBL237,Kappa opioid receptor,Ki,=,10.0,nM,CHEMBL5055736,B,Displacement of [3H]-Diprenorphine from kappa opiod receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL5075588,CHEMBL237,Kappa opioid receptor,Ki,=,29.2,nM,CHEMBL5055736,B,Displacement of [3H]-Diprenorphine from kappa opiod receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,CC(=O)N[C@H]1Cc2cccc(c2)OC/C=C/COc2ccc(cc2)C[C@@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)NC1=O
CHEMBL5074966,CHEMBL237,Kappa opioid receptor,Ki,=,11.7,nM,CHEMBL5055736,B,Displacement of [3H]-Diprenorphine from kappa opiod receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,CC(=O)N[C@H]1Cc2ccc(cc2)OC/C=C/COc2ccc(cc2)C[C@@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)NC1=O
CHEMBL5080421,CHEMBL237,Kappa opioid receptor,Ki,=,41.2,nM,CHEMBL5055736,B,Displacement of [3H]-Diprenorphine from kappa opiod receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,C=CCOc1ccc(C[C@H](NC(=O)[C@H](Cc2cccc(OCC=C)c2)NC(=O)[C@H](Cc2ccccc2)NC(C)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)cc1
CHEMBL5086931,CHEMBL237,Kappa opioid receptor,Ki,=,11.7,nM,CHEMBL5055736,B,Displacement of [3H]-Diprenorphine from kappa opiod receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,C=CCOc1ccc(C[C@H](NC(=O)[C@H](Cc2ccccc2)NC(C)=O)C(=O)N[C@@H](Cc2cccc(OCC=C)c2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)cc1
CHEMBL5069790,CHEMBL237,Kappa opioid receptor,Ki,=,15.4,nM,CHEMBL5055736,B,Displacement of [3H]-Diprenorphine from kappa opiod receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H]1Cc2cccc(c2)OC/C=C\COc2cccc(c2)C[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)NC1=O
CHEMBL5090249,CHEMBL237,Kappa opioid receptor,Ki,=,39.2,nM,CHEMBL5055736,B,Displacement of [3H]-Diprenorphine from kappa opiod receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H]1Cc2cccc(c2)OC/C=C/COc2ccc(cc2)C[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)NC1=O
CHEMBL5076268,CHEMBL237,Kappa opioid receptor,Ki,=,19.8,nM,CHEMBL5055736,B,Displacement of [3H]-Diprenorphine from kappa opiod receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H]1Cc2ccc(cc2)OC/C=C/COc2cccc(c2)C[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)NC1=O
CHEMBL5086984,CHEMBL237,Kappa opioid receptor,Ki,=,14.7,nM,CHEMBL5055736,B,Displacement of [3H]-Diprenorphine from kappa opiod receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H]1Cc2ccc(cc2)OC/C=C/COc2ccc(cc2)C[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)NC1=O
CHEMBL5077286,CHEMBL237,Kappa opioid receptor,Ki,=,68.2,nM,CHEMBL5055736,B,Displacement of [3H]-Diprenorphine from kappa opiod receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,CC(=O)N[C@H]1Cc2cccc(c2)OC/C=C/COc2cccc(c2)C[C@@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)NC1=O
CHEMBL5072730,CHEMBL237,Kappa opioid receptor,Ki,=,56.7,nM,CHEMBL5055736,B,Displacement of [3H]-Diprenorphine from kappa opiod receptor (unknown origin) expressed in CHO cells incubated for 90 mins in presence of peptidase inhibitors,CHEMBL5055617,KI,CC(=O)N[C@H]1Cc2ccc(cc2)OC/C=C/COc2cccc(c2)C[C@@H](C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCN)C(N)=O)NC1=O
CHEMBL4558518,CHEMBL237,Kappa opioid receptor,Ki,=,3305.0,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL4507288,KI,CC(C)(C)OC(=O)N1CCCC1CNC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1
CHEMBL4558518,CHEMBL237,Kappa opioid receptor,Ki,=,3311.31,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL4507288,KI,CC(C)(C)OC(=O)N1CCCC1CNC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1
CHEMBL5201355,CHEMBL237,Kappa opioid receptor,Ki,=,3576.0,nM,CHEMBL5116798,B,Binding affinity to KOR (unknown origin) assessed as inhibition constant by radioligand binding assay,CHEMBL5113446,KI,CN(CCCNC(=O)c1ccc2ccccc2n1)Cc1ccccc1
CHEMBL5169420,CHEMBL237,Kappa opioid receptor,Ki,=,2390.0,nM,CHEMBL5116798,B,Binding affinity to KOR (unknown origin) assessed as inhibition constant by radioligand binding assay,CHEMBL5113446,KI,CN(CCCNC(=O)c1cc2ccccc2o1)Cc1ccccc1
CHEMBL5201238,CHEMBL237,Kappa opioid receptor,Ki,=,4172.0,nM,CHEMBL5116798,B,Binding affinity to KOR (unknown origin) assessed as inhibition constant by radioligand binding assay,CHEMBL5113446,KI,COc1ccc(CN(C)CCCNC(=O)c2ccco2)cc1OC
CHEMBL441765,CHEMBL237,Kappa opioid receptor,Ki,=,1.1,nM,CHEMBL5116798,B,Binding affinity to KOR (unknown origin) assessed as inhibition constant by radioligand binding assay,CHEMBL5113446,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL5176887,CHEMBL237,Kappa opioid receptor,Ki,=,8620.0,nM,CHEMBL5127512,B,Displacement of [3H]U69593 from KOP (unknown origin) stably expressed in HEK293 cells by liquid scintillation counter analysis,CHEMBL5126521,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](C)N(C)C(=O)[C@@H](N)Cc1c(C)cc(O)cc1C)c1ccccc1
CHEMBL5175179,CHEMBL237,Kappa opioid receptor,Ki,=,6700.0,nM,CHEMBL5127512,B,Displacement of [3H]U69593 from KOP (unknown origin) stably expressed in HEK293 cells by liquid scintillation counter analysis,CHEMBL5126521,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](C)N(C)C(=O)[C@@H](N)Cc1c(C)cc(O)cc1C)c1ccco1
CHEMBL5182849,CHEMBL237,Kappa opioid receptor,Ki,=,8310.0,nM,CHEMBL5127512,B,Displacement of [3H]U69593 from KOP (unknown origin) stably expressed in HEK293 cells by liquid scintillation counter analysis,CHEMBL5126521,KI,C=C(C(N)=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](C)N(C)C(=O)[C@@H](N)Cc1c(C)cc(O)cc1C)c1ccco1
CHEMBL5197271,CHEMBL237,Kappa opioid receptor,Ki,=,283.0,nM,CHEMBL5127520,B,Displacement of [3H]U69593 from human KOP expressed in CHO-K1 cell membrane incubated for 60 mins by Microscint-counting analysis,CHEMBL5126521,KI,NC(=O)[C@@H]1CCC(=O)NCCCC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1
CHEMBL5171745,CHEMBL237,Kappa opioid receptor,Ki,=,51.0,nM,CHEMBL5127520,B,Displacement of [3H]U69593 from human KOP expressed in CHO-K1 cell membrane incubated for 60 mins by Microscint-counting analysis,CHEMBL5126521,KI,NC(=O)[C@@H]1CC(=O)NCCCC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1
CHEMBL5198915,CHEMBL237,Kappa opioid receptor,Ki,=,5119.0,nM,CHEMBL5127520,B,Displacement of [3H]U69593 from human KOP expressed in CHO-K1 cell membrane incubated for 60 mins by Microscint-counting analysis,CHEMBL5126521,KI,NC(=O)CNC(=O)[C@@H]1CCC(=O)NCCCC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1
CHEMBL5196331,CHEMBL237,Kappa opioid receptor,Ki,=,242.0,nM,CHEMBL5127520,B,Displacement of [3H]U69593 from human KOP expressed in CHO-K1 cell membrane incubated for 60 mins by Microscint-counting analysis,CHEMBL5126521,KI,NC(=O)[C@@H]1CCCCNC(=O)CC[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1
CHEMBL5186493,CHEMBL237,Kappa opioid receptor,Ki,=,248.0,nM,CHEMBL5127527,B,Binding affinity to KOP (unknown origin),CHEMBL5126521,KI,N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]1CCCCNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC1=O
CHEMBL333357,CHEMBL237,Kappa opioid receptor,Ki,=,5240.0,nM,CHEMBL5127527,B,Binding affinity to KOP (unknown origin),CHEMBL5126521,KI,NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccc(O)cc1
CHEMBL278789,CHEMBL237,Kappa opioid receptor,Ki,=,8162.0,nM,CHEMBL5127527,B,Binding affinity to KOP (unknown origin),CHEMBL5126521,KI,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O
CHEMBL60444,CHEMBL237,Kappa opioid receptor,Ki,=,4230.0,nM,CHEMBL5127527,B,Binding affinity to KOP (unknown origin),CHEMBL5126521,KI,NCCCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCN=C(N)N)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(N)=O
CHEMBL299031,CHEMBL237,Kappa opioid receptor,Ki,=,772.0,nM,CHEMBL5127527,B,Binding affinity to KOP (unknown origin),CHEMBL5126521,KI,CC[C@@H]1CN2CCc3c([nH]c4cccc(OC)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL5178409,CHEMBL237,Kappa opioid receptor,Ki,=,188.0,nM,CHEMBL5127527,B,Binding affinity to KOP (unknown origin),CHEMBL5126521,KI,CC[C@@H]1CN2CC[C@]3(O)c4c(cccc4OC)NC3[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL4848517,CHEMBL237,Kappa opioid receptor,Ki,=,2560.0,nM,CHEMBL5127527,B,Binding affinity to KOP (unknown origin),CHEMBL5126521,KI,C=C[C@H]1CN2CCc3c([nH]c4cccc(OC)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL4859858,CHEMBL237,Kappa opioid receptor,Ki,=,3200.0,nM,CHEMBL5127527,B,Binding affinity to KOP (unknown origin),CHEMBL5126521,KI,CC[C@H]1CN2CCc3c([nH]c4cccc(OC)c34)[C@@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL4546925,CHEMBL237,Kappa opioid receptor,Ki,=,329.0,nM,CHEMBL5127527,B,Binding affinity to KOP (unknown origin),CHEMBL5126521,KI,CC[C@@H]1CN2CCc3c([nH]c4cccc(OC)c34)[C@H]2C[C@@H]1/C(=C\OC)C(=O)OC
CHEMBL2181202,CHEMBL237,Kappa opioid receptor,Ki,=,2407.0,nM,CHEMBL5127592,B,Binding affinity to KOP (unknown origin) by two-site binding model,CHEMBL5126521,KI,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL5182362,CHEMBL237,Kappa opioid receptor,Ki,=,8.0,nM,CHEMBL5127606,B,Displacement of [3H]diprenorphine from KOP (unknown origin) stably expressed in CHO cell membrane incubated for 90 mins by scintillation counter analysis,CHEMBL5126521,KI,C[C@@H]1NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]2CCCN2C1=O
CHEMBL5177485,CHEMBL237,Kappa opioid receptor,Ki,=,113.0,nM,CHEMBL5127606,B,Displacement of [3H]diprenorphine from KOP (unknown origin) stably expressed in CHO cell membrane incubated for 90 mins by scintillation counter analysis,CHEMBL5126521,KI,C[C@@H]1C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1C
CHEMBL5206240,CHEMBL237,Kappa opioid receptor,Ki,=,663.0,nM,CHEMBL5127606,B,Displacement of [3H]diprenorphine from KOP (unknown origin) stably expressed in CHO cell membrane incubated for 90 mins by scintillation counter analysis,CHEMBL5126521,KI,C[C@@H]1NC(=O)[C@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC1=O
CHEMBL5186131,CHEMBL237,Kappa opioid receptor,Ki,=,1550.0,nM,CHEMBL5127606,B,Displacement of [3H]diprenorphine from KOP (unknown origin) stably expressed in CHO cell membrane incubated for 90 mins by scintillation counter analysis,CHEMBL5126521,KI,C[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC1=O
CHEMBL5186247,CHEMBL237,Kappa opioid receptor,Ki,=,5120.0,nM,CHEMBL5127606,B,Displacement of [3H]diprenorphine from KOP (unknown origin) stably expressed in CHO cell membrane incubated for 90 mins by scintillation counter analysis,CHEMBL5126521,KI,O=C1N[C@H](Cc2ccccc2)C(=O)N2CCC[C@@H]2C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H]1Cc1c[nH]c2ccccc12
CHEMBL5189722,CHEMBL237,Kappa opioid receptor,Ki,=,362.0,nM,CHEMBL5127606,B,Displacement of [3H]diprenorphine from KOP (unknown origin) stably expressed in CHO cell membrane incubated for 90 mins by scintillation counter analysis,CHEMBL5126521,KI,O=C1N[C@@H](Cc2ccccc2)C(=O)N2CCC[C@@H]2C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H]1Cc1c[nH]c2ccccc12
CHEMBL5170333,CHEMBL237,Kappa opioid receptor,Ki,=,2560.0,nM,CHEMBL5127606,B,Displacement of [3H]diprenorphine from KOP (unknown origin) stably expressed in CHO cell membrane incubated for 90 mins by scintillation counter analysis,CHEMBL5126521,KI,O=C1N[C@H](Cc2ccccc2)C(=O)N2CCC[C@@H]2C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H]1Cc1c[nH]c2ccccc12
CHEMBL5208209,CHEMBL237,Kappa opioid receptor,Ki,=,353.0,nM,CHEMBL5127606,B,Displacement of [3H]diprenorphine from KOP (unknown origin) stably expressed in CHO cell membrane incubated for 90 mins by scintillation counter analysis,CHEMBL5126521,KI,O=C1N[C@H](Cc2ccccc2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](Cc2ccccc2)C(=O)N2CCC[C@H]12
CHEMBL2381583,CHEMBL237,Kappa opioid receptor,Ki,=,0.59,nM,CHEMBL5127628,B,Displacement of [3H]U69593 from human KOP stably expressed in CHO cells by competitive binding assay,CHEMBL5126521,KI,COC(=O)[C@@H]1C[C@H](OC(=O)CSC#N)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL267495,CHEMBL237,Kappa opioid receptor,Ki,=,0.019,nM,CHEMBL5133575,B,Displacement of [3H]DPDPE from human KOR expressed in HEK293 cell membrane,CHEMBL5131431,KI,CN(C(=O)/C=C/c1ccoc1)[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL5185211,CHEMBL237,Kappa opioid receptor,Ki,=,0.0272,nM,CHEMBL5133575,B,Displacement of [3H]DPDPE from human KOR expressed in HEK293 cell membrane,CHEMBL5131431,KI,CN(C(=O)/C=C/c1ccoc1)[C@@H]1CCC2[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL5188658,CHEMBL237,Kappa opioid receptor,Ki,=,0.0356,nM,CHEMBL5133575,B,Displacement of [3H]DPDPE from human KOR expressed in HEK293 cell membrane,CHEMBL5131431,KI,CN(C(=O)/C=C/c1ccoc1)[C@@H]1CC=C2[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL5181937,CHEMBL237,Kappa opioid receptor,Ki,=,283.0,nM,CHEMBL5133575,B,Displacement of [3H]DPDPE from human KOR expressed in HEK293 cell membrane,CHEMBL5131431,KI,CN(C(=O)/C=C/c1ccoc1)[C@@H]1CCC2[C@H]3Cc4ccc(O)c5c4[C@@]2(CN3CC2CC2)[C@H]1O5
CHEMBL5186673,CHEMBL237,Kappa opioid receptor,Ki,=,1410.0,nM,CHEMBL5133575,B,Displacement of [3H]DPDPE from human KOR expressed in HEK293 cell membrane,CHEMBL5131431,KI,CN(C(=O)/C=C/c1ccoc1)[C@@H]1CC=C2[C@H]3Cc4ccc(O)c5c4[C@@]2(CN3CC2CC2)[C@H]1O5
CHEMBL5177908,CHEMBL237,Kappa opioid receptor,Ki,=,4.9,nM,CHEMBL5141730,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5137076,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@]4(C)CO)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL5200910,CHEMBL237,Kappa opioid receptor,Ki,=,264.8,nM,CHEMBL5141730,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5137076,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@]4(C)C=O)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL5178795,CHEMBL237,Kappa opioid receptor,Ki,=,3.3,nM,CHEMBL5141730,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5137076,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@]4(C)[C@H](O)c4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL5188701,CHEMBL237,Kappa opioid receptor,Ki,=,13.1,nM,CHEMBL5141730,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5137076,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@]4(C)[C@H](O)c4ccc(C)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL5171735,CHEMBL237,Kappa opioid receptor,Ki,=,6.1,nM,CHEMBL5141730,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5137076,KI,COc1ccc([C@@H](O)[C@]2(C)C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(OC)ccc6c5[C@@]23CCN(CC2CC2)[C@@H]4C6)cc1
CHEMBL5190163,CHEMBL237,Kappa opioid receptor,Ki,=,16.8,nM,CHEMBL5141730,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5137076,KI,COc1cccc([C@@H](O)[C@]2(C)C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(OC)ccc6c5[C@@]23CCN(CC2CC2)[C@@H]4C6)c1
CHEMBL5205530,CHEMBL237,Kappa opioid receptor,Ki,=,0.051,nM,CHEMBL5141730,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5137076,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@]4(C)[C@H](O)c4ccc(C(F)(F)F)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL5179816,CHEMBL237,Kappa opioid receptor,Ki,=,175.3,nM,CHEMBL5141730,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5137076,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@]4(C)[C@H](O)c4ccc(C(C)C)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL5189127,CHEMBL237,Kappa opioid receptor,Ki,=,2408.0,nM,CHEMBL5141730,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5137076,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@]4(C)[C@H](O)c4ccc(Cl)c(Cl)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL5180450,CHEMBL237,Kappa opioid receptor,Ki,=,40.4,nM,CHEMBL5141730,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5137076,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@]4(C)C(=O)c4ccccc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL5199796,CHEMBL237,Kappa opioid receptor,Ki,=,83.0,nM,CHEMBL5141730,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5137076,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@]4(C)C(=O)c4ccc(C)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL5198378,CHEMBL237,Kappa opioid receptor,Ki,=,146.7,nM,CHEMBL5141730,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5137076,KI,COc1ccc(C(=O)[C@]2(C)C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(OC)ccc6c5[C@@]23CCN(CC2CC2)[C@@H]4C6)cc1
CHEMBL5206165,CHEMBL237,Kappa opioid receptor,Ki,=,125.0,nM,CHEMBL5141730,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5137076,KI,COc1cccc(C(=O)[C@]2(C)C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(OC)ccc6c5[C@@]23CCN(CC2CC2)[C@@H]4C6)c1
CHEMBL5202222,CHEMBL237,Kappa opioid receptor,Ki,=,350.0,nM,CHEMBL5141730,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5137076,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@]4(C)C(=O)c4ccc(C(F)(F)F)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL5207736,CHEMBL237,Kappa opioid receptor,Ki,=,32.9,nM,CHEMBL5141730,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5137076,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@]4(C)C(=O)c4ccc(C(C)C)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL5173533,CHEMBL237,Kappa opioid receptor,Ki,=,79.8,nM,CHEMBL5141730,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5137076,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@]4(C)C(=O)c4cc(C)cc(C)c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL5170846,CHEMBL237,Kappa opioid receptor,Ki,=,86.2,nM,CHEMBL5141730,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5137076,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@]4(C)C(=O)c4ccc6ccccc6c4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL5173537,CHEMBL237,Kappa opioid receptor,Ki,=,463.1,nM,CHEMBL5141730,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5137076,KI,COc1ccc2c3c1O[C@H]1[C@@]4(OC)CC[C@@]5(C[C@@]4(C)C(=O)c4ccc(-c6ccccc6)cc4)[C@@H](C2)N(CC2CC2)CC[C@]315
CHEMBL485583,CHEMBL237,Kappa opioid receptor,Ki,=,0.13,nM,CHEMBL5144872,B,Displacement of [3H]-U-69593 from recombinant human KOR expressed in CHO cell membranes measured after 2 hrs by microbeta scintillation counting method,CHEMBL5143548,KI,CN(C(=O)/C=C/c1ccoc1)[C@@H]1CC[C@@]2(O)[C@H]3Cc4cccc5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL5186730,CHEMBL237,Kappa opioid receptor,Ki,=,0.14,nM,CHEMBL5144872,B,Displacement of [3H]-U-69593 from recombinant human KOR expressed in CHO cell membranes measured after 2 hrs by microbeta scintillation counting method,CHEMBL5143548,KI,O=C(N[C@@H]1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@]32CC[C@@H]1O2)c1ccccc1
CHEMBL5178511,CHEMBL237,Kappa opioid receptor,Ki,=,0.193,nM,CHEMBL5144872,B,Displacement of [3H]-U-69593 from recombinant human KOR expressed in CHO cell membranes measured after 2 hrs by microbeta scintillation counting method,CHEMBL5143548,KI,O=C(Cc1ccccc1)N[C@@H]1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@]32CC[C@@H]1O2
CHEMBL5200218,CHEMBL237,Kappa opioid receptor,Ki,=,0.197,nM,CHEMBL5144872,B,Displacement of [3H]-U-69593 from recombinant human KOR expressed in CHO cell membranes measured after 2 hrs by microbeta scintillation counting method,CHEMBL5143548,KI,O=C(CCc1ccccc1)N[C@@H]1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@]32CC[C@@H]1O2
CHEMBL5208385,CHEMBL237,Kappa opioid receptor,Ki,=,10.6,nM,CHEMBL5144872,B,Displacement of [3H]-U-69593 from recombinant human KOR expressed in CHO cell membranes measured after 2 hrs by microbeta scintillation counting method,CHEMBL5143548,KI,O=C(N[C@H]1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@]32CC[C@@H]1O2)c1ccccc1
CHEMBL5175717,CHEMBL237,Kappa opioid receptor,Ki,=,1.71,nM,CHEMBL5144872,B,Displacement of [3H]-U-69593 from recombinant human KOR expressed in CHO cell membranes measured after 2 hrs by microbeta scintillation counting method,CHEMBL5143548,KI,O=C(Cc1ccccc1)N[C@H]1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@]32CC[C@@H]1O2
CHEMBL5170301,CHEMBL237,Kappa opioid receptor,Ki,=,2.36,nM,CHEMBL5144872,B,Displacement of [3H]-U-69593 from recombinant human KOR expressed in CHO cell membranes measured after 2 hrs by microbeta scintillation counting method,CHEMBL5143548,KI,O=C(CCc1ccccc1)N[C@H]1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@]32CC[C@@H]1O2
CHEMBL5200050,CHEMBL237,Kappa opioid receptor,Ki,=,0.256,nM,CHEMBL5144872,B,Displacement of [3H]-U-69593 from recombinant human KOR expressed in CHO cell membranes measured after 2 hrs by microbeta scintillation counting method,CHEMBL5143548,KI,CN(C(=O)c1ccccc1)[C@@H]1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@]32CC[C@@H]1O2
CHEMBL5185996,CHEMBL237,Kappa opioid receptor,Ki,=,0.278,nM,CHEMBL5144872,B,Displacement of [3H]-U-69593 from recombinant human KOR expressed in CHO cell membranes measured after 2 hrs by microbeta scintillation counting method,CHEMBL5143548,KI,CN(C(=O)Cc1ccccc1)[C@@H]1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@]32CC[C@@H]1O2
CHEMBL5200992,CHEMBL237,Kappa opioid receptor,Ki,=,0.332,nM,CHEMBL5144872,B,Displacement of [3H]-U-69593 from recombinant human KOR expressed in CHO cell membranes measured after 2 hrs by microbeta scintillation counting method,CHEMBL5143548,KI,CN(C(=O)CCc1ccccc1)[C@@H]1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@]32CC[C@@H]1O2
CHEMBL5169644,CHEMBL237,Kappa opioid receptor,Ki,=,210.0,nM,CHEMBL5158767,B,Binding affinity towards human kappa opioid receptor,CHEMBL5154735,KI,CCOC(=O)[C@]12C[C@@H]1[C@@H](n1ccc3c(NCCc4ccccc4)nc(C#Cc4ccccc4)nc31)[C@H](O)[C@@H]2O
CHEMBL4796803,CHEMBL237,Kappa opioid receptor,Ki,=,2785.0,nM,CHEMBL5214333,B,Selectivity interaction (GPCR panel (PDSP screen)) EUB0000289bCl OPRK1,CHEMBL5212743,KI,CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC.Cl
CHEMBL4520788,CHEMBL237,Kappa opioid receptor,Ki,=,841.37,nM,CHEMBL5213960,B,Selectivity interaction (GPCR panel (PDSP screen)) EUB0000743a OPRK1,CHEMBL5212743,KI,CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1
CHEMBL4592872,CHEMBL237,Kappa opioid receptor,Ki,=,3135.0,nM,CHEMBL5214360,B,Selectivity interaction (GPCR panel (PDSP screen)) EUB0000340a OPRK1,CHEMBL5212743,KI,O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@H]1c1ccc(F)cc1
CHEMBL4458424,CHEMBL237,Kappa opioid receptor,Ki,=,7634.84,nM,CHEMBL5214243,B,"Selectivity interaction (GPCR panel (Eurofins, Bayer)) EUB0000240b OPRK1",CHEMBL5212743,KI,O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1
CHEMBL4558518,CHEMBL237,Kappa opioid receptor,Ki,=,3305.0,nM,CHEMBL5213929,B,Selectivity interaction (GPCR panel (PDSP screen)) EUB0000741a OPRK1,CHEMBL5212743,KI,CC(C)(C)OC(=O)N1CCCC1CNC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1
CHEMBL4789678,CHEMBL237,Kappa opioid receptor,Ki,=,3800.0,nM,CHEMBL5214693,B,"Selectivity interaction (Enzyme panel (ion channels, GPCRs, other targets)) EUB0000196bCl OPRK1",CHEMBL5212743,KI,Cl.O=C([C@@H](Cc1cccc(C(F)(F)F)c1)NS(=O)(=O)c1cc(F)c2c(c1)CCNC2)N1CCCC1
CHEMBL4546802,CHEMBL237,Kappa opioid receptor,Ki,=,391.0,nM,CHEMBL5213407,B,Selectivity interaction (GPCR panel (PDSP screen)) EUB0000709a OPRK1,CHEMBL5212743,KI,Cn1cc(Cl)c2c(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)ccnc21
CHEMBL1971943,CHEMBL237,Kappa opioid receptor,Ki,=,187.33,nM,CHEMBL5213491,B,Selectivity interaction (GPCR panel (PDSP screen)) EUB0000716a OPRK1,CHEMBL5212743,KI,Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12
CHEMBL3907057,CHEMBL237,Kappa opioid receptor,Ki,=,124.61,nM,CHEMBL5213452,B,Selectivity interaction (GPCR panel (PDSP screen)) EUB0000713a OPRK1,CHEMBL5212743,KI,Cc1cc(C)c(-n2ccn3nc(-c4cccnc4)cc23)cc1NC(=O)c1cc(C#N)cc(S(F)(F)(F)(F)F)c1
CHEMBL4576555,CHEMBL237,Kappa opioid receptor,Ki,=,990.0,nM,CHEMBL5213385,B,Selectivity interaction (GPCR panel (PDSP screen)) EUB0000705a OPRK1,CHEMBL5212743,KI,CN1CCN(C(=O)C(C)(C)c2ccc(C(=O)Nc3cn4cc(-c5cc(C(C)(C)C)cc(C(C)(C)C)c5)ccc4n3)cc2)CC1
CHEMBL5277326,CHEMBL237,Kappa opioid receptor,Ki,=,7.9,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,CN(C)CC1CN(CCc2cccc(C(F)(F)F)c2)CCC1(O)c1cccc(O)c1
CHEMBL5277743,CHEMBL237,Kappa opioid receptor,Ki,=,673.1,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,COc1cccc(C2(O)CCN(CCc3cccc(C(F)(F)F)c3)CC2CN(C)C)c1
CHEMBL5274208,CHEMBL237,Kappa opioid receptor,Ki,=,169.1,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,CN(C)CC1CN(C(=O)Cc2ccccc2)CCC1(O)c1cccc(O)c1
CHEMBL5270488,CHEMBL237,Kappa opioid receptor,Ki,=,1277.0,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,CN(C)CC1CN(C(=O)Cc2ccccc2)CCC1(O)c1ccccc1
CHEMBL5272744,CHEMBL237,Kappa opioid receptor,Ki,=,241.8,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,CN(C)CC1CN(C(=O)Cc2ccccc2F)CCC1(O)c1cccc(O)c1
CHEMBL5281561,CHEMBL237,Kappa opioid receptor,Ki,=,169.3,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,CN(C)CC1CN(C(=O)Cc2cccc(F)c2)CCC1(O)c1cccc(O)c1
CHEMBL5272486,CHEMBL237,Kappa opioid receptor,Ki,=,41.9,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,CN(C)CC1CN(C(=O)Cc2ccc(F)cc2)CCC1(O)c1cccc(O)c1
CHEMBL5277164,CHEMBL237,Kappa opioid receptor,Ki,=,675.4,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,CN(C)CC1CN(C(=O)Cc2ccccc2OC(F)(F)F)CCC1(O)c1cccc(O)c1
CHEMBL5272171,CHEMBL237,Kappa opioid receptor,Ki,=,94.2,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,CN(C)CC1CN(C(=O)Cc2cccc(OC(F)(F)F)c2)CCC1(O)c1cccc(O)c1
CHEMBL5269558,CHEMBL237,Kappa opioid receptor,Ki,=,93.6,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,CN(C)CC1CN(C(=O)Cc2ccc(OC(F)(F)F)cc2)CCC1(O)c1cccc(O)c1
CHEMBL5281864,CHEMBL237,Kappa opioid receptor,Ki,=,227.4,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,Cc1ccccc1CC(=O)N1CCC(O)(c2cccc(O)c2)C(CN(C)C)C1
CHEMBL5274664,CHEMBL237,Kappa opioid receptor,Ki,=,74.4,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,Cc1cccc(CC(=O)N2CCC(O)(c3cccc(O)c3)C(CN(C)C)C2)c1
CHEMBL5275873,CHEMBL237,Kappa opioid receptor,Ki,=,61.2,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,Cc1ccc(CC(=O)N2CCC(O)(c3cccc(O)c3)C(CN(C)C)C2)cc1
CHEMBL5282901,CHEMBL237,Kappa opioid receptor,Ki,=,277.1,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,CN(C)CC1CN(C(=O)Cc2ccccc2Cl)CCC1(O)c1cccc(O)c1
CHEMBL5270915,CHEMBL237,Kappa opioid receptor,Ki,=,19.7,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,CN(C)CC1CN(C(=O)Cc2cccc(Cl)c2)CCC1(O)c1cccc(O)c1
CHEMBL5272258,CHEMBL237,Kappa opioid receptor,Ki,=,43.1,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,CN(C)CC1CN(C(=O)Cc2ccc(Cl)cc2)CCC1(O)c1cccc(O)c1
CHEMBL5274117,CHEMBL237,Kappa opioid receptor,Ki,=,648.9,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,CN(C)CC1CN(C(=O)CCc2ccccc2)CCC1(O)c1cccc(O)c1
CHEMBL5281054,CHEMBL237,Kappa opioid receptor,Ki,=,163.9,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,CN(C)CC1CN(C(=O)CCc2ccccc2C(F)(F)F)CCC1(O)c1cccc(O)c1
CHEMBL5287792,CHEMBL237,Kappa opioid receptor,Ki,=,104.9,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,CN(C)CC1CN(C(=O)CCc2cccc(C(F)(F)F)c2)CCC1(O)c1cccc(O)c1
CHEMBL440765,CHEMBL237,Kappa opioid receptor,Ki,=,0.9,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL5288358,CHEMBL237,Kappa opioid receptor,Ki,=,205.0,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,COc1cccc(C2(O)CCN(C(=O)C3(c4ccccc4)CCC3)CC2CN(C)C)c1
CHEMBL5281114,CHEMBL237,Kappa opioid receptor,Ki,=,1009.0,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,COc1cccc(C2(O)CCN(C(=O)Cc3cccc(Cl)c3)CC2CN(C)C)c1
CHEMBL5275209,CHEMBL237,Kappa opioid receptor,Ki,=,287.6,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,COc1cccc(C2(O)CCN(C(=O)Cc3ccc(Cl)c(Cl)c3)CC2CN(C)C)c1
CHEMBL5278225,CHEMBL237,Kappa opioid receptor,Ki,=,2357.0,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,COc1cccc(C2(O)CCN(C(=O)Cc3cccc(F)c3)CC2CN(C)C)c1
CHEMBL5268603,CHEMBL237,Kappa opioid receptor,Ki,=,3031.0,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,COc1cccc(C2(O)CCN(C(=O)Cc3cccc(C(F)(F)F)c3)CC2CN(C)C)c1
CHEMBL5290025,CHEMBL237,Kappa opioid receptor,Ki,=,4424.0,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,COc1cccc(C2(O)CCN(C(=O)Cc3cc(C(F)(F)F)cc(C(F)(F)F)c3)CC2CN(C)C)c1
CHEMBL5283662,CHEMBL237,Kappa opioid receptor,Ki,=,1987.0,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,COc1cccc(C2(O)CCN(C(=O)Cc3cccc([N+](=O)[O-])c3)CC2CN(C)C)c1
CHEMBL5287093,CHEMBL237,Kappa opioid receptor,Ki,=,2651.0,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,COc1cccc(C2(O)CCN(C(=O)Cc3ccc4ccccc4c3)CC2CN(C)C)c1
CHEMBL5285920,CHEMBL237,Kappa opioid receptor,Ki,=,1701.0,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,COc1cccc(C2(O)CCN(C(=O)Cc3cccc4ccccc34)CC2CN(C)C)c1
CHEMBL5288272,CHEMBL237,Kappa opioid receptor,Ki,=,3098.0,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,COc1cccc(C2(O)CCN(C(=O)Cc3c[nH]c4ccccc34)CC2CN(C)C)c1
CHEMBL5273683,CHEMBL237,Kappa opioid receptor,Ki,=,4055.0,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,COc1cccc(C2(O)CCN(C(=O)Cn3ccc4ccccc43)CC2CN(C)C)c1
CHEMBL5273356,CHEMBL237,Kappa opioid receptor,Ki,=,64.1,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,CN(C)CC1CN(C(=O)Cc2cc(F)c(F)cc2F)CCC1(O)c1cccc(O)c1
CHEMBL5279890,CHEMBL237,Kappa opioid receptor,Ki,=,126.9,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,CN(C)C[C@@H]1CN(C(=O)Cc2cc(F)c(F)cc2F)CC[C@@]1(O)c1cccc(O)c1
CHEMBL5287134,CHEMBL237,Kappa opioid receptor,Ki,=,42.3,nM,CHEMBL5227857,B,Displacement of [3H]U69593 from human KOR expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting method,CHEMBL5226314,KI,CN(C)C[C@H]1CN(C(=O)Cc2cc(F)c(F)cc2F)CC[C@]1(O)c1cccc(O)c1
CHEMBL5201437,CHEMBL237,Kappa opioid receptor,Ki,=,42.0,nM,CHEMBL5233341,B,Binding affinity to KOR (unknown origin),CHEMBL5233204,KI,CCOC(=O)[C@]12C[C@@H]1[C@@H](n1ccc3c(NC)nc(C#Cc4ccc(Cl)s4)nc31)[C@H](O)[C@@H]2O
CHEMBL5169644,CHEMBL237,Kappa opioid receptor,Ki,=,207.0,nM,CHEMBL5233341,B,Binding affinity to KOR (unknown origin),CHEMBL5233204,KI,CCOC(=O)[C@]12C[C@@H]1[C@@H](n1ccc3c(NCCc4ccccc4)nc(C#Cc4ccccc4)nc31)[C@H](O)[C@@H]2O
CHEMBL5291340,CHEMBL237,Kappa opioid receptor,Ki,=,330.0,nM,CHEMBL5251243,B,Displacement of [3H]-U69593 from kappa opioid receptor (unknown origin) assessed as inhibition constant incubated for 180 mins by competitive radioligand binding assay,CHEMBL5247645,KI,C/C=C1/CN2CC[C@@]34c5cc(O)c(Br)cc5N(C)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL5276128,CHEMBL237,Kappa opioid receptor,Ki,=,580.0,nM,CHEMBL5251243,B,Displacement of [3H]-U69593 from kappa opioid receptor (unknown origin) assessed as inhibition constant incubated for 180 mins by competitive radioligand binding assay,CHEMBL5247645,KI,C/C=C1/CN2CC[C@@]34c5cc(O)c(I)cc5N(C)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL5280172,CHEMBL237,Kappa opioid receptor,Ki,=,1170.0,nM,CHEMBL5251243,B,Displacement of [3H]-U69593 from kappa opioid receptor (unknown origin) assessed as inhibition constant incubated for 180 mins by competitive radioligand binding assay,CHEMBL5247645,KI,C/C=C1\CN2CC[C@@]34c5ccccc5N(CC)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL5288483,CHEMBL237,Kappa opioid receptor,Ki,=,49.0,nM,CHEMBL5251243,B,Displacement of [3H]-U69593 from kappa opioid receptor (unknown origin) assessed as inhibition constant incubated for 180 mins by competitive radioligand binding assay,CHEMBL5247645,KI,C/C=C1\CN2CC[C@@]34c5ccccc5N(Cc5ccccc5)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL5290432,CHEMBL237,Kappa opioid receptor,Ki,=,580.0,nM,CHEMBL5251243,B,Displacement of [3H]-U69593 from kappa opioid receptor (unknown origin) assessed as inhibition constant incubated for 180 mins by competitive radioligand binding assay,CHEMBL5247645,KI,C/C=C1\CN2CC[C@@]34c5ccccc5N(CCc5ccccc5)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL441765,CHEMBL237,Kappa opioid receptor,Ki,=,0.5,nM,CHEMBL5251243,B,Displacement of [3H]-U69593 from kappa opioid receptor (unknown origin) assessed as inhibition constant incubated for 180 mins by competitive radioligand binding assay,CHEMBL5247645,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL4871880,CHEMBL237,Kappa opioid receptor,Ki,=,1670.0,nM,CHEMBL5251243,B,Displacement of [3H]-U69593 from kappa opioid receptor (unknown origin) assessed as inhibition constant incubated for 180 mins by competitive radioligand binding assay,CHEMBL5247645,KI,C/C=C1/CN2CC[C@@]34c5cc(O)ccc5N(C)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL4846243,CHEMBL237,Kappa opioid receptor,Ki,=,2250.0,nM,CHEMBL5251243,B,Displacement of [3H]-U69593 from kappa opioid receptor (unknown origin) assessed as inhibition constant incubated for 180 mins by competitive radioligand binding assay,CHEMBL5247645,KI,C/C=C1/CN2CC[C@@]34c5ccccc5N(C)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL5291340,CHEMBL237,Kappa opioid receptor,Ki,=,251.19,nM,CHEMBL5251243,B,Displacement of [3H]-U69593 from kappa opioid receptor (unknown origin) assessed as inhibition constant incubated for 180 mins by competitive radioligand binding assay,CHEMBL5247645,KI,C/C=C1/CN2CC[C@@]34c5cc(O)c(Br)cc5N(C)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL5276128,CHEMBL237,Kappa opioid receptor,Ki,=,630.96,nM,CHEMBL5251243,B,Displacement of [3H]-U69593 from kappa opioid receptor (unknown origin) assessed as inhibition constant incubated for 180 mins by competitive radioligand binding assay,CHEMBL5247645,KI,C/C=C1/CN2CC[C@@]34c5cc(O)c(I)cc5N(C)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL5280172,CHEMBL237,Kappa opioid receptor,Ki,=,1258.93,nM,CHEMBL5251243,B,Displacement of [3H]-U69593 from kappa opioid receptor (unknown origin) assessed as inhibition constant incubated for 180 mins by competitive radioligand binding assay,CHEMBL5247645,KI,C/C=C1\CN2CC[C@@]34c5ccccc5N(CC)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL5288483,CHEMBL237,Kappa opioid receptor,Ki,=,50.12,nM,CHEMBL5251243,B,Displacement of [3H]-U69593 from kappa opioid receptor (unknown origin) assessed as inhibition constant incubated for 180 mins by competitive radioligand binding assay,CHEMBL5247645,KI,C/C=C1\CN2CC[C@@]34c5ccccc5N(Cc5ccccc5)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL5290432,CHEMBL237,Kappa opioid receptor,Ki,=,630.96,nM,CHEMBL5251243,B,Displacement of [3H]-U69593 from kappa opioid receptor (unknown origin) assessed as inhibition constant incubated for 180 mins by competitive radioligand binding assay,CHEMBL5247645,KI,C/C=C1\CN2CC[C@@]34c5ccccc5N(CCc5ccccc5)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL441765,CHEMBL237,Kappa opioid receptor,Ki,=,0.3162,nM,CHEMBL5251243,B,Displacement of [3H]-U69593 from kappa opioid receptor (unknown origin) assessed as inhibition constant incubated for 180 mins by competitive radioligand binding assay,CHEMBL5247645,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL4871880,CHEMBL237,Kappa opioid receptor,Ki,=,1584.89,nM,CHEMBL5251243,B,Displacement of [3H]-U69593 from kappa opioid receptor (unknown origin) assessed as inhibition constant incubated for 180 mins by competitive radioligand binding assay,CHEMBL5247645,KI,C/C=C1/CN2CC[C@@]34c5cc(O)ccc5N(C)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL4846243,CHEMBL237,Kappa opioid receptor,Ki,=,2511.89,nM,CHEMBL5251243,B,Displacement of [3H]-U69593 from kappa opioid receptor (unknown origin) assessed as inhibition constant incubated for 180 mins by competitive radioligand binding assay,CHEMBL5247645,KI,C/C=C1/CN2CC[C@@]34c5ccccc5N(C)[C@]35OC[C@@]4(C(=O)OC)[C@H]1C[C@H]25
CHEMBL5273273,CHEMBL237,Kappa opioid receptor,Ki,=,0.28,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O
CHEMBL415330,CHEMBL237,Kappa opioid receptor,Ki,=,0.4,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL5270075,CHEMBL237,Kappa opioid receptor,Ki,=,1474.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,CC[C@H](C)[C@@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]2CSSC[C@@H](C(N)=O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](N)CC(N)=O)C(=O)N2)NC1=O
CHEMBL5270697,CHEMBL237,Kappa opioid receptor,Ki,=,580.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,CC[C@H](C)[C@@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]2CSSC[C@H](NC1=O)C(=O)N[C@H](C(N)=O)CSSC[C@H](NC(=O)[C@@H](N)CC(N)=O)C(=O)N2
CHEMBL5282726,CHEMBL237,Kappa opioid receptor,Ki,=,80.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC(N)=O)C(=O)N1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5287856,CHEMBL237,Kappa opioid receptor,Ki,=,170.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC(N)=O)C(=O)N1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5267695,CHEMBL237,Kappa opioid receptor,Ki,=,406.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC(N)=O)C(=O)N1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5272472,CHEMBL237,Kappa opioid receptor,Ki,=,133.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC(N)=O)C(=O)N1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5277750,CHEMBL237,Kappa opioid receptor,Ki,=,2452.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,C[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC(N)=O)C(=O)N1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5281790,CHEMBL237,Kappa opioid receptor,Ki,=,67.5,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H]2CCC(=O)N2)C(=O)N1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5271835,CHEMBL237,Kappa opioid receptor,Ki,=,40.3,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)N1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5282938,CHEMBL237,Kappa opioid receptor,Ki,=,23003.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CCCNC(=N)N)C(N)=O
CHEMBL5277806,CHEMBL237,Kappa opioid receptor,Ki,=,14662.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC(N)=O)C(=O)N1)C(N)=O
CHEMBL5272359,CHEMBL237,Kappa opioid receptor,Ki,=,270.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5283510,CHEMBL237,Kappa opioid receptor,Ki,=,191.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5285832,CHEMBL237,Kappa opioid receptor,Ki,=,664.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,CC(C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC(N)=O)C(=O)N1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5284138,CHEMBL237,Kappa opioid receptor,Ki,=,24.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,CC(C)C[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC(N)=O)C(=O)N1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5280066,CHEMBL237,Kappa opioid receptor,Ki,=,1.3,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC(N)=O)C(=O)N1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5277937,CHEMBL237,Kappa opioid receptor,Ki,=,28.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC(N)=O)C(=O)N1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5266718,CHEMBL237,Kappa opioid receptor,Ki,=,2.9,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC(N)=O)C(=O)N1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1cccc2ccccc12)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5281057,CHEMBL237,Kappa opioid receptor,Ki,=,137.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC(N)=O)C(=O)N1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5269763,CHEMBL237,Kappa opioid receptor,Ki,=,85.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC(N)=O)C(=O)N1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5266854,CHEMBL237,Kappa opioid receptor,Ki,=,426.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC(N)=O)C(=O)N1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5290212,CHEMBL237,Kappa opioid receptor,Ki,=,208.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC(N)=O)C(=O)N1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5271719,CHEMBL237,Kappa opioid receptor,Ki,=,218.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC(N)=O)C(=O)N1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5277548,CHEMBL237,Kappa opioid receptor,Ki,=,387.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC(N)=O)C(=O)N1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5267287,CHEMBL237,Kappa opioid receptor,Ki,=,6.7,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@H](NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5274492,CHEMBL237,Kappa opioid receptor,Ki,=,13.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5268235,CHEMBL237,Kappa opioid receptor,Ki,=,16.1,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@H](NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5268886,CHEMBL237,Kappa opioid receptor,Ki,=,3.9,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5280357,CHEMBL237,Kappa opioid receptor,Ki,=,5.4,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)c1ccc(F)cc1)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5288478,CHEMBL237,Kappa opioid receptor,Ki,=,5.3,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)c1cccc(Br)c1)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5271178,CHEMBL237,Kappa opioid receptor,Ki,=,6.7,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)c1cccc(Cl)c1)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5282859,CHEMBL237,Kappa opioid receptor,Ki,=,1.2,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)Cc1ccc(F)cc1)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5278992,CHEMBL237,Kappa opioid receptor,Ki,=,1.2,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)Cc1cccc(Br)c1)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5276129,CHEMBL237,Kappa opioid receptor,Ki,=,2.1,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)Cc1cccc(Cl)c1)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5280997,CHEMBL237,Kappa opioid receptor,Ki,=,0.64,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)c1cc2ccccc2cc1N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5284775,CHEMBL237,Kappa opioid receptor,Ki,=,0.71,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)c1cnc2ccccc2c1)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5276702,CHEMBL237,Kappa opioid receptor,Ki,=,0.91,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H]1Cc2ccccc2CN1)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5275165,CHEMBL237,Kappa opioid receptor,Ki,=,1.18,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@H]1NCCc2ccccc21)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5273346,CHEMBL237,Kappa opioid receptor,Ki,=,0.07,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccc2ccccc2c1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5289754,CHEMBL237,Kappa opioid receptor,Ki,=,0.13,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccc(Cl)cc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5281912,CHEMBL237,Kappa opioid receptor,Ki,=,0.25,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5283811,CHEMBL237,Kappa opioid receptor,Ki,=,0.59,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,COc1ccc(C(=O)N2CCC[C@H]2C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@H]2CSSC[C@@H](C(N)=O)NC2=O)cc1
CHEMBL5285730,CHEMBL237,Kappa opioid receptor,Ki,=,0.98,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccc(Cl)c(Cl)c1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5270523,CHEMBL237,Kappa opioid receptor,Ki,=,1.2,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccc(O)cc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5279518,CHEMBL237,Kappa opioid receptor,Ki,=,2.2,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccc([N+](=O)[O-])cc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5289642,CHEMBL237,Kappa opioid receptor,Ki,=,1.3,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,CC1(C)SSC[C@@H](C(N)=O)NC(=O)[C@H]1NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCC(=O)N1
CHEMBL5286045,CHEMBL237,Kappa opioid receptor,Ki,=,1140.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,CC1(C)SSC[C@@H](C(N)=O)NC(=O)[C@H]1NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccccc1
CHEMBL5288247,CHEMBL237,Kappa opioid receptor,Ki,=,15.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,CN(C(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccccc1)[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5265822,CHEMBL237,Kappa opioid receptor,Ki,=,135.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CN[C@H]1CSSC[C@@H](C(N)=O)NC1=O)CC1CCCCC1
CHEMBL5282326,CHEMBL237,Kappa opioid receptor,Ki,=,0.48,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O)C1CCCCC1
CHEMBL5272099,CHEMBL237,Kappa opioid receptor,Ki,=,783.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CCSSC[C@@H](C(N)=O)NC1=O
CHEMBL5280506,CHEMBL237,Kappa opioid receptor,Ki,=,1573.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSCC[C@@H](C(N)=O)NC1=O
CHEMBL5266402,CHEMBL237,Kappa opioid receptor,Ki,=,241.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CCSSCC[C@@H](C(N)=O)NC1=O
CHEMBL5288155,CHEMBL237,Kappa opioid receptor,Ki,=,2.4,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H]1Cc2ccccc2CN1)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1C[Se][Se]C[C@@H](C(N)=O)NC1=O
CHEMBL5276505,CHEMBL237,Kappa opioid receptor,Ki,=,7.8,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1C[Se]SC[C@@H](C(N)=O)NC1=O
CHEMBL5283182,CHEMBL237,Kappa opioid receptor,Ki,=,233.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CC(=O)NC[C@@H](C(N)=O)NC1=O
CHEMBL5279099,CHEMBL237,Kappa opioid receptor,Ki,=,15.8,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSCSC[C@@H](C(N)=O)NC1=O
CHEMBL5289743,CHEMBL237,Kappa opioid receptor,Ki,=,465.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSCCN(CC(N)=O)C1=O
CHEMBL5288697,CHEMBL237,Kappa opioid receptor,Ki,=,199.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N1CCSSC[C@@H](C(N)=O)NC(=O)C1
CHEMBL5285705,CHEMBL237,Kappa opioid receptor,Ki,=,12939.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@H](NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CCCCN(CC(N)=O)C1=O
CHEMBL5291379,CHEMBL237,Kappa opioid receptor,Ki,=,786.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N1C[C@@H]2C[C@H]1C(=O)N[C@H](C(N)=O)CSS2
CHEMBL5279252,CHEMBL237,Kappa opioid receptor,Ki,=,208.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSS[C@H]2C[C@@H](C(N)=O)N(C2)C1=O
CHEMBL5271048,CHEMBL237,Kappa opioid receptor,Ki,=,229.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccc2ccccc2c1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(=O)O)NC1=O
CHEMBL5283425,CHEMBL237,Kappa opioid receptor,Ki,=,795.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccc(Cl)cc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(=O)O)NC1=O
CHEMBL5273967,CHEMBL237,Kappa opioid receptor,Ki,=,2141.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(=O)O)NC1=O
CHEMBL5275056,CHEMBL237,Kappa opioid receptor,Ki,=,22504.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(N)=O
CHEMBL5288658,CHEMBL237,Kappa opioid receptor,Ki,=,0.61,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccccc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5273114,CHEMBL237,Kappa opioid receptor,Ki,=,0.23,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccccc1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5278935,CHEMBL237,Kappa opioid receptor,Ki,=,0.59,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5286081,CHEMBL237,Kappa opioid receptor,Ki,=,0.29,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,C[C@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccccc1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5283084,CHEMBL237,Kappa opioid receptor,Ki,=,1.4,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,CC(C)C[C@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccccc1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5279208,CHEMBL237,Kappa opioid receptor,Ki,=,0.42,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5283035,CHEMBL237,Kappa opioid receptor,Ki,=,0.59,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5281808,CHEMBL237,Kappa opioid receptor,Ki,=,0.16,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccccc1)C(=O)NCC(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5276565,CHEMBL237,Kappa opioid receptor,Ki,=,10.2,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccccc1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5267374,CHEMBL237,Kappa opioid receptor,Ki,=,19.4,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccccc1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5276375,CHEMBL237,Kappa opioid receptor,Ki,=,60.0,nM,CHEMBL5253113,B,Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO-K1 cells incubated for 1 hr by 1450 microbeta scintillation counter analysis,CHEMBL5252514,KI,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccccc1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5275914,CHEMBL237,Kappa opioid receptor,Ki,=,1000.0,nM,CHEMBL5254615,B,Inhibition of human kappa opioid receptor assessed as inhibition constant,CHEMBL5252547,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](C(=O)Nc3ccccc3)C[C@]21C
CHEMBL5280329,CHEMBL237,Kappa opioid receptor,Ki,=,6400.0,nM,CHEMBL5264048,B,Displacement of [3H]-diprenorphine from KOR receptor (unknown origin) assessed as inhibition constant in presence of D-Ala-N-MePhe-Gly-ol-enkephalin and D-Ala-DLeu-enkephalin,CHEMBL5260834,KI,C[C@@H]1[C@@H]2Cc3ccccc3[C@]1(C)CCN2CCN1CCCC1
CHEMBL5289807,CHEMBL237,Kappa opioid receptor,Ki,=,6500.0,nM,CHEMBL5264048,B,Displacement of [3H]-diprenorphine from KOR receptor (unknown origin) assessed as inhibition constant in presence of D-Ala-N-MePhe-Gly-ol-enkephalin and D-Ala-DLeu-enkephalin,CHEMBL5260834,KI,C[C@@H]1[C@@H]2Cc3ccccc3[C@]1(C)CCN2CCNc1ccccc1
CHEMBL5274252,CHEMBL237,Kappa opioid receptor,Ki,=,0.41,nM,CHEMBL5264059,B,Displacement of [3H]-U69593 from KOR receptor (unknown origin) assessed as inhibition constant,CHEMBL5260834,KI,COC(=O)[C@]1(c2ccc(Cl)cc2)C[C@@H]1CN1CC[C@]2(C)c3cc(O)ccc3C[C@@H]1[C@@H]2C
CHEMBL5291473,CHEMBL237,Kappa opioid receptor,Ki,=,240.0,nM,CHEMBL5264059,B,Displacement of [3H]-U69593 from KOR receptor (unknown origin) assessed as inhibition constant,CHEMBL5260834,KI,COC(=O)[C@]1(c2ccccc2)C[C@@H]1CN1CC[C@]2(C)c3cc(O)ccc3C[C@@H]1[C@@H]2C
CHEMBL4558518,CHEMBL237,Kappa opioid receptor,Ki,=,3305.0,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL4507288,KI,CC(C)(C)OC(=O)N1CCCC1CNC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1
CHEMBL4558518,CHEMBL237,Kappa opioid receptor,Ki,=,3311.31,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL4507288,KI,CC(C)(C)OC(=O)N1CCCC1CNC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1
CHEMBL4576555,CHEMBL237,Kappa opioid receptor,Ki,=,990.27,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL4507307,KI,CN1CCN(C(=O)C(C)(C)c2ccc(C(=O)Nc3cn4cc(-c5cc(C(C)(C)C)cc(C(C)(C)C)c5)ccc4n3)cc2)CC1
CHEMBL4576555,CHEMBL237,Kappa opioid receptor,Ki,=,977.24,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL4507307,KI,CN1CCN(C(=O)C(C)(C)c2ccc(C(=O)Nc3cn4cc(-c5cc(C(C)(C)C)cc(C(C)(C)C)c5)ccc4n3)cc2)CC1
CHEMBL3640116,CHEMBL237,Kappa opioid receptor,Ki,=,4948.48,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL4800723,KI,CC[C@H](CC(=O)O)n1c(=O)c2ncccc2n(Cc2cn(C)c3cc(C)cc(C)c23)c1=O
CHEMBL3640116,CHEMBL237,Kappa opioid receptor,Ki,=,4786.3,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL4800723,KI,CC[C@H](CC(=O)O)n1c(=O)c2ncccc2n(Cc2cn(C)c3cc(C)cc(C)c23)c1=O
CHEMBL4802039,CHEMBL237,Kappa opioid receptor,Ki,=,773.3,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL4800731,KI,CC(=O)Nc1ncc(CN2CCC[C@H](Cc3cc(C)nc(C)c3)C2)s1
CHEMBL4802039,CHEMBL237,Kappa opioid receptor,Ki,=,741.31,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL4800731,KI,CC(=O)Nc1ncc(CN2CCC[C@H](Cc3cc(C)nc(C)c3)C2)s1
CHEMBL5094181,CHEMBL237,Kappa opioid receptor,Ki,=,1168.96,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL5058647,KI,O=C(NCCCn1ccnc1)c1cc2nc(-c3ccccc3)cc(-c3ccccc3)n2n1
CHEMBL5094181,CHEMBL237,Kappa opioid receptor,Ki,=,1174.9,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL5058647,KI,O=C(NCCCn1ccnc1)c1cc2nc(-c3ccccc3)cc(-c3ccccc3)n2n1
CHEMBL5092747,CHEMBL237,Kappa opioid receptor,Ki,=,197.79,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL5058647,KI,CC(=O)Nc1ccc(-c2cc(-c3ccccc3)nc3cc(C(=O)NCCCn4ccnc4)nn23)cc1
CHEMBL5092747,CHEMBL237,Kappa opioid receptor,Ki,=,199.53,nM,CHEMBL4880044,B,GPCRScan assay: inhibition of KOR,CHEMBL5058647,KI,CC(=O)Nc1ccc(-c2cc(-c3ccccc3)nc3cc(C(=O)NCCCn4ccnc4)nn23)cc1
CHEMBL5395401,CHEMBL237,Kappa opioid receptor,Ki,=,1107.0,nM,CHEMBL5319343,B,Binding affinity to KOR receptor (unknown origin) assessed as inhibition constant,CHEMBL5316327,KI,CCN(CC)CCCC(C)Nc1cnc(C(=O)Nc2ccc(Cl)c3cccnc23)cn1
CHEMBL5431371,CHEMBL237,Kappa opioid receptor,Ki,=,713.0,nM,CHEMBL5319343,B,Binding affinity to KOR receptor (unknown origin) assessed as inhibition constant,CHEMBL5316327,KI,CCN(CC)CCCC(C)Nc1cnc(C(=O)Nc2cc(F)cc3cccnc23)cn1
CHEMBL5424523,CHEMBL237,Kappa opioid receptor,Ki,=,277.0,nM,CHEMBL5326491,B,Displacement of [3H]U69593 from human KOR expressed in HEK cell membranes assessed as inhibition constant incubated for 60 mins by microbeta 2 scintillation counting method,CHEMBL5325418,KI,COC(=O)C(Cc1cccc(OC)c1I)NC(=O)CNCc1ccccc1
CHEMBL5437720,CHEMBL237,Kappa opioid receptor,Ki,=,4185.0,nM,CHEMBL5326491,B,Displacement of [3H]U69593 from human KOR expressed in HEK cell membranes assessed as inhibition constant incubated for 60 mins by microbeta 2 scintillation counting method,CHEMBL5325418,KI,COC(=O)C(Cc1ccccc1I)NC(=O)CN(Cc1ccccc1)C(=O)OC(C)(C)C
CHEMBL5433205,CHEMBL237,Kappa opioid receptor,Ki,=,123.0,nM,CHEMBL5326491,B,Displacement of [3H]U69593 from human KOR expressed in HEK cell membranes assessed as inhibition constant incubated for 60 mins by microbeta 2 scintillation counting method,CHEMBL5325418,KI,COC(=O)C(Cc1cccc(C)c1I)NC(=O)CNCc1ccccc1
CHEMBL5440141,CHEMBL237,Kappa opioid receptor,Ki,=,190.0,nM,CHEMBL5326491,B,Displacement of [3H]U69593 from human KOR expressed in HEK cell membranes assessed as inhibition constant incubated for 60 mins by microbeta 2 scintillation counting method,CHEMBL5325418,KI,COC(=O)C(Cc1cccc(OC)c1C)NC(=O)CNCc1ccccc1
CHEMBL5398392,CHEMBL237,Kappa opioid receptor,Ki,=,765.0,nM,CHEMBL5326491,B,Displacement of [3H]U69593 from human KOR expressed in HEK cell membranes assessed as inhibition constant incubated for 60 mins by microbeta 2 scintillation counting method,CHEMBL5325418,KI,COC(=O)C(Cc1cccc(OC)c1I)NC(=O)CNC(C)c1ccccc1
CHEMBL5417743,CHEMBL237,Kappa opioid receptor,Ki,=,2170.0,nM,CHEMBL5326491,B,Displacement of [3H]U69593 from human KOR expressed in HEK cell membranes assessed as inhibition constant incubated for 60 mins by microbeta 2 scintillation counting method,CHEMBL5325418,KI,COC(=O)C(Cc1cccc(OC)c1I)NC(=O)[C@@H](N)Cc1ccccc1
CHEMBL5419716,CHEMBL237,Kappa opioid receptor,Ki,=,802.0,nM,CHEMBL5326491,B,Displacement of [3H]U69593 from human KOR expressed in HEK cell membranes assessed as inhibition constant incubated for 60 mins by microbeta 2 scintillation counting method,CHEMBL5325418,KI,COC(=O)C(Cc1cccc(OC)c1I)NC(=O)CNCCc1ccccc1
CHEMBL5405049,CHEMBL237,Kappa opioid receptor,Ki,=,1230.0,nM,CHEMBL5326491,B,Displacement of [3H]U69593 from human KOR expressed in HEK cell membranes assessed as inhibition constant incubated for 60 mins by microbeta 2 scintillation counting method,CHEMBL5325418,KI,COC(=O)C(Cc1cccc(OC)c1I)NC(=O)CCNCc1ccccc1
CHEMBL5416937,CHEMBL237,Kappa opioid receptor,Ki,=,1443.0,nM,CHEMBL5326491,B,Displacement of [3H]U69593 from human KOR expressed in HEK cell membranes assessed as inhibition constant incubated for 60 mins by microbeta 2 scintillation counting method,CHEMBL5325418,KI,COc1cccc(CC(NC(=O)CNCc2ccccc2)C(=O)OC(C)C)c1I
CHEMBL5439837,CHEMBL237,Kappa opioid receptor,Ki,=,256.0,nM,CHEMBL5326491,B,Displacement of [3H]U69593 from human KOR expressed in HEK cell membranes assessed as inhibition constant incubated for 60 mins by microbeta 2 scintillation counting method,CHEMBL5325418,KI,COC(=O)C(Cc1cccc(OC)c1I)NC(=O)CN(C)Cc1ccccc1
CHEMBL5426289,CHEMBL237,Kappa opioid receptor,Ki,=,924.0,nM,CHEMBL5326491,B,Displacement of [3H]U69593 from human KOR expressed in HEK cell membranes assessed as inhibition constant incubated for 60 mins by microbeta 2 scintillation counting method,CHEMBL5325418,KI,COc1cccc(CC2NC(=O)CN(Cc3ccccc3)C2=O)c1I
CHEMBL5403335,CHEMBL237,Kappa opioid receptor,Ki,=,510.0,nM,CHEMBL5326491,B,Displacement of [3H]U69593 from human KOR expressed in HEK cell membranes assessed as inhibition constant incubated for 60 mins by microbeta 2 scintillation counting method,CHEMBL5325418,KI,COc1cc(CC2NC(=O)CN(Cc3ccccc3)C2=O)c(I)c(OC)c1
CHEMBL5429995,CHEMBL237,Kappa opioid receptor,Ki,=,600.0,nM,CHEMBL5326491,B,Displacement of [3H]U69593 from human KOR expressed in HEK cell membranes assessed as inhibition constant incubated for 60 mins by microbeta 2 scintillation counting method,CHEMBL5325418,KI,COc1cccc(CC2NC(=O)CN(Cc3ccccc3)C2=O)c1C
CHEMBL5425679,CHEMBL237,Kappa opioid receptor,Ki,=,5110.0,nM,CHEMBL5326491,B,Displacement of [3H]U69593 from human KOR expressed in HEK cell membranes assessed as inhibition constant incubated for 60 mins by microbeta 2 scintillation counting method,CHEMBL5325418,KI,COc1cccc(CC2NC(=O)CN(CCc3ccccc3)C2=O)c1I
CHEMBL5405776,CHEMBL237,Kappa opioid receptor,Ki,=,7000.0,nM,CHEMBL5326491,B,Displacement of [3H]U69593 from human KOR expressed in HEK cell membranes assessed as inhibition constant incubated for 60 mins by microbeta 2 scintillation counting method,CHEMBL5325418,KI,COc1cccc(CC2NC(=O)CN(CCCc3ccccc3)C2=O)c1I
CHEMBL4435280,CHEMBL237,Kappa opioid receptor,Ki,=,1594.0,nM,CHEMBL5328970,B,Displacement of [3H]-U69593 from human KOP expressed in CHO cells membrane incubated for 60 mins by beta liquid scintillation counting method,CHEMBL5325508,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3ccc4ccccc43)CC2)CC1
CHEMBL4548515,CHEMBL237,Kappa opioid receptor,Ki,=,1737.0,nM,CHEMBL5328970,B,Displacement of [3H]-U69593 from human KOP expressed in CHO cells membrane incubated for 60 mins by beta liquid scintillation counting method,CHEMBL5325508,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3cc(CN)c4ccccc43)CC2)CC1
CHEMBL5405339,CHEMBL237,Kappa opioid receptor,Ki,=,25.21,nM,CHEMBL5328970,B,Displacement of [3H]-U69593 from human KOP expressed in CHO cells membrane incubated for 60 mins by beta liquid scintillation counting method,CHEMBL5325508,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3c(CN)cc4ccccc43)CC2)CC1
CHEMBL5426012,CHEMBL237,Kappa opioid receptor,Ki,=,62.07,nM,CHEMBL5328970,B,Displacement of [3H]-U69593 from human KOP expressed in CHO cells membrane incubated for 60 mins by beta liquid scintillation counting method,CHEMBL5325508,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3c(CCN)cc4ccccc43)CC2)CC1
CHEMBL5403724,CHEMBL237,Kappa opioid receptor,Ki,=,73.15,nM,CHEMBL5328970,B,Displacement of [3H]-U69593 from human KOP expressed in CHO cells membrane incubated for 60 mins by beta liquid scintillation counting method,CHEMBL5325508,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3c(CO)cc4ccccc43)CC2)CC1
CHEMBL5404274,CHEMBL237,Kappa opioid receptor,Ki,=,51.68,nM,CHEMBL5328970,B,Displacement of [3H]-U69593 from human KOP expressed in CHO cells membrane incubated for 60 mins by beta liquid scintillation counting method,CHEMBL5325508,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3c(CCO)cc4ccccc43)CC2)CC1
CHEMBL5412738,CHEMBL237,Kappa opioid receptor,Ki,=,176.0,nM,CHEMBL5328970,B,Displacement of [3H]-U69593 from human KOP expressed in CHO cells membrane incubated for 60 mins by beta liquid scintillation counting method,CHEMBL5325508,KI,CC(=O)NCc1cc2ccccc2n1C1CCN([C@H]2CC[C@@H](C(C)C)CC2)CC1
CHEMBL5419235,CHEMBL237,Kappa opioid receptor,Ki,=,408.0,nM,CHEMBL5328970,B,Displacement of [3H]-U69593 from human KOP expressed in CHO cells membrane incubated for 60 mins by beta liquid scintillation counting method,CHEMBL5325508,KI,CCOC(=O)NCc1cc2ccccc2n1C1CCN([C@H]2CC[C@@H](C(C)C)CC2)CC1
CHEMBL5413519,CHEMBL237,Kappa opioid receptor,Ki,=,177.0,nM,CHEMBL5328970,B,Displacement of [3H]-U69593 from human KOP expressed in CHO cells membrane incubated for 60 mins by beta liquid scintillation counting method,CHEMBL5325508,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3c(CNS(C)(=O)=O)cc4ccccc43)CC2)CC1
CHEMBL5423260,CHEMBL237,Kappa opioid receptor,Ki,=,20.93,nM,CHEMBL5328970,B,Displacement of [3H]-U69593 from human KOP expressed in CHO cells membrane incubated for 60 mins by beta liquid scintillation counting method,CHEMBL5325508,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3c(CNS(N)(=O)=O)cc4ccccc43)CC2)CC1
CHEMBL5415010,CHEMBL237,Kappa opioid receptor,Ki,=,32.15,nM,CHEMBL5328970,B,Displacement of [3H]-U69593 from human KOP expressed in CHO cells membrane incubated for 60 mins by beta liquid scintillation counting method,CHEMBL5325508,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3c(CN4CCS(=O)(=O)CC4)cc4ccccc43)CC2)CC1
CHEMBL5416582,CHEMBL237,Kappa opioid receptor,Ki,=,30.62,nM,CHEMBL5328970,B,Displacement of [3H]-U69593 from human KOP expressed in CHO cells membrane incubated for 60 mins by beta liquid scintillation counting method,CHEMBL5325508,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3c(CN4CCCC4)cc4ccccc43)CC2)CC1
CHEMBL5407403,CHEMBL237,Kappa opioid receptor,Ki,=,113.0,nM,CHEMBL5328970,B,Displacement of [3H]-U69593 from human KOP expressed in CHO cells membrane incubated for 60 mins by beta liquid scintillation counting method,CHEMBL5325508,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3c(CNC(=O)c4cccnc4)cc4ccccc43)CC2)CC1
CHEMBL5416899,CHEMBL237,Kappa opioid receptor,Ki,=,12.1,nM,CHEMBL5328970,B,Displacement of [3H]-U69593 from human KOP expressed in CHO cells membrane incubated for 60 mins by beta liquid scintillation counting method,CHEMBL5325508,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3c(CNC(=O)c4cnco4)cc4ccccc43)CC2)CC1
CHEMBL5394355,CHEMBL237,Kappa opioid receptor,Ki,=,253.0,nM,CHEMBL5328970,B,Displacement of [3H]-U69593 from human KOP expressed in CHO cells membrane incubated for 60 mins by beta liquid scintillation counting method,CHEMBL5325508,KI,CC(C)[C@H]1CC[C@@H](N2CCC(n3c(CNC(=O)c4ccc(C(F)(F)F)o4)cc4ccccc43)CC2)CC1
CHEMBL5421947,CHEMBL237,Kappa opioid receptor,Ki,=,0.72,nM,CHEMBL5341722,B,Binding affinity to kappa opioid receptor (unknown origin) assessed as inhibition constant,CHEMBL5338767,KI,N[11C](=O)c1ccc(Oc2ccc(CN3CCC[C@H]3c3cccnc3)cc2)c(Cl)c1
CHEMBL5404473,CHEMBL237,Kappa opioid receptor,Ki,=,0.28,nM,CHEMBL5341722,B,Binding affinity to kappa opioid receptor (unknown origin) assessed as inhibition constant,CHEMBL5338767,KI,CCN(CC)C[C@@H]1CN(C(=O)CO[11CH3])CCN1C(=O)Cc1ccc(C)c(C)c1
CHEMBL5428920,CHEMBL237,Kappa opioid receptor,Ki,=,0.28,nM,CHEMBL5341722,B,Binding affinity to kappa opioid receptor (unknown origin) assessed as inhibition constant,CHEMBL5338767,KI,CCN(CC)C[C@@H]1CN(C(=O)COC)CCN1C(=O)Cc1ccc(C)c(C)c1
CHEMBL5405248,CHEMBL237,Kappa opioid receptor,Ki,=,0.43,nM,CHEMBL5341722,B,Binding affinity to kappa opioid receptor (unknown origin) assessed as inhibition constant,CHEMBL5338767,KI,CCN(CCF)C[C@@H]1CN(C(=O)COC)CCN1C(=O)Cc1ccc(C)c(C)c1
CHEMBL5409958,CHEMBL237,Kappa opioid receptor,Ki,=,1800.0,nM,CHEMBL5359155,B,Inhibition of human KOR assessed as inhibition constant by microbeta scintillation counting method,CHEMBL5357012,KI,OC[C@H]1O[C@@H](n2cc(C(F)(F)F)c3c(NCc4ccccc4)ncnc32)[C@H](O)[C@@H]1O
CHEMBL5397467,CHEMBL237,Kappa opioid receptor,Ki,=,1900.0,nM,CHEMBL5359155,B,Inhibition of human KOR assessed as inhibition constant by microbeta scintillation counting method,CHEMBL5357012,KI,C[C@H](Nc1ncnc2c1c(C(F)(F)F)cn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O)c1ccccc1
CHEMBL440765,CHEMBL237,Kappa opioid receptor,Ki,=,0.3,nM,CHEMBL5360966,B,Binding affinity to KOR (unknown origin) assessed as inhibition constant,CHEMBL5360528,KI,CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL5402380,CHEMBL237,Kappa opioid receptor,Ki,=,2.5,nM,CHEMBL5360966,B,Binding affinity to KOR (unknown origin) assessed as inhibition constant,CHEMBL5360528,KI,C#Cc1occc1[C@@H]1C[C@@]2(C)[C@@H](CC[C@@]3(C)[C@H](C(=O)OC)C[C@H](OC(C)=O)C(=O)[C@@]32C)C(=O)O1
CHEMBL2180640,CHEMBL237,Kappa opioid receptor,Ki,=,10.9,nM,CHEMBL5360966,B,Binding affinity to KOR (unknown origin) assessed as inhibition constant,CHEMBL5360528,KI,CCCCN(CCc1ccccc1)CCc1cccc(O)c1
CHEMBL100116,CHEMBL237,Kappa opioid receptor,Ki,=,7.6,nM,CHEMBL5360966,B,Binding affinity to KOR (unknown origin) assessed as inhibition constant,CHEMBL5360528,KI,CC(C)=CCN1CCC2(C)c3cc(O)ccc3CC1C2C
CHEMBL60542,CHEMBL237,Kappa opioid receptor,Ki,=,7.6,nM,CHEMBL5360966,B,Binding affinity to KOR (unknown origin) assessed as inhibition constant,CHEMBL5360528,KI,CC(C)=CCN1CC[C@]2(C)c3cc(O)ccc3C[C@H]1[C@H]2C
CHEMBL157302,CHEMBL237,Kappa opioid receptor,Ki,=,0.42,nM,CHEMBL5360966,B,Binding affinity to KOR (unknown origin) assessed as inhibition constant,CHEMBL5360528,KI,C[C@H]1[C@H]2Cc3ccc(C(N)=O)cc3[C@]1(C)CCN2CC1CC1
CHEMBL592,CHEMBL237,Kappa opioid receptor,Ki,=,2.3,nM,CHEMBL5360966,B,Binding affinity to KOR (unknown origin) assessed as inhibition constant,CHEMBL5360528,KI,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13
CHEMBL5401204,CHEMBL237,Kappa opioid receptor,Ki,=,3.46,nM,CHEMBL5360966,B,Binding affinity to KOR (unknown origin) assessed as inhibition constant,CHEMBL5360528,KI,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1cc[n+](Cc2ccccc2)cc1.[Br-]
CHEMBL5406584,CHEMBL237,Kappa opioid receptor,Ki,=,49.7,nM,CHEMBL5360966,B,Binding affinity to KOR (unknown origin) assessed as inhibition constant,CHEMBL5360528,KI,COC(=O)[C@@H]1C[C@H](OC(=O)C2=Cc3ccccc3C2)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL4458783,CHEMBL237,Kappa opioid receptor,Ki,=,2.4,nM,CHEMBL5360966,B,Binding affinity to KOR (unknown origin) assessed as inhibition constant,CHEMBL5360528,KI,Cc1ccc(CSc2nnc(-c3ccccn3)n2Cc2ccco2)cc1C(F)(F)F
CHEMBL5418013,CHEMBL237,Kappa opioid receptor,Ki,=,0.24,nM,CHEMBL5360966,B,Binding affinity to KOR (unknown origin) assessed as inhibition constant,CHEMBL5360528,KI,CCCC[C@@H](NC(=O)[C@@H](CC1=CC=CCC1)NC(=O)[C@H](N)Cc1ccccc1)C(=O)N[C@H](CCCNC(=N)N)C(=O)NCc1ccncc1
CHEMBL5426627,CHEMBL237,Kappa opioid receptor,Ki,=,0.08,nM,CHEMBL5360966,B,Binding affinity to KOR (unknown origin) assessed as inhibition constant,CHEMBL5360528,KI,CC(C)C[C@@H](NC(=O)[C@@H](CC1=CC=CCC1)NC(=O)[C@H](N)Cc1ccccc1)C(=O)N[C@H](CCCN)C(=O)N1CCOCC1
CHEMBL5428706,CHEMBL237,Kappa opioid receptor,Ki,=,0.32,nM,CHEMBL5360966,B,Binding affinity to KOR (unknown origin) assessed as inhibition constant,CHEMBL5360528,KI,CC(C)C[C@@H](NC(=O)[C@@H](CC1=CC=CCC1)NC(=O)[C@H](N)Cc1ccccc1)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(C(=O)O)CC1
CHEMBL445332,CHEMBL237,Kappa opioid receptor,Ki,=,4.0,nM,CHEMBL5360970,B,Binding affinity to KOR (unknown origin),CHEMBL5360528,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL445332,CHEMBL237,Kappa opioid receptor,Ki,=,16.0,nM,CHEMBL5360972,B,Binding affinity to KOR (unknown origin) expressed in HEK293 cells assessed as inhibition constant,CHEMBL5360528,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL118865,CHEMBL237,Kappa opioid receptor,Ki,=,8.6,nM,CHEMBL5360976,B,Binding affinity to KOR receptor (unknown origin) assessed as inhibition constant,CHEMBL5360528,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)C1CCC2(CCCO2)CC1N1CCCC1
CHEMBL610279,CHEMBL237,Kappa opioid receptor,Ki,=,1.15,nM,CHEMBL5360980,B,Binding affinity to human KOR receptor stably expressed in HEK293 cells assessed as inhibition constant by GTPgammaS assay,CHEMBL5360528,KI,N=C(N)Nc1ccc2c3c([nH]c2c1)[C@@H]1Oc2c(O)ccc4c2[C@@]12CCN(CC1CC1)[C@H](C4)[C@]2(O)C3
CHEMBL445332,CHEMBL237,Kappa opioid receptor,Ki,=,40.0,nM,CHEMBL5360986,B,Binding affinity to wild type human KOR assessed as inhibition constant,CHEMBL5360528,KI,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL5414016,CHEMBL237,Kappa opioid receptor,Ki,=,9.0,nM,CHEMBL5360986,B,Binding affinity to wild type human KOR assessed as inhibition constant,CHEMBL5360528,KI,O=C(O[C@@H]1[C@@H]2[C@H]3C[C@@H](C[C@H]2C(=O)O[C@H]1c1ccoc1)OC3=O)c1ccccc1
CHEMBL5431513,CHEMBL237,Kappa opioid receptor,Ki,=,0.006,nM,CHEMBL5360986,B,Binding affinity to wild type human KOR assessed as inhibition constant,CHEMBL5360528,KI,O=C(N[C@@H]1C=C[C@H]2[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1cccc(I)c1
CHEMBL5405541,CHEMBL237,Kappa opioid receptor,Ki,=,0.3,nM,CHEMBL5360986,B,Binding affinity to wild type human KOR assessed as inhibition constant,CHEMBL5360528,KI,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(OCCCc2ccccc2)[C@H]1C5
CHEMBL5419132,CHEMBL237,Kappa opioid receptor,Ki,=,1.19,nM,CHEMBL5360989,B,Binding affinity to human KOR expressed in HEK293 cells assessed as inhibition constant incubated for 90 mins by liquid scintillation assay,CHEMBL5360528,KI,O=C1CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)CCN1
CHEMBL1190199,CHEMBL237,Kappa opioid receptor,Ki,=,5.6,nM,CHEMBL5361008,B,Binding affinity to human recombinant KOR assessed as inhibition constant,CHEMBL5360528,KI,CN(C(=O)C(c1ccccc1)c1ccccc1)[C@H](CN1CC[C@H](O)C1)c1ccccc1
CHEMBL5430894,CHEMBL237,Kappa opioid receptor,Ki,=,100.0,nM,CHEMBL5384107,B,Displacement of [3H]diprenorphine from human KOR expressed in HEK293 cells assessed as inhibition constant incubated for 60 mins by liquid scintillation method,CHEMBL5380841,KI,COc1cccc(Cn2nc(CNCc3cccc(OCc4ccccc4)c3)c3c4cc(OC)c(OC)cc4c(-c4ccccc4Cl)nc32)c1
CHEMBL440765,CHEMBL237,Kappa opioid receptor,Ki,=,2.68,nM,CHEMBL5384107,B,Displacement of [3H]diprenorphine from human KOR expressed in HEK293 cells assessed as inhibition constant incubated for 60 mins by liquid scintillation method,CHEMBL5380841,KI,CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL1600943,CHEMBL237,Kappa opioid receptor,Ki,=,2122.51,nM,CHEMBL5442187,B,"PDSP Secondary Binding target: OPRK1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,Cl.Cl.Cl.c1ccc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)nc1
CHEMBL4750757,CHEMBL237,Kappa opioid receptor,Ki,=,0.5913,nM,CHEMBL5442187,B,"PDSP Secondary Binding target: OPRK1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,Cl.O=C(Cc1ccc(Cl)c(Cl)c1)N1CCCC[C@H]1CN1CCCC1
CHEMBL83894,CHEMBL237,Kappa opioid receptor,Ki,=,2874.09,nM,CHEMBL5442187,B,"PDSP Secondary Binding target: OPRK1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,O=S1(=O)c2cccc3cccc(c23)N1CCCN1CCN(c2ccc(F)cc2)CC1
CHEMBL1255661,CHEMBL237,Kappa opioid receptor,Ki,=,2.143,nM,CHEMBL5442187,B,"PDSP Secondary Binding target: OPRK1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,Cl.Oc1ccc2c3c1O[C@H]1c4[nH]c5c(c4C[C@@]4(O)[C@@H](C2)N(CC2CC2)CC[C@]314)C[C@@]1(O)[C@H]2Cc3ccc(O)c4c3[C@@]1(CCN2CC1CC1)[C@H]5O4
CHEMBL405355,CHEMBL237,Kappa opioid receptor,Ki,=,346.85,nM,CHEMBL5442187,B,"PDSP Secondary Binding target: OPRK1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,COC(=O)C1=C(C)NC(C)=C(C(=O)OCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)[C@H]1c1cccc([N+](=O)[O-])c1
CHEMBL300555,CHEMBL237,Kappa opioid receptor,Ki,=,711.3,nM,CHEMBL5442187,B,"PDSP Secondary Binding target: OPRK1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,O=C1NCN(c2ccccc2)C12CCN(CC1COc3ccccc3O1)CC2
CHEMBL1256750,CHEMBL237,Kappa opioid receptor,Ki,=,1.792,nM,CHEMBL5442187,B,"PDSP Secondary Binding target: OPRK1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)C(CN1CCCC1)c1cccc(OCC(=O)O)c1.Cl
CHEMBL25230,CHEMBL237,Kappa opioid receptor,Ki,=,23.34,nM,CHEMBL5442187,B,"PDSP Secondary Binding target: OPRK1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,C=CCN1C[C@H](C)N([C@H](c2ccc(C(=O)N(CC)CC)cc2)c2cccc(O)c2)C[C@H]1C
CHEMBL2391908,CHEMBL237,Kappa opioid receptor,Ki,=,1110.2,nM,CHEMBL5442187,B,"PDSP Secondary Binding target: OPRK1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,C[C@H](NC[C@H](O)CP(=O)(O)CC1CCCCC1)c1ccc(Cl)c(Cl)c1.Cl
CHEMBL2107572,CHEMBL237,Kappa opioid receptor,Ki,=,1403.62,nM,CHEMBL5442187,B,"PDSP Secondary Binding target: OPRK1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,COc1cccc([C@@H](C)NCCCc2ccccc2Cl)c1.Cl
CHEMBL103769,CHEMBL237,Kappa opioid receptor,Ki,=,1113.27,nM,CHEMBL5442187,B,"PDSP Secondary Binding target: OPRK1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,S=C(NCCCc1c[nH]cn1)NCCCN(Cc1ccc(Cl)c(Cl)c1)c1ccc(Br)cn1
CHEMBL59898,CHEMBL237,Kappa opioid receptor,Ki,=,1941.19,nM,CHEMBL5442187,B,"PDSP Secondary Binding target: OPRK1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,CCOC(=O)c1c(C)[nH]c2ccc3c(c12)CN1CCc2cc(OC)ccc2C1O3
CHEMBL542139,CHEMBL237,Kappa opioid receptor,Ki,=,898.05,nM,CHEMBL5442187,B,"PDSP Secondary Binding target: OPRK1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1.Cl
CHEMBL74355,CHEMBL237,Kappa opioid receptor,Ki,=,102.71,nM,CHEMBL5442187,B,"PDSP Secondary Binding target: OPRK1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC
CHEMBL267777,CHEMBL237,Kappa opioid receptor,Ki,=,1445.44,nM,CHEMBL5442187,B,"PDSP Secondary Binding target: OPRK1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,Cc1nc2sccn2c(=O)c1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1
CHEMBL1256844,CHEMBL237,Kappa opioid receptor,Ki,=,447.61,nM,CHEMBL5442187,B,"PDSP Secondary Binding target: OPRK1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1.Cl
CHEMBL1200776,CHEMBL237,Kappa opioid receptor,Ki,=,444.22,nM,CHEMBL5442187,B,"PDSP Secondary Binding target: OPRK1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12.Cl
CHEMBL2110363,CHEMBL237,Kappa opioid receptor,Ki,=,703.8,nM,CHEMBL5442187,B,"PDSP Secondary Binding target: OPRK1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,Cc1nc(C(=O)N2CCC[C@H]2Cc2nnc(-c3ccccc3)o2)c(-c2ccccc2F)s1
CHEMBL79834,CHEMBL237,Kappa opioid receptor,Ki,=,913.9,nM,CHEMBL5442187,B,"PDSP Secondary Binding target: OPRK1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,O=C1NCN(c2ccccc2)C12CCN(CCCOc1ccc(F)cc1)CC2
CHEMBL360648,CHEMBL237,Kappa opioid receptor,Ki,=,2048.33,nM,CHEMBL5442187,B,"PDSP Secondary Binding target: OPRK1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,Cc1cc(C(=O)N2Cc3cnn(C)c3Nc3ccccc32)ccc1CNC(=O)N1CCC[C@H]1C(=S)N1CCCN(C)CC1
CHEMBL1707,CHEMBL237,Kappa opioid receptor,Ki,=,71.57,nM,CHEMBL5442187,B,"PDSP Secondary Binding target: OPRK1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1.Cl
CHEMBL4202825,CHEMBL237,Kappa opioid receptor,Ki,=,406.53,nM,CHEMBL5442187,B,"PDSP Secondary Binding target: OPRK1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,N#Cc1c(N)nc(SCC(N)=O)c(C#N)c1-c1ccc(OCC2CC2)cc1
CHEMBL256470,CHEMBL237,Kappa opioid receptor,Ki,=,493.97,nM,CHEMBL5442187,B,"PDSP Secondary Binding target: OPRK1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,Cc1csc2c(N[C@@H](C)CN3CCN(S(=O)(=O)c4ccc(Cl)c(Cl)c4)CC3)ncnc12
CHEMBL259656,CHEMBL237,Kappa opioid receptor,Ki,=,502.75,nM,CHEMBL5442187,B,"PDSP Secondary Binding target: OPRK1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,O=C(c1cc2c(cc1F)OC(c1ccc(F)cc1)(c1ccc(Cl)cc1Cl)O2)N1CCOCC1
CHEMBL513136,CHEMBL237,Kappa opioid receptor,Ki,=,76.12,nM,CHEMBL5442187,B,"PDSP Secondary Binding target: OPRK1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,Cc1ccccc1C(c1ccccc1C)N1C2CCC1CC(O)(c1ccccc1)C2
CHEMBL502182,CHEMBL237,Kappa opioid receptor,Ki,=,2383.41,nM,CHEMBL5442187,B,"PDSP Secondary Binding target: OPRK1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)[O-])c3ccccc3)c2=O)c1F.[Na+]
CHEMBL2181226,CHEMBL237,Kappa opioid receptor,Ki,=,1133.31,nM,CHEMBL5442187,B,"PDSP Secondary Binding target: OPRK1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,Cc1ccc(C)c(Oc2ccncc2C(=O)N2CCN(C3CC3)c3ccccc32)c1
CHEMBL1474387,CHEMBL237,Kappa opioid receptor,Ki,=,118.1,nM,CHEMBL5442187,B,"PDSP Secondary Binding target: OPRK1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,Cc1c(P(=S)(c2ccccc2)c2ccccc2)n2ccccc2[n+]1C/C=C/c1ccccc1.[Br-]
CHEMBL3342358,CHEMBL237,Kappa opioid receptor,Ki,=,997.55,nM,CHEMBL5442187,B,"PDSP Secondary Binding target: OPRK1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,CNc1nc(NCc2ccc(NS(C)(=O)=O)cc2Cl)cc(-c2ccccn2)n1
CHEMBL3039520,CHEMBL237,Kappa opioid receptor,Ki,=,356.57,nM,CHEMBL5442187,B,"PDSP Secondary Binding target: OPRK1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,CN1CCC(C(=O)c2cccc(NC(=O)c3c(F)cc(F)cc3F)n2)CC1
CHEMBL5076917,CHEMBL237,Kappa opioid receptor,Ki,=,4.034,nM,CHEMBL5442187,B,"PDSP Secondary Binding target: OPRK1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,Cc1ccccc1N1CCN(S(=O)(=O)C[C@]23CC[C@H](C[C@@H]2NC(=O)[C@@H](N)CCS(C)(=O)=O)C3(C)C)CC1.Cl
CHEMBL2018875,CHEMBL237,Kappa opioid receptor,Ki,=,194.98,nM,CHEMBL5442187,B,"PDSP Secondary Binding target: OPRK1 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.",CHEMBL5442175,KI,COc1ccc2cc(S(=O)(=O)N[C@H](CC(=O)N[C@H](Cc3ccc(CN4[C@H](C)CCC[C@@H]4C)cc3)C(=O)N(C)C(C)C)c3ccc4c(c3)OCO4)ccc2c1.Cl
CHEMBL1169583,CHEMBL237,Kappa opioid receptor,EC50,=,18.4,nM,CHEMBL754921,B,"EC50 for binding of [35S]- GTPdeltaS in cloned human Opioid receptor kappa 1 (U-69,593) transfected onto CHO cells",CHEMBL1132936,EC50,CO[C@H](C)[C@@H]1CC23C=C[C@]1(OC)[C@H]1Oc4c(O)ccc5c4C12CCN(C)C3C5
CHEMBL2113671,CHEMBL237,Kappa opioid receptor,EC50,=,0.1,nM,CHEMBL754921,B,"EC50 for binding of [35S]- GTPdeltaS in cloned human Opioid receptor kappa 1 (U-69,593) transfected onto CHO cells",CHEMBL1132936,EC50,CO[C@]12C=C[C@@]3(C[C@H]1[C@@H](C)OCc1ccccc1)[C@H]1Cc4ccc(O)c5c4C3(CCN1C)[C@@H]2O5
CHEMBL1169580,CHEMBL237,Kappa opioid receptor,EC50,=,13.9,nM,CHEMBL754921,B,"EC50 for binding of [35S]- GTPdeltaS in cloned human Opioid receptor kappa 1 (U-69,593) transfected onto CHO cells",CHEMBL1132936,EC50,CCC[C@](C)(O)[C@@H]1CC23C=C[C@]1(OC)[C@H]1Oc4c(O)ccc5c4C12CCN(C)C3C5
CHEMBL2113672,CHEMBL237,Kappa opioid receptor,EC50,=,0.8,nM,CHEMBL754921,B,"EC50 for binding of [35S]- GTPdeltaS in cloned human Opioid receptor kappa 1 (U-69,593) transfected onto CHO cells",CHEMBL1132936,EC50,CO[C@]12C=C[C@@]3(C[C@H]1[C@H](C)OCc1ccccc1)[C@H]1Cc4ccc(O)c5c4C3(CCN1C)[C@@H]2O5
CHEMBL1169584,CHEMBL237,Kappa opioid receptor,EC50,=,559.0,nM,CHEMBL754921,B,"EC50 for binding of [35S]- GTPdeltaS in cloned human Opioid receptor kappa 1 (U-69,593) transfected onto CHO cells",CHEMBL1132936,EC50,CCO[C@@H](C)[C@@H]1CC23C=C[C@]1(OC)[C@H]1Oc4c(O)ccc5c4C12CCN(C)C3C5
CHEMBL2113670,CHEMBL237,Kappa opioid receptor,EC50,=,0.61,nM,CHEMBL754921,B,"EC50 for binding of [35S]- GTPdeltaS in cloned human Opioid receptor kappa 1 (U-69,593) transfected onto CHO cells",CHEMBL1132936,EC50,CCO[C@H](C)[C@@H]1C[C@@]23C=C[C@]1(OC)[C@H]1Oc4c(O)ccc5c4C12CCN(C)[C@@H]3C5
CHEMBL1169582,CHEMBL237,Kappa opioid receptor,EC50,=,161.0,nM,CHEMBL754921,B,"EC50 for binding of [35S]- GTPdeltaS in cloned human Opioid receptor kappa 1 (U-69,593) transfected onto CHO cells",CHEMBL1132936,EC50,CO[C@@H](C)[C@@H]1CC23C=C[C@]1(OC)[C@H]1Oc4c(O)ccc5c4C12CCN(C)C3C5
CHEMBL1169585,CHEMBL237,Kappa opioid receptor,EC50,=,2.0,nM,CHEMBL754921,B,"EC50 for binding of [35S]- GTPdeltaS in cloned human Opioid receptor kappa 1 (U-69,593) transfected onto CHO cells",CHEMBL1132936,EC50,CCC[C@@](C)(O)[C@@H]1CC23C=C[C@]1(OC)[C@H]1Oc4c(O)ccc5c4C12CCN(C)C3C5
CHEMBL2113380,CHEMBL237,Kappa opioid receptor,EC50,=,96.5,nM,CHEMBL755511,B,"Stimulation of U-69,593 binding at human recombinant Opioid receptor kappa 1 transfected into CHO cells.",CHEMBL1144921,EC50,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccccc4c2C[C@@]3(CCCc2ccccc2)C1C5
CHEMBL2113379,CHEMBL237,Kappa opioid receptor,EC50,=,96.2,nM,CHEMBL755511,B,"Stimulation of U-69,593 binding at human recombinant Opioid receptor kappa 1 transfected into CHO cells.",CHEMBL1144921,EC50,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccccc4c2C[C@@]3(NC(=O)Cc2ccccc2)C1C5
CHEMBL2113377,CHEMBL237,Kappa opioid receptor,EC50,=,936.0,nM,CHEMBL755511,B,"Stimulation of U-69,593 binding at human recombinant Opioid receptor kappa 1 transfected into CHO cells.",CHEMBL1144921,EC50,CCCCN[C@@]12Cc3c([nH]c4ccccc34)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)C2C5
CHEMBL38874,CHEMBL237,Kappa opioid receptor,EC50,=,4365.0,nM,CHEMBL755511,B,"Stimulation of U-69,593 binding at human recombinant Opioid receptor kappa 1 transfected into CHO cells.",CHEMBL1144921,EC50,C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)NCCO
CHEMBL2113378,CHEMBL237,Kappa opioid receptor,EC50,=,27.2,nM,CHEMBL755511,B,"Stimulation of U-69,593 binding at human recombinant Opioid receptor kappa 1 transfected into CHO cells.",CHEMBL1144921,EC50,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccccc4c2C[C@@]3(NCCCc2ccccc2)C1C5
CHEMBL2113382,CHEMBL237,Kappa opioid receptor,EC50,=,16.4,nM,CHEMBL755511,B,"Stimulation of U-69,593 binding at human recombinant Opioid receptor kappa 1 transfected into CHO cells.",CHEMBL1144921,EC50,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2c2[nH]c4ccccc4c2C[C@@]3(NCCc2ccccc2)C1C5
CHEMBL440765,CHEMBL237,Kappa opioid receptor,EC50,=,26.1,nM,CHEMBL755511,B,"Stimulation of U-69,593 binding at human recombinant Opioid receptor kappa 1 transfected into CHO cells.",CHEMBL1144921,EC50,CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL2113381,CHEMBL237,Kappa opioid receptor,EC50,=,56.9,nM,CHEMBL755511,B,"Stimulation of U-69,593 binding at human recombinant Opioid receptor kappa 1 transfected into CHO cells.",CHEMBL1144921,EC50,CCCCC(=O)N[C@@]12Cc3c([nH]c4ccccc34)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)C2C5
CHEMBL216640,CHEMBL237,Kappa opioid receptor,EC50,=,0.74,nM,CHEMBL755508,B,Human kOpioid receptor kappa 1 mediated stimulation of [35S]- GTPgammaS binding in CHO cells (Agonist potency).,CHEMBL1133465,EC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL441765,CHEMBL237,Kappa opioid receptor,EC50,=,14.4,nM,CHEMBL755506,B,Human Opioid receptor kappa 1<br>mediated stimulation of [35S]- GTPgammaS binding in CHO cells (Agonist potency).,CHEMBL1133465,EC50,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL405190,CHEMBL237,Kappa opioid receptor,EC50,=,6.1,nM,CHEMBL755507,B,Human Opioid receptor kappa 1 mediated stimulation of [35S]- GTPgammaS binding in CHO cells (Agonist potency).,CHEMBL1133465,EC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](C)NC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](CCCCN)C(N)=O
CHEMBL421520,CHEMBL237,Kappa opioid receptor,EC50,=,24.3,nM,CHEMBL754918,B,Agonist potency using GTP-gamma [35S]- binding assay for opioid receptor kappa 1,CHEMBL1134689,EC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1C/N=C(/S)NC(C)(C)C
CHEMBL76573,CHEMBL237,Kappa opioid receptor,EC50,=,1.4,nM,CHEMBL754918,B,Agonist potency using GTP-gamma [35S]- binding assay for opioid receptor kappa 1,CHEMBL1134689,EC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1CNCC(C)(C)C
CHEMBL80463,CHEMBL237,Kappa opioid receptor,EC50,=,161.0,nM,CHEMBL754918,B,Agonist potency using GTP-gamma [35S]- binding assay for opioid receptor kappa 1,CHEMBL1134689,EC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1CNC(=O)Nc1ccccc1
CHEMBL77001,CHEMBL237,Kappa opioid receptor,EC50,=,6.8,nM,CHEMBL754918,B,Agonist potency using GTP-gamma [35S]- binding assay for opioid receptor kappa 1,CHEMBL1134689,EC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1CNCc1ccccc1
CHEMBL310842,CHEMBL237,Kappa opioid receptor,EC50,=,6.9,nM,CHEMBL754918,B,Agonist potency using GTP-gamma [35S]- binding assay for opioid receptor kappa 1,CHEMBL1134689,EC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1CNC(=O)NC(C)(C)C
CHEMBL77804,CHEMBL237,Kappa opioid receptor,EC50,=,11.5,nM,CHEMBL754918,B,Agonist potency using GTP-gamma [35S]- binding assay for opioid receptor kappa 1,CHEMBL1134689,EC50,Cc1cc(O)cc(C)c1C[C@H](N)C(=O)N1Cc2ccccc2C[C@H]1CNC(=O)NC12CC3CC(CC(C3)C1)C2
CHEMBL13470,CHEMBL237,Kappa opioid receptor,EC50,=,5264.0,nM,CHEMBL3271447,B,Agonist activity at human kappa opioid receptor expressed in HEK293 cells by CellKey method,CHEMBL3259551,EC50,C=CCN1C[C@H](C)N([C@H](c2ccc(C(=O)N(CC)CC)cc2)c2cccc(OC)c2)C[C@H]1C
CHEMBL3264742,CHEMBL237,Kappa opioid receptor,EC50,=,39.8,nM,CHEMBL3271447,B,Agonist activity at human kappa opioid receptor expressed in HEK293 cells by CellKey method,CHEMBL3259551,EC50,O=C1[C@H]2O[C@@]34CC[C@@]5(OCOc6c(O)ccc7c6[C@@]3(CCN(CC3CC3)[C@@H]4C7)[C@H]25)N1Cc1ccccc1
CHEMBL3264743,CHEMBL237,Kappa opioid receptor,EC50,=,307.0,nM,CHEMBL3271447,B,Agonist activity at human kappa opioid receptor expressed in HEK293 cells by CellKey method,CHEMBL3259551,EC50,CN1CC[C@@]23c4c5ccc(O)c4OCO[C@]46CC[C@@]2(O[C@H](C(=O)N4Cc2ccccc2)[C@H]63)[C@H]1C5
CHEMBL3264744,CHEMBL237,Kappa opioid receptor,EC50,=,333.0,nM,CHEMBL3271447,B,Agonist activity at human kappa opioid receptor expressed in HEK293 cells by CellKey method,CHEMBL3259551,EC50,CC(C)CN1CC[C@@]23c4c5ccc(O)c4OCO[C@]46CC[C@@]2(O[C@H](C(=O)N4Cc2ccccc2)[C@H]63)[C@H]1C5
CHEMBL3264746,CHEMBL237,Kappa opioid receptor,EC50,=,12530.0,nM,CHEMBL3271447,B,Agonist activity at human kappa opioid receptor expressed in HEK293 cells by CellKey method,CHEMBL3259551,EC50,O=C1[C@H]2O[C@@]34CC[C@@]5(OCOc6c(O)ccc7c6[C@@]3(CCN(CCc3ccccc3)[C@@H]4C7)[C@H]25)N1Cc1ccccc1
CHEMBL3264747,CHEMBL237,Kappa opioid receptor,EC50,=,1.2,nM,CHEMBL3271447,B,Agonist activity at human kappa opioid receptor expressed in HEK293 cells by CellKey method,CHEMBL3259551,EC50,O=C1[C@H]2O[C@@]34CC[C@@]5(OCOc6c(O)ccc7c6[C@@]3(CCN(CC3CC3)[C@@H]4C7)[C@H]25)N1c1ccccc1
CHEMBL3264748,CHEMBL237,Kappa opioid receptor,EC50,=,2.4,nM,CHEMBL3271447,B,Agonist activity at human kappa opioid receptor expressed in HEK293 cells by CellKey method,CHEMBL3259551,EC50,O=C1[C@H]2O[C@@]34CC[C@@]5(OCOc6c(O)ccc7c6[C@@]3(CCN(CC3CC3)[C@@H]4C7)[C@H]25)N1CCc1ccccc1
CHEMBL445332,CHEMBL237,Kappa opioid receptor,EC50,=,40.0,nM,CHEMBL3381495,B,Agonist activity at KOR (unknown origin),CHEMBL3352005,EC50,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL146756,CHEMBL237,Kappa opioid receptor,EC50,=,4.3,nM,CHEMBL3762593,B,Agonist activity at human kappa opioid receptor expressed in CHO cell membrane by [35S]GTP-gammaS binding assay,CHEMBL3758122,EC50,O=C(/C=C/C(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL147511,CHEMBL237,Kappa opioid receptor,EC50,=,0.85,nM,CHEMBL3762593,B,Agonist activity at human kappa opioid receptor expressed in CHO cell membrane by [35S]GTP-gammaS binding assay,CHEMBL3758122,EC50,O=C(CCCCCCCCC(=O)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3)Oc1ccc2c(c1)[C@@]13CCCC[C@H]1[C@@H](C2)N(CC1CCC1)CC3
CHEMBL3323509,CHEMBL237,Kappa opioid receptor,EC50,=,33.0,nM,CHEMBL3790689,B,Agonist activity at human kappa opioid receptor expressed in HEK-293 cells after 45 mins by [35S]GTP-gamma-S binding assay in presence of 10 uM of GDP,CHEMBL3785048,EC50,O=C(Cc1ccc(Cl)c(Cl)c1)N1CCNC2CCCC(N3CCCC3)C21
CHEMBL3323510,CHEMBL237,Kappa opioid receptor,EC50,=,35.0,nM,CHEMBL3790689,B,Agonist activity at human kappa opioid receptor expressed in HEK-293 cells after 45 mins by [35S]GTP-gamma-S binding assay in presence of 10 uM of GDP,CHEMBL3785048,EC50,O=C(Cc1ccc(Cl)c(Cl)c1)N1CCNC2CCCC(N3CCC(O)C3)C21
CHEMBL3786640,CHEMBL237,Kappa opioid receptor,EC50,=,20.0,nM,CHEMBL3790689,B,Agonist activity at human kappa opioid receptor expressed in HEK-293 cells after 45 mins by [35S]GTP-gamma-S binding assay in presence of 10 uM of GDP,CHEMBL3785048,EC50,COC(=O)N1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)C2C(N3CCCC3)CCCC21
CHEMBL3323522,CHEMBL237,Kappa opioid receptor,EC50,=,79.0,nM,CHEMBL3790689,B,Agonist activity at human kappa opioid receptor expressed in HEK-293 cells after 45 mins by [35S]GTP-gamma-S binding assay in presence of 10 uM of GDP,CHEMBL3785048,EC50,COC(=O)N1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)C2C(N3CCC(O)C3)CCCC21
CHEMBL3785955,CHEMBL237,Kappa opioid receptor,EC50,=,34.0,nM,CHEMBL3790689,B,Agonist activity at human kappa opioid receptor expressed in HEK-293 cells after 45 mins by [35S]GTP-gamma-S binding assay in presence of 10 uM of GDP,CHEMBL3785048,EC50,O=C(Cc1ccc(Cl)c(Cl)c1)N1CCN(Cc2cccnc2)C2CCCC(N3CCCC3)C21
CHEMBL3786545,CHEMBL237,Kappa opioid receptor,EC50,=,77.0,nM,CHEMBL3790689,B,Agonist activity at human kappa opioid receptor expressed in HEK-293 cells after 45 mins by [35S]GTP-gamma-S binding assay in presence of 10 uM of GDP,CHEMBL3785048,EC50,O=C(Cc1ccc(Cl)c(Cl)c1)N1CCN(Cc2cccnc2)C2CCCC(N3CCC(O)C3)C21
CHEMBL440765,CHEMBL237,Kappa opioid receptor,EC50,=,12.0,nM,CHEMBL3790689,B,Agonist activity at human kappa opioid receptor expressed in HEK-293 cells after 45 mins by [35S]GTP-gamma-S binding assay in presence of 10 uM of GDP,CHEMBL3785048,EC50,CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL441765,CHEMBL237,Kappa opioid receptor,EC50,=,630.96,nM,CHEMBL3802791,B,Agonist activity at human KOR expressed in EE-HEK293 cells,CHEMBL3797063,EC50,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL3797228,CHEMBL237,Kappa opioid receptor,EC50,=,10000.0,nM,CHEMBL3802792,B,"Activity at human KOR expressed in EE-HEK293 cells assessed as pEC50 for effect on (-)U50,488H-induced response (Rvb = 6.2 +/- 0.04 No_unit)",CHEMBL3797063,EC50,C[C@H]1[C@H]2Cc3ccc(O)cc3[C@]1(C)CCN2CCC(=O)Nc1cccc2ccccc12
CHEMBL3809091,CHEMBL237,Kappa opioid receptor,EC50,=,580.0,nM,CHEMBL3812009,B,Agonist activity at human KOR expressed in CHO cell membranes after 60 mins by [35S]GTP-gamma-S binding assay,CHEMBL3808393,EC50,CN(C)C[C@H]1CCc2cc(-c3ccccc3)ccc2[C@]1(O)c1cccc(O)c1
CHEMBL3809864,CHEMBL237,Kappa opioid receptor,EC50,=,1500.0,nM,CHEMBL3810954,B,Agonist activity at KOP receptor (unknown origin),CHEMBL3808387,EC50,Nc1ccnc(-c2cc(-c3ccon3)n(Cc3ccccc3F)n2)n1
CHEMBL895,CHEMBL237,Kappa opioid receptor,EC50,=,25.1,nM,CHEMBL3888041,B,"GTPyS binding assay: Test compound and/or vehicle was preincubated with the cell membranes and 3 uM GDP in modified HEPES buffer (pH 7.4) for 20 minutes, followed by addition of SPA beads for another 60 minutes at 30 C. The reaction is initiated by 0.3 nM [35S]GTP gamma S for an additional 30 minutes incubation period. Test compound-induced increase of [35S]GTP gamma S binding by 50 percent or more (250%) relative to the receptor subtype-specific agonist response indicates possible opiate receptor agonist activity. 0.1 uM DPDPE, 1 uM U-69593 and 1 uM DAMGO were used as the specific agonists for the delta, kappa and mu opioid receptors respectively. Opioid receptor antagonist activity was measured using inhibition of agonist-induced increase of [35S]GTP gammaS binding response by 50 percent or more (250%). Nalbuphine, 6-O-mPEG3-Nalbuphine, 6-O-mPEG6-Nalbuphine, 6-O-mPEG9-Nalbuphine were screened at concentrations of 10, 1, 0.1, 0.01 and 0.001 uM in both agonist and antagonist mode. EC50 or IC50 values were calculated from the dose-response curves as a measure of the agonist or antagonist activity of the test compounds respectively.",CHEMBL3886551,EC50,Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
CHEMBL3954154,CHEMBL237,Kappa opioid receptor,EC50,=,26.8,nM,CHEMBL3888041,B,"GTPyS binding assay: Test compound and/or vehicle was preincubated with the cell membranes and 3 uM GDP in modified HEPES buffer (pH 7.4) for 20 minutes, followed by addition of SPA beads for another 60 minutes at 30 C. The reaction is initiated by 0.3 nM [35S]GTP gamma S for an additional 30 minutes incubation period. Test compound-induced increase of [35S]GTP gamma S binding by 50 percent or more (250%) relative to the receptor subtype-specific agonist response indicates possible opiate receptor agonist activity. 0.1 uM DPDPE, 1 uM U-69593 and 1 uM DAMGO were used as the specific agonists for the delta, kappa and mu opioid receptors respectively. Opioid receptor antagonist activity was measured using inhibition of agonist-induced increase of [35S]GTP gammaS binding response by 50 percent or more (250%). Nalbuphine, 6-O-mPEG3-Nalbuphine, 6-O-mPEG6-Nalbuphine, 6-O-mPEG9-Nalbuphine were screened at concentrations of 10, 1, 0.1, 0.01 and 0.001 uM in both agonist and antagonist mode. EC50 or IC50 values were calculated from the dose-response curves as a measure of the agonist or antagonist activity of the test compounds respectively.",CHEMBL3886551,EC50,COCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CCC2)C1O5
CHEMBL3947626,CHEMBL237,Kappa opioid receptor,EC50,=,164.0,nM,CHEMBL3888041,B,"GTPyS binding assay: Test compound and/or vehicle was preincubated with the cell membranes and 3 uM GDP in modified HEPES buffer (pH 7.4) for 20 minutes, followed by addition of SPA beads for another 60 minutes at 30 C. The reaction is initiated by 0.3 nM [35S]GTP gamma S for an additional 30 minutes incubation period. Test compound-induced increase of [35S]GTP gamma S binding by 50 percent or more (250%) relative to the receptor subtype-specific agonist response indicates possible opiate receptor agonist activity. 0.1 uM DPDPE, 1 uM U-69593 and 1 uM DAMGO were used as the specific agonists for the delta, kappa and mu opioid receptors respectively. Opioid receptor antagonist activity was measured using inhibition of agonist-induced increase of [35S]GTP gammaS binding response by 50 percent or more (250%). Nalbuphine, 6-O-mPEG3-Nalbuphine, 6-O-mPEG6-Nalbuphine, 6-O-mPEG9-Nalbuphine were screened at concentrations of 10, 1, 0.1, 0.01 and 0.001 uM in both agonist and antagonist mode. EC50 or IC50 values were calculated from the dose-response curves as a measure of the agonist or antagonist activity of the test compounds respectively.",CHEMBL3886551,EC50,COCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CCC2)C1O5
CHEMBL3919846,CHEMBL237,Kappa opioid receptor,EC50,=,485.0,nM,CHEMBL3888041,B,"GTPyS binding assay: Test compound and/or vehicle was preincubated with the cell membranes and 3 uM GDP in modified HEPES buffer (pH 7.4) for 20 minutes, followed by addition of SPA beads for another 60 minutes at 30 C. The reaction is initiated by 0.3 nM [35S]GTP gamma S for an additional 30 minutes incubation period. Test compound-induced increase of [35S]GTP gamma S binding by 50 percent or more (250%) relative to the receptor subtype-specific agonist response indicates possible opiate receptor agonist activity. 0.1 uM DPDPE, 1 uM U-69593 and 1 uM DAMGO were used as the specific agonists for the delta, kappa and mu opioid receptors respectively. Opioid receptor antagonist activity was measured using inhibition of agonist-induced increase of [35S]GTP gammaS binding response by 50 percent or more (250%). Nalbuphine, 6-O-mPEG3-Nalbuphine, 6-O-mPEG6-Nalbuphine, 6-O-mPEG9-Nalbuphine were screened at concentrations of 10, 1, 0.1, 0.01 and 0.001 uM in both agonist and antagonist mode. EC50 or IC50 values were calculated from the dose-response curves as a measure of the agonist or antagonist activity of the test compounds respectively.",CHEMBL3886551,EC50,COCCOCCOCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CCC2)C1O5
CHEMBL511142,CHEMBL237,Kappa opioid receptor,EC50,=,0.56,nM,CHEMBL3888320,B,"-Opioid Receptor Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886656,EC50,CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL4107585,CHEMBL237,Kappa opioid receptor,EC50,=,22.66,nM,CHEMBL3888320,B,"-Opioid Receptor Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886656,EC50,CC(C)(C)[C@@]1(C)OCO[C@]23CC[C@@]4(C[C@@H]21)[C@H]1Cc2ccc(O)c5c2[C@@]4(CCN1CC1CC1)[C@H]3O5
CHEMBL4113162,CHEMBL237,Kappa opioid receptor,EC50,=,4.42,nM,CHEMBL3888320,B,"-Opioid Receptor Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886656,EC50,CCC1O[C@]23CC[C@@]4(C[C@@H]2[C@@](C)(C(C)(C)C)O1)[C@H]1Cc2ccc(O)c5c2[C@@]4(CCN1CC1CC1)[C@H]3O5
CHEMBL4111049,CHEMBL237,Kappa opioid receptor,EC50,=,9.48,nM,CHEMBL3888320,B,"-Opioid Receptor Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886656,EC50,CCCC1O[C@]23CC[C@@]4(C[C@@H]2[C@@](C)(C(C)(C)C)O1)[C@H]1Cc2ccc(O)c5c2[C@@]4(CCN1CC1CC1)[C@H]3O5
CHEMBL4109805,CHEMBL237,Kappa opioid receptor,EC50,=,7.76,nM,CHEMBL3888320,B,"-Opioid Receptor Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886656,EC50,CC(C)(C)[C@@]1(C)OCO[C@]23C=C[C@@]4(C[C@@H]21)[C@H]1Cc2ccc(O)c5c2[C@@]4(CCN1CC1CC1)[C@H]3O5
CHEMBL4115892,CHEMBL237,Kappa opioid receptor,EC50,=,593.0,nM,CHEMBL3888320,B,"-Opioid Receptor Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886656,EC50,
CHEMBL4115893,CHEMBL237,Kappa opioid receptor,EC50,=,855.0,nM,CHEMBL3888320,B,"-Opioid Receptor Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886656,EC50,
CHEMBL4108929,CHEMBL237,Kappa opioid receptor,EC50,=,570.4,nM,CHEMBL3888409,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours.",CHEMBL3886698,EC50,NC(=O)c1cc2c([nH]c1=O)C[C@@]13CCN(CC4CC4)C[C@@]1(Cc1ccc(O)cc13)C2
CHEMBL3916263,CHEMBL237,Kappa opioid receptor,EC50,=,384.2,nM,CHEMBL3888409,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours.",CHEMBL3886698,EC50,O=C1NC(=O)[C@@]2(CC[C@@]34Cc5ccc(O)cc5[C@@]3(CCN(CC3CC3)C4)C2)N1
CHEMBL3981333,CHEMBL237,Kappa opioid receptor,EC50,=,318.8,nM,CHEMBL3888409,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours.",CHEMBL3886698,EC50,O=C1NC(=O)[C@]2(CC[C@@]34Cc5ccc(O)cc5[C@@]3(CCN(CC3CC3)C4)C2)N1
CHEMBL4113753,CHEMBL237,Kappa opioid receptor,EC50,=,5114.25,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CCOC(=O)C[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(OC)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL3935417,CHEMBL237,Kappa opioid receptor,EC50,=,4435.58,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)C[C@H](CC(=O)O)C(=O)C3
CHEMBL3890527,CHEMBL237,Kappa opioid receptor,EC50,=,17.3,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,O=C(O)C[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL3923032,CHEMBL237,Kappa opioid receptor,EC50,=,220.91,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,C[C@H](NC(=O)C[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O)C(=O)O
CHEMBL3906641,CHEMBL237,Kappa opioid receptor,EC50,=,201.13,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CC(C)C[C@H](NC(=O)C[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O)C(=O)O
CHEMBL4106563,CHEMBL237,Kappa opioid receptor,EC50,=,362.3,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)C[C@H](CCOCc1ccccc1)C(=O)C3
CHEMBL3971169,CHEMBL237,Kappa opioid receptor,EC50,=,5.02,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,O=C1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@]3(O)C[C@@H]1CCO
CHEMBL4108710,CHEMBL237,Kappa opioid receptor,EC50,=,4.3,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CC(C)CC[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL3976681,CHEMBL237,Kappa opioid receptor,EC50,=,1052.0,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@@H]1C[C@@H](C(C)C)C(=O)C3
CHEMBL3948713,CHEMBL237,Kappa opioid receptor,EC50,=,6.07,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CC(C)[C@@H]1C[C@H]2[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL4111936,CHEMBL237,Kappa opioid receptor,EC50,=,3.52,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CC(C)[C@H]1C[C@H]2[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL4111457,CHEMBL237,Kappa opioid receptor,EC50,=,5560.0,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)C1C[C@H](OCC(C)C)C(=O)C3
CHEMBL4115581,CHEMBL237,Kappa opioid receptor,EC50,=,317.1,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)C1[C@@H](O)[C@H](OCc1ccccc1)C(=O)C3
CHEMBL3942489,CHEMBL237,Kappa opioid receptor,EC50,=,876.5,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)C[C@H](O)C(=O)C3
CHEMBL3924522,CHEMBL237,Kappa opioid receptor,EC50,=,7213.0,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)C[C@H](NC(=O)C(C)C)C(=O)C3
CHEMBL3928981,CHEMBL237,Kappa opioid receptor,EC50,=,24.7,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CC(C)C(=O)N[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL3970877,CHEMBL237,Kappa opioid receptor,EC50,=,27.1,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CC(=O)N[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL4112403,CHEMBL237,Kappa opioid receptor,EC50,=,14.6,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CCC(=O)N[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL4108329,CHEMBL237,Kappa opioid receptor,EC50,=,1.61,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CC(C)CCC(=O)N[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL4112548,CHEMBL237,Kappa opioid receptor,EC50,=,2.59,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CC(C)CCCC(=O)N[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL3891748,CHEMBL237,Kappa opioid receptor,EC50,=,17.5,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CC(C)(C)C(=O)N[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL3924605,CHEMBL237,Kappa opioid receptor,EC50,=,36.1,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CC(C)CC(=O)N[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL3952294,CHEMBL237,Kappa opioid receptor,EC50,=,12.6,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,O=C(N[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O)C1CC1
CHEMBL4113094,CHEMBL237,Kappa opioid receptor,EC50,=,13.6,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,O=C(N[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O)C1CCCC1
CHEMBL4110493,CHEMBL237,Kappa opioid receptor,EC50,=,4.28,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,O=C(N[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O)c1ccccc1
CHEMBL4109056,CHEMBL237,Kappa opioid receptor,EC50,=,42.1,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CC[C@H](C)C(=O)N[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL4110263,CHEMBL237,Kappa opioid receptor,EC50,=,2.3,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,O=C(N[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O)C1CCCCC1
CHEMBL3922780,CHEMBL237,Kappa opioid receptor,EC50,=,1016.0,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)C[C@H](CCO)C(=O)C3
CHEMBL4106563,CHEMBL237,Kappa opioid receptor,EC50,=,225.1,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)C[C@H](CCOCc1ccccc1)C(=O)C3
CHEMBL3932459,CHEMBL237,Kappa opioid receptor,EC50,=,1282.0,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COCC[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(OC)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL3904456,CHEMBL237,Kappa opioid receptor,EC50,=,7896.0,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COc1ccc2c(c1)[C@]13CCN(C)[C@H](C2)[C@]1(O)C[C@H](CCOCc1ccccc1)C(=O)C3
CHEMBL3971169,CHEMBL237,Kappa opioid receptor,EC50,=,4.82,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,O=C1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@]3(O)C[C@@H]1CCO
CHEMBL3945031,CHEMBL237,Kappa opioid receptor,EC50,=,838.8,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,O=C1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(OCc5ccccc5)cc42)[C@]3(O)C[C@@H]1CCO
CHEMBL3890045,CHEMBL237,Kappa opioid receptor,EC50,=,14890.0,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COc1ccc2c(c1)[C@]13CCN(C)[C@H](C2)[C@]1(O)C[C@H](CC(=O)O)C(=O)C3
CHEMBL3927022,CHEMBL237,Kappa opioid receptor,EC50,=,963.2,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CN1CC[C@]23CC(=O)[C@@H](CC(=O)O)C[C@@]2(O)[C@H]1Cc1ccc(O)cc13
CHEMBL4111757,CHEMBL237,Kappa opioid receptor,EC50,=,3067.0,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@]1(O)C/C(=C\CC(C)C)C(=O)C3
CHEMBL4108710,CHEMBL237,Kappa opioid receptor,EC50,=,4.71,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CC(C)CC[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL4111028,CHEMBL237,Kappa opioid receptor,EC50,=,2.57,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,O=C1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@]3(O)C[C@@H]1CC1CCCC1
CHEMBL4114481,CHEMBL237,Kappa opioid receptor,EC50,=,7.57,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CCC(C)C[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL4110924,CHEMBL237,Kappa opioid receptor,EC50,=,3.0,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CCCC[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL3961125,CHEMBL237,Kappa opioid receptor,EC50,=,20.5,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CC(C)(C)C[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL3940268,CHEMBL237,Kappa opioid receptor,EC50,=,9.52,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CC(C)C[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL4111704,CHEMBL237,Kappa opioid receptor,EC50,=,4.01,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,O=C1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@]3(O)C[C@@H]1CC1CCCCC1
CHEMBL4113124,CHEMBL237,Kappa opioid receptor,EC50,=,5.6,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,O=C1C[C@]23CCN(CC4CC4)[C@H](Cc4ccc(O)cc42)[C@]3(O)C[C@@H]1Cc1ccccc1
CHEMBL3976681,CHEMBL237,Kappa opioid receptor,EC50,=,302.8,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,COc1ccc2c(c1)[C@]13CCN(CC4CC4)[C@H](C2)[C@@H]1C[C@@H](C(C)C)C(=O)C3
CHEMBL3948713,CHEMBL237,Kappa opioid receptor,EC50,=,1.92,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CC(C)[C@@H]1C[C@H]2[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL4111936,CHEMBL237,Kappa opioid receptor,EC50,=,1.42,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CC(C)[C@H]1C[C@H]2[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3CC2CC2)CC1=O
CHEMBL3895514,CHEMBL237,Kappa opioid receptor,EC50,=,16592.0,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,C[C@H](NC(=O)C[C@H]1C[C@@]2(O)[C@H]3Cc4ccc(O)cc4[C@@]2(CCN3C)CC1=O)C(=O)O
CHEMBL3963622,CHEMBL237,Kappa opioid receptor,EC50,=,1198.0,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CN1CC[C@]23CC(=O)[C@@H](CC(=O)N4CCCCC4)C[C@@]2(O)[C@H]1Cc1ccc(O)cc13
CHEMBL3925461,CHEMBL237,Kappa opioid receptor,EC50,=,6508.0,nM,CHEMBL3888721,B,"[35S]GTPS Functional Assay: Functional [35S]GTPS binding assays were conducted as follows.  opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 g/l  membrane protein (in-house), 10 g/mL saponin, 3 M GDP and 0.20 nM [35S]GTPS to binding buffer (100 mM NaCl, 10 mM MgCl2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane solution (190 l/well) was transferred to 96-shallow well polypropylene plates containing 10 l of 20 concentrated stock solutions of agonist prepared in DMSO. Plates were incubated for 30 min at a temperature of about 25 C. with shaking. Reactions were terminated by rapid filtration onto 96-well Unifilter GF/B filter plates (Perkin Elmer, Shelton, Conn.) using a 96-well tissue harvester (Packard) and followed by three filtration washes with 200 l ice-cold binding buffer (10 mM NaH2PO4, 10 mM Na2HPO4, pH 7.4). Filter plates were subsequently dried at 50 C. for 2-3 hours. Fifty l/well scintillation cocktail (Perkin Elmer, Shelton, Conn.) was added and plates were counted in a Packard Top-Count for 1 min/well.",CHEMBL3886801,EC50,CN1CC[C@]23CC(=O)[C@@H](CC(=O)N4CCC(O)CC4)C[C@@]2(O)[C@H]1Cc1ccc(O)cc13
CHEMBL4073100,CHEMBL237,Kappa opioid receptor,EC50,=,4129.0,nM,CHEMBL4036864,B,Agonist activity at human kappa opioid receptor expressed in CHO cells assessed as beta-arrestin2 recruitment by enzyme fragment complementation method,CHEMBL4033764,EC50,Cc1cc(CSc2nnc(-c3ccccn3)n2Cc2ccco2)ccc1C(F)(F)F
CHEMBL1708421,CHEMBL237,Kappa opioid receptor,EC50,=,8990.0,nM,CHEMBL4036864,B,Agonist activity at human kappa opioid receptor expressed in CHO cells assessed as beta-arrestin2 recruitment by enzyme fragment complementation method,CHEMBL4033764,EC50,Clc1ccc(CSc2nnc(-c3ccccn3)n2Cc2ccco2)cc1Cl
CHEMBL102999,CHEMBL237,Kappa opioid receptor,EC50,=,56.6,nM,CHEMBL4036864,B,Agonist activity at human kappa opioid receptor expressed in CHO cells assessed as beta-arrestin2 recruitment by enzyme fragment complementation method,CHEMBL4033764,EC50,CN(CCc1ccc(Cl)c(Cl)c1)[C@@H]1CCCC[C@H]1N1CCCC1
CHEMBL226997,CHEMBL237,Kappa opioid receptor,EC50,=,63.2,nM,CHEMBL4036864,B,Agonist activity at human kappa opioid receptor expressed in CHO cells assessed as beta-arrestin2 recruitment by enzyme fragment complementation method,CHEMBL4033764,EC50,CN(C(=O)Cc1ccccc1)[C@H]1CC[C@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL4092454,CHEMBL237,Kappa opioid receptor,EC50,=,8100.0,nM,CHEMBL4050978,B,Agonist activity at KOR (unknown origin) expressed in HTLA cells assessed as beta-arrestin recruitment incubated overnight by Bright-Glo luminescence assay,CHEMBL4049419,EC50,CC(NCc1nccn1C)c1cccc(O)c1
CHEMBL490665,CHEMBL237,Kappa opioid receptor,EC50,=,0.0082,nM,CHEMBL4057024,B,Agonist activity at kappa opioid receptor (unknown origin),CHEMBL4052747,EC50,CN(C(=O)/C=C/c1ccoc1)[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5.Cl
CHEMBL4103819,CHEMBL237,Kappa opioid receptor,EC50,=,0.025,nM,CHEMBL4057026,B,Agonist activity at human kappa opioid receptor,CHEMBL4052747,EC50,CN(C(=O)/C=C/c1ccoc1)[C@@H]1CC[C@@]2(O)[C@H]3[C@@H](O)c4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL8234,CHEMBL237,Kappa opioid receptor,EC50,=,80.0,nM,CHEMBL4371120,B,Activation of kappa opioid receptor (unknown origin) expressed in CHO cells,CHEMBL4371002,EC50,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O
CHEMBL267495,CHEMBL237,Kappa opioid receptor,EC50,=,110.0,nM,CHEMBL4371547,B,Agonist activity at FLAG-tagged human kappa opioid receptor expressed in HEK293 cells assessed as increase in beta-arrestin mediated p38 phosphorylation after 5 mins by Western blot analysis,CHEMBL4371007,EC50,CN(C(=O)/C=C/c1ccoc1)[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL267495,CHEMBL237,Kappa opioid receptor,EC50,=,1.4,nM,CHEMBL4371543,B,Agonist activity at FLAG-tagged human kappa opioid receptor expressed in HEK293 cells assessed as increase in ERK1/2 phosphorylation after 5 mins by Western blot analysis,CHEMBL4371007,EC50,CN(C(=O)/C=C/c1ccoc1)[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
CHEMBL610279,CHEMBL237,Kappa opioid receptor,EC50,=,1.6,nM,CHEMBL4371539,B,Partial agonist activity at full-length Renilla luciferase 8 fused with c-terminal human kappa opioid receptor expressed in HEK293T cells assessed as increase in beta-arrestin recruitment after 5 mins by BRET assay,CHEMBL4371007,EC50,N=C(N)Nc1ccc2c3c([nH]c2c1)[C@@H]1Oc2c(O)ccc4c2[C@@]12CCN(CC1CC1)[C@H](C4)[C@]2(O)C3
CHEMBL2381583,CHEMBL237,Kappa opioid receptor,EC50,=,1130.0,nM,CHEMBL4371517,B,Agonist activity at kappa opioid receptor (unknown origin) assessed as increase in venus-tagged N-terminal beta-arrestin-2 recruitment by BRET assay,CHEMBL4371007,EC50,COC(=O)[C@@H]1C[C@H](OC(=O)CSC#N)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL445332,CHEMBL237,Kappa opioid receptor,EC50,=,10.0,nM,CHEMBL4371517,B,Agonist activity at kappa opioid receptor (unknown origin) assessed as increase in venus-tagged N-terminal beta-arrestin-2 recruitment by BRET assay,CHEMBL4371007,EC50,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL440765,CHEMBL237,Kappa opioid receptor,EC50,=,5.4,nM,CHEMBL4371532,B,Agonist activity at human kappa opioid receptor expressed in human U2OS cells assessed as increase in ERK1/2 phosphorylation after 10 mins by Western blot analysis,CHEMBL4371007,EC50,CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL4458783,CHEMBL237,Kappa opioid receptor,EC50,=,329.0,nM,CHEMBL4371532,B,Agonist activity at human kappa opioid receptor expressed in human U2OS cells assessed as increase in ERK1/2 phosphorylation after 10 mins by Western blot analysis,CHEMBL4371007,EC50,Cc1ccc(CSc2nnc(-c3ccccn3)n2Cc2ccco2)cc1C(F)(F)F
CHEMBL440765,CHEMBL237,Kappa opioid receptor,EC50,=,205.0,nM,CHEMBL4371531,B,Agonist activity at human kappa opioid receptor expressed in human U2OS cells co-transfected with GFP and beta-arrestin-2 assessed as increase in beta-arrestin-2 recruitment after 20 mins by Hoechst staining-based assay,CHEMBL4371007,EC50,CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL4458783,CHEMBL237,Kappa opioid receptor,EC50,=,3138.0,nM,CHEMBL4371531,B,Agonist activity at human kappa opioid receptor expressed in human U2OS cells co-transfected with GFP and beta-arrestin-2 assessed as increase in beta-arrestin-2 recruitment after 20 mins by Hoechst staining-based assay,CHEMBL4371007,EC50,Cc1ccc(CSc2nnc(-c3ccccn3)n2Cc2ccco2)cc1C(F)(F)F
CHEMBL440765,CHEMBL237,Kappa opioid receptor,EC50,=,131.0,nM,CHEMBL4371529,B,Agonist activity at human kappa opioid receptor expressed in human U2OS cells co-transfected with EFC and beta-arrestin-2 assessed as increase in beta-arrestin-2 recruitment after 90 mins by luminescence assay,CHEMBL4371007,EC50,CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL4458783,CHEMBL237,Kappa opioid receptor,EC50,=,4129.0,nM,CHEMBL4371529,B,Agonist activity at human kappa opioid receptor expressed in human U2OS cells co-transfected with EFC and beta-arrestin-2 assessed as increase in beta-arrestin-2 recruitment after 90 mins by luminescence assay,CHEMBL4371007,EC50,Cc1ccc(CSc2nnc(-c3ccccn3)n2Cc2ccco2)cc1C(F)(F)F
CHEMBL1708421,CHEMBL237,Kappa opioid receptor,EC50,=,870.0,nM,CHEMBL4371529,B,Agonist activity at human kappa opioid receptor expressed in human U2OS cells co-transfected with EFC and beta-arrestin-2 assessed as increase in beta-arrestin-2 recruitment after 90 mins by luminescence assay,CHEMBL4371007,EC50,Clc1ccc(CSc2nnc(-c3ccccn3)n2Cc2ccco2)cc1Cl
CHEMBL4537962,CHEMBL237,Kappa opioid receptor,EC50,=,10090.0,nM,CHEMBL4371531,B,Agonist activity at human kappa opioid receptor expressed in human U2OS cells co-transfected with GFP and beta-arrestin-2 assessed as increase in beta-arrestin-2 recruitment after 20 mins by Hoechst staining-based assay,CHEMBL4371007,EC50,Ic1ccc(CSc2nnc(-c3ccccn3)n2Cc2cccnc2)cc1
CHEMBL4483681,CHEMBL237,Kappa opioid receptor,EC50,=,42.0,nM,CHEMBL4372810,B,Agonist activity at Tango-KOR (unknown origin) expressed in HTLA cells harboring TEV-fused-beta-arrestin 2 assessed as increase in beta arrestin 2 recruitment after overnight incubation by BrightGlo reagent based assay,CHEMBL4371059,EC50,CC(C)(C)OC(=O)N1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)[C@@H]2[C@@H](N3CCCC3)CCC[C@@H]21
CHEMBL4069231,CHEMBL237,Kappa opioid receptor,EC50,=,3.8,nM,CHEMBL4372810,B,Agonist activity at Tango-KOR (unknown origin) expressed in HTLA cells harboring TEV-fused-beta-arrestin 2 assessed as increase in beta arrestin 2 recruitment after overnight incubation by BrightGlo reagent based assay,CHEMBL4371059,EC50,O=C(Cc1ccc(Cl)c(Cl)c1)N1CCN[C@H]2CCC[C@H](N3CCCC3)[C@H]21
CHEMBL4462000,CHEMBL237,Kappa opioid receptor,EC50,=,17.0,nM,CHEMBL4372810,B,Agonist activity at Tango-KOR (unknown origin) expressed in HTLA cells harboring TEV-fused-beta-arrestin 2 assessed as increase in beta arrestin 2 recruitment after overnight incubation by BrightGlo reagent based assay,CHEMBL4371059,EC50,CN1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)[C@H]2[C@@H]1CCC[C@@H]2N1CCCC1
CHEMBL4467644,CHEMBL237,Kappa opioid receptor,EC50,=,12.0,nM,CHEMBL4372810,B,Agonist activity at Tango-KOR (unknown origin) expressed in HTLA cells harboring TEV-fused-beta-arrestin 2 assessed as increase in beta arrestin 2 recruitment after overnight incubation by BrightGlo reagent based assay,CHEMBL4371059,EC50,CCN1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)[C@H]2[C@@H]1CCC[C@@H]2N1CCCC1
CHEMBL4582146,CHEMBL237,Kappa opioid receptor,EC50,=,7.9,nM,CHEMBL4372810,B,Agonist activity at Tango-KOR (unknown origin) expressed in HTLA cells harboring TEV-fused-beta-arrestin 2 assessed as increase in beta arrestin 2 recruitment after overnight incubation by BrightGlo reagent based assay,CHEMBL4371059,EC50,CCCN1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)[C@@H]2[C@@H](N3CCCC3)CCC[C@@H]21
CHEMBL4561040,CHEMBL237,Kappa opioid receptor,EC50,=,33.0,nM,CHEMBL4372810,B,Agonist activity at Tango-KOR (unknown origin) expressed in HTLA cells harboring TEV-fused-beta-arrestin 2 assessed as increase in beta arrestin 2 recruitment after overnight incubation by BrightGlo reagent based assay,CHEMBL4371059,EC50,CCCCN1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)[C@@H]2[C@@H](N3CCCC3)CCC[C@@H]21
CHEMBL4438714,CHEMBL237,Kappa opioid receptor,EC50,=,247.0,nM,CHEMBL4372810,B,Agonist activity at Tango-KOR (unknown origin) expressed in HTLA cells harboring TEV-fused-beta-arrestin 2 assessed as increase in beta arrestin 2 recruitment after overnight incubation by BrightGlo reagent based assay,CHEMBL4371059,EC50,O=C(Cc1ccc(Cl)c(Cl)c1)N1CCN(Cc2ccc(F)cc2)[C@H]2CCC[C@H](N3CCCC3)[C@H]21
CHEMBL4463652,CHEMBL237,Kappa opioid receptor,EC50,=,43.0,nM,CHEMBL4372810,B,Agonist activity at Tango-KOR (unknown origin) expressed in HTLA cells harboring TEV-fused-beta-arrestin 2 assessed as increase in beta arrestin 2 recruitment after overnight incubation by BrightGlo reagent based assay,CHEMBL4371059,EC50,O=C(Cc1ccc(Cl)c(Cl)c1)N1CCN(Cc2cn(CCF)nn2)[C@H]2CCC[C@H](N3CCCC3)[C@H]21
CHEMBL4555496,CHEMBL237,Kappa opioid receptor,EC50,=,227.0,nM,CHEMBL4372810,B,Agonist activity at Tango-KOR (unknown origin) expressed in HTLA cells harboring TEV-fused-beta-arrestin 2 assessed as increase in beta arrestin 2 recruitment after overnight incubation by BrightGlo reagent based assay,CHEMBL4371059,EC50,O=C(Cc1ccc(Cl)c(Cl)c1)N1CCN(C(=O)COCCF)[C@H]2CCC[C@H](N3CCCC3)[C@H]21
CHEMBL445332,CHEMBL237,Kappa opioid receptor,EC50,=,5.1,nM,CHEMBL4372810,B,Agonist activity at Tango-KOR (unknown origin) expressed in HTLA cells harboring TEV-fused-beta-arrestin 2 assessed as increase in beta arrestin 2 recruitment after overnight incubation by BrightGlo reagent based assay,CHEMBL4371059,EC50,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL8234,CHEMBL237,Kappa opioid receptor,EC50,=,80.0,nM,CHEMBL4399462,B,Agonist activity at kappa opioid receptor (unknown origin) expressed in CHO cells,CHEMBL4396923,EC50,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)O
CHEMBL2180638,CHEMBL237,Kappa opioid receptor,EC50,=,449.0,nM,CHEMBL4409328,B,Inhibition of kappa opioid receptor (unknown origin) assessed as increase in beta-arrestin 2 recruitment,CHEMBL4406853,EC50,Oc1cccc(CCN(CCc2ccccc2)CC2CC2)c1
CHEMBL2180639,CHEMBL237,Kappa opioid receptor,EC50,=,463.0,nM,CHEMBL4409328,B,Inhibition of kappa opioid receptor (unknown origin) assessed as increase in beta-arrestin 2 recruitment,CHEMBL4406853,EC50,Oc1cccc(CCN(CCc2ccccc2)CC2CCC2)c1
CHEMBL4464797,CHEMBL237,Kappa opioid receptor,EC50,=,0.19,nM,CHEMBL4409302,B,Inhibition of kappa opioid receptor (unknown origin),CHEMBL4406853,EC50,COC(=O)[C@@H]1C[C@H](OC(=O)Cl)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL2381583,CHEMBL237,Kappa opioid receptor,EC50,=,0.077,nM,CHEMBL4409302,B,Inhibition of kappa opioid receptor (unknown origin),CHEMBL4406853,EC50,COC(=O)[C@@H]1C[C@H](OC(=O)CSC#N)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL4435747,CHEMBL237,Kappa opioid receptor,EC50,=,107.4,nM,CHEMBL4409309,B,Inhibition of kappa opioid receptor (unknown origin) assessed as effect on ERK2 phosphorylation,CHEMBL4406853,EC50,Ic1ccc(CSc2nnc(-c3ccccn3)n2Cc2ccccn2)cc1
CHEMBL4435747,CHEMBL237,Kappa opioid receptor,EC50,=,107.4,nM,CHEMBL4409308,B,Inhibition of kappa opioid receptor (unknown origin) assessed as effect on ERK1 phosphorylation,CHEMBL4406853,EC50,Ic1ccc(CSc2nnc(-c3ccccn3)n2Cc2ccccn2)cc1
CHEMBL4435747,CHEMBL237,Kappa opioid receptor,EC50,=,10090.0,nM,CHEMBL4409304,B,Inhibition of kappa opioid receptor (unknown origin) assessed as increase in beta arrestin 2 recruitment,CHEMBL4406853,EC50,Ic1ccc(CSc2nnc(-c3ccccn3)n2Cc2ccccn2)cc1
CHEMBL4458783,CHEMBL237,Kappa opioid receptor,EC50,=,4129.0,nM,CHEMBL4409304,B,Inhibition of kappa opioid receptor (unknown origin) assessed as increase in beta arrestin 2 recruitment,CHEMBL4406853,EC50,Cc1ccc(CSc2nnc(-c3ccccn3)n2Cc2ccco2)cc1C(F)(F)F
CHEMBL1708421,CHEMBL237,Kappa opioid receptor,EC50,=,140000.0,nM,CHEMBL4409305,B,Inhibition of kappa opioid receptor (unknown origin) assessed as increase in beta arrestin 2 recruitment relative to control,CHEMBL4406853,EC50,Clc1ccc(CSc2nnc(-c3ccccn3)n2Cc2ccco2)cc1Cl
CHEMBL1708421,CHEMBL237,Kappa opioid receptor,EC50,=,870.0,nM,CHEMBL4409304,B,Inhibition of kappa opioid receptor (unknown origin) assessed as increase in beta arrestin 2 recruitment,CHEMBL4406853,EC50,Clc1ccc(CSc2nnc(-c3ccccn3)n2Cc2ccco2)cc1Cl
CHEMBL4754111,CHEMBL237,Kappa opioid receptor,EC50,=,885.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](NCC(=O)NCC(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4792012,CHEMBL237,Kappa opioid receptor,EC50,=,1884.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](N[C@H](C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)O)C(C)C)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4789014,CHEMBL237,Kappa opioid receptor,EC50,=,330.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](N[C@H](C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)O)C(C)C)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4740464,CHEMBL237,Kappa opioid receptor,EC50,=,3396.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](NCCCC(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4743953,CHEMBL237,Kappa opioid receptor,EC50,=,2034.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](NCCCC(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4757463,CHEMBL237,Kappa opioid receptor,EC50,=,622.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](NCCC(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4776879,CHEMBL237,Kappa opioid receptor,EC50,=,186.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](NCCC(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4781006,CHEMBL237,Kappa opioid receptor,EC50,=,572.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CC[C@H](N[C@@H]1CC[C@@]2(OC)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3C)[C@H]1O5)C(=O)O
CHEMBL4797321,CHEMBL237,Kappa opioid receptor,EC50,=,942.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CC[C@H](N[C@H]1CC[C@@]2(OC)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3C)[C@H]1O5)C(=O)O
CHEMBL4750229,CHEMBL237,Kappa opioid receptor,EC50,=,282.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](N[C@H](C(=O)O)C3CCCCC3)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4748047,CHEMBL237,Kappa opioid receptor,EC50,=,250.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](N[C@H](C(=O)O)C3CCCCC3)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4783612,CHEMBL237,Kappa opioid receptor,EC50,=,611.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](N[C@H](Cc3ccccc3)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4757240,CHEMBL237,Kappa opioid receptor,EC50,=,215.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](N[C@H](Cc3ccccc3)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4795517,CHEMBL237,Kappa opioid receptor,EC50,=,1278.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](N[C@@H](C(=O)O)C(C)C)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4741203,CHEMBL237,Kappa opioid receptor,EC50,=,2218.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](N[C@@H](C(=O)O)C(C)C)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4780909,CHEMBL237,Kappa opioid receptor,EC50,=,1001.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](N[C@H](C)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4777389,CHEMBL237,Kappa opioid receptor,EC50,=,254.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](N[C@H](C)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4740918,CHEMBL237,Kappa opioid receptor,EC50,=,2233.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](N[C@@H](CCC(=O)O)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4761211,CHEMBL237,Kappa opioid receptor,EC50,=,1167.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](N[C@@H](CCC(=O)O)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4747179,CHEMBL237,Kappa opioid receptor,EC50,=,753.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](N[C@@H](CC(=O)O)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4740360,CHEMBL237,Kappa opioid receptor,EC50,=,2991.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](N[C@@H](CC(=O)O)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4763225,CHEMBL237,Kappa opioid receptor,EC50,=,1410.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](N[C@@H](CCC(N)=O)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4755501,CHEMBL237,Kappa opioid receptor,EC50,=,185.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](N[C@@H](CCC(N)=O)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4760163,CHEMBL237,Kappa opioid receptor,EC50,=,923.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](N[C@@H](CC(N)=O)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4761784,CHEMBL237,Kappa opioid receptor,EC50,=,81.7,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](N[C@@H](CC(N)=O)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4788003,CHEMBL237,Kappa opioid receptor,EC50,=,181.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](N[C@@H](Cc3c[nH]c4ccccc34)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4755067,CHEMBL237,Kappa opioid receptor,EC50,=,70.1,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](N[C@@H](Cc3c[nH]c4ccccc34)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4745745,CHEMBL237,Kappa opioid receptor,EC50,=,774.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](N[C@@H](Cc3ccc(O)cc3)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4753934,CHEMBL237,Kappa opioid receptor,EC50,=,100.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](N[C@@H](Cc3ccc(O)cc3)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4741873,CHEMBL237,Kappa opioid receptor,EC50,=,525.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](N[C@@H](CCCCN)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4793888,CHEMBL237,Kappa opioid receptor,EC50,=,118.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](N[C@@H](CCCCN)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4782629,CHEMBL237,Kappa opioid receptor,EC50,=,1117.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](N[C@H](C(=O)O)C(C)C)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4793953,CHEMBL237,Kappa opioid receptor,EC50,=,462.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](N[C@H](C(=O)O)C(C)C)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4788604,CHEMBL237,Kappa opioid receptor,EC50,=,201.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](N[C@@H](CO)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4741308,CHEMBL237,Kappa opioid receptor,EC50,=,1213.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](N[C@@H](CO)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4795312,CHEMBL237,Kappa opioid receptor,EC50,=,1172.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](N[C@@H](Cc3ccccc3)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4754944,CHEMBL237,Kappa opioid receptor,EC50,=,219.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](N[C@@H](Cc3ccccc3)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4763643,CHEMBL237,Kappa opioid receptor,EC50,=,392.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@@H](N[C@@H](C)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4782642,CHEMBL237,Kappa opioid receptor,EC50,=,214.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](N[C@@H](C)C(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL4755734,CHEMBL237,Kappa opioid receptor,EC50,=,361.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@H](NCC(=O)O)CC[C@@]3(O)[C@H]1C5
CHEMBL1672084,CHEMBL237,Kappa opioid receptor,EC50,=,399.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CC[C@H](NCC(=O)O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL607405,CHEMBL237,Kappa opioid receptor,EC50,=,116.0,nM,CHEMBL4675316,B,Agonist activity at human KOR expressed in CHO cell membranes incubated for 60 mins scintillation counting assay,CHEMBL4673223,EC50,CO[C@@]12CCC(=O)[C@@H]3Oc4c(O)ccc5c4[C@@]31CCN(C)[C@@H]2C5
CHEMBL5277326,CHEMBL237,Kappa opioid receptor,EC50,=,267.3,nM,CHEMBL5227868,B,Agonist activity at KOR (unknown origin) expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding measured after 60 mins by liquid scintillation counting analysis,CHEMBL5226314,EC50,CN(C)CC1CN(CCc2cccc(C(F)(F)F)c2)CCC1(O)c1cccc(O)c1
CHEMBL5270915,CHEMBL237,Kappa opioid receptor,EC50,=,342.8,nM,CHEMBL5227868,B,Agonist activity at KOR (unknown origin) expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding measured after 60 mins by liquid scintillation counting analysis,CHEMBL5226314,EC50,CN(C)CC1CN(C(=O)Cc2cccc(Cl)c2)CCC1(O)c1cccc(O)c1
CHEMBL5287792,CHEMBL237,Kappa opioid receptor,EC50,=,105.4,nM,CHEMBL5227868,B,Agonist activity at KOR (unknown origin) expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding measured after 60 mins by liquid scintillation counting analysis,CHEMBL5226314,EC50,CN(C)CC1CN(C(=O)CCc2cccc(C(F)(F)F)c2)CCC1(O)c1cccc(O)c1
CHEMBL440765,CHEMBL237,Kappa opioid receptor,EC50,=,2.8,nM,CHEMBL5227868,B,Agonist activity at KOR (unknown origin) expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding measured after 60 mins by liquid scintillation counting analysis,CHEMBL5226314,EC50,CN(C(=O)Cc1ccccc1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
CHEMBL5273356,CHEMBL237,Kappa opioid receptor,EC50,=,75.4,nM,CHEMBL5227868,B,Agonist activity at KOR (unknown origin) expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding measured after 60 mins by liquid scintillation counting analysis,CHEMBL5226314,EC50,CN(C)CC1CN(C(=O)Cc2cc(F)c(F)cc2F)CCC1(O)c1cccc(O)c1
CHEMBL5279890,CHEMBL237,Kappa opioid receptor,EC50,=,1032.0,nM,CHEMBL5227868,B,Agonist activity at KOR (unknown origin) expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding measured after 60 mins by liquid scintillation counting analysis,CHEMBL5226314,EC50,CN(C)C[C@@H]1CN(C(=O)Cc2cc(F)c(F)cc2F)CC[C@@]1(O)c1cccc(O)c1
CHEMBL5287134,CHEMBL237,Kappa opioid receptor,EC50,=,500.2,nM,CHEMBL5227868,B,Agonist activity at KOR (unknown origin) expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding measured after 60 mins by liquid scintillation counting analysis,CHEMBL5226314,EC50,CN(C)C[C@H]1CN(C(=O)Cc2cc(F)c(F)cc2F)CC[C@]1(O)c1cccc(O)c1
CHEMBL5273273,CHEMBL237,Kappa opioid receptor,EC50,=,0.95,nM,CHEMBL5253118,B,Agonist activity at human kappa opioid receptor expressed in CHO-K1 cells assessed as ERK phosphorylation incubated for 2 hrs by Alphascreen surefire method,CHEMBL5252514,EC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O
CHEMBL5282726,CHEMBL237,Kappa opioid receptor,EC50,=,9848.0,nM,CHEMBL5253118,B,Agonist activity at human kappa opioid receptor expressed in CHO-K1 cells assessed as ERK phosphorylation incubated for 2 hrs by Alphascreen surefire method,CHEMBL5252514,EC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC(N)=O)C(=O)N1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5281790,CHEMBL237,Kappa opioid receptor,EC50,=,5864.0,nM,CHEMBL5253118,B,Agonist activity at human kappa opioid receptor expressed in CHO-K1 cells assessed as ERK phosphorylation incubated for 2 hrs by Alphascreen surefire method,CHEMBL5252514,EC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H]2CCC(=O)N2)C(=O)N1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5283510,CHEMBL237,Kappa opioid receptor,EC50,=,7486.0,nM,CHEMBL5253118,B,Agonist activity at human kappa opioid receptor expressed in CHO-K1 cells assessed as ERK phosphorylation incubated for 2 hrs by Alphascreen surefire method,CHEMBL5252514,EC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5267287,CHEMBL237,Kappa opioid receptor,EC50,=,1580.0,nM,CHEMBL5253118,B,Agonist activity at human kappa opioid receptor expressed in CHO-K1 cells assessed as ERK phosphorylation incubated for 2 hrs by Alphascreen surefire method,CHEMBL5252514,EC50,N=C(N)NCCC[C@H](NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5268886,CHEMBL237,Kappa opioid receptor,EC50,=,1105.0,nM,CHEMBL5253118,B,Agonist activity at human kappa opioid receptor expressed in CHO-K1 cells assessed as ERK phosphorylation incubated for 2 hrs by Alphascreen surefire method,CHEMBL5252514,EC50,N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5281912,CHEMBL237,Kappa opioid receptor,EC50,=,0.36,nM,CHEMBL5253118,B,Agonist activity at human kappa opioid receptor expressed in CHO-K1 cells assessed as ERK phosphorylation incubated for 2 hrs by Alphascreen surefire method,CHEMBL5252514,EC50,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5289642,CHEMBL237,Kappa opioid receptor,EC50,=,450.0,nM,CHEMBL5253118,B,Agonist activity at human kappa opioid receptor expressed in CHO-K1 cells assessed as ERK phosphorylation incubated for 2 hrs by Alphascreen surefire method,CHEMBL5252514,EC50,CC1(C)SSC[C@@H](C(N)=O)NC(=O)[C@H]1NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCC(=O)N1
CHEMBL5282326,CHEMBL237,Kappa opioid receptor,EC50,=,0.62,nM,CHEMBL5253118,B,Agonist activity at human kappa opioid receptor expressed in CHO-K1 cells assessed as ERK phosphorylation incubated for 2 hrs by Alphascreen surefire method,CHEMBL5252514,EC50,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O)C1CCCCC1
CHEMBL5273273,CHEMBL237,Kappa opioid receptor,EC50,=,1.2,nM,CHEMBL5253119,B,Agonist activity at human kappa opioid receptor expressed in CHO-K1 cells assessed as inhibition of forskolin-stimulated cAMP production incubated for 30 mins by LANCE cAMP assay,CHEMBL5252514,EC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O
CHEMBL5282726,CHEMBL237,Kappa opioid receptor,EC50,=,9446.0,nM,CHEMBL5253119,B,Agonist activity at human kappa opioid receptor expressed in CHO-K1 cells assessed as inhibition of forskolin-stimulated cAMP production incubated for 30 mins by LANCE cAMP assay,CHEMBL5252514,EC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CC(N)=O)C(=O)N1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5281790,CHEMBL237,Kappa opioid receptor,EC50,=,11.5,nM,CHEMBL5253119,B,Agonist activity at human kappa opioid receptor expressed in CHO-K1 cells assessed as inhibition of forskolin-stimulated cAMP production incubated for 30 mins by LANCE cAMP assay,CHEMBL5252514,EC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H]2CCC(=O)N2)C(=O)N1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5283510,CHEMBL237,Kappa opioid receptor,EC50,=,1.9,nM,CHEMBL5253119,B,Agonist activity at human kappa opioid receptor expressed in CHO-K1 cells assessed as inhibition of forskolin-stimulated cAMP production incubated for 30 mins by LANCE cAMP assay,CHEMBL5252514,EC50,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5267287,CHEMBL237,Kappa opioid receptor,EC50,=,15.2,nM,CHEMBL5253119,B,Agonist activity at human kappa opioid receptor expressed in CHO-K1 cells assessed as inhibition of forskolin-stimulated cAMP production incubated for 30 mins by LANCE cAMP assay,CHEMBL5252514,EC50,N=C(N)NCCC[C@H](NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5268886,CHEMBL237,Kappa opioid receptor,EC50,=,12.6,nM,CHEMBL5253119,B,Agonist activity at human kappa opioid receptor expressed in CHO-K1 cells assessed as inhibition of forskolin-stimulated cAMP production incubated for 30 mins by LANCE cAMP assay,CHEMBL5252514,EC50,N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5281912,CHEMBL237,Kappa opioid receptor,EC50,=,0.41,nM,CHEMBL5253119,B,Agonist activity at human kappa opioid receptor expressed in CHO-K1 cells assessed as inhibition of forskolin-stimulated cAMP production incubated for 30 mins by LANCE cAMP assay,CHEMBL5252514,EC50,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O
CHEMBL5289642,CHEMBL237,Kappa opioid receptor,EC50,=,10.5,nM,CHEMBL5253119,B,Agonist activity at human kappa opioid receptor expressed in CHO-K1 cells assessed as inhibition of forskolin-stimulated cAMP production incubated for 30 mins by LANCE cAMP assay,CHEMBL5252514,EC50,CC1(C)SSC[C@@H](C(N)=O)NC(=O)[C@H]1NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCC(=O)N1
CHEMBL5282326,CHEMBL237,Kappa opioid receptor,EC50,=,0.39,nM,CHEMBL5253119,B,Agonist activity at human kappa opioid receptor expressed in CHO-K1 cells assessed as inhibition of forskolin-stimulated cAMP production incubated for 30 mins by LANCE cAMP assay,CHEMBL5252514,EC50,N=C(N)NCCC[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)c1ccccc1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC1=O)C1CCCCC1
CHEMBL445332,CHEMBL237,Kappa opioid receptor,EC50,=,2.2,nM,CHEMBL5360971,B,Displacement of [35S]GTPgammaS binding from human KOR assessed as inhibition constant,CHEMBL5360528,EC50,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL2311186,CHEMBL237,Kappa opioid receptor,Kd,=,0.029,nM,CHEMBL821385,B,Binding affinity towards Wild-type kappa opioid receptor expressed in HEK cells,CHEMBL1132988,KD,[3H]C1[C@H](C(C)(C)O)[C@]2(OC)CC[C@]13[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
CHEMBL1795714,CHEMBL237,Kappa opioid receptor,Kd,=,0.027,nM,CHEMBL1799270,B,Binding affinity to KOR-1 expressed in CHO cells after 90 mins,CHEMBL1795226,KD,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1cccc([125I])c1
CHEMBL1795715,CHEMBL237,Kappa opioid receptor,Kd,=,0.05,nM,CHEMBL1799270,B,Binding affinity to KOR-1 expressed in CHO cells after 90 mins,CHEMBL1795226,KD,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@H](NC(=O)c2cccc([125I])c2)CC[C@@]3(O)[C@H]1C5
CHEMBL3745782,CHEMBL237,Kappa opioid receptor,Kd,=,426.58,nM,CHEMBL3748895,B,Antagonist activity at human KOR expressed in CHO-FlpIn cell membranes assessed as inhibition of ICI199441-induced ERK phosphorylation after 30 mins by Gaddum-Schild plot analysis,CHEMBL3745681,KD,COc1nnc(OCCCC(=O)NCCCCCCNC(=O)[C@H]2C[C@@]34CC[C@]2(OC)[C@@H]2Oc5c(O)ccc6c5[C@@]23CCN(C)[C@@H]4C6)nn1
CHEMBL3747555,CHEMBL237,Kappa opioid receptor,Kd,=,501.19,nM,CHEMBL3748895,B,Antagonist activity at human KOR expressed in CHO-FlpIn cell membranes assessed as inhibition of ICI199441-induced ERK phosphorylation after 30 mins by Gaddum-Schild plot analysis,CHEMBL3745681,KD,CCN1/C(=C/C=C/C=C/C2=[N+](CCCCCC(=O)NCCCCCCNC(=O)[C@H]3C[C@@]45CC[C@]3(OC)[C@@H]3Oc6c(O)ccc7c6[C@@]34CCN(C)[C@@H]5C7)c3ccc(S(=O)(=O)O)cc3C2(C)C)C(C)(C)c2cc(S(=O)(=O)O)ccc21
CHEMBL3746198,CHEMBL237,Kappa opioid receptor,Kd,=,190.55,nM,CHEMBL3748895,B,Antagonist activity at human KOR expressed in CHO-FlpIn cell membranes assessed as inhibition of ICI199441-induced ERK phosphorylation after 30 mins by Gaddum-Schild plot analysis,CHEMBL3745681,KD,CO[C@]12CC[C@@]3(C[C@@H]1C(=O)NCCCCCCNC(=O)CCCCCNC(=O)COc1ccc(/C=C/C4=[N+]5C(=Cc6ccc(-c7cccs7)n6[B-]5(F)F)C=C4)cc1)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL3746169,CHEMBL237,Kappa opioid receptor,Kd,=,123.03,nM,CHEMBL3748895,B,Antagonist activity at human KOR expressed in CHO-FlpIn cell membranes assessed as inhibition of ICI199441-induced ERK phosphorylation after 30 mins by Gaddum-Schild plot analysis,CHEMBL3745681,KD,CO[C@]12CC[C@@]3(C[C@@H]1C(=O)NCCCCCCNC(=O)CCN1C(=O)c4cccc5c(N)ccc(c45)C1=O)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1C)[C@H]2O5
CHEMBL4459592,CHEMBL237,Kappa opioid receptor,Kd,=,18.8,nM,CHEMBL4344762,B,Binding affinity to recombinant human KOR transiently expressed in CHOK1 cells measured after 20 mins by TIRF microscopic analysis,CHEMBL4342472,KD,CN1/C(=C/C=C/C2=[N+](CCCCCC(=O)NCCCNC(=N)Nc3ccc4[nH]c5c(c4c3)C[C@@]3(O)[C@H]4Cc6ccc(O)c7c6[C@@]3(CCN4CC3CC3)[C@H]5O7)c3ccc(S(=O)(=O)[O-])cc3C2(C)C)C(C)(C)c2cc(S(=O)(=O)O)ccc21
CHEMBL4463414,CHEMBL237,Kappa opioid receptor,Kd,=,9.5,nM,CHEMBL4344762,B,Binding affinity to recombinant human KOR transiently expressed in CHOK1 cells measured after 20 mins by TIRF microscopic analysis,CHEMBL4342472,KD,CN1/C(=C/C=C/C=C/C2=[N+](CCCCCC(=O)NCCCNC(=N)Nc3ccc4[nH]c5c(c4c3)C[C@@]3(O)[C@H]4Cc6ccc(O)c7c6[C@@]3(CCN4CC3CC3)[C@H]5O7)c3ccc(S(=O)(=O)[O-])cc3C2(C)C)C(C)(C)c2cc(S(=O)(=O)O)ccc21
CHEMBL4577693,CHEMBL237,Kappa opioid receptor,Kd,=,4.8,nM,CHEMBL4344762,B,Binding affinity to recombinant human KOR transiently expressed in CHOK1 cells measured after 20 mins by TIRF microscopic analysis,CHEMBL4342472,KD,CN1/C(=C/C=C/C=C/C2=[N+](CCCCCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCCCNC(=N)Nc3ccc4[nH]c5c(c4c3)C[C@@]3(O)[C@H]4Cc6ccc(O)c7c6[C@@]3(CCN4CC3CC3)[C@H]5O7)c3ccc(S(=O)(=O)[O-])cc3C2(C)C)C(C)(C)c2cc(S(=O)(=O)O)ccc21
CHEMBL4464797,CHEMBL237,Kappa opioid receptor,Kd,=,2.1,nM,CHEMBL4409301,B,Binding affinity to kappa opioid receptor (unknown origin),CHEMBL4406853,KD,COC(=O)[C@@H]1C[C@H](OC(=O)Cl)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL2381583,CHEMBL237,Kappa opioid receptor,Kd,=,0.59,nM,CHEMBL4409301,B,Binding affinity to kappa opioid receptor (unknown origin),CHEMBL4406853,KD,COC(=O)[C@@H]1C[C@H](OC(=O)CSC#N)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
CHEMBL5421947,CHEMBL237,Kappa opioid receptor,Kd,=,0.028,nM,CHEMBL5341723,B,Binding affinity to kappa opioid receptor (unknown origin),CHEMBL5338767,KD,N[11C](=O)c1ccc(Oc2ccc(CN3CCC[C@H]3c3cccnc3)cc2)c(Cl)c1
